Famotidine	Famotidine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
associated	associate	VBN	B-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
six	six	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Famotidine	Famotidine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
histamine	histamine	NN	I-NP	B	O
H2	H2	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
inpatient	inpatient	NN	B-NP	O	O
settings	setting	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
prevention	prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
stress	stress	NN	B-NP	O	O
ulcers	ulcer	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
showing	show	VBG	I-VP	O	O
increasing	increase	VBG	B-NP	O	O
popularity	popularity	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
low	low	JJ	I-NP	O	O
cost	cost	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
currently	currently	RB	I-NP	O	O
available	available	JJ	I-NP	O	O
H2	H2	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
propensity	propensity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
delirium	delirium	NN	B-NP	O	B-Disease
,	,	,	O	O	O
only	only	RB	B-NP	O	O
two	two	CD	I-NP	O	O
previously	previously	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
report	report	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
six	six	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
hospitalized	hospitalize	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
cleared	clear	VBD	B-VP	O	O
completely	completely	RB	B-ADVP	O	O
upon	upon	IN	B-PP	O	O
removal	removal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
famotidine	famotidine	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
implications	implication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
famotidine	famotidine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
persons	person	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
depleted	deplete	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
indomethacin	indomethacin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
IDM	IDM	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
to	to	TO	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
depleted	deplete	VBD	B-VP	O	O
rats	rat	NNS	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
renin	renin	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
PRA	PRA	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
systolic	systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
fell	fall	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
within	within	IN	B-PP	O	O
four	four	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
repleted	replete	VBN	B-VP	O	O
animals	animal	NNS	B-NP	O	O
indomethacin	indomethacin	NN	I-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
systolic	systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
BP	BP	NN	B-NP	B	O
)	)	)	O	O	O
although	although	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
renin	renin	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
by	by	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
may	may	MD	B-VP	O	O
diminish	diminish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
maintaining	maintain	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stimulated	stimulate	VBN	I-NP	O	O
renin	renin	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
system	system	NN	I-NP	O	O
in	in	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
.	.	.	O	O	O

Late	Late	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
onset	onset	NN	I-NP	O	O
scleroderma	scleroderma	NN	I-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
crisis	crisis	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
prednisolone	prednisolone	NN	I-NP	B	B-Chemical
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

Scleroderma	Scleroderma	NN	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
crisis	crisis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SRC	SRC	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	B-Disease
sclerosis	sclerosis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SSc	SSc	NN	B-NP	O	B-Disease
)	)	)	O	O	O
but	but	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
severe	severe	JJ	B-ADJP	O	O
enough	enough	RB	I-ADJP	O	O
to	to	TO	B-VP	O	O
require	require	VB	I-VP	O	O
temporary	temporary	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
permanent	permanent	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Moderate	Moderate	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
high	high	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	B-Chemical
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recognized	recognize	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
SRC	SRC	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
thrombotic	thrombotic	JJ	B-NP	O	B-Disease
microangiopathy	microangiopathy	NN	I-NP	O	I-Disease
precipitated	precipitate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
SSc	SSc	NN	B-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
article	article	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
SRC	SRC	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
work	work	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
call	call	VB	I-VP	O	O
attention	attention	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
SSc	SSc	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
and	and	CC	O	O	O
associated	associate	VBN	B-VP	O	O
factors	factor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
psychosis	psychosis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Malaysia	Malaysia	NNP	B-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lifetime	lifetime	NN	B-NP	O	O
and	and	CC	O	O	O
current	current	JJ	B-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
psychosis	psychosis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
dependence	dependence	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
psychiatric	psychiatric	JJ	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
psychosis	psychosis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
cross	cross	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
sectional	sectional	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
conducted	conduct	VBN	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
teaching	teaching	NN	I-NP	O	O
hospital	hospital	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
rehabilitation	rehabilitation	NN	I-NP	O	O
center	center	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Malaysia	Malaysia	NNP	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
DSM	DSM	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
IV	IV	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
interviewed	interview	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
Mini	Mini	NNP	I-NP	O	O
International	International	NNP	I-NP	O	O
Neuropsychiatric	Neuropsychiatric	NNP	I-NP	O	O
Interview	Interview	NNP	I-NP	O	O
(	(	(	O	O	O
M.I.N.I.	M.I.N.I.	NNP	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
psychosis	psychosis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
Axis	Axis	NN	I-NP	O	O
I	I	CD	I-NP	O	O
psychiatric	psychiatric	JJ	I-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
information	information	NN	I-NP	O	O
on	on	IN	B-PP	O	O
sociodemographic	sociodemographic	JJ	B-NP	O	O
background	background	NN	I-NP	O	O
and	and	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
use	use	NN	I-NP	O	O
history	history	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
interview	interview	NN	B-NP	O	O
or	or	CC	O	O	O
medical	medical	JJ	B-NP	O	O
records	record	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Of	Of	IN	B-NP	O	O
292	292	CD	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
47.9	47.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
past	past	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychotic	psychotic	JJ	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
13.0	13.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
having	have	VBG	I-VP	O	O
current	current	JJ	B-NP	O	O
psychotic	psychotic	JJ	I-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Co	Co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
morbid	morbid	JJ	I-NP	O	O
major	major	JJ	I-NP	O	O
depressive	depressive	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7.18	7.18	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
2.612	2.612	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
19.708	19.708	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
13.807	13.807	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
5.194	5.194	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
36.706	36.706	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
antisocial	antisocial	JJ	B-NP	O	B-Disease
personality	personality	NN	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12.619	12.619	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
6.702	6.702	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
23.759	23.759	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
heavy	heavy	JJ	B-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
uses	use	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lifetime	lifetime	NN	B-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
psychosis	psychosis	NN	I-NP	O	B-Disease
after	after	IN	B-SBAR	O	O
adjusted	adjust	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Major	Major	JJ	B-NP	O	B-Disease
depressive	depressive	JJ	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
2.870	2.870	CD	B-NP	O	O
,	,	,	O	O	O
CI	CI	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1.154	1.154	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
7.142	7.142	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
antisocial	antisocial	JJ	B-NP	O	B-Disease
personality	personality	NN	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
3.299	3.299	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.375	1.375	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
7.914	7.914	CD	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	JJ	I-NP	O	O
factors	factor	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
psychosis	psychosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychosis	psychosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
dependence	dependence	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
morbid	morbid	NN	I-NP	O	O
affective	affective	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
,	,	,	O	O	O
antisocial	antisocial	JJ	B-NP	O	B-Disease
personality	personality	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
heavy	heavy	JJ	B-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
all	all	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
dependence	dependence	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
screened	screen	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
psychotic	psychotic	JJ	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Cerebellar	Cerebellar	JJ	B-NP	O	O
sensory	sensory	JJ	I-NP	O	O
processing	processing	NN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
impact	impact	VBP	B-VP	O	O
motor	motor	NN	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
:	:	:	O	O	O
clues	clue	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
dyskinetic	dyskinetic	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
motor	motor	NN	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
(	(	(	O	O	O
M1	M1	NN	B-NP	B	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PD	PD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
(	(	(	O	O	O
LIDs	LID	NNS	B-NP	B	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
severely	severely	RB	B-ADJP	O	O
impaired	impaired	JJ	I-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
recently	recently	RB	B-ADVP	O	O
reported	report	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
that	that	IN	B-NP	O	O
inhibitory	inhibitory	JJ	B-NP	O	O
cerebellar	cerebellar	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
enhanced	enhance	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
sensorimotor	sensorimotor	NN	I-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
M1	M1	NN	B-NP	B	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
paired	paired	JJ	B-NP	O	O
associative	associative	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
(	(	(	O	O	O
PAS	PAS	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
demonstrates	demonstrate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
deficient	deficient	JJ	I-NP	O	O
sensorimotor	sensorimotor	NN	I-NP	O	O
M1	M1	NN	I-NP	B	O
plasticity	plasticity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
16	16	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
LIDs	LID	NNS	B-NP	B	B-Disease
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reinstated	reinstate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
session	session	NN	I-NP	O	O
of	of	IN	B-PP	O	O
real	real	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
cerebellar	cerebellar	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
sham	sham	NN	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
only	only	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
sensory	sensory	JJ	I-NP	O	O
component	component	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasticity	plasticity	NN	B-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
cerebellar	cerebellar	JJ	B-NP	O	O
sensory	sensory	JJ	I-NP	O	O
processing	processing	NN	I-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
resurgence	resurgence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
M1	M1	NN	B-NP	B	O
plasticity	plasticity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
benefit	benefit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibitory	inhibitory	JJ	B-NP	O	O
cerebellar	cerebellar	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
on	on	IN	B-PP	O	O
LIDs	LID	NNS	B-NP	B	B-Disease
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
explore	explore	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
benefit	benefit	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
linked	link	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
restoration	restoration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensorimotor	sensorimotor	NN	B-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
M1	M1	NN	B-NP	B	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
conducted	conduct	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
looking	look	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
LIDs	LID	NNS	B-NP	B	B-Disease
and	and	CC	I-NP	O	O
PAS	PAS	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
after	after	IN	B-PP	O	O
10	10	CD	B-NP	O	O
sessions	session	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	B-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
,	,	,	I-NP	O	O
real	real	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
cerebellar	cerebellar	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
or	or	CC	I-NP	O	O
sham	sham	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
real	real	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
not	not	RB	I-NP	O	O
sham	sham	NN	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
antidyskinetic	antidyskinetic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
paralleled	parallel	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
resurgence	resurgence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sensorimotor	sensorimotor	NN	I-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
M1	M1	NN	B-NP	B	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cerebellar	cerebellar	JJ	B-NP	O	O
sensory	sensory	JJ	I-NP	O	O
processing	processing	NN	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
occurring	occur	VBG	B-VP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
basal	basal	JJ	I-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
signals	signal	NNS	I-NP	O	O
reaching	reach	VBG	B-VP	O	O
it	it	PRP	B-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
element	element	NN	I-NP	O	O
contributing	contribute	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
maladaptive	maladaptive	JJ	I-NP	O	O
sensorimotor	sensorimotor	NN	I-NP	O	O
plasticity	plasticity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
M1	M1	NN	B-NP	B	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
emergence	emergence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	B-Disease
involuntary	involuntary	JJ	I-NP	O	I-Disease
movements	movement	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
and	and	CC	I-NP	O	O
NK1	NK1	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
explore	explore	VB	I-VP	O	O
the	the	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
and	and	CC	I-NP	O	O
NK1	NK1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Sixty	Sixty	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
(	(	(	O	O	O
SD	SD	NNP	B-NP	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
(	(	(	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
injected	inject	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
0.9	0.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
saline	saline	NN	I-NP	B	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
model	model	NN	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
i.p.	i.p.	RB	I-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intervention	intervention	NN	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
i.p.	i.p.	RB	I-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
subsequently	subsequently	RB	B-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
with	with	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
and	and	CC	I-NP	O	O
NK1	NK1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
,	,	,	O	O	O
Suramin	Suramin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
GR	GR	NN	B-NP	B	B-Chemical
82334	82334	CD	I-NP	I	I-Chemical
.	.	.	O	O	O

Spontaneous	Spontaneous	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
behaviors	behavior	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Urodynamic	Urodynamic	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
,	,	,	O	O	O
bladder	bladder	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
volume	volume	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
,	,	,	O	O	O
maximum	maximum	JJ	B-NP	O	O
voiding	voiding	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
MVP	MVP	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
maximum	maximum	JJ	B-NP	O	O
cystometric	cystometric	JJ	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
(	(	(	O	O	O
MCC	MCC	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

Pathological	Pathological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Immunofluorescence	Immunofluorescence	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
detect	detect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
and	and	CC	I-NP	O	O
NK1	NK1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Cyclophosphamide	Cyclophosphamide	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
spontaneous	spontaneous	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
behaviors	behaviors	NN	I-NP	O	O
scores	score	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
instability	instability	NN	I-NP	O	O
during	during	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
storage	storage	NN	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
model	model	NN	B-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
intervention	intervention	NN	B-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
X	X	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
7.619	7.619	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.007	0.007	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
control	control	NN	B-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
X	X	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
13.755	13.755	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.000	0.000	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

MCC	MCC	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
model	model	NN	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intervention	intervention	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Histological	Histological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
evident	evident	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
model	model	NN	B-NP	O	O
and	and	CC	I-NP	O	O
intervention	intervention	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
rats	rat	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
included	include	VBD	B-VP	O	O
edema	edema	NN	B-NP	O	B-Disease
,	,	,	O	O	O
vasodilation	vasodilation	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
infiltration	infiltration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
model	model	NN	B-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
urothelium	urothelium	NN	B-NP	O	O
and	and	CC	I-NP	O	O
suburothelium	suburothelium	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
NK1	NK1	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
suburothelium	suburothelium	NN	B-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
in	in	IN	B-PP	O	O
intervention	intervention	NN	B-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
and	and	CC	I-NP	O	O
NK1	NK1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
urothelium	urothelium	NN	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
suburothelium	suburothelium	NN	B-NP	O	O
.	.	.	O	O	O

Perfusion	Perfusion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
with	with	IN	B-PP	O	O
P2X3	P2X3	NN	B-NP	O	O
and	and	CC	I-NP	O	O
NK1	NK1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
ameliorated	ameliorate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
and	and	CC	O	O	O
review	review	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
recognition	recognition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
responsible	responsible	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
difficult	difficult	JJ	B-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
acute	acute	JJ	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
strongly	strongly	RB	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
accurate	accurate	JJ	I-NP	O	O
medical	medical	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
.	.	.	O	O	O

Reports	Report	NNS	B-NP	O	O
about	about	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
clopidogrel	clopidogrel	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
increasing	increase	VBG	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
believe	believe	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
carefully	carefully	RB	I-VP	O	O
consider	consider	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
when	when	WRB	B-ADVP	O	O
clopidogrel	clopidogrel	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
.	.	.	O	O	O

Bortezomib	Bortezomib	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
as	as	IN	B-PP	O	O
salvage	salvage	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
relapsed	relapse	VBN	B-NP	O	O
/	/	SYM	I-NP	O	O
refractory	refractory	JJ	I-NP	O	O
multiple	multiple	JJ	I-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
:	:	:	O	O	O
analysis	analysis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

Bortezomib	Bortezomib	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
bort	bort	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
dex	dex	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
relapsed	relapse	VBN	B-NP	O	O
/	/	SYM	I-NP	O	O
refractory	refractory	NN	I-NP	O	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
R	R	NN	I-NP	O	O
)	)	)	I-NP	O	O
multiple	multiple	JJ	I-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MM	MM	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bort	bort	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
1.3	1.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	I-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
11	11	CD	B-NP	O	O
every	every	DT	B-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
dex	dex	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
bort	bort	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
as	as	IN	B-PP	O	O
salvage	salvage	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
85	85	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
R	R	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
R	R	NN	I-NP	O	O
MM	MM	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
autologous	autologous	JJ	I-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
or	or	CC	O	O	O
conventional	conventional	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
lines	line	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
2	2	CD	B-NP	O	O
.	.	.	O	O	O

Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
seven	seven	CD	I-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
immunomodulatory	immunomodulatory	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
included	include	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
line	line	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
before	before	IN	B-PP	O	O
bort	bort	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
dex	dex	NN	I-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bort	bort	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
dex	dex	NN	I-NP	O	B-Chemical
cycles	cycle	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
6	6	CD	B-NP	O	O
,	,	,	O	O	O
up	up	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
cycles	cycle	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
an	an	DT	B-NP	O	O
intention	intention	NN	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
treat	treat	NN	I-NP	O	O
basis	basis	NN	I-NP	O	O
,	,	,	O	O	O
55	55	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
achieved	achieve	VBD	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
partial	partial	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
19	19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CR	CR	NN	I-NP	B	O
and	and	CC	O	O	O
35	35	CD	B-NP	O	O
%	%	NN	I-NP	O	O
achieved	achieve	VBD	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
very	very	RB	I-NP	O	O
good	good	JJ	I-NP	O	O
partial	partial	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
durations	duration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
,	,	,	O	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
next	next	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
interval	interval	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
8	8	CD	B-NP	O	O
,	,	,	I-NP	O	O
11.2	11.2	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
5.1	5.1	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
relevant	relevant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
78	78	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
grade	grade	NN	B-NP	O	O
II	II	CD	I-NP	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
grade	grade	NN	B-NP	O	O
III	III	CD	I-NP	O	O
,	,	,	O	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
follow	follow	VB	B-VP	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
22	22	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
median	median	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
progression	progression	NN	B-NP	O	O
,	,	,	O	O	O
progression	progression	NN	B-NP	O	O
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
(	(	(	O	O	O
PFS	PFS	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
overall	overall	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
(	(	(	O	O	O
OS	OS	NN	B-NP	B	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
8.9	8.9	CD	B-NP	O	O
,	,	,	I-NP	O	O
8.7	8.7	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
22	22	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Prolonged	Prolonged	JJ	B-NP	O	O
PFS	PFS	NN	I-NP	O	O
and	and	CC	I-NP	O	O
OS	OS	NN	I-NP	B	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
achieving	achieve	VBG	B-VP	O	O
CR	CR	NN	B-NP	B	O
and	and	CC	O	O	O
receiving	receive	VBG	B-VP	O	O
bort	bort	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
dex	dex	NN	I-NP	O	B-Chemical
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
line	line	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Bort	Bort	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
dex	dex	NN	I-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
salvage	salvage	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
MM	MM	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
relapse	relapse	NN	I-NP	O	O
.	.	.	O	O	O

Pubertal	Pubertal	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Bisphenol	Bisphenol	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
increases	increase	VBZ	B-VP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
and	and	CC	O	O	O
decreases	decrease	VBZ	B-VP	O	O
acetylcholinesterase	acetylcholinesterase	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hippocampus	hippocampus	NN	B-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Bisphenol	Bisphenol	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
BPA	BPA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
on	on	IN	B-PP	O	O
neurodevelopment	neurodevelopment	NN	B-NP	O	O
and	and	CC	I-NP	O	O
behaviors	behavior	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
well	well	RB	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Acetylcholinesterase	Acetylcholinesterase	NN	B-NP	O	O
(	(	(	O	O	O
AChE	AChE	NN	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
regulatory	regulatory	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
behavioral	behavioral	JJ	B-NP	O	O
phenotypes	phenotype	NNS	I-NP	O	O
and	and	CC	O	O	O
AChE	AChE	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
BPA	BPA	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
during	during	IN	B-PP	O	O
puberty	puberty	NN	B-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
postnatal	postnatal	JJ	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
PND	PND	NN	B-NP	O	O
)	)	)	O	O	O
35	35	CD	B-NP	O	O
,	,	,	O	O	O
male	male	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
50mg	50mg	CD	B-NP	O	O
BPA	BPA	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
diet	diet	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
35	35	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
PND71	PND71	NN	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
assay	assay	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
plus	plus	CC	O	O	O
maze	maze	NN	B-NP	O	O
(	(	(	O	O	O
EPM	EPM	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
light	light	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dark	dark	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
AChE	AChE	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prefrontal	prefrontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
,	,	,	I-NP	O	O
hypothalamus	hypothalamus	NN	I-NP	O	O
,	,	,	I-NP	O	O
cerebellum	cerebellum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
phenotyping	phenotyping	NN	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
-	-	HYPH	B-VP	O	O
like	like	JJ	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
BPA	BPA	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

AChE	AChE	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
BPA	BPA	NN	B-NP	B	B-Chemical
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
control	control	NN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prefrontal	prefrontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
,	,	,	I-NP	O	O
hypothalamus	hypothalamus	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cerebellum	cerebellum	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
pubertal	pubertal	JJ	B-NP	O	O
BPA	BPA	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
AChE	AChE	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
signaling	signaling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PBE	PBE	NN	B-NP	B	O
induced	induce	VBD	B-VP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
behaviors	behavior	NNS	I-NP	O	O
.	.	.	O	O	O

Biochemical	Biochemical	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Solidago	Solidago	NNP	B-NP	B	O
virgaurea	virgaurea	NNP	I-NP	I	O
extract	extract	NN	I-NP	O	O
on	on	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
CVDs	CVD	NNS	B-NP	O	B-Disease
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
problem	problem	NN	I-NP	O	O
of	of	IN	B-PP	O	O
advanced	advance	VBN	O	B	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
developing	develop	VBG	B-NP	O	O
countries	country	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
world	world	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Solidago	Solidago	NNP	I-NP	B	O
virgaurea	virgaurea	NNP	I-NP	I	O
extract	extract	NN	I-NP	O	O
on	on	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
into	into	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
twice	twice	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
lactate	lactate	NN	I-NP	B	B-Chemical
dehydrogenase	dehydrogenase	NN	I-NP	O	O
,	,	,	O	O	O
creatine	creatine	NN	B-NP	B	B-Chemical
phosphokinase	phosphokinase	NN	I-NP	O	O
,	,	,	O	O	O
alanine	alanine	NN	B-NP	B	B-Chemical
transaminase	transaminase	NN	I-NP	O	O
,	,	,	O	O	O
aspartate	aspartate	NN	B-NP	B	B-Chemical
transaminase	transaminase	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
converting	convert	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
activities	activity	NNS	I-NP	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
triglycerides	triglyceride	NNS	B-NP	B	B-Chemical
,	,	,	O	O	O
free	free	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
fatty	fatty	JJ	I-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
malondialdehyde	malondialdehyde	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
MDA	MDA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
nitric	nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
glutathione	glutathione	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
superoxide	superoxide	NN	I-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
S.	S.	NNP	B-NP	O	O
virgaurea	virgaurea	NNP	I-NP	O	O
extract	extract	NN	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
.	.	.	O	O	O

Captopril	Captopril	NNP	B-NP	B	B-Chemical
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
converting	convert	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
used	use	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
cardioprotective	cardioprotective	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
S.	S.	NNP	B-NP	O	O
virgaurea	virgaurea	NNP	I-NP	O	O
extract	extract	NN	I-NP	O	O
exerts	exert	VBZ	B-VP	O	O
its	its	PRP$	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
by	by	IN	B-PP	O	O
decreasing	decrease	VBG	B-VP	O	O
MDA	MDA	NN	B-NP	B	B-Chemical
level	level	NN	I-NP	O	O
and	and	CC	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
in	in	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
emphasizes	emphasize	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
S.	S.	NNP	B-NP	O	O
virgaurea	virgaurea	NNP	I-NP	O	O
extract	extract	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cardioprotective	cardioprotective	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

"	"	``	O	O	O
Real	Real	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
world	world	NN	I-NP	O	O
"	"	''	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lenalidomide	lenalidomide	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
relapsed	relapse	VBN	B-NP	O	O
/	/	SYM	I-NP	O	O
refractory	refractory	JJ	I-NP	O	O
multiple	multiple	JJ	I-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
practice	practice	NN	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Greek	Greek	NNP	I-NP	O	O
Myeloma	Myeloma	NNP	I-NP	O	B-Disease
Study	Study	NNP	I-NP	O	O
Group	Group	NNP	I-NP	O	O
.	.	.	O	O	O

Lenalidomide	Lenalidomide	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
RD	RD	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
standard	standard	NN	I-NP	O	O
of	of	IN	B-PP	O	O
care	care	NN	B-NP	O	O
for	for	IN	B-PP	O	O
relapsed	relapse	VBN	B-NP	O	O
/	/	SYM	I-NP	O	O
refractory	refractory	JJ	I-NP	O	O
multiple	multiple	JJ	I-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
(	(	(	O	O	O
RRMM	RRMM	NN	B-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limit	VBN	I-VP	O	O
published	publish	VBN	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
"	"	``	I-NP	O	O
real	real	JJ	I-NP	O	O
world	world	NN	I-NP	O	O
"	"	''	O	O	O
(	(	(	O	O	O
RW	RW	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
International	International	NNP	I-NP	O	O
Society	Society	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Pharmacoeconomics	Pharmacoeconomics	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Outcomes	Outcomes	NNP	I-NP	O	O
Research	Research	NNP	I-NP	O	O
definition	definition	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
212	212	CD	B-NP	O	O
RRMM	RRMM	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
RD	RD	NN	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
RW	RW	NN	B-NP	O	O
.	.	.	O	O	O

Objective	Objective	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
PR	PR	NN	I-NP	O	O
(	(	(	O	O	O
partial	partial	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
rate	rate	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
77.4	77.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
complete	complete	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
(	(	(	O	O	O
CR	CR	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
20.2	20.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
best	good	JJS	I-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
2	2	CD	B-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
CR	CR	NN	B-NP	B	O
when	when	WRB	B-ADVP	O	O
RD	RD	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
2nd	2nd	CD	B-NP	O	O
or	or	CC	O	O	O
>	>	JJR	B-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
nd	nd	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
line	line	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
and	and	CC	I-NP	O	O
11	11	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Quality	Quality	NN	B-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
independent	independent	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
lines	line	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapies	therapy	NNS	B-NP	O	O
or	or	CC	O	O	O
previous	previous	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
bortezomib	bortezomib	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
34.4	34.4	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
RD	RD	NN	B-NP	O	B-Chemical
until	until	IN	B-PP	O	O
progression	progression	NN	B-NP	O	O
(	(	(	O	O	O
not	not	RB	B-VP	O	O
reached	reach	VBN	I-VP	O	O
versus	versus	IN	B-PP	O	O
19	19	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Improvement	Improvement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
humoral	humoral	JJ	B-NP	O	O
immunity	immunity	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
responders	responder	NNS	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
achieved	achieve	VBD	B-VP	O	O
stable	stable	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
68.9	68.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
myelosuppression	myelosuppression	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
49.4	49.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
12.7	12.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
needed	need	VBD	B-VP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
.	.	.	O	O	O

Peripheral	Peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
deep	deep	JJ	B-NP	O	B-Disease
vein	vein	NN	I-NP	O	I-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
5.7	5.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
needed	need	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
permanent	permanent	JJ	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
38.9	38.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
16.8	16.8	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Performance	Performance	NN	B-NP	O	O
status	status	NN	I-NP	O	O
(	(	(	O	O	O
PS	PS	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
initial	initial	JJ	B-NP	O	O
lenalidomide	lenalidomide	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
predicted	predict	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
.	.	.	O	O	O

Extra	Extra	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
medullary	medullary	JJ	I-NP	O	O
relapses	relapse	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
3.8	3.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
study	study	NN	I-NP	O	O
confirms	confirm	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
RD	RD	NN	B-NP	O	B-Chemical
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
safe	safe	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
RRMM	RRMM	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
RW	RW	NN	I-NP	O	O
;	;	:	O	O	O
it	it	PRP	B-NP	O	O
produces	produce	VBZ	B-VP	O	O
durable	durable	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
continue	continue	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
till	till	NN	I-NP	O	O
progression	progression	NN	I-NP	O	O
and	and	CC	O	O	O
improves	improve	VBZ	B-VP	O	O
humoral	humoral	JJ	B-NP	O	O
immunity	immunity	NN	I-NP	O	O
even	even	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cytogenetic	cytogenetic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
mesna	mesna	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
combination	combination	NN	I-NP	O	O
on	on	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
rabbit	rabbit	NN	I-NP	O	O
lymphocytes	lymphocyte	NNS	I-NP	O	O
:	:	:	O	O	O
an	an	DT	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
/	/	SYM	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
cytogenetic	cytogenetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Ifosfamide	Ifosfamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
alkylating	alkylate	VBG	I-NP	O	O
nitrogen	nitrogen	NN	I-NP	B	B-Chemical
mustard	mustard	NN	I-NP	I	O
,	,	,	O	O	O
administrated	administrate	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antineoplasmic	antineoplasmic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
intense	intense	JJ	I-NP	O	O
urotoxic	urotoxic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
cystitis	cystitis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
raises	raise	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
requirement	requirement	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
sulfanylethanesulfonate	sulfanylethanesulfonate	NN	B-NP	O	I-Chemical
(	(	(	O	O	O
Mesna	Mesna	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
aiming	aim	VBG	B-VP	O	O
to	to	TO	I-VP	O	O
avoid	avoid	VB	I-VP	O	O
or	or	CC	I-VP	O	O
minimize	minimize	VB	I-VP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

IFO	IFO	NNP	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
Mesna	Mesna	NNP	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
administrated	administrate	VBN	I-VP	O	O
separately	separately	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
rabbit	rabbit	NN	B-NP	O	O
's	's	POS	B-NP	O	O
lymphocytes	lymphocyte	NNS	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
later	later	RB	I-VP	O	O
developed	develop	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Cytogenetic	Cytogenetic	JJ	B-NP	O	O
markers	marker	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
sister	sister	NN	B-NP	O	O
chromatid	chromatid	NN	I-NP	O	O
exchanges	exchange	NNS	I-NP	O	O
(	(	(	O	O	O
SCEs	SCE	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
proliferation	proliferation	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
index	index	NN	I-NP	O	O
(	(	(	O	O	O
PRI	PRI	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Mitotic	Mitotic	JJ	B-NP	O	O
Index	Index	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

Mesna	Mesna	NNP	B-NP	B	B-Chemical
's	's	POS	B-NP	O	O
action	action	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SCEs	SCE	NNS	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SCEs	SCE	NNS	I-NP	O	O
recordings	recording	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
when	when	WRB	B-ADVP	O	O
IFO	IFO	NNP	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Mesna	Mesna	NNP	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
alone	alone	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PRI	PRI	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
,	,	,	O	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
acting	act	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lymphocytes	lymphocyte	NNS	I-NP	O	O
.	.	.	O	O	O

Mesna	Mesna	NNP	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
reduces	reduce	VBZ	B-VP	O	O
IFO	IFO	NNP	B-NP	B	B-Chemical
's	's	POS	B-NP	O	O
genotoxicity	genotoxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
it	it	PRP	B-NP	O	O
acts	act	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytostatic	cytostatic	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
and	and	CC	O	O	O
predictors	predictor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesia	dyskinesia	NN	I-NP	O	B-Disease
among	among	IN	B-PP	O	O
multiethnic	multiethnic	JJ	B-NP	O	O
Malaysians	Malaysian	NNPS	I-NP	O	O
with	with	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
pulsatile	pulsatile	JJ	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PD	PD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
and	and	CC	O	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
predictors	predictor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesia	dyskinesia	NN	I-NP	O	B-Disease
among	among	IN	B-PP	O	O
multiethnic	multiethnic	JJ	B-NP	O	O
Malaysian	Malaysian	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
cross	cross	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
sectional	sectional	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
95	95	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
on	on	IN	B-PP	O	O
uninterrupted	uninterrupted	JJ	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
6	6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
instrument	instrument	NN	I-NP	O	O
used	use	VBN	B-VP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
UPDRS	UPDRS	NNP	I-NP	O	O
questionnaires	questionnaire	VBZ	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
predictors	predictor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
multivariate	multivariate	JJ	B-NP	O	O
logistic	logistic	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
65.6	65.6	CD	B-NP	O	O
+	+	SYM	O	O	O
8.5	8.5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
onset	onset	NN	I-NP	O	O
age	age	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
58.5	58.5	CD	B-NP	O	O
+	+	SYM	O	O	O
9.8	9.8	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
duration	duration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
6	6	CD	B-NP	O	O
(	(	(	O	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
years	year	NNS	B-NP	O	O
.	.	.	O	O	O

Dyskinesia	Dyskinesia	NNP	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
42	42	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
median	median	JJ	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
64.3	64.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
Chinese	Chinese	JJ	B-ADJP	O	O
,	,	,	O	O	O
31	31	CD	B-NP	O	O
%	%	NN	I-NP	O	O
Malays	Malay	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3.7	3.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
Indians	Indian	NNPS	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
ethnic	ethnic	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
had	have	VBD	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
had	have	VBD	B-VP	O	O
lower	low	JJR	B-NP	O	O
onset	onset	NN	I-NP	O	O
age	age	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
longer	long	JJR	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
longer	long	JJR	B-NP	O	O
disease	disease	NN	I-NP	O	O
duration	duration	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
total	total	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
higher	high	JJR	B-NP	O	O
total	total	JJ	I-NP	O	O
UPDRS	UPDRS	NN	I-NP	O	O
scores	score	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.005	0.005	CD	B-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
three	three	CD	I-NP	O	O
significant	significant	JJ	I-NP	O	O
predictors	predictor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
onset	onset	NN	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
total	total	JJ	B-NP	O	O
daily	daily	JJ	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesia	dyskinesia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
significant	significant	JJ	I-NP	O	O
predictors	predictor	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
daily	daily	JJ	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
onset	onset	NN	B-NP	O	O
age	age	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
unexpected	unexpected	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
AL	AL	JJ	B-NP	O	B-Disease
amyloidosis	amyloidosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Proteinuria	Proteinuria	NNP	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
expected	expected	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
in	in	IN	B-PP	O	O
transplant	transplant	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
mammalian	mammalian	JJ	B-NP	O	O
target	target	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rapamycin	rapamycin	NN	B-NP	B	B-Chemical
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
mTOR	mTOR	NN	B-NP	O	O
-	-	HYPH	O	O	O
i	i	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
clinical	clinical	JJ	B-NP	O	O
suspicion	suspicion	NN	I-NP	O	O
should	should	MD	B-VP	O	O
always	always	RB	I-VP	O	O
be	be	VB	I-VP	O	O
supported	support	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
histological	histological	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
alternate	alternate	JJ	I-NP	O	O
diagnoses	diagnosis	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
acute	acute	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
rejection	rejection	NN	I-NP	O	O
,	,	,	O	O	O
interstitial	interstitial	JJ	B-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
tubular	tubular	JJ	B-NP	O	O
atrophy	atrophy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
or	or	CC	O	O	O
recurrent	recurrent	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
de	de	FW	I-NP	O	O
novo	novo	FW	I-NP	O	O
glomerulopathy	glomerulopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
unexpected	unexpected	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amyloidosis	amyloidosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
monoclonal	monoclonal	JJ	I-NP	O	O
gammapathy	gammapathy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
undetermined	undetermined	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
conversion	conversion	NN	B-NP	O	O
from	from	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
everolimus	everolimus	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

An	An	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
persons	person	NNS	I-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
tenofovir	tenofovir	VB	I-VP	B	B-Chemical
disoproxil	disoproxil	NN	B-NP	I	I-Chemical
fumarate	fumarate	NN	I-NP	I	I-Chemical
:	:	:	O	O	O
an	an	DT	B-NP	O	O
examination	examination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
database	database	NN	I-NP	O	O
(	(	(	O	O	O
MHRA	MHRA	NN	B-NP	O	O
database	database	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
tenofovir	tenofovir	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
syndromes	syndrome	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
mechanistic	mechanistic	JJ	O	O	O
and	and	CC	O	O	O
randomised	randomise	VBD	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
exact	exact	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
uncertain	uncertain	JJ	B-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
undertook	undertake	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
descriptive	descriptive	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Yellow	Yellow	NNP	B-NP	O	O
Card	Card	NNP	I-NP	O	O
records	record	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
407	407	CD	B-NP	O	O
HIV	HIV	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
persons	person	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
tenofovir	tenofovir	NN	B-NP	B	B-Chemical
disoproxil	disoproxil	NN	I-NP	I	I-Chemical
fumarate	fumarate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
TDF	TDF	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
and	and	CC	O	O	O
submitted	submit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
Medicines	Medicines	NNP	I-NP	O	O
and	and	CC	O	O	O
Healthcare	Healthcare	NNP	B-NP	O	O
Products	Products	NNP	I-NP	O	O
Regulatory	Regulatory	NNP	I-NP	O	O
Agency	Agency	NNP	I-NP	O	O
(	(	(	O	O	O
MHRA	MHRA	NN	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Reports	Report	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
satisfy	satisfy	VBP	B-VP	O	O
defined	define	VBN	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
classified	classify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
kidney	kidney	NN	B-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
Fanconi	Fanconi	NNP	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
407	407	CD	I-NP	O	O
Yellow	Yellow	NNP	I-NP	O	O
Card	Card	NNP	I-NP	O	O
records	record	NNS	I-NP	O	O
analysed	analyse	VBD	B-VP	O	O
,	,	,	O	O	O
106	106	CD	B-NP	O	O
satisfied	satisfied	JJ	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
TDF	TDF	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
kidney	kidney	NN	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
53	53	CD	B-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
features	feature	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
,	,	,	O	O	O
35	35	CD	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
features	feature	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
18	18	CD	B-NP	O	O
(	(	(	O	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
Fanconi	Fanconi	NNP	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
TDF	TDF	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
316	316	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
interquartile	interquartile	JJ	B-NP	O	O
range	range	NN	I-NP	O	O
120	120	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
740	740	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hospitalisation	hospitalisation	NN	B-NP	O	O
for	for	IN	B-PP	O	O
TDF	TDF	NN	B-NP	B	B-Chemical
kidney	kidney	NN	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
high	high	JJ	B-ADJP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
amongst	amongst	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
features	feature	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Fanconi	Fanconi	NNP	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
syndromes	syndrome	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
population	population	NN	I-NP	O	O
series	series	NN	I-NP	O	O
mirrors	mirror	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
reported	report	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
randomised	randomise	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Cessation	Cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
TDF	TDF	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
complete	complete	JJ	B-NP	O	O
restoration	restoration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
up	up	RP	B-PRT	O	O
half	half	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

Incidence	Incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
high	high	JJ	B-ADJP	O	O
even	even	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
population	population	NN	I-NP	O	O
without	without	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
Postoperative	Postoperative	JJ	B-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
recognized	recognize	VBN	I-NP	O	O
complication	complication	NN	I-NP	O	O
in	in	IN	B-PP	O	O
populations	population	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
postoperative	postoperative	JJ	I-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
population	population	NN	I-NP	O	O
without	without	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
ICU	ICU	NN	I-NP	O	O
for	for	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
after	after	IN	B-PP	O	O
elective	elective	JJ	B-NP	O	O
major	major	JJ	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
secondary	secondary	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
investigated	investigate	VBN	B-VP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
eventual	eventual	JJ	B-NP	O	O
independent	independent	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
among	among	IN	B-PP	O	O
demographic	demographic	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
and	and	CC	O	O	O
anesthetic	anesthetic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
used	use	VBN	B-VP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
An	An	DT	B-NP	O	O
observational	observational	JJ	I-NP	O	O
,	,	,	I-NP	O	O
prospective	prospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
cohort	cohort	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
ICU	ICU	NN	I-NP	O	O
within	within	IN	B-PP	O	O
and	and	CC	B-PP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
24	24	CD	I-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
.	.	.	O	O	O

Exclusion	Exclusion	NN	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
any	any	DT	B-NP	O	O
preexisting	preexisting	JJ	I-NP	O	O
predisposing	predispose	VBG	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
delirium	delirium	NN	B-NP	O	B-Disease
or	or	CC	O	O	O
other	other	JJ	B-ADJP	O	O
potentially	potentially	RB	B-VP	O	O
confounding	confound	VBG	I-VP	O	O
neurological	neurological	JJ	B-NP	O	B-Disease
dysfunctions	dysfunction	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
daily	daily	RB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
confusion	confusion	NN	I-NP	O	B-Disease
assessment	assessment	NN	I-NP	O	O
method	method	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ICU	ICU	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
.	.	.	O	O	O

Early	Early	RB	B-NP	O	O
postoperative	postoperative	JJ	I-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	I-Disease
incidence	incidence	NN	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
then	then	RB	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
three	three	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
According	Accord	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
confusion	confusion	NN	I-NP	O	O
assessment	assessment	NN	I-NP	O	O
method	method	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ICU	ICU	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
,	,	,	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
postoperative	postoperative	JJ	I-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thiopentone	thiopentone	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
eight	eight	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
higher	high	JJR	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
delirium	delirium	NN	B-NP	O	B-Disease
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
57.1	57.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

7.1	7.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
RR	RR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8.0	8.0	CD	B-NP	O	O
,	,	,	O	O	O
X2	X2	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
4.256	4.256	CD	B-NP	O	O
;	;	:	O	O	O
df	df	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1	1	CD	B-NP	O	O
;	;	:	O	O	O
0.05	0.05	CD	B-NP	O	O
<	<	JJR	I-NP	O	O
p	p	NN	I-NP	O	O
<	<	JJR	I-NP	O	O
0.02	0.02	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
early	early	JJ	B-NP	O	O
postoperative	postoperative	JJ	I-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
very	very	RB	I-NP	O	O
common	common	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
after	after	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
population	population	NN	I-NP	O	O
without	without	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Thiopentone	Thiopentone	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
independently	independently	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
relative	relative	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
long	long	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
lasting	last	VBG	B-VP	O	O
depressive	depressive	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Methamphetamine	Methamphetamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
METH	METH	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
triggers	trigger	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
disruption	disruption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
monoaminergic	monoaminergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
and	and	CC	I-NP	O	O
METH	METH	NN	I-NP	B	B-Chemical
abuse	abuse	NN	I-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
negative	negative	JJ	B-NP	O	O
emotional	emotional	JJ	I-NP	O	O
states	state	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
depressive	depressive	JJ	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
currently	currently	RB	B-ADJP	O	O
unknown	unknown	JJ	I-ADJP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
METH	METH	NN	B-NP	B	B-Chemical
also	also	RB	B-ADVP	O	O
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
long	long	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
lasting	last	VBG	B-VP	O	O
depressive	depressive	JJ	B-NP	O	B-Disease
phenotype	phenotype	NN	I-NP	O	O
and	and	CC	O	O	O
persistent	persistent	JJ	B-NP	O	O
monoaminergic	monoaminergic	JJ	I-NP	O	O
deficits	deficit	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
now	now	RB	B-ADVP	O	O
assessed	assess	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
depressive	depressive	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
periods	period	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
high	high	JJ	I-NP	O	O
METH	METH	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

METH	METH	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
motor	motor	NN	I-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
procedural	procedural	JJ	B-NP	O	O
memory	memory	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
as	as	IN	B-SBAR	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
swimming	swim	VBG	B-VP	O	O
speed	speed	NN	B-NP	O	O
and	and	CC	I-NP	O	O
escape	escape	NN	I-NP	O	O
latency	latency	NN	I-NP	O	O
to	to	TO	B-VP	O	O
find	find	VB	I-VP	O	O
the	the	DT	B-NP	O	O
platform	platform	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cued	cue	VBN	I-NP	O	O
version	version	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
water	water	NN	I-NP	B	O
maze	maze	NN	I-NP	O	O
task	task	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
METH	METH	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
immobility	immobility	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tail	tail	NN	I-NP	O	O
suspension	suspension	NN	I-NP	O	O
test	test	NN	I-NP	O	O
at	at	IN	B-PP	O	O
3	3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
49	49	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
depressive	depressive	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
profile	profile	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
METH	METH	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
frontostriatal	frontostriatal	JJ	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
neurotransmission	neurotransmission	NN	I-NP	O	O
,	,	,	O	O	O
indicated	indicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
DOPAC	DOPAC	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
HVA	HVA	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
tyrosine	tyrosine	NN	B-NP	B	B-Chemical
hydroxylase	hydroxylase	NN	I-NP	O	O
and	and	CC	I-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
observed	observe	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
both	both	CC	B-NP	O	O
3	3	CD	I-NP	O	O
and	and	CC	I-NP	O	O
49	49	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
parallel	parallel	NN	B-NP	O	O
,	,	,	O	O	O
another	another	DT	B-NP	O	O
neurochemical	neurochemical	JJ	I-NP	O	O
feature	feature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depression	depression	NN	B-NP	O	B-Disease
-	-	HYPH	O	O	O
-	-	HYPH	O	O	O
astroglial	astroglial	JJ	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
-	-	HYPH	O	O	O
-	-	SYM	B-NP	O	O
was	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cortex	cortex	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
striatal	striatal	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
astrocytic	astrocytic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
marker	marker	NN	I-NP	O	O
,	,	,	O	O	O
glial	glial	JJ	B-NP	O	O
fibrillary	fibrillary	JJ	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
transiently	transiently	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
that	that	IN	B-ADVP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
METH	METH	NN	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
long	long	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
lasting	last	VBG	B-VP	O	O
depressive	depressive	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
persistent	persistent	JJ	I-NP	O	O
disruption	disruption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
frontostriatal	frontostriatal	JJ	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
homoeostasis	homoeostasis	NN	I-NP	O	O
.	.	.	O	O	O

Linezolid	Linezolid	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
optic	optic	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Many	Many	JJ	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
antimicrobials	antimicrobial	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
ocular	ocular	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
especially	especially	RB	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
multidrug	multidrug	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
one	one	CD	I-NP	O	O
drug	drug	NN	I-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
loss	loss	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
vision	vision	NN	B-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
linezolid	linezolid	JJ	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
45	45	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
second	second	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	O	O	O
tuberculous	tuberculous	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
linezolid	linezolid	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
ethambutol	ethambutol	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
extensively	extensively	RB	B-NP	O	B-Disease
drug	drug	NN	I-NP	O	I-Disease
-	-	HYPH	B-NP	O	I-Disease
resistant	resistant	JJ	I-NP	O	I-Disease
tuberculosis	tuberculosis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
XDR	XDR	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
TB	TB	NN	I-NP	O	I-Disease
)	)	)	O	O	O
presented	present	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
us	us	PRP	B-NP	O	O
with	with	IN	B-PP	O	O
painless	painless	JJ	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
loss	loss	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
vision	vision	NN	B-NP	O	I-Disease
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
.	.	.	O	O	O

Color	Color	NN	B-NP	O	O
vision	vision	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
defective	defective	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
fundus	fundus	NN	I-NP	O	O
examination	examination	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
optic	optic	JJ	B-NP	O	B-Disease
disc	disc	NN	I-NP	O	I-Disease
edema	edema	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
.	.	.	O	O	O

Ethambutol	Ethambutol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
toxic	toxic	JJ	I-NP	O	B-Disease
optic	optic	JJ	I-NP	O	I-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
suspected	suspect	VBN	I-VP	O	O
and	and	CC	O	O	O
tablet	tablet	NN	B-NP	O	O
ethambutol	ethambutol	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

Deterioration	Deterioration	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
vision	vision	NN	B-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
despite	despite	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Discontinuation	Discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
linezolid	linezolid	NN	B-NP	B	B-Chemical
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
marked	marked	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vision	vision	NN	B-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
report	report	NN	I-NP	O	O
emphasizes	emphasize	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
linezolid	linezolid	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Resuscitation	Resuscitation	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
both	both	CC	O	O	O
in	in	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
newborn	newborn	JJ	B-NP	O	O
piglets	piglet	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
emulsion	emulsion	NN	I-NP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
both	both	DT	O	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
yet	yet	RB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anaesthetic	anaesthetic	JJ	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
(	(	(	O	O	O
LAST	LAST	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Newborn	Newborn	JJ	B-NP	O	O
piglets	piglet	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
until	until	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
collapse	collapse	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
.	.	.	O	O	O

Standard	Standard	JJ	B-NP	O	O
cardiopulmonary	cardiopulmonary	JJ	I-NP	O	O
resuscitation	resuscitation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
started	start	VBN	I-VP	O	O
and	and	CC	O	O	O
electrocardiogram	electrocardiogram	NN	B-NP	O	O
(	(	(	O	O	O
ECG	ECG	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
fibrillation	fibrillation	NN	B-NP	O	B-Disease
,	,	,	O	O	O
or	or	CC	O	O	O
QRS	QRS	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
.	.	.	O	O	O

Piglets	Piglet	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
then	then	RB	I-VP	O	O
randomly	randomly	RB	I-VP	O	O
allocated	allocate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
four	four	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
control	control	NN	B-NP	O	O
(	(	(	O	O	O
saline	saline	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
Intralipid	Intralipid	NN	B-NP	O	O
(	(	(	O	O	O
)	)	)	O	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Intralipd	Intralipd	NNP	B-NP	O	O
plus	plus	CC	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Resuscitation	Resuscitation	NN	B-NP	O	O
continued	continue	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
or	or	CC	B-PP	O	O
until	until	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
return	return	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
circulation	circulation	NN	I-NP	O	O
(	(	(	O	O	O
ROSC	ROSC	NN	B-NP	O	O
)	)	)	O	O	O
accompanied	accompany	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
or	or	CC	O	O	O
superior	superior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
baseline	baseline	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
normal	normal	JJ	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
ROSC	ROSC	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
only	only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
piglets	piglet	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treated	treat	VBN	I-NP	O	O
piglets	piglet	NNS	I-NP	O	O
.	.	.	O	O	O

Mortality	Mortality	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
significantly	significantly	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
three	three	CD	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
zero	zero	CD	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Intralipid	Intralipid	NN	I-NP	O	O
only	only	RB	B-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
14	14	CD	B-NP	O	O
and	and	CC	I-NP	O	O
17	17	CD	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
plus	plus	CC	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Lipid	Lipid	NN	B-NP	O	O
emulsion	emulsion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
were	be	VBD	B-VP	O	O
equally	equally	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
achieving	achieve	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
return	return	NN	I-NP	O	O
to	to	TO	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
circulation	circulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LAST	LAST	NN	B-NP	O	O
.	.	.	O	O	O

Epinephrine	Epinephrine	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
emulsion	emulsion	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Incidence	Incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
and	and	CC	O	O	O
postoperative	postoperative	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
count	count	NN	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
graft	graft	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
cohort	cohort	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Thrombocytopenia	Thrombocytopenia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
end	end	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
disorder	disorder	NN	I-NP	O	O
caused	cause	VBD	B-VP	O	O
mainly	mainly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
portal	portal	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
,	,	,	O	O	O
low	low	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thrombopoetin	thrombopoetin	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
endotoxemia	endotoxemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
impact	impact	NN	I-NP	O	O
of	of	IN	B-PP	O	O
immune	immune	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
mediated	mediate	VBN	I-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
(	(	(	O	O	O
HIT	HIT	NN	B-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
)	)	)	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
yet	yet	RB	I-VP	O	O
understood	understand	VBN	I-VP	O	O
,	,	,	O	O	O
with	with	IN	B-SBAR	O	O
few	few	JJ	B-NP	O	O
literature	literature	NN	I-NP	O	O
citations	citation	NNS	I-NP	B	O
reporting	report	VBG	B-VP	O	O
contradictory	contradictory	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
perioperative	perioperative	JJ	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
and	and	CC	O	O	O
determine	determine	VB	B-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
HIT	HIT	NN	I-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
records	record	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
205	205	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
adult	adult	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
full	full	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
size	size	NN	I-NP	O	O
liver	liver	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
2006	2006	CD	I-NP	O	O
and	and	CC	O	O	O
December	December	NNP	B-NP	O	O
2010	2010	CD	I-NP	O	O
due	due	IN	B-ADVP	O	O
to	to	TO	B-VP	O	O
end	end	VB	I-VP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
or	or	CC	O	O	I-Disease
malignant	malignant	JJ	B-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Preoperative	Preoperative	JJ	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
count	count	NN	I-NP	O	O
,	,	,	O	O	O
postoperative	postoperative	JJ	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelets	platelet	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
155	155	CD	B-NP	O	O
(	(	(	O	O	O
75.6	75.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
205	205	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
before	before	IN	B-PP	O	O
transplantation	transplantation	NN	B-NP	O	O
,	,	,	O	O	O
significantly	significantly	RB	B-VP	O	O
influenced	influence	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Model	Model	NN	B-NP	O	O
of	of	IN	B-PP	O	O
End	End	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
Stage	Stage	NN	I-NP	O	I-Disease
Liver	Liver	NN	I-NP	O	I-Disease
Disease	Disease	NN	I-NP	O	I-Disease
score	score	NN	I-NP	O	O
and	and	CC	O	O	O
liver	liver	NN	B-NP	O	B-Disease
cirrhosis	cirrhosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
count	count	NN	I-NP	O	O
exceeded	exceed	VBD	B-VP	O	O
100,000	100,000	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
uL	uL	NN	I-NP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
193	193	CD	B-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
medium	medium	NN	I-NP	O	O
of	of	IN	B-PP	O	O
7	7	CD	B-NP	O	O
d	d	NN	I-NP	O	O
.	.	.	O	O	O

Regarding	Regard	VBG	B-VP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
II	II	CD	I-NP	O	I-Disease
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
four	four	CD	B-NP	O	O
(	(	(	O	O	O
1.95	1.95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
background	background	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
end	end	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
hepatic	hepatic	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
about	about	RB	B-NP	O	O
1.95	1.95	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
rare	rare	JJ	B-ADJP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
further	far	JJR	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
type	type	NN	I-NP	O	I-Disease
II	II	CD	I-NP	O	I-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
prophylactic	prophylactic	JJ	I-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
molecular	molecular	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
after	after	IN	B-PP	O	O
normalization	normalization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
count	count	NN	I-NP	O	O
.	.	.	O	O	O

Takotsubo	Takotsubo	NN	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
or	or	CC	O	O	O
apical	apical	JJ	B-NP	O	B-Disease
ballooning	ballooning	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
)	)	)	O	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Zolmitriptan	Zolmitriptan	NNP	B-NP	B	B-Chemical
.	.	.	O	O	O

Takotsubo	Takotsubo	NN	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
TS	TS	NN	B-NP	B	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
also	also	RB	B-VP	O	O
known	know	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
broken	broken	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricle	ventricle	NN	I-NP	O	O
apical	apical	JJ	I-NP	O	O
ballooning	ballooning	NN	I-NP	O	O
with	with	IN	B-PP	O	O
elevated	elevated	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
biomarkers	biomarker	NNS	I-NP	O	O
and	and	CC	O	O	O
electrocardiographic	electrocardiographic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
suggestive	suggestive	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
coronary	coronary	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
ST	ST	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
segment	segment	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
,	,	,	O	O	O
T	T	NN	B-NP	O	O
wave	wave	NN	I-NP	O	O
inversions	inversion	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
pathologic	pathologic	JJ	B-NP	O	O
Q	Q	NN	I-NP	O	O
waves	wave	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
54	54	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
medical	medical	JJ	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mitral	mitral	JJ	B-NP	O	B-Disease
valve	valve	NN	I-NP	O	I-Disease
prolapse	prolapse	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
migraines	migraine	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
substernal	substernal	JJ	B-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
1	1	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
ST	ST	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
segment	segment	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
leads	lead	NNS	B-NP	O	O
II	II	CD	B-NP	O	O
,	,	,	I-NP	O	O
III	III	CD	I-NP	O	O
,	,	,	O	O	O
aVF	aVF	NN	B-NP	O	O
,	,	,	O	O	O
V5	V5	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
V6	V6	NN	B-NP	O	O
and	and	CC	O	O	O
positive	positive	JJ	B-NP	O	O
troponin	troponin	NN	I-NP	O	O
I	I	CD	I-NP	O	O
.	.	.	O	O	O

Emergent	Emergent	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
angiogram	angiogram	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
normal	normal	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
moderately	moderately	RB	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
wall	wall	NN	B-NP	O	O
motion	motion	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
TS	TS	NN	B-NP	B	B-Disease
.	.	.	O	O	O

Detailed	Detailed	JJ	B-NP	O	O
history	history	NN	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
took	take	VBD	B-VP	O	O
zolmitriptan	zolmitriptan	NN	B-NP	B	B-Chemical
sparingly	sparingly	RB	B-ADVP	O	O
only	only	RB	O	O	O
when	when	WRB	B-ADVP	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
migraines	migraine	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

But	But	CC	O	O	O
before	before	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
event	event	NN	I-NP	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
zolmitriptan	zolmitriptan	NN	B-NP	B	B-Chemical
2	2	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
daily	daily	RB	I-NP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
persistent	persistent	JJ	I-NP	O	O
migraine	migraine	NN	I-NP	O	B-Disease
headache	headache	NN	I-NP	O	I-Disease
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
otherwise	otherwise	RB	B-ADVP	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
she	she	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
quite	quite	RB	B-ADJP	O	O
active	active	JJ	I-ADJP	O	O
,	,	,	O	O	O
rides	ride	NNS	B-NP	O	O
horses	horse	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
does	do	VBZ	B-VP	O	O
show	show	VB	I-VP	O	O
jumping	jump	VBG	B-VP	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
limitations	limitation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
physical	physical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
recent	recent	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
or	or	CC	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
migrainosus	migrainosus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Extensive	Extensive	JJ	B-NP	O	O
literature	literature	NN	I-NP	O	O
search	search	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
vasospasm	vasospasm	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
zolmitriptan	zolmitriptan	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TS	TS	NN	B-NP	B	B-Disease
.	.	.	O	O	O

Depression	Depression	NN	B-NP	O	B-Disease
,	,	,	O	O	O
impulsiveness	impulsiveness	NN	B-NP	O	B-Disease
,	,	,	O	O	O
sleep	sleep	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
memory	memory	NN	B-NP	O	O
in	in	IN	B-PP	O	O
past	past	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
present	present	JJ	I-NP	O	O
polydrug	polydrug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
3,4	3,4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
MDMA	MDMA	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
ecstasy	ecstasy	JJ	B-ADJP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

RATIONALE	RATIONALE	NN	B-NP	O	O
:	:	:	O	O	O
Ecstasy	Ecstasy	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3,4	3,4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	NN	I-NP	I	I-Chemical
,	,	,	I-NP	O	O
MDMA	MDMA	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
worldwide	worldwide	RB	I-NP	O	O
recreational	recreational	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abuse	abuse	NN	B-NP	O	O
.	.	.	O	O	O

Unfortunately	Unfortunately	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
investigating	investigate	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
psychological	psychological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
inconsistent	inconsistent	JJ	B-ADJP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
largest	large	JJS	I-NP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
in	in	IN	B-PP	O	O
sample	sample	NN	B-NP	O	O
size	size	NN	I-NP	O	O
and	and	CC	I-NP	O	O
5HT	5HT	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
behaviors	behavior	NNS	I-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
to	to	TO	B-VP	O	O
compare	compare	VB	I-VP	O	O
present	present	JJ	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
past	past	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
an	an	DT	B-NP	O	O
abstinence	abstinence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
to	to	TO	B-VP	O	O
include	include	VB	I-VP	O	O
robust	robust	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
recreational	recreational	JJ	I-NP	O	O
substances	substance	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
sample	sample	NN	I-NP	O	O
of	of	IN	B-PP	O	O
997	997	CD	B-NP	O	O
participants	participant	NNS	I-NP	O	O
(	(	(	O	O	O
52	52	CD	B-NP	O	O
%	%	NN	I-NP	O	O
male	male	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
recruited	recruit	VBN	I-VP	B	O
to	to	TO	B-PP	O	O
four	four	CD	B-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
drug	drug	NN	B-NP	O	O
(	(	(	O	O	O
ND	ND	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
/	/	SYM	O	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
AN	AN	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
cannabis	cannabis	NN	B-NP	O	B-Chemical
/	/	SYM	I-NP	O	O
alcohol	alcohol	NN	I-NP	B	B-Chemical
/	/	SYM	O	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CAN	CAN	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
polydrug	polydrug	NN	I-NP	O	O
(	(	(	O	O	O
PD	PD	NN	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
two	two	CD	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
polydrug	polydrug	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
present	present	JJ	B-ADJP	O	O
(	(	(	O	O	O
MDMA	MDMA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
past	past	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
(	(	(	O	O	O
EX	EX	NN	B-NP	O	O
-	-	HYPH	O	O	O
MDMA	MDMA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Participants	Participant	NNS	B-NP	O	O
completed	complete	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
history	history	NN	I-NP	O	O
questionnaire	questionnaire	NN	I-NP	O	O
,	,	,	O	O	O
Beck	Beck	NNP	B-NP	O	O
Depression	Depression	NNP	I-NP	O	B-Disease
Inventory	Inventory	NNP	I-NP	O	O
,	,	,	O	O	O
Barratt	Barratt	NNP	B-NP	O	O
Impulsiveness	Impulsiveness	NNP	I-NP	O	B-Disease
Scale	Scale	NNP	I-NP	O	O
,	,	,	O	O	O
Pittsburgh	Pittsburgh	NNP	B-NP	O	O
Sleep	Sleep	NNP	I-NP	O	O
Quality	Quality	NNP	I-NP	O	O
Index	Index	NNP	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Wechsler	Wechsler	NNP	B-NP	O	O
Memory	Memory	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
-	-	HYPH	O	O	O
Revised	Revise	VBN	B-VP	O	O
which	which	WDT	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
total	total	NN	B-NP	O	O
,	,	,	O	O	O
provided	provide	VBN	B-PP	O	O
13	13	CD	B-NP	O	O
psychometric	psychometric	JJ	I-NP	O	O
measures	measure	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
While	While	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
CAN	CAN	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
PD	PD	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
tended	tend	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
record	record	VB	I-VP	O	O
greater	great	JJR	B-NP	O	O
deficits	deficit	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
controls	control	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
MDMA	MDMA	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
EX	EX	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
MDMA	MDMA	NN	I-NP	B	B-Chemical
groups	group	NNS	I-NP	O	O
recorded	record	VBD	B-VP	O	O
greater	great	JJR	B-NP	O	O
deficits	deficit	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
ten	ten	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
13	13	CD	I-NP	O	O
psychometric	psychometric	JJ	I-NP	O	O
measures	measure	NNS	I-NP	O	O
.	.	.	O	O	O

Strikingly	Strikingly	RB	B-ADVP	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
abstinence	abstinence	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
,	,	,	O	O	O
4.98	4.98	CD	B-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
9	9	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
past	past	IN	B-PP	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
few	few	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
.	.	.	O	O	O

Compared	Compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
present	present	JJ	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
past	past	JJ	I-NP	O	O
users	user	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ten	ten	CD	B-NP	O	O
measures	measure	NNS	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
measures	measure	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
improvement	improvement	NN	B-NP	O	O
on	on	IN	B-PP	O	O
just	just	RB	B-NP	O	O
one	one	CD	I-NP	O	O
measure	measure	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Given	Give	VBN	B-VP	O	O
this	this	DT	B-NP	O	O
record	record	NN	I-NP	O	O
of	of	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
memory	memory	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
depression	depression	NN	B-NP	O	B-Disease
,	,	,	O	O	O
impulsiveness	impulsiveness	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
sleep	sleep	NN	B-NP	O	B-Disease
disturbance	disturbance	NN	I-NP	O	I-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prognosis	prognosis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
generation	generation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
for	for	IN	B-PP	O	O
concern	concern	NN	B-NP	O	O
.	.	.	O	O	O

Association	Association	NN	B-NP	O	O
of	of	IN	B-PP	O	O
common	common	JJ	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
variants	variant	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HOMER1	HOMER1	NN	B-NP	O	O
gene	gene	NN	I-NP	O	O
with	with	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Levodopa	Levodopa	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
effective	effective	JJ	I-NP	O	O
symptomatic	symptomatic	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
its	its	PRP$	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
could	could	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
motor	motor	NN	B-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
,	,	,	O	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
visual	visual	JJ	B-NP	O	B-Disease
hallucinations	hallucination	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

HOMER1	HOMER1	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
protein	protein	NN	I-NP	O	O
with	with	IN	B-PP	O	O
pivotal	pivotal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glutamate	glutamate	NN	B-NP	B	B-Chemical
transmission	transmission	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigates	investigate	VBZ	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
polymorphisms	polymorphism	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HOMER1	HOMER1	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
promoter	promoter	NN	I-NP	O	O
region	region	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
205	205	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
idiopathic	idiopathic	JJ	B-NP	O	B-Disease
Parkinson	Parkinson	NNP	I-NP	O	I-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
genotyped	genotype	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
rs4704559	rs4704559	NN	B-NP	O	O
,	,	,	I-NP	O	O
rs10942891	rs10942891	NN	I-NP	O	O
and	and	CC	I-NP	O	O
rs4704560	rs4704560	NN	I-NP	O	O
by	by	IN	B-PP	O	O
allelic	allelic	JJ	B-NP	O	O
discrimination	discrimination	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Taqman	Taqman	NN	B-NP	O	O
assays	assay	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rs4704559	rs4704559	NN	I-NP	O	O
G	G	NN	I-NP	O	O
allele	allele	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
prevalence	prevalence	NN	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
(	(	(	O	O	O
PR	PR	NN	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
0.615	0.615	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
CI	CI	NN	B-NP	O	O
)	)	)	O	O	O
0.426	0.426	CD	B-NP	O	O
-	-	HYPH	O	O	O
0.887	0.887	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.009	0.009	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
visual	visual	JJ	B-NP	O	B-Disease
hallucinations	hallucination	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
PR	PR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.515	0.515	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
0.295	0.295	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
0.899	0.899	CD	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.020	0.020	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
HOMER1	HOMER1	NN	B-NP	O	O
rs4704559	rs4704559	NN	I-NP	O	O
G	G	NN	I-NP	O	O
allele	allele	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Crocin	Crocin	NN	B-NP	B	B-Chemical
improves	improve	VBZ	B-VP	O	O
lipid	lipid	NN	B-NP	O	O
dysregulation	dysregulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
subacute	subacute	JJ	B-NP	O	O
diazinon	diazinon	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
through	through	IN	B-PP	O	O
ERK1	ERK1	NN	B-NP	O	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
pathway	pathway	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

INTRODUCTION	INTRODUCTION	NN	B-NP	O	O
:	:	:	O	O	O
Diazinon	Diazinon	NNP	B-NP	B	B-Chemical
Yis	Yis	NNP	I-NP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
broadly	broadly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
organophosphorus	organophosphorus	NN	I-NP	O	B-Chemical
insecticides	insecticide	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
agriculture	agriculture	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
interfere	interfere	VB	I-VP	O	O
with	with	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
hypolipidemic	hypolipidemic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
crocin	crocin	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Earlier	Early	JJR	B-NP	O	O
studies	study	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Extracellular	Extracellular	JJ	B-NP	O	O
signal	signal	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
regulated	regulate	VBN	I-NP	O	O
kinase	kinase	NN	I-NP	O	O
(	(	(	O	O	O
ERK	ERK	NN	B-NP	O	O
)	)	)	O	O	O
pathways	pathway	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
density	density	NN	I-NP	O	O
lipoprotein	lipoprotein	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
(	(	(	O	O	O
LDLr	LDLr	NN	B-NP	O	O
)	)	)	O	O	O
expression	expression	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
,	,	,	O	O	O
ERK	ERK	NN	B-NP	O	O
and	and	CC	O	O	O
LDLr	LDLr	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
subacute	subacute	JJ	B-NP	O	O
diazinon	diazinon	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
ameliorating	ameliorate	VBG	B-VP	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
crocin	crocin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
disturbed	disturbed	JJ	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
homeostasis	homeostasis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
24	24	CD	B-NP	O	O
Rats	Rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
4	4	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
and	and	CC	O	O	O
received	receive	VBD	B-VP	O	O
following	follow	VBG	B-PP	O	O
treatments	treatment	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
;	;	:	O	O	O
Corn	Corn	NN	B-NP	B	O
oil	oil	NN	I-NP	I	O
(	(	(	O	O	O
control	control	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
15mg	15mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
,	,	,	O	O	O
orally	orally	RB	B-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
crocin	crocin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
12.5	12.5	CD	B-NP	O	O
and	and	CC	O	O	O
25mg	25mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
,	,	,	O	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cholesterol	cholesterol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
LDL	LDL	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
mRNA	mRNA	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
LDLr	LDLr	NN	B-NP	O	O
and	and	CC	I-NP	O	O
ERK1	ERK1	NN	I-NP	O	O
/	/	SYM	O	O	O
2	2	CD	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
protein	protein	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
activated	activated	JJ	I-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ERK1	ERK1	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
liver	liver	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Western	Western	JJ	B-NP	O	O
blotting	blotting	NN	I-NP	O	O
and	and	CC	O	O	O
quantitative	quantitative	JJ	B-NP	O	O
real	real	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
polymerase	polymerase	NN	I-NP	O	O
chain	chain	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
subacute	subacute	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-VP	O	O
diazinon	diazinon	VB	I-VP	B	B-Chemical
significantly	significantly	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cholesterol	cholesterol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
LDL	LDL	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-NP	O	O
diazinon	diazinon	NN	I-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
ERK1	ERK1	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
protein	protein	NN	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
and	and	CC	O	O	O
LDLr	LDLr	NN	B-NP	O	O
transcript	transcript	NN	I-NP	O	O
.	.	.	O	O	O

Crocin	Crocin	NN	B-NP	B	B-Chemical
reduced	reduce	VBD	B-VP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ERK	ERK	NN	B-NP	O	O
activation	activation	NN	I-NP	O	O
and	and	CC	O	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hyperlipemia	hyperlipemia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
LDLr	LDLr	NN	B-NP	O	O
transcript	transcript	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Crocin	Crocin	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
protective	protective	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperlipemia	hyperlipemia	NN	I-NP	O	B-Disease
through	through	IN	B-PP	O	O
modulating	modulating	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ERK	ERK	NN	B-NP	O	O
pathway	pathway	NN	I-NP	O	O
and	and	CC	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LDLr	LDLr	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
P	P	NN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
active	active	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
relapsed	relapse	VBN	B-NP	O	O
Hodgkin	Hodgkin	NN	I-NP	O	B-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Hodgkin	Hodgkin	NN	B-NP	O	B-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
(	(	(	O	O	O
HL	HL	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
chemosensitive	chemosensitive	JJ	I-NP	O	O
malignancy	malignancy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
those	those	DT	B-NP	O	O
who	who	WP	B-NP	O	O
relapse	relapse	NN	B-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
autologous	autologous	JJ	B-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
choice	choice	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
relies	rely	VBZ	B-VP	O	O
on	on	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
control	control	NN	I-NP	O	O
with	with	IN	B-PP	O	O
salvage	salvage	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

Regimens	Regimen	NNS	B-NP	O	O
commonly	commonly	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
often	often	RB	B-ADVP	O	O
require	require	VBP	B-VP	O	O
inpatient	inpatient	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
and	and	CC	O	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
difficult	difficult	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
deliver	deliver	VB	I-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Gemcitabine	Gemcitabine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
activity	activity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
HL	HL	NN	B-NP	O	B-Disease
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
overlapping	overlap	VBG	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
chemotherapeutics	chemotherapeutic	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
delivered	deliver	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
outpatient	outpatient	NN	I-NP	O	O
setting	setting	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
centre	centre	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
relapsed	relapsed	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
refractory	refractory	JJ	I-NP	O	O
HL	HL	NN	I-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
gemcitabine	gemcitabine	NN	B-NP	B	B-Chemical
1,000	1,000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
day	day	NN	B-NP	O	O
(	(	(	O	O	O
D	D	NN	B-NP	O	O
)	)	)	O	O	O
1	1	CD	B-NP	O	O
,	,	,	O	O	O
D8	D8	NN	B-NP	O	O
and	and	CC	I-NP	O	O
D15	D15	NN	I-NP	O	O
;	;	:	O	O	O
methylprednisolone	methylprednisolone	NN	B-NP	B	B-Chemical
1,000	1,000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
D1	D1	NN	I-NP	O	O
-	-	HYPH	O	O	O
5	5	CD	B-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
D15	D15	NN	B-NP	O	O
,	,	,	O	O	O
every	every	DT	B-NP	O	O
28	28	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
P	P	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
.	.	.	O	O	O

Demographic	Demographic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
survival	survival	NN	I-NP	O	O
,	,	,	I-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
data	datum	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

Forty	Forty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
eligible	eligible	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
:	:	:	O	O	O
median	median	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
27	27	CD	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
and	and	CC	I-NP	O	O
twenty	twenty	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
two	two	CD	I-NP	O	O
cycles	cycle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
total	total	NN	B-NP	O	O
(	(	(	O	O	O
median	median	NN	B-NP	O	O
3	3	CD	B-NP	O	O
cycles	cycle	NNS	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
6	6	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
of	of	IN	B-PP	O	O
41	41	CD	B-NP	O	O
(	(	(	O	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
as	as	IN	B-PP	O	O
second	second	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
and	and	CC	O	O	O
11	11	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
41	41	CD	I-NP	O	O
(	(	(	O	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
third	third	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Overall	Overall	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
ORR	ORR	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
entire	entire	JJ	I-NP	O	O
cohort	cohort	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
complete	complete	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
(	(	(	O	O	O
CR	CR	NN	B-NP	B	O
)	)	)	O	O	O
37	37	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
partial	partial	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
14	14	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
15	15	CD	I-NP	O	O
CR	CR	NN	I-NP	B	O
confirmed	confirm	VBD	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
CR	CR	NN	I-NP	B	O
on	on	IN	B-PP	O	O
PET	PET	NN	B-NP	O	O
and	and	CC	I-NP	O	O
ORR	ORR	NN	I-NP	O	O
of	of	IN	B-PP	O	O
85	85	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
20	20	CD	I-NP	O	O
second	second	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
grade	grade	NN	I-NP	O	O
3	3	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
4	4	CD	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
haematological	haematological	JJ	B-ADJP	O	O
:	:	:	O	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
54	54	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
51	51	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
start	start	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
4.5	4.5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
P	P	NN	I-NP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
progression	progression	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
CI	CI	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
62	62	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
overall	overall	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
59	59	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
43	43	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
74	74	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Fourteen	Fourteen	CD	B-NP	O	O
of	of	IN	B-PP	O	O
41	41	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
proceeded	proceed	VBD	B-VP	O	O
directly	directly	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
autologous	autologous	JJ	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
.	.	.	O	O	O

GEM	GEM	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
P	P	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
salvage	salvage	NN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
relatively	relatively	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
successful	successful	JJ	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
appropriate	appropriate	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
relapsed	relapsed	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
refractory	refractory	JJ	I-NP	O	O
HL	HL	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Basal	Basal	JJ	B-NP	O	O
functioning	functioning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypothalamic	hypothalamic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenal	adrenal	JJ	I-NP	O	O
(	(	(	O	O	O
HPA	HPA	JJ	B-ADJP	O	O
)	)	)	O	O	O
axis	axis	NN	B-NP	O	O
and	and	CC	O	O	O
psychological	psychological	JJ	B-NP	O	O
distress	distress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
recreational	recreational	JJ	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
polydrug	polydrug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

RATIONALE	RATIONALE	NN	B-NP	O	O
:	:	:	O	O	O
Ecstasy	Ecstasy	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
MDMA	MDMA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
psychostimulant	psychostimulant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
increasingly	increasingly	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
psychobiological	psychobiological	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
recent	recent	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
acute	acute	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
neuroendocrine	neuroendocrine	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
less	less	JJR	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
about	about	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HPA	HPA	NN	B-NP	O	O
functionality	functionality	NN	I-NP	O	O
in	in	IN	B-PP	O	O
recreational	recreational	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
to	to	TO	B-VP	O	O
explore	explore	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
polydrug	polydrug	NN	I-NP	O	O
use	use	NN	I-NP	O	O
on	on	IN	B-PP	O	O
psychological	psychological	JJ	B-NP	O	O
distress	distress	NN	I-NP	O	O
and	and	CC	O	O	O
basal	basal	JJ	B-NP	O	O
functioning	functioning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
HPA	HPA	JJ	I-NP	O	O
axis	axis	NN	I-NP	O	O
through	through	IN	B-PP	O	O
assessing	assess	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cortisol	cortisol	NN	B-NP	B	B-Chemical
across	across	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diurnal	diurnal	JJ	I-NP	B	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
Seventy	Seventy	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
six	six	CD	I-NP	O	O
participants	participant	NNS	I-NP	O	O
(	(	(	O	O	O
21	21	CD	B-NP	O	O
nonusers	nonuser	NNS	I-NP	O	O
,	,	,	O	O	O
29	29	CD	B-NP	O	O
light	light	JJ	I-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
polydrug	polydrug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
26	26	CD	B-NP	O	O
heavy	heavy	JJ	I-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
polydrug	polydrug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
)	)	)	O	O	O
completed	complete	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
substance	substance	NN	I-NP	O	O
use	use	NN	I-NP	O	O
inventory	inventory	NN	I-NP	O	O
and	and	CC	I-NP	O	O
measures	measure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
psychological	psychological	JJ	B-NP	O	O
distress	distress	NN	I-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
then	then	RB	O	O	O
two	two	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cortisol	cortisol	NN	B-NP	B	B-Chemical
sampling	sampling	NN	I-NP	O	O
(	(	(	O	O	O
on	on	IN	B-PP	O	O
awakening	awaken	VBG	B-VP	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
post	post	NN	I-NP	O	O
awakening	awakening	NN	I-NP	O	O
,	,	,	O	O	O
between	between	IN	B-PP	O	O
1400	1400	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1600	1600	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	O	O	O
pre	pre	JJ	B-NP	O	O
bedtime	bedtime	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
participants	participant	NNS	B-NP	O	O
also	also	RB	B-ADVP	O	O
attended	attend	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
to	to	TO	B-VP	O	O
complete	complete	VB	I-VP	O	O
a	a	DT	B-NP	O	O
20	20	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
min	min	NN	I-NP	O	O
multitasking	multitasking	JJ	I-NP	O	O
stressor	stressor	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Both	Both	CC	O	O	O
user	us	JJR	B-NP	O	O
groups	group	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
greater	great	JJR	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
than	than	IN	B-PP	O	O
nonusers	nonuser	NNS	B-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
participants	participant	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
cortisol	cortisol	NN	I-NP	B	B-Chemical
profile	profile	NN	I-NP	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
light	light	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
pre	pre	AFX	O	O	O
-	-	HYPH	O	O	O
bed	bed	NN	B-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
heavy	heavy	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
elevated	elevated	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
upon	upon	IN	B-PP	O	O
awakening	awaken	VBG	B-VP	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
polydrug	polydrug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
elevated	elevate	VBN	I-VP	B	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
bed	bed	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Significant	Significant	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
group	group	NN	B-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
afternoon	afternoon	NN	B-NP	O	O
cortisol	cortisol	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
overall	overall	JJ	B-NP	O	O
cortisol	cortisol	NN	I-NP	B	B-Chemical
secretion	secretion	NN	I-NP	O	O
across	across	IN	B-PP	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
line	line	NN	B-NP	O	O
with	with	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
observations	observation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
recreational	recreational	JJ	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
polydrug	polydrug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Dysregulated	Dysregulate	VBN	B-NP	O	O
diurnal	diurnal	JJ	I-NP	B	O
cortisol	cortisol	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
indicative	indicative	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
inappropriate	inappropriate	JJ	B-NP	O	O
anticipation	anticipation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
forthcoming	forthcoming	JJ	B-NP	O	O
demands	demand	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hypersecretion	hypersecretion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
psychological	psychological	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
physical	physical	JJ	I-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
heavy	heavy	JJ	B-NP	O	O
recreational	recreational	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ecstasy	ecstasy	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Ifosfamide	Ifosfamide	NN	B-NP	B	B-Chemical
related	related	JJ	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
:	:	:	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
timely	timely	JJ	I-NP	O	O
EEG	EEG	NN	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Ifosfamide	Ifosfamide	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
alkylating	alkylate	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
wide	wide	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancers	cancer	NNS	B-NP	O	B-Disease
including	include	VBG	B-PP	O	O
sarcomas	sarcoma	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
lymphoma	lymphoma	NN	B-NP	O	B-Disease
,	,	,	O	O	O
gynecologic	gynecologic	JJ	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
testicular	testicular	JJ	I-NP	O	I-Disease
cancers	cancer	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Encephalopathy	Encephalopathy	NN	B-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
IV	IV	CD	I-NP	O	O
ifosfamide	ifosfamide	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
highlight	highlight	VB	I-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
electroencephalogram	electroencephalogram	NN	B-NP	O	O
(	(	(	O	O	O
EEG	EEG	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
detection	detection	NN	I-NP	O	O
and	and	CC	I-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
related	related	JJ	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Retrospective	Retrospective	JJ	B-NP	O	O
chart	chart	NN	I-NP	O	O
review	review	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
EEG	EEG	NN	I-NP	O	O
recordings	recording	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
done	do	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
MD	MD	NNP	B-NP	B	O
Anderson	Anderson	NNP	I-NP	O	O
Cancer	Cancer	NNP	I-NP	O	B-Disease
Center	Center	NNP	I-NP	O	O
between	between	IN	B-PP	O	O
years	year	NNS	B-NP	O	O
2009	2009	CD	B-NP	O	O
and	and	CC	I-NP	O	O
2012	2012	CD	I-NP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
related	related	JJ	I-NP	O	O
acute	acute	JJ	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
five	five	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
soon	soon	RB	B-ADVP	O	O
after	after	IN	B-SBAR	O	O
(	(	(	O	O	O
within	within	IN	B-PP	O	O
12	12	CD	B-NP	O	O
h	h	NN	I-NP	O	O
-	-	HYPH	O	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
receiving	receive	VBG	B-VP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
generalized	generalize	VBN	B-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
while	while	IN	B-SBAR	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
non	non	AFX	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
convulsive	convulsive	JJ	I-NP	O	I-Disease
status	status	NN	I-NP	O	I-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
(	(	(	O	O	O
NCSE	NCSE	NN	B-NP	O	B-Disease
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
required	require	VBD	B-VP	O	O
ICU	ICU	NN	B-NP	O	O
admission	admission	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intubation	intubation	NN	I-NP	O	O
.	.	.	O	O	O

Initial	Initial	JJ	B-NP	O	O
EEG	EEG	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
epileptiform	epileptiform	NN	B-NP	O	O
discharges	discharge	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
;	;	:	O	O	O
run	run	NN	B-NP	O	O
of	of	IN	B-PP	O	O
triphasic	triphasic	JJ	B-NP	O	O
waves	wave	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
and	and	CC	O	O	O
moderate	moderate	JJ	B-NP	O	O
degree	degree	NN	I-NP	O	O
diffuse	diffuse	JJ	B-ADJP	O	O
generalized	generalize	VBN	B-VP	O	O
slowing	slow	VBG	B-VP	O	O
.	.	.	O	O	O

Mixed	Mix	VBN	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
sharps	sharp	NNS	I-NP	O	O
and	and	CC	O	O	O
triphasic	triphasic	JJ	B-NP	O	O
waves	wave	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
noted	note	VBN	I-VP	O	O
.	.	.	O	O	O

Repeat	Repeat	NN	B-NP	O	O
EEGs	EEG	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
24_h	24_h	NN	B-NP	O	O
of	of	IN	B-PP	O	O
symptom	symptom	NN	B-NP	O	O
onset	onset	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
marked	marked	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Severity	Severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
related	related	JJ	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
correlates	correlate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
EEG	EEG	NN	B-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
timely	timely	JJ	I-NP	O	O
EEG	EEG	NN	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
who	who	WP	B-NP	O	O
develop	develop	VBP	B-VP	O	O
features	feature	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Incidence	Incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
hospitalised	hospitalised	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
contrast	contrast	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
(	(	(	O	O	O
CIN	CIN	NN	B-NP	B	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
hospitalised	hospitalised	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Ninety	Ninety	CD	B-NP	O	O
adult	adult	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
excluded	exclude	VBN	I-VP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
before	before	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
enhanced	enhance	VBN	B-VP	O	O
computed	compute	VBN	B-NP	O	O
tomography	tomography	NN	I-NP	O	O
(	(	(	O	O	O
CT	CT	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
serially	serially	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
thereafter	thereafter	RB	B-ADVP	O	O
.	.	.	O	O	O

CIN	CIN	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
Cr	Cr	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
elevation	elevation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Cr	Cr	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
over	over	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
.	.	.	O	O	O

Relationships	Relationship	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
CIN	CIN	NN	B-NP	B	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
CIN	CIN	NN	B-NP	B	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
18	18	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
90	90	CD	I-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

CIN	CIN	NN	B-NP	O	O
developed	develop	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
25.5	25.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	O	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.1	0.1	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CIN	CIN	NN	B-NP	O	O
more	more	RBR	B-VP	O	O
frequently	frequently	RB	I-VP	O	O
developed	develop	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
undergone	undergo	VBN	I-VP	O	O
CT	CT	NN	B-NP	B	O
within	within	IN	B-PP	O	O
45	45	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.005	0.005	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
independent	independent	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.017	0.017	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CIN	CIN	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
more	more	JJR	I-ADJP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
bevacizumab	bevacizumab	NN	B-NP	B	B-Chemical
/	/	SYM	O	O	O
irinotecan	irinotecan	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.021	0.021	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.044	0.044	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CIN	CIN	NN	B-NP	B	O
after	after	IN	B-PP	O	O
CT	CT	NN	B-NP	B	O
in	in	IN	B-PP	O	O
hospitalised	hospitalised	JJ	B-NP	O	O
oncological	oncological	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

CIN	CIN	NN	B-NP	O	O
developed	develop	VBD	B-VP	O	O
4.5	4.5	CD	B-NP	O	O
-	-	HYPH	O	O	O
times	time	NNS	B-NP	O	O
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
undergone	undergo	VBN	I-VP	O	O
recent	recent	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

Hypertension	Hypertension	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bevacizumab	bevacizumab	NN	B-NP	B	B-Chemical
/	/	SYM	O	O	O
irinotecan	irinotecan	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
additional	additional	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
CIN	CIN	NN	B-NP	B	O
development	development	NN	I-NP	O	O
.	.	.	O	O	O

KEY	KEY	NN	B-NP	O	O
POINTS	POINTS	NNS	I-NP	O	O
:	:	:	O	O	O
.	.	.	O	O	O

Contrast	Contrast	NN	B-NP	O	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
(	(	(	O	O	O
CIN	CIN	NN	B-NP	B	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
concern	concern	NN	I-NP	O	O
for	for	IN	B-PP	O	O
oncological	oncological	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
CT	CT	NN	B-NP	B	O
.	.	.	O	O	O
.	.	.	O	O	O

CIN	CIN	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
more	more	RBR	B-ADVP	O	O
often	often	RB	I-ADVP	O	O
when	when	WRB	B-ADVP	O	O
CT	CT	NN	B-NP	B	O
is	be	VBZ	B-VP	O	O
performed	perform	VBN	I-VP	O	O
<	<	SYM	B-NP	O	O
45	45	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O
.	.	.	O	O	O

Hypertension	Hypertension	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
bevacizumab	bevacizumab	NN	B-NP	B	B-Chemical
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
additional	additional	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Syndrome	Syndrome	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
inappropriate	inappropriate	JJ	B-NP	O	I-Disease
antidiuretic	antidiuretic	JJ	I-NP	B	I-Disease
hormone	hormone	NN	I-NP	I	I-Disease
secretion	secretion	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
desvenlafaxine	desvenlafaxine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
syndrome	syndrome	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
inappropriate	inappropriate	JJ	B-NP	O	I-Disease
anti	anti	AFX	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
diuretic	diuretic	JJ	I-NP	O	I-Disease
hormone	hormone	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
)	)	)	O	O	O
secretion	secretion	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
desvenlafaxine	desvenlafaxine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
SUMMARY	SUMMARY	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
57	57	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
old	old	JJ	I-NP	O	O
female	female	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hyponatraemia	hyponatraemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
medications	medication	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
desvenlafaxine	desvenlafaxine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
symptoms	symptom	NNS	B-NP	O	O
included	include	VBD	B-VP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
confusion	confusion	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
120	120	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	O	O	O
L	L	NN	B-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
osmolality	osmolality	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
263	263	CD	B-NP	O	O
mosmol	mosmol	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
urine	urine	NN	B-NP	O	O
osmolality	osmolality	NN	I-NP	O	O
410	410	CD	I-NP	O	O
mosmol	mosmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
63	63	CD	I-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
,	,	,	O	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Desvenlafaxine	Desvenlafaxine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
ceased	cease	VBN	I-VP	O	O
and	and	CC	O	O	O
fluid	fluid	NN	B-NP	O	O
restriction	restriction	NN	I-NP	O	O
implemented	implement	VBD	B-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
128	128	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	B-NP	O	O
and	and	CC	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
restriction	restriction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
relaxed	relax	VBN	I-VP	B	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
further	further	JJ	I-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
inpatient	inpatient	JJ	I-NP	O	O
admission	admission	NN	I-NP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
ranged	range	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
134	134	CD	B-NP	O	O
to	to	TO	I-NP	O	O
137	137	CD	I-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	O	O	O
L	L	NN	B-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

DISCUSSION	DISCUSSION	NN	B-NP	O	O
:	:	:	O	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
widely	widely	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
desvenlafaxine	desvenlafaxine	NN	B-NP	B	B-Chemical
might	might	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
hyponatremia	hyponatremia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Clinicians	Clinician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
hyponatremia	hyponatremia	NN	B-NP	O	B-Disease
,and	,and	,	O	O	O
take	take	VB	B-VP	O	O
appropriate	appropriate	JJ	B-NP	O	O
corrective	corrective	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
necessary	necessary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Oxidative	Oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
remains	remain	VBZ	B-VP	O	O
controversial	controversial	JJ	B-ADJP	O	O
.	.	.	O	O	O

Wistar	Wistar	NNP	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
66	66	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
2	2	CD	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
protocols	protocol	NNS	I-NP	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
1	1	LS	I-LST	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
(	(	(	O	O	O
+	+	SYM	O	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
acute	acute	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	O	O	O
(	(	(	B-LST	O	O
2	2	LS	I-LST	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
58	58	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
4	4	CD	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
(	(	(	O	O	O
M0	M0	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
week	week	NN	I-NP	O	O
after	after	IN	B-PP	O	O
each	each	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
(	(	(	O	O	O
M1	M1	NN	B-NP	B	O
,	,	,	O	O	O
M2	M2	NN	B-NP	O	O
,	,	,	O	O	O
M3	M3	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
M4	M4	NN	B-NP	B	O
)	)	)	O	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
chronological	chronological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
used	use	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
M0	M0	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
moment	moment	NN	B-NP	B	O
-	-	HYPH	O	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
total	total	JJ	I-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
performance	performance	NN	I-NP	O	O
(	(	(	O	O	O
TAP	TAP	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
DNA	DNA	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
morphology	morphology	NN	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
at	at	IN	B-PP	O	O
each	each	DT	B-NP	O	O
time	time	NN	I-NP	O	O
point	point	NN	I-NP	O	O
.	.	.	O	O	O

Single	Single	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
disarrangement	disarrangement	NN	I-NP	O	I-Disease
,	,	,	O	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
DNA	DNA	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
(	(	(	O	O	O
strand	strand	NN	B-NP	O	O
breaks	break	NNS	I-NP	O	O
(	(	(	O	O	O
SBs	SB	NNS	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
oxidized	oxidize	VBN	B-NP	O	O
pyrimidines	pyrimidine	NNS	I-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
decreased	decrease	VBN	B-NP	O	O
TAP	TAP	NN	I-NP	B	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
chronological	chronological	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
on	on	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
0.99	0.99	CD	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.011	0.011	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1.00	1.00	CD	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.004	0.004	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
TAP	TAP	NN	B-NP	B	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.95	0.95	CD	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.049	0.049	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
DNA	DNA	NN	B-NP	O	O
SBs	SB	NNS	I-NP	B	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
0.95	0.95	CD	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.049	0.049	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

DNA	DNA	NN	B-NP	O	O
SBs	SB	NNS	I-NP	B	O
damage	damage	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
negatively	negatively	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
TAP	TAP	NN	B-NP	B	O
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
0.98	0.98	CD	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.018	0.018	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
R	R	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
0.97	0.97	CD	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.027	0.027	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
oxidative	oxidative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
only	only	RB	B-ADVP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
plausible	plausible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
different	different	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
versus	versus	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Tacrolimus	Tacrolimus	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
related	relate	VBN	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
-	-	:	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
center	center	NN	I-NP	O	O
experience	experience	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
new	new	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
onset	onset	NN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
LT	LT	NN	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
implications	implication	NNS	I-NP	O	O
and	and	CC	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
prognosis	prognosis	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
laboratory	laboratory	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
27	27	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
children	child	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
LT	LT	NNP	B-NP	O	O
from	from	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
2007	2007	CD	I-NP	O	O
to	to	TO	B-PP	O	O
December	December	NNP	B-NP	O	O
2010	2010	CD	I-NP	O	O
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
center	center	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
group	group	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Pre	Pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	B-ADJP	O	O
,	,	,	O	O	O
intra	intra	AFX	O	O	O
-	-	HYPH	O	O	O
operative	operative	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
collected	collect	VBN	I-VP	O	O
.	.	.	O	O	O

Seizures	Seizure	NNS	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
four	four	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
14.8	14.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
generalized	generalize	VBN	I-VP	O	O
tonic	tonic	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
clonic	clonic	JJ	I-NP	O	I-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
wk	wk	NN	I-NP	O	O
after	after	IN	B-PP	O	O
LT	LT	NN	B-NP	O	O
.	.	.	O	O	O

Univariate	Univariate	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
LT	LT	NN	I-NP	O	O
included	include	VBD	B-VP	O	O
gender	gender	NN	B-NP	O	O
,	,	,	O	O	O
pediatric	pediatric	JJ	B-NP	O	O
end	end	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
stage	stage	NN	B-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
score	score	NN	I-NP	O	O
before	before	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
,	,	,	O	O	O
Child	Child	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Pugh	Pugh	NNP	I-NP	O	O
score	score	NN	I-NP	O	O
before	before	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
total	total	JJ	I-NP	B	O
bilirubin	bilirubin	NN	I-NP	I	B-Chemical
after	after	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
trough	trough	NN	B-NP	O	O
TAC	TAC	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Multivariate	Multivariate	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
trough	trough	NN	B-NP	O	O
TAC	TAC	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
independent	independent	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

All	All	DT	B-NP	O	O
children	child	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
experienced	experience	VBD	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
survived	survive	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
good	good	JJ	B-NP	O	O
graft	graft	NN	I-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
remained	remain	VBD	B-VP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
-	-	HYPH	B-ADJP	O	O
free	free	JJ	I-ADJP	O	O
without	without	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
epileptic	epileptic	JJ	I-NP	O	B-Disease
drugs	drug	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
up	up	RP	B-PRT	O	O
period	period	NN	B-NP	O	O
of	of	IN	B-PP	O	O
33.7	33.7	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
14.6	14.6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
trough	trough	NN	I-NP	O	O
TAC	TAC	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
predominant	predominant	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
contributed	contribute	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
after	after	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
LT	LT	NN	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
PELD	PELD	NN	I-NP	O	O
and	and	CC	O	O	O
Child	Child	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Pugh	Pugh	NNP	I-NP	O	O
scores	score	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
LT	LT	NN	B-NP	O	O
and	and	CC	O	O	O
high	high	JJ	B-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
Tbil	Tbil	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
contributory	contributory	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
TAC	TAC	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
flavonoid	flavonoid	JJ	I-NP	O	B-Chemical
apigenin	apigenin	NN	I-NP	B	B-Chemical
delays	delay	VBZ	B-VP	O	O
forgetting	forgetting	NN	B-NP	O	O
of	of	IN	B-PP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
conditioning	conditioning	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
flavonoid	flavonoid	NN	I-NP	O	B-Chemical
apigenin	apigenin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
(	(	(	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
h	h	NN	I-NP	O	O
before	before	IN	B-PP	O	O
acquisition	acquisition	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
and	and	CC	O	O	O
forgetting	forgetting	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
step	step	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
through	through	IN	B-PP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
task	task	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
apigenin	apigenin	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
treated	treat	VBN	I-NP	O	O
groups	group	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
24	24	CD	I-NP	O	O
h	h	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
apigenin	apigenin	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
scopolamine	scopolamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1mg	1mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acquisition	acquisition	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
saline	saline	NN	I-NP	B	O
-	-	HYPH	B-ADVP	O	O
and	and	CC	I-ADVP	O	O
apigenin	apigenin	NN	I-ADVP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
step	step	VB	I-VP	O	O
through	through	RP	B-PRT	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dark	dark	JJ	I-NP	O	O
compartment	compartment	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cut	cut	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
off	off	RP	B-PRT	O	O
time	time	NN	B-NP	O	O
(	(	(	O	O	O
540	540	CD	B-NP	O	O
s	s	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
retested	reteste	VBN	I-VP	O	O
weekly	weekly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
eight	eight	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
saline	saline	NN	I-NP	B	O
treated	treated	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
significant	significant	JJ	I-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
four	four	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
complete	complete	JJ	B-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
five	five	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acquisition	acquisition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
task	task	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
apigenin	apigenin	NN	B-NP	B	B-Chemical
still	still	RB	B-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
step	step	VB	I-VP	O	O
through	through	IN	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
1	1	LS	B-LST	O	O
)	)	)	O	O	O
apigenin	apigenin	NN	B-NP	B	B-Chemical
delays	delay	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
forgetting	forgetting	NN	I-NP	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
modulate	modulate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
24	24	CD	I-NP	O	O
h	h	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fear	fear	NN	B-NP	O	O
memory	memory	NN	I-NP	O	O
and	and	CC	O	O	O
2	2	LS	B-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
obtained	obtain	VBN	I-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
apigenin	apigenin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
conditioning	conditioning	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
implicate	implicate	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
action	action	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscarinic	muscarinic	JJ	I-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Cholecystokinin	Cholecystokinin	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
octapeptide	octapeptide	NN	I-NP	O	I-Chemical
restored	restore	VBD	B-VP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
impairment	impairment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Cholecystokinin	Cholecystokinin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
octapeptide	octapeptide	NN	B-NP	O	I-Chemical
(	(	(	O	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
8	8	CD	B-NP	O	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
gut	gut	NN	I-NP	O	O
peptide	peptide	NN	I-NP	O	O
,	,	,	O	O	O
exerts	exert	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
wide	wide	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
biological	biological	JJ	B-NP	O	O
activities	activity	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
significantly	significantly	RB	I-NP	O	O
alleviated	alleviate	VBN	I-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
reversed	reverse	VBD	B-VP	O	O
spine	spine	NN	B-NP	O	O
density	density	NN	I-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CA1	CA1	NN	I-NP	O	O
region	region	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
on	on	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
potentiation	potentiation	NN	I-NP	O	O
(	(	(	O	O	O
LTP	LTP	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
perforant	perforant	JJ	I-NP	O	O
path	path	NN	I-NP	O	O
(	(	(	O	O	O
LPP	LPP	NN	B-NP	B	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
granule	granule	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
synapse	synapse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
dentate	dentate	NN	I-NP	O	O
gyrus	gyrus	NN	I-NP	O	O
(	(	(	O	O	O
DG	DG	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
saline	saline	NN	I-NP	B	O
or	or	CC	I-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Population	Population	NN	B-NP	O	O
spikes	spike	NNS	I-NP	O	O
(	(	(	O	O	O
PS	PS	NNS	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
evoked	evoke	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
stimulation	stimulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LPP	LPP	NN	I-NP	B	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DG	DG	NN	I-NP	O	O
region	region	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
30mg	30mg	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c.	s.c.	JJ	B-ADJP	O	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
attenuated	attenuate	VBD	B-VP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
LTP	LTP	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CCK	CCK	NN	I-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
8	8	CD	B-NP	O	I-Chemical
(	(	(	O	O	O
1ug	1ug	NN	B-NP	O	O
,	,	,	O	O	O
i.c.v.	i.c.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
restored	restore	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PS	PS	NNP	B-NP	B	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
attenuated	attenuate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
microinjection	microinjection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
8	8	CD	B-NP	O	I-Chemical
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1ug	1ug	CD	I-NP	O	O
,	,	,	O	O	O
i.c.v.	i.c.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
significantly	significantly	RB	B-ADVP	O	O
augmented	augment	VBD	B-VP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
LTP	LTP	NN	I-NP	O	O
in	in	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
(	(	(	O	O	O
1ml	1ml	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c.	s.c.	JJ	B-ADJP	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Pre	Pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CCK2	CCK2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
L	L	NN	I-NP	O	O
-	-	HYPH	O	O	O
365,260	365,260	CD	B-NP	O	O
(	(	(	O	O	O
10ug	10ug	CD	B-NP	O	O
,	,	,	O	O	O
i.c.v	i.c.v	JJ	B-ADJP	O	O
)	)	)	O	O	O
reversed	reverse	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
CCK1	CCK1	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
L	L	NN	I-NP	B	O
-	-	HYPH	O	I	O
364,718	364,718	CD	B-NP	I	O
(	(	(	O	O	O
10ug	10ug	CD	B-NP	O	O
,	,	,	O	O	O
i.c.v	i.c.v	JJ	B-ADJP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
attenuates	attenuate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
LTP	LTP	NN	I-NP	O	O
through	through	IN	B-PP	O	O
CCK2	CCK2	NN	B-NP	O	O
receptors	receptor	NNS	I-NP	O	O
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
ameliorative	ameliorative	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
8	8	CD	B-NP	O	I-Chemical
on	on	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Glial	Glial	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
and	and	CC	O	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
synaptic	synaptic	JJ	B-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
:	:	:	O	O	O
the	the	DT	B-NP	O	O
key	key	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Streptozotocin	Streptozotocin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ICV	ICV	NN	B-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
memory	memory	NN	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glial	glial	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
and	and	CC	O	O	O
post	post	NN	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
ICV	ICV	NN	B-NP	O	O
Streptozotocin	Streptozotocin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
memory	memory	NN	B-NP	O	B-Disease
impaired	impaired	JJ	I-NP	O	I-Disease
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
explored	explore	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
experiment	experiment	NN	B-NP	O	O
set	set	VBN	B-VP	O	O
up	up	RP	B-PRT	O	O
1	1	CD	B-NP	O	O
:	:	SYM	I-NP	O	O
Memory	Memory	NN	I-NP	O	B-Disease
deficit	deficit	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Morris	Morris	NNP	B-NP	O	O
water	water	NN	I-NP	B	O
maze	maze	NN	I-NP	O	O
test	test	NN	I-NP	O	O
on	on	IN	B-PP	O	O
14	14	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
16	16	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ICV	ICV	NN	B-NP	O	O
;	;	:	O	O	O
3mg	3mg	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Kg	Kg	NN	I-NP	O	O
)	)	)	O	O	O
administration	administration	NN	B-NP	O	O
.	.	.	O	O	O

STZ	STZ	NN	B-NP	O	B-Chemical
causes	cause	VBZ	B-VP	O	O
increased	increase	VBN	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GFAP	GFAP	NN	B-NP	O	O
,	,	,	I-NP	O	O
CD11b	CD11b	NN	I-NP	O	O
and	and	CC	I-NP	O	O
TNF	TNF	NN	I-NP	B	O
-	-	:	O	O	O
a	a	DT	B-NP	O	O
indicating	indicate	VBG	I-NP	O	O
glial	glial	JJ	I-NP	O	O
activation	activation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neuroinflammation	neuroinflammation	NN	I-NP	O	B-Disease
.	.	.	O	O	O

STZ	STZ	NN	B-NP	O	B-Chemical
also	also	RB	B-ADVP	O	O
significantly	significantly	RB	B-VP	O	O
increased	increase	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ROS	ROS	NN	B-NP	B	O
,	,	,	O	O	O
nitrite	nitrite	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	B-NP	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
and	and	CC	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
synaptosomal	synaptosomal	JJ	B-NP	O	O
preparation	preparation	NN	I-NP	O	O
illustrating	illustrate	VBG	B-VP	O	O
free	free	JJ	B-NP	O	O
radical	radical	NN	I-NP	O	O
generation	generation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
excitotoxicity	excitotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Increased	Increase	VBN	B-VP	O	O
expression	expression	NN	B-NP	O	O
and	and	CC	O	O	O
activity	activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Caspase	Caspase	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
treated	treated	JJ	I-NP	O	O
rat	rat	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
specify	specify	VBP	B-VP	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
death	death	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hippocampus	hippocampus	NN	B-NP	O	O
and	and	CC	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
.	.	.	O	O	O

STZ	STZ	NN	B-NP	O	B-Chemical
treatment	treatment	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
decrease	decrease	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
post	post	JJ	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
markers	marker	NNS	I-NP	O	O
CaMKIIa	CaMKIIa	NN	I-NP	O	O
and	and	CC	I-NP	O	O
PSD	PSD	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
95	95	CD	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
,	,	,	O	O	O
expression	expression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pre	pre	JJ	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
markers	marker	NNS	I-NP	O	O
(	(	(	O	O	O
synaptophysin	synaptophysin	NN	B-NP	O	O
and	and	CC	I-NP	O	O
SNAP	SNAP	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
25	25	CD	I-NP	O	O
)	)	)	O	O	O
remains	remain	VBZ	B-VP	O	O
unaltered	unaltered	JJ	B-NP	O	O
indicating	indicate	VBG	I-NP	O	O
selective	selective	JJ	I-NP	O	O
post	post	NN	I-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Memantine	Memantine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10mg	10mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Ibuprofen	Ibuprofen	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
13	13	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
attenuated	attenuate	VBD	B-VP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
induced	induced	JJ	I-NP	O	O
glial	glial	JJ	I-NP	O	O
activation	activation	NN	I-NP	O	O
,	,	,	O	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
death	death	NN	I-NP	O	O
and	and	CC	O	O	O
post	post	NN	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
experiment	experiment	NN	B-NP	O	O
set	set	VBN	B-VP	O	O
up	up	RP	B-PRT	O	O
2	2	CD	B-NP	O	O
:	:	:	O	O	O
where	where	WRB	B-ADVP	O	O
memory	memory	NN	B-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
i.e	i.e	NN	B-NP	O	O
.	.	.	O	O	O

7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
9	9	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GFAP	GFAP	NN	B-NP	O	O
,	,	,	O	O	O
CD11b	CD11b	NN	B-NP	O	O
,	,	,	O	O	O
TNF	TNF	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
a	a	NN	I-NP	O	O
,	,	,	I-NP	O	O
ROS	ROS	NN	I-NP	B	O
and	and	CC	I-NP	O	O
nitrite	nitrite	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
marker	marker	NN	I-NP	O	O
,	,	,	O	O	O
synaptic	synaptic	JJ	B-NP	O	O
markers	marker	NNS	I-NP	O	O
,	,	,	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
levels	level	NNS	B-NP	O	O
remained	remain	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
.	.	.	O	O	O

Collective	Collective	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
neuroinflammatory	neuroinflammatory	JJ	B-NP	O	B-Disease
process	process	NN	I-NP	O	O
and	and	CC	O	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
earlier	early	JJR	B-ADVP	O	O
to	to	TO	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
and	and	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
memory	memory	NN	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Present	Present	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
clearly	clearly	RB	B-ADVP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
glial	glial	JJ	B-NP	O	O
activation	activation	NN	I-NP	O	O
and	and	CC	O	O	O
post	post	NN	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
key	key	JJ	I-NP	O	O
factors	factor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
memory	memory	NN	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
neuronal	neuronal	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

Comparison	Comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
prevention	prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

INTRODUCTION	INTRODUCTION	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
OBJECTIVE	OBJECTIVE	NN	I-NP	O	O
:	:	:	O	O	O
Contrast	Contrast	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
(	(	(	O	O	O
CIN	CIN	NN	B-NP	B	O
)	)	)	O	O	O
significantly	significantly	RB	B-VP	O	O
increases	increase	VBZ	I-VP	O	O
the	the	DT	B-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
and	and	CC	I-VP	O	O
compare	compare	VB	I-VP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
bicarbonate	bicarbonate	NN	I-NP	I	I-Chemical
infusion	infusion	NN	I-NP	O	O
and	and	CC	O	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
infusion	infusion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
CIN	CIN	NN	B-NP	B	O
.	.	.	O	O	O

MATERIALS	MATERIALS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
study	study	NN	I-NP	O	O
included	include	VBD	B-VP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
60	60	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
of	of	IN	B-PP	O	O
iodinated	iodinate	VBN	B-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
percutaneous	percutaneous	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
angiography	angiography	NN	I-NP	O	O
(	(	(	O	O	O
PCAG	PCAG	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
with	with	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
values	value	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
1.1	1.1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
3.1	3.1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
and	and	CC	O	O	O
each	each	DT	B-NP	O	O
group	group	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
;	;	:	O	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
solution	solution	NN	I-NP	O	O
that	that	IN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
dextrose	dextrose	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
bicarbonate	bicarbonate	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
the	the	DT	B-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	B	B-Chemical
the	the	DT	B-NP	O	O
day	day	NN	I-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	B-NP	O	O
first	first	JJ	I-NP	O	O
2	2	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
blood	blood	NN	I-NP	O	B-Chemical
urea	urea	NN	I-NP	B	I-Chemical
nitrogen	nitrogen	NN	I-NP	B	I-Chemical
(	(	(	O	O	O
BUN	BUN	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
seventh	seventh	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
material	material	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
basal	basal	JJ	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
all	all	DT	B-NP	O	O
three	three	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
>	>	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
included	include	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
16	16	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ARF	ARF	NN	B-NP	B	B-Disease
)	)	)	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	B-Chemical
material	material	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
(	(	(	O	O	O
26.6	26.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
ARF	ARF	NN	B-NP	B	B-Disease
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
five	five	CD	B-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
six	six	CD	B-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
five	five	CD	B-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
>	>	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
bicarbonate	bicarbonate	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
isotonic	isotonic	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
with	with	IN	B-PP	O	O
diltiazem	diltiazem	NN	B-NP	B	B-Chemical
application	application	NN	I-NP	O	O
in	in	IN	B-PP	O	O
prevention	prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CIN	CIN	NN	B-NP	B	O
.	.	.	O	O	O

Neurocognitive	Neurocognitive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neuroradiologic	neuroradiologic	JJ	I-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
late	late	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
Pediatric	Pediatric	NNP	B-NP	O	O
Oncology	Oncology	NNP	I-NP	O	O
Group	Group	NNP	I-NP	O	O
(	(	(	O	O	O
POG	POG	NN	B-NP	O	O
)	)	)	O	O	O
P9605	P9605	NN	B-NP	O	O
(	(	(	O	O	O
standard	standard	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
P9201	P9201	NN	B-NP	O	O
(	(	(	O	O	O
lesser	less	JJR	B-NP	O	O
risk	risk	NN	I-NP	O	O
)	)	)	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
protocols	protocol	NNS	I-NP	O	O
(	(	(	O	O	O
ACCL0131	ACCL0131	NN	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
consequence	consequence	NN	I-NP	O	O
?	?	.	O	O	O

A	A	DT	B-NP	O	O
report	report	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Children	Children	NNP	I-NP	O	O
's	's	POS	B-NP	O	O
Oncology	Oncology	NNP	I-NP	O	O
Group	Group	NNP	I-NP	O	O
.	.	.	O	O	O

Concerns	Concern	NNS	B-NP	O	O
about	about	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
MTX	MTX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1990s	1990	NNS	I-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
modifications	modification	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
intrathecal	intrathecal	JJ	O	O	O
(	(	(	O	O	O
IT	IT	JJ	B-ADJP	O	O
)	)	)	O	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
leucovorin	leucovorin	NN	B-NP	B	O
rescue	rescue	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
frequency	frequency	NN	B-NP	O	O
of	of	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
MTX	MTX	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
neurocognitive	neurocognitive	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
and	and	CC	O	O	O
neuroradiologic	neuroradiologic	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
leukoencephalopathy	leukoencephalopathy	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
intense	intense	JJ	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
directed	direct	VBN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
P9605	P9605	NN	B-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
fewer	few	JJR	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
-	-	HYPH	O	O	O
directed	direct	VBN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
days	day	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
intensive	intensive	JJ	B-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
(	(	(	O	O	O
P9201	P9201	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
66	66	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
16	16	CD	B-NP	O	O
Pediatric	Pediatric	NNP	I-NP	O	O
Oncology	Oncology	NNP	I-NP	O	O
Group	Group	NNP	I-NP	O	O
institutions	institution	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
"	"	``	O	O	O
standard	standard	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
risk	risk	NN	I-NP	O	O
"	"	''	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
1.00	1.00	CD	B-NP	O	O
to	to	TO	I-NP	O	O
9.99	9.99	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
,	,	,	O	O	O
without	without	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CNS	CNS	NN	B-NP	O	O
leukemia	leukemia	NN	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
ACCL0131	ACCL0131	NN	B-NP	O	O
:	:	:	O	O	O
28	28	CD	B-NP	O	O
from	from	IN	B-PP	O	O
P9201	P9201	NN	B-NP	O	O
and	and	CC	O	O	O
38	38	CD	B-NP	O	O
from	from	IN	B-PP	O	O
P9605	P9605	NN	B-NP	O	O
.	.	.	O	O	O

Magnetic	Magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
scans	scan	NNS	I-NP	O	O
and	and	CC	O	O	O
standard	standard	JJ	B-NP	O	O
neuropsychological	neuropsychological	JJ	I-NP	O	O
tests	test	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
>	>	SYM	B-NP	O	O
2.6	2.6	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Significantly	Significantly	RB	B-NP	O	O
more	more	JJR	I-NP	O	O
P9605	P9605	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
leukoencephalopathy	leukoencephalopathy	NN	B-NP	O	B-Disease
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
P9201	P9201	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
68	68	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
49	49	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
83	83	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
identified	identify	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
late	late	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
7.7	7.7	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
scored	score	VBD	B-VP	O	O
<	<	SYM	B-NP	O	O
85	85	CD	I-NP	O	O
on	on	IN	B-PP	O	O
either	either	DT	B-NP	O	O
Verbal	Verbal	NNP	I-NP	O	O
or	or	CC	I-NP	O	O
Performance	Performance	NNP	I-NP	O	O
IQ	IQ	NNP	I-NP	B	O
.	.	.	O	O	O

Children	Child	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
both	both	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	B-Disease
problems	problem	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
P9605	P9605	NN	B-NP	O	O
children	child	NNS	I-NP	O	O
scored	score	VBN	B-VP	O	O
below	below	IN	B-PP	O	O
average	average	NN	B-NP	O	O
on	on	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
neurocognitive	neurocognitive	JJ	I-NP	O	O
measures	measure	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
treated	treat	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
P9201	P9201	NN	B-NP	O	O
(	(	(	O	O	O
82	82	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
14	14	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
17	17	CD	I-NP	O	O
measures	measure	NNS	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
4	4	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
17	17	CD	I-NP	O	O
measures	measure	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
supports	support	VBZ	B-VP	O	O
ongoing	ongoing	JJ	B-NP	O	O
concerns	concern	NNS	I-NP	O	O
about	about	IN	B-PP	O	O
intensive	intensive	JJ	B-NP	O	O
MTX	MTX	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
contributor	contributor	NN	I-NP	O	O
to	to	TO	B-PP	O	O
CNS	CNS	NN	B-NP	O	O
late	late	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Tranexamic	Tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
overdosage	overdosage	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
generalized	generalize	VBN	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
45	45	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
lady	lady	NN	I-NP	B	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
stage	stage	NN	I-NP	O	O
4	4	CD	I-NP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
tubulointerstial	tubulointerstial	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
center	center	NN	I-NP	O	O
for	for	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
menorrhagia	menorrhagia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
renal	renal	JJ	B-NP	O	I-Disease
function	function	NN	I-NP	O	I-Disease
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
infused	infuse	VBN	I-VP	O	O
three	three	CD	B-NP	O	O
units	unit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
packed	packed	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
session	session	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hemodialysis	hemodialysis	NN	B-NP	O	O
.	.	.	O	O	O

Tranexamic	Tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
TNA	TNA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
1	1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
8	8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hourly	hourly	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
her	her	PRP	B-NP	O	O
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
bleeding	bleed	VBG	I-VP	O	B-Disease
per	per	IN	B-PP	O	O
vaginum	vaginum	NN	B-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sixth	sixth	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TNA	TNA	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
episode	episode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
generalized	generalize	VBN	B-NP	O	O
tonic	tonic	JJ	I-NP	O	B-Disease
clonic	clonic	JJ	I-NP	O	I-Disease
convulsions	convulsion	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

TNA	TNA	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Investigations	Investigation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
structural	structural	JJ	I-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	B-Disease
system	system	NN	I-NP	O	I-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
have	have	VB	I-VP	O	O
provoked	provoke	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
any	any	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
dialytic	dialytic	JJ	I-NP	O	O
support	support	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
episodes	episode	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
convulsion	convulsion	NN	B-NP	O	B-Disease
till	till	IN	B-PP	O	O
dis	dis	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
charge	charge	NN	I-NP	O	O
and	and	CC	B-PP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
precipitating	precipitate	VBG	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
believed	believe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
overdose	overdose	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
TNA	TNA	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Pre	Pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
using	use	VBG	B-VP	O	O
different	different	JJ	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
formulations	formulation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Pre	Pre	NN	B-NP	O	O
-	-	HYPH	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
emulsions	emulsion	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
lethal	lethal	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
content	content	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
alleviate	alleviate	VB	I-VP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
intralipid	intralipid	NN	B-NP	O	O
or	or	CC	I-NP	O	O
medialipid	medialipid	NN	I-NP	O	O
emulsions	emulsion	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Rats	Rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
anaesthetised	anaesthetise	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ketamine	ketamine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
min	min	NN	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
intralipid	intralipid	NN	B-NP	O	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
P	P	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
medialipid	medialipid	NN	B-NP	O	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	B	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
C	C	NN	I-NP	O	O
)	)	)	O	O	O
over	over	IN	B-PP	O	O
20	20	CD	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

Thereafter	Thereafter	RB	B-ADVP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
0.5	0.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
infused	infuse	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
recorded	record	VBD	B-VP	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
dysrhythmia	dysrhythmia	NN	I-NP	O	B-Disease
occurrence	occurrence	NN	I-NP	O	O
,	,	,	O	O	O
respective	respective	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
HR	HR	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
asystole	asystole	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
total	total	JJ	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
and	and	CC	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
samples	sample	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
collected	collect	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
asystole	asystole	NN	B-NP	O	B-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
dysrhythmia	dysrhythmia	NN	I-NP	O	B-Disease
occurrence	occurrence	NN	I-NP	O	O
,	,	,	O	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HR	HR	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
asystole	asystole	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
longer	long	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
P	P	NN	I-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
those	those	DT	B-NP	O	O
time	time	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
P	P	NN	I-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
P	P	NN	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
C	C	NN	I-NP	O	O
.	.	.	O	O	O

Bupivacaine	Bupivacaine	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
P	P	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Group	Group	NN	I-NP	O	O
L	L	NN	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
C	C	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
intralipid	intralipid	NN	B-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
medialipid	medialipid	NN	B-NP	O	O
or	or	CC	I-NP	O	O
saline	saline	NN	I-NP	B	O
,	,	,	O	O	O
delayed	delay	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cardiotoxic	cardiotoxic	JJ	I-NP	O	B-Disease
effects	effect	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
reduced	reduce	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
explore	explore	VB	I-VP	O	O
tissue	tissue	NN	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
medialipid	medialipid	NN	B-NP	O	O
and	and	CC	O	O	O
adapt	adapt	VB	B-VP	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	B-Disease
-	-	HYPH	B-VP	O	I-Disease
Induced	Induce	VBN	B-NP	O	I-Disease
Acute	Acute	JJ	I-NP	O	I-Disease
Liver	Liver	NN	I-NP	O	I-Disease
Injury	Injury	NN	I-NP	O	I-Disease
Within	Within	IN	B-PP	O	O
12	12	CD	B-NP	O	O
Hours	Hour	NNS	I-NP	O	O
After	After	IN	B-PP	O	O
Fluvastatin	Fluvastatin	NN	B-NP	B	B-Chemical
Therapy	Therapy	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
statins	statin	NNS	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
generally	generally	RB	B-ADVP	O	O
well	well	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
tolerated	tolerate	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
recent	recent	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
induced	induce	VBN	B-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
52	52	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
reported	report	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
liver	liver	NN	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
appeared	appear	VBD	B-VP	O	O
12	12	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
beginning	begin	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fluvastatin	fluvastatin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Patient	Patient	NN	B-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
complaints	complaint	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
anorexia	anorexia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
upper	upper	JJ	B-NP	O	O
abdominal	abdominal	JJ	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

His	His	PRP$	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
elevated	elevated	JJ	B-NP	O	O
creatine	creatine	NN	I-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
and	and	CC	I-NP	O	O
transaminases	transaminase	NNS	I-NP	O	O
.	.	.	O	O	O

Testing	Test	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
autoantibodies	autoantibody	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
negative	negative	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
biochemistries	biochemistry	NNS	I-NP	O	O
eventually	eventually	RB	B-ADVP	O	O
normalized	normalize	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
stopping	stop	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
fluvastatin	fluvastatin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
prescribing	prescribe	VBG	B-NP	O	O
statins	statin	NNS	I-NP	B	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
.	.	.	O	O	O

Fluconazole	Fluconazole	NN	B-NP	B	B-Chemical
associated	associate	VBN	I-NP	O	O
agranulocytosis	agranulocytosis	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	B	B-Chemical
associated	associate	VBN	I-NP	O	O
agranulocytosis	agranulocytosis	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
upon	upon	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
began	begin	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
white	white	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	O	O	O
platelets	platelet	NNS	B-NP	O	O
within	within	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
began	begin	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
recover	recover	VB	I-VP	O	O
with	with	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
of	of	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
highlights	highlight	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
blood	blood	NN	I-NP	O	B-Disease
dyscrasias	dyscrasia	NNS	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
unexpectedly	unexpectedly	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
thought	think	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
"	"	``	B-ADJP	O	O
safe	safe	JJ	I-ADJP	O	O
"	"	''	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
According	Accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
Naranjo	Naranjo	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
algorithm	algorithm	NN	I-NP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
agranulocytosis	agranulocytosis	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
probable	probable	JJ	B-ADJP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
six	six	CD	B-NP	O	O
points	point	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
feel	feel	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
weight	weight	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
strong	strong	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
the	the	DT	B-NP	O	O
temporal	temporal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bone	bone	NN	B-NP	O	B-Disease
marrow	marrow	NN	I-NP	O	I-Disease
suppression	suppression	NN	I-NP	O	I-Disease
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluconazole	fluconazole	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
abatement	abatement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
reversed	reverse	VBD	B-VP	O	O
immediately	immediately	RB	I-VP	O	O
following	follow	VBG	I-VP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
dimensional	dimensional	JJ	I-NP	O	O
speckle	speckle	NN	I-NP	O	O
tracking	track	VBG	B-VP	O	O
echocardiography	echocardiography	NN	B-NP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
troponin	troponin	NN	I-NP	O	O
T	T	NN	I-NP	O	O
in	in	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
detection	detection	NN	I-NP	O	O
and	and	CC	O	O	O
prediction	prediction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
epirubicine	epirubicine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

AIMS	AIMS	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
alterations	alteration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
strain	strain	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
troponin	troponin	NN	I-NP	O	O
T	T	NN	I-NP	O	O
(	(	(	O	O	O
cTnT	cTnT	NN	B-NP	O	O
)	)	)	O	O	O
could	could	MD	B-VP	O	O
predict	predict	VB	I-VP	O	O
future	future	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Seventy	Seventy	CD	B-NP	O	O
-	-	HYPH	O	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
Hodgkin	Hodgkin	NN	I-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
collection	collection	NN	I-NP	O	O
and	and	CC	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
completion	completion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
echocardiography	echocardiography	NN	B-NP	O	O
during	during	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

Global	Global	JJ	B-NP	O	O
longitudinal	longitudinal	JJ	I-NP	O	O
(	(	(	O	O	O
GLS	GLS	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
circumferential	circumferential	JJ	B-ADJP	O	O
(	(	(	O	O	O
GCS	GCS	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
radial	radial	JJ	B-NP	O	O
strain	strain	NN	I-NP	O	O
(	(	(	O	O	O
GRS	GRS	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
speckle	speckle	NN	B-NP	O	O
tracking	tracking	NN	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
.	.	.	O	O	O

Left	Leave	VBN	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
analysed	analyse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
real	real	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
time	time	NN	I-NP	O	O
3D	3D	NN	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
.	.	.	O	O	O

Cardiotoxicity	Cardiotoxicity	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LVEF	LVEF	NN	I-NP	O	O
of	of	IN	B-PP	O	O
>	>	JJR	B-NP	O	O
5	5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
<	<	SYM	B-NP	O	O
55	55	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
an	an	DT	B-NP	O	O
asymptomatic	asymptomatic	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LVEF	LVEF	NN	I-NP	O	O
of	of	IN	B-PP	O	O
>	>	JJR	B-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
<	<	SYM	B-NP	O	O
55	55	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Fourteen	Fourteen	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
18.67	18.67	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
developed	develop	VBD	B-VP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

GLS	GLS	NN	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
18.48	18.48	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
1.72	1.72	CD	I-NP	O	O
%	%	NN	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

-	-	SYM	O	O	O
15.96	15.96	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
1.6	1.6	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
GCS	GCS	NN	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
20.93	20.93	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
2.86	2.86	CD	I-NP	O	O
%	%	NN	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

-	-	SYM	O	O	O
19.20	19.20	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
3.21	3.21	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
GRS	GRS	NN	B-NP	O	O
(	(	(	O	O	O
39.23	39.23	CD	B-NP	O	O
+	+	SYM	O	O	O
6.44	6.44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

34.98	34.98	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
6.2	6.2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
markedly	markedly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
and	and	CC	O	O	O
cTnT	cTnT	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
elevated	elevate	VBN	I-VP	B	O
from	from	IN	B-PP	O	O
0.0010	0.0010	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
0.0020	0.0020	CD	B-NP	O	O
to	to	TO	I-NP	O	O
0.0073	0.0073	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
0.0038	0.0038	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
all	all	DT	B-NP	O	O
<	<	SYM	I-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
completion	completion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
>	>	SYM	I-NP	O	O
15.9	15.9	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GLS	GLS	NN	B-NP	O	O
[	[	(	O	O	O
sensitivity	sensitivity	NN	B-NP	O	O
,	,	,	O	O	O
86	86	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
specificity	specificity	NN	B-NP	O	O
,	,	,	O	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
area	area	NN	B-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
AUC	AUC	NN	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
0.815	0.815	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
]	]	)	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
>	>	JJR	I-NP	O	O
0.004	0.004	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cTnT	cTnT	NN	B-NP	O	O
(	(	(	O	O	O
sensitivity	sensitivity	NN	B-NP	O	O
,	,	,	O	O	O
79	79	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
specificity	specificity	NN	B-NP	O	O
,	,	,	O	O	O
64	64	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
AUC	AUC	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.757	0.757	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.005	0.005	CD	B-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
predicted	predict	VBD	B-VP	O	O
later	later	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GLS	GLS	NN	B-NP	O	O
remained	remain	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
independent	independent	JJ	I-NP	O	O
predictor	predictor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.000	0.000	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
GLS	GLS	NN	B-NP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cTnT	cTnT	NN	B-NP	O	O
may	may	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
a	a	DT	B-NP	O	O
reliable	reliable	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
invasive	invasive	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
anthracycline	anthracycline	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

Prevention	Prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myoclonus	myoclonus	NN	I-NP	O	B-Disease
:	:	:	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
superior	superior	JJ	B-ADJP	O	O
:	:	:	O	O	O
Fentanyl	Fentanyl	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
?	?	.	O	O	O

A	A	DT	B-NP	O	O
Retrospective	Retrospective	JJ	I-NP	O	O
comparative	comparative	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
comparative	comparative	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
compare	compare	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
midazolam	midazolam	NN	I-NP	B	B-Chemical
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myoclonus	myoclonus	NN	I-NP	O	B-Disease
.	.	.	O	O	O

MATERIAL	MATERIAL	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
records	record	NNS	I-NP	O	O
.	.	.	O	O	O

Depending	Depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
with	with	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
separated	separate	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
4	4	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
no	no	DT	B-NP	O	O
pretreatment	pretreatment	NN	I-NP	O	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
NP	NP	NN	I-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
1	1	CD	I-NP	O	O
ug.kg	ug.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
F	F	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
midazolam	midazolam	NN	B-NP	B	B-Chemical
0.03	0.03	CD	I-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
M	M	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
midazolam	midazolam	NN	B-NP	B	B-Chemical
0.015	0.015	CD	I-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
fentanyl	fentanyl	NN	I-NP	B	B-Chemical
0.5	0.5	CD	I-NP	O	O
ug.kg	ug.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
FM	FM	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
selected	select	VBN	I-VP	O	O
:	:	:	O	O	O
2	2	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pretreatment	pretreatment	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
anesthesia	anesthesia	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
induced	induce	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
0.3	0.3	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
etomidate	etomidate	NN	I-NP	B	B-Chemical
injected	inject	VBN	B-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
30	30	CD	I-NP	O	O
seconds	second	NNS	I-NP	O	O
.	.	.	O	O	O

Myoclonic	Myoclonic	JJ	B-NP	O	B-Disease
movements	movement	NNS	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
graded	grade	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
severity	severity	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pain	pain	NN	B-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
etomidate	etomidate	VB	I-VP	B	B-Chemical
injection	injection	NN	B-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Study	Study	NN	B-NP	O	O
results	result	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
myoclonus	myoclonus	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
85	85	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Group	Group	NNP	B-NP	O	O
NP	NP	NNP	I-NP	B	O
,	,	,	O	O	O
Group	Group	NNP	B-NP	O	O
F	F	NNP	I-NP	O	O
,	,	,	O	O	O
Group	Group	NNP	B-NP	O	O
M	M	NNP	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Group	Group	NNP	B-NP	O	O
FM	FM	NNP	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
F	F	NN	I-NP	O	O
and	and	CC	O	O	O
Group	Group	NN	B-NP	O	O
FM	FM	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
midazolam	midazolam	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myoclonus	myoclonus	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Cholestatic	Cholestatic	JJ	B-NP	O	B-Disease
presentation	presentation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
yellow	yellow	JJ	B-NP	B	O
phosphorus	phosphorus	NN	I-NP	I	B-Chemical
poisoning	poisoning	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Yellow	Yellow	JJ	B-NP	B	O
phosphorus	phosphorus	NN	I-NP	I	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
component	component	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
pesticide	pesticide	NN	I-NP	O	O
pastes	paste	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
fireworks	firework	NNS	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Poisoning	Poison	VBG	B-VP	O	B-Disease
with	with	IN	B-PP	O	O
yellow	yellow	JJ	B-NP	B	O
phosphorus	phosphorus	NN	I-NP	I	B-Chemical
classically	classically	RB	B-ADVP	O	O
manifests	manifest	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
yellow	yellow	JJ	B-NP	B	O
phosphorus	phosphorus	NN	I-NP	I	B-Chemical
poisoning	poisoning	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
florid	florid	JJ	B-NP	B	O
clinical	clinical	JJ	I-NP	O	O
features	feature	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cholestasis	cholestasis	NN	B-NP	O	B-Disease
highlighting	highlight	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
fact	fact	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
cholestasis	cholestasis	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
rarely	rarely	RB	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
presenting	present	VBG	I-NP	O	O
feature	feature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
yellow	yellow	JJ	B-NP	B	O
phosphorus	phosphorus	NN	I-NP	I	B-Chemical
hepatotoxicity	hepatotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Vasovagal	Vasovagal	JJ	B-NP	O	B-Disease
syncope	syncope	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
intranasal	intranasal	JJ	B-NP	O	O
dexmedetomidine	dexmedetomidine	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
procedural	procedural	JJ	I-NP	O	O
sedation	sedation	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
syncope	syncope	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
11	11	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
girl	girl	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
intranasal	intranasal	JJ	B-NP	O	O
dexmedetomidine	dexmedetomidine	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
sedation	sedation	NN	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
voiding	void	VBG	I-NP	O	O
cystourethrogram	cystourethrogram	NN	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
successful	successful	JJ	B-NP	O	O
completion	completion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VCUG	VCUG	NN	B-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
60	60	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
min	min	NN	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
consciousness	consciousness	NN	B-NP	O	O
and	and	CC	O	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
presedation	presedation	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Upon	Upon	IN	B-PP	O	O
leaving	leave	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
area	area	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
collapsed	collapse	VBD	B-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
inciting	incite	VBG	I-NP	O	O
event	event	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
quickly	quickly	RB	B-ADVP	O	O
regained	regain	VBD	B-VP	O	O
consciousness	consciousness	NN	B-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
injury	injury	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
abnormality	abnormality	NN	I-NP	O	O
found	find	VBN	B-VP	O	O
was	be	VBD	B-VP	O	O
persistent	persistent	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
she	she	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
telemetric	telemetric	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
lasted	last	VBD	B-VP	O	O
~	~	RB	B-NP	O	O
2	2	CD	I-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
further	further	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
workup	workup	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
abnormality	abnormality	NN	I-NP	O	O
.	.	.	O	O	O

Unanticipated	Unanticipated	JJ	B-ADJP	O	O
and	and	CC	O	O	O
previously	previously	RB	B-NP	O	O
unreported	unreported	JJ	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
witnessed	witness	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
we	we	PRP	B-NP	O	O
expand	expand	VBP	B-VP	B	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
sedatives	sedative	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
alternative	alternative	JJ	B-NP	O	O
routes	route	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
.	.	.	O	O	O

Paradoxical	Paradoxical	JJ	B-NP	O	O
severe	severe	JJ	I-NP	O	O
agitation	agitation	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
add	add	NN	B-NP	O	O
-	-	HYPH	B-ADVP	O	O
on	on	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
doses	dose	NNS	I-NP	O	O
quetiapine	quetiapine	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
schizo	schizo	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
affective	affective	JJ	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
35	35	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
schizo	schizo	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
affective	affective	JJ	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
19	19	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
treated	treat	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
antipsychotics	antipsychotic	NNS	I-NP	O	O
,	,	,	O	O	O
zuclopenthixol	zuclopenthixol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1200	1200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
serum	serum	NN	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
=	=	SYM	B-VP	O	O
0.85	0.85	CD	B-NP	O	O
mEq	mEq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
associated	associate	VBN	I-NP	O	O
personality	personality	NN	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
particularly	particularly	RB	B-NP	O	O
no	no	DT	I-NP	O	O
antisocial	antisocial	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
substance	substance	NN	I-NP	O	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Within	Within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
48	48	CD	I-NP	O	O
h	h	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
gradual	gradual	JJ	I-NP	B	O
introduction	introduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
600	600	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
severe	severe	JJ	B-NP	O	O
agitation	agitation	NN	I-NP	O	B-Disease
without	without	IN	B-PP	O	O
an	an	DT	B-NP	O	O
environmental	environmental	JJ	I-NP	O	O
explanation	explanation	NN	I-NP	O	O
,	,	,	O	O	O
contrasting	contrast	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aggressiveness	aggressiveness	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
personality	personality	NN	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
diagnoses	diagnosis	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
manic	manic	JJ	B-NP	O	B-Disease
shift	shift	NN	I-NP	O	O
and	and	CC	I-NP	O	O
akathisia	akathisia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
dismissed	dismiss	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
gradual	gradual	JJ	I-NP	B	O
reintroduction	reintroduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
another	another	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
agitation	agitation	NN	I-NP	O	B-Disease
,	,	,	O	O	O
enabled	enable	VBD	B-VP	O	O
us	us	PRP	B-NP	O	O
to	to	TO	B-VP	O	O
attribute	attribute	VB	I-VP	O	O
the	the	DT	B-NP	O	O
agitation	agitation	NN	I-NP	O	B-Disease
specifically	specifically	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Antioxidant	Antioxidant	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	O	O
lactoferrin	lactoferrin	NN	I-NP	O	O
on	on	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
(	(	(	O	O	O
Dex	Dex	NN	B-NP	O	B-Chemical
-	-	SYM	O	O	O
)	)	)	O	O	O
induced	induce	VBN	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
.	.	.	O	O	O

Lactoferrin	Lactoferrin	NN	B-NP	O	O
(	(	(	O	O	O
LF	LF	NN	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
iron	iron	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
binding	bind	VBG	B-VP	O	O
glycoprotein	glycoprotein	NN	B-NP	B	O
with	with	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LF	LF	NN	B-NP	O	O
on	on	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
upon	upon	IN	B-PP	O	O
Dex	Dex	NN	B-NP	O	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
Dex	Dex	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
u	u	SYM	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
subcutaneously	subcutaneously	RB	B-ADVP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	B	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
bovine	bovine	JJ	I-NP	O	O
LF	LF	NN	I-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
100	100	CD	I-NP	O	O
,	,	,	I-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
day	day	NN	B-NP	O	O
8	8	CD	I-NP	O	O
to	to	TO	B-PP	O	O
14	14	CD	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reversal	reversal	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
rats	rat	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
LF	LF	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Dex	Dex	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
continued	continue	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Systolic	Systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
SBP	SBP	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
tail	tail	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
cuff	cuff	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

Thymus	Thymus	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
marker	marker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
hydrogen	hydrogen	NN	I-NP	B	B-Chemical
peroxide	peroxide	NN	I-NP	I	I-Chemical
(	(	(	O	I	O
H2O2	H2O2	NN	B-NP	I	B-Chemical
)	)	)	O	I	O
concentration	concentration	NN	B-NP	O	O
and	and	CC	O	O	O
ferric	ferric	JJ	B-ADJP	O	O
reducing	reduce	VBG	B-VP	O	O
antioxidant	antioxidant	JJ	B-NP	O	O
power	power	NN	I-NP	O	O
(	(	(	O	O	O
FRAP	FRAP	NN	B-NP	O	O
)	)	)	O	O	O
value	value	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
SBP	SBP	NN	B-NP	O	O
and	and	CC	O	O	O
plasma	plasma	NN	B-NP	O	O
H2O2	H2O2	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
thymus	thymus	NN	B-NP	O	O
and	and	CC	I-NP	O	O
body	body	NN	I-NP	O	O
weights	weight	NNS	I-NP	O	O
.	.	.	O	O	O

LF	LF	NN	B-NP	O	O
lowered	lower	VBD	B-VP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
dose	dose	NN	B-NP	O	O
dependently	dependently	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
(	(	(	O	O	O
P	P	NN	O	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	O	O	O
)	)	)	O	O	O
Dex	Dex	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

LF	LF	NN	B-NP	O	O
prevented	prevent	VBD	B-VP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
reduced	reduce	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
elevated	elevate	VBN	I-NP	B	O
plasma	plasma	NN	I-NP	O	O
H2O2	H2O2	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
FRAP	FRAP	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LF	LF	NN	B-NP	O	O
strongly	strongly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ROS	ROS	NN	B-NP	B	O
and	and	CC	O	O	O
improved	improve	VBN	B-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Dex	Dex	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
as	as	IN	B-PP	O	O
another	another	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LF	LF	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
convulsive	convulsive	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
multivariate	multivariate	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
529	529	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
contemporary	contemporary	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
undertook	undertake	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prospectively	prospectively	RB	B-NP	O	O
collected	collect	VBN	I-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
11	11	CD	B-NP	O	O
529	529	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
bypass	bypass	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
2004	2004	CD	I-NP	O	O
to	to	TO	B-PP	O	O
December	December	NNP	B-NP	O	O
2010	2010	CD	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
convulsive	convulsive	JJ	I-NP	O	B-Disease
seizure	seizure	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
transient	transient	JJ	I-NP	O	O
episode	episode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
disturbed	disturbed	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
function	function	NN	I-NP	O	O
characterised	characterise	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	B-Disease
involuntary	involuntary	JJ	I-NP	O	I-Disease
motor	motor	NN	I-NP	O	I-Disease
movements	movement	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Multivariate	Multivariate	JJ	B-NP	O	O
regression	regression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
identify	identify	VB	I-VP	O	O
independent	independent	JJ	B-NP	O	O
predictors	predictor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
(	(	(	O	O	O
0.9	0.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
developed	develop	VBD	B-VP	O	O
postoperative	postoperative	JJ	B-NP	O	O
convulsive	convulsive	JJ	I-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Generalised	Generalise	VBN	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
focal	focal	JJ	I-NP	O	I-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
68	68	CD	B-NP	O	O
and	and	CC	I-NP	O	O
32	32	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
(	(	(	O	O	O
IQR	IQR	NN	B-NP	O	O
[	[	(	O	O	O
range	range	NN	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
time	time	NN	B-NP	O	O
after	after	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
was	be	VBD	B-VP	O	O
7	7	CD	B-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
12	12	CD	I-NP	O	O
[	[	(	I-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
216	216	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
h	h	NN	B-NP	O	O
and	and	CC	O	O	O
8	8	CD	B-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
11	11	CD	I-NP	O	O
[	[	(	I-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
18	18	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
h	h	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Epileptiform	Epileptiform	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
electroencephalography	electroencephalography	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
19	19	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Independent	Independent	JJ	B-NP	O	O
predictors	predictor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
included	include	VBD	B-VP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
female	female	JJ	B-NP	O	O
sex	sex	NN	I-NP	O	O
,	,	,	O	O	O
redo	redo	VBP	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
,	,	,	O	O	O
calcification	calcification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ascending	ascend	VBG	B-VP	O	O
aorta	aorta	NN	B-NP	O	O
,	,	,	O	O	O
congestive	congestive	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
deep	deep	JJ	B-NP	O	O
hypothermic	hypothermic	JJ	I-NP	O	B-Disease
circulatory	circulatory	JJ	I-NP	O	O
arrest	arrest	NN	I-NP	O	O
,	,	,	O	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
aortic	aortic	JJ	B-NP	O	O
cross	cross	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
clamp	clamp	NN	I-NP	O	O
and	and	CC	O	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
tested	test	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
multivariate	multivariate	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
independent	independent	JJ	I-NP	O	O
predictor	predictor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
14.3	14.3	CD	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
5.5	5.5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
36.7	36.7	CD	I-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
convulsive	convulsive	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	B-Disease
had	have	VBD	B-VP	O	O
2.5	2.5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
higher	high	JJR	B-ADVP	O	O
in	in	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
and	and	CC	O	O	O
twice	twice	RB	B-NP	O	O
the	the	DT	I-NP	O	O
length	length	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hospital	hospital	NN	B-NP	O	O
stay	stay	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
convulsive	convulsive	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Mean	Mean	NN	B-NP	O	O
(	(	(	O	O	O
IQR	IQR	NN	B-NP	O	O
[	[	(	O	O	O
range	range	NN	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
length	length	NN	B-NP	O	O
of	of	IN	B-PP	O	O
stay	stay	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
115	115	CD	B-NP	O	O
(	(	(	O	O	O
49	49	CD	B-NP	O	O
-	-	HYPH	O	O	O
228	228	CD	B-NP	O	O
[	[	(	O	O	O
32	32	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
481	481	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
h	h	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
convulsive	convulsive	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	B-Disease
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
26	26	CD	B-NP	O	O
(	(	(	O	O	O
22	22	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
69	69	CD	I-NP	O	O
[	[	(	O	O	O
14	14	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1080	1080	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
h	h	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Convulsive	Convulsive	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
serious	serious	JJ	I-NP	O	O
postoperative	postoperative	JJ	I-NP	O	B-Disease
complication	complication	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
modifiable	modifiable	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
exceeding	exceed	VBG	B-VP	O	O
80	80	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
weighed	weigh	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Dysfunctional	Dysfunctional	JJ	B-NP	O	B-Disease
overnight	overnight	JJ	I-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
consolidation	consolidation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Sleep	Sleep	NN	B-NP	O	O
plays	play	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
integration	integration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
memory	memory	NN	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
process	process	NN	I-NP	O	O
called	call	VBN	B-VP	O	O
overnight	overnight	JJ	B-NP	O	O
memory	memory	NN	I-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
.	.	.	O	O	O

Previous	Previous	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
marked	mark	VBN	I-VP	O	O
and	and	CC	O	O	O
persistent	persistent	JJ	B-NP	O	O
neurocognitive	neurocognitive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
sleep	sleep	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
related	relate	VBN	I-NP	O	I-Disease
impairments	impairment	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
extend	extend	VBP	B-VP	O	O
past	past	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
by	by	IN	B-PP	O	O
examining	examine	VBG	B-VP	O	O
overnight	overnight	JJ	B-NP	O	O
memory	memory	NN	I-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
among	among	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
drug	drug	NN	B-NP	O	O
naive	naive	JJ	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
controls	control	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
26	26	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Memory	Memory	NN	B-NP	O	O
recall	recall	NN	I-NP	O	O
of	of	IN	B-PP	O	O
word	word	NN	B-NP	O	O
pairs	pair	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sleep	sleep	NN	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
and	and	CC	B-PP	O	O
without	without	IN	B-PP	O	O
interference	interference	NN	B-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
testing	testing	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
assessed	assess	VBD	B-VP	O	O
neurocognitive	neurocognitive	JJ	B-NP	O	O
performances	performance	NNS	I-NP	O	O
across	across	IN	B-PP	O	O
tasks	task	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
,	,	,	O	O	O
memory	memory	NN	B-NP	O	O
and	and	CC	O	O	O
executive	executive	NN	B-NP	O	O
functioning	functioning	NN	I-NP	O	O
.	.	.	O	O	O

Ecstasy	Ecstasy	JJ	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
overnight	overnight	JJ	I-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
consolidation	consolidation	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
following	follow	VBG	B-PP	O	O
associative	associative	JJ	B-NP	O	O
interference	interference	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
ecstasy	ecstasy	JJ	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
impairments	impairment	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
tasks	task	NNS	B-NP	O	O
recruiting	recruit	VBG	B-VP	B	O
frontostriatal	frontostriatal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
neural	neural	JJ	I-NP	O	O
circuitry	circuitry	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
domains	domain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
proactive	proactive	JJ	B-NP	O	O
interference	interference	NN	I-NP	O	O
memory	memory	NN	I-NP	O	O
,	,	,	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
memory	memory	NN	I-NP	O	O
,	,	,	O	O	O
encoding	encode	VBG	B-VP	O	O
,	,	,	O	O	O
working	work	VBG	B-VP	O	O
memory	memory	NN	B-NP	O	O
and	and	CC	O	O	O
complex	complex	JJ	B-NP	O	O
planning	planning	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ecstasy	ecstasy	NN	B-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fronto	fronto	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
temporal	temporal	JJ	I-NP	O	O
circuitry	circuitry	NN	I-NP	O	O
may	may	MD	B-VP	O	O
underlie	underlie	VB	I-VP	O	O
overnight	overnight	JJ	B-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
impairments	impairment	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
ecstasy	ecstasy	JJ	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Normoammonemic	Normoammonemic	JJ	B-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
:	:	:	O	O	O
solely	solely	RB	B-NP	O	O
valproate	valproate	NN	I-NP	B	B-Chemical
induced	induced	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
multiple	multiple	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
?	?	.	O	O	O

A	A	DT	B-NP	O	O
77	77	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
subacute	subacute	JJ	B-NP	O	O
onset	onset	NN	I-NP	O	O
progressive	progressive	JJ	I-NP	O	O
confusion	confusion	NN	I-NP	O	B-Disease
,	,	,	O	O	O
aggression	aggression	NN	B-NP	O	B-Disease
,	,	,	O	O	O
auditory	auditory	JJ	B-NP	O	B-Disease
hallucinations	hallucination	NNS	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
delusions	delusion	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
preceding	precede	VBG	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
admissions	admission	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
unilateral	unilateral	JJ	I-NP	O	O
hemiparesis	hemiparesis	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
facial	facial	JJ	B-NP	O	O
droop	droop	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
started	start	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
presumed	presume	VBN	B-NP	O	O
hemiplegic	hemiplegic	JJ	I-NP	O	B-Disease
migraine	migraine	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
soon	soon	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
and	and	CC	O	O	O
her	her	PRP$	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
abilities	ability	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
gradually	gradually	RB	I-VP	O	O
improved	improve	VBN	I-VP	O	O
over	over	IN	B-PP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
taken	take	VBN	B-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
subtherapeutic	subtherapeutic	JJ	B-ADJP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
normoammonaemic	normoammonaemic	JJ	B-ADJP	O	O
.	.	.	O	O	O

EEG	EEG	NN	B-NP	O	O
undertaken	undertake	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
inpatient	inpatient	NN	B-NP	O	O
stay	stay	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
changes	change	NNS	B-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
low	low	JJ	B-NP	O	O
titre	titre	NN	I-NP	O	O
N	N	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
D	D	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aspartate	aspartate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
NMDA	NMDA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
receptor	receptor	NN	B-NP	O	O
antibodies	antibody	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
aetiologies	aetiology	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
NMDA	NMDA	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
encephalitis	encephalitis	NN	I-NP	O	B-Disease
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
dilemma	dilemma	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
putative	putative	JJ	I-NP	O	O
combinatorial	combinatorial	JJ	I-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
to	to	TO	B-VP	O	O
explain	explain	VB	I-VP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Cerebellar	Cerebellar	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
oculomotor	oculomotor	NN	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
rapid	rapid	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pethidine	pethidine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Pethidine	Pethidine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
opioid	opioid	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
gains	gain	VBZ	B-VP	O	O
its	its	PRP$	B-NP	O	O
popularity	popularity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
control	control	NN	I-NP	O	O
through	through	IN	B-PP	O	O
acting	act	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
opioid	opioid	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
rapid	rapid	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
relief	relief	NN	I-NP	O	O
sometimes	sometimes	RB	B-ADVP	O	O
brings	bring	VBZ	B-VP	O	O
about	about	IN	B-PP	O	O
unfavourable	unfavourable	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
largely	largely	RB	B-ADVP	O	O
limit	limit	VBP	B-VP	O	O
its	its	PRP$	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
utility	utility	NN	I-NP	O	O
.	.	.	O	O	O

Common	Common	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
vomiting	vomiting	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
function	function	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
who	who	WP	B-NP	O	O
need	need	VBP	B-VP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
control	control	NN	I-NP	O	O
,	,	,	O	O	O
pethidine	pethidine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
excitatory	excitatory	JJ	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
)	)	)	O	O	O
effects	effect	NNS	B-NP	O	O
through	through	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
metabolite	metabolite	NN	I-NP	O	O
,	,	,	O	O	O
norpethidine	norpethidine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
irritability	irritability	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
attack	attack	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contrary	contrary	NN	I-NP	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
not	not	RB	O	O	O
clinically	clinically	RB	B-ADJP	O	O
apparent	apparent	JJ	I-ADJP	O	O
,	,	,	O	O	O
pethidine	pethidine	NN	B-NP	B	B-Chemical
potentially	potentially	RB	B-ADVP	O	O
causes	cause	VBZ	B-VP	O	O
inhibitory	inhibitory	JJ	B-NP	O	O
impacts	impact	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
and	and	CC	O	O	O
impairs	impair	VBZ	B-VP	O	O
normal	normal	JJ	B-NP	O	O
cerebellar	cerebellar	NN	I-NP	O	O
and	and	CC	I-NP	O	O
oculomotor	oculomotor	NN	I-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
term	term	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
highlight	highlight	VBP	B-VP	O	O
opioid	opioid	JJ	B-NP	O	O
's	's	POS	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerebellar	cerebellar	JJ	I-NP	O	O
structure	structure	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
causes	cause	VBZ	B-VP	O	O
dysmetria	dysmetria	NN	B-NP	O	B-Disease
,	,	,	O	O	O
dysarthria	dysarthria	NN	B-NP	O	B-Disease
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
smooth	smooth	JJ	B-NP	O	O
pursuit	pursuit	NN	I-NP	B	O
gain	gain	NN	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
saccadic	saccadic	JJ	B-NP	O	O
velocity	velocity	NN	I-NP	O	O
.	.	.	O	O	O

Baboon	Baboon	NN	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
27	27	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
maculopapular	maculopapular	JJ	I-NP	O	B-Disease
eruption	eruption	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
flexural	flexural	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
buttocks	buttock	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
baboon	baboon	NN	I-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
history	history	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
prior	prior	JJ	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
topical	topical	JJ	B-NP	O	O
ketoconazole	ketoconazole	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
physical	physical	JJ	I-NP	O	O
examination	examination	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
histopathological	histopathological	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
.	.	.	O	O	O

Baboon	Baboon	NN	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
or	or	CC	O	O	O
contact	contact	NN	B-NP	O	O
allergen	allergen	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
maculopapular	maculopapular	JJ	I-NP	O	B-Disease
eruption	eruption	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
typically	typically	RB	B-ADVP	O	O
involves	involve	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
flexural	flexural	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
gluteal	gluteal	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
reported	report	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ketoconazole	ketoconazole	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
baboon	baboon	NN	I-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
English	English	JJ	I-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
Case	Case	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Sudden	Sudden	NNP	B-NP	O	B-Disease
Cardiac	Cardiac	NNP	I-NP	O	I-Disease
Death	Death	NNP	I-NP	O	I-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
Pilsicainide	Pilsicainide	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
Induced	Induce	VBN	B-VP	O	O
Torsades	Torsades	NNP	B-NP	O	B-Disease
de	de	IN	I-NP	O	I-Disease
Pointes	Pointes	NNP	I-NP	O	I-Disease
.	.	.	O	O	O

An	An	DT	B-NP	O	O
84	84	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
received	receive	VBN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
pilsicainide	pilsicainide	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
pure	pure	JJ	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
with	with	IN	B-PP	O	O
slow	slow	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
kinetics	kinetic	NNS	I-NP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
convert	convert	VB	I-VP	O	O
his	his	PRP$	B-NP	O	O
paroxysmal	paroxysmal	JJ	I-NP	O	O
atrial	atrial	JJ	I-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
sudden	sudden	JJ	B-NP	O	B-Disease
cardiac	cardiac	JJ	I-NP	O	I-Disease
death	death	NN	I-NP	O	I-Disease
two	two	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Holter	Holter	NNP	I-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
worn	wear	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
chance	chance	NN	B-NP	O	O
,	,	,	O	O	O
revealed	reveal	VBD	B-VP	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
gradually	gradually	RB	B-NP	O	O
prolonged	prolong	VBN	I-NP	O	O
QT	QT	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
rapidly	rapidly	RB	I-VP	O	O
absorbed	absorb	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
excreted	excrete	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
highly	highly	RB	B-ADJP	O	O
impaired	impaired	JJ	I-ADJP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pilsicainide	pilsicainide	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
low	low	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pilsicainide	pilsicainide	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
high	high	JJ	B-ADJP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	I-NP	O	I-Disease
pointes	pointe	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
octogenarian	octogenarian	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
class	class	NN	B-NP	O	O
IC	IC	NN	I-NP	B	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
pilsicainide	pilsicainide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
terminate	terminate	VB	I-VP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
,	,	,	O	O	O
careful	careful	JJ	B-NP	O	O
consideration	consideration	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
taken	take	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
giving	give	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
octogenarians	octogenarian	NNS	B-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
trans	trans	NN	I-NP	I	I-Chemical
retinoic	retinoic	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
myositis	myositis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
promyelocytic	promyelocytic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

All	All	DT	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
trans	trans	NN	I-NP	I	I-Chemical
retinoic	retinoic	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
component	component	NN	I-NP	O	O
of	of	IN	B-PP	O	O
standard	standard	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
promyelocytic	promyelocytic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
APL	APL	NN	B-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
serious	serious	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
treatable	treatable	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
numerous	numerous	JJ	B-NP	O	O
organ	organ	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
rare	rare	JJ	B-NP	O	O
skeletal	skeletal	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
involvement	involvement	NN	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
handful	handful	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myositis	myositis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
none	none	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
radiology	radiology	NN	I-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
such	such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
case	case	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
boy	boy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
APL	APL	NN	B-NP	O	B-Disease
,	,	,	O	O	O
where	where	WRB	B-ADVP	O	O
recognition	recognition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
imaging	image	VBG	B-NP	O	O
findings	finding	NNS	I-NP	O	O
played	play	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
crucial	crucial	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
making	make	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
and	and	CC	O	O	O
facilitated	facilitate	VBD	B-VP	O	O
prompt	prompt	JJ	B-NP	O	O
,	,	,	I-NP	O	O
effective	effective	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Tolerability	Tolerability	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lomustine	lomustine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
lymphoma	lymphoma	NN	B-NP	O	B-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
protocol	protocol	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lomustine	lomustine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CCNU	CCNU	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CTX	CTX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
lymphoma	lymphoma	NN	B-NP	O	B-Disease
.	.	.	O	O	O

CCNU	CCNU	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
per	per	IN	B-PP	O	O
os	o	NNS	B-NP	O	O
(	(	(	O	O	O
PO	PO	NN	B-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
targeted	target	VBN	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
0	0	CD	I-NP	O	O
,	,	,	O	O	O
CTX	CTX	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
PO	PO	NN	B-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
targeted	target	VBN	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
divided	divide	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
0	0	CD	B-NP	O	O
through	through	IN	B-PP	O	O
4	4	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	O
.	.	.	O	O	O

Ninety	Ninety	CD	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
57	57	CD	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
included	include	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Neutropenia	Neutropenia	NNP	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
principal	principal	JJ	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
grade	grade	NN	B-NP	O	O
4	4	CD	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CCNU	CCNU	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
CTX	CTX	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
19	19	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
43	43	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
grade	grade	NN	B-NP	O	O
4	4	CD	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
19.7	19.7	CD	B-NP	O	O
kg	kg	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
13.4	13.4	CD	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
less	less	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
develop	develop	VB	I-VP	O	O
grade	grade	NN	B-NP	O	O
4	4	CD	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
31.7	31.7	CD	B-NP	O	O
kg	kg	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
12.4	12.4	CD	B-NP	O	O
kg	kg	NN	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.005	.005	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
dog	dog	NN	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
developed	develop	VBD	B-VP	O	O
hematologic	hematologic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
suggestive	suggestive	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

No	No	DT	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
cystitis	cystitis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
uncommon	uncommon	JJ	B-ADJP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
reported	report	VBN	B-VP	O	O
herein	herein	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
CCNU	CCNU	NN	B-NP	B	B-Chemical
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
CTX	CTX	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
divided	divide	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
q	q	NN	B-NP	O	O
4	4	CD	I-NP	O	O
wk	wk	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
tolerable	tolerable	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
-	-	HYPH	O	O	O
bearing	bear	VBG	B-VP	O	O
dogs	dog	NNS	B-NP	O	O
.	.	.	O	O	O

Nelarabine	Nelarabine	NN	B-NP	B	B-Chemical
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
intrathecal	intrathecal	JJ	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
:	:	:	O	O	O
Case	Case	NN	B-NP	O	O
report	report	NN	I-NP	O	O
and	and	CC	O	O	O
review	review	NN	B-NP	O	O
of	of	IN	B-PP	O	O
literature	literature	NN	B-NP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
nelarabine	nelarabine	NN	I-NP	B	B-Chemical
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
intrathecal	intrathecal	JJ	I-NP	O	O
(	(	(	O	O	O
IT	IT	JJ	B-ADJP	O	O
)	)	)	O	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
37	37	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
Caucasian	Caucasian	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
T	T	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
relapsed	relapsed	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
originally	originally	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
autologous	autologous	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
relapsed	relapse	VBN	B-NP	O	O
disease	disease	NN	I-NP	O	O
10	10	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
leukemic	leukemic	JJ	B-NP	O	B-Disease
involvement	involvement	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
re	re	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
nelarabine	nelarabine	NN	B-NP	B	B-Chemical
1500	1500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
with	with	IN	B-PP	O	O
1	1	CD	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IT	IT	NN	B-NP	O	O
cytarabine	cytarabine	NN	I-NP	B	B-Chemical
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
as	as	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
)	)	)	O	O	O
prophylaxis	prophylaxis	NN	B-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
sequelae	sequelae	VB	I-VP	O	O
of	of	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
lysis	lysis	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
TLS	TLS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
tolerated	tolerate	VBD	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
well	well	RB	B-ADVP	O	O
,	,	,	O	O	O
entered	enter	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
remission	remission	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
recovered	recover	VBD	B-VP	O	O
her	her	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nelarabine	nelarabine	NN	B-NP	B	B-Chemical
without	without	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
IT	IT	NN	I-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
week	week	NN	I-NP	O	O
after	after	IN	B-PP	O	O
this	this	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
noted	note	VBD	B-VP	O	O
numbness	numbness	NN	B-NP	O	O
in	in	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
lower	low	JJR	I-NP	O	O
extremities	extremity	NNS	I-NP	O	O
.	.	.	O	O	O

Predominantly	Predominantly	RB	B-ADJP	O	O
sensory	sensory	JJ	I-ADJP	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
also	also	RB	B-ADVP	O	O
motor	motor	NN	B-NP	O	O
and	and	CC	O	O	O
autonomic	autonomic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
started	start	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
feet	foot	NNS	I-NP	O	O
,	,	,	O	O	O
ascended	ascend	VBD	B-VP	O	O
proximally	proximally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
mid	mid	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
thoracic	thoracic	JJ	I-NP	O	O
region	region	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
eventually	eventually	RB	B-VP	O	O
included	include	VBD	I-VP	O	O
her	her	PRP	B-NP	O	O
distal	distal	JJ	I-NP	O	O
upper	upper	JJ	I-NP	O	O
extremities	extremity	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
magnetic	magnetic	JJ	I-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
(	(	(	O	O	O
MRI	MRI	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
spine	spine	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
changes	change	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
C2	C2	NN	B-NP	B	O
to	to	TO	B-PP	O	O
C6	C6	NN	B-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
subacute	subacute	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
.	.	.	O	O	O

Nelarabine	Nelarabine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
felt	feel	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	B-Disease
stabilized	stabilize	VBD	B-VP	O	O
and	and	CC	I-VP	O	O
showed	show	VBD	I-VP	O	O
slight	slight	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
and	and	CC	O	O	O
ultimately	ultimately	RB	B-VP	O	O
received	receive	VBD	I-VP	O	O
an	an	DT	B-NP	O	O
unrelated	unrelated	JJ	I-NP	O	O
,	,	,	I-NP	O	O
reduced	reduce	VBN	I-NP	O	O
-	-	HYPH	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
allogeneic	allogeneic	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
complete	complete	JJ	B-NP	O	O
remission	remission	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
relapsed	relapse	VBD	B-VP	O	O
disease	disease	NN	B-NP	O	O
10	10	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
currently	currently	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
best	good	JJS	B-NP	O	O
supportive	supportive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
published	publish	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
nelarabine	nelarabine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
concurrent	concurrent	JJ	B-NP	O	O
IT	IT	NN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hyperammonemic	hyperammonemic	JJ	I-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
transplanted	transplant	VBN	I-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

Neurological	Neurological	JJ	B-NP	O	B-Disease
complications	complication	NNS	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
constitute	constitute	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morbidity	morbidity	NN	B-NP	O	O
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
.	.	.	O	O	O

Their	Their	PRP$	B-NP	O	O
differential	differential	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
difficult	difficult	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
essential	essential	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
management	management	NN	I-NP	O	O
.	.	.	O	O	O

Valproate	Valproate	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hyperammonemic	hyperammonemic	JJ	I-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
uncommon	uncommon	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
serious	serious	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
girl	girl	NN	I-NP	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
revealed	reveal	VBD	B-VP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
consciousness	consciousness	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
hyperammonemia	hyperammonemia	NN	B-NP	O	B-Disease
12	12	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
withdraw	withdraw	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
resolved	resolve	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Clinicians	Clinician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
awareness	awareness	NN	I-NP	O	O
for	for	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
transplanted	transplant	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Necrotising	Necrotise	VBG	B-VP	O	B-Disease
fasciitis	fasciitis	NN	B-NP	O	I-Disease
after	after	IN	B-PP	O	O
bortezomib	bortezomib	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
regimen	regimen	NN	B-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Waldenstrom	Waldenstrom	NNP	B-NP	O	B-Disease
macroglobulinaemia	macroglobulinaemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Bortezomib	Bortezomib	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
regimens	regimen	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
generally	generally	RB	B-ADJP	O	O
tolerable	tolerable	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
few	few	JJ	B-NP	O	O
severe	severe	JJ	I-NP	O	O
bacterial	bacterial	JJ	I-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
B	B	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
malignancies	malignancy	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
information	information	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
limited	limit	VBN	I-VP	O	O
concerning	concern	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
76	76	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Waldenstrom	Waldenstrom	NNP	B-NP	O	B-Disease
macroglobulinaemia	macroglobulinaemia	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
suffered	suffer	VBD	B-VP	O	O
necrotising	necrotise	VBG	I-VP	O	B-Disease
fasciitis	fasciitis	NN	B-NP	O	I-Disease
without	without	IN	B-PP	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
bortezomib	bortezomib	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
rituximab	rituximab	NN	I-NP	B	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
immediate	immediate	JJ	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
succumbed	succumb	VBD	B-VP	O	O
23	23	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
.	.	.	O	O	O

Physicians	Physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
recognise	recognise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
bacterial	bacterial	JJ	I-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
bortezomib	bortezomib	VB	I-VP	B	B-Chemical
plus	plus	CC	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
we	we	PRP	B-NP	O	O
believe	believe	VBP	B-VP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
warrants	warrant	VBZ	B-VP	O	O
further	further	JJ	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
integrated	integrate	VBN	I-NP	O	O
characterization	characterization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serological	serological	JJ	B-NP	O	O
,	,	,	I-NP	O	O
pathological	pathological	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
functional	functional	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Many	Many	JJ	B-NP	O	O
efficacious	efficacious	JJ	I-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
treatments	treatment	NNS	I-NP	O	O
cause	cause	VBP	B-VP	O	O
significant	significant	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
,	,	,	O	O	O
yet	yet	CC	O	O	O
biomarkers	biomarker	NNS	B-NP	O	O
or	or	CC	O	O	O
functional	functional	JJ	B-NP	O	O
indices	index	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
would	would	MD	B-VP	O	O
allow	allow	VB	I-VP	O	O
monitoring	monitoring	NN	B-NP	O	O
and	and	CC	I-NP	O	O
intervention	intervention	NN	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
lacking	lack	VBG	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
utilized	utilize	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
applying	apply	VBG	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
approaches	approach	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
magnetic	magnetic	JJ	I-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
(	(	(	O	O	O
MRI	MRI	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
provide	provide	VB	I-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
comprehensive	comprehensive	JJ	I-NP	O	O
characterization	characterization	NN	I-NP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
timecourse	timecourse	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serological	serological	JJ	B-NP	O	O
,	,	,	I-NP	O	O
pathological	pathological	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
functional	functional	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Hannover	Hannover	NNP	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
dosed	dose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
1.25	1.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
weekly	weekly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
week	week	NN	I-NP	O	O
off	off	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
dosing	dose	VBG	B-VP	O	O
"	"	``	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
"	"	''	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Electron	Electron	NN	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
subcellular	subcellular	JJ	B-NP	O	B-Disease
degeneration	degeneration	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
marked	marked	JJ	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Histopathological	Histopathological	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
progressive	progressive	JJ	B-NP	O	O
cardiomyocyte	cardiomyocyte	NN	I-NP	O	B-Disease
degeneration	degeneration	NN	I-NP	O	I-Disease
,	,	,	O	O	O
hypertrophy	hypertrophy	NN	B-NP	O	B-Disease
/	/	SYM	B-NP	O	O
cytomegaly	cytomegaly	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
extensive	extensive	JJ	B-NP	O	O
vacuolation	vacuolation	NN	I-NP	O	O
after	after	IN	B-PP	O	O
two	two	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Extensive	Extensive	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
(	(	(	O	O	O
quantified	quantify	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Sirius	Sirius	NNP	B-NP	B	O
red	red	JJ	I-NP	O	O
staining	staining	NN	I-NP	O	O
)	)	)	O	O	O
developed	develop	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
off	off	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Functional	Functional	JJ	B-NP	O	O
indices	index	NNS	I-NP	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
MRI	MRI	NN	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
(	(	(	O	O	O
LVEF	LVEF	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
E	E	NN	B-NP	O	O
/	/	SYM	O	O	O
A	A	NN	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
)	)	)	O	O	O
declined	decline	VBD	B-VP	O	O
progressively	progressively	RB	B-ADVP	O	O
,	,	,	O	O	O
reaching	reach	VBG	B-VP	O	O
statistical	statistical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
after	after	IN	B-PP	O	O
two	two	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
and	and	CC	O	O	O
culminating	culminate	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
"	"	``	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
"	"	''	I-NP	O	O
LV	LV	NN	I-NP	B	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
12	12	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Significant	Significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
peak	peak	NN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
contrast	contrast	NN	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
and	and	CC	O	O	O
serological	serological	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
troponin	troponin	NN	I-NP	O	O
I	I	CD	I-NP	O	O
(	(	(	O	O	O
cTnI	cTnI	NN	B-NP	O	O
)	)	)	O	O	O
emerged	emerge	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
importantly	importantly	RB	B-VP	O	O
preceding	precede	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
LVEF	LVEF	NN	I-NP	O	O
decline	decline	NN	I-NP	O	O
to	to	TO	B-PP	O	O
<	<	SYM	B-NP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Troponin	Troponin	NN	B-NP	O	O
I	I	CD	I-NP	O	O
levels	level	NNS	I-NP	O	O
positively	positively	RB	B-ADVP	O	O
correlated	correlate	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
peak	peak	JJ	I-NP	O	O
gadolinium	gadolinium	NN	I-NP	B	B-Chemical
contrast	contrast	NN	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
,	,	,	O	O	O
histopathological	histopathological	JJ	B-NP	O	O
grading	grading	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
diastolic	diastolic	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
summary	summary	NN	B-NP	O	O
,	,	,	O	O	O
subcellular	subcellular	JJ	B-NP	O	O
cardiomyocyte	cardiomyocyte	NN	I-NP	O	B-Disease
degeneration	degeneration	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
earliest	early	JJS	I-NP	O	O
marker	marker	NN	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
functional	functional	JJ	I-NP	O	O
decline	decline	NN	I-NP	O	O
and	and	CC	O	O	O
histopathological	histopathological	JJ	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
.	.	.	O	O	O

Myocardial	Myocardial	JJ	B-NP	O	O
contrast	contrast	NN	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
and	and	CC	O	O	O
elevations	elevation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cTnI	cTnI	NN	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
indices	index	NNS	I-NP	O	O
predated	predate	VBD	B-VP	B	O
"	"	``	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
"	"	''	I-NP	O	O
LV	LV	NN	I-NP	B	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
thus	thus	RB	B-NP	O	O
warrant	warrant	JJ	I-NP	O	O
further	further	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
as	as	IN	B-PP	O	O
predictive	predictive	JJ	B-NP	O	O
biomarkers	biomarker	NNS	I-NP	O	O
.	.	.	O	O	O

Intradermal	Intradermal	JJ	B-NP	O	O
glutamate	glutamate	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
:	:	:	O	O	O
intra	intra	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
interindividual	interindividual	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
provoked	provoked	JJ	B-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
allodynia	allodynia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Intradermal	Intradermal	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glutamate	glutamate	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
attractive	attractive	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
because	because	IN	B-SBAR	O	O
hyperalgesia	hyperalgesia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
allodynia	allodynia	NN	I-NP	O	B-Disease
mimic	mimic	VBP	B-VP	O	O
isolated	isolate	VBN	I-VP	O	O
aspects	aspect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
reproducibility	reproducibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
24	24	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
18	18	CD	I-NP	O	O
-	-	HYPH	O	O	O
38	38	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
intradermal	intradermal	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
glutamate	glutamate	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
volar	volar	JJ	I-NP	O	O
forearm	forearm	NN	I-NP	O	O
.	.	.	O	O	O

Magnitudes	Magnitude	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
secondary	secondary	JJ	B-NP	O	O
pinprick	pinprick	NN	I-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
brush	brush	NN	I-NP	O	O
-	-	HYPH	O	O	O
evoked	evoke	VBN	B-NP	O	O
allodynia	allodynia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
von	von	NNP	B-NP	O	O
Frey	Frey	NNP	I-NP	O	O
filaments	filament	NNS	I-NP	O	O
(	(	(	O	O	O
gauges	gauge	NNS	B-NP	O	O
10	10	CD	I-NP	O	O
,	,	,	I-NP	O	O
15	15	CD	I-NP	O	O
,	,	,	I-NP	O	O
60	60	CD	I-NP	O	O
and	and	CC	I-NP	O	O
100	100	CD	I-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
brush	brush	JJ	B-NP	O	O
strokes	stroke	NNS	I-NP	O	O
.	.	.	O	O	O

Areas	Area	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
secondary	secondary	JJ	B-NP	O	B-Disease
hyperalgesia	hyperalgesia	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
allodynia	allodynia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
quantified	quantify	VBN	I-VP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
and	and	CC	O	O	O
after	after	IN	B-PP	O	O
15	15	CD	B-NP	O	O
,	,	,	I-NP	O	O
30	30	CD	I-NP	O	O
and	and	CC	I-NP	O	O
60	60	CD	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
identical	identical	JJ	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
separated	separate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
7	7	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Reproducibility	Reproducibility	NN	B-NP	O	O
across	across	IN	B-PP	O	O
and	and	CC	I-PP	O	O
within	within	IN	I-PP	O	O
volunteers	volunteer	NNS	B-NP	O	O
(	(	(	O	O	O
inter	inter	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
and	and	CC	O	O	O
intra	intra	AFX	O	O	O
-	-	HYPH	O	O	O
individual	individual	JJ	B-NP	O	O
variation	variation	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
intraclass	intraclass	JJ	B-NP	O	O
correlation	correlation	NN	I-NP	O	O
coefficient	coefficient	NN	I-NP	O	O
(	(	(	O	O	O
ICC	ICC	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
coefficient	coefficient	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
variation	variation	NN	B-NP	O	O
(	(	(	O	O	O
CV	CV	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Secondary	Secondary	JJ	B-NP	O	O
pinprick	pinprick	NN	I-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	O
analogue	analogue	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
(	(	(	O	O	O
VAS	VAS	NN	B-NP	O	O
)	)	)	O	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
von	von	NNP	B-NP	O	O
Frey	Frey	NNP	I-NP	O	O
gauges	gauge	VBZ	B-VP	O	O
60	60	CD	B-NP	O	O
and	and	CC	I-NP	O	O
100	100	CD	I-NP	O	O
g	g	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
glutamate	glutamate	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
capsaicin	capsaicin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
secondary	secondary	JJ	B-NP	O	O
pinprick	pinprick	NN	I-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
all	all	DT	B-NP	O	O
von	von	NNP	I-NP	O	O
Frey	Frey	NNP	I-NP	O	O
gauges	gauge	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Glutamate	Glutamate	NN	B-NP	B	B-Chemical
evoked	evoke	VBD	B-VP	O	O
reproducible	reproducible	JJ	B-NP	O	O
VAS	VAS	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
all	all	DT	B-NP	O	O
von	von	NNP	I-NP	O	O
Frey	Frey	NNP	I-NP	O	O
gauges	gauge	NNS	I-NP	O	O
(	(	(	O	O	O
ICC	ICC	NN	B-NP	O	O
>	>	SYM	O	O	O
0.60	0.60	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
brush	brush	JJ	B-NP	O	O
strokes	stroke	NNS	I-NP	O	O
(	(	(	O	O	O
ICC	ICC	NN	B-NP	O	O
>	>	SYM	O	O	O
0.83	0.83	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Capsaicin	Capsaicin	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reproducible	reproducible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
secondary	secondary	JJ	B-NP	O	B-Disease
hyperalgesia	hyperalgesia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ICC	ICC	NN	B-NP	O	O
>	>	SYM	O	O	O
0.70	0.70	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
allodynia	allodynia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
ICC	ICC	NN	B-NP	O	O
>	>	SYM	O	O	O
0.71	0.71	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Intra	Intra	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
individual	individual	JJ	I-NP	O	O
variability	variability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
generally	generally	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
VAS	VAS	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
von	von	NNP	B-NP	O	O
Frey	Frey	NNP	I-NP	O	O
and	and	CC	O	O	O
brush	brush	NN	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
areas	area	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
secondary	secondary	JJ	B-NP	O	B-Disease
hyperalgesia	hyperalgesia	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
allodynia	allodynia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
glutamate	glutamate	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
capsaicin	capsaicin	NN	B-NP	B	B-Chemical
yield	yield	NN	I-NP	O	O
reproducible	reproducible	JJ	B-NP	O	O
hyperalgesic	hyperalgesic	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
allodynic	allodynic	JJ	I-NP	O	B-Disease
responses	response	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
suited	suit	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
basic	basic	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
for	for	IN	B-PP	O	O
assessing	assess	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
modulation	modulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
phenomena	phenomenon	NNS	I-NP	O	O
.	.	.	O	O	O

Ocular	Ocular	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	I-NP	O	O
ER	ER	NN	I-NP	B	O
stress	stress	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
rescues	rescue	VBZ	B-VP	O	O
glaucoma	glaucoma	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
murine	murine	JJ	B-NP	O	O
glucocorticoid	glucocorticoid	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
glucocorticoids	glucocorticoid	NNS	B-NP	O	O
induces	induce	VBZ	B-VP	O	O
ocular	ocular	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
untreated	untreated	JJ	B-ADJP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
a	a	DT	B-NP	O	O
secondary	secondary	JJ	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
resembles	resemble	VBZ	B-VP	O	O
primary	primary	JJ	B-NP	O	B-Disease
open	open	JJ	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
angle	angle	NN	I-NP	O	I-Disease
glaucoma	glaucoma	NN	I-NP	O	I-Disease
(	(	(	O	O	O
POAG	POAG	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
pathology	pathology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
fully	fully	RB	I-VP	O	O
understood	understand	VBN	I-VP	O	O
,	,	,	O	O	O
due	due	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
to	to	TO	B-PP	O	O
lack	lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
murine	murine	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
exhibits	exhibit	VBZ	B-VP	O	O
glaucoma	glaucoma	NN	B-NP	O	B-Disease
features	feature	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
ocular	ocular	JJ	I-NP	O	O
0.1	0.1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
elevation	elevation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
intraocular	intraocular	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
IOP	IOP	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
functional	functional	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
structural	structural	JJ	I-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
retinal	retinal	JJ	B-NP	O	B-Disease
ganglion	ganglion	NN	I-NP	O	I-Disease
cells	cell	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
axonal	axonal	JJ	B-NP	O	B-Disease
degeneration	degeneration	NN	I-NP	O	I-Disease
,	,	,	O	O	O
resembling	resemble	VBG	B-VP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ocular	ocular	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
ER	ER	NN	I-NP	B	O
stress	stress	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
trabecular	trabecular	JJ	I-NP	O	O
meshwork	meshwork	NN	I-NP	O	O
(	(	(	O	O	O
TM	TM	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

Similar	Similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
withdrawal	withdrawal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
elevated	elevated	JJ	B-NP	O	O
IOP	IOP	NN	I-NP	B	O
and	and	CC	I-NP	O	O
ER	ER	NN	I-NP	B	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Dexamethasone	Dexamethasone	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
transcriptional	transcriptional	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
CHOP	CHOP	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
marker	marker	NN	I-NP	O	O
for	for	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
ER	ER	NN	I-NP	B	O
stress	stress	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anterior	anterior	JJ	I-NP	O	O
segment	segment	NN	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Chop	Chop	NN	B-NP	O	O
deletion	deletion	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
ER	ER	NN	B-NP	B	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
and	and	CC	O	O	O
prevented	prevent	VBD	B-VP	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ocular	ocular	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ER	ER	NN	B-NP	B	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TM	TM	NN	I-NP	B	O
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
4	4	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
phenylbutyrate	phenylbutyrate	NN	I-NP	I	I-Chemical
prevented	prevent	VBD	B-VP	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ocular	ocular	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ER	ER	NN	B-NP	B	O
stress	stress	NN	I-NP	O	O
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ocular	ocular	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
reducing	reduce	VBG	B-VP	O	O
ER	ER	NN	B-NP	B	O
stress	stress	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
potential	potential	NN	B-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
strategy	strategy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
treating	treat	VBG	B-VP	O	O
glucocorticoid	glucocorticoid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
glaucoma	glaucoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ginsenosides	ginsenoside	NNS	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
opioid	opioid	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Opioid	Opioid	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
OIH	OIH	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
nociceptive	nociceptive	JJ	B-NP	O	O
sensitization	sensitization	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cessation	cessation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
opioid	opioid	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

OIH	OIH	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
limit	limit	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	O
analgesics	analgesic	NNS	I-NP	O	O
and	and	CC	O	O	O
complicate	complicate	VBP	B-VP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
from	from	IN	B-PP	O	O
opioid	opioid	JJ	B-NP	O	B-Disease
addiction	addiction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Re	Re	NN	B-NP	B	B-Chemical
,	,	,	O	O	I-Chemical
Rg1	Rg1	NN	B-NP	O	I-Chemical
,	,	,	O	O	I-Chemical
and	and	CC	O	O	I-Chemical
Rb1	Rb1	NN	B-NP	O	I-Chemical
ginsenosides	ginsenoside	NNS	I-NP	B	I-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
bioactive	bioactive	JJ	I-NP	O	O
components	component	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ginseng	ginseng	NN	B-NP	B	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
OIH	OIH	NN	B-NP	O	B-Disease
.	.	.	O	O	O

OIH	OIH	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
subcutaneous	subcutaneous	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
(	(	(	O	O	O
days	day	NNS	B-NP	O	O
8	8	CD	B-NP	O	O
and	and	CC	I-NP	O	O
9	9	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
Re	Re	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
Rg1	Rg1	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
Rb1	Rb1	NN	B-NP	O	B-Chemical
intragastrically	intragastrically	RB	B-ADVP	O	O
two	two	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
day	day	NN	B-NP	O	O
10	10	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
mice	mouse	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
subjected	subject	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
thermal	thermal	JJ	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
test	test	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
acetic	acetic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
writhing	writhing	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Re	Re	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
inhibited	inhibit	VBD	B-VP	O	O
OIH	OIH	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
the	the	DT	I-NP	O	O
thermal	thermal	JJ	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
test	test	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
acetic	acetic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
writhing	writhing	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
Rg1	Rg1	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	I-Chemical
Rb1	Rb1	NN	I-NP	O	I-Chemical
ginsenosides	ginsenoside	NNS	I-NP	B	I-Chemical
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
OIH	OIH	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
either	either	DT	B-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
Rg1	Rg1	NN	B-NP	O	B-Chemical
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
tendency	tendency	NN	I-NP	O	O
to	to	TO	B-VP	O	O
aggravate	aggravate	VB	I-VP	O	O
OIH	OIH	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acetic	acetic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
writhing	writhing	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggested	suggest	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
ginsenoside	ginsenoside	NN	I-NP	B	B-Chemical
Re	Re	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
Rg1	Rg1	NN	B-NP	O	B-Chemical
or	or	CC	O	O	O
Rb1	Rb1	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
toward	toward	IN	B-PP	O	O
reversal	reversal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
OIH	OIH	NN	B-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
sedation	sedation	NN	B-NP	O	O
in	in	IN	B-PP	O	O
neurocritical	neurocritical	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Dexmedetomidine	Dexmedetomidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
commonly	commonly	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
sedatives	sedative	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
neurocritical	neurocritical	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
allow	allow	VBP	B-VP	O	O
for	for	IN	B-PP	O	O
frequent	frequent	JJ	B-NP	O	O
neurologic	neurologic	JJ	I-NP	O	O
examinations	examination	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
compare	compare	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
neurocritical	neurocritical	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
Multicenter	Multicenter	NNP	B-NP	O	O
,	,	,	O	O	O
retrospective	retrospective	JJ	B-NP	O	O
,	,	,	I-NP	O	O
propensity	propensity	NN	I-NP	O	O
-	-	HYPH	O	O	O
matched	match	VBN	B-VP	B	O
cohort	cohort	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

SETTING	SETTING	NN	B-NP	O	O
:	:	:	O	O	O
Neurocritical	Neurocritical	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
units	unit	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
two	two	CD	B-NP	O	O
academic	academic	JJ	I-NP	O	O
medical	medical	JJ	I-NP	O	O
centers	center	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
dedicated	dedicate	VBN	B-NP	O	O
neurocritical	neurocritical	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
teams	team	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
board	board	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
certified	certify	VBN	I-NP	O	O
neurointensivists	neurointensivist	NNS	I-NP	O	O
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
:	:	:	O	O	O
Neurocritical	Neurocritical	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
admitted	admit	VBN	B-VP	O	O
between	between	IN	B-PP	O	O
July	July	NNP	B-NP	O	O
2009	2009	CD	I-NP	O	O
and	and	CC	O	O	O
September	September	NNP	B-NP	O	O
2012	2012	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
and	and	CC	O	O	O
then	then	RB	O	O	O
matched	match	VBD	B-VP	B	O
1	1	CD	B-NP	O	O
:	:	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
propensity	propensity	NN	B-NP	O	O
scoring	scoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
.	.	.	O	O	O

INTERVENTIONS	INTERVENTIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Continuous	Continuous	JJ	B-NP	O	O
sedation	sedation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

MEASUREMENTS	MEASUREMENTS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
MAIN	MAIN	NN	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
342	342	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
105	105	CD	B-NP	O	O
dexmedetomidine	dexmedetomidine	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
237	237	CD	B-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
190	190	CD	B-NP	O	O
matched	match	VBN	B-VP	B	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
group	group	NN	I-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
propensity	propensity	NN	B-NP	O	O
score	score	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
composite	composite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
<	<	SYM	B-NP	O	O
60	60	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
<	<	SYM	B-NP	O	O
50	50	CD	B-NP	O	O
beats	beat	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
sedative	sedative	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
composite	composite	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
the	the	DT	I-NP	O	O
unmatched	unmatched	JJ	I-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.94	0.94	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
matched	match	VBN	B-NP	B	O
cohorts	cohort	NNS	I-NP	O	O
(	(	(	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
34	34	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.35	0.35	CD	B-NP	O	O
)	)	)	O	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
analyzed	analyze	VBN	B-VP	O	O
separately	separately	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
or	or	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
unmatched	unmatched	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
matched	matched	JJ	I-NP	O	O
cohorts	cohort	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Severe	Severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
occur	occur	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neurocritical	neurocritical	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
receive	receive	VBP	B-VP	O	O
dexmedetomidine	dexmedetomidine	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Providers	Provider	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
similarly	similarly	RB	I-VP	O	O
consider	consider	VB	I-VP	O	O
the	the	DT	B-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
before	before	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
either	either	CC	O	O	O
sedative	sedative	JJ	B-ADJP	O	O
.	.	.	O	O	O

Hydroxytyrosol	Hydroxytyrosol	NN	B-NP	B	B-Chemical
ameliorates	ameliorate	VBZ	B-VP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
and	and	CC	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
breast	breast	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Oxidative	Oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
processes	process	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
aging	aging	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Doxorubicin	Doxorubicin	NN	B-NP	B	B-Chemical
causes	cause	VBZ	B-VP	O	O
significant	significant	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
marked	marked	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
and	and	CC	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Herein	Herein	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigate	investigate	VBP	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
chronic	chronic	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
ameliorated	ameliorate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
hydroxytyrosol	hydroxytyrosol	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
breast	breast	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Thirty	Thirty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
six	six	CD	I-NP	O	O
rats	rat	NNS	I-NP	O	O
bearing	bear	VBG	B-VP	O	O
breast	breast	NN	B-NP	O	B-Disease
tumors	tumor	NNS	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
chemically	chemically	RB	B-ADVP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
4	4	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
control	control	NN	B-NP	O	O
,	,	,	O	O	O
hydroxytyrosol	hydroxytyrosol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.5mg	0.5mg	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
5days	5day	NNS	B-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1mg	1mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
plus	plus	CC	I-NP	O	O
hydroxytyrosol	hydroxytyrosol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	B-Disease
disturbances	disturbance	NNS	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cellular	cellular	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
,	,	,	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
electron	electron	NN	I-NP	O	O
transport	transport	NN	I-NP	O	O
chain	chain	NN	I-NP	O	O
complexes	complex	NNS	I-NP	O	O
I	I	CD	I-NP	B	O
-	-	HYPH	I-NP	I	O
IV	IV	CD	I-NP	O	O
and	and	CC	I-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
-	-	HYPH	O	O	O
inducing	induce	VBG	B-VP	O	O
factor	factor	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
markers	marker	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

Hydroxytyrosol	Hydroxytyrosol	NN	B-NP	B	B-Chemical
improved	improve	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
disturbances	disturbance	NNS	I-NP	O	I-Disease
enhanced	enhance	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
by	by	IN	B-PP	O	O
significantly	significantly	RB	B-VP	O	O
reducing	reduce	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
and	and	CC	O	O	O
oxidative	oxidative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
hydroxytyrosol	hydroxytyrosol	NN	B-NP	B	B-Chemical
improve	improve	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
electron	electron	NN	I-NP	O	O
transport	transport	NN	I-NP	O	O
chain	chain	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
demonstrates	demonstrate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
hydroxytyrosol	hydroxytyrosol	NN	B-NP	B	B-Chemical
protect	protect	NN	I-NP	O	O
rat	rat	NN	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
provoked	provoke	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
decreasing	decrease	VBG	B-VP	O	O
oxidative	oxidative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
and	and	CC	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myxoedema	myxoedema	NN	I-NP	O	B-Disease
coma	coma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
62	62	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
hypothermia	hypothermia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Thyroid	Thyroid	NN	B-NP	O	O
-	-	HYPH	O	O	O
stimulating	stimulate	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
168	168	CD	B-NP	O	O
uIU	uIU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	B-NP	O	O
(	(	(	O	O	O
nl	nl	NN	B-NP	O	O
.	.	.	O	O	O

0.3	0.3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
uIU	uIU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
thyroxine	thyroxine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
FT4	FT4	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
<	<	SYM	B-ADJP	O	O
0.2	0.2	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	B-NP	O	O
(	(	(	O	O	O
nl	nl	NN	B-NP	O	O
.	.	.	O	O	O

0.8	0.8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.8	1.8	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
received	receive	VBD	B-VP	O	O
intravenous	intravenous	JJ	B-NP	O	O
fluids	fluid	NNS	I-NP	O	O
,	,	,	O	O	O
vasopressor	vasopressor	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
stress	stress	NN	B-NP	O	O
dose	dose	NN	I-NP	O	O
steroids	steroid	NNS	I-NP	O	B-Chemical
;	;	:	O	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
intubated	intubate	VBN	I-VP	O	O
and	and	CC	O	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
received	receive	VBD	B-VP	O	O
500	500	CD	B-NP	O	O
ug	ug	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
levothyroxine	levothyroxine	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
18	18	CD	I-NP	O	O
h	h	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
150	150	CD	B-NP	O	O
ug	ug	NN	I-NP	O	O
intravenous	intravenous	JJ	B-ADJP	O	O
daily	daily	RB	B-ADVP	O	O
thereafter	thereafter	RB	I-ADVP	O	O
.	.	.	O	O	O

Haemodynamic	Haemodynamic	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
,	,	,	O	O	O
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
complete	complete	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
,	,	,	O	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Twelve	Twelve	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
FT4	FT4	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
0.96	0.96	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
levothyroxine	levothyroxine	NN	B-NP	B	B-Chemical
175	175	CD	I-NP	O	O
(	(	(	O	O	O
g	g	NN	B-NP	O	O
POorally	POorally	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
thyroid	thyroid	JJ	I-NP	O	O
ultrasound	ultrasound	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
diffuse	diffuse	JJ	B-NP	O	O
heterogeneity	heterogeneity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
24	24	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
iodine	iodine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
3657	3657	CD	B-NP	O	O
(	(	(	O	O	O
mcg	mcg	NN	B-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
-	-	HYPH	O	O	O
756	756	CD	B-NP	O	O
(	(	(	O	O	O
mcg	mcg	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
only	only	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myxoedema	myxoedema	NN	I-NP	O	B-Disease
coma	coma	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
report	report	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
death	death	NN	I-NP	O	O
despite	despite	IN	B-PP	O	O
supportive	supportive	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
thyroid	thyroid	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
replacement	replacement	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
represents	represent	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
thoroughly	thoroughly	RB	I-NP	O	O
investigated	investigate	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myxoedema	myxoedema	NN	I-NP	O	B-Disease
coma	coma	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
significant	significant	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
subclinical	subclinical	JJ	B-NP	O	O
thyroid	thyroid	NN	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
catheter	catheter	NN	I-NP	O	O
-	-	HYPH	O	O	O
directed	direct	VBN	B-NP	O	O
thrombolysis	thrombolysis	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
alteplase	alteplase	NN	B-NP	B	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oncology	oncology	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oncology	oncology	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
HITT	HITT	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
plus	plus	CC	I-NP	O	O
catheter	catheter	NN	I-NP	O	O
-	-	HYPH	O	O	O
directed	direct	VBN	B-VP	O	O
thrombolysis	thrombolysis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
CDT	CDT	NN	B-NP	B	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
alteplase	alteplase	NN	B-NP	B	O
is	be	VBZ	B-VP	O	O
presented	present	VBN	I-VP	O	O
.	.	.	O	O	O

SUMMARY	SUMMARY	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
63	63	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
Caucasian	Caucasian	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
amyloidosis	amyloidosis	NN	I-NP	O	B-Disease
undergoing	undergo	VBG	B-VP	O	O
peripheral	peripheral	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
collection	collection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
autologous	autologous	JJ	I-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
extensive	extensive	JJ	B-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
upper	upper	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
extremity	extremity	NN	I-NP	O	I-Disease
deep	deep	JJ	I-NP	O	I-Disease
venous	venous	JJ	I-NP	O	I-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
DVT	DVT	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
embolism	embolism	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
i.v.	i.v.	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
managed	manage	VBN	I-VP	B	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
medical	medical	JJ	I-NP	O	O
floor	floor	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
one	one	CD	B-NP	O	O
week	week	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
transferred	transfer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
compromise	compromise	NN	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
superior	superior	JJ	B-NP	O	B-Disease
vena	vena	NN	I-NP	O	I-Disease
cava	cava	NN	I-NP	O	I-Disease
(	(	(	O	O	I-Disease
SVC	SVC	NN	B-NP	B	I-Disease
)	)	)	O	O	I-Disease
syndrome	syndrome	NN	B-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
percutaneous	percutaneous	JJ	I-NP	O	O
mechanical	mechanical	JJ	I-NP	O	O
thrombectomy	thrombectomy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CDT	CDT	NN	I-NP	B	O
with	with	IN	B-PP	O	O
alteplase	alteplase	NN	B-NP	B	O
were	be	VBD	B-VP	O	O
attempted	attempt	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
aborted	abort	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
epistaxis	epistaxis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
epistaxis	epistaxis	NN	I-NP	O	B-Disease
resolved	resolve	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
restarted	restart	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
percutaneous	percutaneous	JJ	I-NP	O	O
mechanical	mechanical	JJ	I-NP	O	O
thrombectomy	thrombectomy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
six	six	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
and	and	CC	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
partial	partial	JJ	B-NP	O	O
revascularization	revascularization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SVC	SVC	NN	I-NP	B	O
and	and	CC	I-NP	O	O
central	central	JJ	I-NP	O	O
veins	vein	NNS	I-NP	O	O
.	.	.	O	O	O

Postthrombectomy	Postthrombectomy	JJ	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
CDT	CDT	NN	I-NP	B	O
with	with	IN	B-PP	O	O
alteplase	alteplase	NN	B-NP	B	O
was	be	VBD	B-VP	O	O
commenced	commence	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
withheld	withhold	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
complete	complete	JJ	B-NP	O	O
patency	patency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SVC	SVC	NN	I-NP	B	O
and	and	CC	I-NP	O	O
central	central	JJ	I-NP	O	O
veins	vein	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
three	three	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

Alteplase	Alteplase	NN	B-NP	B	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reinitiated	reinitiate	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
ultimately	ultimately	RB	B-ADVP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
transitioned	transitione	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
recovered	recover	VBD	B-VP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
experienced	experience	VBD	B-VP	O	O
permanent	permanent	JJ	B-NP	O	O
vision	vision	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
hearing	hearing	NN	I-NP	O	I-Disease
loss	loss	NN	I-NP	O	I-Disease
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
end	end	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
63	63	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
amyloidosis	amyloidosis	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
SVC	SVC	NN	I-NP	B	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
HITT	HITT	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
successfully	successfully	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
CDT	CDT	NN	I-NP	B	O
with	with	IN	B-PP	O	O
alteplase	alteplase	NN	B-NP	B	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
dehydroepiandrosterone	dehydroepiandrosterone	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dehydroepiandrosterone	dehydroepiandrosterone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DHEA	DHEA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
on	on	IN	B-PP	O	O
animal	animal	NN	B-NP	O	O
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Seventy	Seventy	CD	B-NP	O	O
Swiss	Swiss	JJ	I-NP	O	O
albino	albino	NN	I-NP	O	O
female	female	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
35	35	CD	I-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
4	4	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
free	free	JJ	O	O	O
(	(	(	O	O	O
control	control	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
50	50	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
DHEA	DHEA	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
DHEA	DHEA	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
(	(	(	O	O	O
ip	ip	RB	B-ADVP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Amphetamine	Amphetamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
ip	ip	NN	I-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
hyper	hyper	NN	B-NP	O	B-Disease
locomotion	locomotion	NN	I-NP	O	O
,	,	,	O	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
subcutaneously	subcutaneously	RB	B-ADVP	O	O
[	[	(	O	O	O
sc	sc	NN	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
induced	induce	VBN	B-NP	O	O
climbing	climbing	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
sc	sc	NN	I-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
tests	test	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
animal	animal	NN	B-NP	O	O
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Animal	Animal	NNP	I-NP	O	O
Experiment	Experiment	NNP	I-NP	O	O
Laboratories	Laboratories	NNP	I-NP	O	O
,	,	,	O	O	O
Department	Department	NNP	B-NP	O	O
of	of	IN	B-PP	O	O
Pharmacology	Pharmacology	NNP	B-NP	O	O
,	,	,	O	O	O
Medical	Medical	NNP	B-NP	O	O
School	School	NNP	I-NP	O	O
,	,	,	O	O	O
Eskisehir	Eskisehir	NNP	B-NP	O	O
Osmangazi	Osmangazi	NNP	I-NP	O	O
University	University	NNP	I-NP	O	O
,	,	,	O	O	O
Eskisehir	Eskisehir	NNP	B-NP	O	O
,	,	,	O	O	O
Turkey	Turkey	NNP	B-NP	O	O
between	between	IN	B-PP	O	O
March	March	NNP	B-NP	O	O
and	and	CC	O	O	O
May	May	NNP	B-NP	O	O
2012	2012	CD	I-NP	O	O
.	.	.	O	O	O

Statistical	Statistical	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
using	use	VBG	B-VP	O	O
Kruskal	Kruskal	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Wallis	Wallis	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
hyper	hyper	NN	B-NP	O	B-Disease
locomotion	locomotion	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
ANOVA	ANOVA	NN	I-NP	O	O
for	for	IN	B-PP	O	O
climbing	climbing	NN	B-NP	O	O
and	and	CC	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
locomotion	locomotion	NN	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
movements	movement	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
DHEA	DHEA	NN	B-NP	B	B-Chemical
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
significantly	significantly	RB	B-VP	O	O
decreased	decrease	VBD	I-VP	O	O
all	all	DT	B-NP	O	O
movements	movement	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
locomotion	locomotion	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
haloperidol	haloperidol	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
test	test	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
climbing	climbing	NN	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
apomorphine	apomorphine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	I-VP	O	O
climbing	climb	VBG	B-VP	O	O
test	test	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
>	>	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
DHEA	DHEA	NN	B-NP	B	B-Chemical
reduced	reduce	VBD	B-VP	O	O
locomotor	locomotor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
both	both	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
climbing	climb	VBG	B-VP	O	O
behavior	behavior	NN	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
DHEA	DHEA	NN	B-NP	B	B-Chemical
displays	display	VBZ	B-VP	O	O
typical	typical	JJ	B-NP	O	O
neuroleptic	neuroleptic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Availability	Availability	NN	B-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
induced	induce	VBN	I-NP	O	O
pluripotent	pluripotent	JJ	I-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
derived	derive	VBN	I-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
assessment	assessment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Field	Field	JJ	B-NP	O	O
potential	potential	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
(	(	(	O	O	O
FPD	FPD	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
pluripotent	pluripotent	JJ	I-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
derived	derive	VBN	I-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
(	(	(	O	O	O
hiPS	hiPS	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
CMs	CM	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
express	express	VB	I-VP	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
tool	tool	NN	I-NP	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
K	K	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
channel	channel	NN	B-NP	O	O
and	and	CC	O	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
channel	channel	NN	B-NP	O	O
blocker	blocker	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
report	report	NN	I-NP	O	O
showing	show	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
technique	technique	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
predict	predict	VB	I-VP	O	O
multichannel	multichannel	JJ	B-NP	O	O
blocker	blocker	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
for	for	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
show	show	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
FPD	FPD	NN	B-NP	O	O
from	from	IN	B-PP	O	O
MEA	MEA	NN	B-NP	B	O
(	(	(	O	O	O
Multielectrode	Multielectrode	NN	B-NP	O	O
array	array	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
hiPS	hiPS	NN	B-NP	O	O
-	-	HYPH	O	O	O
CMs	CM	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
detect	detect	VB	I-VP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
multichannel	multichannel	JJ	B-NP	O	O
blockers.	blockers.	NN	I-NP	O	O
hiPS	hiPS	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
CMs	CM	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seeded	seed	VBN	I-VP	O	O
onto	onto	IN	B-PP	O	O
MEA	MEA	NN	B-NP	B	O
and	and	CC	I-NP	O	O
FPD	FPD	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
2min	2min	NN	B-NP	O	O
every	every	DT	B-NP	O	O
10min	10min	NN	I-NP	O	O
for	for	IN	B-PP	O	O
30min	30min	NN	B-NP	O	O
after	after	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
and	and	CC	O	O	O
each	each	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

IKr	IKr	NN	B-NP	O	O
and	and	CC	I-NP	O	O
IKs	IKs	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	O	O	O
dependently	dependently	RB	B-ADVP	O	O
prolonged	prolong	VBD	B-VP	O	O
corrected	correct	VBN	I-VP	O	O
FPD	FPD	NN	B-NP	O	O
(	(	(	O	O	O
FPDc	FPDc	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
channel	channel	NN	B-NP	O	O
blockers	blocker	NNS	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	O	O	O
dependently	dependently	RB	B-ADVP	O	O
shortened	shorten	VBD	B-VP	O	O
FPDc	FPDc	NN	B-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
multichannel	multichannel	JJ	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
Amiodarone	Amiodarone	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
Paroxetine	Paroxetine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
Terfenadine	Terfenadine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
Citalopram	Citalopram	NN	I-NP	B	B-Chemical
prolonged	prolong	VBD	B-VP	O	O
FPDc	FPDc	NN	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Finally	Finally	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
IKr	IKr	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
,	,	,	O	O	O
Terfenadine	Terfenadine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
Citalopram	Citalopram	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
Torsade	Torsade	NNP	B-NP	O	B-Disease
de	de	IN	I-NP	O	I-Disease
Pointes	Pointes	NNP	I-NP	O	I-Disease
(	(	(	O	O	O
TdP	TdP	NN	B-NP	O	B-Disease
)	)	)	O	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
,	,	,	O	O	O
produced	produce	VBD	B-VP	O	O
early	early	JJ	B-NP	O	O
afterdepolarization	afterdepolarization	NN	I-NP	O	O
(	(	(	O	O	O
EAD	EAD	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O
hiPS	hiPS	NN	B-NP	O	O
-	-	HYPH	O	O	O
CMs	CM	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
MEA	MEA	NN	B-NP	B	O
system	system	NN	I-NP	O	O
and	and	CC	I-NP	O	O
FPDc	FPDc	NN	I-NP	O	O
can	can	MD	B-VP	O	O
predict	predict	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
candidates	candidate	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
shows	show	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
assay	assay	NN	I-NP	O	O
can	can	MD	B-VP	O	O
help	help	VB	I-VP	O	O
detect	detect	VB	I-VP	O	O
EAD	EAD	NN	B-NP	O	O
for	for	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

Dermal	Dermal	JJ	B-NP	O	O
developmental	developmental	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
phenylimide	phenylimide	NN	I-NP	B	O
herbicides	herbicide	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
53482	53482	CD	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
S	S	NN	I-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
23121	23121	CD	B-NP	I	I-Chemical
are	be	VBP	B-VP	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
phenylimide	phenylimide	NN	I-NP	B	O
herbicides	herbicide	NNS	I-NP	O	O
and	and	CC	O	O	O
produced	produce	VBD	B-VP	O	O
embryolethality	embryolethality	NN	B-NP	O	B-Disease
,	,	,	O	O	O
teratogenicity	teratogenicity	NN	B-NP	O	B-Disease
(	(	(	O	O	O
mainly	mainly	RB	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
septal	septal	JJ	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
wavy	wavy	NN	B-NP	O	O
ribs	rib	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
growth	growth	NN	B-NP	O	B-Disease
retardation	retardation	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
developmental	developmental	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
objective	objective	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
induce	induce	VBP	B-VP	O	O
developmental	developmental	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dermal	dermal	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
more	more	RBR	B-ADJP	O	O
relevant	relevant	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
occupational	occupational	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
,	,	,	O	O	O
hence	hence	RB	B-ADJP	O	O
better	good	JJR	I-ADJP	O	O
addressing	address	VBG	B-VP	O	O
human	human	JJ	B-NP	O	O
health	health	NN	I-NP	O	O
risks	risk	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
53482	53482	CD	B-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
dermally	dermally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
100	100	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
during	during	IN	B-PP	O	O
organogenesis	organogenesis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
23121	23121	CD	B-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
200	200	CD	B-NP	O	O
,	,	,	I-NP	O	O
400	400	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
applicable	applicable	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
level	level	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Fetuses	Fetus	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Cesarean	Cesarean	JJ	I-NP	O	O
section	section	NN	I-NP	O	O
and	and	CC	O	O	O
examined	examine	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
external	external	JJ	B-NP	O	O
,	,	,	I-NP	O	O
visceral	visceral	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
skeletal	skeletal	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Dermal	Dermal	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
53482	53482	CD	B-NP	I	I-Chemical
at	at	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
patterns	pattern	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
developmental	developmental	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

Toxicity	Toxicity	NN	B-NP	O	B-Disease
included	include	VBD	B-VP	O	O
embryolethality	embryolethality	NN	B-NP	O	B-Disease
,	,	,	O	O	O
teratogenicity	teratogenicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
growth	growth	NN	B-NP	O	B-Disease
retardation	retardation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Dermal	Dermal	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
23121	23121	CD	I-NP	I	I-Chemical
at	at	IN	B-PP	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
embryonic	embryonic	JJ	B-NP	O	B-Disease
death	death	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
septal	septal	JJ	I-NP	O	I-Disease
defect	defect	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
retarded	retard	VBD	B-VP	B	O
fetal	fetal	JJ	B-NP	O	O
growth	growth	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
as	as	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
following	follow	VBG	I-VP	O	O
oral	oral	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
23121	23121	CD	I-NP	I	I-Chemical
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Based	Base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
,	,	,	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
53482	53482	CD	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
S	S	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
23121	23121	CD	B-NP	I	I-Chemical
were	be	VBD	B-VP	O	O
teratogenic	teratogenic	JJ	B-ADJP	O	B-Disease
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
dermally	dermally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
administered	administer	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
investigation	investigation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
human	human	JJ	I-NP	O	O
relevancy	relevancy	NN	I-NP	O	O
become	become	VBP	B-VP	O	O
more	more	RBR	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

Rates	Rate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Renal	Renal	JJ	B-NP	O	B-Disease
Toxicity	Toxicity	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Cancer	Cancer	NNP	B-NP	O	B-Disease
Patients	Patients	NNP	I-NP	O	O
Receiving	Receiving	NNP	I-NP	O	O
Cisplatin	Cisplatin	NNP	I-NP	B	B-Chemical
With	With	IN	B-PP	O	O
and	and	CC	I-PP	O	O
Without	Without	IN	I-PP	O	O
Mannitol	Mannitol	NNP	B-NP	B	B-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Cisplatin	Cisplatin	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
widely	widely	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
antineoplastic	antineoplastic	JJ	B-ADJP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-VP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
many	many	JJ	B-NP	O	O
strategies	strategy	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
this	this	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mannitol	mannitol	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nephroprotectant	nephroprotectant	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
hydration	hydration	NN	B-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
agent	agent	NN	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	B	B-Chemical
with	with	IN	B-PP	O	O
and	and	CC	I-PP	O	O
without	without	IN	I-PP	O	O
mannitol	mannitol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
center	center	NN	I-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
quasi	quasi	JJ	I-NP	O	O
experiment	experiment	NN	I-NP	O	O
created	create	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
national	national	JJ	I-NP	O	O
mannitol	mannitol	NN	I-NP	B	B-Chemical
shortage	shortage	NN	I-NP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
collected	collect	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
agent	agent	NN	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	B	B-Chemical
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
outpatient	outpatient	NN	I-NP	O	O
from	from	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
2011	2011	CD	I-NP	O	O
to	to	TO	B-PP	O	O
September	September	NNP	B-NP	O	O
2012	2012	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AKI	AKI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
143	143	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
single	single	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
agent	agent	NN	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	B	B-Chemical
;	;	:	O	O	O
97.2	97.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
head	head	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
neck	neck	NN	I-NP	O	I-Disease
cancer	cancer	NN	I-NP	O	I-Disease
as	as	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
primary	primary	JJ	I-NP	O	O
malignancy	malignancy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
receive	receive	VB	I-VP	O	O
mannitol	mannitol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
develop	develop	VB	I-VP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
:	:	:	O	O	O
odds	odd	NNS	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
[	[	(	O	O	O
OR	OR	NN	B-NP	O	O
]	]	)	O	O	O
=	=	SYM	O	O	O
2.646	2.646	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.008	1.008	CD	B-NP	O	O
,	,	,	O	O	O
6.944	6.944	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.048	0.048	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
dosing	dosing	NN	B-NP	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
also	also	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
:	:	:	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
11.494	11.494	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
4.149	4.149	CD	B-NP	O	O
,	,	,	O	O	O
32.258	32.258	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.0001	0.0001	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	O	O	O
3.219	3.219	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.228	1.228	CD	B-NP	O	O
,	,	,	O	O	O
8.439	8.439	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.017	0.017	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
When	When	WRB	B-ADVP	O	O
limited	limited	JJ	B-NP	O	O
quantities	quantity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mannitol	mannitol	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
should	should	MD	B-VP	O	O
preferentially	preferentially	RB	I-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
particularly	particularly	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
those	those	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
every	every	DT	B-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
greatest	great	JJS	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
would	would	MD	B-VP	O	O
benefit	benefit	VB	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mannitol	mannitol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Metformin	Metformin	NN	B-NP	B	B-Chemical
protects	protect	VBZ	B-VP	O	O
against	against	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
learning	learning	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
impairments	impairment	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
oxidative	oxidative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
kindling	kindling	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Cognitive	Cognitive	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
severe	severe	JJ	I-NP	O	O
comorbidity	comorbidity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
greatly	greatly	RB	B-VP	O	O
diminishes	diminish	VBZ	I-VP	O	O
the	the	DT	B-NP	O	O
quality	quality	NN	I-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
current	current	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
interventions	intervention	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
also	also	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
untoward	untoward	JJ	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
urgent	urgent	JJ	I-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
new	new	JJ	B-NP	O	O
kinds	kind	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
agents	agent	NNS	B-NP	O	O
targeting	target	VBG	B-VP	O	O
both	both	DT	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
cognition	cognition	NN	I-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Oxidative	Oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
play	play	VB	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
epileptogenesis	epileptogenesis	NN	B-NP	O	O
and	and	CC	O	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
antioxidants	antioxidant	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
putative	putative	JJ	I-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
.	.	.	O	O	O

Metformin	Metformin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
commonly	commonly	RB	I-NP	O	O
prescribed	prescribe	VBN	I-NP	O	O
antidiabetic	antidiabetic	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
antioxidant	antioxidant	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
ameliorative	ameliorative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
brain	brain	NN	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
markers	marker	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
kindling	kindling	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
C57BL	C57BL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
6	6	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
subconvulsive	subconvulsive	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
37	37	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
every	every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
injections	injection	NNS	I-NP	O	O
.	.	.	O	O	O

Metformin	Metformin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
200mg	200mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
alternate	alternate	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
PTZ	PTZ	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
suppressed	suppress	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kindling	kindling	NN	B-NP	O	O
,	,	,	O	O	O
ameliorated	ameliorate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
brain	brain	NN	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
concluded	conclude	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
medicine	medicine	NN	I-NP	O	O
against	against	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

P53	P53	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
exacerbates	exacerbate	VBZ	B-VP	O	O
late	late	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
stage	stage	NN	I-NP	O	O
anthracycline	anthracycline	NN	I-NP	O	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

AIMS	AIMS	NNS	B-NP	O	O
:	:	:	O	O	O
Doxorubicin	Doxorubicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
therapeutic	therapeutic	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
both	both	CC	B-NP	O	O
acute	acute	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
late	late	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
stage	stage	NN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Children	Child	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
impact	impact	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p53	p53	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
on	on	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
vs.	vs.	IN	B-PP	O	O
late	late	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
stage	stage	NN	I-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
juvenile	juvenile	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
Two	Two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
MHC	MHC	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
CB7	CB7	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
(	(	(	O	O	O
which	which	WDT	B-NP	O	O
express	express	VBP	B-VP	O	O
dominant	dominant	JJ	B-ADJP	O	O
-	-	HYPH	O	O	O
interfering	interfere	VBG	B-VP	O	O
p53	p53	NN	B-NP	O	O
in	in	IN	B-PP	O	O
cardiomyocytes	cardiomyocyte	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
transgenic	transgenic	JJ	I-NP	O	O
(	(	(	O	O	O
NON	NON	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
TXG	TXG	NN	I-NP	O	O
)	)	)	O	O	O
littermates	littermate	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
weekly	weekly	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
week	week	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
(	(	(	O	O	O
acute	acute	JJ	B-NP	O	O
stage	stage	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
MHC	MHC	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
CB7	CB7	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
improved	improved	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
lower	low	JJR	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NON	NON	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
TXG	TXG	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Surprisingly	Surprisingly	RB	B-ADVP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
13	13	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
(	(	(	O	O	O
late	late	JJ	B-NP	O	O
stage	stage	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
MHC	MHC	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
CB7	CB7	NN	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
higher	high	JJR	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
NON	NON	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
TXG	TXG	NN	I-NP	O	O
mice.	mice.	NN	I-NP	O	O
p53	p53	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
blocked	block	VBD	B-VP	O	O
transient	transient	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
STAT3	STAT3	NN	I-NP	O	O
activation	activation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MHC	MHC	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
CB7	CB7	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
repair	repair	NN	I-NP	O	O
proteins	protein	NNS	I-NP	O	O
Ku70	Ku70	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Ku80	Ku80	NN	I-NP	O	O
.	.	.	O	O	O

Mice	Mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
restricted	restrict	VBN	I-NP	O	O
deletion	deletion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STAT3	STAT3	NN	B-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
worse	worse	JJR	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
higher	high	JJR	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ku70	Ku70	NN	B-NP	O	O
and	and	CC	I-NP	O	O
Ku80	Ku80	NN	I-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	I-PP	O	O
to	to	TO	I-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
stage	stage	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
control	control	NN	B-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
support	support	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
wherein	wherein	IN	B-PP	O	O
a	a	DT	B-NP	O	O
p53	p53	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
cardioprotective	cardioprotective	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
,	,	,	O	O	O
mediated	mediate	VBN	B-VP	O	O
via	via	IN	B-PP	O	O
STAT3	STAT3	NN	B-NP	O	O
activation	activation	NN	I-NP	O	O
,	,	,	O	O	O
mitigates	mitigate	VBZ	B-VP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
during	during	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
delivery	delivery	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
explanation	explanation	NN	I-NP	O	O
as	as	IN	B-PP	O	O
to	to	TO	B-PP	O	O
how	how	WRB	B-ADVP	O	O
p53	p53	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
cardioprotection	cardioprotection	NN	B-NP	O	O
during	during	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
paradoxically	paradoxically	RB	B-ADVP	O	O
,	,	,	O	O	O
enhanced	enhance	VBN	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
long	long	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cessation	cessation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Metronidazole	Metronidazole	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
:	:	:	O	O	O
an	an	DT	B-NP	O	O
uncommon	uncommon	JJ	I-NP	O	O
scenario	scenario	NN	I-NP	O	O
.	.	.	O	O	O

Metronidazole	Metronidazole	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
produce	produce	VB	I-VP	O	O
neurological	neurological	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
scenario	scenario	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
features	feature	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
metronidazole	metronidazole	NN	I-NP	B	B-Chemical
intake	intake	NN	I-NP	O	O
.	.	.	O	O	O

Magnetic	Magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
(	(	(	O	O	O
MRI	MRI	NN	B-NP	O	O
)	)	)	O	O	O
brain	brain	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
abnormal	abnormal	JJ	B-NP	O	O
signal	signal	NN	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
both	both	CC	O	O	O
dentate	dentate	VBP	B-VP	O	O
nuclei	nucleus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cerebellum	cerebellum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
splenium	splenium	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corpus	corpus	NN	B-NP	O	O
callosum	callosum	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metronidazole	metronidazole	NN	B-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
made	make	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
MRI	MRI	NN	I-NP	O	O
findings	finding	NNS	I-NP	O	O
and	and	CC	O	O	O
supported	support	VBN	B-VP	O	O
clinically	clinically	RB	B-ADVP	O	O
.	.	.	O	O	O

Aconitine	Aconitine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
Ca	Ca	NN	I-NP	B	B-Chemical
2	2	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
overload	overload	NN	I-NP	O	O
causes	cause	VBZ	B-VP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
triggers	trigger	VBZ	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
through	through	IN	B-PP	O	O
p38	p38	NN	B-NP	O	O
MAPK	MAPK	NN	I-NP	O	O
signaling	signaling	NN	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Aconitine	Aconitine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
bioactive	bioactive	JJ	I-NP	O	O
diterpenoid	diterpenoid	NN	I-NP	O	O
alkaloid	alkaloid	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
content	content	NN	I-NP	O	O
derived	derive	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
herbal	herbal	JJ	B-NP	O	O
aconitum	aconitum	NN	I-NP	O	O
plants	plant	NNS	I-NP	O	O
.	.	.	O	O	O

Emerging	Emerge	VBG	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
voltage	voltage	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
Na	Na	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
channels	channel	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
pivotal	pivotal	JJ	B-NP	O	O
roles	role	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
reports	report	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	B-NP	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
in	in	IN	B-PP	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
poisoning	poisoning	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
explored	explore	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pathological	pathological	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
signaling	signaling	NN	B-NP	O	O
in	in	IN	B-PP	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
poisoning	poisoning	NN	I-NP	O	B-Disease
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
overload	overload	NN	B-NP	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
accelerated	accelerate	VBN	B-NP	B	O
beating	beat	VBG	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
rat	rat	NN	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
myocytes	myocyte	NNS	I-NP	O	O
and	and	CC	O	O	O
caused	cause	VBD	B-VP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-ADJP	O	O
freely	freely	RB	B-VP	O	O
moving	move	VBG	I-VP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
cytotoxicity	cytotoxicity	NN	B-NP	O	B-Disease
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neonatal	neonatal	JJ	B-NP	O	O
rat	rat	NN	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
myocytes	myocyte	NNS	I-NP	O	O
(	(	(	O	O	O
NRVMs	NRVM	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
measured	measure	VBN	B-NP	O	O
lactate	lactate	NN	I-NP	B	B-Chemical
dehydrogenase	dehydrogenase	NN	I-NP	O	O
level	level	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
culture	culture	NN	I-NP	O	O
medium	medium	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NRVMs	NRVM	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
activities	activity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
NRVMs	NRVM	NNS	I-NP	O	O
viability	viability	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
dependently	dependently	RB	B-ADVP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
confirm	confirm	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pro	pro	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
apoptotic	apoptotic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
flow	flow	NN	B-NP	O	O
cytometric	cytometric	JJ	I-NP	O	O
detection	detection	NN	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
histology	histology	NN	I-NP	O	O
,	,	,	O	O	O
transmission	transmission	NN	B-NP	O	O
electron	electron	NN	I-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
and	and	CC	O	O	O
terminal	terminal	JJ	B-NP	O	O
deoxynucleotidyl	deoxynucleotidyl	NN	I-NP	O	O
transferase	transferase	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
dUTP	dUTP	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
biotin	biotin	NN	I-NP	B	B-Chemical
nick	nick	NN	I-NP	O	O
end	end	NN	I-NP	O	O
labeling	labeling	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
stimulated	stimulate	VBD	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
dependently	dependently	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	B-NP	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
handling	handle	VBG	B-NP	O	O
proteins	protein	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
promoted	promote	VBD	B-VP	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	B-NP	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
overload	overload	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	B-NP	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
handling	handle	VBG	B-VP	O	O
proteins	protein	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
proteins	protein	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
pro	pro	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
apoptotic	apoptotic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
upregulated	upregulate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
apoptotic	apoptotic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
BCL	BCL	NN	I-NP	O	O
-	-	HYPH	O	O	O
2	2	CD	B-NP	O	O
expression	expression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
downregulated	downregulate	VBN	I-VP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MAPK	MAPK	NN	B-NP	O	O
family	family	NN	I-NP	O	O
members	member	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P38	P38	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
P38	P38	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Hence	Hence	RB	B-ADVP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
aggravates	aggravate	VBZ	B-VP	O	O
Ca	Ca	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	O	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
overload	overload	NN	B-NP	O	O
and	and	CC	O	O	O
causes	cause	VBZ	B-VP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
finally	finally	RB	B-VP	O	O
promotes	promote	VBZ	I-VP	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
development	development	NN	I-NP	O	O
via	via	IN	B-PP	O	O
phosphorylation	phosphorylation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
P38	P38	NN	B-NP	O	O
mitogen	mitogen	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
activated	activate	VBN	B-NP	O	O
protein	protein	NN	I-NP	O	O
kinase	kinase	NN	I-NP	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
suppresses	suppress	VBZ	B-VP	O	O
toll	toll	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
4	4	CD	I-NP	O	O
signaling	signaling	NN	I-NP	O	O
and	and	CC	O	O	O
attenuates	attenuate	VBZ	B-VP	O	O
left	left	JJ	B-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
suppression	suppression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AMP	AMP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
activated	activate	VBN	I-NP	O	O
protein	protein	NN	I-NP	O	O
kinase	kinase	NN	I-NP	O	O
(	(	(	O	O	O
AMPK	AMPK	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
toll	toll	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
4	4	CD	I-NP	O	O
(	(	(	O	O	O
TLR4	TLR4	NN	B-NP	O	O
)	)	)	O	O	O
activities	activity	NNS	B-NP	O	O
following	follow	VBG	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
relation	relation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
AMPK	AMPK	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
normal	normal	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
and	and	CC	I-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
after	after	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
0	0	CD	B-NP	O	O
,	,	,	I-NP	O	O
25	25	CD	I-NP	O	O
,	,	,	I-NP	O	O
50	50	CD	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
100mg	100mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Isoproterenol	Isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
100mg	100mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
subcutaneously	subcutaneously	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
13th	13th	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
14th	14th	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
myocardial	myocardial	JJ	I-NP	O	I-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Isoproterenol	Isoproterenol	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
myocardial	myocardial	JJ	B-NP	O	O
contractility	contractility	NN	I-NP	O	O
indexed	index	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
LVdp	LVdp	NN	B-NP	O	O
/	/	SYM	B-VP	O	O
dtmax	dtmax	NN	B-NP	O	O
and	and	CC	I-NP	O	O
LVdp	LVdp	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dtmin	dtmin	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
left	left	JJ	I-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
25	25	CD	B-NP	O	O
and	and	CC	I-NP	O	O
50mg	50mg	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Metfromin	Metfromin	NN	B-NP	O	O
markedly	markedly	RB	B-ADVP	O	O
lowered	lower	VBD	B-VP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TLR4	TLR4	NN	B-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
,	,	,	O	O	O
myeloid	myeloid	JJ	B-NP	O	O
differentiation	differentiation	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
88	88	CD	I-NP	O	O
(	(	(	O	O	O
MyD88	MyD88	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
tumor	tumor	NN	B-NP	B	B-Disease
necrosis	necrosis	NN	I-NP	I	B-Disease
factor	factor	NN	I-NP	I	O
-	-	HYPH	O	I	O
alpha	alpha	SYM	B-NP	I	O
(	(	(	O	O	O
TNF	TNF	NN	B-NP	B	O
-	-	HYPH	O	O	O
a	a	DT	O	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
interleukin	interleukin	NN	B-NP	O	O
6	6	CD	I-NP	O	O
(	(	(	O	O	O
IL	IL	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
6	6	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Similar	Similar	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TNF	TNF	NN	B-NP	B	O
-	-	HYPH	O	O	O
a	a	DT	B-NP	O	O
and	and	CC	I-NP	O	O
IL	IL	NN	I-NP	O	O
-	-	HYPH	O	O	O
6	6	CD	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
and	and	CC	I-NP	O	O
50mg	50mg	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
100mg	100mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Phosphorylated	Phosphorylate	VBN	B-NP	O	O
AMPKa	AMPKa	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
AMPK	AMPK	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
elevated	elevate	VBN	I-VP	B	O
by	by	IN	B-PP	O	O
25mg	25mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
slightly	slightly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
50mg	50mg	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	B-PP	O	O
but	but	CC	I-PP	O	O
not	not	RB	I-PP	O	O
by	by	IN	B-PP	O	O
100mg	100mg	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	O	O	O
pre	pre	AFX	O	O	O
-	-	HYPH	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
reduces	reduce	VBZ	B-VP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
cardiac	cardiac	JJ	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
and	and	CC	O	O	O
suppresses	suppress	VBZ	B-VP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
TLR4	TLR4	NN	B-NP	O	O
activities	activity	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
target	target	NN	I-NP	O	O
to	to	TO	B-VP	O	O
protect	protect	VB	I-VP	O	O
infarcted	infarcted	JJ	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
tetrabenazine	tetrabenazine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
tiapride	tiapride	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Japanese	Japanese	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Huntington	Huntington	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
terminal	terminal	JJ	I-NP	O	O
stage	stage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
herein	herein	RB	B-ADVP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
81	81	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
Japanese	Japanese	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
36	36	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
tiapride	tiapride	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
tetrabenazine	tetrabenazine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
12.5	12.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
Huntington	Huntington	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
tiapride	tiapride	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
tetrabenazine	tetrabenazine	NN	I-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
advanced	advance	VBN	I-VP	B	O
breast	breast	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
tetrabenazine	tetrabenazine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
tiapride	tiapride	NN	I-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Tetrabenazine	Tetrabenazine	NN	B-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
very	very	RB	B-ADVP	O	O
carefully	carefully	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
neuroleptic	neuroleptic	JJ	I-NP	O	B-Chemical
drugs	drug	NNS	I-NP	O	I-Chemical
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
worsening	worsen	VBG	I-NP	O	O
general	general	JJ	I-NP	O	O
condition	condition	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
metoprolol	metoprolol	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
terbinafine	terbinafine	NN	I-NP	B	B-Chemical
combination	combination	NN	I-NP	O	O
induced	induce	VBD	B-VP	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
a	a	DT	B-NP	O	O
sinus	sinus	NN	I-NP	O	B-Disease
bradycardia	bradycardia	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
terbinafine	terbinafine	NN	I-NP	B	B-Chemical
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
management	management	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
63	63	CD	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
Caucasian	Caucasian	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
on	on	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	B	B-Chemical
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
90	90	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
terbinafine	terbinafine	NN	I-NP	B	B-Chemical
250	250	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
onychomycosis	onychomycosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
49th	49th	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
terbinafine	terbinafine	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
brought	bring	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
room	room	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
global	global	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
status	status	NN	I-NP	O	O
,	,	,	O	O	O
confusion	confusion	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
falls	fall	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
37	37	CD	I-NP	O	O
beats	beat	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
sinus	sinus	NN	I-NP	O	B-Disease
bradycardia	bradycardia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
score	score	NN	I-NP	O	O
of	of	IN	B-PP	O	O
7	7	CD	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Naranjo	Naranjo	NNP	I-NP	O	O
adverse	adverse	JJ	I-NP	O	B-Disease
drug	drug	NN	I-NP	O	I-Disease
reaction	reaction	NN	I-NP	O	I-Disease
probability	probability	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
probable	probable	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
sinus	sinus	NN	I-NP	O	B-Disease
bradycardia	bradycardia	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
terbinafine	terbinafine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
ameliorated	ameliorate	VBN	B-VP	O	O
first	first	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
subsequently	subsequently	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
bisoprolol	bisoprolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
inhibiting	inhibit	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
2D6	2D6	NN	I-NP	O	O
,	,	,	O	O	O
terbinafine	terbinafine	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
metoprolol	metoprolol	NN	B-NP	B	B-Chemical
's	's	POS	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
metoprolol	metoprolol	NN	B-NP	B	B-Chemical
accumulation	accumulation	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
resulted	result	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	B-Disease
bradycardia	bradycardia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Optochiasmatic	Optochiasmatic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
overtreatment	overtreatment	NN	I-NP	O	O
.	.	.	O	O	O

Ethambutol	Ethambutol	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
optic	optic	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
,	,	,	O	O	O
more	more	RBR	B-ADVP	O	O
rarely	rarely	RB	I-ADVP	O	O
,	,	,	O	O	O
axonal	axonal	JJ	B-NP	O	O
polyneuropathy	polyneuropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
characterize	characterize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
,	,	,	I-NP	O	O
neurophysiological	neurophysiological	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
neuroimaging	neuroimaging	NN	B-NP	O	O
findings	finding	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
72	72	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
visual	visual	JJ	B-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
paresthesias	paresthesia	NNS	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
11	11	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
supratherapeutic	supratherapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
demonstrates	demonstrate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
vulnerability	vulnerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anterior	anterior	JJ	I-NP	O	O
visual	visual	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
and	and	CC	O	O	O
peripheral	peripheral	JJ	B-NP	O	O
nerves	nerve	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Testosterone	Testosterone	NN	B-NP	B	B-Chemical
ameliorates	ameliorate	VBZ	B-VP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

AIM	AIM	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
testosterone	testosterone	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Adult	Adult	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
intracerebroventricularly	intracerebroventricularly	RB	B-ADVP	O	O
(	(	(	O	O	O
icv	icv	NN	B-NP	O	O
)	)	)	O	O	O
infused	infuse	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
750	750	CD	B-NP	O	O
ug	ug	NN	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
d	d	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	O	O	O
d	d	NN	B-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
task	task	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Castration	Castration	NN	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
another	another	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
task	task	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
operation	operation	NN	I-NP	O	O
.	.	.	O	O	O

Testosterone	Testosterone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.d	.d	.	O	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
sc	sc	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
androgen	androgen	NN	I-NP	O	B-Chemical
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
flutamide	flutamide	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.d	.d	.	O	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ip	ip	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
estrogen	estrogen	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
tamoxifen	tamoxifen	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.d	.d	.	O	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ip	ip	JJ	B-ADJP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
aromatase	aromatase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
letrozole	letrozole	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.d	.d	.	O	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ip	ip	JJ	B-ADJP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
d	d	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
and	and	CC	O	O	O
castration	castration	NN	B-NP	O	O
markedly	markedly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
both	both	CC	O	O	O
STL1	STL1	NN	B-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
memory	memory	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
STL2	STL2	NN	B-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
memory	memory	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

Testosterone	Testosterone	NN	B-NP	B	B-Chemical
replacement	replacement	NN	I-NP	O	O
almost	almost	RB	B-ADVP	O	O
restored	restore	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
STL1	STL1	NN	I-NP	O	O
and	and	CC	I-NP	O	O
STL2	STL2	NN	I-NP	O	O
in	in	IN	B-PP	O	O
castrated	castrate	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
prolonged	prolong	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
STL1	STL1	NN	I-NP	O	O
and	and	CC	I-NP	O	O
STL2	STL2	NN	I-NP	O	O
in	in	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
flutamide	flutamide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
letrozole	letrozole	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
tamoxifen	tamoxifen	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
impaired	impair	VBD	B-VP	O	B-Disease
the	the	DT	B-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
attenuated	attenuate	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
testosterone	testosterone	NN	I-NP	B	B-Chemical
replacement	replacement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
improving	improve	VBG	B-VP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
castration	castration	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Testosterone	Testosterone	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
ameliorates	ameliorate	VBZ	B-VP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
castration	castration	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Behavioral	Behavioral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neurochemical	neurochemical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
pretreated	pretreate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
garcinielliptone	garcinielliptone	NN	B-NP	O	B-Chemical
FC	FC	NN	I-NP	O	I-Chemical
in	in	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Garcinielliptone	Garcinielliptone	NN	B-NP	O	B-Chemical
FC	FC	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
GFC	GFC	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
hexanic	hexanic	JJ	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
seed	seed	NN	I-NP	O	O
extract	extract	NN	I-NP	O	O
of	of	IN	B-PP	O	O
species	specie	NNS	B-NP	O	O
Platonia	Platonia	NNP	B-NP	O	O
insignis	insigni	VBZ	B-VP	O	O
Mart	Mart	NNP	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
widely	widely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
folk	folk	NN	B-NP	O	O
medicine	medicine	NN	I-NP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
skin	skin	NN	B-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
humans	human	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
animals	animal	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
seed	seed	NN	I-NP	O	O
decoction	decoction	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
treat	treat	VB	I-VP	O	O
diarrheas	diarrhea	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
inflammatory	inflammatory	JJ	B-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
research	research	NN	I-NP	O	O
on	on	IN	B-PP	O	O
GFC	GFC	NN	B-NP	O	B-Chemical
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rodents	rodent	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
GFC	GFC	NN	I-NP	O	B-Chemical
effects	effect	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
,	,	,	I-NP	O	O
50	50	CD	I-NP	O	O
or	or	CC	I-NP	O	O
75	75	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
on	on	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
parameters	parameter	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
amino	amino	NN	B-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
r	r	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
aminobutyric	aminobutyric	JJ	B-NP	B	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
glutamine	glutamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
aspartate	aspartate	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
glutathione	glutathione	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
on	on	IN	B-PP	O	O
acetylcholinesterase	acetylcholinesterase	NN	B-NP	O	O
(	(	(	O	O	O
AChE	AChE	NN	B-NP	O	O
)	)	)	O	O	O
activity	activity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
after	after	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

GFC	GFC	NN	B-NP	O	B-Chemical
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
latency	latency	NN	I-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
,	,	,	O	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
25mg	25mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
20.12	20.12	CD	B-NP	O	O
+	+	SYM	O	O	O
2.20	2.20	CD	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
50mg	50mg	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
20.95	20.95	CD	B-NP	O	O
+	+	SYM	O	O	O
2.21	2.21	CD	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
23.43	23.43	CD	B-NP	O	O
+	+	SYM	O	O	O
1.99	1.99	CD	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
seized	seize	VBN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
content	content	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
GFC75	GFC75	NN	B-NP	O	O
plus	plus	CC	I-NP	O	O
P400	P400	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
46.90	46.90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
seized	seize	VBN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
aspartate	aspartate	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
glutamine	glutamine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
glutamate	glutamate	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
detected	detect	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5.21	5.21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
13.55	13.55	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
21.80	21.80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
GFC75	GFC75	NN	B-NP	O	O
plus	plus	CC	I-NP	O	O
P400	P400	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
seized	seize	VBN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Hippocampus	Hippocampus	NN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
GFC75	GFC75	NN	B-NP	O	O
plus	plus	CC	I-NP	O	O
P400	P400	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AChE	AChE	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
63.30	63.30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
seized	seize	VBN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
GFC	GFC	NN	B-NP	O	B-Chemical
can	can	MD	B-VP	O	O
exert	exert	VB	I-VP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
reduce	reduce	VB	B-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
installation	installation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
demonstrated	demonstrate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
increase	increase	NN	B-NP	O	O
in	in	IN	B-PP	O	O
latency	latency	NN	B-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
decrease	decrease	NN	B-NP	O	O
in	in	IN	B-PP	O	O
mortality	mortality	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
GFC	GFC	NN	B-NP	O	B-Chemical
may	may	MD	B-VP	O	O
influence	influence	VB	I-VP	O	O
in	in	IN	B-PP	O	O
epileptogenesis	epileptogenesis	NN	B-NP	O	O
and	and	CC	O	O	O
promote	promote	VB	B-VP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
model	model	NN	I-NP	O	O
by	by	IN	B-PP	O	O
modulating	modulate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
GABA	GABA	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
glutamate	glutamate	NN	I-NP	B	B-Chemical
contents	content	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
AChE	AChE	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
seized	seize	VBN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
compound	compound	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
neuronal	neuronal	JJ	B-NP	O	O
protection	protection	NN	I-NP	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Standard	Standard	JJ	B-NP	O	O
operating	operating	NN	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
antibiotic	antibiotic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
,	,	,	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
interventional	interventional	JJ	I-NP	O	O
,	,	,	I-NP	O	O
observational	observational	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

INTRODUCTION	INTRODUCTION	NN	B-NP	O	O
:	:	:	O	O	O
Acute	Acute	JJ	B-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AKI	AKI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
occurs	occur	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
7	7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hospitalized	hospitalize	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
66	66	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Intensive	Intensive	JJ	B-NP	O	O
Care	Care	NNP	I-NP	O	O
Unit	Unit	NNP	I-NP	O	O
(	(	(	O	O	O
ICU	ICU	NN	B-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
increases	increase	VBZ	B-VP	O	O
mortality	mortality	NN	B-NP	O	O
,	,	,	O	O	O
hospital	hospital	NN	B-NP	O	O
length	length	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stay	stay	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
costs	cost	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
investigate	investigate	VB	I-VP	O	O
,	,	,	O	O	O
whether	whether	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
adherence	adherence	NN	B-NP	O	O
to	to	TO	B-PP	O	O
guidelines	guideline	NNS	B-NP	O	O
(	(	(	O	O	O
standard	standard	JJ	B-NP	O	O
operating	operating	NN	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
(	(	(	O	O	O
SOP	SOP	NN	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	B-Disease
antibiotics	antibiotic	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AKI	AKI	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
,	,	,	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
interventional	interventional	JJ	I-NP	O	O
,	,	,	I-NP	O	O
observational	observational	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Data	Data	NN	B-NP	O	O
collection	collection	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
170	170	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
ICUs	ICU	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
Charite	Charite	NNP	B-NP	O	O
-	-	HYPH	O	O	O
Universitaetsmedizin	Universitaetsmedizin	NNP	B-NP	O	O
Berlin	Berlin	NNP	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
675	675	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
;	;	:	O	O	O
163	163	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
had	have	VBD	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
tobramycin	tobramycin	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
were	be	VBD	B-VP	O	O
>	>	JJR	B-NP	O	O
18	18	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
treated	treat	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ICU	ICU	NN	I-NP	O	O
for	for	IN	B-PP	O	O
>	>	JJR	B-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adherence	adherence	NN	I-NP	O	O
to	to	TO	B-PP	O	O
SOP	SOP	NN	B-NP	O	O
>	>	SYM	O	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
classified	classify	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
adherence	adherence	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
HAG	HAG	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adherence	adherence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
<	<	SYM	B-NP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
adherence	adherence	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
LAG	LAG	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

AKI	AKI	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
RIFLE	RIFLE	NN	B-NP	B	O
criteria	criterion	NNS	I-NP	O	O
.	.	.	O	O	O

Adherence	Adherence	NN	B-NP	O	O
to	to	TO	B-PP	O	O
SOPs	SOP	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
retrospective	retrospective	JJ	B-NP	O	O
expert	expert	NN	I-NP	O	O
audit	audit	NN	I-NP	O	O
.	.	.	O	O	O

Development	Development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AKI	AKI	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
exact	exact	JJ	B-NP	O	O
Chi2	Chi2	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
test	test	NN	I-NP	O	O
and	and	CC	O	O	O
multivariate	multivariate	JJ	B-NP	O	O
logistic	logistic	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
(	(	(	O	O	O
two	two	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
sided	sided	JJ	I-NP	O	O
P	P	NN	I-NP	O	O
<	<	SYM	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
LAG	LAG	NN	B-NP	O	O
consisted	consist	VBD	B-VP	B	O
of	of	IN	B-PP	O	O
75	75	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
46	46	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
88	88	CD	B-NP	O	O
HAG	HAG	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
54	54	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

AKI	AKI	NN	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
more	more	RBR	I-ADVP	O	O
often	often	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
LAG	LAG	NN	B-NP	O	O
with	with	IN	B-PP	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
versus	versus	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HAG	HAG	NN	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.035	0.035	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Basic	Basic	JJ	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
soft	soft	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
LAG	LAG	NN	B-NP	O	O
.	.	.	O	O	O

Multivariate	Multivariate	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
odds	odd	NNS	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
LAG	LAG	NN	B-NP	O	O
to	to	TO	B-VP	O	O
develop	develop	VB	I-VP	O	O
AKI	AKI	NN	B-NP	O	B-Disease
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
HAG	HAG	NN	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
1.195	1.195	CD	I-NP	O	O
to	to	TO	B-PP	O	O
5.124	5.124	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.039	0.039	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Low	Low	JJ	B-NP	O	O
adherence	adherence	NN	I-NP	O	O
to	to	TO	B-PP	O	O
SOPs	SOP	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
potentially	potentially	RB	B-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	B-Disease
antibiotics	antibiotic	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AKI	AKI	NN	B-NP	O	B-Disease
.	.	.	O	O	O

TRIAL	TRIAL	NN	B-NP	O	O
REGISTRATION	REGISTRATION	NN	I-NP	O	O
:	:	:	O	O	O
Current	Current	NNP	B-NP	O	O
Controlled	Controlled	NNP	I-NP	O	O
Trials	Trial	NNPS	I-NP	O	O
ISRCTN54598675	ISRCTN54598675	NNP	I-NP	O	O
.	.	.	O	O	O

Registered	Register	VBN	B-NP	O	O
17	17	CD	I-NP	O	O
August	August	NNP	I-NP	O	O
2007	2007	CD	I-NP	O	O
.	.	.	O	O	O

Rhabdomyolysis	Rhabdomyolysis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
C	C	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	I-Disease
infected	infected	JJ	I-NP	O	I-Disease
patient	patient	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
telaprevir	telaprevir	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
simvastatin	simvastatin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
46	46	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
old	old	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
C	C	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	I-Disease
infection	infection	NN	I-NP	O	I-Disease
received	receive	VBD	B-VP	O	O
triple	triple	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
pegylated	pegylate	VBN	B-NP	O	B-Chemical
interferon	interferon	NN	I-NP	B	I-Chemical
and	and	CC	I-NP	O	O
telaprevir	telaprevir	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
received	receive	VBD	B-VP	O	O
simvastatin	simvastatin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

One	One	CD	B-NP	O	O
month	month	NN	I-NP	O	O
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
antiviral	antiviral	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
because	because	IN	B-SBAR	O	O
he	he	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

At	At	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
simvastatin	simvastatin	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
antiviral	antiviral	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
because	because	IN	B-SBAR	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
suspected	suspect	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
creatine	creatine	NN	I-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
peaked	peak	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
62,246	62,246	CD	B-NP	O	O
IU	IU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
normal	normal	JJ	I-NP	B	O
saline	saline	NN	I-NP	I	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
.	.	.	O	O	O

Fourteen	Fourteen	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
,	,	,	O	O	O
creatine	creatine	NN	B-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
level	level	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
returned	return	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
230	230	CD	B-NP	O	O
IU	IU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
discharged	discharge	VBN	I-VP	O	O
.	.	.	O	O	O

Telaprevir	Telaprevir	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
probable	probable	JJ	I-NP	O	O
causative	causative	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	B	B-Chemical
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Probability	Probability	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	I-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP3A4	CYP3A4	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
simvastatin	simvastatin	NN	I-NP	B	B-Chemical
clearance	clearance	NN	I-NP	O	O
.	.	.	O	O	O

Simvastatin	Simvastatin	NN	B-NP	B	B-Chemical
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
30	30	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
and	and	CC	I-NP	O	O
statin	statin	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
statin	statin	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
illustrate	illustrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
telaprevir	telaprevir	NN	B-NP	B	B-Chemical
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
statins	statin	NNS	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
.	.	.	O	O	O

Combination	Combination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bortezomib	bortezomib	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VTD	VTD	NN	B-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
after	after	IN	B-PP	O	O
autologous	autologous	JJ	B-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
symptomatic	symptomatic	JJ	B-NP	O	O
multiple	multiple	JJ	I-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Japanese	Japanese	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Consolidation	Consolidation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MM	MM	NN	B-NP	O	B-Disease
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
widely	widely	RB	I-VP	O	O
adopted	adopt	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
improve	improve	VB	I-VP	O	O
treatment	treatment	NN	B-NP	O	O
response	response	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
autologous	autologous	JJ	B-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
analyzed	analyze	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
regimen	regimen	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bortezomib	bortezomib	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VTD	VTD	NN	B-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
consolidation	consolidation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
Japanese	Japanese	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
newly	newly	RB	B-NP	O	O
diagnosed	diagnose	VBN	I-NP	O	O
MM	MM	NN	I-NP	O	B-Disease
.	.	.	O	O	O

VTD	VTD	NN	B-NP	O	O
consisted	consist	VBD	B-VP	B	O
of	of	IN	B-PP	O	O
bortezomib	bortezomib	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1.3	1.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	I-NP	O	O
15	15	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
22	22	CD	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
35	35	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
thalidomide	thalidomide	NN	I-NP	B	B-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Grade	Grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
four	four	CD	B-NP	O	O
and	and	CC	I-NP	O	O
three	three	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
17	17	CD	B-NP	O	O
and	and	CC	I-NP	O	O
13	13	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
drug	drug	NN	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
cytopenia	cytopenia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
required	require	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
case	case	NN	I-NP	O	O
.	.	.	O	O	O

Peripheral	Peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
common	common	JJ	B-ADJP	O	O
(	(	(	O	O	O
63	63	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
severe	severe	JJ	B-NP	O	O
grade	grade	NN	I-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Very	Very	RB	B-NP	O	O
good	good	JJ	I-NP	O	O
partial	partial	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
or	or	CC	O	O	O
better	good	JJR	B-NP	O	O
response	response	NN	I-NP	O	O
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
VGPR	VGPR	NN	I-NP	O	O
)	)	)	O	O	O
rates	rate	NNS	B-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
consolidation	consolidation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
54	54	CD	B-NP	O	O
and	and	CC	I-NP	O	O
79	79	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
probability	probability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
improving	improve	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
<	<	JJR	B-NP	O	O
VGPR	VGPR	NN	I-NP	O	O
before	before	IN	B-PP	O	O
consolidation	consolidation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
to	to	TO	B-PP	O	O
>	>	JJR	B-NP	O	O
VGPR	VGPR	NN	I-NP	O	O
after	after	IN	B-PP	O	O
consolidation	consolidation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.041	0.041	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
VTD	VTD	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safe	safe	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consolidation	consolidation	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MM	MM	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Japanese	Japanese	JJ	B-NP	O	O
population	population	NN	I-NP	O	O
.	.	.	O	O	O

Conversion	Conversion	NN	B-NP	O	O
to	to	TO	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	B	B-Chemical
ameliorates	ameliorate	VBZ	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
:	:	:	O	O	O
focus	focus	NN	B-NP	O	O
on	on	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
,	,	,	O	O	O
urine	urine	NN	B-NP	O	O
,	,	,	O	O	O
gene	gene	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
protein	protein	NN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
expression	expression	NN	I-NP	O	O
biomarkers	biomarker	NNS	I-NP	O	O
.	.	.	O	O	O

Protocols	Protocol	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
conversion	conversion	NN	B-NP	O	O
from	from	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
to	to	TO	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
SRL	SRL	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
widely	widely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
immunotherapy	immunotherapy	NN	B-NP	O	O
after	after	IN	B-PP	O	O
transplantation	transplantation	NN	B-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
these	these	DT	B-NP	O	O
protocols	protocol	NNS	I-NP	O	O
remain	remain	VBP	B-VP	O	O
nuclear	nuclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
identify	identify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
and	and	CC	O	O	O
putative	putative	JJ	B-NP	O	O
biomarkers	biomarker	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
-	-	HYPH	B-ADVP	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
SRL	SRL	NN	I-NP	O	B-Chemical
conversion	conversion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
animal	animal	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
9	9	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
:	:	:	O	O	O
control	control	NN	B-NP	O	O
,	,	,	O	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
SRL	SRL	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
conversion	conversion	NN	B-NP	O	O
(	(	(	O	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
SRL	SRL	NN	B-NP	O	B-Chemical
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Classical	Classical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
emergent	emergent	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
,	,	,	O	O	O
urinary	urinary	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
kidney	kidney	NN	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
(	(	(	O	O	O
gene	gene	NN	B-NP	O	O
and	and	CC	O	O	O
protein	protein	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
)	)	)	O	O	O
markers	marker	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	B-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hematoxylin	hematoxylin	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
eosin	eosin	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
periodic	periodic	JJ	B-NP	B	O
acid	acid	NN	I-NP	I	O
-	-	HYPH	O	O	O
Schiff	Schiff	NNP	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Masson	Masson	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
trichrome	trichrome	NN	I-NP	O	O
stains	stain	NNS	I-NP	O	O
.	.	.	O	O	O

SRL	SRL	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
presented	present	VBD	B-VP	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
NGAL	NGAL	NN	I-NP	O	O
(	(	(	O	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-ADJP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
markers	marker	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Short	Short	JJ	B-NP	O	O
CsA	CsA	NN	I-NP	O	B-Chemical
treatment	treatment	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
slight	slight	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
even	even	RB	I-NP	O	O
absent	absent	JJ	I-NP	O	O
kidney	kidney	NN	I-NP	O	B-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
TGF	TGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
b	b	NN	B-NP	O	O
,	,	,	O	O	O
NF	NF	NN	B-NP	B	O
-	-	HYPH	O	O	O
kb	kb	NN	B-NP	O	O
,	,	,	O	O	O
mTOR	mTOR	NN	B-NP	O	O
,	,	,	O	O	O
PCNA	PCNA	NN	B-NP	O	O
,	,	,	O	O	O
TP53	TP53	NN	B-NP	O	O
,	,	,	O	O	O
KIM	KIM	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
CTGF	CTGF	NN	B-NP	O	O
as	as	IN	B-PP	O	O
relevant	relevant	JJ	B-NP	O	O
gene	gene	NN	I-NP	O	O
and	and	CC	I-NP	O	O
protein	protein	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

Prolonged	Prolong	VBN	B-NP	O	O
CsA	CsA	NN	I-NP	O	B-Chemical
exposure	exposure	NN	I-NP	O	O
aggravated	aggravate	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
,	,	,	O	O	O
without	without	IN	B-PP	O	O
clear	clear	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
traditional	traditional	JJ	I-NP	O	O
markers	marker	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
with	with	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serums	serum	NNS	B-NP	O	O
TGF	TGF	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
b	b	NN	I-NP	O	O
and	and	CC	I-NP	O	O
IL	IL	NN	I-NP	B	O
-	-	HYPH	I-NP	I	O
7	7	CD	I-NP	I	O
,	,	,	O	O	O
TBARs	TBARs	NNP	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
kidney	kidney	NN	B-NP	O	O
TGF	TGF	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
b	b	NN	I-NP	O	O
and	and	CC	I-NP	O	O
mTOR	mTOR	NN	I-NP	O	O
.	.	.	O	O	O

Conversion	Conversion	NN	B-NP	O	O
to	to	TO	B-PP	O	O
SRL	SRL	NN	B-NP	O	B-Chemical
prevented	prevent	VBD	B-VP	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
evolution	evolution	NN	I-NP	O	O
(	(	(	O	O	O
absent	absent	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
mild	mild	JJ	I-NP	O	O
grade	grade	NN	I-NP	O	O
lesions	lesion	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
NGAL	NGAL	NN	B-NP	O	O
(	(	(	O	O	O
serum	serum	NN	B-NP	O	O
versus	versus	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
)	)	)	O	O	O
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
feasible	feasible	JJ	I-NP	O	O
biomarker	biomarker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CsA	CsA	NN	B-NP	O	B-Chemical
replacement	replacement	NN	I-NP	O	O
to	to	TO	B-PP	O	O
SRL	SRL	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Kinin	Kinin	NN	B-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
deletion	deletion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
blockage	blockage	NN	I-NP	O	O
ameliorates	ameliorate	VBZ	B-VP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Cisplatin	Cisplatin	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
adopted	adopt	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
chemotherapies	chemotherapy	NNS	I-NP	O	O
;	;	:	O	O	O
however	however	RB	O	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
can	can	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
due	due	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
negatively	negatively	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
augment	augment	NN	B-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
urea	urea	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
score	score	NN	I-NP	O	O
and	and	CC	O	O	O
up	up	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
regulate	regulate	VB	I-VP	O	O
cytokines	cytokine	NNS	B-NP	O	O
(	(	(	O	O	O
e.g.	e.g.	FW	B-NP	O	O
,	,	,	O	O	O
IL	IL	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
1b	1b	NN	I-NP	O	O
and	and	CC	I-NP	O	O
TNF	TNF	NN	I-NP	B	O
-	-	HYPH	O	O	O
a	a	DT	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
kinin	kinin	NN	I-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inflammation	inflammation	NN	I-NP	O	B-Disease
process	process	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cytokine	cytokine	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
deletion	deletion	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
status	status	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kinin	kinin	NN	I-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
kinin	kinin	NN	B-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
knockout	knockout	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
challenged	challenge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
after	after	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

B2	B2	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
deficient	deficient	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
less	less	RBR	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
WT	WT	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
shown	show	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
weight	weight	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
,	,	,	O	O	O
better	good	JJR	B-NP	O	O
preservation	preservation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
down	down	RB	B-ADVP	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
cytokines	cytokine	NNS	I-NP	O	O
and	and	CC	O	O	O
less	less	RBR	B-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kinin	kinin	NN	I-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
effectively	effectively	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
urea	urea	NN	I-NP	B	B-Chemical
after	after	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
kinin	kinin	NN	I-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
mediating	mediate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
necrotic	necrotic	JJ	I-NP	O	B-Disease
process	process	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
cytokines	cytokine	NNS	I-NP	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
declined	decline	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
highlight	highlight	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
kinin	kinin	NN	I-NP	O	O
B2	B2	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
amelioration	amelioration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Safety	Safety	NN	B-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluocinolone	fluocinolone	NN	B-NP	B	B-Chemical
acetonide	acetonide	NN	I-NP	I	I-Chemical
intravitreal	intravitreal	JJ	I-NP	O	O
implant	implant	NN	I-NP	O	O
(	(	(	O	O	O
0.59	0.59	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
birdshot	birdshot	NN	B-NP	O	B-Disease
retinochoroidopathy	retinochoroidopathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fluocinolone	fluocinolone	NN	I-NP	B	B-Chemical
acetonide	acetonide	NN	I-NP	I	I-Chemical
intravitreal	intravitreal	JJ	I-NP	O	O
implant	implant	NN	I-NP	O	O
(	(	(	O	O	O
0.59	0.59	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
birdshot	birdshot	NN	B-NP	O	B-Disease
retinochoroidopathy	retinochoroidopathy	NN	I-NP	O	I-Disease
whose	whose	WP$	B-NP	O	O
disease	disease	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
refractory	refractory	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
intolerant	intolerant	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
immunomodulatory	immunomodulatory	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
series	series	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
11	11	CD	B-NP	O	O
birdshot	birdshot	NN	I-NP	O	B-Disease
retinochoroidopathy	retinochoroidopathy	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
11	11	CD	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Eleven	Eleven	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
11	11	CD	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
)	)	)	O	O	O
underwent	undergo	VBD	B-VP	O	O
surgery	surgery	NN	B-NP	O	O
for	for	IN	B-PP	O	O
fluocinolone	fluocinolone	NN	B-NP	B	B-Chemical
acetonide	acetonide	NN	I-NP	I	I-Chemical
implant	implant	NN	I-NP	O	O
(	(	(	O	O	O
0.59	0.59	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
interest	interest	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
before	before	IN	B-PP	O	O
fluocinolone	fluocinolone	NN	B-NP	B	B-Chemical
acetonide	acetonide	NN	I-NP	I	I-Chemical
implant	implant	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
year	year	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
beyond	beyond	IN	B-PP	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Disease	Disease	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
markers	marker	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ocular	ocular	JJ	B-NP	O	O
inflammation	inflammation	NN	I-NP	O	B-Disease
,	,	,	O	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
retinal	retinal	JJ	B-NP	O	B-Disease
vasculitis	vasculitis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
Swedish	Swedish	JJ	B-NP	O	O
interactive	interactive	JJ	I-NP	O	O
threshold	threshold	NN	I-NP	O	O
algorithm	algorithm	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
short	short	JJ	I-NP	O	O
wavelength	wavelength	NN	I-NP	O	O
automated	automate	VBD	B-VP	O	O
perimetry	perimetry	NN	B-NP	O	O
Humphrey	Humphrey	NNP	I-NP	O	O
visual	visual	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
electroretinographic	electroretinographic	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
optical	optical	JJ	B-NP	O	O
coherence	coherence	NN	I-NP	O	O
tomography	tomography	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
occurrence	occurrence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cataract	cataract	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
raised	raise	VBD	B-VP	O	B-Disease
intraocular	intraocular	JJ	B-NP	O	I-Disease
pressure	pressure	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
collected	collect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Intraocular	Intraocular	JJ	B-NP	O	O
inflammation	inflammation	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
54.5	54.5	CD	B-NP	O	O
,	,	,	I-NP	O	O
9.9	9.9	CD	I-NP	O	O
,	,	,	I-NP	O	O
11.1	11.1	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
year	year	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
beyond	beyond	IN	B-PP	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
implant	implant	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Active	Active	JJ	B-NP	O	O
vasculitis	vasculitis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
36.3	36.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
and	and	CC	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

More	More	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
20	20	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
47.61	47.61	CD	B-NP	O	O
-	-	HYPH	O	O	O
67.2	67.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
retinal	retinal	JJ	I-NP	O	O
thickness	thickness	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cystoid	cystoid	JJ	B-NP	O	B-Disease
macular	macular	JJ	I-NP	O	I-Disease
edema	edema	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
year	year	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
postimplant	postimplant	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
54.5	54.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
immunomodulatory	immunomodulatory	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
percentage	percentage	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
45.45	45.45	CD	B-NP	O	O
,	,	,	I-NP	O	O
44.4	44.4	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
14.28	14.28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
year	year	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
postimplant	postimplant	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
increased	increase	VBN	B-NP	O	B-Disease
intraocular	intraocular	JJ	I-NP	O	I-Disease
pressure	pressure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
54.5	54.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
cataract	cataract	NN	B-NP	O	B-Disease
formation	formation	NN	I-NP	O	O
(	(	(	O	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
fluocinolone	fluocinolone	NN	B-NP	B	B-Chemical
acetonide	acetonide	NN	I-NP	I	I-Chemical
implant	implant	NN	I-NP	O	O
(	(	(	O	O	O
0.59	0.59	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
helps	help	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
control	control	VB	I-VP	O	O
inflammation	inflammation	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
otherwise	otherwise	RB	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
refractory	refractory	JJ	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
birdshot	birdshot	NN	B-NP	O	B-Disease
retinochoroidopathy	retinochoroidopathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cataract	cataract	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
ocular	ocular	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
requiring	require	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Optimal	Optimal	JJ	B-NP	O	O
precurarizing	precurarize	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
fasciculation	fasciculation	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Succinylcholine	Succinylcholine	NN	B-NP	B	B-Chemical
commonly	commonly	RB	B-ADVP	O	O
produces	produce	VBZ	B-VP	O	O
frequent	frequent	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
fasciculation	fasciculation	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
identified	identify	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
fasciculation	fasciculation	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
speed	speed	NN	I-NP	O	O
of	of	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blinded	blind	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
100	100	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
randomly	randomly	RB	B-VP	O	O
allocated	allocate	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
five	five	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
each	each	DT	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
receive	receive	VB	I-VP	O	O
0.02	0.02	CD	B-NP	O	O
,	,	,	I-NP	O	O
0.03	0.03	CD	I-NP	O	O
,	,	,	I-NP	O	O
0.04	0.04	CD	I-NP	O	O
,	,	,	I-NP	O	O
0.05	0.05	CD	I-NP	O	O
and	and	CC	I-NP	O	O
0.06	0.06	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
rocuronium	rocuronium	NN	I-NP	B	B-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
precurarizing	precurarize	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Neuromuscular	Neuromuscular	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
each	each	DT	B-NP	O	O
precurarizing	precurarize	VBG	I-NP	O	O
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adductor	adductor	NN	I-NP	O	O
pollicis	pollicis	NN	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
acceleromyography	acceleromyography	NN	B-NP	O	O
with	with	IN	B-PP	O	O
train	train	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
of	of	IN	B-PP	O	O
-	-	SYM	B-NP	O	O
four	four	CD	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ulnar	ulnar	JJ	I-NP	O	O
nerve	nerve	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
1.5	1.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
precurarization	precurarization	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fasciculations	fasciculation	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
myalgia	myalgia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
visible	visible	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-Disease
fasciculation	fasciculation	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
less	less	JJR	I-ADJP	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precurarizing	precurarize	VBG	B-VP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Those	Those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
myalgia	myalgia	NN	B-NP	O	B-Disease
tend	tend	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precurarizing	precurarize	VBG	B-VP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significance	significance	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.072	0.072	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
longer	longer	RBR	I-ADJP	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
precurarizing	precurarize	VBG	B-VP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rocuronium	rocuronium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Precurarization	Precurarization	NN	B-NP	O	O
with	with	IN	B-PP	O	O
0.04	0.04	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
rocuronium	rocuronium	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
considering	consider	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fasciculation	fasciculation	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
acceptable	acceptable	JJ	B-NP	O	O
onset	onset	NN	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
safe	safe	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
effective	effective	JJ	I-NP	O	O
precurarization	precurarization	NN	I-NP	O	O
.	.	.	O	O	O

Absence	Absence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PKC	PKC	NN	B-NP	O	O
-	-	HYPH	O	O	O
alpha	alpha	SYM	B-NP	O	O
attenuates	attenuate	VBZ	B-VP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
nephrogenic	nephrogenic	JJ	I-NP	O	B-Disease
diabetes	diabetes	NN	I-NP	O	I-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
,	,	,	O	O	O
induces	induce	VBZ	B-VP	O	O
nephrogenic	nephrogenic	JJ	B-NP	O	B-Disease
diabetes	diabetes	NN	I-NP	O	I-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
(	(	(	O	O	O
NDI	NDI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
in	in	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
concentrate	concentrate	VB	I-VP	O	O
urine	urine	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	RB	B-ADJP	O	O
due	due	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
acutely	acutely	RB	B-VP	O	O
disrupting	disrupt	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
cAMP	cAMP	NN	I-NP	B	B-Chemical
pathway	pathway	NN	I-NP	O	O
and	and	CC	O	O	O
chronically	chronically	RB	B-VP	O	O
reducing	reduce	VBG	I-VP	O	O
urea	urea	NN	B-NP	B	B-Chemical
transporter	transporter	NN	I-NP	O	O
(	(	(	O	O	O
UT	UT	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
A1	A1	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
water	water	NN	B-NP	B	O
channel	channel	NN	I-NP	O	O
(	(	(	O	O	O
AQP2	AQP2	NN	B-NP	O	O
)	)	)	O	O	O
expression	expression	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inner	inner	JJ	I-NP	O	O
medulla	medulla	NN	I-NP	O	O
.	.	.	O	O	O

Targeting	Target	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
signaling	signaling	NN	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
PKC	PKC	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
signaling	signaling	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treating	treat	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
polyuria	polyuria	NN	I-NP	O	B-Disease
.	.	.	O	O	O

PKC	PKC	NN	B-NP	O	O
-	-	HYPH	O	O	O
alpha	alpha	SYM	B-NP	O	O
null	null	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
(	(	(	O	O	O
PKCa	PKCa	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
strain	strain	NN	B-NP	O	O
-	-	HYPH	O	O	O
matched	match	VBN	B-VP	B	O
wild	wild	JJ	B-NP	O	O
type	type	NN	I-NP	O	O
(	(	(	O	O	O
WT	WT	NN	B-NP	O	O
)	)	)	O	O	O
controls	control	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
0	0	CD	B-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
or	or	CC	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
urine	urine	NN	B-NP	O	O
output	output	NN	I-NP	O	O
and	and	CC	O	O	O
lowered	lower	VBD	B-VP	O	O
urine	urine	NN	B-NP	O	O
osmolality	osmolality	NN	I-NP	O	O
after	after	IN	B-PP	O	O
3	3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
whereas	whereas	IN	B-PP	O	O
PKCa	PKCa	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
output	output	NN	I-NP	O	O
or	or	CC	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

Western	Western	NN	B-NP	O	O
blot	blot	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
AQP2	AQP2	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
medullary	medullary	JJ	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
lowered	lower	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
3	3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
AQP2	AQP2	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
PKCa	PKCa	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
.	.	.	O	O	O

Similar	Similar	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
UT	UT	NN	B-NP	O	O
-	-	HYPH	O	O	O
A1	A1	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
19	19	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
fold	fold	RB	I-NP	O	O
increased	increase	VBN	I-NP	O	O
urine	urine	NN	I-NP	O	O
output	output	NN	I-NP	O	O
whereas	whereas	IN	B-PP	O	O
treated	treat	VBN	B-NP	O	O
PKCa	PKCa	NN	I-NP	O	O
KO	KO	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
output	output	NN	B-NP	O	O
.	.	.	O	O	O

AQP2	AQP2	NN	B-NP	O	O
and	and	CC	I-NP	O	O
UT	UT	NN	I-NP	O	O
-	-	HYPH	O	O	O
A1	A1	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lowered	lower	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
week	week	NN	I-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
WT	WT	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
whereas	whereas	IN	B-ADVP	O	O
in	in	IN	B-PP	O	O
treated	treat	VBN	B-NP	O	O
PKCa	PKCa	NN	I-NP	O	O
KO	KO	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
AQP2	AQP2	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
and	and	CC	O	O	O
UT	UT	NN	B-NP	O	O
-	-	HYPH	O	O	O
A1	A1	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
unaffected	unaffected	JJ	B-ADJP	O	O
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
,	,	,	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
elevated	elevate	VBN	I-VP	B	O
in	in	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
fed	feed	VBN	B-NP	O	O
WT	WT	NN	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
fed	feed	VBN	I-NP	O	O
PKCa	PKCa	NN	I-NP	O	O
KO	KO	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ablation	ablation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PKCa	PKCa	NN	B-NP	O	O
preserves	preserve	VBZ	B-VP	O	O
AQP2	AQP2	NN	B-NP	O	O
and	and	CC	I-NP	O	O
UT	UT	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
A1	A1	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
and	and	CC	O	O	O
localization	localization	NN	B-NP	O	O
in	in	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
NDI	NDI	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
prevents	prevent	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
polyuria	polyuria	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Is	Be	VBZ	O	O	O
Dysguesia	Dysguesia	NNP	B-NP	O	B-Disease
Going	Going	NNP	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
Rare	Rare	NN	I-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
Common	Common	JJ	I-NP	O	O
Side	Side	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Amlodipine	Amlodipine	NN	B-NP	B	B-Chemical
?	?	.	O	O	O

A	A	DT	B-NP	O	O
very	very	RB	I-NP	O	O
rare	rare	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	O	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amlodipine	amlodipine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
dysguesia	dysguesia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
case	case	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
about	about	IN	B-PP	O	O
a	a	DT	B-NP	O	O
female	female	NN	I-NP	O	O
with	with	IN	B-PP	O	O
essential	essential	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
on	on	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
amlodipine	amlodipine	NN	B-NP	B	B-Chemical
developed	develop	VBD	B-VP	O	O
loss	loss	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
taste	taste	NN	B-NP	O	I-Disease
sensation	sensation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Condition	Condition	NN	B-NP	O	O
moderately	moderately	RB	B-VP	O	O
improved	improve	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
stoppage	stoppage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
for	for	IN	B-PP	O	O
25	25	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
amlodipine	amlodipine	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
dysguesia	dysguesia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
presentation	presentation	NN	I-NP	O	O
and	and	CC	O	O	O
review	review	VB	B-VP	O	O
the	the	DT	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
literature	literature	NN	I-NP	O	O
on	on	IN	B-PP	O	O
amlodipine	amlodipine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dysguesia	dysguesia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Rhabdomyolysis	Rhabdomyolysis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
increment	increment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Clarithromycin	Clarithromycin	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
documented	document	VBN	I-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
P450	P450	NN	I-NP	O	O
3A4	3A4	NN	I-NP	O	O
(	(	(	O	O	O
CYP3A4	CYP3A4	NN	B-NP	O	O
)	)	)	O	O	O
inhibitor	inhibitor	NN	B-NP	O	O
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
simvastatin	simvastatin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
particular	particular	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
interest	interest	NN	B-NP	O	O
as	as	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
only	only	RB	B-ADVP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clarithromycin	clarithromycin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
raised	raise	VBN	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
biomarkers	biomarker	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
obvious	obvious	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
issues	issue	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
linked	link	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
previously	previously	RB	B-ADVP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
date	date	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
structure	structure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
.	.	.	O	O	O

Clinicians	Clinician	NNS	B-NP	O	O
need	need	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
prescribing	prescribe	VBG	B-VP	O	O
concomitant	concomitant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myopathy	myopathy	NN	B-NP	O	B-Disease
or	or	CC	O	O	O
inhibit	inhibit	VB	B-VP	O	O
the	the	DT	B-NP	O	O
CYP3A4	CYP3A4	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
case	case	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
troponin	troponin	NN	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
statin	statin	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
warrant	warrant	VB	I-VP	O	O
further	further	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Characterization	Characterization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
BCHE	BCHE	NN	I-NP	O	O
"	"	``	B-NP	O	O
silent	silent	JJ	I-NP	O	O
"	"	''	I-NP	O	O
allele	allele	NN	I-NP	O	O
:	:	:	O	O	O
point	point	NN	B-NP	O	O
mutation	mutation	NN	I-NP	O	O
(	(	(	O	O	O
p.Val204Asp	p.Val204Asp	NN	B-NP	O	O
)	)	)	O	O	O
causes	cause	VBZ	B-VP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
and	and	CC	O	O	O
prolonged	prolonged	JJ	B-NP	O	O
apnea	apnea	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Butyrylcholinesterase	Butyrylcholinesterase	NN	B-NP	O	B-Disease
deficiency	deficiency	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
apnea	apnea	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	O
relaxants	relaxant	NNS	I-NP	B	O
(	(	(	O	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
mivacurium	mivacurium	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
mutations	mutation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
BCHE	BCHE	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	O
block	block	NN	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
discovery	discovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
BCHE	BCHE	NN	I-NP	O	O
variant	variant	NN	I-NP	O	O
(	(	(	O	O	O
c.695T	c.695T	NN	B-NP	O	O
>	>	SYM	O	O	O
A	A	NN	B-NP	O	O
,	,	,	I-NP	O	O
p.Val204Asp	p.Val204Asp	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
kinetic	kinetic	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
and	and	CC	O	O	O
molecular	molecular	JJ	B-NP	O	O
dynamics	dynamic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
understand	understand	VB	I-VP	O	O
how	how	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
mutation	mutation	NN	I-NP	O	O
disrupts	disrupt	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
catalytic	catalytic	JJ	I-NP	O	O
triad	triad	NN	I-NP	O	O
and	and	CC	O	O	O
determines	determine	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
"	"	``	I-NP	O	O
silent	silent	JJ	I-NP	O	O
"	"	''	I-NP	O	O
phenotype	phenotype	NN	I-NP	O	O
.	.	.	O	O	O

Low	Low	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
butyrylcholinesterase	butyrylcholinesterase	NN	I-NP	O	O
with	with	IN	B-PP	O	O
butyrylthiocholine	butyrylthiocholine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
BTC	BTC	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
benzoylcholine	benzoylcholine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
values	value	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
dibucaine	dibucaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
fluoride	fluoride	NN	I-NP	B	B-Chemical
numbers	number	NNS	I-NP	O	O
fit	fit	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
heterozygous	heterozygous	JJ	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
silent	silent	JJ	I-NP	O	O
genotype	genotype	NN	I-NP	O	O
.	.	.	O	O	O

Electrophoretic	Electrophoretic	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
BChE	BChE	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
proband	proband	NN	I-NP	O	O
and	and	CC	O	O	O
his	his	PRP$	B-NP	O	O
mother	mother	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
patient	patient	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetrameric	tetrameric	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
minor	minor	JJ	B-NP	O	O
fast	fast	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
moving	move	VBG	I-NP	O	O
BChE	BChE	NN	I-NP	O	O
components	component	NNS	I-NP	O	O
:	:	:	O	O	O
monomer	monomer	NN	B-NP	O	O
,	,	,	O	O	O
dimer	dimer	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
monomer	monomer	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
albumin	albumin	NN	I-NP	O	O
conjugate	conjugate	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
missing	miss	VBG	I-VP	O	O
.	.	.	O	O	O

Kinetic	Kinetic	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
p.Val204Asp	p.Val204Asp	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
p.Asp70Gly	p.Asp70Gly	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
p.Ala539Thr	p.Ala539Thr	NN	I-NP	O	O
BChE	BChE	NN	I-NP	O	O
displays	display	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
pure	pure	JJ	I-NP	O	O
Michaelian	Michaelian	JJ	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
with	with	IN	B-PP	O	O
BTC	BTC	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
catalytic	catalytic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
Km	Km	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
265	265	CD	B-NP	O	O
uM	uM	NN	I-NP	O	O
for	for	IN	B-PP	O	O
BTC	BTC	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
two	two	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
higher	high	JJR	B-ADVP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
Vmax	Vmax	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
against	against	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Molecular	Molecular	JJ	B-NP	O	O
dynamic	dynamic	JJ	I-NP	O	O
(	(	(	O	O	O
MD	MD	NN	B-NP	B	O
)	)	)	O	O	O
simulations	simulation	NNS	B-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mutation	mutation	NN	I-NP	O	O
p.Val204Asp	p.Val204Asp	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
disruption	disruption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hydrogen	hydrogen	NN	B-NP	B	B-Chemical
bonding	bonding	NN	I-NP	O	O
between	between	IN	B-PP	O	O
Gln223	Gln223	NN	B-NP	O	O
and	and	CC	I-NP	O	O
Glu441	Glu441	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-NP	O	O
Ser198	Ser198	NN	I-NP	O	O
and	and	CC	I-NP	O	O
His438	His438	NN	I-NP	O	O
to	to	TO	B-VP	O	O
move	move	VB	I-VP	O	O
away	away	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
with	with	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
disruption	disruption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
catalytic	catalytic	JJ	I-NP	O	O
triad	triad	NN	I-NP	O	O
functionality	functionality	NN	I-NP	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substrate	substrate	NN	B-NP	O	O
.	.	.	O	O	O

MD	MD	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
volume	volume	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
denaturation	denaturation	NN	I-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
fits	fit	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p.Ala204Asp	p.Ala204Asp	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
p.Asp70Gly	p.Asp70Gly	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
p.Ala539Thr	p.Ala539Thr	NN	I-NP	O	O
tetrameric	tetrameric	JJ	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
detectable	detectable	JJ	B-ADJP	O	O
fast	fast	RB	B-VP	O	O
moving	move	VBG	I-VP	O	O
-	-	HYPH	B-NP	O	O
bands	band	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
electrophoresis	electrophoresis	NN	B-NP	O	O
gels	gel	NNS	I-NP	O	O
.	.	.	O	O	O

Delayed	Delay	VBN	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
injectable	injectable	JJ	B-NP	O	O
artesunate	artesunate	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Democratic	Democratic	JJ	I-NP	O	O
Republic	Republic	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Congo	Congo	NNP	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
manageable	manageable	JJ	I-NP	O	O
issue	issue	NN	I-NP	O	O
.	.	.	O	O	O

Cases	Case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
injectable	injectable	JJ	B-NP	O	O
artesunate	artesunate	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
World	World	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Organization	Organization	NNP	I-NP	O	O
(	(	(	O	O	O
WHO	WHO	WP	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	O	O	O
recommended	recommend	VBN	B-NP	O	O
first	first	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
malaria	malaria	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
350	350	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
215	215	CD	B-NP	O	O
[	[	(	O	O	O
61.4	61.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
]	]	)	O	O	O
<	<	SYM	O	O	O
5	5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
and	and	CC	O	O	O
135	135	CD	B-NP	O	O
[	[	(	O	O	O
38.6	38.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
]	]	)	O	O	O
>	>	SYM	O	O	O
5	5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
injectable	injectable	JJ	B-NP	O	O
artesunate	artesunate	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
malaria	malaria	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
hospitals	hospital	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
health	health	NN	I-NP	O	O
centers	center	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Democratic	Democratic	JJ	I-NP	O	O
Republic	Republic	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Congo	Congo	NNP	I-NP	O	O
.	.	.	O	O	O

Complete	Complete	JJ	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hemoglobin	hemoglobin	NN	B-NP	B	O
(	(	(	O	O	O
Hb	Hb	NN	B-NP	O	O
)	)	)	O	O	O
measurements	measurement	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
201	201	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Hb	Hb	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
2	2	CD	B-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
23	23	CD	B-NP	O	O
(	(	(	O	O	O
11.4	11.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
up	up	RP	B-PRT	O	O
period	period	NN	B-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
Hb	Hb	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
below	below	IN	B-PP	O	O
5	5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
during	during	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
one	one	CD	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
visit	visit	NN	B-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
manageable	manageable	JJ	I-ADJP	O	O
and	and	CC	O	O	O
resolved	resolve	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
.	.	.	O	O	O

Regulation	Regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
signal	signal	NN	B-NP	O	O
transducer	transducer	NN	I-NP	O	O
and	and	CC	I-NP	O	O
activator	activator	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transcription	transcription	NN	B-NP	O	O
3	3	CD	I-NP	O	O
and	and	CC	O	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
attenuates	attenuate	VBZ	B-VP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
acute	acute	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cardioprotective	cardioprotective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
experimentally	experimentally	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
focusing	focus	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
signal	signal	NN	B-NP	O	O
transducer	transducer	NN	I-NP	O	O
and	and	CC	I-NP	O	O
activator	activator	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transcription	transcription	NN	B-NP	O	O
3	3	CD	I-NP	O	O
(	(	(	O	O	O
STAT3	STAT3	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Male	Male	NNP	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
100	100	CD	B-NP	O	O
,	,	,	I-NP	O	O
200	200	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
orally	orally	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
40	40	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemic	ischemic	JJ	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
subcutaneous	subcutaneous	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
85	85	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
,	,	,	O	O	O
histopathological	histopathological	JJ	B-NP	O	O
variables	variable	NNS	I-NP	O	O
and	and	CC	O	O	O
expression	expression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
and	and	CC	I-NP	O	O
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
significantly	significantly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
marker	marker	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	O	O	O
prevented	prevent	VBD	B-VP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
remodeling	remodeling	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Western	Western	NN	B-NP	O	O
blot	blot	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STAT3	STAT3	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
or	or	CC	O	O	O
further	further	RBR	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
myocardium	myocardium	NN	B-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
and	and	CC	I-NP	O	O
400	400	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bcl	Bcl	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bax	Bax	NN	B-NP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
causing	cause	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bcl	Bcl	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
Bax	Bax	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
further	further	RBR	I-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
histopathological	histopathological	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
summary	summary	NN	B-NP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
betaine	betaine	NN	B-NP	B	B-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
attenuated	attenuate	VBD	B-VP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
acute	acute	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
STAT3	STAT3	NN	B-NP	O	O
and	and	CC	O	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
.	.	.	O	O	O

Quetiapine	Quetiapine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Quetiapine	Quetiapine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
dibenzothiazepine	dibenzothiazepine	NN	I-NP	B	O
derivative	derivative	NN	I-NP	O	O
,	,	,	O	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
causing	cause	VBG	B-VP	O	O
blood	blood	NN	B-NP	O	B-Disease
dyscrasias	dyscrasia	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
especially	especially	RB	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
some	some	DT	B-NP	O	O
case	case	NN	I-NP	O	O
reports	report	VBZ	B-VP	O	O
about	about	IN	B-PP	O	O
this	this	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
possible	possible	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
seldom	seldom	RB	I-VP	O	O
discussed	discuss	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
developed	develop	VBD	B-VP	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
here	here	RB	B-ADVP	O	O
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
REPORT	REPORT	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
62	62	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
Taiwanese	Taiwanese	JJ	I-NP	O	O
widow	widow	NN	I-NP	O	O
with	with	IN	B-PP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
age	age	NN	B-NP	O	O
60	60	CD	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
leucopenia	leucopenia	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

After	After	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
,	,	,	O	O	O
her	her	PRP$	B-NP	O	O
white	white	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
count	count	NN	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
cautious	cautious	JJ	B-ADJP	O	O
about	about	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
presentation	presentation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
associated	associate	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Hepatic	Hepatic	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
concomitant	concomitant	JJ	B-NP	O	O
fever	fever	NN	I-NP	O	B-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
for	for	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
quetiapine	quetiapine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Lateral	Lateral	JJ	B-NP	O	O
antebrachial	antebrachial	JJ	I-NP	O	O
cutaneous	cutaneous	JJ	I-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
steroid	steroid	NN	B-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
at	at	IN	B-PP	O	O
lateral	lateral	JJ	B-NP	O	O
epicondyle	epicondyle	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
OBJECTIVES	OBJECTIVES	NNS	I-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
aimed	aim	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
present	present	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lateral	lateral	JJ	B-NP	O	O
antebrachial	antebrachial	JJ	I-NP	O	O
cutaneous	cutaneous	JJ	I-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	B-Disease
(	(	(	O	O	O
LACNP	LACNP	NN	B-NP	O	O
)	)	)	O	O	O
that	that	WDT	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
epicondyle	epicondyle	NN	I-NP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
lateral	lateral	JJ	B-NP	O	B-Disease
epicondylitis	epicondylitis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
40	40	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
.	.	.	O	O	O

MATERIAL	MATERIAL	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHOD	METHOD	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
40	40	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
sensation	sensation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
paresthesia	paresthesia	NN	I-NP	O	B-Disease
over	over	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
right	right	JJ	I-NP	O	O
lateral	lateral	JJ	I-NP	O	O
forearm	forearm	NN	I-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
paresthesia	paresthesia	NN	I-NP	O	B-Disease
had	have	VBD	B-VP	O	O
occurred	occur	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
right	right	JJ	I-NP	O	O
lateral	lateral	JJ	I-NP	O	O
epicondyle	epicondyle	NN	I-NP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
before	before	RB	B-ADVP	O	O
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
sensation	sensation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
light	light	JJ	B-NP	O	O
touch	touch	NN	I-NP	O	O
and	and	CC	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
diminished	diminish	VBN	I-VP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
right	right	JJ	I-NP	O	O
forearm	forearm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
wrist	wrist	NN	I-NP	O	O
area	area	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
sensory	sensory	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
right	right	JJ	I-NP	O	O
lateral	lateral	JJ	I-NP	O	O
antebrachial	antebrachial	JJ	I-NP	O	O
cutaneous	cutaneous	JJ	I-NP	O	O
nerve	nerve	NN	I-NP	O	O
(	(	(	O	O	O
LACN	LACN	NN	B-NP	B	O
)	)	)	O	O	O
(	(	(	O	O	O
6.2	6.2	CD	B-NP	O	O
uV	uV	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
(	(	(	O	O	O
13.1	13.1	CD	B-NP	O	O
uV	uV	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amplitude	amplitude	NN	B-NP	O	O
between	between	IN	B-PP	O	O
both	both	DT	B-NP	O	O
sides	side	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significant	significant	JJ	B-ADJP	O	O
because	because	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	B-PP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
right	right	JJ	B-NP	O	O
LACNP	LACNP	NN	I-NP	O	O
(	(	(	O	O	O
mainly	mainly	RB	B-NP	O	O
axonal	axonal	JJ	I-NP	O	O
involvement	involvement	NN	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
manifestation	manifestation	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
electrodiagnostic	electrodiagnostic	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
improved	improve	VBN	B-VP	O	O
through	through	IN	B-PP	O	O
physical	physical	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
but	but	CC	O	O	O
persisted	persist	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
some	some	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
LACNP	LACNP	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
developed	develop	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
steroid	steroid	NN	I-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lateral	lateral	JJ	B-NP	O	B-Disease
epicondylitis	epicondylitis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

An	An	DT	B-NP	O	O
electrodiagnostic	electrodiagnostic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LACN	LACN	NN	I-NP	B	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
helpful	helpful	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
diagnose	diagnose	VB	I-VP	O	O
right	right	JJ	B-NP	O	O
LACNP	LACNP	NN	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
find	find	VB	I-VP	O	O
the	the	DT	B-NP	O	O
passage	passage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LACN	LACN	NN	I-NP	B	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
epicondyle	epicondyle	NN	I-NP	O	O
.	.	.	O	O	O

Curcumin	Curcumin	NN	B-NP	B	B-Chemical
prevents	prevent	VBZ	B-VP	O	O
maleate	maleate	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
:	:	:	O	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
hemodynamic	hemodynamic	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
,	,	,	O	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
,	,	,	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
respiratory	respiratory	JJ	B-NP	O	O
complex	complex	NN	I-NP	O	O
I	I	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dietary	dietary	JJ	I-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
curcumin	curcumin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
Kg	Kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
maleate	maleate	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Tubular	Tubular	JJ	B-NP	O	O
proteinuria	proteinuria	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
maleate	maleate	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Maleate	Maleate	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
included	include	VBD	B-VP	O	O
increase	increase	NN	B-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
neutrophil	neutrophil	NN	B-NP	O	O
gelatinase	gelatinase	NN	I-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
lipocalin	lipocalin	NN	B-NP	O	O
(	(	(	O	O	O
NGAL	NGAL	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	O	O	O
acetyl	acetyl	NN	B-NP	B	O
b	b	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
D	D	NN	I-NP	O	O
-	-	HYPH	O	O	O
glucosaminidase	glucosaminidase	NN	B-NP	O	O
(	(	(	O	O	O
NAG	NAG	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
upregulation	upregulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
molecule	molecule	NN	I-NP	O	O
(	(	(	O	O	O
KIM	KIM	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
decrease	decrease	NN	B-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
and	and	CC	I-NP	O	O
claudin	claudin	NN	I-NP	O	O
-	-	HYPH	O	O	O
2	2	CD	B-NP	O	O
expression	expression	NN	I-NP	O	O
besides	besides	IN	B-PP	O	O
of	of	IN	B-PP	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Oxidative	Oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
measuring	measure	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
oxidation	oxidation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lipids	lipid	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
proteins	protein	NNS	I-NP	O	O
and	and	CC	O	O	O
diminution	diminution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
Nrf2	Nrf2	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
LLC	LLC	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
PK1	PK1	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
mitochondria	mitochondrion	NNS	B-NP	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
kidneys	kidney	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Maleate	Maleate	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
cell	cell	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
and	and	CC	O	O	O
reactive	reactive	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
species	specie	NNS	I-NP	O	O
(	(	(	O	O	O
ROS	ROS	NN	B-NP	B	O
)	)	)	O	O	O
production	production	NN	B-NP	O	O
in	in	IN	B-PP	O	O
LLC	LLC	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
PK1	PK1	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
culture	culture	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
maleate	maleate	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
oxygen	oxygen	NN	B-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ADP	ADP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
stimulated	stimulate	VBN	I-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
and	and	CC	O	O	O
diminished	diminish	VBN	B-VP	O	O
respiratory	respiratory	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
index	index	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
using	use	VBG	B-VP	O	O
malate	malate	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
glutamate	glutamate	NN	I-NP	B	B-Chemical
as	as	IN	B-PP	O	O
substrate	substrate	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
activities	activity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
complex	complex	NN	B-NP	O	O
I	I	CD	I-NP	O	O
and	and	CC	O	O	O
aconitase	aconitase	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
diminished	diminish	VBN	I-VP	O	O
.	.	.	O	O	O

All	All	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
above	above	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
described	describe	VBN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
curcumin	curcumin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
curcumin	curcumin	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
able	able	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
maleate	maleate	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
cell	cell	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
protection	protection	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
and	and	CC	I-NP	O	O
preservation	preservation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
respiratory	respiratory	JJ	B-NP	O	O
complex	complex	NN	I-NP	O	O
I	I	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
protection	protection	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ROS	ROS	NN	B-NP	B	O
production	production	NN	I-NP	O	O
.	.	.	O	O	O

Incidence	Incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
solid	solid	JJ	B-NP	O	O
tumours	tumour	NNS	I-NP	O	B-Disease
among	among	IN	B-PP	O	O
pesticide	pesticide	NN	B-NP	O	O
applicators	applicator	NNS	I-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
organophosphate	organophosphate	NN	I-NP	O	B-Chemical
insecticide	insecticide	NN	I-NP	O	O
diazinon	diazinon	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Agricultural	Agricultural	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
:	:	:	O	O	O
an	an	DT	B-NP	O	O
updated	update	VBN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Diazinon	Diazinon	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
organophosphate	organophosphate	NN	I-NP	O	B-Chemical
insecticide	insecticide	NN	I-NP	O	O
with	with	IN	B-PP	O	O
genotoxic	genotoxic	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
previously	previously	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lung	lung	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Agricultural	Agricultural	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
(	(	(	O	O	O
AHS	AHS	NNP	B-NP	O	O
)	)	)	O	O	O
cohort	cohort	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
few	few	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
epidemiological	epidemiological	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
examined	examine	VBN	I-VP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
risk	risk	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
updated	update	VBN	B-NP	O	O
diazinon	diazinon	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
cancer	cancer	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
information	information	NN	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
solid	solid	JJ	B-NP	O	O
tumour	tumour	NN	I-NP	O	B-Disease
risk	risk	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AHS	AHS	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Male	Male	JJ	B-NP	O	O
pesticide	pesticide	NN	I-NP	O	O
applicators	applicator	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Iowa	Iowa	NNP	B-NP	O	O
and	and	CC	O	O	O
North	North	NNP	B-NP	O	O
Carolina	Carolina	NNP	I-NP	O	O
reported	report	VBD	B-VP	O	O
lifetime	lifetime	NN	B-NP	O	O
diazinon	diazinon	NN	I-NP	B	B-Chemical
use	use	NN	I-NP	O	O
at	at	IN	B-PP	O	O
enrolment	enrolment	NN	B-NP	O	O
(	(	(	O	O	O
1993	1993	CD	B-NP	O	O
-	-	HYPH	O	O	O
1997	1997	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
(	(	(	O	O	O
1998	1998	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2005	2005	CD	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
cancer	cancer	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
2010	2010	CD	B-NP	O	O
(	(	(	O	O	O
North	North	NNP	B-NP	O	O
Carolina	Carolina	NNP	I-NP	O	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
2011	2011	CD	I-NP	O	O
(	(	(	O	O	O
Iowa	Iowa	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
applicators	applicator	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
usage	usage	NN	B-NP	O	O
information	information	NN	I-NP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
exposure	exposure	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
patterns	pattern	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
Poisson	Poisson	NN	B-NP	O	O
regression	regression	NN	I-NP	O	O
to	to	TO	B-VP	O	O
estimate	estimate	VB	I-VP	O	O
adjusted	adjust	VBN	B-NP	O	O
rate	rate	NN	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
(	(	(	O	O	O
RRs	RR	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
sites	site	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
>	>	SYM	B-NP	O	O
10	10	CD	I-NP	O	O
exposed	expose	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
both	both	CC	O	O	O
lifetime	lifetime	NN	B-NP	O	O
(	(	(	O	O	O
LT	LT	NN	B-NP	O	O
)	)	)	O	O	O
exposure	exposure	NN	B-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
-	-	HYPH	O	O	O
weighted	weight	VBN	B-VP	O	O
(	(	(	O	O	O
IW	IW	NN	B-NP	O	O
)	)	)	O	O	O
lifetime	lifetime	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
accounting	accounting	NN	B-NP	O	O
for	for	IN	B-PP	O	O
factors	factor	NNS	B-NP	O	O
impacting	impact	VBG	B-VP	O	O
exposure	exposure	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
elevated	elevated	JJ	B-NP	O	O
lung	lung	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
risks	risk	NNS	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
283	283	CD	B-NP	O	O
)	)	)	O	O	O
among	among	IN	B-PP	O	O
applicators	applicator	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
greatest	great	JJS	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LT	LT	NN	B-NP	O	O
(	(	(	O	O	O
RR	RR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1.60	1.60	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
1.11	1.11	CD	I-NP	O	O
to	to	TO	B-PP	O	O
2.31	2.31	CD	B-NP	O	O
;	;	:	O	O	O
Ptrend	Ptrend	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.02	0.02	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
IW	IW	NN	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
(	(	(	O	O	O
RR	RR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1.41	1.41	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
0.98	0.98	CD	I-NP	O	O
to	to	TO	B-PP	O	O
2.04	2.04	CD	B-NP	O	O
;	;	:	O	O	O
Ptrend	Ptrend	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.08	0.08	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Kidney	Kidney	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
94	94	CD	B-NP	O	O
)	)	)	O	O	O
risks	risk	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
significantly	significantly	RB	B-ADJP	O	O
elevated	elevated	JJ	I-ADJP	O	O
(	(	(	O	O	O
RRLT	RRLT	NN	B-NP	O	O
days	day	NNS	I-NP	O	O
=	=	SYM	B-VP	O	O
1.77	1.77	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
0.90	0.90	CD	I-NP	O	O
to	to	TO	B-PP	O	O
3.51	3.51	CD	B-NP	O	O
;	;	:	O	O	O
Ptrend	Ptrend	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.09	0.09	CD	B-NP	O	O
;	;	:	O	O	O
RRIW	RRIW	NN	B-NP	O	O
days	day	NNS	I-NP	O	O
1.37	1.37	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
0.64	0.64	CD	I-NP	O	O
to	to	TO	B-PP	O	O
2.92	2.92	CD	B-NP	O	O
;	;	:	O	O	O
Ptrend	Ptrend	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.50	0.50	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
were	be	VBD	B-VP	O	O
risks	risk	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
aggressive	aggressive	JJ	B-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
656	656	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
updated	update	VBN	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazinon	diazinon	NN	B-NP	B	B-Chemical
provides	provide	VBZ	B-VP	O	O
additional	additional	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
association	association	NN	I-NP	O	O
with	with	IN	B-PP	O	O
lung	lung	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
risk	risk	NN	I-NP	O	O
.	.	.	O	O	O

Newly	Newly	RB	B-NP	O	O
identified	identify	VBN	I-NP	O	O
links	link	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
kidney	kidney	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
associations	association	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
aggressive	aggressive	JJ	B-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
require	require	VBP	B-VP	O	O
further	far	JJR	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
.	.	.	O	O	O

Associations	Association	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
Ozone	Ozone	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
PM2.5	PM2.5	NN	I-NP	O	O
Concentrations	Concentration	NNS	I-NP	O	O
With	With	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
Disease	Disease	NN	I-NP	O	I-Disease
Among	Among	IN	B-PP	O	O
Participants	Participant	NNPS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Agricultural	Agricultural	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
associations	association	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
ozone	ozone	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
fine	fine	JJ	B-NP	O	O
particulate	particulate	JJ	I-NP	O	B-Chemical
matter	matter	NN	I-NP	O	I-Chemical
with	with	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
observed	observe	VBN	B-VP	O	O
among	among	IN	B-PP	O	O
farmers	farmer	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
North	North	NNP	B-NP	O	O
Carolina	Carolina	NNP	I-NP	O	O
and	and	CC	I-NP	O	O
Iowa	Iowa	NNP	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
logistic	logistic	JJ	B-NP	O	O
regression	regression	NN	I-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
associations	association	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
pollutants	pollutant	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
self	self	NN	B-NP	O	O
-	-	HYPH	O	O	O
reported	report	VBN	B-VP	O	O
,	,	,	O	O	O
doctor	doctor	NN	B-NP	O	O
-	-	HYPH	O	O	O
diagnosed	diagnose	VBN	B-VP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Daily	Daily	NNP	B-NP	O	O
predicted	predict	VBD	B-VP	O	O
pollutant	pollutant	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
derive	derive	VB	I-VP	O	O
surrogates	surrogate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
link	link	VB	B-VP	O	O
them	them	PRP	B-NP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
participants	participant	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
geocoded	geocode	VBN	I-NP	O	O
addresses	address	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
positive	positive	JJ	B-NP	O	O
associations	association	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
ozone	ozone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
odds	odd	NNS	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.39	1.39	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
0.98	0.98	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1.98	1.98	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
fine	fine	JJ	B-NP	O	O
particulate	particulate	JJ	I-NP	O	B-Chemical
matter	matter	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
odds	odd	NNS	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.34	1.34	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
0.93	0.93	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1.93	1.93	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
North	North	NNP	B-NP	O	O
Carolina	Carolina	NNP	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
Iowa	Iowa	NNP	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
plausibility	plausibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ambient	ambient	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
pollutants	pollutant	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
risk	risk	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
supported	support	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
demonstrating	demonstrate	VBG	B-VP	O	O
damage	damage	NN	B-NP	O	O
to	to	TO	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
relevant	relevant	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
address	address	VB	I-VP	O	O
uncertainties	uncertainty	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
confounding	confound	VBG	B-VP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
temporal	temporal	JJ	B-NP	O	O
aspects	aspect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
associations	association	NNS	I-NP	O	O
we	we	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
.	.	.	O	O	O

Low	Low	JJ	B-NP	O	O
functional	functional	JJ	I-NP	O	O
programming	programming	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
AT2R	AT2R	NN	I-NP	O	O
mediates	mediate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
developmental	developmental	JJ	I-NP	O	O
origin	origin	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prenatal	prenatal	JJ	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

UNASSIGNED	UNASSIGNED	VBN	B-VP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
previous	previous	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
indicated	indicate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
prenatal	prenatal	JJ	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
(	(	(	O	O	O
PCE	PCE	NN	B-NP	B	O
)	)	)	O	O	O
could	could	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
intrauterine	intrauterine	JJ	B-NP	O	B-Disease
growth	growth	NN	I-NP	O	I-Disease
retardation	retardation	NN	I-NP	O	I-Disease
(	(	(	O	O	O
IUGR	IUGR	NN	B-NP	O	B-Disease
)	)	)	O	O	O
of	of	IN	B-PP	O	O
offspring	offspring	NN	B-NP	O	O
.	.	.	O	O	O

Recent	Recent	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
suggested	suggest	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
IUGR	IUGR	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
whether	whether	IN	B-SBAR	O	O
PCE	PCE	NN	B-NP	B	O
could	could	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
underlying	underlying	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
remain	remain	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
by	by	IN	B-PP	O	O
PCE	PCE	NN	B-NP	B	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
intrauterine	intrauterine	JJ	I-NP	O	O
programming	programming	NN	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IUGR	IUGR	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
established	establish	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
PCE	PCE	NN	B-NP	B	O
,	,	,	O	O	O
male	male	JJ	B-NP	O	O
fetuses	fetus	NNS	I-NP	O	O
and	and	CC	O	O	O
adult	adult	JJ	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
postnatal	postnatal	JJ	B-NP	O	O
week	week	NN	I-NP	O	O
24	24	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
euthanized	euthanize	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
adult	adult	JJ	I-NP	O	O
offspring	offspring	NN	I-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PCE	PCE	NN	I-NP	B	O
group	group	NN	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
interstitial	interstitial	JJ	B-NP	O	B-Disease
fibrosis	fibrosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
accompanied	accompany	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	B	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
urine	urine	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
II	II	CD	I-NP	I	I-Chemical
receptor	receptor	NN	I-NP	O	O
type	type	NN	I-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
AT2R	AT2R	NN	B-NP	O	O
)	)	)	O	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
PCE	PCE	NN	B-NP	B	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
II	II	CD	I-NP	I	I-Chemical
receptor	receptor	NN	I-NP	O	O
type	type	NN	I-NP	O	O
1a	1a	NN	I-NP	O	O
(	(	(	O	O	O
AT1aR	AT1aR	NN	B-NP	O	O
)	)	)	O	O	O
/	/	SYM	O	O	O
AT2R	AT2R	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fetal	fetal	JJ	I-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PCE	PCE	NN	I-NP	B	O
group	group	NN	I-NP	O	O
displayed	display	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
enlarged	enlarged	JJ	I-NP	O	O
Bowman	Bowman	NNP	I-NP	O	O
's	's	POS	B-NP	O	O
space	space	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
shrunken	shrunken	JJ	I-NP	O	O
glomerular	glomerular	JJ	I-NP	O	O
tuft	tuft	NN	I-NP	O	O
,	,	,	O	O	O
accompanied	accompany	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
width	width	NN	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nephrogenic	nephrogenic	JJ	I-NP	O	O
zone	zone	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
zone	zone	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
.	.	.	O	O	O

Observation	Observation	NN	B-NP	O	O
by	by	IN	B-PP	O	O
electronic	electronic	JJ	B-NP	O	O
microscope	microscope	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
structural	structural	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
podocytes	podocyte	NNS	B-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
expression	expression	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
podocyte	podocyte	NN	B-NP	O	O
marker	marker	NN	I-NP	O	O
genes	gene	NNS	I-NP	O	O
,	,	,	O	O	O
nephrin	nephrin	NN	B-NP	O	O
and	and	CC	O	O	O
podocin	podocin	NN	B-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
q	q	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
PCR	PCR	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
AT2R	AT2R	NN	B-NP	O	O
gene	gene	NN	I-NP	O	O
and	and	CC	O	O	O
protein	protein	NN	B-NP	O	O
expressions	expression	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
fetal	fetal	JJ	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
PCE	PCE	NN	B-NP	B	O
,	,	,	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
repression	repression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glial	glial	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
-	-	HYPH	O	O	O
derived	derive	VBN	B-VP	O	O
neurotrophic	neurotrophic	JJ	B-NP	O	O
factor	factor	NN	I-NP	O	O
(	(	(	O	O	O
GDNF	GDNF	NN	B-NP	O	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
tyrosine	tyrosine	NN	I-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
(	(	(	O	O	O
c	c	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Ret	Ret	NN	I-NP	O	O
)	)	)	O	O	O
signaling	signaling	NN	B-NP	O	O
pathway	pathway	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
PCE	PCE	NN	B-NP	B	O
could	could	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
dysplasia	dysplasia	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
fetal	fetal	JJ	B-NP	O	I-Disease
kidneys	kidney	NNS	I-NP	O	I-Disease
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
functional	functional	JJ	I-NP	O	O
programming	programming	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
AT2R	AT2R	NN	I-NP	O	O
might	might	MD	B-VP	O	O
mediate	mediate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
developmental	developmental	JJ	I-NP	O	O
origin	origin	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
glomerulosclerosis	glomerulosclerosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

1,3	1,3	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Butadiene	Butadiene	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
CML	CML	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
t	t	NN	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
:	:	SYM	O	O	O
22	22	CD	O	O	O
)	)	)	O	O	O
translocation	translocation	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
reality	reality	NN	I-NP	O	O
check	check	NN	I-NP	O	O
.	.	.	O	O	O

UNASSIGNED	UNASSIGNED	VBN	B-VP	O	O
:	:	:	O	O	O
Epidemiological	Epidemiological	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
butadiene	butadiene	NN	I-NP	I	I-Chemical
have	have	VBP	B-VP	O	O
suggest	suggest	VBP	I-VP	O	O
that	that	IN	B-SBAR	O	O
exposures	exposure	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
humans	human	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
myeloid	myeloid	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CML	CML	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

CML	CML	NN	B-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
documented	document	VBN	I-NP	O	O
association	association	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ionizing	ionize	VBG	B-VP	O	O
radiation	radiation	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
associations	association	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chemical	chemical	JJ	B-NP	O	O
exposures	exposure	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
questioned	question	VBN	I-VP	O	O
.	.	.	O	O	O

Ionizing	Ionize	VBG	B-VP	O	O
radiation	radiation	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
inducing	induce	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
requisite	requisite	JJ	I-NP	O	O
CML	CML	NN	I-NP	O	B-Disease
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
t	t	NN	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
:	:	SYM	O	O	O
22	22	CD	O	O	O
)	)	)	O	O	O
translocation	translocation	NN	B-NP	O	O
(	(	(	O	O	O
Philadelphia	Philadelphia	NN	B-NP	O	B-Disease
chromosome	chromosome	NN	I-NP	O	I-Disease
)	)	)	O	O	O
in	in	IN	B-PP	O	O
appropriate	appropriate	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	FW	B-PP	O	O
vitro	vitro	FW	B-NP	O	O
but	but	CC	O	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
far	far	RB	I-ADVP	O	O
,	,	,	O	O	O
chemicals	chemical	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
this	this	DT	B-NP	O	O
capacity	capacity	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
proposed	propose	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
1,3	1,3	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
butadiene	butadiene	NN	I-NP	I	I-Chemical
metabolites	metabolite	NNS	I-NP	O	O
be	be	VB	B-VP	O	O
so	so	RB	I-VP	O	O
tested	test	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reality	reality	NN	I-NP	O	O
check	check	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epidemiological	epidemiological	JJ	I-NP	O	O
reports	report	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
conduct	conduct	VB	I-VP	O	O
reliable	reliable	JJ	B-NP	O	O
testing	testing	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
regard	regard	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
for	for	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
be	be	VB	B-VP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
ionizing	ionize	VBG	I-VP	O	O
radiation	radiation	NN	B-NP	O	O
to	to	TO	B-VP	O	O
develop	develop	VB	I-VP	O	O
such	such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
described	describe	VBN	B-VP	O	O
here	here	RB	B-ADVP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
fact	fact	NN	B-NP	O	O
induce	induce	VBP	B-VP	O	O
pathogenic	pathogenic	JJ	B-NP	O	O
t	t	NN	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
:	:	SYM	O	O	O
22	22	CD	O	O	O
)	)	)	O	O	O
translocations	translocation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
myeloid	myeloid	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
line	line	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
does	do	VBZ	B-VP	O	O
so	so	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
frequencies	frequency	NNS	I-NP	O	O
.	.	.	O	O	O

Conditions	Condition	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
1,3	1,3	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
butadiene	butadiene	NN	I-NP	I	I-Chemical
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Cancer	Cancer	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
metolachlor	metolachlor	NN	I-NP	B	B-Chemical
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Agricultural	Agricultural	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
:	:	:	O	O	O
An	An	DT	B-NP	O	O
update	update	NN	I-NP	O	O
.	.	.	O	O	O

UNASSIGNED	UNASSIGNED	VBN	B-VP	O	O
:	:	:	O	O	O
Metolachlor	Metolachlor	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
widely	widely	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
herbicide	herbicide	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
classified	classify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Group	Group	NN	I-NP	O	O
C	C	NN	I-NP	O	O
carcinogen	carcinogen	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
U.S	U.S	NNP	I-NP	O	O
.	.	.	O	O	O

Environmental	Environmental	NNP	B-NP	O	O
Protection	Protection	NNP	I-NP	O	O
Agency	Agency	NNP	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
neoplasms	neoplasm	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Epidemiologic	Epidemiologic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
health	health	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
limited	limit	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Agricultural	Agricultural	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
(	(	(	O	O	O
AHS	AHS	NNP	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
cohort	cohort	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
licensed	license	VBN	B-NP	O	O
private	private	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
commercial	commercial	JJ	I-NP	O	O
pesticide	pesticide	NN	I-NP	O	O
applicators	applicator	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Iowa	Iowa	NNP	B-NP	O	O
and	and	CC	O	O	O
North	North	NNP	B-NP	O	O
Carolina	Carolina	NNP	I-NP	O	O
enrolled	enrol	VBD	B-VP	O	O
1993	1993	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
1997	1997	CD	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
through	through	IN	B-PP	O	O
2010	2010	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
2011	2011	CD	I-NP	O	O
(	(	(	O	O	O
NC	NC	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
IA	IA	NN	I-NP	B	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
49,616	49,616	CD	B-NP	O	O
applicators	applicator	NNS	I-NP	O	O
,	,	,	O	O	O
53	53	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
reported	report	VBD	B-VP	O	O
ever	ever	RB	I-VP	O	O
using	use	VBG	I-VP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
Poisson	Poisson	NN	B-NP	O	O
regression	regression	NN	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
relations	relation	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
two	two	CD	B-NP	O	O
metrics	metric	NNS	I-NP	B	O
of	of	IN	B-PP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
(	(	(	O	O	O
lifetime	lifetime	NN	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
intensity	intensity	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
weighted	weight	VBN	B-NP	O	O
lifetime	lifetime	NN	I-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
cancer	cancer	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
saw	see	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
and	and	CC	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
cancers	cancer	NNS	I-NP	O	B-Disease
combined	combine	VBN	B-VP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
5,701	5,701	CD	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
lag	lag	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
most	most	JJS	B-NP	O	O
site	site	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
cancers	cancer	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

For	For	IN	B-PP	O	O
liver	liver	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
,	,	,	O	O	O
in	in	IN	B-PP	O	O
analyses	analysis	NNS	B-NP	O	O
restricted	restrict	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
exposed	expose	VBN	B-NP	O	O
workers	worker	NNS	I-NP	O	O
,	,	,	O	O	O
elevations	elevation	NNS	B-NP	O	O
observed	observe	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
categories	category	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
statistically	statistically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
trends	trend	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
both	both	CC	O	O	O
lifetime	lifetime	NN	B-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
-	-	HYPH	O	O	O
weighted	weight	VBN	B-NP	O	O
lifetime	lifetime	NN	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metolachor	metolachor	NN	B-NP	O	B-Chemical
use	use	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
and	and	CC	O	O	O
statistically	statistically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
unexposed	unexposed	JJ	I-NP	O	O
reference	reference	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
follicular	follicular	JJ	B-NP	O	B-Disease
cell	cell	NN	I-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
lymphoma	lymphoma	NN	I-NP	O	B-Disease
subtypes	subtype	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
earlier	early	JJR	I-NP	O	O
suggestion	suggestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
lung	lung	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
risk	risk	NN	I-NP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
cohort	cohort	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
update	update	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
suggestion	suggestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
liver	liver	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
pesticide	pesticide	NN	B-NP	O	O
applicators	applicator	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
finding	finding	NN	I-NP	O	O
and	and	CC	O	O	O
echoes	echo	VBZ	B-VP	O	O
observation	observation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
neoplasms	neoplasm	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
animal	animal	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
both	both	CC	O	O	O
liver	liver	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
follicular	follicular	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
lymphoma	lymphoma	NN	I-NP	O	B-Disease
warrant	warrant	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
to	to	TO	B-VP	O	O
better	well	RBR	I-VP	O	O
differentiate	differentiate	VB	I-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
metolachlor	metolachlor	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
from	from	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Mechanisms	Mechanism	NNS	B-NP	O	O
Underlying	Underlie	VBG	B-VP	O	O
Latent	Latent	JJ	B-NP	O	O
Disease	Disease	NN	I-NP	O	O
Risk	Risk	NN	I-NP	O	O
Associated	Associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
Early	Early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
Life	Life	NN	I-NP	O	O
Arsenic	Arsenic	JJ	I-NP	B	B-Chemical
Exposure	Exposure	NN	I-NP	O	O
:	:	:	O	O	O
Current	Current	NNP	B-NP	O	O
Research	Research	NNP	I-NP	O	O
Trends	Trends	NNP	I-NP	O	O
and	and	CC	O	O	O
Scientific	Scientific	NNP	B-NP	O	O
Gaps	Gaps	NNP	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Millions	Million	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
individuals	individual	NNS	B-NP	O	O
worldwide	worldwide	RB	B-ADVP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
living	live	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
rural	rural	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
developing	develop	VBG	I-NP	O	O
areas	area	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
harmful	harmful	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
inorganic	inorganic	JJ	B-NP	O	B-Chemical
arsenic	arsenic	JJ	I-NP	B	I-Chemical
(	(	(	O	O	O
iAs	iA	NNS	B-NP	O	B-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
drinking	drinking	NN	I-NP	O	O
water	water	NN	I-NP	B	O
.	.	.	O	O	O

Inorganic	Inorganic	JJ	B-ADJP	O	B-Chemical
As	As	IN	B-PP	O	I-Chemical
exposure	exposure	NN	B-NP	O	O
during	during	IN	B-PP	O	O
key	key	JJ	B-NP	O	O
developmental	developmental	JJ	I-NP	O	O
periods	period	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
health	health	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
those	those	DT	B-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
adulthood	adulthood	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
considerable	considerable	JJ	B-NP	O	O
interest	interest	NN	I-NP	O	O
in	in	IN	B-PP	O	O
identifying	identify	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
relate	relate	VBP	B-VP	O	O
early	early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
iAs	iA	NNS	I-NP	O	B-Chemical
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
latent	latent	JJ	I-NP	O	O
diseases	disease	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
relationship	relationship	NN	B-NP	O	O
to	to	TO	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
work	work	NN	I-NP	O	O
summarizes	summarize	VBZ	B-VP	O	O
research	research	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
underlie	underlie	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
development	development	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adulthood	adulthood	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
iAs	iA	NNS	I-NP	O	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

DISCUSSION	DISCUSSION	NN	B-NP	O	O
:	:	:	O	O	O
Epigenetic	Epigenetic	JJ	B-NP	O	O
reprogramming	reprogramming	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
imparts	impart	VBZ	B-VP	O	O
functional	functional	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
stem	stem	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
immunomodulation	immunomodulation	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
plausible	plausible	JJ	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
early	early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
iAs	iA	NNS	I-NP	O	B-Chemical
exposure	exposure	NN	I-NP	O	O
elicits	elicit	VBZ	B-VP	O	O
latent	latent	JJ	B-NP	O	O
carcinogenic	carcinogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Evidence	Evidence	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
mounting	mount	VBG	I-VP	O	O
that	that	DT	B-NP	O	O
relates	relate	VBZ	B-VP	O	O
early	early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
iAs	iA	NNS	I-NP	O	B-Chemical
exposure	exposure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
development	development	NN	I-NP	O	O
later	later	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
life	life	NN	B-NP	O	O
.	.	.	O	O	O

Future	Future	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
should	should	MD	B-VP	O	O
include	include	VB	I-VP	O	O
animal	animal	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
address	address	VBP	B-VP	O	O
mechanistic	mechanistic	JJ	B-NP	O	O
hypotheses	hypothesis	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
populations	population	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
integrate	integrate	VBP	B-VP	O	O
early	early	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
,	,	,	O	O	O
molecular	molecular	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
latent	latent	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
N	N	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
substituted	substitute	VBN	I-NP	O	O
piperazine	piperazine	NN	I-NP	B	B-Chemical
derivative	derivative	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trans	trans	AFX	O	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
amino	amino	JJ	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
3	3	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
hydroxy	hydroxy	NN	I-NP	B	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
1	1	CD	I-NP	O	I-Chemical
,	,	,	I-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
,	,	,	I-NP	O	I-Chemical
3	3	CD	I-NP	O	I-Chemical
,	,	,	I-NP	O	I-Chemical
4	4	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
tetrahydroanaphthalene	tetrahydroanaphthalene	NN	I-NP	O	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
compound	compound	NN	I-NP	O	O
N	N	NN	I-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
(	(	(	O	O	I-Chemical
trans	trans	AFX	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
3	3	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
hydroxy	hydroxy	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
1,2,3,4	1,2,3,4	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
tetrahydro	tetrahydro	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
naphthyl	naphthyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
N	N	NN	I-NP	O	I-Chemical
-	-	HYPH	B-ADJP	O	I-Chemical
(	(	(	O	O	I-Chemical
3	3	CD	B-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
oxo	oxo	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
3	3	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
phenyl	phenyl	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
methylpropyl	methylpropyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
piperazine	piperazine	NN	I-NP	B	I-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
referred	refer	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
as	as	IN	B-PP	O	O
P11	P11	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
studied	study	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
anaesthesized	anaesthesize	VBN	B-NP	O	O
cats	cat	NNS	I-NP	O	O
and	and	CC	O	O	O
Wistar	Wistar	NNP	B-NP	O	O
albino	albino	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
on	on	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
anaesthesized	anaesthesize	VBN	I-NP	O	O
rabbits	rabbit	NNS	I-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
-	-	SYM	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
with	with	IN	B-PP	O	O
BaCl2	BaCl2	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
with	with	IN	B-PP	O	O
chloroform	chloroform	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
adrenaline	adrenaline	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
with	with	IN	B-PP	O	O
strophantine	strophantine	JJ	B-NP	O	B-Chemical
G	G	NN	I-NP	O	I-Chemical
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
aconitine	aconitine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
compound	compound	NN	I-NP	O	O
P11	P11	NN	I-NP	O	B-Chemical
is	be	VBZ	B-VP	O	O
introduced	introduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
and	and	CC	I-NP	O	O
0.50	0.50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
orally	orally	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
compound	compound	NN	I-NP	O	O
manifests	manifest	VBZ	B-VP	O	O
antiarrhythmic	antiarrhythmic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
used	use	VBN	B-VP	O	O
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
greatest	great	JJS	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
chloroform	chloroform	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
adrenaline	adrenaline	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
in	in	IN	B-PP	O	O
90	90	CD	B-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
BaCl2	BaCl2	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
in	in	IN	B-PP	O	O
84	84	CD	B-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoblocking	adrenoblocke	VBG	I-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
membrane	membrane	NN	I-NP	O	O
-	-	HYPH	O	O	O
stabilizing	stabilize	VBG	B-VP	O	O
action	action	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
compound	compound	NN	I-NP	O	O
.	.	.	O	O	O

Experimental	Experimental	JJ	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
muscular	muscular	JJ	I-NP	O	B-Disease
dystrophy	dystrophy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
anabolizing	anabolize	VBG	B-VP	O	O
agents	agent	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
still	still	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
way	way	NN	I-NP	O	O
from	from	IN	B-PP	O	O
discovering	discover	VBG	B-VP	B	O
an	an	DT	B-NP	O	O
unequivocal	unequivocal	JJ	I-NP	O	O
pathogenetic	pathogenetic	JJ	I-NP	O	O
interpretation	interpretation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
muscular	muscular	JJ	I-NP	O	B-Disease
dystrophy	dystrophy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

Noteworthy	Noteworthy	JJ	B-NP	O	O
efforts	effort	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
made	make	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
;	;	:	O	O	O
a	a	DT	B-NP	O	O
recessive	recessive	JJ	I-NP	O	O
autosomic	autosomic	JJ	I-NP	O	O
form	form	NN	I-NP	O	O
found	find	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
bear	bear	VB	I-VP	O	O
the	the	DT	B-NP	O	O
closest	close	JJS	I-NP	O	O
resemblance	resemblance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
form	form	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
point	point	NN	I-NP	O	O
of	of	IN	B-PP	O	O
view	view	NN	B-NP	O	O
.	.	.	O	O	O

Myopathy	Myopathy	NN	B-NP	O	B-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
lack	lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
E	E	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
myopathy	myopathy	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
viruses	virus	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
much	much	JJ	B-NP	O	O
in	in	IN	B-PP	O	O
common	common	JJ	B-ADJP	O	O
anatomically	anatomically	RB	B-ADVP	O	O
and	and	CC	I-ADVP	O	O
pathologically	pathologically	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
form	form	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
induced	induce	VBD	B-VP	O	O
myodystrophy	myodystrophy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
by	by	IN	B-PP	O	O
giving	give	VBG	B-VP	O	O
it	it	PRP	B-NP	O	O
a	a	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
lacking	lack	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
E	E	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
E	E	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
degenerative	degenerative	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
brought	bring	VBD	B-VP	O	O
about	about	RP	B-PRT	O	O
by	by	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscles	muscle	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
illustrated	illustrate	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
thus	thus	RB	I-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
histological	histological	JJ	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
myopathic	myopathic	JJ	B-NP	O	B-Disease
rat	rat	NN	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
experimentally	experimentally	RB	B-ADVP	O	O
are	be	VBP	B-VP	O	O
extraordinarily	extraordinarily	RB	B-ADJP	O	O
similar	similar	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
myopathy	myopathy	NN	I-NP	O	B-Disease
as	as	IN	B-SBAR	O	O
confirmed	confirm	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
biopsies	biopsy	NNS	B-NP	O	O
performed	perform	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Orthopaedic	Orthopaedic	NNP	I-NP	O	O
Traumatological	Traumatological	NNP	I-NP	O	O
Centre	Centre	NNP	I-NP	O	O
,	,	,	O	O	O
Florence	Florence	NNP	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
encouraging	encouraging	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
authoratative	authoratative	JJ	I-NP	O	O
departments	department	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
myopathic	myopathic	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
anabolizing	anabolize	VBG	B-NP	O	O
steroids	steroid	NNS	I-NP	O	B-Chemical
have	have	VBP	B-VP	O	O
encouraged	encourage	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
anabolizing	anabolize	VBG	B-VP	O	O
agent	agent	NN	B-NP	O	O
(	(	(	O	O	O
Dianabol	Dianabol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
CIBA	CIBA	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
rendered	render	VBN	B-VP	O	O
myopathic	myopathic	JJ	B-ADJP	O	B-Disease
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
deficient	deficient	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
E	E	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
way	way	NN	I-NP	O	O
they	they	PRP	B-NP	O	O
obtained	obtain	VBD	B-VP	O	O
appreciable	appreciable	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
(	(	(	O	O	O
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
50	50	CD	B-NP	O	O
to	to	TO	I-NP	O	O
70	70	CD	I-NP	O	O
g	g	NN	I-NP	O	O
after	after	IN	B-PP	O	O
forty	forty	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anabolizing	anabolize	VBG	B-VP	O	O
agent	agent	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
they	they	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
histological	histological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
"	"	``	B-NP	O	O
regenerative	regenerative	JJ	I-NP	O	O
"	"	''	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
however	however	RB	B-ADVP	O	O
maintained	maintain	VBD	B-VP	O	O
its	its	PRP$	B-NP	O	O
myopathic	myopathic	JJ	I-NP	O	B-Disease
characteristics	characteristic	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anabolizing	anabolize	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
conclude	conclude	VBP	B-VP	O	O
by	by	IN	B-PP	O	O
affirming	affirm	VBG	B-VP	B	O
the	the	DT	B-NP	O	O
undoubted	undoubted	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anabolizing	anabolize	VBG	I-NP	O	O
steroids	steroid	NNS	I-NP	O	B-Chemical
in	in	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
myopathic	myopathic	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
they	they	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
reservations	reservation	NNS	B-NP	O	O
as	as	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
transfer	transfer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
,	,	,	O	O	O
where	where	WRB	B-ADVP	O	O
high	high	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
cannot	cannot	MD	B-VP	O	O
be	be	VB	I-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
continuously	continuously	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
on	on	IN	B-PP	O	O
virility	virility	NN	B-NP	O	O
;	;	:	O	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
injury	injury	NN	I-NP	O	O
too	too	RB	B-ADVP	O	O
often	often	RB	I-ADVP	O	O
occurs	occur	VBZ	B-VP	O	O
at	at	IN	B-PP	O	O
an	an	DT	B-NP	O	O
irreversible	irreversible	JJ	I-NP	O	O
stage	stage	NN	I-NP	O	O
vis	vi	NNS	I-NP	O	O
-	-	:	O	O	O
a	a	DT	B-NP	O	O
-	-	:	O	O	O
vis	vi	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
"	"	``	I-NP	O	O
regeneration	regeneration	NN	I-NP	O	O
"	"	''	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
finally	finally	RB	B-ADVP	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dystrophic	dystrophic	JJ	I-NP	O	O
injurious	injurious	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
certainly	certainly	RB	B-ADVP	O	O
not	not	RB	O	O	O
the	the	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
E	E	NN	I-NP	I	I-Chemical
but	but	CC	O	O	O
something	something	NN	B-NP	O	O
as	as	RB	B-ADJP	O	O
yet	yet	RB	I-ADJP	O	O
unknown	unknown	JJ	I-ADJP	O	O
.	.	.	O	O	O

Fetal	Fetal	JJ	B-NP	O	O
risks	risk	NNS	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
mothers	mother	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
valve	valve	NN	I-NP	O	O
prosthesis	prosthesis	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
a	a	DT	B-NP	O	O
caesarean	caesarean	JJ	I-NP	O	O
section	section	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
done	do	VBN	I-VP	O	O
one	one	CD	B-NP	O	O
week	week	NN	I-NP	O	O
after	after	IN	B-PP	O	O
replacement	replacement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
baby	baby	NN	I-NP	O	O
died	die	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
pulmonary	pulmonary	JJ	I-NP	O	I-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
mother	mother	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
male	male	JJ	I-NP	O	O
infant	infant	NN	I-NP	O	O
by	by	IN	B-PP	O	O
caesarean	caesarean	JJ	B-NP	O	O
section	section	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
baby	baby	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
embryopathy	embryopathy	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
nasal	nasal	JJ	B-NP	O	B-Disease
hypoplasia	hypoplasia	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
stippled	stipple	VBN	B-NP	O	B-Disease
epiphyses	epiphysis	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
chondrodysplasia	chondrodysplasia	NN	B-NP	O	B-Disease
punctata	punctata	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Nasal	Nasal	JJ	B-NP	O	B-Disease
hypoplasia	hypoplasia	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
stippled	stipple	VBN	B-NP	O	B-Disease
epiphyses	epiphysis	NNS	I-NP	O	I-Disease
has	have	VBZ	B-VP	O	O
now	now	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
infants	infant	NNS	I-NP	O	O
born	bear	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
mothers	mother	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
trimester	trimester	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
association	association	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
probable	probable	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
view	view	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
both	both	CC	O	O	O
mother	mother	NN	B-NP	O	O
and	and	CC	I-NP	O	O
fetus	fetus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
prosthetic	prosthetic	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
valves	valve	NNS	I-NP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
abortion	abortion	NN	I-NP	O	O
be	be	VB	B-VP	O	O
advised	advise	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
alternative	alternative	NN	I-NP	O	O
.	.	.	O	O	O

Isradipine	Isradipine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Hong	Hong	NNP	B-NP	O	O
Kong	Kong	NNP	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
open	open	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
introduction	introduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Hong	Hong	NNP	B-NP	O	O
Kong	Kong	NNP	I-NP	O	O
.	.	.	O	O	O

303	303	CD	B-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
mild	mild	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
entered	enter	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Side	Side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
caused	cause	VBD	B-VP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
headache	headache	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
dizziness	dizziness	NN	I-NP	O	B-Disease
,	,	,	I-NP	O	O
palpitation	palpitation	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
flushing	flushing	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
frequent	frequent	JJ	I-ADJP	O	O
than	than	IN	B-SBAR	O	O
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
isradipine	isradipine	NN	B-NP	B	B-Chemical
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

Supine	Supine	NN	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
170	170	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
20	20	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
102	102	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
153	153	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
19	19	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
92	92	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	I-NP	O	O
147	147	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
18	18	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
88	88	CD	I-NP	O	O
+	+	SYM	B-VP	O	O
/	/	SYM	B-ADVP	O	O
-	-	SYM	B-NP	O	O
7	7	CD	B-NP	O	O
and	and	CC	I-NP	O	O
144	144	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
14	14	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
87	87	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
,	,	,	I-NP	O	O
4	4	CD	I-NP	O	O
and	and	CC	I-NP	O	O
6	6	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
evaluable	evaluable	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Similar	Similar	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
standing	stand	VBG	B-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
postural	postural	JJ	B-NP	O	B-Disease
hypotension	hypotension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Normalization	Normalization	NN	B-NP	O	O
and	and	CC	I-NP	O	O
responder	responder	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
86	86	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
69	69	CD	B-NP	O	O
%	%	NN	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.d.	b.d.	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.d.	b.d.	NN	I-NP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
diastolic	diastolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
90	90	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
further	further	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
remaining	remain	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.d	b.d	NN	I-NP	O	O
.	.	.	O	O	O

Tachyphylaxis	Tachyphylaxis	NN	B-NP	O	O
to	to	TO	B-PP	O	O
systemic	systemic	JJ	B-ADJP	O	O
but	but	CC	I-ADJP	O	O
not	not	RB	I-ADJP	O	O
to	to	TO	B-PP	O	O
airway	airway	NN	B-NP	O	O
responses	response	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
inhaled	inhale	VBD	B-VP	O	O
salbutamol	salbutamol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
asthmatics	asthmatic	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
inhaled	inhale	VBN	B-NP	O	O
salbutamol	salbutamol	NN	I-NP	B	B-Chemical
produce	produce	VBP	B-VP	O	O
substantial	substantial	JJ	B-NP	O	O
improvements	improvement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
airway	airway	NN	B-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
responses	response	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
tachyphylaxis	tachyphylaxis	NN	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
during	during	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
inhaled	inhale	VBD	B-VP	O	O
salbutamol	salbutamol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Twelve	Twelve	CD	B-NP	O	O
asthmatic	asthmatic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
FEV1	FEV1	NN	B-NP	O	O
,	,	,	O	O	O
81	81	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
predicted	predict	VBN	B-VP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
requiring	require	VBG	B-VP	O	O
only	only	RB	B-NP	O	O
occasional	occasional	JJ	I-NP	O	O
inhaled	inhale	VBD	B-VP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-VP	O	O
agonists	agonist	NNS	B-NP	O	O
as	as	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
sole	sole	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
inhaled	inhale	VBD	B-VP	O	O
salbutamol	salbutamol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
HDS	HDS	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
4,000	4,000	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
daily	daily	JJ	B-NP	O	O
,	,	,	I-NP	O	O
low	low	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
inhaled	inhale	VBD	B-VP	O	O
salbutamol	salbutamol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
LDS	LDS	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
800	800	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
PI	PI	NN	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
metered	meter	VBN	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
inhaler	inhaler	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
randomized	randomize	VBN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
design	design	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
run	run	VB	B-VP	O	O
-	-	HYPH	B-NP	O	O
in	in	IN	B-PP	O	O
and	and	CC	I-PP	O	O
during	during	IN	I-PP	O	O
washout	washout	NN	B-NP	O	O
periods	period	NNS	I-NP	O	O
,	,	,	O	O	O
inhaled	inhale	VBD	B-VP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-VP	O	O
agonists	agonist	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
withheld	withhold	VBN	I-VP	O	O
and	and	CC	O	O	O
ipratropium	ipratropium	NN	B-NP	B	B-Chemical
bromide	bromide	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
substituted	substitute	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
rescue	rescue	NN	B-NP	O	O
purposes	purpose	NNS	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
response	response	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
(	(	(	O	O	O
DRC	DRC	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
airway	airway	NN	B-NP	O	O
(	(	(	O	O	O
FEV1	FEV1	NN	B-NP	O	O
,	,	,	O	O	O
FEF25	FEF25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
75	75	CD	I-NP	O	O
)	)	)	O	O	O
chronotropic	chronotropic	JJ	O	O	O
(	(	(	O	O	O
HR	HR	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
tremor	tremor	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
metabolic	metabolic	JJ	B-ADJP	O	O
(	(	(	O	O	O
K	K	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
Glu	Glu	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
responses	response	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
each	each	DT	B-NP	O	O
step	step	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
100	100	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4,000	4,000	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
FEV1	FEV1	NN	B-NP	O	O
and	and	CC	O	O	O
FEF25	FEF25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
75	75	CD	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HDS	HDS	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
displace	displace	VB	I-VP	O	O
the	the	DT	B-NP	O	O
DRC	DRC	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
right	right	NN	I-NP	O	O
.	.	.	O	O	O

DRC	DRC	NN	B-NP	O	O
for	for	IN	B-PP	O	O
HR	HR	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
K	K	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Glu	Glu	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.005	0.005	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
attenuated	attenuate	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
HDS	HDS	NN	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
PI	PI	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
differences	difference	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
HDS	HDS	NN	B-NP	O	O
and	and	CC	I-NP	O	O
LDS	LDS	NN	I-NP	O	O
for	for	IN	B-PP	O	O
HR	HR	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Glu	Glu	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
responses	response	NNS	B-NP	O	O
.	.	.	O	O	O

Frequency	Frequency	NN	B-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subjective	subjective	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
HDS	HDS	NN	B-NP	O	O
:	:	:	O	O	O
tremor	tremor	NN	B-NP	O	B-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
palpitations	palpitation	NNS	B-NP	O	B-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Increased	Increase	VBN	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
panic	panic	NN	B-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
behavioral	behavioral	JJ	B-NP	O	O
ratings	rating	NNS	I-NP	O	O
,	,	,	O	O	O
somatic	somatic	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
methoxy	methoxy	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
4	4	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
hydroxyphenethyleneglycol	hydroxyphenethyleneglycol	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
MHPG	MHPG	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
cortisol	cortisol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
17	17	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	O	O	O
21	21	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
meeting	meet	VBG	B-VP	O	O
DSM	DSM	NN	B-NP	B	O
-	-	HYPH	O	O	O
III	III	CD	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
agoraphobia	agoraphobia	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
panic	panic	JJ	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
or	or	CC	O	O	O
panic	panic	NN	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
greater	great	JJR	I-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
subject	subject	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
rated	rat	VBN	B-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
,	,	,	O	O	O
nervousness	nervousness	NN	B-NP	O	O
,	,	,	O	O	O
fear	fear	NN	B-NP	O	O
,	,	,	O	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
palpitations	palpitation	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
restlessness	restlessness	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
tremors	tremor	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
the	the	DT	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Seventy	Seventy	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
experienced	experience	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
panic	panic	NN	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
plasma	plasma	NN	B-NP	O	O
MHPG	MHPG	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
the	the	DT	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
or	or	CC	O	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
cortisol	cortisol	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
equally	equally	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
and	and	CC	O	O	O
healthy	healthy	JJ	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
panic	panic	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
abnormalities	abnormality	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
neuronal	neuronal	JJ	B-NP	O	I-Disease
systems	system	NNS	I-NP	O	I-Disease
involving	involve	VBG	B-VP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
benefit	benefit	VB	I-VP	O	O
by	by	IN	B-PP	O	O
avoiding	avoid	VBG	B-VP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
foods	food	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
beverages	beverage	NNS	I-NP	O	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
canine	canine	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
vasoactive	vasoactive	JJ	I-NP	B	O
intestinal	intestinal	JJ	I-NP	I	O
polypeptide	polypeptide	NN	I-NP	I	O
:	:	:	O	O	O
decrease	decrease	NN	B-NP	O	O
with	with	IN	B-PP	O	O
heart	heart	NN	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Vasoactive	Vasoactive	JJ	B-NP	B	O
intestinal	intestinal	JJ	I-NP	I	O
polypeptide	polypeptide	NN	I-NP	I	O
(	(	(	O	O	O
VIP	VIP	NN	B-NP	B	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
vasodilator	vasodilator	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
positive	positive	JJ	B-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

Myocardial	Myocardial	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
VIP	VIP	NN	B-NP	B	O
were	be	VBD	B-VP	O	O
assayed	assay	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
canine	canine	JJ	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
,	,	,	I-NP	O	O
cobalt	cobalt	NN	I-NP	B	B-Chemical
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
;	;	:	O	O	O
VIP	VIP	NN	B-NP	B	O
(	(	(	O	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
35	35	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
11	11	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	O	O	O
mg	mg	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
SD	SD	NN	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	O	O	O
mg	mg	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
six	six	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
VIP	VIP	NN	B-NP	B	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
31	31	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
7	7	CD	B-NP	O	O
to	to	TO	B-PP	O	O
11	11	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	O	O	O
mg	mg	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
VIP	VIP	NN	B-NP	B	O
content	content	NN	I-NP	O	O
of	of	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
of	of	IN	B-PP	O	O
resected	resecte	VBN	B-NP	O	O
failing	fail	VBG	I-NP	O	O
hearts	heart	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
papillary	papillary	JJ	I-NP	O	O
muscles	muscle	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
five	five	CD	B-NP	O	O
with	with	IN	B-PP	O	O
rheumatic	rheumatic	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
nine	nine	CD	B-NP	O	O
with	with	IN	B-PP	O	O
myxomatous	myxomatous	JJ	B-NP	O	B-Disease
degeneration	degeneration	NN	I-NP	O	I-Disease
)	)	)	O	O	O
receiving	receive	VBG	B-VP	O	O
mitral	mitral	JJ	B-NP	O	O
valve	valve	NN	I-NP	O	O
prostheses	prosthesis	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lowest	low	JJS	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
VIP	VIP	NN	I-NP	B	O
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
and	and	CC	O	O	O
three	three	CD	B-NP	O	O
receiving	receive	VBG	I-NP	O	O
mitral	mitral	JJ	I-NP	O	O
prostheses	prosthesis	NNS	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
6.3	6.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.9	1.9	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mg	mg	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
transplantation	transplantation	NN	B-NP	O	O
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
VIP	VIP	NN	I-NP	B	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
8.8	8.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3.9	3.9	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	O	O	O
mg	mg	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
average	average	JJ	B-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
group	group	NN	I-NP	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
VIP	VIP	NN	I-NP	B	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
14.1	14.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
7.9	7.9	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mg	mg	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
hearts	heart	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Myocardial	Myocardial	JJ	B-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	B-Chemical
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
;	;	:	O	O	O
a	a	DT	B-NP	O	O
weak	weak	JJ	I-NP	O	O
correlation	correlation	NN	I-NP	O	O
(	(	(	O	O	O
r	r	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.57	0.57	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
VIP	VIP	NN	B-NP	B	O
and	and	CC	I-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
noted.	noted.	RB	B-ADVP	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Interstrain	Interstrain	NN	B-NP	O	O
variation	variation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
among	among	IN	B-PP	O	O
inbred	inbred	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
males	male	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
inbred	inbred	JJ	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
strains	strain	NNS	I-NP	O	O
(	(	(	O	O	O
A	A	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
J	J	NN	I-NP	O	O
,	,	,	O	O	O
BALB	BALB	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
cJ	cJ	NN	I-NP	O	O
,	,	,	O	O	O
CBA	CBA	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
J	J	NN	I-NP	O	O
,	,	,	O	O	O
C3H	C3H	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
HeJ	HeJ	NN	I-NP	O	O
,	,	,	O	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
6J	6J	NN	I-NP	O	O
,	,	,	O	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	I-NP	O	O
2J	2J	NN	I-NP	O	O
,	,	,	O	O	O
SWR	SWR	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
J	J	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
6J	6J	NN	I-NP	O	O
,	,	,	O	O	O
chosen	choose	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
"	"	``	I-NP	O	O
prototypic	prototypic	JJ	I-NP	O	O
"	"	''	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
strain	strain	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
behavioral	behavioral	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
broad	broad	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
phenotypic	phenotypic	JJ	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
-	-	HYPH	O	O	O
-	-	HYPH	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
righting	righting	NN	B-NP	O	O
ability	ability	NN	I-NP	O	O
,	,	,	O	O	O
clonic	clonic	JJ	B-NP	O	B-Disease
seizure	seizure	NN	I-NP	O	I-Disease
induction	induction	NN	I-NP	O	O
,	,	,	O	O	O
stress	stress	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
lethality	lethality	NN	I-NP	O	O
,	,	,	O	O	O
death	death	NN	B-NP	O	O
without	without	IN	B-PP	O	O
external	external	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
-	-	SYM	B-NP	O	O
were	be	VBD	B-VP	O	O
scored	score	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
naive	naive	JJ	I-NP	O	O
animals	animal	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
empirically	empirically	RB	B-NP	O	O
optimized	optimize	VBN	B-VP	O	O
,	,	,	O	O	O
rigidly	rigidly	RB	B-NP	O	O
constant	constant	JJ	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

Mice	Mouse	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
for	for	IN	B-PP	O	O
each	each	DT	B-NP	O	O
point	point	NN	I-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
single	single	JJ	B-NP	O	O
IP	IP	NN	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
fixed	fix	VBN	I-NP	O	O
volume	volume	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
g	g	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
of	of	IN	B-PP	O	O
physiological	physiological	JJ	B-NP	O	O
saline	saline	NN	I-NP	B	O
carrier	carrier	NN	I-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
125	125	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Loss	Loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
righting	righting	NN	B-NP	O	O
ability	ability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
scored	score	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	I-NP	O	O
5	5	CD	I-NP	O	O
min	min	NN	I-NP	O	O
post	post	NN	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
5	5	CD	B-NP	O	O
min	min	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
thereafter	thereafter	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
20	20	CD	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
animals	animal	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonic	clonic	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
scored	score	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
to	to	TO	B-PP	O	O
time	time	NN	B-NP	O	O
of	of	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
20	20	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
proceeded	proceed	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
tonic	tonic	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
death	death	NN	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
20	20	CD	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
surviving	survive	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
20	20	CD	B-NP	O	O
min	min	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
immediately	immediately	RB	I-VP	O	O
stressed	stress	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
swim	swim	NN	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
25	25	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
C	C	NN	I-NP	O	O
water	water	NN	I-NP	B	O
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
-	-	HYPH	O	O	O
producing	produce	VBG	B-VP	O	O
tonic	tonic	JJ	B-NP	O	B-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
scored	score	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
15	15	CD	B-NP	O	O
or	or	CC	I-NP	O	O
60	60	CD	I-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
any	any	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
criterion	criterion	NN	I-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
,	,	,	O	O	O
marked	marked	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
strains	strain	NNS	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
behavioral	behavioral	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
testing	testing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alkylxanthines	alkylxanthine	NNS	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
strain	strain	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
misleading	misleading	JJ	B-ADJP	O	O
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
toxic	toxic	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
compounds	compound	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
genetically	genetically	RB	I-VP	O	O
influenced	influence	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mammals	mammal	NNS	B-NP	O	O
.	.	.	O	O	O

Invasive	Invasive	JJ	B-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
pelvis	pelvis	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
nonmalignant	nonmalignant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
47	47	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
right	right	JJ	B-NP	O	O
hydroureteronephrosis	hydroureteronephrosis	NN	I-NP	O	B-Disease
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
ureterovesical	ureterovesical	JJ	B-NP	O	O
junction	junction	NN	I-NP	O	O
obstruction	obstruction	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
gross	gross	JJ	B-NP	O	O
hematuria	hematuria	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
five	five	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
wtih	wtih	VBP	B-VP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
vasculitis	vasculitis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
right	right	JJ	I-NP	O	O
nephroureterectomy	nephroureterectomy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
required	require	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
control	control	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bleeding	bleed	VBG	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pathology	pathology	NN	I-NP	O	O
specimen	specimen	NN	I-NP	O	O
contained	contain	VBD	B-VP	O	O
clinically	clinically	RB	B-NP	O	O
occult	occult	JJ	I-NP	O	O
invasive	invasive	JJ	I-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
pelvis	pelvis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
cause	cause	VB	I-VP	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
cystitis	cystitis	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
urine	urine	NN	B-NP	O	O
cytologic	cytologic	JJ	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
indistinguishable	indistinguishable	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
grade	grade	NN	I-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
less	less	RBR	I-VP	O	O
widely	widely	RB	I-VP	O	O
appreciated	appreciate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
carcinoma	carcinoma	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
urinary	urinary	JJ	I-NP	O	I-Disease
tract	tract	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
carcinomas	carcinoma	NNS	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
urinary	urinary	JJ	I-NP	O	I-Disease
bladder	bladder	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
prostate	prostate	NN	I-NP	O	I-Disease
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
pelvis	pelvis	NN	I-NP	O	I-Disease
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
urinary	urinary	JJ	I-NP	O	B-Disease
tract	tract	NN	I-NP	O	I-Disease
cancer	cancer	NN	I-NP	O	I-Disease
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
nonmalignant	nonmalignant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
association	association	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
preexisting	preexist	VBG	B-VP	O	O
hydroureteronephrosis	hydroureteronephrosis	NN	B-NP	O	B-Disease
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
stasis	stasis	NN	B-NP	O	O
prolonged	prolong	VBD	B-VP	O	O
and	and	CC	I-VP	O	O
intensified	intensify	VBD	I-VP	O	O
exposure	exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
upper	upper	JJ	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
candidates	candidate	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
routinely	routinely	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
obstructive	obstructive	JJ	B-NP	O	B-Disease
uropathy	uropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Ascending	Ascend	VBG	B-VP	O	O
dose	dose	NN	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intramuscular	intramuscular	JJ	B-NP	O	O
carbetocin	carbetocin	NN	I-NP	B	B-Chemical
administered	administer	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
vaginal	vaginal	JJ	I-NP	O	O
birth	birth	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
tolerated	tolerate	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
MTD	MTD	NN	B-NP	B	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
carbetocin	carbetocin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
a	a	DT	B-NP	O	O
long	long	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	B-VP	O	O
synthetic	synthetic	JJ	B-NP	O	O
analogue	analogue	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxytocin	oxytocin	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
vaginal	vaginal	JJ	B-NP	O	O
delivery	delivery	NN	I-NP	O	O
at	at	IN	B-PP	O	O
term	term	NN	B-NP	O	O
.	.	.	O	O	O

MATERIALS	MATERIALS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
Carbetocin	Carbetocin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
intramuscular	intramuscular	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
birth	birth	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
infant	infant	NN	I-NP	O	O
in	in	IN	B-PP	O	O
45	45	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
singleton	singleton	JJ	I-NP	O	O
pregnancies	pregnancy	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
delivered	deliver	VBD	B-VP	O	O
vaginally	vaginally	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
term	term	NN	B-NP	O	O
.	.	.	O	O	O

Dosage	Dosage	NN	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
,	,	,	I-NP	O	O
30	30	CD	I-NP	O	O
,	,	,	I-NP	O	O
50	50	CD	I-NP	O	O
,	,	,	I-NP	O	O
75	75	CD	I-NP	O	O
,	,	,	I-NP	O	O
100	100	CD	I-NP	O	O
,	,	,	I-NP	O	O
125	125	CD	I-NP	O	O
,	,	,	I-NP	O	O
150	150	CD	I-NP	O	O
,	,	,	I-NP	O	O
175	175	CD	I-NP	O	O
or	or	CC	I-NP	O	O
200	200	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
carbetocin	carbetocin	NN	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
blocks	block	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
continual	continual	JJ	I-NP	O	O
reassessment	reassessment	NN	I-NP	O	O
method	method	NN	I-NP	O	O
(	(	(	O	O	O
CRM	CRM	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
consisted	consist	VBD	B-VP	B	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
100	100	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
200	200	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Recorded	Record	VBN	B-VP	O	O
were	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
:	:	:	O	O	O
hyper	hyper	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
or	or	CC	O	O	I-Disease
hypotension	hypotension	NN	B-NP	O	I-Disease
(	(	(	O	O	O
three	three	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
abdominal	abdominal	JJ	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
(	(	(	O	O	O
0	0	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
vomiting	vomit	VBG	B-VP	O	B-Disease
(	(	(	O	O	O
0	0	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
retained	retain	VBD	B-VP	O	B-Disease
placenta	placenta	NN	B-NP	O	I-Disease
(	(	(	O	O	O
four	four	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Serious	Serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
:	:	:	O	O	O
six	six	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
1000	1000	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
,	,	,	O	O	O
four	four	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
manual	manual	JJ	B-NP	O	O
placenta	placenta	NN	I-NP	O	O
removal	removal	NN	I-NP	O	O
,	,	,	O	O	O
five	five	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
oxytocics	oxytocic	NNS	I-NP	B	O
administration	administration	NN	I-NP	O	O
and	and	CC	O	O	O
five	five	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
.	.	.	O	O	O

Maximum	Maximum	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
greatest	great	JJS	B-ADJP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
upper	upper	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
lower	low	JJR	I-NP	O	O
dose	dose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
lowest	low	JJS	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
70	70	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
125	125	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
range	range	NN	I-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
out	out	IN	I-NP	O	O
of	of	IN	I-NP	O	O
six	six	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
1000	1000	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
200	200	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
additional	additional	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxytocics	oxytocic	NNS	B-NP	B	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
)	)	)	O	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
retained	retain	VBN	I-NP	O	O
placentae	placenta	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
MTD	MTD	NN	I-NP	B	O
was	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
200	200	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
carbetocin	carbetocin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
pilot	pilot	NN	I-NP	O	O
study	study	NN	I-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
stress	stress	NN	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
department	department	NN	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

STUDY	STUDY	NN	B-NP	O	O
OBJECTIVE	OBJECTIVE	NN	I-NP	O	O
:	:	:	O	O	O
Chest	Ch	JJS	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
setting	setting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
poses	pose	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
dilemma	dilemma	NN	I-NP	O	O
.	.	.	O	O	O

Dobutamine	Dobutamine	NN	B-NP	B	B-Chemical
stress	stress	NN	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
(	(	(	O	O	O
DSE	DSE	NN	B-NP	B	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
widely	widely	RB	I-NP	O	O
available	available	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
evaluating	evaluate	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
theoretical	theoretical	JJ	I-NP	O	O
concern	concern	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
setting	setting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
conducted	conduct	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
pilot	pilot	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DSE	DSE	NN	B-NP	B	O
in	in	IN	B-PP	O	O
emergency	emergency	NN	B-NP	O	O
department	department	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
series	series	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intensive	intensive	JJ	I-NP	O	O
diagnostic	diagnostic	NN	I-NP	O	O
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ED	ED	NN	I-NP	B	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
urban	urban	JJ	I-NP	O	O
tertiary	tertiary	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
care	care	NN	I-NP	O	O
teaching	teaching	NN	I-NP	O	O
hospital	hospital	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
eligible	eligible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
DSE	DSE	NN	B-NP	B	O
if	if	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
preceding	precede	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chest	chest	NN	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
ECG	ECG	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tropinin	tropinin	NN	I-NP	O	O
I	I	CD	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
exhibiting	exhibit	VBG	B-VP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
continuing	continue	VBG	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
excluded	exclude	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
testing	testing	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DSE	DSE	NN	I-NP	B	O
testing	testing	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intensive	intensive	JJ	I-NP	O	O
diagnostic	diagnostic	NN	I-NP	O	O
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
four	four	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
inadequate	inadequate	JJ	B-NP	O	O
resting	rest	VBG	I-NP	O	O
images	image	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
DSE	DSE	NN	I-NP	B	O
was	be	VBD	B-VP	O	O
terminated	terminate	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
inferior	inferior	JJ	B-NP	O	O
hypokinesis	hypokinesis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
another	another	DT	B-NP	O	O
DSE	DSE	NN	I-NP	B	O
was	be	VBD	B-VP	O	O
terminated	terminate	VBN	I-VP	O	O
because	because	RB	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
atrial	atrial	JJ	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
deficit	deficit	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reach	reach	VB	I-VP	O	O
the	the	DT	B-NP	O	O
target	target	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
19	19	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
completed	complete	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
DSE	DSE	NN	I-NP	B	O
and	and	CC	O	O	O
reached	reach	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
target	target	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
.	.	.	O	O	O

None	None	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
exaggerated	exaggerated	JJ	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
200	200	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tachydysrhythmias	tachydysrhythmia	NNS	B-NP	O	B-Disease
(	(	(	O	O	O
excluding	exclude	VBG	B-VP	O	O
sinus	sinus	NN	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Further	Further	RB	B-ADVP	O	O
suggesting	suggest	VBG	B-VP	O	O
lack	lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
exaggerated	exaggerated	JJ	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
,	,	,	O	O	O
13	13	CD	B-NP	O	O
(	(	(	O	O	O
65	65	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
required	require	VBD	B-VP	O	O
supplemental	supplemental	JJ	B-NP	O	O
atropine	atropine	NN	I-NP	B	B-Chemical
to	to	TO	B-VP	O	O
reach	reach	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
target	target	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
No	No	DT	B-NP	O	O
exaggerated	exaggerated	JJ	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-VP	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
irrigation	irrigation	NN	I-NP	O	O
:	:	:	O	O	O
an	an	DT	B-NP	O	O
unusual	unusual	JJ	I-NP	O	O
presentation	presentation	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
-	-	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
early	early	JJ	B-ADVP	O	O
(	(	(	O	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
(	(	(	O	O	O
TdP	TdP	NN	B-NP	O	B-Disease
)	)	)	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Consistent	Consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
context	context	NN	I-NP	O	O
of	of	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
exacerbating	exacerbating	JJ	I-NP	O	O
factors	factor	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
digoxin	digoxin	NN	I-NP	B	B-Chemical
excess	excess	NN	I-NP	O	O
.	.	.	O	O	O

Transient	Transient	JJ	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
during	during	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
irrigation	irrigation	NN	I-NP	O	O
prompted	prompt	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
episode	episode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
exacerbates	exacerbate	NNS	I-NP	O	O
acquired	acquire	VBN	B-VP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
speculate	speculate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
vagal	vagal	JJ	I-NP	O	O
tone	tone	NN	I-NP	O	O
during	during	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
irrigation	irrigation	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
vagal	vagal	JJ	I-NP	O	O
maneuver	maneuver	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
context	context	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
proarrhythmia	proarrhythmia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
bladder	bladder	NN	I-NP	O	O
irrigation	irrigation	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
despite	despite	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
hypomagnesemia	hypomagnesemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
insufficiency	insufficiency	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
melphalan	melphalan	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	B-Disease
systemic	systemic	JJ	I-NP	O	I-Disease
amyloidosis	amyloidosis	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
stem	stem	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	B-Disease
systemic	systemic	JJ	I-NP	O	I-Disease
amyloidosis	amyloidosis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AL	AL	NN	B-NP	O	B-Disease
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
poor	poor	JJ	I-NP	O	O
prognosis	prognosis	NN	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
time	time	NN	I-NP	O	O
from	from	IN	B-PP	O	O
standard	standard	JJ	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
only	only	RB	B-NP	O	O
17	17	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
melphalan	melphalan	NN	I-NP	B	B-Chemical
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
stem	stem	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
(	(	(	O	O	O
PBSCT	PBSCT	NN	B-NP	O	O
)	)	)	O	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
promising	promising	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
treatment	treatment	NN	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
high	high	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
noted	note	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
insufficiency	insufficiency	NN	I-NP	O	I-Disease
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
melphalan	melphalan	NN	B-NP	B	B-Chemical
conditioning	conditioning	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
further	further	RB	I-VP	O	O
examine	examine	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
and	and	CC	O	O	O
impact	impact	NN	B-NP	O	O
on	on	IN	B-PP	O	O
posttransplant	posttransplant	NN	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Consecutive	Consecutive	JJ	B-NP	O	O
AL	AL	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
PBSCT	PBSCT	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
insufficiency	insufficiency	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ARI	ARI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
melphalan	melphalan	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
minimum	minimum	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	B-NP	O	O
(	(	(	O	O	O
44	44	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
conditioning	condition	VBG	B-VP	O	O
.	.	.	O	O	O

Urine	Urine	NN	B-NP	O	O
sediment	sediment	NN	I-NP	O	O
score	score	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
sum	sum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
individual	individual	JJ	I-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sediment	sediment	NN	B-NP	O	O
identified	identify	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
80	80	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
,	,	,	O	O	O
ARI	ARI	NN	B-NP	O	B-Disease
developed	develop	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
18.8	18.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
melphalan	melphalan	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Univariate	Univariate	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
identified	identify	VBD	B-VP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
hypoalbuminemia	hypoalbuminemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
heavy	heavy	JJ	B-NP	O	O
proteinuria	proteinuria	NN	I-NP	O	B-Disease
,	,	,	O	O	O
diuretic	diuretic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
urine	urine	NN	B-NP	O	O
sediment	sediment	NN	I-NP	O	O
score	score	NN	I-NP	O	O
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
3	3	CD	I-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Age	Age	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
sediment	sediment	NN	I-NP	O	O
score	score	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
independently	independently	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
multivariate	multivariate	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
ARI	ARI	NN	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
melphalan	melphalan	NN	I-NP	B	B-Chemical
underwent	undergo	VBD	B-VP	O	O
dialysis	dialysis	NN	B-NP	O	O
more	more	RBR	B-ADVP	O	O
often	often	RB	I-ADVP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.007	0.007	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
worse	worse	JJR	I-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
survival	survival	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.03	0.03	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
timing	timing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
strongly	strongly	RB	B-ADVP	O	O
suggests	suggest	VBZ	B-VP	O	O
melphalan	melphalan	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
causative	causative	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

Ongoing	Ongoe	VBG	B-VP	O	O
tubular	tubular	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
prerequisite	prerequisite	NN	I-NP	O	O
for	for	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
melphalan	melphalan	NN	B-NP	B	B-Chemical
as	as	IN	B-SBAR	O	O
evidenced	evidence	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
sediment	sediment	NN	I-NP	O	O
.	.	.	O	O	O

Development	Development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ARI	ARI	NN	B-NP	O	B-Disease
adversely	adversely	RB	B-VP	O	O
affected	affect	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
outcome	outcome	NN	I-NP	O	O
after	after	IN	B-PP	O	O
PBSCT	PBSCT	NN	B-NP	O	O
.	.	.	O	O	O

Effective	Effective	JJ	B-NP	O	O
preventive	preventive	JJ	I-NP	O	O
measures	measure	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
help	help	VB	I-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PBSCT	PBSCT	NN	B-NP	O	O
in	in	IN	B-PP	O	O
AL	AL	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Impaired	Impaired	JJ	B-NP	O	B-Disease
fear	fear	NN	I-NP	O	I-Disease
recognition	recognition	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
recreational	recreational	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

INTRODUCTION	INTRODUCTION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
read	read	VB	I-VP	O	O
facial	facial	JJ	B-NP	O	O
expressions	expression	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
human	human	JJ	I-NP	O	O
social	social	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
conduct	conduct	VB	I-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
investigation	investigation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
facial	facial	JJ	B-NP	O	O
expression	expression	NN	I-NP	O	O
recognition	recognition	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
recreational	recreational	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

MATERIALS	MATERIALS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
Three	Three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
comprised	comprise	VBN	B-VP	O	O
of	of	IN	B-PP	O	O
21	21	CD	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
naive	naive	JJ	I-NP	O	O
participants	participant	NNS	I-NP	O	O
(	(	(	O	O	O
CN	CN	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
occasional	occasional	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
OC	OC	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
48	48	CD	B-NP	O	O
regular	regular	JJ	I-NP	O	O
recreational	recreational	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
RC	RC	NN	B-NP	O	O
)	)	)	O	O	O
users	user	NNS	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
emotional	emotional	JJ	I-NP	O	O
facial	facial	JJ	I-NP	O	O
expression	expression	NN	I-NP	O	O
(	(	(	O	O	O
EFE	EFE	NN	B-NP	O	O
)	)	)	O	O	O
task	task	NN	B-NP	O	O
consisting	consist	VBG	B-VP	B	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
male	male	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
face	face	NN	I-NP	O	O
expressing	express	VBG	B-VP	O	O
six	six	CD	B-NP	O	O
basic	basic	JJ	I-NP	O	O
emotions	emotion	NNS	I-NP	B	O
(	(	(	O	O	O
happiness	happiness	NN	B-NP	O	O
,	,	,	O	O	O
surprise	surprise	NN	B-NP	O	O
,	,	,	O	O	O
sadness	sadness	NN	B-NP	O	O
,	,	,	O	O	O
anger	anger	NN	B-NP	O	O
,	,	,	O	O	O
fear	fear	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
disgust	disgust	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
percent	percent	NN	I-NP	O	O
accuracy	accuracy	NN	I-NP	O	O
and	and	CC	O	O	O
latencies	latency	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
correct	correct	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
across	across	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
presentations	presentation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
basic	basic	JJ	I-NP	O	O
emotion	emotion	NN	I-NP	B	O
were	be	VBD	B-VP	O	O
derived	derive	VBN	I-VP	O	O
.	.	.	O	O	O

Participants	Participant	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
"	"	``	I-NP	O	O
Eyes	Eyes	NNP	I-NP	O	O
task	task	NN	I-NP	O	O
"	"	''	O	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
recognize	recognize	VB	I-VP	O	O
more	more	RBR	B-NP	O	O
complex	complex	JJ	I-NP	O	O
emotional	emotional	JJ	I-NP	O	O
states	state	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Symptom	Symptom	NNP	I-NP	O	O
CheckList	CheckList	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
90	90	CD	I-NP	O	O
-	-	HYPH	B-VP	O	O
Revised	Revise	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
measure	measure	VB	I-VP	O	O
psychopathology	psychopathology	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
group	group	NN	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
psychopathology	psychopathology	NN	B-NP	O	O
or	or	CC	O	O	O
"	"	``	O	O	O
eyes	eye	NNS	B-NP	O	O
task	task	NN	I-NP	O	O
"	"	``	O	O	O
performance	performance	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
RC	RC	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
otherwise	otherwise	RB	B-ADVP	O	O
had	have	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
illicit	illicit	JJ	I-NP	O	O
substance	substance	NN	I-NP	O	O
use	use	NN	I-NP	O	O
histories	history	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
OC	OC	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
exhibited	exhibit	VBD	B-VP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
fear	fear	NN	I-NP	O	I-Disease
recognition	recognition	NN	I-NP	O	I-Disease
accuracy	accuracy	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
OC	OC	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CN	CN	NN	I-NP	B	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
RC	RC	NNP	I-NP	O	O
group	group	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
correctly	correctly	RB	B-VP	O	O
identified	identify	VBN	I-VP	O	O
anger	anger	NN	B-NP	O	O
,	,	,	O	O	O
fear	fear	NN	B-NP	O	O
,	,	,	O	O	O
happiness	happiness	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
surprise	surprise	NN	B-NP	O	O
,	,	,	O	O	O
more	more	RBR	B-ADVP	O	O
slowly	slowly	RB	I-ADVP	O	O
than	than	IN	B-PP	O	O
CN	CN	NN	B-NP	B	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
OC	OC	NN	B-NP	O	O
participants	participant	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
OC	OC	NNP	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
slower	slow	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
CN	CN	NN	B-NP	B	O
when	when	WRB	B-ADVP	O	O
correctly	correctly	RB	B-ADVP	O	O
identifying	identify	VBG	B-VP	O	O
disgust	disgust	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
deficit	deficit	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
fear	fear	NN	B-NP	O	I-Disease
recognition	recognition	NN	I-NP	O	I-Disease
accuracy	accuracy	NN	I-NP	O	O
manifested	manifest	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
RC	RC	NN	I-NP	O	O
group	group	NN	I-NP	O	O
cannot	cannot	MD	B-VP	O	O
be	be	VB	I-VP	O	O
explained	explain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subacute	subacute	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
ecstasy	ecstasy	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
recent	recent	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
less	less	RBR	I-NP	O	O
recent	recent	JJ	I-NP	O	O
users	user	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
this	this	DT	B-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
similarly	similarly	RB	B-ADJP	O	O
impaired	impaired	JJ	I-ADJP	O	O
.	.	.	O	O	O

Possible	Possible	JJ	B-NP	O	O
parallels	parallel	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
RC	RC	NN	B-NP	O	O
users	user	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
psychopaths	psychopath	NNS	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
fear	fear	NN	I-NP	O	I-Disease
recognition	recognition	NN	I-NP	O	I-Disease
,	,	,	O	O	O
amygdala	amygdala	NN	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
etiology	etiology	NN	B-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Corneal	Corneal	JJ	B-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
aerosolized	aerosolize	VBN	B-NP	O	O
crack	crack	NN	I-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
4	4	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
corneal	corneal	JJ	B-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
drug	drug	NN	B-NP	O	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
ulcers	ulcer	NNS	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
reviewed	review	VBN	I-VP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Review	Review	NN	B-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
corneal	corneal	JJ	B-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
drug	drug	NN	B-NP	O	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
seen	see	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
institution	institution	NN	I-NP	O	O
from	from	IN	B-PP	O	O
July	July	NNP	B-NP	O	O
2006	2006	CD	I-NP	O	O
to	to	TO	B-PP	O	O
December	December	NNP	B-NP	O	O
2006	2006	CD	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Four	Four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
corneal	corneal	JJ	B-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
use	use	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
corneal	corneal	JJ	I-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
cultured	culture	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
intensive	intensive	JJ	B-NP	O	O
topical	topical	JJ	I-NP	O	O
antibiotic	antibiotic	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
comprehensive	comprehensive	JJ	B-NP	O	O
health	health	NN	I-NP	O	O
care	care	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
medical	medical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
substance	substance	NN	I-NP	O	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
consultations	consultation	NNS	I-NP	O	O
.	.	.	O	O	O

Streptococcal	Streptococcal	JJ	B-NP	O	O
organisms	organism	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
and	and	CC	O	O	O
Capnocytophaga	Capnocytophaga	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Brevibacterium	Brevibacterium	NNP	I-NP	O	O
casei	casei	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
responded	respond	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
antibiotic	antibiotic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
needed	need	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
tarsorrhaphy	tarsorrhaphy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
epithelial	epithelial	JJ	I-NP	O	B-Disease
defects	defect	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Aerosolized	Aerosolize	VBN	B-NP	O	O
crack	crack	NN	I-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
use	use	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
corneal	corneal	JJ	B-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
provides	provide	VBZ	B-VP	O	O
additional	additional	JJ	B-NP	O	O
challenges	challenge	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
management	management	NN	B-NP	O	O
.	.	.	O	O	O

Not	Not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
poor	poor	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
noncompliance	noncompliance	NN	B-NP	O	O
need	need	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
addressed	address	VBN	I-VP	O	O
.	.	.	O	O	O

Comprehensive	Comprehensive	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
may	may	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
the	the	DT	B-NP	O	O
opportunity	opportunity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
substance	substance	NN	I-NP	O	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
,	,	,	O	O	O
improve	improve	VB	B-VP	O	O
their	their	PRP$	B-NP	O	O
overall	overall	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
prevent	prevent	VB	B-VP	O	O
future	future	JJ	B-NP	O	O
corneal	corneal	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

Levetiracetam	Levetiracetam	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adjunct	adjunct	NN	I-NP	O	O
to	to	TO	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
idiopathic	idiopathic	JJ	I-NP	O	B-Disease
epilepsy	epilepsy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
pharmacokinetics	pharmacokinetic	NNS	B-NP	O	O
,	,	,	O	O	O
efficacy	efficacy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
tolerability	tolerability	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
levetiracetam	levetiracetam	NN	I-NP	B	B-Chemical
administered	administer	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adjunct	adjunct	NN	I-NP	O	O
to	to	TO	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
poorly	poorly	RB	B-NP	O	O
controlled	control	VBN	I-NP	O	O
suspected	suspect	VBN	I-NP	O	O
idiopathic	idiopathic	JJ	I-NP	O	B-Disease
epilepsy	epilepsy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Open	Open	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
,	,	,	O	O	O
noncomparative	noncomparative	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

ANIMALS	ANIMALS	NNS	B-NP	O	O
:	:	:	O	O	O
12	12	CD	B-NP	O	O
cats	cat	NNS	I-NP	O	O
suspected	suspect	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
idiopathic	idiopathic	JJ	B-NP	O	B-Disease
epilepsy	epilepsy	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
poorly	poorly	RB	I-VP	O	O
controlled	control	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
that	that	WDT	B-NP	O	O
had	have	VBD	B-VP	O	O
unacceptable	unacceptable	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

PROCEDURES	PROCEDURES	NNS	B-NP	O	O
:	:	:	O	O	O
Cats	Cat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
[	[	(	O	O	O
9.1	9.1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
lb	lb	NN	I-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
PO	PO	NN	B-NP	O	O
,	,	,	O	O	O
q	q	NN	B-NP	O	O
8	8	CD	I-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
a	a	DT	B-NP	O	O
minimum	minimum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
week	week	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
levetiracetam	levetiracetam	NN	I-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	I-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
maximum	maximum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
minimum	minimum	NN	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
elimination	elimination	NN	B-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
life	life	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
.	.	.	O	O	O

Seizure	Seizure	NN	B-NP	O	B-Disease
frequencies	frequency	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Median	Median	JJ	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
levetiracetam	levetiracetam	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
25.5	25.5	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
,	,	,	O	O	O
median	median	JJ	B-NP	O	O
minimum	minimum	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
levetiracetam	levetiracetam	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
8.3	8.3	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
median	median	JJ	B-NP	O	O
elimination	elimination	NN	I-NP	O	O
half	half	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
2.9	2.9	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
frequency	frequency	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
2.1	2.1	CD	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
/	/	SYM	B-NP	O	O
mo	mo	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
median	median	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
frequency	frequency	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
(	(	(	O	O	O
0.42	0.42	CD	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
/	/	SYM	B-NP	O	O
mo	mo	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
7	7	CD	B-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
cats	cat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
classified	classify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
having	have	VBG	B-VP	O	O
responded	respond	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
levetiracetam	levetiracetam	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
(	(	(	O	O	O
ie	ie	FW	B-NP	O	O
,	,	,	O	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cats	cat	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
transient	transient	JJ	B-NP	O	O
lethargy	lethargy	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
inappetence	inappetence	NN	I-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
AND	AND	CC	O	O	O
CLINICAL	CLINICAL	JJ	B-NP	O	O
RELEVANCE	RELEVANCE	NN	I-NP	O	O
:	:	:	O	O	O
Results	Result	NNS	B-NP	O	O
suggested	suggest	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
levetiracetam	levetiracetam	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adjunct	adjunct	NN	I-NP	O	O
to	to	TO	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
idiopathic	idiopathic	JJ	B-NP	O	B-Disease
epilepsy	epilepsy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	O
haemorrhagic	haemorrhagic	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
globus	globus	NN	I-NP	O	I-Disease
pallidus	pallidus	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
alcohol	alcohol	NN	I-NP	B	B-Chemical
intoxication	intoxication	NN	I-NP	O	O
.	.	.	O	O	O

Cocaine	Cocaine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
both	both	CC	B-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
haemorrhagic	haemorrhagic	JJ	I-NP	O	I-Disease
stroke	stroke	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
31	31	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
globus	globus	NN	I-NP	O	I-Disease
pallidus	pallidus	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
excessive	excessive	JJ	B-NP	O	O
alcohol	alcohol	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
intranasal	intranasal	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
related	relate	VBN	I-NP	O	O
globus	globus	NN	I-NP	O	B-Disease
pallidus	pallidus	NN	I-NP	O	I-Disease
infarctions	infarction	NNS	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
most	most	RBS	I-VP	O	O
often	often	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
heroin	heroin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	O
basal	basal	JJ	I-NP	O	B-Disease
ganglia	ganglia	NNS	I-NP	O	I-Disease
infarcts	infarct	NNS	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
without	without	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
heroin	heroin	NN	I-NP	B	B-Chemical
use	use	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
never	never	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
transient	transient	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
arrhythmia	arrhythmia	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
respiratory	respiratory	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
ethanol	ethanol	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
likely	likely	JJ	I-NP	O	O
causes	cause	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
hypoperfusion	hypoperfusion	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ileostomy	ileostomy	NN	B-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
HD	HD	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
MTX	MTX	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Burkitt	Burkitt	NN	B-NP	O	B-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hepatic	hepatic	JJ	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
when	when	WRB	B-ADVP	O	O
its	its	PRP$	B-NP	O	O
clearance	clearance	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
delayed	delay	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
HD	HD	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
MTX	MTX	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ileostomy	ileostomy	NN	B-NP	O	O
,	,	,	O	O	O
The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
boy	boy	NN	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
living	living	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
congenital	congenital	JJ	B-NP	O	O
biliary	biliary	JJ	I-NP	O	B-Disease
atresia	atresia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

At	At	IN	B-PP	O	O
day	day	NN	B-NP	O	O
833	833	CD	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
PTLD	PTLD	NN	B-NP	O	B-Disease
(	(	(	O	O	O
post	post	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
transplantation	transplantation	NN	I-NP	O	I-Disease
lymphoproliferative	lymphoproliferative	JJ	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
,	,	,	O	O	O
Burkitt	Burkitt	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
type	type	NN	I-NP	O	I-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
suffered	suffer	VBD	B-VP	O	O
ileal	ileal	JJ	B-NP	O	O
perforation	perforation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ileostomy	ileostomy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Subsequent	Subsequent	JJ	B-NP	O	O
HD	HD	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
MTX	MTX	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
caused	cause	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
required	require	VBD	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
hemodialysis	hemodialysis	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
supposed	suppose	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
intravascular	intravascular	JJ	B-NP	O	O
hypovolemia	hypovolemia	NN	I-NP	O	B-Disease
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
substantial	substantial	JJ	B-NP	O	O
drainage	drainage	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ileostoma	ileostoma	NN	I-NP	O	O
caused	cause	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
prerenal	prerenal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
of	of	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
could	could	MD	B-VP	O	O
safely	safely	RB	I-VP	O	O
treat	treat	VB	I-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
HD	HD	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
MTX	MTX	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
by	by	IN	B-PP	O	O
controlling	control	VBG	B-VP	O	O
drainage	drainage	NN	B-NP	O	O
from	from	IN	B-PP	O	O
ileostoma	ileostoma	NN	B-NP	O	O
with	with	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
parenteral	parenteral	JJ	I-NP	O	O
nutrition	nutrition	NN	I-NP	O	O
.	.	.	O	O	O

Antithrombotic	Antithrombotic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
use	use	NN	I-NP	O	O
,	,	,	O	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
microbleeds	microbleed	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
intracerebral	intracerebral	JJ	B-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
systematic	systematic	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
published	publish	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
unpublished	unpublished	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
PURPOSE	PURPOSE	NN	I-NP	O	O
:	:	:	O	O	O
Cerebral	Cerebral	JJ	B-NP	O	B-Disease
microbleeds	microbleed	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
MB	MB	NN	B-NP	B	B-Disease
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
potential	potential	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
intracerebral	intracerebral	JJ	B-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ICH	ICH	NN	B-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
contraindication	contraindication	NN	I-NP	O	O
to	to	TO	B-PP	O	O
using	use	VBG	B-VP	O	O
antithrombotic	antithrombotic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Insights	Insight	NNS	B-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
gained	gain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pooling	pool	VBG	B-VP	O	O
data	datum	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
frequency	frequency	NN	I-NP	O	O
stratified	stratify	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
antithrombotic	antithrombotic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cohorts	cohort	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
stroke	stroke	NN	I-NP	O	I-Disease
(	(	(	O	O	O
IS	IS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
transient	transient	JJ	I-NP	O	B-Disease
ischemic	ischemic	JJ	I-NP	O	I-Disease
attack	attack	NN	I-NP	O	I-Disease
(	(	(	O	O	O
TIA	TIA	NN	B-NP	B	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
systematic	systematic	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
published	publish	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
unpublished	unpublished	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
cohorts	cohort	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
stroke	stroke	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
TIA	TIA	NN	I-NP	B	B-Disease
to	to	TO	B-VP	O	O
compare	compare	VB	I-VP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
in	in	IN	B-PP	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
1	1	LS	I-LST	O	O
)	)	)	O	O	O
antithrombotic	antithrombotic	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
vs	vs	IN	B-PP	O	O
nonantithrombotic	nonantithrombotic	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
;	;	:	O	O	O
(	(	(	B-LST	O	O
2	2	LS	I-LST	O	O
)	)	)	O	O	O
antithrombotic	antithrombotic	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
vs	vs	IN	B-PP	O	O
nonusers	nonuser	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
IS	IS	NN	B-NP	O	B-Disease
/	/	SYM	B-NP	O	O
TIA	TIA	NN	I-NP	B	B-Disease
;	;	:	O	O	O
and	and	CC	O	O	O
(	(	(	B-LST	O	O
3	3	LS	I-LST	O	O
)	)	)	O	O	O
ICH	ICH	NN	B-NP	O	B-Disease
vs	vs	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
events	event	NNS	I-NP	O	O
stratified	stratify	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
antithrombotic	antithrombotic	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
analyzed	analyze	VBD	B-VP	O	O
published	publish	VBN	B-VP	O	O
and	and	CC	O	O	O
unpublished	unpublished	JJ	B-VP	O	O
follow	follow	VB	I-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
data	datum	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
antithrombotic	antithrombotic	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pooled	pooled	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1460	1460	CD	B-NP	O	O
ICH	ICH	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
3817	3817	CD	B-NP	O	O
IS	IS	NN	I-NP	O	B-Disease
/	/	SYM	O	O	O
TIA	TIA	NN	B-NP	B	B-Disease
,	,	,	O	O	O
MB	MB	NN	B-NP	B	B-Disease
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
frequent	frequent	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
vs	vs	IN	B-PP	O	O
IS	IS	NN	B-NP	O	B-Disease
/	/	SYM	B-NP	O	O
TIA	TIA	NN	I-NP	B	B-Disease
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
excess	excess	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
2.8	2.8	CD	B-NP	O	O
(	(	(	O	O	O
odds	odd	NNS	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
2.3	2.3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
3.5	3.5	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
nonantithrombotic	nonantithrombotic	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
5.7	5.7	CD	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
3.4	3.4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
9.7	9.7	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
and	and	CC	O	O	O
8.0	8.0	CD	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
3.5	3.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
17.8	17.8	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
difference	difference	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
excess	excess	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
in	in	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
vs	vs	IN	B-PP	O	O
nonusers	nonuser	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
,	,	,	O	O	O
2.7	2.7	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.6	1.6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4.4	4.4	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
but	but	CC	O	O	O
none	none	NN	B-NP	O	O
in	in	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
IS	IS	NN	B-NP	O	B-Disease
/	/	SYM	O	O	O
TIA	TIA	NN	B-NP	B	B-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
,	,	,	O	O	O
1.3	1.3	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
0.9	0.9	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.7	1.7	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.33	0.33	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
difference	difference	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
smaller	small	JJR	I-NP	O	O
excess	excess	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
in	in	IN	B-PP	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
vs	vs	IN	B-PP	O	O
nonusers	nonuser	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
,	,	,	O	O	O
1.7	1.7	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.3	1.3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2.3	2.3	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
findings	finding	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
antiplatelet	antiplatelet	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
IS	IS	NN	B-NP	O	B-Disease
/	/	SYM	O	O	O
TIA	TIA	NN	B-NP	B	B-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
,	,	,	O	O	O
1.4	1.4	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
1.2	1.2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.7	1.7	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-ADJP	O	O
0.001	0.001	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
difference	difference	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
0.25	0.25	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
pooled	pool	VBN	B-VP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
data	datum	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
768	768	CD	B-NP	O	O
antithrombotic	antithrombotic	JJ	I-NP	O	O
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
presence	presence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
substantially	substantially	RB	I-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
ICH	ICH	NN	I-NP	O	B-Disease
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
,	,	,	O	O	O
12.1	12.1	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
3.4	3.4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
42.5	42.5	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
excess	excess	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MB	MB	NN	B-NP	B	B-Disease
in	in	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ICH	ICH	NN	B-NP	O	B-Disease
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
groups	group	NNS	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
MB	MB	NN	B-NP	B	B-Disease
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
ICH	ICH	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Limited	Limit	VBN	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
corroborate	corroborate	VBP	B-VP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
larger	large	JJR	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
urgently	urgently	RB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	B	B-Chemical
stimulation	stimulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
:	:	:	O	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prolactin	prolactin	NN	B-NP	B	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
anatomic	anatomic	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
stalk	stalk	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

AIM	AIM	NN	B-NP	O	O
:	:	:	O	O	O
Verapamil	Verapamil	NN	B-NP	B	B-Chemical
stimulation	stimulation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
previously	previously	RB	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tool	tool	NN	I-NP	O	O
for	for	IN	B-PP	O	O
differential	differential	JJ	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
with	with	IN	B-PP	O	O
conflicting	conflict	VBG	B-VP	O	O
results	result	NNS	B-NP	O	O
.	.	.	O	O	O

Macroprolactinemia	Macroprolactinemia	NNP	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
never	never	RB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
re	re	VB	I-VP	O	O
-	-	HYPH	O	O	O
investigate	investigate	VB	B-VP	O	O
the	the	DT	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
population	population	NN	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
all	all	DT	O	O	O
screened	screen	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
macroprolactinemia	macroprolactinemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Prolactin	Prolactin	NN	B-NP	B	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
verapamil	verapamil	VB	I-VP	B	B-Chemical
in	in	IN	B-PP	O	O
65	65	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
age	age	NN	B-NP	O	O
:	:	:	O	O	O
29.9	29.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8.1	8.1	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
descriptive	descriptive	JJ	I-NP	O	O
,	,	,	I-NP	O	O
matched	match	VBN	I-NP	B	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Verapamil	Verapamil	NN	B-NP	B	B-Chemical
80	80	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
p.o.	p.o.	FW	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	O	O	O
PRL	PRL	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
8th	8th	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
16th	16th	JJ	I-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
immunometric	immunometric	JJ	B-NP	O	O
chemiluminescence	chemiluminescence	NN	I-NP	O	O
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	B	B-Chemical
responsiveness	responsiveness	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
peak	peak	NN	B-NP	O	O
percent	percent	NN	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
basal	basal	JJ	B-NP	O	O
prolactin	prolactin	NN	I-NP	B	O
levels	level	NNS	I-NP	O	O
(	(	(	O	O	O
PRL	PRL	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Verapamil	Verapamil	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
PRL	PRL	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
(	(	(	O	O	O
N	N	NN	B-NP	O	O
.	.	.	O	O	O

8	8	CD	B-NP	O	O
,	,	,	O	O	O
PRL	PRL	NN	B-NP	O	O
:	:	:	O	O	O
183	183	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
macroprolactinoma	macroprolactinoma	NN	B-NP	O	B-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
.	.	.	O	O	O

8	8	CD	B-NP	O	O
,	,	,	O	O	O
PRL	PRL	NN	B-NP	O	O
:	:	:	O	O	O
7	7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
microprolactinoma	microprolactinoma	NN	B-NP	O	B-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
.	.	.	O	O	O

19	19	CD	B-NP	O	O
,	,	,	O	O	O
PRL	PRL	NN	B-NP	O	O
:	:	:	O	O	O
21	21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
macroprolactinemia	macroprolactinemia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
.	.	.	O	O	O

23	23	CD	B-NP	O	O
,	,	,	O	O	O
PRL	PRL	NN	B-NP	O	O
:	:	:	O	O	O
126	126	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
pseudoprolactinoma	pseudoprolactinoma	NN	B-NP	O	B-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
.	.	.	O	O	O

8	8	CD	B-NP	O	O
,	,	,	O	O	O
PRL	PRL	NN	B-NP	O	O
:	:	:	O	O	O
0.8	0.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
N	N	NN	B-NP	O	O
.	.	.	O	O	O

7	7	CD	B-NP	O	O
,	,	,	O	O	O
PRL	PRL	NN	B-NP	O	O
:	:	:	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

ROC	ROC	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
unresponsiveness	unresponsiveness	NN	B-NP	O	O
to	to	TO	B-PP	O	O
verapamil	verapamil	NN	B-NP	B	B-Chemical
defined	define	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
PRL	PRL	NN	B-NP	O	O
<	<	SYM	O	O	O
7	7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
discriminated	discriminate	VBN	B-VP	O	O
anatomical	anatomical	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
stalk	stalk	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
(	(	(	O	O	O
sensitivity	sensitivity	NN	B-NP	O	O
:	:	:	O	O	O
74	74	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
specificity	specificity	NN	B-NP	O	O
:	:	:	O	O	O
73	73	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
AUC	AUC	NN	B-NP	O	O
:	:	:	O	O	O
0.855	0.855	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.04	0.04	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
,	,	,	O	O	O
CI	CI	NNP	B-NP	O	O
:	:	:	O	O	O
0.768	0.768	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.942	0.942	CD	I-NP	O	O
)	)	)	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
pseudoprolactinoma	pseudoprolactinoma	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Verapamil	Verapamil	NN	B-NP	B	B-Chemical
responsiveness	responsiveness	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
reliable	reliable	JJ	I-NP	O	O
finding	finding	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
differential	differential	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	B	B-Chemical
unresponsiveness	unresponsiveness	NN	I-NP	O	O
discriminates	discriminate	VBZ	B-VP	O	O
stalk	stalk	NN	B-NP	O	O
effect	effect	NN	I-NP	O	O
(	(	(	O	O	O
i.e.	i.e.	FW	B-NP	O	O
,	,	,	O	O	O
anatomically	anatomically	RB	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
functionally	functionally	RB	I-VP	O	O
inhibited	inhibit	VBD	I-VP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
tonus	tonus	NN	I-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
causes	cause	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
varying	vary	VBG	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
responsiveness	responsiveness	NN	B-NP	O	O
.	.	.	O	O	O

Central	Central	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
narcotic	narcotic	JJ	B-NP	O	O
analgesics	analgesic	NNS	I-NP	O	O
.	.	.	O	O	O

Part	Part	NN	B-NP	O	O
IV	IV	CD	I-NP	O	O
.	.	.	O	O	O

Noradrenergic	Noradrenergic	JJ	B-NP	O	O
influences	influence	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
analgesics	analgesic	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
naphazoline	naphazoline	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
xylometazoline	xylometazoline	NN	I-NP	B	B-Chemical
on	on	IN	B-PP	O	O
analgesia	analgesia	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
codeine	codeine	NN	I-NP	B	B-Chemical
,	,	,	I-NP	O	O
fentanyl	fentanyl	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pentazocine	pentazocine	NN	I-NP	B	B-Chemical
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
on	on	IN	B-PP	O	O
cataleptic	cataleptic	JJ	B-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
codine	codine	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
fentanyl	fentanyl	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
assays	assay	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
analgesics	analgesic	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
turnover	turnover	NN	I-NP	O	O
of	of	IN	B-PP	O	O
noradrenaline	noradrenaline	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
NA	NA	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
three	three	CD	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
stimulating	stimulate	VBG	B-VP	O	O
central	central	JJ	B-NP	O	O
NA	NA	NN	I-NP	O	B-Chemical
receptors	receptor	NNS	I-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
ED50	ED50	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
antinociceptive	antinociceptive	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
they	they	PRP	B-NP	O	O
enhanced	enhance	VBD	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
fentanyl	fentanyl	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Codeine	Codeine	NN	B-NP	B	B-Chemical
catalepsy	catalepsy	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
decreased	decrease	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
naphazoline	naphazoline	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
xylometazoline	xylometazoline	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NA	NA	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
fentanyl	fentanyl	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
codeine	codeine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
45	45	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
slightly	slightly	RB	B-ADVP	O	O
enhanced	enhance	VBD	B-VP	O	O
it	it	PRP	B-NP	O	O
.	.	.	O	O	O

Pentazocine	Pentazocine	NN	B-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependently	dependently	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NA	NA	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NA	NA	NN	B-NP	O	B-Chemical
turnover	turnover	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
altered	alter	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
analgesics	analgesic	NNS	B-NP	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.2	0.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
following	follow	VBG	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
disappearance	disappearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NA	NA	NN	B-NP	O	B-Chemical
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
diminished	diminish	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
light	light	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
and	and	CC	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
uniform	uniform	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
NA	NA	NN	I-NP	O	B-Chemical
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
less	less	RBR	I-NP	O	O
important	important	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
monoamines	monoamine	NNS	I-NP	O	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
behavioural	behavioural	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
analgesics	analgesic	NNS	I-NP	O	O
.	.	.	O	O	O

Modification	Modification	NN	B-NP	O	O
by	by	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
induced	induce	VBN	B-NP	O	O
hypoglycaemia	hypoglycaemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycaemia	hypoglycaemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
and	and	CC	O	O	O
without	without	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	O	O	O
blockade	blockade	NN	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
fourteen	fourteen	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
men	man	NNS	I-NP	O	O
.	.	.	O	O	O

Eight	Eight	CD	B-NP	O	O
received	receive	VBD	B-VP	O	O
insulin	insulin	NN	B-NP	B	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
eight	eight	CD	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
two	two	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
original	original	JJ	I-NP	O	O
insulin	insulin	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
only	only	RB	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
insulin	insulin	NN	I-NP	B	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
group	group	NN	I-NP	O	O
the	the	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypoglycaemia	hypoglycaemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diastolic	diastolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
group	group	NN	I-NP	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diastolic	diastolic	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Typical	Typical	JJ	B-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
T	T	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
T	T	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
group	group	NN	I-NP	O	O
but	but	CC	B-PP	O	O
in	in	IN	B-PP	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
insulin	insulin	NN	I-NP	B	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Hypertension	Hypertension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
diabetics	diabetic	NNS	B-NP	O	B-Disease
prone	prone	JJ	B-ADJP	B	O
to	to	TO	B-PP	O	O
hypoglycaemia	hypoglycaemia	NN	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	O	O	O
blockers	blocker	NNS	B-NP	O	O
because	because	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
a	a	DT	B-NP	O	O
sharp	sharp	JJ	I-NP	O	O
rise	rise	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Prevention	Prevention	NN	B-NP	O	O
and	and	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endometrial	endometrial	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
climacteric	climacteric	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
oestrogen	oestrogen	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
74	74	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
endometrial	endometrial	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
850	850	CD	B-NP	O	O
climacteric	climacteric	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
oestrogen	oestrogen	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Cystic	Cystic	JJ	B-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
unopposed	unopposed	JJ	B-NP	O	O
oestrogen	oestrogen	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
without	without	IN	B-PP	O	O
progestagen	progestagen	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
courses	course	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
norethisterone	norethisterone	NN	I-NP	B	B-Chemical
daily	daily	RB	B-ADVP	O	O
caused	cause	VBD	B-VP	O	O
reversion	reversion	NN	B-NP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
57	57	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cystic	cystic	JJ	B-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
6	6	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
8	8	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
atypical	atypical	JJ	B-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

4	4	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
endometrial	endometrial	JJ	B-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
referred	refer	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
elsewhere	elsewhere	RB	B-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
problems	problem	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
inappropriate	inappropriate	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
unsupervised	unsupervised	JJ	I-NP	O	O
unopposed	unopposed	JJ	I-NP	O	O
oestrogen	oestrogen	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
difficulty	difficulty	NN	I-NP	O	O
in	in	IN	B-PP	O	O
distinguishing	distinguish	VBG	B-VP	O	O
severe	severe	JJ	B-NP	O	O
hyperplasia	hyperplasia	NN	I-NP	O	B-Disease
from	from	IN	B-PP	O	O
malignancy	malignancy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Cyclical	Cyclical	JJ	B-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
oestrogen	oestrogen	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	SYM	I-NP	O	O
13	13	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
progestagen	progestagen	NN	B-NP	O	B-Chemical
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
seem	seem	VB	I-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endometrial	endometrial	JJ	B-NP	O	B-Disease
hyperplasia	hyperplasia	NN	I-NP	O	I-Disease
or	or	CC	I-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Pure	Pure	NN	B-NP	O	B-Disease
red	red	JJ	I-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
aplasia	aplasia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
toxic	toxic	JJ	B-NP	O	B-Disease
dermatitis	dermatitis	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
taking	take	VBG	B-VP	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
generalized	generalize	VBN	I-NP	O	O
skin	skin	NN	I-NP	O	B-Disease
rash	rash	NN	I-NP	O	I-Disease
,	,	,	O	O	O
lymphadenopathy	lymphadenopathy	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
pure	pure	JJ	B-NP	O	B-Disease
red	red	JJ	I-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
aplasia	aplasia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pharmacon	pharmacon	NN	I-NP	O	O
all	all	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
disappeared	disappear	VBD	B-VP	O	O
spontaneously	spontaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

Skin	Skin	NN	B-NP	O	B-Disease
rash	rash	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
known	know	VBN	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
is	be	VBZ	B-VP	O	O
benign	benign	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
malignant	malignant	JJ	I-NP	O	O
lymphadenopathy	lymphadenopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Pure	Pure	NN	B-NP	O	B-Disease
red	red	JJ	I-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
aplasia	aplasia	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	B	B-Chemical
medication	medication	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
exact	exact	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	B	B-Chemical
exerts	exert	VBZ	B-VP	O	O
its	its	PRP$	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
relation	relation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ingestion	ingestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diphenylhydantoin	diphenylhydantoin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
skin	skin	NN	I-NP	O	B-Disease
rash	rash	NN	I-NP	O	I-Disease
,	,	,	O	O	O
lymphadenopathy	lymphadenopathy	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
pure	pure	JJ	B-NP	O	B-Disease
red	red	JJ	I-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
aplasia	aplasia	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
very	very	RB	B-ADJP	O	O
suggestive	suggestive	JJ	I-ADJP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
connection	connection	NN	I-NP	O	O
.	.	.	O	O	O

Continuous	Continuous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
tobramycin	tobramycin	NN	I-NP	B	B-Chemical
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
carbenicillin	carbenicillin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
infections	infection	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cure	cure	JJ	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
infections	infection	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
adversely	adversely	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1,000	1,000	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
mm3	mm3	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
100	100	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
mm3	mm3	NN	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
poor	poor	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
overcome	overcome	VB	I-VP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
tobramycin	tobramycin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
and	and	CC	O	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
carbenicillin	carbenicillin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Tobramycin	Tobramycin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
and	and	CC	I-NP	O	O
carbenicillin	carbenicillin	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
gm	gm	NN	I-NP	O	O
every	every	DT	B-NP	O	O
four	four	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
125	125	CD	B-NP	O	O
infectious	infectious	JJ	I-NP	O	O
episodes	episode	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
116	116	CD	B-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
myelosuppressive	myelosuppressive	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
cure	cure	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Pneumonia	Pneumonia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
infection	infection	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
61	61	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
59	59	CD	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
cured	cure	VBN	I-VP	O	O
.	.	.	O	O	O

Gram	Gram	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
negative	negative	JJ	I-NP	O	O
bacilli	bacilli	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
causative	causative	JJ	I-NP	O	O
organisms	organism	NNS	I-NP	O	O
and	and	CC	O	O	O
69	69	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
cured	cure	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
pathogen	pathogen	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
Klebsiella	Klebsiella	NNP	B-NP	O	O
pneumoniae	pneumoniae	NNP	I-NP	O	B-Disease
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
Escherichia	Escherichia	FW	B-NP	O	O
coli	coli	FW	I-NP	O	O
and	and	CC	O	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	O
aeruginosa	aeruginosa	NN	I-NP	O	O
,	,	,	O	O	O
accounted	account	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
74	74	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
gram	gram	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
negative	negative	JJ	I-NP	O	I-Disease
bacillary	bacillary	JJ	I-NP	O	I-Disease
infections	infection	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Response	Response	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influenced	influence	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
neutrophil	neutrophil	NN	I-NP	O	O
count	count	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
62	62	CD	I-NP	O	O
%	%	NN	I-NP	O	O
cure	cure	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
39	39	CD	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
failure	failure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neutrophil	neutrophil	NN	I-NP	O	O
count	count	NN	I-NP	O	O
to	to	TO	B-VP	O	O
increase	increase	VB	I-VP	O	O
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
adversely	adversely	RB	B-VP	O	O
affected	affect	VBD	I-VP	O	O
response	response	NN	B-NP	O	O
.	.	.	O	O	O

Azotemia	Azotemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
recognized	recognize	VBD	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
episodes	episode	NNS	B-NP	O	O
.	.	.	O	O	O

Major	Major	JJ	B-NP	O	O
azotemia	azotemia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	B-NP	O	O
or	or	CC	I-NP	O	O
BUN	BUN	NN	I-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
)	)	)	O	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
only	only	RB	B-NP	O	O
2	2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Azotemia	Azotemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
or	or	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
tobramycin	tobramycin	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
antibiotic	antibiotic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
both	both	CC	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	O	O	O
acceptable	acceptable	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Recurrent	Recurrent	JJ	B-NP	O	O
subarachnoid	subarachnoid	JJ	I-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
aminocaproic	aminocaproic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
artery	artery	NN	I-NP	O	I-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Case	Case	NN	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

Epsilon	Epsilon	NN	B-NP	B	B-Chemical
aminocaproic	aminocaproic	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
EACA	EACA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
rebleeding	rebleede	VBG	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
subarachnoid	subarachnoid	JJ	B-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SAH	SAH	NN	B-NP	B	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
decrease	decrease	VB	I-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rebleeding	rebleede	VBG	B-VP	O	O
,	,	,	O	O	O
several	several	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
thrombotic	thrombotic	JJ	B-NP	O	B-Disease
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
EACA	EACA	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
complications	complication	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
included	include	VBN	I-VP	O	O
clinical	clinical	JJ	B-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
and	and	CC	O	O	O
intracranial	intracranial	JJ	B-NP	O	B-Disease
vascular	vascular	JJ	I-NP	O	I-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
SAH	SAH	NN	B-NP	B	B-Disease
,	,	,	O	O	O
arteriolar	arteriolar	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
capillary	capillary	JJ	I-NP	O	O
fibrin	fibrin	NN	I-NP	B	O
thrombi	thrombi	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
fibrinolytic	fibrinolytic	JJ	B-NP	O	O
syndromes	syndrome	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
EACA	EACA	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
thromboembolic	thromboembolic	JJ	I-NP	O	B-Disease
phenomena	phenomenon	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
intravascular	intravascular	JJ	B-NP	O	O
fibrin	fibrin	NN	I-NP	B	O
thrombi	thrombi	NN	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
often	often	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
fibrinolytic	fibrinolytic	JJ	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
,	,	,	O	O	O
EACA	EACA	NN	B-NP	B	B-Chemical
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fibrin	fibrin	NN	B-NP	B	O
thrombi	thrombi	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
disseminated	disseminate	VBN	B-NP	O	B-Disease
intravascular	intravascular	JJ	I-NP	O	I-Disease
coagulation	coagulation	NN	I-NP	O	I-Disease
or	or	CC	I-NP	O	O
other	other	JJ	I-NP	O	O
"	"	''	I-NP	O	O
consumption	consumption	NN	I-NP	O	B-Disease
coagulopathies	coagulopathy	NNS	I-NP	O	I-Disease
.	.	.	O	O	O
"	"	''	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
subtotal	subtotal	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
a	a	DT	B-NP	O	I-Disease
normal	normal	JJ	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
artery	artery	NN	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
occlusion	occlusion	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
EACA	EACA	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
SAH	SAH	NN	B-NP	B	B-Disease
and	and	CC	O	O	O
histopathological	histopathological	JJ	B-NP	O	O
documentation	documentation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
SAH	SAH	NN	I-NP	B	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
corresponding	correspond	VBG	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
marked	marked	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
abrupt	abrupt	JJ	B-NP	O	O
neurological	neurological	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
:	:	:	O	O	O
maternal	maternal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
fetal	fetal	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
found	find	VBN	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
position	position	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
practice	practice	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medicine	medicine	NN	B-NP	O	O
.	.	.	O	O	O

Its	Its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
question	question	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
detrimental	detrimental	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fetus	fetus	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neonate	neonate	NN	I-NP	O	O
.	.	.	O	O	O

Ten	Ten	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
12	12	CD	B-NP	O	O
pregnancies	pregnancy	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
where	where	WRB	B-ADVP	O	O
chronic	chronic	JJ	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
pregnancies	pregnancy	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
and	and	CC	B-PP	O	O
without	without	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
examined	examine	VBN	I-VP	O	O
.	.	.	O	O	O

Maternal	Maternal	JJ	B-NP	O	O
,	,	,	I-NP	O	O
fetal	fetal	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
neonatal	neonatal	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
examined	examine	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
attempt	attempt	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
made	make	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
differentiate	differentiate	VB	I-VP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
complications	complication	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
maternal	maternal	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
-	-	HYPH	I-NP	O	O
related	relate	VBN	I-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
previously	previously	RB	B-NP	O	O
reported	report	VBN	I-NP	O	O
hypoglycemia	hypoglycemia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
hyperbilirubinemia	hyperbilirubinemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
polycythemia	polycythemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
neonatal	neonatal	JJ	B-NP	O	B-Disease
apnea	apnea	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
invariable	invariable	JJ	B-ADJP	O	O
and	and	CC	O	O	O
cannot	cannot	MD	B-VP	O	O
be	be	VB	I-VP	O	O
statistically	statistically	RB	I-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Growth	Growth	NN	B-NP	O	B-Disease
retardation	retardation	NN	I-NP	O	I-Disease
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
significant	significant	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
series	series	NN	I-NP	O	O
.	.	.	O	O	O

Use	Use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
idiopathic	idiopathic	JJ	B-NP	O	B-Disease
orthostatic	orthostatic	JJ	I-NP	O	I-Disease
hypotension	hypotension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
idiopathic	idiopathic	JJ	B-NP	O	B-Disease
orthostatic	orthostatic	JJ	I-NP	O	I-Disease
hypotension	hypotension	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
physiologic	physiologic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
autonomic	autonomic	JJ	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
all	all	DT	O	O	O
exhibited	exhibit	VBD	B-VP	O	O
markedly	markedly	RB	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	B-Chemical
and	and	CC	O	O	O
plasma	plasma	NN	B-NP	O	O
renin	renin	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
recumbent	recumbent	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
upright	upright	JJ	I-NP	O	O
positions	position	NNS	I-NP	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
marked	mark	VBN	I-VP	O	O
hypersensitivity	hypersensitivity	NN	B-NP	O	B-Disease
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
infused	infuse	VBN	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
propanolol	propanolol	NN	B-NP	B	B-Chemical
administered	administer	VBN	B-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
produced	produce	VBD	B-VP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
supine	supine	NN	B-NP	O	O
and	and	CC	O	O	O
upright	upright	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
4	4	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	O
individuals	individual	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
rises	rise	NNS	B-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
11	11	CD	B-NP	O	O
/	/	SYM	B-ADJP	O	O
6	6	CD	B-NP	O	O
to	to	TO	I-NP	O	O
22	22	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
11	11	CD	I-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
40	40	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
160	160	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
elevated	elevate	VBD	B-VP	B	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressures	pressure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
order	order	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
35	35	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
15	15	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
25	25	CD	I-NP	O	O
mmg	mmg	NN	I-NP	O	O
being	be	VBG	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
marked	marked	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
otherwise	otherwise	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
continued	continue	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
13	13	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
persistence	persistence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
some	some	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
with	with	IN	B-PP	O	O
time	time	NN	B-NP	O	O
.	.	.	O	O	O

Hemodynamic	Hemodynamic	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
and	and	CC	O	O	O
essentially	essentially	RB	B-NP	O	O
no	no	DT	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
in	in	IN	B-PP	O	O
selected	select	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
idiopathic	idiopathic	JJ	I-NP	O	B-Disease
orthostatic	orthostatic	JJ	I-NP	O	I-Disease
hypotension	hypotension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Total	Total	JJ	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
with	with	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

III	III	CD	B-NP	O	O
.	.	.	O	O	O

Some	Some	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
required	require	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
maintain	maintain	VB	I-VP	O	O
sleep	sleep	NN	B-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
surgery	surgery	NN	B-NP	O	O
under	under	IN	B-PP	O	O
regional	regional	JJ	B-NP	O	O
local	local	JJ	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Premedication	Premedication	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
atropine	atropine	NN	I-NP	B	B-Chemical
0.5	0.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sleep	sleep	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
and	and	CC	I-VP	O	O
maintained	maintain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
0.1	0.1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
whenever	whenever	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
would	would	MD	B-VP	O	O
open	open	VB	I-VP	O	O
his	his	PRP$	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
request	request	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
overall	overall	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
17.4	17.4	CD	I-NP	O	O
microgram	microgram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min.	min.	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
maintain	maintain	VB	I-VP	O	O
sleep	sleep	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
great	great	JJ	B-NP	O	O
individual	individual	JJ	I-NP	O	O
variation	variation	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
requiring	require	VBG	B-VP	O	O
less	less	JJR	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
18	18	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
myoclonia	myoclonia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
caused	cause	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
technique	technique	NN	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
abandoned	abandon	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
considered	consider	VBN	I-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
will	will	MD	B-VP	O	O
prove	prove	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypnotic	hypnotic	NN	I-NP	O	O
of	of	IN	B-PP	O	O
choice	choice	NN	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
totally	totally	RB	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
technique	technique	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myoclonia	myoclonia	NN	B-NP	O	B-Disease
after	after	IN	B-SBAR	O	O
prolonged	prolonged	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
uncontrollable	uncontrollable	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
movements	movement	NNS	I-NP	O	O
persisted	persist	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
complete	complete	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
consciousness	consciousness	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
method	method	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tremor	tremor	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tocolytic	tocolytic	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
mimetics	mimetic	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
method	method	NN	I-NP	O	O
permitting	permit	VBG	B-VP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
finger	finger	NN	B-NP	O	O
tremor	tremor	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
displacement	displacement	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curve	curve	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
test	test	NN	I-NP	O	O
system	system	NN	I-NP	O	O
with	with	IN	B-PP	O	O
simple	simple	JJ	B-NP	O	O
amplitude	amplitude	NN	I-NP	O	O
calibration	calibration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
coordinates	coordinate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inversion	inversion	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
displacement	displacement	NN	I-NP	O	O
-	-	HYPH	O	O	O
time	time	NN	B-NP	O	O
curves	curve	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
transferred	transfer	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
graphical	graphical	JJ	B-NP	O	O
input	input	NN	I-NP	O	O
equipment	equipment	NN	I-NP	O	O
to	to	TO	B-PP	O	O
punched	punch	VBN	B-NP	B	O
tape	tape	NN	I-NP	B	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
computer	computer	NN	I-NP	O	O
program	program	NN	I-NP	O	O
,	,	,	O	O	O
periods	period	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
amplitudes	amplitude	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tremor	tremor	NN	B-NP	O	B-Disease
oscillations	oscillation	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
and	and	CC	O	O	O
classified	classify	VBN	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
event	event	NN	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
for	for	IN	B-PP	O	O
each	each	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
periods	period	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
amplitudes	amplitude	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
fenoterol	fenoterol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
hydrobromide	hydrobromide	NN	I-NP	O	I-Chemical
,	,	,	O	O	O
ritodrin	ritodrin	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
HCl	HCl	NN	I-NP	B	I-Chemical
and	and	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
given	give	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
10	10	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
both	both	DT	B-NP	O	O
substances	substance	NNS	I-NP	O	O
raised	raise	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
tremor	tremor	NN	I-NP	O	B-Disease
amplitude	amplitude	NN	I-NP	O	O
to	to	TO	B-PP	O	O
about	about	IN	B-NP	O	O
three	three	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
control	control	NN	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
within	within	IN	B-PP	O	O
each	each	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amplitudes	amplitude	NNS	B-NP	O	O
shortened	shorten	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	SYM	I-NP	O	O
20	20	CD	I-NP	O	O
ms	m	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
periods	period	NNS	I-NP	O	O
calculated	calculate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
all	all	DT	B-NP	O	O
oscillations	oscillation	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fenoterol	fenoterol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
hydrobromide	hydrobromide	NN	I-NP	O	I-Chemical
infusion	infusion	NN	I-NP	O	O
,	,	,	O	O	O
tremor	tremor	NN	B-NP	O	B-Disease
amplitudes	amplitude	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
faster	fast	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
ritodrin	ritodrin	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
HCl	HCl	NN	I-NP	B	I-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	O
retinal	retinal	JJ	I-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
choriocapillaris	choriocapillaris	NN	I-NP	O	I-Disease
occlusion	occlusion	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	B-Chemical
suspensions	suspension	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
:	:	:	O	O	O
I	I	LS	B-LST	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
documented	document	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
retinal	retinal	JJ	I-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
choriocapillaris	choriocapillaris	NN	I-NP	O	I-Disease
occlusions	occlusion	NNS	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
blindness	blindness	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
head	head	NN	B-NP	O	O
and	and	CC	O	O	O
neck	neck	NN	B-NP	O	O
soft	soft	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
injection	injection	NN	I-NP	O	O
with	with	IN	B-PP	O	O
methylprednisolone	methylprednisolone	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
penicillin	penicillin	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
case	case	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
unilateral	unilateral	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
observations	observation	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
hazy	hazy	JJ	B-NP	O	O
sensorium	sensorium	NN	I-NP	O	O
,	,	,	O	O	O
superior	superior	JJ	B-NP	O	O
gaze	gaze	NN	I-NP	O	O
palsy	palsy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
pupillary	pupillary	JJ	B-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
conjunctival	conjunctival	JJ	B-NP	O	O
hemorrhages	hemorrhage	NNS	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
edema	edema	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Follow	Follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
changes	change	NNS	B-NP	O	O
showed	show	VBD	B-VP	O	O
marked	marked	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
,	,	,	O	O	O
constricted	constrict	VBN	B-VP	O	O
visual	visual	JJ	B-NP	O	O
fields	field	NNS	I-NP	O	O
,	,	,	O	O	O
optic	optic	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
pallor	pallor	NN	I-NP	O	O
,	,	,	O	O	O
vascular	vascular	JJ	B-NP	O	O
attenuation	attenuation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
chorioretinal	chorioretinal	JJ	B-NP	O	B-Disease
atrophy	atrophy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
causes	cause	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Cephalothin	Cephalothin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
immune	immune	JJ	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
developed	develop	VBD	B-VP	O	O
Coombs	Coombs	NNP	B-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
while	while	IN	B-SBAR	O	O
receiving	receive	VBG	B-VP	O	O
cephalothin	cephalothin	JJ	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
cephalothin	cephalothin	NN	I-NP	B	B-Chemical
IgG	IgG	NN	I-NP	O	O
antibody	antibody	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
eluates	eluate	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
erythrocytes	erythrocyte	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
nonimmunologic	nonimmunologic	JJ	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
and	and	CC	O	O	O
patient	patient	NN	B-NP	O	O
's	's	POS	B-NP	O	O
serum	serum	NN	I-NP	O	O
proteins	protein	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
her	her	PRP$	B-NP	O	O
own	own	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
cephalothin	cephalothin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
coated	coat	VBN	B-NP	O	O
normal	normal	JJ	I-NP	O	O
red	red	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
.	.	.	O	O	O

Skin	Skin	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
lymphocyte	lymphocyte	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
sensitized	sensitize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
cephalothin	cephalothin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
ampicillin	ampicillin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemias	anemia	NNS	I-NP	O	I-Disease
reveals	reveal	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
complexity	complexity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immune	immune	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
involved	involve	VBN	B-VP	O	O
.	.	.	O	O	O

Kaliuretic	Kaliuretic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
dopa	dopa	NN	B-NP	I	I-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Hypokalemia	Hypokalemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
sometimes	sometimes	RB	B-ADJP	O	O
severe	severe	JJ	I-ADJP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
L	L	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
dopa	dopa	NN	I-NP	I	I-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
dopa	dopa	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
normokalemic	normokalemic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
determination	determination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
,	,	,	O	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
urinary	urinary	JJ	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
aldosterone	aldosterone	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

L	L	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
Dopa	Dopa	NN	I-NP	B	I-Chemical
intake	intake	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
sometimes	sometimes	RB	B-ADVP	O	O
also	also	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypokalemic	hypokalemic	JJ	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
the	the	DT	B-NP	O	O
normokalemic	normokalemic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prohibited	prohibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
dopa	dopa	NN	I-NP	B	O
decarbodylase	decarbodylase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
why	why	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
others	other	NNS	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
our	our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
correlation	correlation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
aldosterone	aldosterone	NN	B-NP	B	B-Chemical
production	production	NN	I-NP	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
dopa	dopa	NN	B-NP	I	I-Chemical
.	.	.	O	O	O

Phenytoin	Phenytoin	NN	B-NP	B	B-Chemical
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
probable	probable	JJ	B-NP	O	O
idiosyncratic	idiosyncratic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
:	:	:	O	O	O
case	case	NN	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DPH	DPH	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
EEG	EEG	NN	I-NP	O	O
and	and	CC	I-NP	O	O
mental	mental	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DPH	DPH	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
daily	daily	NN	I-NP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
very	very	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
(	(	(	O	O	O
2.8	2.8	CD	B-NP	O	O
microgramg	microgramg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
probably	probably	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
idiosyncratic	idiosyncratic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
not	not	RB	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
allergic	allergic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
fact	fact	NN	B-NP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
DPH	DPH	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
retarded	retard	VBN	I-NP	B	O
morbilliform	morbilliform	NN	I-NP	O	O
rash	rash	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
DPH	DPH	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
protidogram	protidogram	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
intradermic	intradermic	JJ	I-NP	O	O
DPH	DPH	NN	I-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
local	local	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
starting	start	VBG	B-VP	O	O
DPH	DPH	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
an	an	DT	B-NP	O	O
unexpected	unexpected	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
EEG	EEG	NN	B-NP	O	O
and	and	CC	O	O	O
mental	mental	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
occurring	occur	VBG	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
,	,	,	O	O	O
should	should	MD	B-VP	O	O
alert	alert	VB	I-VP	O	O
the	the	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
eliminating	eliminate	VBG	B-VP	O	O
DPH	DPH	NN	B-NP	B	B-Chemical
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
low	low	JJ	B-ADJP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Ninety	Ninety	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
three	three	CD	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
exercise	exercise	NN	I-NP	O	O
-	-	HYPH	O	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
E	E	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
exercise	exercise	NN	B-NP	O	O
control	control	NN	I-NP	O	O
(	(	(	O	O	O
EC	EC	NN	B-NP	O	O
)	)	)	O	O	O
groups	group	NNS	B-NP	O	O
exercised	exercise	VBN	B-VP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
thirty	thirty	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
treadmill	treadmill	NN	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
mph	mph	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
grade	grade	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
animals	animal	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sedentary	sedentary	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
)	)	)	O	O	O
group	group	NN	B-NP	O	O
remained	remain	VBD	B-VP	O	O
sedentary	sedentary	JJ	B-ADJP	O	O
.	.	.	O	O	O

Eight	Eight	CD	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
sedentary	sedentary	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
(	(	(	O	O	O
SC	SC	NN	B-NP	O	O
)	)	)	O	O	O
group	group	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
remained	remain	VBD	B-VP	O	O
sedentary	sedentary	JJ	B-ADJP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Forty	Forty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
eight	eight	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
final	final	JJ	I-NP	O	O
exercise	exercise	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
and	and	CC	I-NP	O	O
E	E	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
group	group	NN	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
(	(	(	O	O	O
Pp	Pp	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
greater	great	JJR	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
than	than	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
E	E	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
CPK	CPK	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
E	E	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
for	for	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
S	S	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	CD	I-NP	O	O
and	and	CC	O	O	O
EC	EC	NNP	B-NP	O	O
groups	group	NNS	I-NP	O	O
twenty	twenty	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
treated	treat	VBN	I-NP	O	O
groups	group	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
severity	severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
induced	induce	VBN	I-NP	O	O
lesions	lesion	NNS	I-NP	O	O
,	,	,	O	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
heart	heart	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
to	to	TO	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
exercise	exercise	NN	B-NP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
dosages	dosage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
but	but	CC	O	O	O
had	have	VBD	B-VP	O	O
little	little	JJ	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
infarction	infarction	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
Glucarates	Glucarate	NNS	B-NP	I	I-Chemical
on	on	IN	B-PP	O	O
basic	basic	JJ	B-NP	O	O
antibiotic	antibiotic	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Dehydrated	Dehydrate	VBN	B-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
regularly	regularly	RB	B-ADVP	O	O
develop	develop	VBP	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
single	single	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
antibiotics	antibiotic	NNS	I-NP	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
dextran	dextran	NN	B-NP	B	O
or	or	CC	B-PP	O	O
of	of	IN	B-PP	O	O
antibiotics	antibiotic	NNS	B-NP	O	O
only	only	RB	B-ADVP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2,5	2,5	CD	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
di	di	AFX	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
O	O	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
acetyl	acetyl	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
D	D	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
glucaro	glucaro	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
1,4	1,4	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
6,3	6,3	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
dilactone	dilactone	NN	I-NP	O	I-Chemical
protected	protect	VBD	B-VP	O	O
rats	rat	NNS	B-NP	O	O
against	against	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
kanamycin	kanamycin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
dextran	dextran	NN	I-NP	B	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
prevalent	prevalent	JJ	B-ADJP	O	O
among	among	IN	B-PP	O	O
D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
glucarates	glucarate	NNS	I-NP	I	I-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
other	other	JJ	B-NP	O	O
saccharic	saccharic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
hexauronic	hexauronic	JJ	B-NP	O	B-Chemical
acids	acid	NNS	I-NP	O	I-Chemical
and	and	CC	O	O	O
hexaaldonic	hexaaldonic	JJ	B-NP	O	B-Chemical
acids	acid	NNS	I-NP	O	I-Chemical
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
degree	degree	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
hexaaldose	hexaaldose	NN	I-NP	O	O
,	,	,	O	O	O
sugar	sugar	NN	B-NP	B	B-Chemical
alcohols	alcohol	NNS	I-NP	B	I-Chemical
,	,	,	O	O	O
substances	substance	NNS	B-NP	O	O
inthe	inthe	VBP	B-VP	O	O
TCA	TCA	NN	B-NP	B	B-Chemical
cycle	cycle	NN	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
acidic	acidic	JJ	I-NP	O	O
compounds	compound	NNS	I-NP	O	O
.	.	.	O	O	O

D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Glucarates	Glucarate	NNS	I-NP	I	I-Chemical
were	be	VBD	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
against	against	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
peptide	peptide	NN	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
various	various	JJ	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	B-Chemical
antibitocis	antibitocis	NN	I-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
responses	response	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Glucarates	Glucarate	NNS	I-NP	I	I-Chemical
.	.	.	O	O	O

With	With	IN	B-PP	O	O
a	a	DT	B-NP	O	O
D	D	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
glucarate	glucarate	NN	I-NP	I	I-Chemical
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
fixed	fix	VBN	I-NP	O	O
size	size	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
,	,	,	O	O	O
approximately	approximately	RB	B-NP	O	O
the	the	DT	I-NP	O	O
same	same	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protection	protection	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damages	damage	NNS	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
basic	basic	JJ	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	O
despite	despite	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
disparities	disparity	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	O
.	.	.	O	O	O

D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Glucarates	Glucarate	NNS	I-NP	I	I-Chemical
had	have	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
but	but	CC	O	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
cure	cure	VB	I-VP	O	O
it	it	PRP	B-NP	O	O
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
excreted	excrete	VBD	B-VP	O	O
acidic	acidic	JJ	B-NP	O	O
urine	urine	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
they	they	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
spared	spar	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
monosaccharides	monosaccharide	NNS	B-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
glucarates	glucarate	NNS	B-NP	I	I-Chemical
against	against	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
basic	basic	JJ	B-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Paraplegia	Paraplegia	NNP	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
:	:	:	O	O	O
report	report	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
and	and	CC	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
paraplegia	paraplegia	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
intrathecal	intrathecal	JJ	I-NP	O	O
instillation	instillation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
discribed	discribe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ten	ten	CD	I-NP	O	O
previously	previously	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
unusual	unusual	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
factors	factor	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
predispose	predispose	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
:	:	:	O	O	O
abnormal	abnormal	JJ	B-NP	O	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
dynamics	dynamic	NNS	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
epidural	epidural	JJ	B-NP	O	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
leakage	leakage	NN	I-NP	O	O
;	;	:	O	O	O
elevated	elevate	VBN	B-NP	B	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
methothexate	methothexate	NN	I-NP	O	B-Chemical
concentration	concentration	NN	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
dynamics	dynamic	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
inappropriately	inappropriately	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
based	base	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
calculations	calculation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
children	child	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
adults	adult	NNS	I-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurotoxic	neurotoxic	JJ	B-NP	O	B-Disease
preservatives	preservative	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
commercially	commercially	RB	B-NP	O	O
available	available	JJ	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
preparations	preparation	NNS	I-NP	I	O
and	and	CC	I-NP	O	O
diluents	diluent	NNS	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	B	B-Chemical
diluents	diluent	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
unphysiologic	unphysiologic	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
,	,	,	O	O	O
ionic	ionic	JJ	B-NP	O	O
content	content	NN	I-NP	O	O
and	and	CC	I-NP	O	O
osmolarity	osmolarity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	B	B-Chemical
contaminants	contaminant	NNS	I-NP	O	O
,	,	,	O	O	O
local	local	JJ	B-NP	O	O
folate	folate	JJ	I-NP	B	B-Disease
deficiency	deficiency	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
cranial	cranial	JJ	B-NP	O	O
irradiation	irradiation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	B-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
employing	employ	VBG	B-VP	O	O
lower	low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methotrexate	methotrexate	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
children	child	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
adults	adult	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epidural	epidural	JJ	B-NP	O	O
leakage	leakage	NN	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
preservative	preservative	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
free	free	JJ	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
Elliott	Elliott	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
B	B	NN	I-NP	O	O
Solution	Solution	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
not	not	RB	O	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Periodic	Periodic	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cerebruspinal	cerebruspinal	JJ	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
predictive	predictive	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Centrally	Centrally	RB	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intracisternal	intracisternal	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbachol	carbachol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
intracisternal	intracisternal	JJ	I-NP	O	O
(	(	(	O	O	O
i.c.	i.c.	JJ	B-ADJP	O	O
)	)	)	O	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carbachol	carbachol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
(	(	(	O	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
guanethidine	guanethidine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
hexamethonium	hexamethonium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
phentolamine	phentolamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
conversely	conversely	RB	B-ADVP	O	O
,	,	,	O	O	O
potentiated	potentiate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
i.v	i.v	NN	B-NP	O	O
.	.	.	O	O	O

desmethylimipramine	desmethylimipramine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.3	0.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
i.v.	i.v.	NN	B-NP	O	O
selectively	selectively	RB	B-ADVP	O	O
inhibited	inhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
enlargement	enlargement	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
pulse	pulse	NN	B-NP	O	I-Disease
pressure	pressure	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

carbachol	carbachol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

carbachol	carbachol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
almost	almost	RB	I-VP	O	O
completely	completely	RB	I-VP	O	O
blocked	block	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

atropine	atropine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
hexamethonium	hexamethonium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

chlorpromazine	chlorpromazine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
but	but	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

desmethylimipramine	desmethylimipramine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

carbachol	carbachol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mug	mug	NN	I-NP	O	O
)	)	)	O	O	O
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
sectioning	section	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
cervical	cervical	JJ	I-NP	O	O
vagal	vagal	JJ	I-NP	O	O
nerves	nerve	NNS	I-NP	O	O
but	but	CC	O	O	O
disappeared	disappear	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
sectioning	section	VBG	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
cord	cord	NN	I-NP	O	O
(	(	(	O	O	O
C7	C7	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
C8	C8	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

From	From	IN	B-PP	O	O
the	the	DT	B-NP	O	O
above	above	JJ	I-NP	O	O
result	result	NN	I-NP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
i.c	i.c	NN	B-NP	O	O
.	.	.	O	O	O

carbachol	carbachol	NN	B-NP	B	B-Chemical
ortral	ortral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
trunk	trunk	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
.	.	.	O	O	O

Hyperglycemic	Hyperglycemic	JJ	B-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amino	amino	JJ	B-NP	O	B-Chemical
compounds	compound	NNS	I-NP	O	O
structurally	structurally	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
caproate	caproate	VB	I-VP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
feeding	feeding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
small	small	JJ	B-NP	O	O
amounts	amount	NNS	I-NP	O	O
(	(	(	O	O	O
0.3	0.3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
3	3	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diet	diet	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
amino	amino	NN	I-NP	O	B-Chemical
derivatives	derivative	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
caproate	caproate	NN	B-NP	B	B-Chemical
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
hyperglycemia	hyperglycemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
an	an	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
tolerance	tolerance	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
occasionally	occasionally	RB	B-ADVP	O	O
,	,	,	O	O	O
glucosuria	glucosuria	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Effective	Effective	JJ	B-NP	O	O
compounds	compound	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
norleucine	norleucine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
norvaline	norvaline	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
glutamate	glutamate	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
epsilon	epsilon	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
aminocaproate	aminocaproate	NN	B-NP	I	I-Chemical
,	,	,	O	O	O
methionine	methionine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
leucine	leucine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Fatty	Fatty	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
response	response	NN	I-NP	O	O
relationships	relationship	NNS	I-NP	O	O
and	and	CC	O	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sex	sex	NN	B-NP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
response	response	NN	I-NP	O	O
relationships	relationship	NNS	I-NP	O	O
,	,	,	O	O	O
biochemical	biochemical	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
fatty	fatty	JJ	I-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intact	intact	JJ	I-NP	O	O
rat	rat	NN	I-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
isolated	isolate	VBN	I-NP	O	O
perfused	perfuse	VBN	I-NP	O	O
rat	rat	NN	I-NP	O	O
liver	liver	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intact	intact	JJ	I-NP	O	O
male	male	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
rat	rat	NN	I-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

With	With	IN	B-PP	O	O
provision	provision	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
oleic	oleic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
substrate	substrate	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
isolated	isolate	VBN	I-NP	O	O
perfused	perfuse	VBN	I-NP	O	O
liver	liver	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
both	both	CC	O	O	O
accumulation	accumulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	I-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
output	output	NN	B-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
by	by	IN	B-PP	O	O
livers	liver	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
female	female	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Marked	Marked	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
male	male	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
base	base	NN	B-NP	O	O
line	line	NN	I-NP	O	O
(	(	(	O	O	O
control	control	NN	B-NP	O	O
)	)	)	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
output	output	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Accumulation	Accumulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
triglyceride	triglyceride	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	O	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
graded	grade	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
between	between	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
,	,	,	I-NP	O	O
female	female	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pregnant	pregnant	JJ	I-NP	O	O
rat	rat	NN	I-NP	O	O
livers	liver	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
livers	liver	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
female	female	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
especially	especially	RB	B-NP	O	O
pregnant	pregnant	JJ	I-NP	O	O
female	female	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
strikingly	strikingly	RB	B-ADJP	O	O
resistant	resistant	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
depression	depression	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
output	output	NN	B-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
under	under	IN	B-PP	O	O
these	these	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sexes	sex	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
altered	altered	JJ	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
altered	altered	JJ	B-NP	O	O
uptake	uptake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oleic	oleic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Depressed	Depress	VBN	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
accounted	account	VBD	B-VP	O	O
only	only	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
30	30	CD	B-NP	O	O
to	to	TO	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
accumulated	accumulate	VBN	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
triglyceride	triglyceride	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
additional	additional	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
production	production	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
triglyceride	triglyceride	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
rich	rich	JJ	I-NP	O	O
fatty	fatty	JJ	I-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
response	response	NN	I-PP	O	O
to	to	TO	I-PP	O	O
tetracycline	tetracycline	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Fatal	Fatal	JJ	B-NP	O	O
myeloencephalopathy	myeloencephalopathy	NN	I-NP	O	B-Disease
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
vincristine	vincristine	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Vincristine	Vincristine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
accidentally	accidentally	RB	I-VP	O	O
given	give	VBN	I-VP	O	O
intrathecally	intrathecally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
child	child	NN	I-NP	O	O
with	with	IN	B-PP	O	O
leukaemia	leukaemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
producing	produce	VBG	B-VP	O	O
sensory	sensory	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
motor	motor	NN	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

Separate	Separate	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
administering	administer	VBG	B-VP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

Progesterone	Progesterone	NN	B-NP	B	B-Chemical
potentiation	potentiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
arrhythmogenicity	arrhythmogenicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
anesthetized	anesthetize	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
and	and	CC	O	O	O
beating	beat	VBG	B-VP	O	O
rat	rat	NN	B-NP	O	O
heart	heart	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
cultures	culture	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
progesterone	progesterone	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
arrhythmogenicity	arrhythmogenicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
beating	beat	VBG	B-VP	O	O
rat	rat	NN	B-NP	O	O
heart	heart	NN	I-NP	O	O
myocyte	myocyte	NN	I-NP	O	O
cultures	culture	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
determining	determine	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
AD50	AD50	NN	I-NP	O	O
(	(	(	O	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
that	that	WDT	B-NP	O	O
caused	cause	VBD	B-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
beating	beat	VBG	I-NP	O	O
rat	rat	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
myocyte	myocyte	NN	I-NP	O	O
cultures	culture	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
become	become	VB	I-VP	O	O
arrhythmic	arrhythmic	JJ	B-ADJP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
determined	determine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
progesterone	progesterone	NN	I-NP	B	B-Chemical
HCl	HCl	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
on	on	IN	B-PP	O	O
myocyte	myocyte	NN	B-NP	O	O
contractile	contractile	JJ	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progesterone	progesterone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
6.25	6.25	CD	B-NP	O	O
,	,	,	I-NP	O	O
12.5	12.5	CD	I-NP	O	O
,	,	,	I-NP	O	O
25	25	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AD50	AD50	NN	I-NP	O	O
for	for	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Estradiol	Estradiol	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
arrhythmogenicity	arrhythmogenicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
myocyte	myocyte	NN	B-NP	O	O
cultures	culture	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
fourth	fourth	JJ	I-NP	O	O
as	as	IN	B-PP	O	O
potent	potent	JJ	B-ADJP	O	O
as	as	IN	B-PP	O	O
progesterone	progesterone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
progesterone	progesterone	NN	B-NP	B	B-Chemical
nor	nor	CC	O	O	O
estradiol	estradiol	NN	B-NP	B	B-Chemical
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
arrhythmogenicity	arrhythmogenicity	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
potentiated	potentiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
progesterone	progesterone	NN	I-NP	B	B-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
arrhythmogenicity	arrhythmogenicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
pentobarbital	pentobarbital	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
anesthetized	anesthetize	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
onset	onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	B-Disease
as	as	IN	B-PP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
control	control	NN	B-NP	O	O
nonprogesterone	nonprogesterone	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
6.2	6.2	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.3	1.3	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

30.8	30.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.5	2.5	CD	B-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
SE	SE	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
progesterone	progesterone	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
arrhythmogenicity	arrhythmogenicity	NN	I-NP	O	O
both	both	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
.	.	.	O	O	O

Potentiation	Potentiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
myocyte	myocyte	NN	B-NP	O	O
cultures	culture	NNS	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
partly	partly	RB	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocyte	myocyte	NN	I-NP	O	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
occurring	occur	VBG	B-VP	O	O
during	during	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
desferrioxamine	desferrioxamine	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
recovery	recovery	NN	B-NP	O	O
after	after	IN	B-PP	O	O
haemodialysis	haemodialysis	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
transfusion	transfusion	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
thalassemia	thalassemia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
undergoing	undergo	VBG	I-VP	O	O
home	home	NN	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
desferrioxamine	desferrioxamine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
DFX	DFX	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
totally	totally	RB	I-NP	O	O
implanted	implant	VBN	I-NP	O	O
system	system	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
his	his	PRP$	B-NP	O	O
poor	poor	JJ	I-NP	O	O
compliance	compliance	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nightly	nightly	RB	I-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Due	Due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
accidental	accidental	JJ	I-NP	O	O
malfunctioning	malfunctioning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
pump	pump	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
inadvertently	inadvertently	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
caused	cause	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	B-Disease
insufficiency	insufficiency	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decision	decision	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
made	make	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
introduce	introduce	VB	I-VP	O	O
haemodialytical	haemodialytical	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
remove	remove	VB	I-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
reduce	reduce	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

From	From	IN	B-PP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
,	,	,	O	O	O
haemodialysis	haemodialysis	NN	B-NP	O	O
can	can	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rare	rare	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
desferrioxamine	desferrioxamine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
associated	associate	VBN	I-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Can	Can	MD	O	O	O
it	it	PRP	B-NP	O	O
be	be	VB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
?	?	.	O	O	O

Six	Six	CD	B-NP	O	O
stable	stable	JJ	I-NP	O	O
psychiatric	psychiatric	JJ	I-NP	O	O
outpatients	outpatient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
amenorrhea	amenorrhea	NN	I-NP	O	B-Disease
/	/	SYM	B-NP	O	O
oligomenorrhea	oligomenorrhea	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
neuroleptic	neuroleptic	JJ	I-NP	O	B-Chemical
medications	medication	NNS	I-NP	O	I-Chemical
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Daily	Daily	JJ	B-NP	O	O
dosages	dosage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
corrected	correct	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
restored	restore	VBD	B-VP	O	O
menstruation	menstruation	NN	B-NP	O	O
in	in	IN	B-PP	O	O
four	four	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
six	six	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
woman	woman	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
developed	develop	VBN	B-VP	O	O
worsened	worsen	VBD	B-VP	O	O
psychiatric	psychiatric	JJ	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
while	while	IN	B-SBAR	O	O
taking	take	VBG	B-VP	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
three	three	CD	B-NP	O	O
of	of	IN	I-NP	O	O
six	six	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
menstrual	menstrual	JJ	I-NP	O	O
irregularity	irregularity	NN	I-NP	O	O
successfully	successfully	RB	B-VP	O	O
corrected	correct	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
further	further	RBR	B-ADJP	O	O
evaluated	evaluate	VBN	I-ADJP	O	O
as	as	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
associated	associate	VBN	I-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
amenorrhea	amenorrhea	NN	I-NP	O	B-Disease
/	/	SYM	B-NP	O	O
galactorrhea	galactorrhea	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Ethacrynic	Ethacrynic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
brain	brain	NN	I-NP	O	O
neurotransmitters	neurotransmitter	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Intracerebroventricular	Intracerebroventricular	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethacrynic	ethacrynic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
convulsive	convulsive	JJ	I-NP	O	B-Disease
dose	dose	NN	I-NP	O	O
;	;	:	O	O	O
50	50	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
)	)	)	O	O	O
accelerated	accelerate	VBD	B-VP	B	O
the	the	DT	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
turnover	turnover	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxytryptamine	hydroxytryptamine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
)	)	)	O	O	O
but	but	CC	O	O	O
suppressed	suppress	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gamma	gamma	SYM	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
acetylcholine	acetylcholine	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
mouse	mouse	NN	B-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
completely	completely	RB	I-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
glutamate	glutamate	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
N	N	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
D	D	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aspartate	aspartate	NN	I-NP	I	I-Chemical
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
aminophosphonovaleric	aminophosphonovaleric	JJ	B-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
ethacrynic	ethacrynic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
these	these	DT	B-NP	O	O
neurotransmitter	neurotransmitter	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
differentially	differentially	RB	I-VP	O	O
modulated	modulate	VBN	I-VP	O	O
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
glutaminergic	glutaminergic	JJ	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

Pharmacology	Pharmacology	NN	B-NP	O	O
of	of	IN	B-PP	O	O
gamma	gamma	SYM	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
A	A	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
complex	complex	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anxioselective	anxioselective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
beta	beta	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
carboline	carboline	NN	I-NP	I	I-Chemical
derivative	derivative	NN	I-NP	O	O
abecarnil	abecarnil	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rodents	rodent	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
carboline	carboline	NN	I-NP	I	I-Chemical
derivative	derivative	JJ	I-NP	O	O
isopropyl	isopropyl	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
6	6	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
benzyloxy	benzyloxy	NN	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
4	4	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
methoxymethyl	methoxymethyl	NN	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
beta	beta	SYM	B-NP	B	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
carboline	carboline	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
3	3	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
carboxylate	carboxylate	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
abecarrnil	abecarrnil	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
ligand	ligand	NN	I-NP	O	O
for	for	IN	B-PP	O	O
benzodiazepine	benzodiazepine	NN	B-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
possessing	possess	VBG	B-VP	O	O
anxiolytic	anxiolytic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
gamma	gamma	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	B-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
A	A	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
complex	complex	NN	I-NP	O	O
,	,	,	O	O	O
both	both	CC	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Added	Add	VBN	B-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
to	to	TO	B-PP	O	O
rat	rat	NN	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
preparation	preparation	NN	I-NP	O	O
,	,	,	O	O	O
abecarnil	abecarnil	NN	B-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
[	[	(	O	O	O
3H	3H	NN	B-NP	O	O
]	]	)	I-NP	O	O
GABA	GABA	NN	I-NP	B	B-Chemical
binding	binding	NN	I-NP	O	O
,	,	,	O	O	O
enhanced	enhance	VBD	B-VP	O	O
muscimol	muscimol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
stimulated	stimulate	VBN	B-NP	O	O
36Cl	36Cl	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
uptake	uptake	NN	I-NP	O	O
and	and	CC	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
t	t	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
[	[	(	I-NP	O	I-Chemical
35S	35S	NN	I-NP	B	I-Chemical
]	]	)	I-NP	O	I-Chemical
butylbicyclophosphorothionate	butylbicyclophosphorothionate	JJ	I-NP	O	I-Chemical
(	(	(	O	O	O
[	[	(	O	O	B-Chemical
35S	35S	NN	B-NP	B	I-Chemical
]	]	)	I-NP	O	I-Chemical
TBPS	TBPS	NN	I-NP	O	I-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
partial	partial	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
Ro	Ro	NN	I-NP	B	B-Chemical
16	16	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
6028	6028	CD	I-NP	I	I-Chemical
(	(	(	O	O	O
tert	tert	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
butyl	butyl	NN	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
(	(	(	O	O	I-Chemical
S	S	NN	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
bromo	bromo	AFX	I-NP	B	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
11,12,13,13a	11,12,13,13a	SYM	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
tetrahydro	tetrahydro	AFX	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
9	9	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
oxo	oxo	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
9H	9H	NN	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
imidazo	imidazo	NN	I-NP	O	I-Chemical
[	[	(	O	O	I-Chemical
1,5	1,5	CD	B-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
a	a	DT	B-NP	O	I-Chemical
]	]	)	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
pyrrolo	pyrrolo	AFX	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
[	[	(	B-NP	O	I-Chemical
2,1	2,1	NN	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
c	c	NN	I-NP	O	I-Chemical
]	]	)	O	O	I-Chemical
[	[	(	O	O	I-Chemical
1,4	1,4	CD	O	O	I-Chemical
]	]	)	O	O	I-Chemical
benzodiazepine	benzodiazepine	NN	B-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
1	1	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
carboxylate	carboxylate	NN	I-NP	O	I-Chemical
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
very	very	RB	B-NP	O	O
weak	weak	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
i.p.	i.p.	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
abecarnil	abecarnil	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-ADJP	O	O
(	(	(	O	O	O
0.25	0.25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
manner	manner	NN	B-NP	O	O
[	[	(	O	O	B-Chemical
35S	35S	NN	B-NP	B	I-Chemical
]	]	)	O	O	I-Chemical
TBPS	TBPS	NN	B-NP	O	I-Chemical
binding	binding	NN	I-NP	O	O
measured	measure	VBN	B-VP	O	O
ex	ex	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
antagonized	antagonize	VBD	B-VP	O	O
completely	completely	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
convulsant	convulsant	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
[	[	(	B-NP	O	B-Chemical
35S	35S	NN	I-NP	B	I-Chemical
]	]	)	I-NP	O	I-Chemical
TBPS	TBPS	NN	I-NP	O	I-Chemical
binding	binding	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
isoniazide	isoniazide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
350	350	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
s.c.	s.c.	NN	I-NP	O	O
)	)	)	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
[	[	(	B-NP	O	B-Chemical
35S	35S	NN	I-NP	B	I-Chemical
]	]	)	I-NP	O	I-Chemical
TBPS	TBPS	NN	I-NP	O	I-Chemical
binding	binding	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
foot	foot	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
shock	shock	NN	I-NP	O	O
stress	stress	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
better	well	RBR	I-VP	O	O
correlate	correlate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abecarnil	abecarnil	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
[	[	(	B-NP	O	B-Chemical
35S	35S	NN	I-NP	B	I-Chemical
]	]	)	I-NP	O	I-Chemical
TBPS	TBPS	NN	I-NP	O	I-Chemical
binding	binding	NN	I-NP	O	O
,	,	,	O	O	O
exploratory	exploratory	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
abecarnil	abecarnil	NN	B-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
paralleled	parallel	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
dependent	dependent	JJ	B-ADJP	O	O
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
motor	motor	NN	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
and	and	CC	O	O	O
cortical	cortical	JJ	B-NP	O	O
[	[	(	I-NP	O	O
35S	35S	NN	I-NP	B	O
]	]	)	I-NP	O	O
TBPS	TBPS	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
0.05	0.05	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
beta	beta	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
carboline	carboline	NN	I-NP	I	I-Chemical
reduced	reduce	VBD	B-VP	O	O
markedly	markedly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
[	[	(	B-NP	O	B-Chemical
35S	35S	NN	I-NP	B	I-Chemical
]	]	)	I-NP	O	I-Chemical
TBPS	TBPS	NN	I-NP	O	I-Chemical
binding	binding	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
s.c.	s.c.	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Recurrent	Recurrent	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
postpartum	postpartum	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Myocardial	Myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
puerperium	puerperium	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
infrequently	infrequently	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Spasm	Spasm	NN	B-NP	O	B-Disease
,	,	,	O	O	O
coronary	coronary	JJ	B-NP	O	O
dissection	dissection	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
atheromatous	atheromatous	JJ	B-NP	O	O
etiology	etiology	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Bromocriptine	Bromocriptine	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
previous	previous	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
puerperium	puerperium	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
case	case	NN	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
inadvertent	inadvertent	JJ	I-NP	O	O
rechallenge	rechallenge	NN	I-NP	O	O
)	)	)	O	O	O
suggests	suggest	VBZ	B-VP	O	O
such	such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
generally	generally	RB	B-ADVP	O	O
regarded	regard	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
"	"	``	O	O	O
safe	safe	JJ	B-ADJP	O	O
,	,	,	O	O	O
"	"	''	O	O	O
possible	possible	JJ	B-NP	O	O
serious	serious	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bromocriptine	bromocriptine	NN	B-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
acknowledged	acknowledge	VBN	I-VP	O	O
.	.	.	O	O	O

Asterixis	Asterixis	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
very	very	RB	B-NP	O	O
few	few	JJ	I-NP	O	O
reports	report	NNS	I-NP	O	O
about	about	IN	B-PP	O	O
asterixis	asterixis	NN	B-NP	O	B-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
psychopharmacologic	psychopharmacologic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
report	report	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
four	four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
asterixis	asterixis	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
triggered	trigger	VBN	I-VP	O	O
either	either	CC	O	O	O
by	by	IN	B-PP	O	O
adding	add	VBG	B-VP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CBZ	CBZ	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
nor	nor	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CBZ	CBZ	NN	B-NP	O	B-Chemical
were	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
range	range	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
consider	consider	VBP	B-VP	O	O
asterixis	asterixis	NN	B-NP	O	B-Disease
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
easily	easily	RB	I-NP	O	O
overlooked	overlook	VBN	I-NP	O	O
sign	sign	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
even	even	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
moderate	moderate	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
certain	certain	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
clozapine	clozapine	NN	I-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CBZ	CBZ	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Pharmacodynamics	Pharmacodynamic	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
i.v	i.v	NN	B-NP	O	O
.	.	.	O	O	O

levodopa	levodopa	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
fluctuating	fluctuating	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
concentration	concentration	NN	B-NP	O	O
dependent	dependent	JJ	B-ADJP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
fit	fit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
Emax	Emax	NN	I-NP	O	O
model	model	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fluctuating	fluctuate	VBG	B-VP	O	O
responders	responder	NNS	B-NP	O	O
.	.	.	O	O	O

Stable	Stable	JJ	B-NP	O	O
responders	responder	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Baseline	Baseline	NN	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressures	pressure	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
fluctuating	fluctuate	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
;	;	:	O	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
baseline	baseline	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
correlated	correlate	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Antiparkinsonian	Antiparkinsonian	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
temporally	temporally	RB	B-ADVP	O	O
correlated	correlate	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

Phenylalanine	Phenylalanine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
neutral	neutral	JJ	I-NP	O	O
amino	amino	NN	I-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
LNAA	LNAA	NN	B-NP	O	O
)	)	)	O	O	O
competing	compete	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
transport	transport	NN	B-NP	O	O
across	across	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
antiparkinsonian	antiparkinsonian	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
action	action	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
parallels	parallel	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
motor	motor	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
fluctuating	fluctuate	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
baseline	baseline	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
fluctuating	fluctuate	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
stable	stable	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Syndrome	Syndrome	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
inappropriate	inappropriate	JJ	B-NP	O	I-Disease
secretion	secretion	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	I-Disease
antidiuretic	antidiuretic	JJ	B-NP	B	I-Disease
hormone	hormone	NN	I-NP	I	I-Disease
after	after	IN	B-PP	O	O
infusional	infusional	JJ	B-NP	O	O
vincristine	vincristine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
77	77	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
multiple	multiple	JJ	I-NP	O	B-Disease
myeloma	myeloma	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
continuous	continuous	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Nine	Nine	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
second	second	JJ	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
she	she	PRP	B-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
lethargy	lethargy	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
weakness	weakness	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hyponatremia	hyponatremia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Evaluation	Evaluation	NN	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
inappropriate	inappropriate	JJ	B-NP	O	I-Disease
secretion	secretion	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	I-Disease
antidiuretic	antidiuretic	JJ	B-NP	B	I-Disease
hormone	hormone	NN	I-NP	I	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
vincristine	vincristine	NN	I-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
,	,	,	O	O	O
further	further	JJ	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
chemotherapy	chemotherapy	NN	I-NP	O	O
without	without	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
this	this	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
.	.	.	O	O	O

Heart	Heart	NN	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
:	:	:	O	O	O
to	to	TO	B-VP	O	O
digitalise	digitalise	VB	I-VP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
?	?	.	O	O	O

The	The	DT	B-NP	O	O
view	view	NN	I-NP	O	O
against	against	IN	B-PP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
extensive	extensive	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
digoxin	digoxin	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
still	still	RB	B-ADVP	O	O
not	not	RB	O	O	O
well	well	RB	B-ADJP	O	O
defined	define	VBN	I-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
digoxin	digoxin	NN	I-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
beneficial	beneficial	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	O
rate	rate	NN	I-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
sinus	sinus	NN	B-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	VBP	B-VP	O	I-Disease
the	the	DT	B-NP	O	O
situation	situation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
less	less	RBR	B-ADJP	O	O
clear	clear	JJ	I-ADJP	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
narrow	narrow	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
:	:	:	O	O	O
toxic	toxic	JJ	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
and	and	CC	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
digoxin	digoxin	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
undesirable	undesirable	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
increasing	increase	VBG	B-VP	O	O
peripheral	peripheral	JJ	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
demands	demand	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
causing	cause	VBG	B-VP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
paucity	paucity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
data	data	NN	B-NP	O	O
from	from	IN	B-PP	O	O
well	well	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
designed	design	VBN	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
available	available	JJ	B-ADJP	O	O
are	be	VBP	B-VP	O	O
generally	generally	RB	B-ADJP	O	O
small	small	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
limitations	limitation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
design	design	NN	B-NP	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
show	show	NN	I-NP	O	O
variation	variation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
benefit	benefit	NN	I-NP	O	O
.	.	.	O	O	O

More	More	RBR	B-NP	O	O
convincing	convincing	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
showing	show	VBG	I-VP	O	O
that	that	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	B	B-Chemical
improves	improve	VBZ	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
or	or	CC	O	O	O
exercise	exercise	NN	B-NP	O	O
capacity	capacity	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
trial	trial	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
had	have	VBN	I-VP	O	O
sufficient	sufficient	JJ	B-NP	O	O
power	power	NN	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
mortality	mortality	NN	B-NP	O	O
.	.	.	O	O	O

Pooled	Pool	VBN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
shows	show	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
excess	excess	JJ	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
and	and	CC	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
digoxin	digoxin	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
mortality	mortality	NN	B-NP	O	O
after	after	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MI	MI	NN	B-NP	B	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Angiotensin	Angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
converting	convert	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
(	(	(	O	O	O
ACE	ACE	NN	B-NP	O	O
)	)	)	O	O	O
inhibitors	inhibitor	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
first	first	RB	B-ADVP	O	O
as	as	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
safer	safe	JJR	B-ADJP	O	O
,	,	,	O	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
level	level	NN	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
,	,	,	O	O	O
modify	modify	VBP	B-VP	O	O
progression	progression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
disease	disease	NN	B-NP	O	O
,	,	,	O	O	O
relieve	relieve	VB	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
,	,	,	O	O	O
improve	improve	VB	B-VP	O	O
exercise	exercise	NN	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
and	and	CC	O	O	O
reduce	reduce	VB	B-VP	O	O
mortality	mortality	NN	B-NP	O	O
.	.	.	O	O	O

Caution	Caution	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
exercised	exercise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
digoxin	digoxin	NN	B-NP	B	B-Chemical
until	until	IN	B-SBAR	O	O
large	large	JJ	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
trials	trial	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
completed	complete	VBN	I-VP	O	O
showing	show	VBG	I-VP	O	O
either	either	CC	O	O	O
benefit	benefit	NN	B-NP	O	O
or	or	CC	I-NP	O	O
harm	harm	NN	I-NP	O	O
.	.	.	O	O	O

Until	Until	IN	B-PP	O	O
then	then	RB	B-NP	O	O
digoxin	digoxin	NN	I-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
line	line	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Intravascular	Intravascular	JJ	B-NP	O	O
hemolysis	hemolysis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
rifampin	rifampin	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampin	rifampin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Intravascular	Intravascular	JJ	B-NP	O	O
hemolysis	hemolysis	NN	I-NP	O	B-Disease
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
rifampin	rifampin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
extremely	extremely	RB	B-ADJP	O	O
rare	rare	JJ	I-ADJP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
leprosy	leprosy	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
hemolysis	hemolysis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
rifampin	rifampin	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Zidovudine	Zidovudine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
zidovudine	zidovudine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
38	38	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
AIDS	AIDS	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
presented	present	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
whereby	whereby	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
known	know	VBN	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
tolerated	tolerate	VBD	B-VP	O	O
well	well	RB	B-ADVP	O	O
an	an	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
reverse	reverse	JJ	I-NP	O	O
transcriptase	transcriptase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
2'3	2'3	NN	B-NP	B	B-Chemical
'	'	POS	B-NP	I	I-Chemical
dideoxyinosine	dideoxyinosine	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Physicians	Physician	NNS	B-NP	O	O
caring	care	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
AIDS	AIDS	NN	B-NP	O	B-Disease
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
hitherto	hitherto	NN	I-NP	O	O
rarely	rarely	RB	B-ADVP	O	O
reported	report	VBD	B-VP	O	O
complication	complication	NN	B-NP	O	O
.	.	.	O	O	O

Thoracic	Thoracic	JJ	B-NP	O	B-Disease
hematomyelia	hematomyelia	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
coumadin	coumadin	NN	B-NP	B	B-Chemical
anticoagulant	anticoagulant	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thoracic	thoracic	JJ	B-NP	O	B-Disease
hematomyelia	hematomyelia	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
presented	present	VBN	I-VP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
features	feature	NNS	I-NP	O	O
,	,	,	O	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
2	2	CD	B-NP	O	O
other	other	JJ	I-NP	O	O
previously	previously	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
suspicion	suspicion	NN	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
quick	quick	JJ	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
and	and	CC	O	O	O
successful	successful	JJ	B-NP	O	O
decompressive	decompressive	JJ	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

Mania	Mania	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adolescents	adolescent	NNS	B-NP	O	O
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
gaining	gain	VBG	I-VP	O	O
increased	increase	VBN	B-NP	O	O
acceptance	acceptance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adolescent	adolescent	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Generally	Generally	RB	B-ADJP	O	O
safe	safe	JJ	I-ADJP	O	O
and	and	CC	O	O	O
well	well	RB	B-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
,	,	,	O	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
induce	induce	VB	I-VP	O	O
mania	mania	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
five	five	CD	B-NP	O	O
depressed	depressed	JJ	I-NP	O	B-Disease
adolescents	adolescent	NNS	I-NP	O	O
,	,	,	O	O	O
14	14	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
16	16	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
mania	mania	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
pharmacotherapy	pharmacotherapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
here	here	RB	B-ADVP	O	O
.	.	.	O	O	O

Apparent	Apparent	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mania	mania	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
hypomania	hypomania	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
pharmacotherapy	pharmacotherapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
population	population	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
attention	attention	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
deficit	deficit	NN	I-NP	O	I-Disease
hyperactivity	hyperactivity	NN	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
affective	affective	JJ	B-NP	O	O
instability	instability	NN	I-NP	O	O
;	;	:	O	O	O
major	major	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
psychotic	psychotic	JJ	B-NP	O	B-Disease
features	feature	NNS	I-NP	O	O
;	;	:	O	O	O
a	a	DT	B-NP	O	O
family	family	NN	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
affective	affective	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
,	,	,	O	O	O
especially	especially	RB	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
;	;	:	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
optimal	optimal	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
individual	individual	JJ	B-NP	O	O
vulnerability	vulnerability	NN	I-NP	O	O
to	to	TO	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
mania	mania	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
adolescents	adolescent	NNS	B-NP	O	O
.	.	.	O	O	O

Gemfibrozil	Gemfibrozil	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
lovastatin	lovastatin	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
hyperlipoproteinemias	hyperlipoproteinemia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
observational	observational	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
safety	safety	NN	B-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
(	(	(	O	O	O
21	21	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
patient	patient	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
open	open	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
,	,	,	O	O	O
gemfibrozil	gemfibrozil	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
lovastatin	lovastatin	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
80	80	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
mixed	mixed	JJ	I-NP	O	O
hyperlipidemia	hyperlipidemia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
68	68	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
atherosclerotic	atherosclerotic	JJ	B-NP	O	B-Disease
vascular	vascular	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
ideal	ideal	JJ	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
targets	target	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reached	reach	VBN	I-VP	O	O
(	(	(	O	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
density	density	NN	I-NP	O	O
lipoprotein	lipoprotein	NN	I-NP	O	O
(	(	(	O	O	O
LDL	LDL	NN	B-NP	O	O
)	)	)	O	O	O
cholesterol	cholesterol	NN	B-NP	B	B-Chemical
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
130	130	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
dl	dl	NN	I-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
density	density	NN	I-NP	O	O
lipoprotein	lipoprotein	NN	I-NP	O	O
(	(	(	O	O	O
HDL	HDL	NN	B-NP	O	O
)	)	)	O	O	O
cholesterol	cholesterol	NN	B-NP	O	B-Chemical
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
35	35	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
dl	dl	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
total	total	JJ	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
HDL	HDL	NN	I-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
4.5	4.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
diet	diet	NN	B-NP	O	O
plus	plus	CC	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
gemfibrozil	gemfibrozil	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1.2	1.2	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
lovastatin	lovastatin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
primarily	primarily	RB	B-NP	O	O
20	20	CD	I-NP	O	O
or	or	CC	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
.	.	.	O	O	O

Follow	Follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
visits	visit	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
scheduled	schedule	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
every	every	DT	B-NP	O	O
6	6	CD	I-NP	O	O
to	to	TO	I-NP	O	O
8	8	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10.3	10.3	CD	B-NP	O	O
visits	visit	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
741	741	CD	B-NP	O	O
batteries	battery	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
and	and	CC	O	O	O
714	714	CD	B-NP	O	O
creatine	creatine	NN	I-NP	B	B-Chemical
phosphokinase	phosphokinase	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
measured	measure	VBN	B-VP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
1	1	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4,446	4,446	CD	I-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
(	(	(	O	O	O
0.02	0.02	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
gamma	gamma	NN	I-NP	O	O
glutamyl	glutamyl	NN	I-NP	O	O
transferase	transferase	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
or	or	CC	O	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
3	3	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
normal	normal	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
714	714	CD	I-NP	O	O
creatine	creatine	NN	I-NP	B	B-Chemical
phosphokinase	phosphokinase	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
high	high	JJ	B-ADJP	O	O
;	;	:	O	O	O
only	only	RB	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
or	or	CC	O	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
3	3	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
normal	normal	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
total	total	JJ	I-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
from	from	IN	B-PP	O	O
255	255	CD	B-NP	O	O
to	to	TO	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
dl	dl	NN	B-NP	O	O
,	,	,	O	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
35	35	CD	B-NP	O	O
%	%	NN	I-NP	O	O
from	from	IN	B-PP	O	O
236	236	CD	B-NP	O	O
to	to	TO	I-NP	O	O
154	154	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
dl	dl	NN	B-NP	O	O
,	,	,	O	O	O
LDL	LDL	NN	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
from	from	IN	B-PP	O	O
176	176	CD	B-NP	O	O
to	to	TO	I-NP	O	O
131	131	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
/	/	SYM	B-VP	O	O
HDL	HDL	NN	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
ratio	ratio	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
from	from	IN	B-PP	O	O
7.1	7.1	CD	B-NP	O	O
to	to	TO	B-PP	O	O
5.4	5.4	CD	B-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
p	p	NN	I-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
or	or	CC	O	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
0.0001	0.0001	CD	B-NP	O	O
.	.	.	O	O	O

Myositis	Myositis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
attributable	attributable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
and	and	CC	O	O	O
symptomatic	symptomatic	JJ	B-ADJP	O	O
enough	enough	RB	I-ADJP	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
it	it	PRP	B-NP	O	O
,	,	,	O	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
creatine	creatine	NN	I-NP	B	B-Chemical
phosphokinase	phosphokinase	NN	I-NP	O	O
(	(	(	O	O	O
769	769	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
liter	liter	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
no	no	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
myoglobinuria	myoglobinuria	NN	I-NP	O	B-Disease
.	.	.	O	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Hepatocellular	Hepatocellular	JJ	B-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Fanconi	Fanconi	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
anemia	anemia	NN	I-NP	O	I-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
androgen	androgen	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
11	11	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
boy	boy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
Fanconi	Fanconi	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
anemia	anemia	NN	I-NP	O	I-Disease
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
androgens	androgen	NNS	B-NP	O	B-Chemical
,	,	,	I-NP	O	O
corticosteroids	corticosteroid	NNS	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
transfusions	transfusion	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
death	death	NN	I-NP	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
readmitted	readmitte	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
aplastic	aplastic	JJ	B-NP	O	O
crisis	crisis	NN	I-NP	O	O
with	with	IN	B-PP	O	O
septicemia	septicemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
marked	marked	JJ	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
died	die	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
bronchopneumonia	bronchopneumonia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

At	At	IN	B-PP	O	O
autopsy	autopsy	NN	B-NP	O	O
peliosis	peliosis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
multiple	multiple	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
tumors	tumor	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
which	which	WDT	B-NP	O	O
histologically	histologically	RB	B-ADVP	O	O
proved	prove	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
well	well	RB	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
differentiated	differentiate	VBN	B-NP	O	O
hepatocellular	hepatocellular	JJ	I-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
observations	observation	NNS	I-NP	O	O
that	that	IN	B-NP	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
metastasizing	metastasize	VBG	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	B-Disease
neoplasms	neoplasm	NNS	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
peliosis	peliosis	NN	I-NP	O	B-Disease
can	can	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
androgen	androgen	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
Fanconi	Fanconi	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
anemia	anemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rostral	rostral	JJ	B-NP	O	O
ventrolateral	ventrolateral	JJ	I-NP	O	O
medulla	medulla	NN	I-NP	O	O
in	in	IN	B-PP	O	O
spontaneously	spontaneously	RB	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
selective	selective	JJ	I-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
lesion	lesion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rostral	rostral	JJ	B-NP	O	O
ventrolateral	ventrolateral	JJ	I-NP	O	O
medulla	medulla	NN	I-NP	O	O
on	on	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
neurogenic	neurogenic	JJ	B-NP	O	O
tone	tone	NN	I-NP	O	O
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
,	,	,	I-NP	O	O
unrestrained	unrestrained	JJ	I-NP	O	O
spontaneously	spontaneously	RB	I-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
placed	place	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
microinjections	microinjection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
nmol	nmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
200	200	CD	B-NP	O	O
nl	nl	NN	I-NP	O	O
N	N	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
D	D	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aspartic	aspartic	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
restimulation	restimulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
area	area	NN	I-NP	O	O
with	with	IN	B-PP	O	O
N	N	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
D	D	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
aspartic	aspartic	JJ	B-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
15	15	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
postlesion	postlesion	NN	I-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
produce	produce	VB	I-VP	O	O
a	a	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
day	day	NN	I-NP	O	O
postlesion	postlesion	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
resting	rest	VBG	I-NP	O	O
mean	mean	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
lesioned	lesione	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
sham	sham	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
100	100	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
7	7	CD	B-NP	O	O
versus	versus	IN	B-PP	O	O
173	173	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
4	4	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Fifteen	Fifteen	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
lesioned	lesione	VBN	I-NP	O	O
group	group	NN	I-NP	O	O
still	still	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
values	value	NNS	B-NP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sham	sham	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
150	150	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
versus	versus	IN	I-NP	O	O
167	167	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sham	sham	NN	I-NP	O	O
and	and	CC	O	O	O
lesioned	lesione	VBD	B-VP	O	O
groups	group	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ganglionic	ganglionic	JJ	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
trimethaphan	trimethaphan	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
caused	cause	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
lesioned	lesione	VBN	I-NP	O	O
and	and	CC	I-NP	O	O
sham	sham	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
trimethaphan	trimethaphan	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
lesioned	lesione	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
32	32	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
13	13	CD	B-NP	O	O
beats	beat	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
minute	minute	NN	B-NP	O	O
)	)	)	O	O	O
but	but	CC	O	O	O
a	a	DT	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
sham	sham	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
33	33	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
beats	beat	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
minute	minute	NN	B-NP	O	O
)	)	)	O	O	O
1	1	CD	B-NP	O	O
day	day	NN	I-NP	O	O
postlesion	postlesion	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
rostral	rostral	JJ	B-NP	O	O
ventrolateral	ventrolateral	JJ	I-NP	O	O
medulla	medulla	NN	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
play	play	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
maintaining	maintain	VBG	B-VP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
spontaneously	spontaneously	RB	I-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Spinal	Spinal	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
suprabulbar	suprabulbar	JJ	I-NP	O	O
structures	structure	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gradual	gradual	JJ	I-NP	B	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lesioned	lesione	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Damage	Damage	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
substantia	substantia	NN	B-NP	O	I-Disease
nigra	nigra	NN	I-NP	O	I-Disease
pars	par	NNS	I-NP	O	I-Disease
reticulata	reticulata	VBP	B-VP	O	I-Disease
during	during	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
:	:	:	O	O	O
immunohistochemical	immunohistochemical	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
,	,	,	O	O	O
astrocytes	astrocyte	NNS	B-NP	O	O
and	and	CC	O	O	O
serum	serum	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
protein	protein	NN	I-NP	O	O
extravasation	extravasation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
substantia	substantia	NN	I-NP	O	O
nigra	nigra	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
gating	gate	VBG	I-NP	B	O
function	function	NN	I-NP	O	O
controlling	control	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
spread	spread	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epileptic	epileptic	JJ	B-NP	O	B-Disease
seizure	seizure	NN	I-NP	O	I-Disease
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
models	model	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	B-Disease
status	status	NN	I-NP	O	I-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
the	the	DT	B-NP	O	O
pars	par	NNS	I-NP	O	O
reticulata	reticulata	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
substantia	substantia	NN	B-NP	O	O
nigra	nigra	NN	I-NP	O	O
(	(	(	O	O	O
SNR	SNR	NN	B-NP	O	O
)	)	)	O	O	O
suffers	suffer	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
massive	massive	JJ	I-NP	O	O
lesion	lesion	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
arise	arise	VB	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
massive	massive	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	B-Disease
derangement	derangement	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
hyperexcitation	hyperexcitation	NN	I-NP	O	O
developing	develop	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activated	activate	VBN	I-NP	O	O
SNR	SNR	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
neuropathology	neuropathology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
immunohistochemical	immunohistochemical	JJ	B-NP	O	O
techniques	technique	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
emphasis	emphasis	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
astrocytes	astrocyte	NNS	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
surviving	survive	VBG	B-VP	O	O
20	20	CD	B-NP	O	O
,	,	,	I-NP	O	O
30	30	CD	I-NP	O	O
,	,	,	I-NP	O	O
40	40	CD	I-NP	O	O
,	,	,	I-NP	O	O
60	60	CD	I-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	I-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
perfusion	perfusion	NN	B-NP	O	O
-	-	HYPH	O	O	O
fixed	fix	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
brains	brain	NNS	B-NP	O	O
processed	process	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
immunohistochemical	immunohistochemical	JJ	B-NP	O	O
staining	staining	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
.	.	.	O	O	O

Nissl	Nissl	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
staining	staining	NN	I-NP	O	O
and	and	CC	I-NP	O	O
antibodies	antibody	NNS	I-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuron	neuron	NN	I-NP	O	O
-	-	HYPH	O	O	O
specific	specific	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
binding	bind	VBG	B-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
parvalbumin	parvalbumin	NN	B-NP	O	O
,	,	,	O	O	O
served	serve	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
detect	detect	VB	I-VP	O	O
neuronal	neuronal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
.	.	.	O	O	O

Antibodies	Antibody	NNS	B-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
astroglia	astroglia	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
cytoskeletal	cytoskeletal	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
glial	glial	JJ	B-NP	O	O
fibrillary	fibrillary	JJ	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
(	(	(	O	O	O
GFAP	GFAP	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glial	glial	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
binding	bind	VBG	B-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
100	100	CD	I-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
status	status	NN	I-NP	O	O
of	of	IN	B-PP	O	O
astrocytes	astrocyte	NNS	B-NP	O	O
.	.	.	O	O	O

Immunohistochemical	Immunohistochemical	JJ	B-NP	O	O
staining	staining	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
albumin	albumin	NN	I-NP	O	O
and	and	CC	I-NP	O	O
immunoglobulins	immunoglobulin	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
indicator	indicator	NN	B-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
and	and	CC	O	O	O
vasogenic	vasogenic	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
formation	formation	NN	I-NP	O	O
.	.	.	O	O	O

Immunohistochemical	Immunohistochemical	JJ	B-NP	O	O
staining	staining	NN	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
loss	loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
GFAP	GFAP	NN	B-NP	O	O
-	-	HYPH	O	O	O
staining	stain	VBG	B-VP	O	O
already	already	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oval	oval	NN	I-NP	O	O
focus	focus	NN	I-NP	O	O
situated	situate	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
center	center	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
while	while	IN	B-SBAR	O	O
sparing	spar	VBG	B-VP	O	O
medial	medial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
lateral	lateral	JJ	I-NP	O	O
aspects	aspect	NNS	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
1	1	CD	B-NP	O	O
h	h	NN	I-NP	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
additional	additional	JJ	B-NP	O	O
vacuolation	vacuolation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
S	S	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
100	100	CD	I-NP	O	O
protein	protein	NN	I-NP	O	O
staining	staining	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
parvalbumin	parvalbumin	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
staining	staining	NN	I-NP	O	O
changed	change	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
SNR	SNR	NN	I-NP	O	O
indicating	indicate	VBG	B-VP	O	O
neuronal	neuronal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
Nissl	Nissl	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
staining	stain	VBG	I-VP	O	O
visualized	visualize	VBN	I-VP	O	O
some	some	DT	B-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
distortion	distortion	NN	I-NP	O	O
.	.	.	O	O	O

Staining	Stain	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
proteins	protein	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patchy	patchy	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
forebrain	forebrain	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
6	6	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
vasogenic	vasogenic	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
covered	cover	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
lesioned	lesione	VBN	I-NP	O	B-Disease
SNR	SNR	NN	I-NP	O	I-Disease
.	.	.	O	O	O

By	By	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
glial	glial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
markers	marker	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
massive	massive	JJ	I-NP	O	O
lesion	lesion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
center	center	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
48	48	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
72	72	CD	I-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
astrocytes	astrocyte	NNS	B-NP	O	O
surrounding	surround	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
size	size	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
polymorphic	polymorphic	JJ	B-NP	O	O
phagocytotic	phagocytotic	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
invaded	invade	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
damaged	damage	VBN	I-NP	O	O
area	area	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
surviving	survive	VBG	B-VP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
conventional	conventional	JJ	B-NP	O	O
paraffin	paraffin	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
sections	section	NNS	I-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
neuronal	neuronal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
glial	glial	JJ	I-NP	O	O
damage	damage	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
SNR	SNR	NN	B-NP	O	I-Disease
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
pathology	pathology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
quality	quality	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
globus	globus	NN	I-NP	O	O
pallidus	pallidus	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
astrocytes	astrocyte	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
always	always	RB	I-VP	O	O
damaged	damage	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
parallel	parallel	NN	B-NP	O	O
with	with	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
proposed	propose	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
anatomical	anatomical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
interrelationship	interrelationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
astrocytes	astrocyte	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
tight	tight	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
SNR	SNR	NN	B-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
elements	element	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
suffer	suffer	VB	I-VP	O	O
in	in	IN	B-PP	O	O
common	common	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
disturbance	disturbance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neurotransmitter	neurotransmitter	NN	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
as	as	IN	B-PP	O	O
occur	occur	NN	B-NP	O	O
during	during	IN	B-PP	O	O
massive	massive	JJ	B-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
given	give	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
N	N	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
(	(	(	O	I	I-Chemical
2	2	CD	B-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxypropyl	hydroxypropyl	NN	I-NP	I	I-Chemical
)	)	)	O	I	I-Chemical
methacrylamide	methacrylamide	NN	B-NP	I	I-Chemical
conjugates	conjugate	NNS	I-NP	O	O
:	:	:	O	O	O
and	and	CC	O	O	O
experimental	experimental	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
acute	acute	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
late	late	JJ	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
given	give	VBN	B-VP	O	O
either	either	CC	O	O	O
as	as	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
N	N	NN	I-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
(	(	(	O	I	I-Chemical
2	2	CD	B-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxypropyl	hydroxypropyl	NN	I-NP	I	I-Chemical
)	)	)	O	I	I-Chemical
methacrylamide	methacrylamide	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
HPMA	HPMA	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
copolymer	copolymer	NN	B-NP	O	O
conjugates	conjugate	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
HPMA	HPMA	NN	I-NP	O	B-Chemical
copolymers	copolymer	NNS	I-NP	O	O
,	,	,	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
covalently	covalently	RB	I-VP	O	O
bound	bind	VBN	I-VP	O	O
via	via	IN	B-PP	O	O
peptide	peptide	NN	B-NP	O	O
linkages	linkage	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
either	either	CC	O	O	O
non	non	AFX	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
biodegradable	biodegradable	JJ	I-ADJP	O	O
(	(	(	O	O	O
Gly	Gly	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
Gly	Gly	NN	I-NP	I	O
)	)	)	O	O	O
or	or	CC	O	O	O
degradable	degradable	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
lysosomal	lysosomal	JJ	B-NP	O	O
proteinases	proteinas	NNS	I-NP	O	O
(	(	(	O	O	O
Gly	Gly	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
Phe	Phe	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
Leu	Leu	NN	I-NP	B	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
Gly	Gly	NN	I-NP	B	I-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
biodegradable	biodegradable	JJ	I-NP	O	O
conjugate	conjugate	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
galactosamine	galactosamine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
;	;	:	O	O	O
this	this	DT	B-NP	O	O
residue	residue	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
targeted	target	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Over	Over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
i.v.	i.v.	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
polymer	polymer	NN	I-NP	O	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
all	all	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
transient	transient	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
maximal	maximal	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
polymer	polymer	NN	B-NP	O	O
-	-	HYPH	O	O	O
bound	bind	VBN	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
free	free	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
mixture	mixture	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unmodified	unmodified	JJ	I-NP	O	O
parent	parent	NN	I-NP	O	O
HPMA	HPMA	NN	I-NP	O	B-Chemical
copolymer	copolymer	NN	I-NP	O	O
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Throughout	Throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
deaths	death	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
either	either	CC	O	O	O
free	free	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
mixture	mixture	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HPMA	HPMA	NN	B-NP	O	B-Chemical
copolymer	copolymer	NN	I-NP	O	O
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
;	;	:	O	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
histological	histological	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
marked	marked	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Sequential	Sequential	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
in	in	IN	B-PP	O	O
surviving	survive	VBG	B-VP	O	O
animals	animal	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
either	either	CC	O	O	O
free	free	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
mixture	mixture	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HPMA	HPMA	NN	B-NP	O	B-Chemical
copolymer	copolymer	NN	I-NP	O	O
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
30	30	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
function	function	NN	B-NP	O	O
beginning	begin	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4th	4th	JJ	I-NP	O	O
week	week	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
12	12	CD	I-NP	O	O
%	%	NN	I-NP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
measured	measure	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
age	age	NN	B-NP	O	O
-	-	HYPH	O	O	O
matched	match	VBN	B-NP	B	O
control	control	NN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
HPMA	HPMA	NN	I-NP	O	B-Chemical
copolymer	copolymer	NN	I-NP	O	O
conjugates	conjugate	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
exhibited	exhibit	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
histological	histological	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HPMA	HPMA	NN	B-NP	O	B-Chemical
copolymer	copolymer	NN	I-NP	O	O
conjugates	conjugate	NNS	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
beginning	begin	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
8	8	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-SBAR	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
400	400	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Topical	Topical	JJ	B-NP	O	O
0.025	0.025	CD	I-NP	O	O
%	%	NN	I-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
post	post	AFX	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
herpetic	herpetic	JJ	I-NP	O	I-Disease
neuralgia	neuralgia	NN	I-NP	O	I-Disease
:	:	:	O	O	O
efficacy	efficacy	NN	B-NP	O	O
,	,	,	O	O	O
predictors	predictor	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
and	and	CC	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
course	course	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
time	time	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
and	and	CC	I-NP	O	O
predictors	predictor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
topical	topical	JJ	B-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
39	39	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
post	post	AFX	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
herpetic	herpetic	JJ	I-NP	O	I-Disease
neuralgia	neuralgia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PHN	PHN	NN	B-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
median	median	JJ	B-NP	O	O
duration	duration	NN	I-NP	O	O
24	24	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
0.025	0.025	CD	B-NP	O	O
%	%	NN	I-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
cream	cream	NN	I-NP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
rated	rat	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	O
analogue	analogue	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
(	(	(	O	O	O
VAS	VAS	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
verbal	verbal	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
investigation	investigation	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
12	12	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-SBAR	O	O
study	study	NN	B-NP	O	O
onset	onset	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
improved	improve	VBN	I-VP	O	O
.	.	.	O	O	O

Nineteen	Nineteen	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
48.7	48.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
substantially	substantially	RB	B-VP	O	O
improved	improve	VBD	I-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
;	;	:	O	O	O
5	5	CD	B-NP	O	O
(	(	(	O	O	O
12.8	12.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
discontinued	discontinue	VBD	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
side	side	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
effects	effect	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
intolerable	intolerable	JJ	B-NP	O	O
capsaicin	capsaicin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
burning	burning	NN	I-NP	O	O
sensations	sensation	NNS	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
mastitis	mastitis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
15	15	CD	B-NP	O	O
(	(	(	O	O	O
38.5	38.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
reported	report	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
benefit	benefit	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
VAS	VAS	NN	B-NP	O	O
ratings	rating	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significant	significant	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
responders	responder	NNS	I-NP	O	O
72.2	72.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
still	still	RB	I-VP	O	O
improved	improve	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
;	;	:	O	O	O
only	only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	I-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
continued	continue	VBN	I-VP	O	O
application	application	NN	B-NP	O	O
irregularly	irregularly	RB	B-ADVP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
dependent	dependent	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
's	's	POS	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
duration	duration	NN	B-NP	O	O
or	or	CC	O	O	O
localization	localization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PHN	PHN	NN	B-NP	O	B-Disease
(	(	(	O	O	O
trigeminal	trigeminal	JJ	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
excluded	exclude	VBN	I-VP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
sensory	sensory	JJ	B-NP	O	B-Disease
disturbance	disturbance	NN	I-NP	O	I-Disease
or	or	CC	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
character	character	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
,	,	,	O	O	O
time	time	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
course	course	NN	I-NP	O	O
or	or	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
capsaicin	capsaicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
burning	burning	NN	I-NP	O	O
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
confirmed	confirm	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
controlled	controlled	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
,	,	,	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
randomized	randomize	VBN	B-NP	O	O
study	study	NN	I-NP	O	O
might	might	MD	B-VP	O	O
indicate	indicate	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
capsaicin	capsaicin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
PHN	PHN	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
both	both	CC	O	O	O
interference	interference	NN	B-NP	O	O
with	with	IN	B-PP	O	O
neuropeptide	neuropeptide	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
and	and	CC	O	O	O
morphological	morphological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
(	(	(	O	O	O
perhaps	perhaps	RB	B-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
nociceptive	nociceptive	JJ	B-NP	O	O
afferents	afferent	NNS	I-NP	O	O
.	.	.	O	O	O

Serotonin	Serotonin	NN	B-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
paranoia	paranoia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
ventral	ventral	JJ	I-NP	O	O
basal	basal	JJ	I-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
.	.	.	O	O	O

Antidepressants	Antidepressant	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
paranoid	paranoid	JJ	B-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
psychiatric	psychiatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
paranoid	paranoid	JJ	B-NP	O	B-Disease
exacerbation	exacerbation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
amitriptyline	amitriptyline	NN	I-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
here	here	RB	B-ADVP	O	O
.	.	.	O	O	O

Elements	Element	NNS	B-NP	O	O
common	common	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paranoid	paranoid	JJ	B-NP	O	B-Disease
symptomatology	symptomatology	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
depressive	depressive	JJ	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
psychotic	psychotic	JJ	I-NP	O	I-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Complicated	Complicate	VBN	B-NP	O	O
depressive	depressive	JJ	I-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
atypicality	atypicality	NN	B-NP	O	O
of	of	IN	B-PP	O	O
course	course	NN	B-NP	O	O
and	and	CC	I-NP	O	O
symptomatology	symptomatology	NN	I-NP	O	O
,	,	,	O	O	O
chronicity	chronicity	NN	B-NP	O	O
,	,	,	O	O	O
psychosis	psychosis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
bipolarity	bipolarity	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
secondary	secondary	JJ	B-NP	O	O
onset	onset	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
psychosis	psychosis	NN	I-NP	O	B-Disease
)	)	)	O	O	O
may	may	MD	B-VP	O	O
present	present	VB	I-VP	O	O
particular	particular	JJ	B-NP	O	O
vulnerability	vulnerability	NN	I-NP	O	O
to	to	TO	B-PP	O	O
paranoid	paranoid	JJ	B-NP	O	B-Disease
exacerbations	exacerbation	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacology	pharmacology	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neurobiology	neurobiology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paranoia	paranoia	NN	B-NP	O	B-Disease
remain	remain	VBP	B-VP	O	O
cryptic	cryptic	JJ	B-ADJP	O	O
,	,	,	O	O	O
several	several	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
5HT3	5HT3	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
release	release	NN	I-NP	O	O
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
downregulation	downregulation	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
GABAB	GABAB	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
upregulation	upregulation	NN	I-NP	O	O
acting	act	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vicinity	vicinity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ventral	ventral	JJ	I-NP	O	O
basal	basal	JJ	I-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
(	(	(	O	O	O
possibly	possibly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
lateral	lateral	JJ	B-NP	O	O
orbitofrontal	orbitofrontal	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
anterior	anterior	JJ	I-NP	O	O
cingulate	cingulate	JJ	I-NP	O	O
circuits	circuit	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
might	might	MD	B-VP	O	O
apply	apply	VB	I-VP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
call	call	VBP	B-VP	O	O
attention	attention	NN	B-NP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
paranoid	paranoid	JJ	I-NP	O	B-Disease
exacerbations	exacerbation	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
select	select	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
raise	raise	VB	B-VP	O	O
neurobiological	neurobiological	JJ	B-NP	O	O
considerations	consideration	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
paranoia	paranoia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
encephalitis	encephalitis	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
loiasis	loiasis	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
diethylcarbamazine	diethylcarbamazine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
encephalitis	encephalitis	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
diethylcarbamazine	diethylcarbamazine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DEC	DEC	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Congolese	Congolese	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Loa	Loa	NN	B-NP	O	O
loa	loa	NN	I-NP	O	O
filariasis	filariasis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
fatal	fatal	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
sequelae	sequela	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
notable	notable	JJ	I-NP	O	O
fact	fact	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
hospitalized	hospitalize	VBN	B-VP	O	O
before	before	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
began	begin	VBD	B-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
particularly	particularly	RB	B-ADVP	O	O
strict	strict	VBP	B-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
precautions	precaution	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
,	,	,	O	O	O
i.e.	i.e.	FW	O	O	O
,	,	,	O	O	O
initial	initial	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DEC	DEC	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
very	very	RB	B-NP	O	O
gradual	gradual	JJ	I-NP	B	O
dose	dose	NN	I-NP	O	O
increases	increase	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
associated	associate	VBN	B-VP	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	B-NP	O	O
allergic	allergic	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
complication	complication	NN	I-NP	O	O
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
that	that	RB	B-ADJP	O	O
uncommon	uncommon	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
highly	highly	RB	B-NP	O	O
endemic	endemic	JJ	I-NP	O	O
regions	region	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
primarily	primarily	RB	B-ADVP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	B-ADVP	O	O
exclusively	exclusively	RB	I-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
presenting	present	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
microfilarial	microfilarial	JJ	I-NP	O	O
load	load	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
encephalitis	encephalitis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
microfilaremia	microfilaremia	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pathophysiological	pathophysiological	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
light	light	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
observations	observation	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
other	other	JJ	I-NP	O	O
comments	comment	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
this	this	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
published	publish	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

Delirium	Delirium	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
possibly	possibly	RB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Misoprostol	Misoprostol	NNP	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
gastrointestinal	gastrointestinal	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
gynecologic	gynecologic	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
headache	headache	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
an	an	DT	B-NP	O	O
89	89	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
care	care	NN	I-NP	O	O
facility	facility	NN	I-NP	O	O
became	become	VBD	B-VP	O	O
confused	confuse	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
first	first	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
nine	nine	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
significantly	significantly	RB	B-VP	O	O
improved	improve	VBD	I-VP	O	O
after	after	IN	B-SBAR	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
her	her	PRP$	B-NP	O	O
mental	mental	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
within	within	IN	B-PP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
no	no	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
factors	factor	NNS	I-NP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
changed	change	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
experienced	experience	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
possibly	possibly	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Hepatocellular	Hepatocellular	JJ	B-NP	O	O
oxidant	oxidant	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
reperfusion	reperfusion	NN	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Reperfusion	Reperfusion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
intestine	intestine	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
release	release	NN	I-NP	O	O
into	into	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
,	,	,	O	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
bile	bile	NN	B-NP	O	O
flow	flow	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
neutrophil	neutrophil	NN	B-NP	O	O
sequestration	sequestration	NN	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pathophysiology	pathophysiology	NN	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
oxidants	oxidant	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
indirect	indirect	JJ	I-NP	O	O
methods	method	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
assessing	assess	VBG	B-VP	O	O
oxidant	oxidant	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
subjected	subject	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
standardized	standardized	JJ	I-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
reperfusion	reperfusion	NN	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Hepatic	Hepatic	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assayed	assay	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
peroxidation	peroxidation	NN	I-NP	O	O
products	product	NNS	I-NP	O	O
and	and	CC	O	O	O
oxidized	oxidize	VBN	B-VP	O	B-Chemical
and	and	CC	O	O	I-Chemical
reduced	reduce	VBN	B-NP	O	I-Chemical
glutathione	glutathione	NN	I-NP	B	I-Chemical
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
glutathione	glutathione	NN	I-NP	B	B-Chemical
following	follow	VBG	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
reperfusion	reperfusion	NN	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Oxidized	Oxidize	VBN	B-NP	O	B-Chemical
glutathione	glutathione	NN	I-NP	B	I-Chemical
(	(	(	O	O	O
GSSG	GSSG	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
following	follow	VBG	I-VP	O	O
30	30	CD	B-NP	O	O
and	and	CC	I-NP	O	O
60	60	CD	I-NP	O	O
min	min	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reperfusion	reperfusion	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
products	product	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
peroxidation	peroxidation	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
injury	injury	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GSSG	GSSG	NN	B-NP	B	B-Chemical
within	within	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
during	during	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
reperfusion	reperfusion	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
exposure	exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatocytes	hepatocyte	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
oxidant	oxidant	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
products	product	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
peroxidation	peroxidation	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
oxidant	oxidant	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
insufficient	insufficient	JJ	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
to	to	TO	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
irreversible	irreversible	JJ	B-NP	O	O
injury	injury	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hepatocyte	hepatocyte	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
membranes	membrane	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tissue	tissue	NN	B-NP	O	O
GSSG	GSSG	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
indicator	indicator	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidant	oxidant	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
than	than	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
products	product	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
peroxidation	peroxidation	NN	I-NP	O	O
.	.	.	O	O	O

Diphenhydramine	Diphenhydramine	NN	B-NP	B	B-Chemical
prevents	prevent	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
haemodynamic	haemodynamic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
ICU	ICU	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Cimetidine	Cimetidine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
histamine	histamine	NN	I-NP	B	B-Chemical
2	2	CD	I-NP	O	O
(	(	(	O	O	O
H2	H2	NN	B-NP	B	O
)	)	)	O	O	O
antagonist	antagonist	NN	B-NP	O	O
,	,	,	O	O	O
produces	produce	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
vasodilatation	vasodilatation	NN	B-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
critically	critically	RB	B-NP	O	O
ill	ill	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
because	because	IN	B-SBAR	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
acts	act	VBZ	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
histamine	histamine	NN	I-NP	B	B-Chemical
agonist	agonist	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
histamine	histamine	NN	I-NP	B	B-Chemical
1	1	CD	I-NP	O	O
(	(	(	O	O	O
H1	H1	NN	B-NP	O	O
)	)	)	O	O	O
receptor	receptor	NN	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
diphenhydramine	diphenhydramine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
haemodynamic	haemodynamic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
ICU	ICU	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
two	two	CD	B-NP	O	O
separate	separate	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
random	random	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
received	receive	VBD	B-VP	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
iv	iv	NN	I-NP	O	O
on	on	IN	B-PP	O	O
one	one	CD	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
pretreatment	pretreatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diphenhydramine	diphenhydramine	NN	B-NP	B	B-Chemical
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
iv	iv	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
iv	iv	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
pretreatment	pretreatment	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
MAP	MAP	NN	B-NP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
107.4	107.4	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8.4	8.4	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
86.7	86.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
11.4	11.4	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
two	two	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
(	(	(	O	O	O
SVR	SVR	NN	B-NP	B	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
eight	eight	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
minute	minute	NN	I-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pretreatment	pretreatment	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
little	little	JJ	B-NP	O	O
haemodynamic	haemodynamic	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
H1	H1	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
iv	iv	NN	B-NP	O	O
cimetidine	cimetidine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
vasodilating	vasodilate	VBG	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cimetidine	cimetidine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
,	,	,	O	O	O
through	through	IN	B-PP	O	O
the	the	DT	B-NP	O	O
H1	H1	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
23	23	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
bacteriologically	bacteriologically	RB	B-NP	O	O
proven	prove	VBN	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	B-Disease
tuberculosis	tuberculosis	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
various	various	JJ	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antituberculosis	antituberculosis	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
nearly	nearly	RB	B-NP	O	O
15	15	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Rifampicin	Rifampicin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
thrice	thrice	NN	B-NP	O	O
as	as	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
drug	drug	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
and	and	CC	O	O	O
each	each	DT	B-NP	O	O
time	time	NN	I-NP	O	O
he	he	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
untoward	untoward	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
like	like	IN	B-PP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
vomiting	vomiting	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
fever	fever	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
chills	chill	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
rigors	rigor	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
such	such	JJ	I-NP	O	O
episode	episode	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
failure	failure	NN	I-NP	O	O
at	at	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
stage	stage	NN	B-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
made	make	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
full	full	JJ	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
polyneuropathy	polyneuropathy	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
motor	motor	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
after	after	IN	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
thiotepa	thiotepa	NN	I-NP	B	B-Chemical
combination	combination	NN	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
:	:	:	O	O	O
description	description	NN	B-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
neurologic	neurologic	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intrathecal	intrathecal	JJ	O	O	O
(	(	(	O	O	O
IT	IT	JJ	B-ADJP	O	O
)	)	)	O	O	O
combination	combination	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
thiotepa	thiotepa	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
TSPA	TSPA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
presented	present	VBN	I-VP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
axonal	axonal	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
predominance	predominance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
extremities	extremity	NNS	I-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
6	6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
IT	IT	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

Neurologic	Neurologic	JJ	B-NP	O	B-Disease
toxicities	toxicity	NNS	I-NP	O	I-Disease
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
IT	IT	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
IT	IT	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
cytosine	cytosine	NN	I-NP	B	B-Chemical
arabinoside	arabinoside	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
IT	IT	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
TSPA	TSPA	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

To	To	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
axonal	axonal	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
three	three	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
spite	spite	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fact	fact	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
TSPA	TSPA	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
IT	IT	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
combination	combination	NN	I-NP	O	O
with	with	IN	B-PP	O	O
MTX	MTX	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
ara	ara	AFX	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
C	C	NN	I-NP	O	I-Chemical
and	and	CC	I-NP	O	O
radiotherapy	radiotherapy	NN	I-NP	O	O
could	could	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
unexpected	unexpected	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
research	research	NN	I-NP	O	O
on	on	IN	B-PP	O	O
IT	IT	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
TSPA	TSPA	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cromakalim	cromakalim	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pinacidil	pinacidil	NN	I-NP	B	B-Chemical
on	on	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
epicardial	epicardial	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
small	small	JJ	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
i.v.	i.v.	JJ	B-NP	O	O
bolus	bolus	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cromakalim	cromakalim	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	O	O	O
10	10	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
pinacidil	pinacidil	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
100	100	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
(	(	(	I-NP	O	O
circumflex	circumflex	NN	I-NP	O	O
artery	artery	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
small	small	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
hemodynamics	hemodynamic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
chronically	chronically	RB	B-NP	O	O
instrumented	instrument	VBN	I-NP	O	O
conscious	conscious	JJ	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
and	and	CC	O	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.03	0.03	CD	B-NP	O	O
-	-	HYPH	O	O	O
10	10	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Nitroglycerin	Nitroglycerin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
0.3	0.3	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
selectively	selectively	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
circumflex	circumflex	NN	B-NP	O	O
artery	artery	NN	I-NP	O	O
diameter	diameter	NN	I-NP	O	O
(	(	(	O	O	O
CxAD	CxAD	NN	B-NP	O	O
)	)	)	O	O	O
without	without	IN	B-PP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
affecting	affect	VBG	B-VP	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
parameter	parameter	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
cromakalim	cromakalim	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pinacidil	pinacidil	NN	I-NP	B	B-Chemical
at	at	IN	B-PP	O	O
all	all	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
nitroglycerin	nitroglycerin	NN	I-NP	B	B-Chemical
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.3	0.3	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
and	and	CC	O	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
dependently	dependently	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
CxAD	CxAD	NN	I-NP	O	O
,	,	,	O	O	O
coronary	coronary	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
coronary	coronary	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
and	and	CC	O	O	O
aortic	aortic	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Cromakalim	Cromakalim	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
approximately	approximately	RB	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
to	to	TO	B-PP	O	O
9.5	9.5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
pinacidil	pinacidil	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
CxAD	CxAD	NN	B-NP	O	O
.	.	.	O	O	O

Vasodilation	Vasodilation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
small	small	JJ	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
vessels	vessel	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cromakalim	cromakalim	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pinacidil	pinacidil	NN	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
combined	combined	JJ	I-NP	O	O
beta	beta	NN	I-NP	O	B-Chemical
adrenergic	adrenergic	JJ	I-NP	O	I-Chemical
and	and	CC	I-NP	O	I-Chemical
muscarinic	muscarinic	JJ	I-NP	O	I-Chemical
receptors	receptor	NNS	I-NP	O	I-Chemical
blockade	blockade	NN	I-NP	O	I-Chemical
but	but	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
abolished	abolish	VBN	I-VP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
circumflex	circumflex	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
constant	constant	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
CxAD	CxAD	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cromakalim	cromakalim	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
pinacidil	pinacidil	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
68	68	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
7	7	CD	I-NP	O	O
,	,	,	I-NP	O	O
54	54	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-ADJP	O	O
9	9	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1	1	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B	B-Chemical
preferentially	preferentially	RB	B-ADVP	O	O
and	and	CC	O	O	O
flow	flow	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
independently	independently	RB	B-ADVP	O	O
dilates	dilate	VBZ	B-VP	O	O
large	large	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
,	,	,	O	O	O
cromakalim	cromakalim	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pinacidil	pinacidil	NN	I-NP	B	B-Chemical
dilate	dilate	VBP	B-VP	O	O
both	both	CC	O	O	O
large	large	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
small	small	JJ	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
arteries	artery	NNS	I-NP	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
dependent	dependent	JJ	B-ADJP	O	O
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
beta	beta	NN	I-NP	O	O
adrenoceptors	adrenoceptor	NNS	I-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
rise	rise	NN	I-NP	O	O
in	in	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
demand	demand	NN	I-NP	O	O
.	.	.	O	O	O

Finally	Finally	RB	B-ADVP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
,	,	,	O	O	O
direct	direct	JJ	B-NP	O	O
vasodilation	vasodilation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
flow	flow	NN	I-NP	O	O
dependency	dependency	NN	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cromakalim	cromakalim	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
pinacidil	pinacidil	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
CxAD	CxAD	NN	B-NP	O	O
.	.	.	O	O	O

Mefenamic	Mefenamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
females	female	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypothyroidism	hypothyroidism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
mefenamic	mefenamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-VP	O	O
non	non	AFX	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
oliguric	oliguric	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
occurring	occur	VBG	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
elderly	elderly	JJ	I-NP	O	O
females	female	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
maturation	maturation	NN	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myeloid	myeloid	JJ	I-NP	O	O
series	series	NN	I-NP	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
hypothyroid	hypothyroid	JJ	B-ADJP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
clear	clear	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
predisposing	predispose	VBG	I-NP	O	O
factor	factor	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
would	would	MD	B-VP	O	O
seem	seem	VB	I-VP	O	O
prudent	prudent	JJ	B-ADJP	O	O
not	not	RB	O	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
mefenamic	mefenamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
hypothyroid	hypothyroid	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
until	until	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypothyroidism	hypothyroidism	NN	I-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
corrected	correct	VBN	I-VP	O	O
.	.	.	O	O	O

Etiology	Etiology	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
hemodialysis	hemodialysis	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
carbonate	carbonate	NN	I-NP	I	I-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Fourteen	Fourteen	CD	B-NP	O	O
of	of	IN	B-PP	O	O
39	39	CD	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
became	become	VBD	B-VP	O	O
hypercalcemic	hypercalcemic	JJ	B-ADJP	O	B-Disease
after	after	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
carbonate	carbonate	NN	I-NP	I	I-Chemical
as	as	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
principal	principal	JJ	I-NP	O	O
phosphate	phosphate	NN	I-NP	B	B-Chemical
binder	binder	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
indirect	indirect	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
reabsorption	reabsorption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
bone	bone	NN	I-NP	O	O
turnover	turnover	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
14	14	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
results	result	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
eucalcemic	eucalcemic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
matched	match	VBN	B-VP	B	O
for	for	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	O	O
,	,	,	O	O	O
length	length	NN	B-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
on	on	IN	B-PP	O	O
dialysis	dialysis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
etiology	etiology	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
experiencing	experience	VBG	B-VP	O	O
hypercalcemic	hypercalcemic	JJ	B-NP	O	B-Disease
episodes	episode	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
peak	peak	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
2.7	2.7	CD	B-NP	O	O
to	to	TO	I-NP	O	O
3.8	3.8	CD	I-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
(	(	(	O	O	O
10.7	10.7	CD	B-NP	O	O
to	to	TO	O	O	O
15.0	15.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypercalcemic	hypercalcemic	JJ	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
before	before	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
switch	switch	NN	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
7	7	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
observation	observation	NN	B-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
switch	switch	NN	I-NP	O	O
(	(	(	O	O	O
2.4	2.4	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.03	0.03	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.03	0.03	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
[	[	(	O	O	O
9.7	9.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.2	0.2	CD	B-NP	O	O
to	to	TO	B-PP	O	O
10.2	10.2	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.1	0.1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.006	0.006	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
eucalcemic	eucalcemic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
values	value	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
period	period	NN	I-NP	O	O
(	(	(	O	O	O
2.3	2.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.3	2.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
mmol	mmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
[	[	(	O	O	O
9.2	9.2	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.2	0.2	CD	B-NP	O	O
to	to	TO	B-PP	O	O
9.2	9.2	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.2	0.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CaCO3	CaCO3	NN	B-NP	B	B-Chemical
dosage	dosage	NN	I-NP	O	O
,	,	,	O	O	O
calculated	calculate	VBN	B-VP	O	O
dietary	dietary	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
intake	intake	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
circulating	circulate	VBG	B-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
D	D	NN	I-NP	I	I-Chemical
metabolites	metabolite	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Physical	Physical	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
index	index	NN	I-NP	O	O
and	and	CC	O	O	O
predialysis	predialysis	NN	B-NP	O	O
serum	serum	NN	I-NP	O	O
bicarbonate	bicarbonate	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
parameters	parameter	NNS	B-NP	O	O
reflecting	reflect	VBG	B-VP	O	O
bone	bone	NN	B-NP	O	O
turnover	turnover	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
groups.	groups.	NN	B-NP	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Methyldopa	Methyldopa	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
year	year	NN	I-NP	O	O
old	old	JJ	I-NP	O	O
presenting	presenting	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
near	near	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
syncope	syncope	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Methyldopa	Methyldopa	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
available	available	JJ	B-ADJP	O	O
generically	generically	RB	B-ADVP	O	O
and	and	CC	O	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
trade	trade	NN	I-NP	O	O
name	name	NN	I-NP	O	O
Aldomet	Aldomet	NN	I-NP	B	B-Chemical
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
widely	widely	RB	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adult	adult	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
and	and	CC	O	O	O
infrequently	infrequently	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
.	.	.	O	O	O

Methyldopa	Methyldopa	NN	B-NP	B	B-Chemical
causes	cause	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
autoimmune	autoimmune	JJ	I-NP	O	B-Disease
hemolytic	hemolytic	JJ	I-NP	O	I-Disease
anemia	anemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
take	take	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methyldopa	methyldopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
boy	boy	NN	I-NP	O	O
who	who	WP	B-NP	O	O
presented	present	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	B-Disease
department	department	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
near	near	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
syncope	syncope	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
boy	boy	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
methyldopa	methyldopa	NN	I-NP	B	B-Chemical
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
trauma	trauma	NN	I-NP	O	B-Disease
admission	admission	NN	I-NP	O	O
seven	seven	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
presentation	presentation	NN	B-NP	O	O
.	.	.	O	O	O

Evaluation	Evaluation	NN	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
hemoglobin	hemoglobin	NN	I-NP	B	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
grams	gram	NNS	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
Coombs	Coombs	NNP	I-NP	O	O
'	'	POS	B-NP	O	O
test	test	NN	I-NP	O	O
with	with	IN	B-PP	O	O
polyspecific	polyspecific	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
human	human	JJ	I-NP	O	O
globulin	globulin	NN	I-NP	O	O
and	and	CC	I-NP	O	O
monospecific	monospecific	JJ	I-NP	O	O
IgG	IgG	NN	I-NP	O	O
reagents	reagent	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
warm	warm	JJ	I-NP	O	O
reacting	react	VBG	I-NP	O	O
autoantibody	autoantibody	NN	I-NP	O	O
.	.	.	O	O	O

Transfusion	Transfusion	NN	B-NP	O	O
and	and	CC	I-NP	O	O
corticosteroid	corticosteroid	NN	I-NP	O	B-Chemical
therapy	therapy	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

Emergency	Emergency	NN	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
treating	treat	VBG	B-VP	O	O
children	child	NNS	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
diagnose	diagnose	VB	I-VP	O	O
and	and	CC	I-VP	O	O
treat	treat	VB	I-VP	O	O
it	it	PRP	B-NP	O	O
correctly	correctly	RB	B-ADVP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
brief	brief	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
autoimmune	autoimmune	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemias	anemia	NNS	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
provided	provide	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
danazol	danazol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hereditary	hereditary	JJ	B-NP	O	B-Disease
angioedema	angioedema	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
safety	safety	NN	I-NP	O	O
(	(	(	O	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
or	or	CC	O	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
danazol	danazol	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
established	establish	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
settings	setting	NNS	B-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
information	information	NN	I-NP	O	O
exists	exist	VBZ	B-VP	O	O
as	as	IN	B-SBAR	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
safety	safety	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
therefore	therefore	RB	B-ADVP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
danazol	danazol	NN	B-NP	B	B-Chemical
by	by	IN	B-PP	O	O
performing	perform	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
chart	chart	NN	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hereditary	hereditary	JJ	B-NP	O	B-Disease
angioedema	angioedema	NN	I-NP	O	I-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
danazol	danazol	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
or	or	CC	O	O	O
longer	long	JJR	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
35.2	35.2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
59.7	59.7	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Virtually	Virtually	RB	B-ADVP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Menstrual	Menstrual	JJ	B-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
79	79	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
weight	weight	NN	B-NP	O	B-Disease
gain	gain	NN	I-NP	O	I-Disease
(	(	(	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
muscle	muscle	NN	B-NP	O	B-Disease
cramps	cramp	NNS	I-NP	O	I-Disease
/	/	SYM	O	O	O
myalgias	myalgia	NNS	B-NP	O	B-Disease
(	(	(	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
transaminase	transaminase	NN	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
(	(	(	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
8	8	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
died	die	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
suffered	suffer	VBN	I-VP	O	O
any	any	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
sequelae	sequela	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
directly	directly	RB	B-ADJP	O	O
attributable	attributable	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
a	a	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
,	,	,	O	O	O
danazol	danazol	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
proven	prove	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
remarkably	remarkably	RB	B-ADJP	O	O
safe	safe	JJ	I-ADJP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Patient	Patient	NN	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
chlorhexidine	chlorhexidine	NN	I-NP	B	B-Chemical
diphosphanilate	diphosphanilate	NN	I-NP	I	I-Chemical
:	:	:	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
topical	topical	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
burns	burn	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

Effective	Effective	JJ	B-NP	O	O
topical	topical	JJ	I-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
decrease	decrease	VBP	B-VP	O	O
infection	infection	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
in	in	IN	B-PP	O	O
burn	burn	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Chlorhexidine	Chlorhexidine	NN	B-NP	B	B-Chemical
phosphanilate	phosphanilate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
CHP	CHP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
broad	broad	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
spectrum	spectrum	NN	I-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
topical	topical	JJ	I-NP	O	O
burn	burn	NN	I-NP	O	B-Disease
wound	wound	NN	I-NP	O	O
dressing	dress	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
cream	cream	NN	B-NP	O	O
form	form	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
preliminary	preliminary	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
painful	painful	JJ	B-ADJP	O	O
upon	upon	IN	B-PP	O	O
application	application	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
compared	compare	VBD	B-VP	O	O
various	various	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CHP	CHP	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
tolerable	tolerable	JJ	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
identified	identify	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
retention	retention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
antimicrobial	antimicrobial	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nine	nine	CD	I-NP	O	O
burn	burn	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
each	each	DT	B-NP	O	O
with	with	IN	B-PP	O	O
two	two	CD	B-NP	O	O
similar	similar	JJ	I-NP	O	O
burns	burn	NNS	I-NP	O	B-Disease
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
separately	separately	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
pairs	pair	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
treatments	treatment	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
successive	successive	JJ	B-NP	O	O
12	12	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
h	h	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
burn	burn	NN	I-NP	O	B-Disease
site	site	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
each	each	DT	B-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
CHP	CHP	NN	I-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
to	to	TO	B-PP	O	O
2	2	CD	B-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
silver	silver	NN	I-NP	B	B-Chemical
sulphadiazine	sulphadiazine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
AgSD	AgSD	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
cream	cream	NN	B-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
frequently	frequently	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
burn	burn	NN	B-NP	O	B-Disease
wounds	wound	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
site	site	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
always	always	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
AgSD	AgSD	NN	B-NP	O	B-Chemical
cream	cream	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
CHP	CHP	NN	B-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
ratings	rating	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pain	pain	NN	B-NP	O	B-Disease
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
analogue	analogue	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
0.25	0.25	CD	I-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
CHP	CHP	NN	I-NP	B	B-Chemical
cream	cream	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
closest	closest	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
AgSD	AgSD	NN	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
pain	pain	NN	B-NP	O	B-Disease
tolerance	tolerance	NN	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
differed	differ	VBD	B-VP	O	O
statistically	statistically	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
AgSD	AgSD	NN	B-NP	O	B-Chemical
or	or	CC	B-PP	O	O
from	from	IN	B-PP	O	O
each	each	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
ease	ease	NN	B-NP	O	O
of	of	IN	B-PP	O	O
application	application	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CHP	CHP	NN	B-NP	B	B-Chemical
creams	cream	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
less	less	RBR	B-ADJP	O	O
satisfactory	satisfactory	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
AgSD	AgSD	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
formulations	formulation	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
or	or	CC	I-PP	O	O
below	below	IN	I-PP	O	O
0.5	0.5	CD	B-NP	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
CHP	CHP	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
prove	prove	VB	I-VP	O	O
acceptable	acceptable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
wound	wound	NN	B-NP	O	O
care	care	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
system	system	NN	I-NP	O	O
needs	need	VBZ	B-VP	O	O
pharmaceutical	pharmaceutical	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
to	to	TO	B-VP	O	O
render	render	VB	I-VP	O	O
it	it	PRP	B-NP	O	O
more	more	RBR	B-ADJP	O	O
tolerable	tolerable	JJ	I-ADJP	O	O
and	and	CC	O	O	O
easier	easy	JJR	B-ADJP	O	O
to	to	TO	B-VP	O	O
use	use	VB	I-VP	O	O
.	.	.	O	O	O

Dose	Dose	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Busulfan	Busulfan	NNP	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
neurotoxic	neurotoxic	JJ	B-ADJP	O	B-Disease
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
humans	human	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
its	its	PRP$	B-NP	O	O
acute	acute	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
remains	remain	VBZ	B-VP	O	O
poorly	poorly	RB	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
here	here	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
123	123	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
(	(	(	O	O	O
median	median	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
6.5	6.5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
before	before	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
malignant	malignant	JJ	B-NP	O	O
solid	solid	JJ	I-NP	O	O
tumors	tumor	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
brain	brain	NN	B-NP	O	B-Disease
tumors	tumor	NNS	I-NP	O	I-Disease
excluded	exclude	VBD	B-VP	O	O
.	.	.	O	O	O

Busulfan	Busulfan	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
p.o.	p.o.	FW	B-NP	O	O
,	,	,	O	O	O
every	every	DT	B-NP	O	O
6	6	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
16	16	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
total	total	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
consecutively	consecutively	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
:	:	:	O	O	O
16	16	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
then	then	RB	O	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
calculation	calculation	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
children	child	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
16	16	CD	B-NP	O	O
to	to	TO	I-NP	O	O
28	28	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Ninety	Ninety	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
six	six	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
given	give	VBN	I-VP	O	O
anticonvulsive	anticonvulsive	JJ	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
;	;	:	O	O	O
7	7	CD	B-NP	O	O
(	(	(	O	O	O
7.5	7.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
developed	develop	VBD	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4	4	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
course	course	NN	I-NP	O	O
or	or	CC	B-PP	O	O
within	within	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
account	account	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
among	among	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
16	16	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
of	of	IN	B-PP	O	O
57	57	CD	B-NP	O	O
,	,	,	O	O	O
1.7	1.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	B-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
of	of	IN	B-PP	O	O
39	39	CD	B-NP	O	O
,	,	,	O	O	O
15.4	15.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.02	0.02	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
seven	seven	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
600	600	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
m2	m2	NN	I-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
total	total	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
with	with	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
i.v.	i.v.	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
none	none	NN	B-NP	O	O
had	have	VBD	B-VP	O	O
any	any	DT	B-NP	O	O
neurological	neurological	JJ	I-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Busulfan	Busulfan	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
gas	gas	NN	I-NP	O	O
chromatographic	chromatographic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
mass	mass	NN	I-NP	O	O
spectrometry	spectrometry	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
of	of	IN	B-PP	O	O
9	9	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
under	under	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
with	with	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
busulfan	busulfan	NN	B-NP	B	B-Chemical
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
:	:	:	O	O	O
plasma	plasma	NN	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
1.39	1.39	CD	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.02	0.02	CD	B-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
:	:	:	O	O	O
plasma	plasma	NN	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
previously	previously	RB	B-VP	O	O
defined	define	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
16	16	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
busulfan	busulfan	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
shows	show	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
busulfan	busulfan	NN	B-NP	B	B-Chemical
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	O	O	O
dependent	dependent	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
and	and	CC	O	O	O
efficiently	efficiently	RB	B-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
busulfan	busulfan	JJ	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
calculated	calculate	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
children	child	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
close	close	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
neurotoxicity	neurotoxicity	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
plasma	plasma	NN	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
faster	fast	JJR	I-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
may	may	MD	B-VP	O	O
approximate	approximate	VB	I-VP	O	O
more	more	RBR	B-ADVP	O	O
closely	closely	RB	I-ADVP	O	O
the	the	DT	B-NP	O	O
adult	adult	JJ	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
usual	usual	JJ	I-NP	O	O
16	16	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
inferences	inference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
anticancer	anticancer	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
myeloablative	myeloablative	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
busulfan	busulfan	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
infants	infant	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reconsidered	reconsider	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pharmacokinetic	pharmacokinetic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Histamine	Histamine	NN	B-NP	B	B-Chemical
antagonists	antagonist	NNS	I-NP	O	O
and	and	CC	O	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
tubocurarine	tubocurarine	NN	I-NP	I	I-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Hemodynamic	Hemodynamic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
histamine	histamine	NN	B-NP	B	B-Chemical
release	release	NN	I-NP	O	O
by	by	IN	B-PP	O	O
bolus	bolus	NN	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.35	0.35	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
tubocurarine	tubocurarine	NN	I-NP	I	I-Chemical
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

H1	H1	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
H2	H2	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
histamine	histamine	NN	I-NP	B	B-Chemical
antagonists	antagonist	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
with	with	IN	B-PP	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
tubocurarine	tubocurarine	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
fashion	fashion	NN	I-NP	O	O
to	to	TO	B-PP	O	O
four	four	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
group	group	NN	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	HYPH	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
;	;	:	O	O	O
group	group	NN	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	HYPH	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
plus	plus	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
;	;	:	O	O	O
group	group	NN	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	HYPH	I-NP	O	O
chlorpheniramine	chlorpheniramine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
0.1	0.1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
plus	plus	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
group	group	NN	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	HYPH	I-NP	O	O
cimetidine	cimetidine	NN	I-NP	B	B-Chemical
plus	plus	CC	I-NP	O	O
chlorpheniramine	chlorpheniramine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Histamine	Histamine	NN	B-NP	B	B-Chemical
release	release	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
level	level	NN	I-NP	O	O
2	2	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
tubocurarine	tubocurarine	NN	I-NP	I	I-Chemical
dosing	dosing	NN	I-NP	O	O
.	.	.	O	O	O

Group	Group	NN	B-NP	O	O
1	1	CD	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
negative	negative	JJ	I-NP	O	O
correlation	correlation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
histamine	histamine	NN	I-NP	B	B-Chemical
change	change	NN	I-NP	O	O
and	and	CC	O	O	O
systemic	systemic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
(	(	(	O	O	O
r	r	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.58	0.58	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
not	not	RB	O	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
group	group	NN	B-NP	O	O
4	4	CD	I-NP	O	O
.	.	.	O	O	O

Prior	Prior	JJ	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antagonists	antagonist	NNS	B-NP	O	O
partially	partially	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
tubocurarine	tubocurarine	NN	I-NP	I	I-Chemical
dosing	dosing	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
only	only	RB	I-VP	O	O
partially	partially	RB	I-VP	O	O
explained	explain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
histamine	histamine	NN	B-NP	B	B-Chemical
release	release	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-NP	O	O
prior	prior	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
with	with	IN	B-PP	O	O
H1	H1	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
H2	H2	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
provides	provide	VBZ	B-VP	O	O
only	only	RB	B-NP	O	O
partial	partial	JJ	I-NP	O	O
protection	protection	NN	I-NP	O	O
.	.	.	O	O	O

Convulsant	Convulsant	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
regional	regional	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Lindane	Lindane	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
gamma	gamma	SYM	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
organochlorine	organochlorine	NN	I-NP	O	O
insecticide	insecticide	NN	I-NP	O	O
with	with	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Its	Its	PRP$	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
action	action	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
well	well	RB	B-VP	O	O
understood	understand	VBN	I-VP	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
proposed	propose	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
acts	act	VBZ	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
competitive	competitive	JJ	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gamma	gamma	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
A	A	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
GABAergic	GABAergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
measuring	measure	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
7	7	CD	B-NP	O	O
brain	brain	NN	I-NP	O	O
areas	area	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

All	All	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
suffered	suffer	VBD	B-VP	O	O
tonic	tonic	JJ	B-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
18.3	18.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.4	1.4	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
slightly	slightly	RB	I-VP	O	O
but	but	CC	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
decreased	decrease	VBD	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
colliculi	colliculi	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
modifications	modification	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mesencephalon	mesencephalon	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
DOPAC	DOPAC	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mesencephalon	mesencephalon	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
striatum	striatum	NN	I-NP	O	O
.	.	.	O	O	O

Unusual	Unusual	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antithyroid	antithyroid	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
four	four	CD	B-NP	O	O
case	case	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
and	and	CC	O	O	O
review	review	NN	B-NP	O	O
of	of	IN	B-PP	O	O
literature	literature	NN	B-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propylthiouracil	propylthiouracil	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
acute	acute	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
one	one	CD	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
methimazole	methimazole	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	B-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propylthiouracil	propylthiouracil	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
lupus	lupus	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
like	like	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
antithyroid	antithyroid	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
complications	complication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thyroidectomy	thyroidectomy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
radioiodine	radioiodine	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
antithyroid	antithyroid	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
circumstances	circumstance	NNS	I-NP	O	O
131I	131I	NN	I-NP	B	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
choice	choice	NN	B-NP	O	O
for	for	IN	B-PP	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Anticonvulsant	Anticonvulsant	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
801	801	CD	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

MK	MK	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
801	801	CD	B-NP	O	I-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
noncompetitive	noncompetitive	JJ	I-NP	O	O
N	N	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
D	D	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
aspartate	aspartate	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
NMDA	NMDA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
receptor	receptor	NN	B-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
two	two	CD	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
,	,	,	O	O	O
coadministration	coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
major	major	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

First	First	RB	B-ADVP	O	O
,	,	,	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
801	801	CD	B-NP	I	I-Chemical
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
with	with	IN	I-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
different	different	JJ	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
control	control	VBP	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

Second	Second	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
801	801	CD	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
only	only	RB	B-ADVP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
periods	period	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
demonstration	demonstration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conclusion	conclusion	NN	I-NP	O	O
derived	derive	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
that	that	IN	B-SBAR	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
801	801	CD	B-NP	I	I-Chemical
binding	binding	NN	I-NP	O	O
requires	require	VBZ	B-VP	O	O
agonist	agonist	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
opening	opening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
channel	channel	NN	I-NP	O	O
sites	site	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NMDA	NMDA	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
.	.	.	O	O	O

Third	Third	RB	B-ADVP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
relatively	relatively	RB	B-ADJP	O	O
easy	easy	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
block	block	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
by	by	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anticonvulsants	anticonvulsant	NNS	B-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
more	more	RBR	B-ADJP	O	O
difficult	difficult	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
terminate	terminate	VB	I-VP	O	O
ongoing	ongoing	JJ	B-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
block	block	VB	B-VP	O	O
the	the	DT	B-NP	O	O
lethality	lethality	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
801	801	CD	B-NP	I	I-Chemical
30	30	CD	I-NP	O	O
or	or	CC	I-NP	O	O
60	60	CD	I-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
i.e.	i.e.	FW	B-NP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
,	,	,	O	O	O
gradually	gradually	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
electrical	electrical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
greatly	greatly	RB	B-VP	O	O
enhanced	enhance	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
survival	survival	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
NMDA	NMDA	NN	B-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
plays	play	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
brain	brain	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
further	further	RB	I-VP	O	O
supported	support	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
results	result	NNS	B-NP	O	O
showing	show	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
nonconvulsive	nonconvulsive	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NMDA	NMDA	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
synergistic	synergistic	JJ	B-ADJP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
subsequent	subsequent	JJ	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
.	.	.	O	O	O

Nifedipine	Nifedipine	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
autonomic	autonomic	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

An	An	DT	B-NP	O	O
80	80	CD	I-NP	O	O
year	year	NN	I-NP	O	O
old	old	JJ	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
male	male	NN	I-NP	O	O
with	with	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
autonomic	autonomic	JJ	I-NP	O	I-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chest	chest	NN	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
flutter	flutter	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
70	70	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
min	min	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
slowed	slow	VBD	B-VP	O	O
down	down	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
40	40	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
min	min	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
divided	divide	VBN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
paced	pace	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
70	70	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
inconsistent	inconsistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
established	establish	VBN	I-NP	O	O
finding	finding	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
tachycardia	tachycardia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
normally	normally	RB	B-NP	O	O
innervated	innervate	VBN	I-NP	O	O
hearts	heart	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
hearts	heart	NNS	B-NP	O	O
deprived	deprive	VBN	B-VP	O	O
of	of	IN	B-PP	O	O
compensatory	compensatory	JJ	B-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
drive	drive	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
intoxication	intoxication	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
toxic	toxic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
intraperitoneal	intraperitoneal	JJ	O	O	O
(	(	(	O	O	O
i.p.	i.p.	JJ	B-ADJP	O	O
)	)	)	O	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
75	75	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
death	death	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
70	70	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
82	82	CD	B-NP	O	O
%	%	NN	I-NP	O	O
death	death	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Haloperidol	Haloperidol	NN	B-NP	B	B-Chemical
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
lower	low	JJR	B-ADVP	O	O
the	the	DT	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
at	at	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
doses	dose	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
.	.	.	O	O	O

Haloperidol	Haloperidol	NN	B-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
highest	high	JJS	I-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
lowering	lowering	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reach	reach	VB	I-VP	O	O
statistical	statistical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
at	at	IN	B-PP	O	O
any	any	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
blocker	blocker	NN	I-NP	O	O
haloperidol	haloperidol	NN	I-NP	B	B-Chemical
against	against	IN	B-PP	O	O
death	death	NN	B-NP	O	O
from	from	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
without	without	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
demonstrated	demonstrate	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
without	without	IN	B-PP	O	O
significantly	significantly	RB	B-VP	O	O
reducing	reduce	VBG	I-VP	O	O
mortality	mortality	NN	B-NP	O	O
.	.	.	O	O	O

Autoradiographic	Autoradiographic	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	B	B-Chemical
binding	binding	NN	I-NP	O	O
sites	site	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
nuclei	nucleus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
diethylstilbesterol	diethylstilbesterol	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
hamster	hamster	NN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
carcinomas	carcinoma	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Estrogen	Estrogen	NN	B-NP	B	B-Chemical
binding	binding	NN	I-NP	O	O
sites	site	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
autoradiography	autoradiography	NN	B-NP	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
transplantable	transplantable	JJ	I-NP	O	O
and	and	CC	O	O	O
five	five	CD	B-NP	O	O
primary	primary	JJ	I-NP	O	O
diethylstilbesterol	diethylstilbesterol	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	B-Disease
carcinomas	carcinoma	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
hamsters	hamster	NNS	I-NP	O	O
.	.	.	O	O	O

Radiolabelling	Radiolabelling	NN	B-NP	O	O
,	,	,	O	O	O
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3H	3H	NN	B-NP	O	O
-	-	HYPH	O	O	O
17	17	CD	B-NP	B	O
beta	beta	SYM	I-NP	I	O
estradiol	estradiol	NN	I-NP	I	B-Chemical
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nuclei	nucleus	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
cells	cell	NNS	I-NP	O	O
;	;	:	O	O	O
stereologic	stereologic	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
4.5	4.5	CD	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
6.7	6.7	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
times	time	NNS	I-NP	O	O
higher	high	JJR	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
silver	silver	NN	I-NP	B	B-Chemical
grains	grain	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
nuclei	nucleus	NNS	B-NP	O	O
than	than	IN	B-PP	O	O
cytoplasm	cytoplasm	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
rapid	rapid	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
estradiol	estradiol	NN	B-NP	B	B-Chemical
which	which	WDT	B-NP	O	O
peaked	peak	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
1	1	CD	I-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
bind	bind	VB	I-VP	O	O
the	the	DT	B-NP	O	O
ligand	ligand	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
published	publish	VBN	I-NP	O	O
report	report	NN	I-NP	O	O
documenting	document	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
preferential	preferential	JJ	I-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
binding	binding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
nuclei	nucleus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cells	cell	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
hamster	hamster	NN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
carcinomas	carcinoma	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Bradycardia	Bradycardia	NNP	B-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
biperiden	biperiden	VB	I-VP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
38	38	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
postzosteric	postzosteric	JJ	I-NP	O	B-Disease
trigeminal	trigeminal	JJ	I-NP	O	B-Disease
neuralgia	neuralgia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
biperiden	biperiden	JJ	I-NP	B	B-Chemical
lactate	lactate	NN	I-NP	I	I-Chemical
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
long	long	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
lasting	last	VBG	B-VP	O	O
paradoxical	paradoxical	JJ	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
considerable	considerable	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
dysarthria	dysarthria	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
dysphagia	dysphagia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
back	back	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
within	within	IN	B-PP	O	O
12	12	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
upon	upon	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
orciprenaline	orciprenaline	NN	B-NP	B	B-Chemical
under	under	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
.	.	.	O	O	O

Bradycardia	Bradycardia	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
biperiden	biperiden	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
speed	speed	NN	I-NP	O	O
of	of	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
dual	dual	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
muscarine	muscarine	NN	B-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

Deliberate	Deliberate	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
halothane	halothane	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
enflurane	enflurane	NN	I-NP	B	B-Chemical
or	or	CC	I-NP	O	O
isoflurane	isoflurane	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
middle	middle	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
ear	ear	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
feasibility	feasibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
labetalol	labetalol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
alpha	alpha	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
blocking	block	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
hypotensive	hypotensive	JJ	I-NP	O	B-Disease
agent	agent	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
inhalation	inhalation	NN	B-NP	O	O
anaesthetics	anaesthetic	NNS	I-NP	O	O
(	(	(	O	O	O
halothane	halothane	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
enflurane	enflurane	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
isoflurane	isoflurane	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
23	23	CD	B-NP	O	O
adult	adult	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
middle	middle	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
ear	ear	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
86	86	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
5	5	CD	B-NP	O	O
(	(	(	O	O	O
s.e.	s.e.	NN	B-NP	O	O
mean	mean	NN	I-NP	O	O
)	)	)	O	O	O
mmHg	mmHg	NN	B-NP	O	O
to	to	TO	B-PP	O	O
52	52	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1	1	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
(	(	(	O	O	O
11.5	11.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
to	to	TO	B-PP	O	O
6.9	6.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.1	0.1	CD	B-NP	O	O
kPa	kPa	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
98	98	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
10	10	CD	B-NP	O	O
min	min	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
halothane	halothane	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
H	H	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
group	group	NN	B-NP	O	O
,	,	,	O	O	O
from	from	IN	B-PP	O	O
79	79	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
5	5	CD	B-NP	O	O
to	to	TO	B-PP	O	O
53	53	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1	1	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
(	(	(	O	O	O
10.5	10.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
to	to	TO	B-PP	O	O
7.1	7.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.1	0.1	CD	B-NP	O	O
kPa	kPa	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
129	129	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
11	11	CD	B-NP	O	O
min	min	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
enflurane	enflurane	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
E	E	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
group	group	NN	B-NP	O	O
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
from	from	IN	B-PP	O	O
80	80	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
to	to	TO	B-PP	O	O
49	49	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1	1	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
(	(	(	O	O	O
10.7	10.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.5	0.5	CD	B-NP	O	O
to	to	TO	B-PP	O	O
6.5	6.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.1	0.1	CD	B-NP	O	O
kPa	kPa	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
135	135	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
15	15	CD	B-NP	O	O
min	min	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
isoflurane	isoflurane	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
I	I	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
group	group	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
H	H	NN	I-NP	O	B-Chemical
concentration	concentration	NN	I-NP	O	O
during	during	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inspiratory	inspiratory	JJ	I-NP	O	O
gas	gas	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
0.7	0.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.1	0.1	CD	B-NP	O	O
vol	vol	NN	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
E	E	NN	I-NP	O	B-Chemical
concentration	concentration	NN	I-NP	O	O
1.6	1.6	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.2	0.2	CD	B-NP	O	O
vol	vol	NN	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
I	I	CD	I-NP	O	B-Chemical
concentration	concentration	NN	I-NP	O	O
1.0	1.0	CD	B-NP	O	O
+	+	SYM	I-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
0.1	0.1	CD	B-NP	O	O
vol	vol	NN	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
d	d	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
tubocurarine	tubocurarine	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
labetalol	labetalol	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
lowering	lower	VBG	B-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
,	,	,	O	O	O
0.52	0.52	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.59	0.59	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
stable	stable	JJ	B-ADJP	O	O
without	without	IN	B-PP	O	O
tachy	tachy	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
or	or	CC	I-NP	O	I-Disease
bradycardia	bradycardia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
operating	operating	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
bleeding	bleeding	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
rose	rise	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
values	value	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
returned	return	VBD	B-VP	O	O
postoperatively	postoperatively	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
the	the	DT	B-NP	O	O
isoflurane	isoflurane	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
rebound	rebound	NN	I-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
or	or	CC	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
labetalol	labetalol	NN	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
easily	easily	RB	B-NP	O	O
adjustable	adjustable	JJ	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
without	without	IN	B-PP	O	O
compensatory	compensatory	JJ	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
rebound	rebound	VB	B-VP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Convulsion	Convulsion	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
fluorescein	fluorescein	NN	I-NP	B	B-Chemical
angiography	angiography	NN	I-NP	O	O
.	.	.	O	O	O

Tonic	Tonic	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
clonic	clonic	JJ	I-NP	O	I-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
followed	follow	VBD	B-VP	O	O
intravenous	intravenous	JJ	B-NP	O	O
fluorescein	fluorescein	NN	I-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
fundus	fundus	NN	B-NP	O	O
angiography	angiography	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
47	47	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	NN	I-NP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
precautions	precaution	NNS	B-NP	O	O
this	this	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
recurred	recur	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
re	re	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
fluorescein	fluorescein	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Pharmacology	Pharmacology	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ACC	ACC	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
9653	9653	CD	I-NP	I	I-Chemical
(	(	(	O	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
prodrug	prodrug	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

ACC	ACC	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
9653	9653	CD	B-NP	O	I-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
disodium	disodium	NN	I-NP	B	B-Chemical
phosphate	phosphate	NN	I-NP	I	I-Chemical
ester	ester	NN	I-NP	B	I-Chemical
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
hydroxymethyl	hydroxymethyl	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
5,5	5,5	CD	I-NP	B	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
diphenylhydantoin	diphenylhydantoin	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
prodrug	prodrug	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
advantageous	advantageous	JJ	B-NP	O	O
physicochemical	physicochemical	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

ACC	ACC	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
9653	9653	CD	B-NP	O	I-Chemical
is	be	VBZ	B-VP	O	O
rapidly	rapidly	RB	I-VP	O	O
converted	convert	VBN	I-VP	O	O
enzymatically	enzymatically	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

ACC	ACC	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
9653	9653	CD	I-NP	O	I-Chemical
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
have	have	VBP	B-VP	O	O
equivalent	equivalent	JJ	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
against	against	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
maximal	maximal	JJ	B-NP	O	O
electroshock	electroshock	NN	I-NP	O	O
(	(	(	O	O	O
MES	MES	NN	B-NP	B	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
following	follow	VBG	B-PP	O	O
i.p.	i.p.	JJ	B-NP	O	O
,	,	,	I-NP	O	O
oral	oral	JJ	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
i.v.	i.v.	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ED50	ED50	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
16	16	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
i.v	i.v	NN	B-NP	O	O
.	.	.	O	O	O

ACC	ACC	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
9653	9653	CD	I-NP	O	I-Chemical
and	and	CC	I-NP	O	O
8	8	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
i.v	i.v	NN	B-NP	O	O
.	.	.	O	O	O

phenytoin	phenytoin	NN	B-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

ACC	ACC	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
9653	9653	CD	I-NP	O	I-Chemical
and	and	CC	I-NP	O	O
phenytoin	phenytoin	NN	I-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
have	have	VBP	B-VP	O	O
similar	similar	JJ	B-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
against	against	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ACC	ACC	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
9653	9653	CD	I-NP	I	I-Chemical
or	or	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
necessary	necessary	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
convert	convert	VB	I-VP	O	O
the	the	DT	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
24	24	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
6	6	CD	B-NP	O	O
and	and	CC	I-NP	O	O
14	14	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
3	3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
displayed	display	VBD	B-VP	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
against	against	IN	B-PP	O	O
strophanthidin	strophanthidin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
guinea	guinea	NN	B-NP	O	O
pig	pig	NN	I-NP	O	O
right	right	JJ	I-NP	O	O
atria	atria	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACC	ACC	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
9653	9653	CD	B-NP	I	I-Chemical
(	(	(	O	O	O
31	31	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
infused	infuse	VBN	I-VP	O	O
over	over	IN	B-NP	O	O
15	15	CD	I-NP	O	O
,	,	,	I-NP	O	O
20	20	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
responses	response	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
equimolar	equimolar	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
21	21	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ACC	ACC	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
9653	9653	CD	I-NP	I	I-Chemical
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
treatments	treatment	NNS	I-NP	O	O
produced	produce	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
marked	marked	JJ	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
diastolic	diastolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
contractile	contractile	JJ	B-NP	O	O
force	force	NN	I-NP	O	O
(	(	(	O	O	O
LVdP	LVdP	NN	B-NP	O	O
/	/	SYM	O	O	O
dt	dt	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
maximum	maximum	NN	B-NP	O	O
phenytoin	phenytoin	NN	I-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ACC	ACC	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
9653	9653	CD	I-NP	I	I-Chemical
and	and	CC	O	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
,	,	,	O	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
rabbits	rabbit	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
dogs	dog	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
i.v.	i.v.	JJ	B-NP	O	O
,	,	,	I-NP	O	O
i.m.	i.m.	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
i.p.	i.p.	JJ	B-NP	O	O
routes	route	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
and	and	CC	O	O	O
occurred	occur	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
equivalent	equivalent	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Importantly	Importantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
local	local	JJ	I-NP	O	O
irritation	irritation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACC	ACC	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
9653	9653	CD	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
markedly	markedly	RB	B-ADJP	O	O
less	less	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
sodium	sodium	NN	I-NP	I	I-Chemical
following	follow	VBG	B-PP	O	O
i.m.	i.m.	JJ	B-NP	O	O
administration.	administration.	NN	I-NP	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Phenytoin	Phenytoin	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
fatal	fatal	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
61	61	CD	I-NP	O	O
year	year	NN	I-NP	O	O
old	old	JJ	I-NP	O	O
female	female	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
fatal	fatal	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
multisystem	multisystem	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
precedes	precede	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hematologic	hematologic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pathologic	pathologic	JJ	I-NP	O	O
features	feature	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
mixed	mixed	JJ	I-NP	O	O
hepatocellular	hepatocellular	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	B-Disease
hypersensitivity	hypersensitivity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
phenytoin	phenytoin	NN	B-NP	B	B-Chemical
who	who	WP	B-NP	O	O
presents	present	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
viral	viral	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
illness	illness	NN	I-NP	O	O
,	,	,	O	O	O
early	early	JJ	B-NP	O	O
recognition	recognition	NN	I-NP	O	O
and	and	CC	O	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
mandatory	mandatory	JJ	B-ADJP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lethal	lethal	JJ	B-NP	O	O
pertussis	pertussis	NN	I-NP	O	B-Chemical
vaccine	vaccine	NN	I-NP	O	I-Chemical
reaction	reaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
histamine	histamine	NN	B-NP	B	B-Chemical
H1	H1	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
mortality	mortality	NN	B-NP	O	O
after	after	IN	B-PP	O	O
pertussis	pertussis	NN	B-NP	O	B-Disease
immunization	immunization	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
.	.	.	O	O	O

Without	Without	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
73	73	CD	B-NP	O	O
of	of	IN	B-PP	O	O
92	92	CD	B-NP	O	O
animals	animal	NNS	I-NP	O	O
(	(	(	O	O	O
80	80	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
died	die	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bovine	bovine	JJ	B-NP	O	O
serum	serum	NN	I-NP	B	O
albumin	albumin	NN	I-NP	I	O
(	(	(	O	O	O
BSA	BSA	NN	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
+	+	SYM	O	O	O
7	7	CD	B-NP	O	O
of	of	IN	B-PP	O	O
pertussis	pertussis	NN	B-NP	O	B-Disease
immunization	immunization	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
3	3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyproheptadine	cyproheptadine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
mianserin	mianserin	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
chlorpheniramine	chlorpheniramine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
only	only	RB	B-NP	O	O
5	5	CD	I-NP	O	O
of	of	IN	B-PP	O	O
105	105	CD	B-NP	O	O
animals	animal	NNS	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
died	die	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
BSA	BSA	NN	B-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
+	+	SYM	O	O	O
7	7	CD	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Blockade	Blockade	NN	B-NP	O	O
of	of	IN	B-PP	O	O
histamine	histamine	NN	B-NP	B	B-Chemical
H1	H1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
mortality	mortality	NN	B-NP	O	O
in	in	IN	B-PP	O	O
pertussis	pertussis	NN	B-NP	O	B-Disease
immunization	immunization	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Support	Support	NN	B-NP	O	O
for	for	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
hypothesis	hypothesis	NN	I-NP	O	O
:	:	:	O	O	O
18	18	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
after	after	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
adrenaline	adrenaline	NN	I-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
crossover	crossover	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
6	6	CD	I-NP	O	O
h	h	NN	I-NP	O	O
infusions	infusion	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
15	15	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
min	min	NN	I-NP	O	O
;	;	:	O	O	O
1	1	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
5.458	5.458	CD	B-NP	O	O
pmol	pmol	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
noradrenaline	noradrenaline	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
;	;	:	O	O	O
1	1	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
5.911	5.911	CD	B-NP	O	O
pmol	pmol	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
dextrose	dextrose	NN	I-NP	B	B-Chemical
solution	solution	NN	I-NP	O	O
(	(	(	O	O	O
5.4	5.4	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
ten	ten	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
random	random	JJ	B-NP	O	O
order	order	NN	I-NP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
apart	apart	RB	B-ADVP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
intra	intra	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
ambulatory	ambulatory	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
the	the	DT	B-NP	O	O
haemodynamic	haemodynamic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
18	18	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
infusions	infusion	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

Adrenaline	Adrenaline	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
noradrenaline	noradrenaline	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
and	and	CC	O	O	O
protracted	protract	VBD	B-VP	O	O
pressor	pressor	NN	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Over	Over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
postinfusion	postinfusion	NN	I-NP	O	O
period	period	NN	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
6	6	CD	B-NP	O	O
(	(	(	O	O	O
SEM	SEM	NN	B-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
and	and	CC	I-NP	O	O
7	7	CD	I-NP	O	O
(	(	NN	I-NP	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
after	after	IN	B-PP	O	O
dextrose	dextrose	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
(	(	(	O	O	O
ANOVA	ANOVA	NN	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
"	"	``	B-NP	O	O
stress	stress	NN	I-NP	O	O
"	"	''	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
230	230	CD	B-NP	O	O
pg	pg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
h	h	NN	I-NP	O	O
cause	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
and	and	CC	I-NP	O	O
protracted	protract	VBN	I-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
strong	strong	JJ	B-NP	O	O
support	support	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adrenaline	adrenaline	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
hypothesis	hypothesis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alkylxanthines	alkylxanthine	NNS	B-NP	O	B-Chemical
on	on	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Adenosine	Adenosine	NN	B-NP	B	B-Chemical
antagonists	antagonist	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
benefit	benefit	NN	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
ischaemic	ischaemic	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
nephrotoxic	nephrotoxic	JJ	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ARF	ARF	NN	B-NP	B	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
three	three	CD	B-NP	O	O
alkylxanthines	alkylxanthine	NNS	I-NP	O	B-Chemical
with	with	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
potencies	potency	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
antagonists	antagonist	NNS	I-NP	O	O
8	8	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
phenyltheophylline	phenyltheophylline	NN	I-NP	I	I-Chemical
,	,	,	I-NP	O	O
theophylline	theophylline	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
enprofylline	enprofylline	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
developing	develop	VBG	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
4	4	CD	B-NP	O	O
daily	daily	JJ	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
biochemical	biochemical	JJ	B-NP	O	O
(	(	(	O	O	O
plasma	plasma	NN	B-NP	O	O
urea	urea	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
functional	functional	JJ	B-ADJP	O	O
(	(	(	O	O	O
urine	urine	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
and	and	CC	O	O	O
[	[	(	B-NP	O	O
3H	3H	NN	I-NP	O	O
]	]	)	I-NP	O	O
inulin	inulin	NN	I-NP	B	O
and	and	CC	O	O	O
[	[	(	B-NP	O	O
14C	14C	NN	I-NP	B	O
]	]	)	I-NP	O	O
p	p	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aminohippuric	aminohippuric	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
clearances	clearance	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
morphological	morphological	JJ	B-NP	O	O
(	(	(	O	O	O
degree	degree	NN	B-NP	O	O
of	of	IN	B-PP	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
)	)	)	O	O	O
indices	index	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
various	various	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
treatments	treatment	NNS	I-NP	O	O
produced	produce	VBD	B-VP	O	O
improvements	improvement	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	B-NP	O	O
all	all	DT	I-NP	O	O
,	,	,	O	O	O
measurements	measurement	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
any	any	DT	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
largely	largely	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
exerted	exert	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
(	(	(	O	O	O
polyethylene	polyethylene	NN	B-NP	B	B-Chemical
glycol	glycol	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
NaOH	NaOH	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
consistent	consistent	JJ	I-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
noted	note	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alkylxanthines	alkylxanthine	NNS	I-NP	O	B-Chemical
tested	test	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
plays	play	VBZ	B-VP	O	O
little	little	JJ	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
,	,	,	O	O	O
pathophysiological	pathophysiological	JJ	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ARF	ARF	NN	I-NP	B	B-Disease
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
ocular	ocular	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
possibly	possibly	RB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
isotretinoin	isotretinoin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
261	261	CD	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
237	237	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
isotretinoin	isotretinoin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
drug	drug	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
cystic	cystic	JJ	I-NP	O	O
acne	acne	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Blepharoconjunctivitis	Blepharoconjunctivitis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
subjective	subjective	JJ	B-NP	O	O
complaints	complaint	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dry	dry	JJ	B-NP	O	B-Disease
eyes	eye	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
blurred	blur	VBD	B-VP	O	B-Disease
vision	vision	NN	B-NP	O	I-Disease
,	,	,	O	O	O
contact	contact	NN	B-NP	B	O
lens	lens	NN	I-NP	I	O
intolerance	intolerance	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
photodermatitis	photodermatitis	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
reversible	reversible	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

More	More	RBR	B-NP	O	O
serious	serious	JJ	I-NP	O	O
ocular	ocular	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
papilledema	papilledema	NN	B-NP	O	B-Disease
,	,	,	O	O	O
pseudotumor	pseudotumor	NN	B-NP	O	B-Disease
cerebri	cerebri	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
white	white	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
gray	gray	JJ	I-NP	O	O
subepithelial	subepithelial	JJ	I-NP	O	O
corneal	corneal	JJ	I-NP	O	B-Disease
opacities	opacity	NNS	I-NP	O	I-Disease
;	;	:	O	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
reversible	reversible	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
.	.	.	O	O	O

Reported	Report	VBN	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
dark	dark	JJ	I-NP	O	O
adaptation	adaptation	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
under	under	IN	B-PP	O	O
investigation	investigation	NN	B-NP	O	O
.	.	.	O	O	O

Isotretinoin	Isotretinoin	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
many	many	JJ	I-NP	O	O
reported	report	VBD	B-VP	O	O
congenital	congenital	JJ	B-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
maternal	maternal	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
(	(	(	O	O	O
including	include	VBG	B-PP	O	O
microphthalmos	microphthalmo	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
orbital	orbital	JJ	B-NP	O	O
hypertelorism	hypertelorism	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
optic	optic	JJ	B-NP	O	B-Disease
nerve	nerve	NN	I-NP	O	I-Disease
hypoplasia	hypoplasia	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Procaterol	Procaterol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
terbutaline	terbutaline	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
bronchial	bronchial	JJ	B-NP	O	B-Disease
asthma	asthma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
cross	cross	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
over	over	IN	B-PP	O	O
study	study	NN	B-NP	O	O
.	.	.	O	O	O

Procaterol	Procaterol	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
beta	beta	SYM	I-NP	B	O
-	-	HYPH	I-NP	I	O
2	2	CD	I-NP	I	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
stimulant	stimulant	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
cross	cross	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
over	over	IN	B-PP	O	O
trial	trial	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
bronchial	bronchial	JJ	B-NP	O	B-Disease
asthma	asthma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
procaterol	procaterol	NN	I-NP	B	B-Chemical
50	50	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
b.d.	b.d.	NN	I-NP	O	O
,	,	,	O	O	O
procaterol	procaterol	NN	B-NP	B	B-Chemical
100	100	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
b.d.	b.d.	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
terbutaline	terbutaline	NN	B-NP	B	B-Chemical
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
t.i.d.	t.i.d.	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
randomly	randomly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
periods	period	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
best	well	RBS	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
terbutaline	terbutaline	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Both	Both	CC	O	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	B-NP	O	O
asthmatic	asthmatic	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
tremorgenic	tremorgenic	JJ	I-NP	O	B-Disease
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
procaterol	procaterol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
related	relate	VBN	I-ADJP	O	O
.	.	.	O	O	O

Procaterol	Procaterol	NNP	B-NP	B	B-Chemical
appeared	appear	VBD	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
twice	twice	RB	I-NP	O	O
daily	daily	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
would	would	MD	B-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
suitable	suitable	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Subacute	Subacute	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
B	B	NN	B-NP	O	O
24	24	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
76	76	CD	B-NP	O	O
on	on	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
rat	rat	NN	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
correlation	correlation	NN	B-NP	O	O
with	with	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
B	B	NN	B-NP	O	O
24	24	CD	I-NP	O	O
/	/	SYM	O	O	O
76	76	CD	B-NP	O	O
i.e	i.e	NN	I-NP	O	O
.	.	.	O	O	O

1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
(	(	(	O	O	O
2,4	2,4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
dichlorophenoxy	dichlorophenoxy	NN	I-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
[	[	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
3,4	3,4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
dimethoxyphenyl	dimethoxyphenyl	NN	I-NP	O	O
)	)	)	O	O	O
ethanolamino	ethanolamino	NN	B-NP	O	O
]	]	)	O	O	O
-	-	HYPH	B-NP	O	O
prop	prop	NN	I-NP	O	O
an	an	DT	B-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	B	O
ol	ol	NN	I-NP	I	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
blocking	blocking	NN	I-NP	O	O
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
stimulating	stimulate	VBG	B-VP	O	O
properties	property	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
correlation	correlation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
neither	neither	DT	B-NP	O	O
found	find	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
nor	nor	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
attempt	attempt	NN	I-NP	O	O
to	to	TO	B-VP	O	O
suppress	suppress	VB	I-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	O	O	O
blockers	blocker	NNS	B-NP	O	O
influenced	influence	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertrophy	hypertrophy	NN	B-NP	O	B-Disease
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
reproducible	reproducible	JJ	B-NP	O	O
extent	extent	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
suppress	suppress	VB	I-VP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
ornithine	ornithine	NN	I-NP	B	B-Chemical
decarboxylase	decarboxylase	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
with	with	IN	B-PP	O	O
both	both	CC	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
blockers	blocker	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
hypertrophied	hypertrophied	JJ	B-NP	O	B-Disease
hearts	heart	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
mass	mass	NN	I-NP	O	O
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
nor	nor	CC	O	O	O
B	B	NN	B-NP	O	O
24	24	CD	I-NP	O	O
/	/	SYM	O	O	O
76	76	CD	B-NP	O	O
could	could	MD	B-VP	O	O
stop	stop	VB	I-VP	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
characteristic	characteristic	JJ	I-NP	O	O
myosin	myosin	NN	I-NP	O	O
isoenzyme	isoenzyme	NN	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypertrophied	hypertrophied	JJ	I-NP	O	B-Disease
rat	rat	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
provide	provide	VB	I-VP	O	O
any	any	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
B	B	NN	I-NP	O	O
24	24	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
76	76	CD	I-NP	O	O
have	have	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
potency	potency	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
from	from	IN	B-PP	O	O
producing	produce	VBG	B-VP	O	O
heart	heart	NN	B-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Comparison	Comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxitropium	oxitropium	NN	B-NP	B	B-Chemical
bromide	bromide	NN	I-NP	I	I-Chemical
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
slow	slow	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	B	B-Chemical
on	on	IN	B-PP	O	O
nocturnal	nocturnal	JJ	B-NP	O	O
asthma	asthma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
inhaled	inhaled	JJ	I-NP	O	O
antimuscarinic	antimuscarinic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
oxitropium	oxitropium	NN	B-NP	B	B-Chemical
bromide	bromide	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
slow	slow	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
theophylline	theophylline	NN	I-NP	B	B-Chemical
preparation	preparation	NN	I-NP	I	O
upon	upon	IN	B-PP	O	O
nocturnal	nocturnal	JJ	B-NP	O	O
asthma	asthma	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
samples	sample	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
:	:	:	O	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
oxitropium	oxitropium	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
600	600	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
at	at	IN	B-PP	O	O
400	400	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
t.i.d	t.i.d	NN	I-NP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
6	6	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
)	)	)	O	O	O
whereas	whereas	IN	O	O	O
11	11	CD	B-NP	O	O
received	receive	VBD	B-VP	O	O
theophylline	theophylline	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
.	.	.	O	O	O

Morning	Morne	VBG	B-NP	O	O
dipping	dipping	NN	I-NP	O	O
,	,	,	O	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
peak	peak	NN	B-NP	O	O
flow	flow	NN	I-NP	O	O
overnight	overnight	RB	B-ADVP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
periods	period	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
either	either	CC	O	O	O
active	active	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noticed	notice	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noticed	notice	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
results	result	NNS	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	B-NP	O	O
active	active	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
dosage	dosage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oxitropium	oxitropium	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

No	No	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
reported	report	VBD	B-VP	O	O
side	side	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oxitropium	oxitropium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
three	three	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
reporting	report	VBG	B-VP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
vomiting	vomiting	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
tremors	tremor	NNS	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Oxitropium	Oxitropium	NN	B-NP	B	B-Chemical
proves	prove	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
valuable	valuable	JJ	I-NP	O	O
alternative	alternative	NN	I-NP	O	O
to	to	TO	B-PP	O	O
theophylline	theophylline	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
nocturnal	nocturnal	JJ	B-NP	O	O
asthma	asthma	NN	I-NP	O	B-Disease
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
equally	equally	RB	B-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
,	,	,	O	O	O
safer	safe	JJR	B-ADJP	O	O
and	and	CC	O	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
require	require	VB	I-VP	O	O
the	the	DT	B-NP	O	O
titration	titration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosage	dosage	NN	B-NP	O	O
.	.	.	O	O	O

Penicillin	Penicillin	NN	B-NP	B	B-Chemical
anaphylaxis	anaphylaxis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
penicillin	penicillin	NN	I-NP	B	B-Chemical
anaphylaxis	anaphylaxis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
terminology	terminology	NN	I-NP	O	O
,	,	,	O	O	O
occurrence	occurrence	NN	B-NP	O	O
,	,	,	O	O	O
clinical	clinical	JJ	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
,	,	,	O	O	O
pathogenesis	pathogenesis	NN	B-NP	O	O
,	,	,	O	O	O
prevention	prevention	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anaphylaxis	anaphylaxis	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
.	.	.	O	O	O

Emergency	Emergency	NN	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
penicillin	penicillin	NN	I-NP	B	B-Chemical
anaphylaxis	anaphylaxis	NN	I-NP	O	B-Disease
in	in	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
by	by	IN	B-PP	O	O
prescribing	prescribe	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
antibiotic	antibiotic	JJ	I-NP	O	O
judiciously	judiciously	RB	B-ADVP	O	O
and	and	CC	I-ADVP	O	O
knowledgeably	knowledgeably	RB	I-ADVP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
offer	offer	VB	I-VP	O	O
optimal	optimal	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
once	once	RB	O	O	O
this	this	DT	B-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
threatening	threaten	VBG	I-VP	O	O
reaction	reaction	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
begun	begin	VBN	I-VP	O	O
.	.	.	O	O	O

Reversible	Reversible	JJ	B-NP	O	O
valproic	valproic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dementia	dementia	NN	I-NP	O	B-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

Reversible	Reversible	JJ	B-NP	O	O
valproic	valproic	JJ	I-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dementia	dementia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
21	21	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insidious	insidious	JJ	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
global	global	JJ	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
abilities	ability	NNS	I-NP	O	O
documented	document	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
neuropsychological	neuropsychological	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Repeat	Repeat	NN	B-NP	O	O
neuropsychological	neuropsychological	JJ	I-NP	O	O
testing	testing	NN	I-NP	O	O
7	7	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
dramatic	dramatic	JJ	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
IQ	IQ	NN	B-NP	B	O
,	,	,	O	O	O
memory	memory	NN	B-NP	O	O
,	,	,	O	O	O
naming	naming	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
tasks	task	NNS	I-NP	O	O
commensurate	commensurate	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
in	in	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
intellectual	intellectual	JJ	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
.	.	.	O	O	O

Possible	Possible	JJ	B-NP	O	O
pathophysiological	pathophysiological	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
operative	operative	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
include	include	VBP	B-VP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
)	)	)	O	O	O
toxic	toxic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
;	;	:	O	O	O
a	a	DT	B-NP	O	O
paradoxical	paradoxical	JJ	I-NP	O	O
epileptogenic	epileptogenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
indirect	indirect	JJ	I-NP	O	O
CNS	CNS	NN	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
mediated	mediate	VBN	B-VP	O	O
through	through	IN	B-PP	O	O
valproic	valproic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperammonemia	hyperammonemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Reversal	Reversal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
scopolamine	scopolamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
by	by	IN	B-PP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
training	training	NN	I-NP	O	O
naloxone	naloxone	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
five	five	CD	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
modulating	modulate	VBG	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
scopolamine	scopolamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
retention	retention	NN	I-NP	O	B-Disease
deficit	deficit	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
paradigm	paradigm	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Scopolamine	Scopolamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
methyl	methyl	NN	B-NP	B	B-Chemical
scopolamine	scopolamine	NN	I-NP	B	I-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
induced	induce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
latency	latency	NN	B-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
.	.	.	O	O	O

Naloxone	Naloxone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.3	0.3	CD	B-NP	O	O
,	,	,	I-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
injected	inject	VBN	B-VP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
training	training	NN	B-NP	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
retention	retention	NN	I-NP	O	B-Disease
deficit	deficit	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
peak	peak	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
at	at	IN	B-PP	O	O
3	3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	B	B-Chemical
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
demonstrating	demonstrate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
opioid	opioid	JJ	I-NP	O	O
specificity	specificity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
naloxone	naloxone	NN	I-NP	B	B-Chemical
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Post	Post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
training	training	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
or	or	CC	O	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
split	split	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
scopolamine	scopolamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Control	Control	NN	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
neither	neither	CC	B-NP	O	O
an	an	DT	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pain	pain	NN	B-NP	O	B-Disease
sensitivity	sensitivity	NN	I-NP	O	O
(	(	(	O	O	O
pre	pre	AFX	O	O	O
-	-	HYPH	O	O	O
training	training	NN	B-NP	O	O
naloxone	naloxone	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
nor	nor	CC	O	O	O
an	an	DT	B-NP	O	O
induced	induce	VBN	I-NP	O	O
aversive	aversive	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
(	(	(	O	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
training	training	NN	B-NP	O	O
naloxone	naloxone	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
responsible	responsible	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
naloxone	naloxone	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
scopolamine	scopolamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
retention	retention	NN	I-NP	O	B-Disease
deficit	deficit	NN	I-NP	O	I-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
extend	extend	VBP	B-VP	O	O
previous	previous	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
implicating	implicate	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
opioid	opioid	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
memory	memory	NN	B-NP	O	O
processes	process	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
septo	septo	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Electron	Electron	NN	B-NP	O	O
microscopic	microscopic	JJ	I-NP	O	O
investigations	investigation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
lesions	lesion	NNS	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
urinary	urinary	JJ	I-NP	O	I-Disease
bladder	bladder	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
by	by	IN	B-PP	O	O
mesna	mesna	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Fully	Fully	RB	B-NP	O	O
developed	develop	VBN	I-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
nearly	nearly	RB	B-NP	O	O
complete	complete	JJ	I-NP	O	O
detachment	detachment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urothelium	urothelium	NN	I-NP	O	O
,	,	,	O	O	O
severe	severe	JJ	B-NP	O	O
submucosal	submucosal	JJ	I-NP	O	O
edema	edema	NN	I-NP	O	B-Disease
owing	owe	VBG	B-VP	O	O
to	to	TO	I-VP	O	O
damage	damage	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
microvascular	microvascular	JJ	I-NP	O	O
bed	bed	NN	I-NP	O	O
and	and	CC	O	O	O
focal	focal	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
necroses	necros	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
attack	attack	NN	I-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	B	B-Chemical
metabolites	metabolite	NNS	I-NP	O	O
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
fragmentation	fragmentation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
luminal	luminal	JJ	I-NP	O	B-Chemical
membrane	membrane	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
damages	damage	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
cellular	cellular	JJ	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypertonic	hypertonic	JJ	I-NP	O	O
urine	urine	NN	I-NP	O	O
.	.	.	O	O	O

Subsequent	Subsequent	JJ	B-NP	O	O
breaks	break	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
membranes	membrane	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
superficial	superficial	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
membranes	membrane	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intermediate	intermediate	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
basal	basal	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
,	,	,	O	O	O
intercellular	intercellular	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
edema	edema	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
disintegration	disintegration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
desmosomes	desmosome	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
hemidesmosomes	hemidesmosome	NNS	I-NP	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
detachment	detachment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
and	and	CC	I-NP	O	O
splitting	splitting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basal	basal	JJ	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
morphological	morphological	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
endothelial	endothelial	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
become	become	VBP	B-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
later	later	JJ	I-NP	O	O
stages	stage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
experiment	experiment	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
vessels	vessel	NNS	I-NP	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
diameter	diameter	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
location	location	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
damage	damage	NN	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
damage	damage	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
preceded	precede	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mediator	mediator	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
permeability	permeability	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
morphological	morphological	JJ	I-NP	O	O
correlate	correlate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gaps	gap	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interendothelial	interendothelial	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
connections	connection	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
venules	venule	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
effectively	effectively	RB	I-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
mesna	mesna	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
only	only	JJ	I-NP	O	O
sign	sign	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
involvement	involvement	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
granules	granule	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
presumed	presumed	JJ	I-NP	O	O
lysosomal	lysosomal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
superficial	superficial	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

Increase	Increase	NN	B-NP	O	O
in	in	IN	B-PP	O	O
intragastric	intragastric	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
during	during	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
muscle	muscle	NN	I-NP	O	B-Disease
fasciculations	fasciculation	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
:	:	:	O	O	O
inhibition	inhibition	NN	B-NP	O	O
by	by	IN	B-PP	O	O
alfentanil	alfentanil	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
intragastric	intragastric	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
1.5	1.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
i.v.	i.v.	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
32	32	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
6.9	6.9	CD	I-NP	O	O
yr	yr	NN	I-NP	O	O
)	)	)	O	O	O
pretreated	pretreate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	B-NP	O	O
physiological	physiological	JJ	I-NP	O	O
saline	saline	NN	I-NP	B	O
or	or	CC	I-NP	O	O
alfentanil	alfentanil	NN	I-NP	B	B-Chemical
50	50	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
kg	kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
.	.	.	O	O	O

Anaesthesia	Anaesthesia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
thiopentone	thiopentone	NN	B-NP	B	B-Chemical
5	5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
fasciculations	fasciculation	NNS	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alfentanil	alfentanil	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
intragastric	intragastric	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
during	during	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
fasciculations	fasciculation	NNS	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
16	16	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
(	(	(	O	O	O
SEM	SEM	NN	B-NP	O	O
)	)	)	O	O	O
cm	cm	NN	B-NP	O	O
H2O	H2O	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alfentanil	alfentanil	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
(	(	(	O	O	O
7.7	7.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.5	1.5	CD	B-NP	O	O
(	(	(	O	O	O
SEM	SEM	NN	B-NP	O	O
)	)	)	O	O	O
cm	cm	NN	B-NP	O	O
H2O	H2O	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
intragastric	intragastric	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
directly	directly	RB	B-ADJP	O	O
related	relate	VBN	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
fasciculations	fasciculation	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
regression	regression	NN	B-NP	O	O
line	line	NN	I-NP	O	O
:	:	:	O	O	O
y	y	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.5	0.5	CD	B-NP	O	O
+	+	SYM	O	O	O
4.78x	4.78x	NN	B-NP	O	O
with	with	IN	B-PP	O	O
r	r	NN	B-NP	O	O
of	of	IN	B-PP	O	O
0.78	0.78	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
intragastric	intragastric	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
fasciculations	fasciculation	NNS	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
children	child	NNS	I-NP	O	O
.	.	.	O	O	O

Alfentanil	Alfentanil	NNP	B-NP	B	B-Chemical
50	50	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
kg	kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
effectively	effectively	RB	B-ADVP	O	O
inhibits	inhibit	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
muscle	muscle	NN	I-NP	O	B-Disease
fasciculations	fasciculation	NNS	I-NP	O	I-Disease
;	;	:	O	O	O
moreover	moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
intragastric	intragastric	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
remains	remain	VBZ	B-VP	O	O
at	at	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
control	control	NN	I-NP	O	O
value	value	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
treatment	treatment	NN	I-NP	O	O
normalizes	normalize	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
resistance	resistance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cardiotoxic	cardiotoxic	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
diabetic	diabetic	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
morphometric	morphometric	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	O
treatment	treatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
earlier	early	JJR	I-NP	O	O
reported	report	VBD	B-VP	O	O
protective	protective	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
diabetes	diabete	NNS	I-NP	O	B-Disease
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiotoxic	cardiotoxic	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Thirty	Thirty	CD	B-NP	O	O
to	to	TO	I-NP	O	O
135	135	CD	I-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
crystalline	crystalline	NN	B-NP	B	O
insulin	insulin	NN	I-NP	I	O
,	,	,	O	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
subcutaneously	subcutaneously	RB	B-ADVP	O	O
and	and	CC	O	O	O
when	when	WRB	B-ADVP	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
induced	induce	VBD	B-VP	O	O
fibrosis	fibrosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
morphometrically	morphometrically	RB	I-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
highly	highly	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
correlation	correlation	NN	I-NP	O	O
(	(	(	O	O	O
r	r	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.83	0.83	CD	B-NP	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
p	p	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
0.006	0.006	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
slope	slope	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
after	after	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	O
treatment	treatment	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
content	content	NN	I-NP	O	O
of	of	IN	B-PP	O	O
catecholamines	catecholamine	NNS	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
8	8	CD	I-NP	O	O
day	day	NN	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
norepinephrine	norepinephrine	NN	I-NP	B	B-Chemical
content	content	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
while	while	IN	B-SBAR	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
enhanced	enhance	VBN	I-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consequent	consequent	JJ	I-NP	O	O
down	down	JJ	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenergic	adrenergic	JJ	B-NP	O	O
receptors	receptor	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
,	,	,	O	O	O
therefore	therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
explain	explain	VB	B-VP	O	O
this	this	DT	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	B-Chemical
resistance	resistance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
reversion	reversion	NN	I-NP	O	O
after	after	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	O
treatment	treatment	NN	I-NP	O	O
excludes	exclude	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
itself	itself	PRP	B-NP	O	O
causes	cause	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
ISO	ISO	NN	I-NP	O	B-Chemical
resistance	resistance	NN	I-NP	O	O
and	and	CC	O	O	O
points	point	NNS	B-NP	O	O
towards	towards	IN	B-PP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
insulin	insulin	NN	I-NP	B	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
catecholamine	catecholamine	NN	I-NP	O	B-Chemical
sensitivity	sensitivity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
described	describe	VBN	B-VP	O	O
might	might	MD	B-VP	O	O
elucidate	elucidate	VB	I-VP	O	O
pathogenetic	pathogenetic	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
behind	behind	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
possibly	possibly	RB	I-VP	O	O
have	have	VB	I-VP	O	O
relevance	relevance	NN	B-NP	O	O
for	for	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Differential	Differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
muscarinic	muscarinic	JJ	I-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
widespread	widespread	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
forebrain	forebrain	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
salicylate	salicylate	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
mefenamic	mefenamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
on	on	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
salicylate	salicylate	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
ED50	ED50	NN	B-NP	O	O
103	103	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
174	174	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
phenylbutazone	phenylbutazone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
59	59	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
70	70	CD	I-NP	O	O
)	)	)	O	O	O
converted	convert	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
convulsant	convulsant	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
convulsant	convulsant	JJ	I-NP	O	O
one	one	CD	I-NP	O	O
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
modulate	modulate	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Mefenamic	Mefenamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
26	26	CD	B-NP	O	O
(	(	(	O	O	O
22	22	CD	B-NP	O	O
-	-	HYPH	O	O	O
30	30	CD	O	O	O
)	)	)	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
prevented	prevent	VBD	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
protected	protected	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
-	-	HYPH	B-PP	O	O
related	relate	VBN	B-NP	O	O
brain	brain	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
380	380	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
differentially	differentially	RB	B-ADVP	O	O
modulate	modulate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
for	for	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
neurologic	neurologic	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
etoposide	etoposide	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
malignant	malignant	JJ	B-NP	O	B-Disease
glioma	glioma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Etoposide	Etoposide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VP	VP	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
16	16	CD	B-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
213	213	CD	I-NP	I	I-Chemical
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
solid	solid	JJ	I-NP	O	O
tumors	tumor	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
hematologic	hematologic	JJ	B-NP	O	B-Disease
malignancies	malignancy	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
conjunction	conjunction	NN	B-NP	O	O
with	with	IN	B-PP	O	O
autologous	autologous	JJ	B-NP	O	O
bone	bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
activity	activity	NN	B-NP	O	O
against	against	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
resistant	resistant	JJ	I-NP	O	O
cancers	cancer	NNS	I-NP	O	B-Disease
including	include	VBG	B-PP	O	O
malignant	malignant	JJ	B-NP	O	B-Disease
glioma	glioma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
six	six	CD	B-NP	O	O
of	of	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
who	who	WP	B-NP	O	O
we	we	PRP	B-NP	O	O
treated	treat	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
resistant	resistant	JJ	I-NP	O	O
glioma	glioma	NN	I-NP	O	B-Disease
,	,	,	O	O	O
sudden	sudden	JJ	B-NP	O	O
severe	severe	JJ	I-NP	O	O
neurologic	neurologic	JJ	I-NP	O	B-Disease
deterioration	deterioration	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
median	median	NN	I-NP	O	O
of	of	IN	B-PP	O	O
9	9	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
etoposide	etoposide	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Significant	Significant	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
included	include	VBN	I-VP	O	O
confusion	confusion	NN	B-NP	O	B-Disease
,	,	,	O	O	O
papilledema	papilledema	NN	B-NP	O	B-Disease
,	,	,	O	O	O
somnolence	somnolence	NN	B-NP	O	B-Disease
,	,	,	O	O	O
exacerbation	exacerbation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
motor	motor	NN	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
sharp	sharp	JJ	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
resolved	resolve	VBD	B-VP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
dexamethasone	dexamethasone	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
computerized	computerize	VBD	B-VP	O	O
tomographic	tomographic	JJ	B-NP	O	O
(	(	(	O	O	O
CT	CT	NN	B-NP	B	O
)	)	)	O	O	O
brain	brain	NN	B-NP	O	O
scans	scan	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
stability	stability	NN	B-NP	O	O
in	in	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
size	size	NN	I-NP	O	O
and	and	CC	I-NP	O	O
peritumor	peritumor	NN	I-NP	O	O
edema	edema	NN	I-NP	O	B-Disease
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
pretransplant	pretransplant	NN	B-NP	O	O
scans	scan	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
represent	represent	VB	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
new	new	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
etoposide	etoposide	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
malignant	malignant	JJ	B-NP	O	B-Disease
glioma	glioma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Progressive	Progressive	JJ	B-NP	O	O
bile	bile	NN	I-NP	O	B-Disease
duct	duct	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
thiabendazole	thiabendazole	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
27	27	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
yr	yr	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
jaundice	jaundice	NN	B-NP	O	B-Disease
2	2	CD	I-NP	O	O
wk	wk	NN	I-NP	O	O
after	after	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
thiabendazole	thiabendazole	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Cholestasis	Cholestasis	NN	B-NP	O	B-Disease
persisted	persist	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
yr	yr	NN	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
time	time	NN	I-NP	O	O
a	a	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
liver	liver	NN	I-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
specimens	specimen	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
hepatectomy	hepatectomy	NN	I-NP	O	O
specimen	specimen	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
remarkable	remarkable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
almost	almost	RB	B-NP	O	O
complete	complete	JJ	I-NP	O	O
disappearance	disappearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interlobular	interlobular	JJ	B-NP	O	O
bile	bile	NN	I-NP	O	O
ducts	duct	NNS	I-NP	O	O
.	.	.	O	O	O

Prominent	Prominent	JJ	B-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	O
regeneration	regeneration	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
present	present	JJ	B-ADJP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
lobular	lobular	JJ	I-NP	O	O
architecture	architecture	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
preserved	preserve	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
represents	represent	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
example	example	NN	I-NP	O	O
of	of	IN	B-PP	O	O
"	"	``	B-NP	O	O
idiosyncratic	idiosyncratic	JJ	I-NP	O	O
"	"	''	I-NP	O	O
drug	drug	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
induced	induce	VBN	B-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
of	of	IN	B-PP	O	O
injury	injury	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
bile	bile	NN	I-NP	O	O
duct	duct	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
autoimmune	autoimmune	JJ	I-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bile	bile	NN	I-NP	O	B-Disease
duct	duct	NN	I-NP	O	I-Disease
destruction	destruction	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
.	.	.	O	O	O

Differential	Differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1,4	1,4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
dihydropyridine	dihydropyridine	NN	I-NP	I	I-Chemical
calcium	calcium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	I-Chemical
blockers	blocker	NNS	I-NP	O	I-Chemical
:	:	:	O	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
implications	implication	NNS	I-NP	O	O
.	.	.	O	O	O

Increasing	Increase	VBG	B-VP	O	O
recognition	recognition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
has	have	VBZ	B-VP	O	O
stimulated	stimulate	VBN	I-VP	O	O
research	research	NN	B-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
channel	channel	NN	I-NP	O	I-Chemical
blocking	block	VBG	B-VP	O	I-Chemical
agents	agent	NNS	B-NP	O	I-Chemical
for	for	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
favorable	favorable	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
make	make	VBP	B-VP	O	O
them	them	PRP	B-NP	O	O
attractive	attractive	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
modalities	modality	NNS	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
applications	application	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
channel	channel	NN	I-NP	O	I-Chemical
blockers	blocker	NNS	I-NP	O	I-Chemical
parallel	parallel	VBP	B-VP	O	O
their	their	PRP$	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
selectivity	selectivity	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
to	to	TO	B-PP	O	O
verapamil	verapamil	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
roughly	roughly	RB	B-ADJP	O	O
equipotent	equipotent	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
actions	action	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
and	and	CC	O	O	O
vascular	vascular	JJ	B-NP	O	O
smooth	smooth	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dihydropyridine	dihydropyridine	NN	I-NP	B	B-Chemical
calcium	calcium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	I-Chemical
blockers	blocker	NNS	I-NP	O	I-Chemical
are	be	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
vasodilator	vasodilator	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
exert	exert	VBP	B-VP	O	O
minimal	minimal	JJ	B-NP	O	O
electrophysiologic	electrophysiologic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
nodal	nodal	NN	I-NP	O	O
or	or	CC	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
dihydropyridine	dihydropyridine	NN	I-NP	B	B-Chemical
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	State	NNPS	I-NP	O	O
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
controls	control	VBZ	B-VP	O	O
angina	angina	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
minimal	minimal	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Additional	Additional	JJ	B-NP	O	O
members	member	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
channel	channel	NN	I-NP	O	I-Chemical
blockers	blocker	NNS	I-NP	O	I-Chemical
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
studied	study	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indications	indication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
offer	offer	VB	I-VP	O	O
advantages	advantage	NNS	B-NP	O	O
over	over	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Once	Once	RB	B-ADVP	O	O
or	or	CC	O	O	O
twice	twice	RB	B-NP	O	O
daily	daily	RB	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
possible	possible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
nitrendipine	nitrendipine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
nisoldipine	nisoldipine	NN	I-NP	B	B-Chemical
offers	offer	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
convenient	convenient	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
encourages	encourage	VBZ	B-VP	O	O
patient	patient	NN	B-NP	O	O
compliance	compliance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
vasodilating	vasodilate	VBG	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nisoldipine	nisoldipine	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
led	lead	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
in	in	IN	B-PP	O	O
angina	angina	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Selectivity	Selectivity	NN	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerebrovascular	cerebrovascular	JJ	I-NP	O	O
bed	bed	NN	I-NP	O	O
makes	make	VBZ	B-VP	O	O
nimodipine	nimodipine	NN	B-NP	B	B-Chemical
potentially	potentially	RB	B-ADJP	O	O
useful	useful	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subarachnoid	subarachnoid	JJ	B-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
,	,	,	O	O	O
migraine	migraine	NN	B-NP	O	B-Disease
headache	headache	NN	I-NP	O	I-Disease
,	,	,	O	O	O
dementia	dementia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
stroke	stroke	NN	B-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
general	general	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dihydropyridine	dihydropyridine	NN	I-NP	B	B-Chemical
calcium	calcium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	I-Chemical
blockers	blocker	NNS	I-NP	O	I-Chemical
are	be	VBP	B-VP	O	O
usually	usually	RB	I-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
headache	headache	NN	B-NP	O	B-Disease
,	,	,	O	O	O
facial	facial	JJ	B-NP	O	O
flushing	flushing	NN	I-NP	O	B-Disease
,	,	,	O	O	O
palpitations	palpitation	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
edema	edema	NN	B-NP	O	B-Disease
,	,	,	O	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
anorexia	anorexia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
dizziness	dizziness	NN	B-NP	O	B-Disease
being	be	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminonucleoside	aminonucleoside	NN	B-NP	B	B-Chemical
nephrosis	nephrosis	NN	I-NP	O	B-Disease
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protamine	protamine	NN	B-NP	B	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
focal	focal	JJ	B-NP	O	B-Disease
segmental	segmental	JJ	I-NP	O	I-Disease
glomerular	glomerular	JJ	I-NP	O	I-Disease
sclerosis	sclerosis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
FSGS	FSGS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
developed	develop	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
puromycin	puromycin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
aminonucleoside	aminonucleoside	NN	B-NP	B	I-Chemical
(	(	(	O	O	O
AMNS	AMNS	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
protamine	protamine	NN	B-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
PS	PS	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
uninephrectomized	uninephrectomized	JJ	B-VP	O	O
three	three	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
before	before	RB	B-ADVP	O	O
,	,	,	O	O	O
received	receive	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
subcutaneous	subcutaneous	JJ	B-NP	O	O
AMNS	AMNS	NN	I-NP	O	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
100	100	CD	B-NP	O	O
g	g	NN	I-NP	O	O
body	body	NN	I-NP	O	O
wt	wt	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
PS	PS	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
2	2	CD	B-NP	O	O
separated	separate	VBN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
100	100	CD	B-NP	O	O
g	g	NN	I-NP	O	O
body	body	NN	I-NP	O	O
wt	wt	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
four	four	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
injections	injection	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
repeated	repeat	VBN	I-VP	O	O
another	another	DT	B-NP	O	O
three	three	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
day	day	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
sacrificed	sacrifice	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
24	24	CD	I-NP	O	O
,	,	,	I-NP	O	O
52	52	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
80	80	CD	B-NP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
nephrotic	nephrotic	JJ	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
finally	finally	RB	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
course	course	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
clearance	clearance	NN	I-NP	O	O
dropped	drop	VBD	B-VP	O	O
and	and	CC	I-VP	O	O
showed	show	VBD	I-VP	O	O
significant	significant	JJ	B-NP	O	O
difference	difference	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
,	,	,	O	O	O
AMNS	AMNS	NN	B-NP	O	B-Chemical
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
PS	PS	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	B	O
injected	inject	VBN	B-VP	O	O
.	.	.	O	O	O

Their	Their	PRP$	B-NP	O	O
glomeruli	glomerulus	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
changes	change	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
FSGS	FSGS	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ultrastructural	ultrastructural	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
stage	stage	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
particles	particle	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
perfused	perfuse	VBN	B-NP	O	O
ruthenium	ruthenium	NN	I-NP	B	B-Chemical
red	red	VBD	B-VP	I	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lamina	lamina	NN	I-NP	O	O
rara	rara	NN	I-NP	O	O
externa	externa	NN	I-NP	O	O
and	and	CC	O	O	O
marked	marked	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
epithelial	epithelial	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
cytoplasm	cytoplasm	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PS	PS	NNP	B-NP	B	B-Chemical
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
AMNS	AMNS	NN	B-NP	O	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glomerulus	glomerulus	NN	I-NP	O	O
and	and	CC	O	O	O
readily	readily	RB	B-VP	O	O
produces	produce	VBZ	I-VP	O	O
progressive	progressive	JJ	B-NP	O	O
FSGS	FSGS	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	B	B-Chemical
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
theophylline	theophylline	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
altered	alter	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
pregnancy	pregnancy	NN	I-NP	O	O
.	.	.	O	O	O

Sprague	Sprague	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
20	20	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
pregnant	pregnant	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
nonpregnant	nonpregnant	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
and	and	CC	I-NP	O	O
strain	strain	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
infusions	infusion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aminophylline	aminophylline	NN	B-NP	B	B-Chemical
until	until	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
maximal	maximal	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
which	which	WDT	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
28	28	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
this	this	DT	B-NP	O	O
endpoint	endpoint	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
(	(	(	O	O	O
total	total	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
CSF	CSF	NN	B-NP	B	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
but	but	CC	O	O	O
serum	serum	NN	B-NP	O	O
(	(	(	O	O	O
free	free	JJ	B-ADJP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
brain	brain	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
slightly	slightly	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Theophylline	Theophylline	NN	B-NP	B	B-Chemical
serum	serum	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
determined	determine	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
equilibrium	equilibrium	NN	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
pregnant	pregnant	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Fetal	Fetal	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
onset	onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mother	mother	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
maternal	maternal	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CSF	CSF	NN	I-NP	B	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
correlated	correlate	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
former	former	JJ	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
advanced	advance	VBN	B-NP	B	O
pregnancy	pregnancy	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
negligible	negligible	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
theophylline	theophylline	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Hyperkalemia	Hyperkalemia	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
naproxen	naproxen	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
reversed	reverse	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
fludrocortisone	fludrocortisone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
rheumatoid	rheumatoid	JJ	I-NP	O	B-Disease
arthritis	arthritis	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mefenamic	mefenamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
inappropriate	inappropriate	JJ	B-NP	O	O
hypoaldosteronism	hypoaldosteronism	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
both	both	CC	O	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
naproxen	naproxen	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
without	without	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
preexisting	preexist	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
predisposed	predispose	VBD	B-VP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
to	to	TO	B-PP	O	O
type	type	NN	B-NP	O	B-Disease
IV	IV	CD	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
acidosis	acidosis	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B	B-Chemical
synthetase	synthetase	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
unable	unable	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
discontinue	discontinue	VB	I-VP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
fludrocortisone	fludrocortisone	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
,	,	,	O	O	O
correcting	correct	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
hyperkalemia	hyperkalemia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
allowing	allow	VBG	B-VP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
continued	continue	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	B-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
manifestation	manifestation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
developed	develop	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
colorectal	colorectal	JJ	I-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
while	while	IN	B-SBAR	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CDDP	CDDP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
left	left	JJ	I-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

All	All	DT	B-NP	O	O
three	three	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
required	require	VBD	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
remained	remain	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
despite	despite	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
(	(	(	O	O	O
EKG	EKG	NN	B-NP	O	O
)	)	)	I-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
presentation	presentation	NN	I-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
(	(	(	O	O	O
hemodynamic	hemodynamic	JJ	B-ADJP	O	O
,	,	,	O	O	O
echocardiographic	echocardiographic	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
scintigraphic	scintigraphic	JJ	B-ADJP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
new	new	JJ	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
influenced	influence	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CDDP	CDDP	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
pathophysiologic	pathophysiologic	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Fatal	Fatal	JJ	B-NP	O	O
aplastic	aplastic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
aplastic	aplastic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
epileptic	epileptic	JJ	I-NP	O	B-Disease
woman	woman	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
concerns	concern	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
bone	bone	NN	I-NP	O	B-Disease
marrow	marrow	NN	I-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
only	only	RB	B-NP	O	O
the	the	DT	I-NP	O	O
fourth	fourth	JJ	I-NP	O	O
documented	document	VBN	I-NP	O	O
and	and	CC	I-NP	O	O
published	publish	VBN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

Carbamazepine	Carbamazepine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
safe	safe	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
physicians	physician	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
exceedingly	exceedingly	RB	I-NP	O	O
rare	rare	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
potentially	potentially	RB	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
better	well	RBR	B-ADJP	O	O
prevented	prevent	VBN	I-ADJP	O	O
by	by	IN	B-PP	O	O
clinical	clinical	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
by	by	IN	B-PP	O	O
laboratory	laboratory	NN	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

Participation	Participation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bulbospinal	bulbospinal	JJ	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
brain	brain	NN	I-NP	O	O
in	in	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
microinjection	microinjection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	O	O	O
10	10	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
microliter	microliter	NN	I-NP	O	O
)	)	)	O	O	O
into	into	IN	B-PP	O	O
a	a	DT	B-NP	O	O
region	region	NN	I-NP	O	O
adjacent	adjacent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
ventrolateral	ventrolateral	JJ	I-NP	O	O
surface	surface	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medulla	medulla	NN	I-NP	O	O
oblongata	oblongata	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
urethane	urethane	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
anesthetized	anesthetize	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Intramedullary	Intramedullary	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
saline	saline	NN	B-NP	B	O
vehicle	vehicle	NN	I-NP	O	O
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
the	the	DT	I-NP	O	O
mean	mean	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clonidine	clonidine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
transection	transection	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
bilateral	bilateral	JJ	B-NP	O	O
vagotomy	vagotomy	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
clonidine	clonidine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
antagonized	antagonize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
vagotomy	vagotomy	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
spinal	spinal	JJ	B-NP	O	O
transection	transection	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
selective	selective	JJ	B-NP	O	O
destruction	destruction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
5	5	CD	I-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
nerves	nerve	NNS	I-NP	O	O
,	,	,	O	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5,7	5,7	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
dihydroxytryptamine	dihydroxytryptamine	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vasodepressor	vasodepressor	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
bradycardiac	bradycardiac	JJ	I-NP	O	B-Disease
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
microinjected	microinjecte	VBN	B-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
near	near	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ventrolateral	ventrolateral	JJ	I-NP	O	O
surface	surface	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medulla	medulla	NN	I-NP	O	O
oblongata	oblongata	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
bulbospinal	bulbospinal	JJ	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
brought	bring	VBN	I-VP	O	O
about	about	RP	B-PRT	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
efferent	efferent	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
induced	induce	VBN	I-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vagal	vagal	JJ	B-NP	O	O
efferent	efferent	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Hypertension	Hypertension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
neuroblastoma	neuroblastoma	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
imipramine	imipramine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Hypertension	Hypertension	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
known	know	VBN	I-NP	O	O
finding	finding	NN	I-NP	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
neuroblastoma	neuroblastoma	NN	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
previously	previously	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Imipramine	Imipramine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
(	(	(	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
190	190	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
160	160	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
girl	girl	NN	I-NP	O	O
with	with	IN	B-PP	O	O
neuroblastoma	neuroblastoma	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
Imipramine	Imipramine	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
control	control	VB	I-VP	O	O
a	a	DT	B-NP	O	O
behavior	behavior	NN	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
later	later	RB	B-ADVP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
recurring	recur	VBG	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
episode	episode	NN	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
and	and	CC	O	O	O
none	none	NN	B-NP	O	O
following	follow	VBG	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Imipramine	Imipramine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
when	when	WRB	B-ADVP	O	O
she	she	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
florid	florid	JJ	B-NP	B	O
relapse	relapse	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
believe	believe	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
rather	rather	RB	B-CONJP	O	O
than	than	IN	I-CONJP	O	O
her	her	PRP$	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
disease	disease	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
caused	cause	VBD	B-VP	O	O
her	her	PRP$	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
believed	believe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
vasoactive	vasoactive	JJ	B-NP	O	O
catecholamines	catecholamine	NNS	I-NP	O	B-Chemical
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
interference	interference	NN	B-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
physiologic	physiologic	JJ	I-NP	O	O
inactivation	inactivation	NN	I-NP	O	O
by	by	IN	B-PP	O	O
Imipramine	Imipramine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

From	From	IN	B-PP	O	O
this	this	DT	B-NP	O	O
experience	experience	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
urge	urge	VBP	B-VP	O	O
extreme	extreme	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tricyclic	tricyclic	JJ	B-NP	O	O
antidepressants	antidepressant	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
active	active	JJ	B-NP	O	O
neuroblastoma	neuroblastoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Rechallenge	Rechallenge	NN	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
oral	oral	JJ	B-NP	O	B-Disease
candidiasis	candidiasis	NN	I-NP	O	I-Disease
or	or	CC	I-NP	O	O
hoarseness	hoarseness	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
beclomethasone	beclomethasone	NN	B-NP	B	B-Chemical
dipropionate	dipropionate	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
158	158	CD	B-NP	O	O
asthmatic	asthmatic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
placed	place	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
inhaled	inhale	VBN	B-NP	O	O
beclomethasone	beclomethasone	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
15	15	CD	B-NP	O	O
(	(	(	O	O	O
9.5	9.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
developed	develop	VBD	B-VP	O	O
either	either	CC	O	O	O
hoarseness	hoarseness	NN	B-NP	O	B-Disease
(	(	(	O	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
thrush	thrush	NN	I-NP	O	B-Disease
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
their	their	PRP$	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
subsided	subside	VBD	B-VP	O	O
,	,	,	O	O	O
seven	seven	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
15	15	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
rechallenged	rechallenge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
inhaled	inhale	VBN	B-NP	O	O
beclomethasone	beclomethasone	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

These	These	DT	B-NP	O	O
included	include	VBD	B-VP	O	O
five	five	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
hoarseness	hoarseness	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
three	three	CD	B-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
Candidiasis	Candidiasis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

One	One	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
both	both	DT	B-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
thrush	thrush	NN	I-NP	O	B-Disease
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
recur	recur	VB	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hoarseness	hoarseness	NN	B-NP	O	B-Disease
had	have	VBD	B-VP	O	O
recurrence	recurrence	NN	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
restarted	restart	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
inhaled	inhale	VBN	B-NP	O	O
beclomethasone	beclomethasone	NN	I-NP	B	B-Chemical
when	when	WRB	B-ADVP	O	O
clinically	clinically	RB	B-ADVP	O	O
indicated	indicate	VBN	B-VP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
develop	develop	VBP	B-VP	O	O
hoarseness	hoarseness	NN	B-NP	O	B-Disease
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
re	re	AFX	B-ADJP	O	O
-	-	HYPH	I-ADJP	O	O
challenged	challenge	VBN	B-VP	O	O
.	.	.	O	O	O

Concomitant	Concomitant	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
prednisone	prednisone	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
topical	topical	JJ	B-NP	O	O
beclomethasone	beclomethasone	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
hoarseness	hoarseness	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
candidiasis	candidiasis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Cyclophosphamide	Cyclophosphamide	NN	B-NP	B	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
:	:	:	O	O	O
an	an	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dosing	dosing	NN	B-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
undergo	undergo	VBP	B-VP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
generally	generally	RB	I-VP	O	O
immunosuppressed	immunosuppresse	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
usually	usually	RB	I-VP	O	O
calculated	calculate	VBN	I-VP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
weight	weight	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
these	these	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
serious	serious	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
definitive	definitive	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
chemotherapeutic	chemotherapeutic	JJ	B-NP	O	O
agent	agent	NN	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
generally	generally	RB	B-ADVP	O	O
correlates	correlate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
per	per	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
calculated	calculate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
transplanted	transplant	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
institution	institution	NN	I-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
correlated	correlate	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
per	per	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
.	.	.	O	O	O

Eighty	Eighty	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
receive	receive	VB	I-VP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
for	for	IN	B-PP	O	O
four	four	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
preparation	preparation	NN	B-NP	O	O
for	for	IN	B-PP	O	O
marrow	marrow	NN	B-NP	O	O
grafting	grafting	NN	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
84	84	CD	B-NP	O	O
transplants	transplant	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
aplastic	aplastic	JJ	B-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
Wiskott	Wiskott	NNP	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
Aldrich	Aldrich	NNP	I-NP	B	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
,	,	,	O	O	O
or	or	CC	O	O	O
severe	severe	JJ	B-NP	O	B-Disease
combined	combined	JJ	I-NP	O	I-Disease
immunodeficiency	immunodeficiency	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Fourteen	Fourteen	CD	B-NP	O	O
of	of	IN	B-PP	O	O
84	84	CD	B-NP	O	O
(	(	(	O	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
signs	sign	NNS	I-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
within	within	IN	B-PP	O	O
ten	ten	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
receiving	receive	VBG	B-VP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Six	Six	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
14	14	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
died	die	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
congestive	congestive	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
per	per	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
two	two	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
CYA	CYA	NN	I-NP	O	B-Chemical
dose	dose	NN	I-NP	O	O
:	:	:	O	O	O
Group	Group	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
or	or	CC	O	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
1.55	1.55	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
;	;	:	O	O	O
Group	Group	NN	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
1.55	1.55	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
d	d	NN	I-NP	O	O
.	.	.	O	O	O

Cardiotoxicity	Cardiotoxicity	NN	B-NP	O	B-Disease
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
thought	think	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
32	32	CD	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
/	/	SYM	O	O	O
52	52	CD	B-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.025	0.025	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Congestive	Congestive	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
caused	cause	VBD	B-VP	O	O
or	or	CC	I-VP	O	O
contributed	contribute	VBD	I-VP	O	O
to	to	TO	B-PP	O	O
death	death	NN	B-NP	O	O
in	in	IN	B-PP	O	O
0	0	CD	B-NP	O	O
/	/	SYM	O	O	O
32	32	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
1	1	CD	I-NP	O	O
v	v	NN	I-NP	O	O
6	6	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
52	52	CD	I-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.25	0.25	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
engraftment	engraftment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
evaluable	evaluable	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
CYA	CYA	NN	I-NP	O	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
correlates	correlate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
CYA	CYA	NN	B-NP	O	B-Chemical
dosage	dosage	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
calculated	calculate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
aplastic	aplastic	JJ	B-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
immunodeficiencies	immunodeficiency	NNS	I-NP	O	B-Disease
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
effectively	effectively	RB	I-VP	O	O
prepared	prepare	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
grafting	graft	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
CYA	CYA	NN	I-NP	O	B-Chemical
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1.55	1.55	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
for	for	IN	B-PP	O	O
four	four	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
than	than	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
whose	whose	WP$	B-NP	O	O
CYA	CYA	NN	I-NP	O	B-Chemical
dosage	dosage	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
weight	weight	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
reaffirms	reaffirm	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
principle	principle	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
drug	drug	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
correlates	correlate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
per	per	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
area	area	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
epidemiology	epidemiology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
fully	fully	RB	I-VP	O	O
understood	understand	VBN	I-VP	O	O
.	.	.	O	O	O

Experimental	Experimental	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
human	human	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	B-Chemical
cause	cause	VBP	B-VP	O	O
proximal	proximal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
damage	damage	NN	I-NP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
rarely	rarely	RB	B-ADVP	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
ever	ever	RB	B-ADVP	O	O
,	,	,	O	O	O
cause	cause	VBP	B-VP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
or	or	CC	I-NP	O	I-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycosides	aminoglycoside	NNS	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
seriously	seriously	RB	B-NP	O	O
ill	ill	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
ranges	range	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
8	8	CD	B-NP	O	O
to	to	TO	B-PP	O	O
10	10	CD	B-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
attributable	attributable	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
aminoglycoside	aminoglycoside	NN	I-NP	O	B-Chemical
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
liver	liver	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
advanced	advanced	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
high	high	JJ	B-NP	O	O
initial	initial	JJ	I-NP	O	O
estimated	estimate	VBN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
clearance	clearance	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
,	,	,	O	O	O
female	female	JJ	B-NP	O	O
gender	gender	NN	I-NP	O	O
all	all	DT	O	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
causes	cause	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
shock	shock	NN	B-NP	O	B-Disease
,	,	,	O	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Predictive	Predictive	JJ	B-NP	O	O
models	model	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
developed	develop	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
these	these	DT	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
identifying	identify	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
models	model	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
insights	insight	NNS	B-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathophysiology	pathophysiology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Flurothyl	Flurothyl	NN	B-NP	B	B-Chemical
seizure	seizure	NN	I-NP	O	B-Disease
thresholds	threshold	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
neonatally	neonatally	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
monosodium	monosodium	NN	B-NP	B	B-Chemical
glutamate	glutamate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
MSG	MSG	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
:	:	:	O	O	O
evaluation	evaluation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
flurothyl	flurothyl	NN	B-NP	B	B-Chemical
seizure	seizure	NN	I-NP	O	B-Disease
testing	testing	NN	I-NP	O	O
.	.	.	O	O	O

Monosodium	Monosodium	NN	B-NP	B	B-Chemical
glutamate	glutamate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
MSG	MSG	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
administration	administration	NN	B-NP	O	O
to	to	TO	B-PP	O	O
neonatal	neonatal	JJ	B-NP	O	O
rodents	rodent	NNS	I-NP	O	O
produces	produce	VBZ	B-VP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
numerous	numerous	JJ	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
deficits	deficit	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
neonatal	neonatal	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MSG	MSG	NN	B-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
permanent	permanent	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
susceptibility	susceptibility	NN	I-NP	O	O
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
previous	previous	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
inconclusive	inconclusive	JJ	B-ADJP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
flurothyl	flurothyl	NN	I-NP	B	B-Chemical
ether	ether	NN	I-NP	B	B-Chemical
seizure	seizure	NN	I-NP	O	B-Disease
screening	screening	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
susceptibility	susceptibility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
neonatal	neonatal	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MSG	MSG	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
g	g	NN	I-NP	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

MSG	MSG	NN	B-NP	O	B-Chemical
treatment	treatment	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whole	whole	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
threshold	threshold	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
naloxone	naloxone	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
challenge	challenge	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
thresholds	threshold	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
control	control	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MSG	MSG	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Flurothyl	Flurothyl	NN	B-NP	B	B-Chemical
ether	ether	NN	I-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
hypothermia	hypothermia	NN	B-NP	O	B-Disease
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flurothyl	flurothyl	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypothermia	hypothermia	NN	B-NP	O	B-Disease
to	to	TO	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
induction	induction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
.	.	.	O	O	O

Flurothyl	Flurothyl	NN	B-NP	B	B-Chemical
seizure	seizure	NN	I-NP	O	B-Disease
testing	testing	NN	I-NP	O	O
proved	prove	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
reliable	reliable	JJ	I-NP	O	O
technique	technique	NN	I-NP	O	O
with	with	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
susceptibility	susceptibility	NN	I-NP	O	O
.	.	.	O	O	O

Susceptibility	Susceptibility	NN	B-NP	O	O
to	to	TO	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
microinjection	microinjection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
gamma	gamma	SYM	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
vinyl	vinyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
GABA	GABA	NN	I-NP	I	I-Chemical
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substantia	substantia	NN	I-NP	O	O
nigra	nigra	NN	I-NP	O	O
.	.	.	O	O	O

Pilocarpine	Pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
given	give	VBN	B-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
reproduces	reproduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
neuropathological	neuropathological	JJ	I-NP	O	O
sequelae	sequela	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
temporal	temporal	JJ	B-NP	O	B-Disease
lobe	lobe	NN	I-NP	O	I-Disease
epilepsy	epilepsy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
provides	provide	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
for	for	IN	B-PP	O	O
studying	study	VBG	B-VP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
buildup	buildup	NN	B-NP	O	O
of	of	IN	B-PP	O	O
convulsive	convulsive	JJ	B-NP	O	B-Disease
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
pathways	pathway	NNS	B-NP	O	O
operative	operative	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
generalization	generalization	NN	I-NP	O	O
and	and	CC	I-NP	O	O
propagation	propagation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
forebrain	forebrain	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
manipulating	manipulate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gamma	gamma	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substantia	substantia	NN	I-NP	O	O
nigra	nigra	NN	I-NP	O	O
on	on	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
pretreated	pretreate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
microinjections	microinjection	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
150	150	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
GABA	GABA	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
synthesizing	synthesize	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
,	,	,	O	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
glutamic	glutamic	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
decarboxylase	decarboxylase	NN	I-NP	O	O
,	,	,	O	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substantia	substantia	NN	I-NP	O	O
nigra	nigra	NN	I-NP	O	O
pars	par	NNS	I-NP	O	O
reticulata	reticulata	NN	I-NP	O	O
(	(	(	O	O	O
SNR	SNR	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
bilaterally	bilaterally	RB	B-ADVP	O	O
,	,	,	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
convulsant	convulsant	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
100	100	CD	B-NP	O	O
and	and	CC	I-NP	O	O
200	200	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
motor	motor	NN	I-NP	O	O
limbic	limbic	JJ	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Electroencephalographic	Electroencephalographic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
profound	profound	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
for	for	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Morphological	Morphological	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
frontal	frontal	JJ	B-NP	O	O
forebrain	forebrain	NN	I-NP	O	O
sections	section	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
light	light	JJ	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
damage	damage	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
formation	formation	NN	I-NP	O	O
,	,	,	O	O	O
thalamus	thalamus	NN	B-NP	O	O
,	,	,	O	O	O
amygdala	amygdala	NN	B-NP	O	O
,	,	,	O	O	O
olfactory	olfactory	JJ	B-NP	O	O
cortex	cortex	NN	I-NP	O	O
,	,	,	O	O	O
substantia	substantia	NN	B-NP	O	O
nigra	nigra	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neocortex	neocortex	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
typically	typically	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
exceeding	exceed	VBG	B-VP	O	O
350	350	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	O
intrastriatal	intrastriatal	JJ	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
isoniazid	isoniazid	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
augment	augment	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Application	Application	NN	B-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
irreversible	irreversible	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
transaminase	transaminase	NN	I-NP	O	O
,	,	,	O	O	O
gamma	gamma	SYM	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
vinyl	vinyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
GABA	GABA	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
D,L	D,L	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
4	4	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
amino	amino	JJ	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
hex	hex	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
5	5	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
enoic	enoic	JJ	I-NP	O	I-Chemical
acid	acid	NN	I-NP	O	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
,	,	,	O	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SNR	SNR	NN	I-NP	O	O
,	,	,	O	O	O
bilaterally	bilaterally	RB	B-ADVP	O	O
,	,	,	O	O	O
suppressed	suppress	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
electrographic	electrographic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
380	380	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
protect	protect	VB	I-VP	O	O
animals	animal	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
brain	brain	NN	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Microinjections	Microinjection	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
gamma	gamma	SYM	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
vinyl	vinyl	NN	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
GABA	GABA	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
5	5	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
,	,	,	O	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dorsal	dorsal	JJ	I-NP	O	O
striatum	striatum	NN	I-NP	O	O
,	,	,	O	O	O
bilaterally	bilaterally	RB	B-ADVP	O	O
,	,	,	O	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
380	380	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
for	for	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
subjected	subject	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
GABA	GABA	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substantia	substantia	NN	I-NP	O	O
nigra	nigra	NN	I-NP	O	O
.	.	.	O	O	O

Non	Non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
invasive	invasive	JJ	I-NP	O	O
detection	detection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
body	body	NN	B-NP	O	O
surface	surface	NN	I-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
mapping	mapping	NN	I-NP	O	O
after	after	IN	B-PP	O	O
dipyridamole	dipyridamole	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Electrocardiographic	Electrocardiographic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
dipyridamole	dipyridamole	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
(	(	(	O	O	O
0.568	0.568	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
4	4	CD	I-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
41	41	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
after	after	IN	B-PP	O	O
submaximal	submaximal	JJ	B-NP	O	O
treadmill	treadmill	NN	I-NP	O	O
exercise	exercise	NN	I-NP	O	O
by	by	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
surface	surface	NN	I-NP	O	O
mapping	mapping	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
;	;	:	O	O	O
19	19	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
group	group	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
14	14	CD	B-NP	O	O
with	with	IN	B-PP	O	O
anterior	anterior	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ANT	ANT	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
MI	MI	NN	I-NP	B	I-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
eight	eight	CD	B-NP	O	O
with	with	IN	B-PP	O	O
inferior	inferior	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
INF	INF	NN	B-NP	B	B-Disease
-	-	HYPH	B-NP	O	I-Disease
MI	MI	NN	I-NP	B	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
seven	seven	CD	I-NP	O	O
unipolar	unipolar	JJ	I-NP	O	O
electrocardiograms	electrocardiogram	NNS	I-NP	O	O
(	(	(	O	O	O
ECGs	ECG	NNS	B-NP	O	O
)	)	)	O	O	O
distributed	distribute	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
entire	entire	JJ	I-NP	O	O
thoracic	thoracic	JJ	I-NP	O	O
surface	surface	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
simultaneously	simultaneously	RB	I-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
dipyridamole	dipyridamole	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
ST	ST	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
segment	segment	NN	I-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
84	84	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
group	group	NN	I-NP	O	O
,	,	,	O	O	O
29	29	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ANT	ANT	NN	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
MI	MI	NN	I-NP	B	I-Disease
group	group	NN	I-NP	O	O
,	,	,	O	O	O
63	63	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
INF	INF	NN	I-NP	B	B-Disease
-	-	HYPH	I-NP	O	I-Disease
MI	MI	NN	I-NP	B	I-Disease
group	group	NN	I-NP	O	O
and	and	CC	O	O	O
61	61	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
.	.	.	O	O	O

Exercise	Exercise	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ST	ST	NN	I-NP	B	O
depression	depression	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
84	84	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
group	group	NN	I-NP	O	O
,	,	,	O	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ANT	ANT	NN	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
MI	MI	NN	I-NP	B	I-Disease
group	group	NN	I-NP	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
INF	INF	NN	I-NP	B	B-Disease
-	-	HYPH	I-NP	O	I-Disease
MI	MI	NN	I-NP	B	I-Disease
group	group	NN	I-NP	O	O
and	and	CC	O	O	O
61	61	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
obvious	obvious	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
body	body	NN	I-NP	O	O
surface	surface	NN	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ST	ST	JJ	B-NP	B	O
depression	depression	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pressure	pressure	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
product	product	NN	I-NP	O	O
after	after	IN	B-PP	O	O
dipyridamole	dipyridamole	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
less	less	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treadmill	treadmill	NN	I-NP	O	O
exercise	exercise	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dipyridamole	dipyridamole	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inhomogenous	inhomogenous	JJ	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dipyridamole	dipyridamole	NN	I-NP	B	B-Chemical
ECG	ECG	NN	I-NP	O	O
test	test	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
as	as	RB	B-ADJP	O	O
useful	useful	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
exercise	exercise	NN	I-NP	O	O
ECG	ECG	NN	I-NP	O	O
test	test	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
assessment	assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Bradycardia	Bradycardia	NNP	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
methylprednisolone	methylprednisolone	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
5	5	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	B-Disease
arthritis	arthritis	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
intravenous	intravenous	JJ	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
methylprednisolone	methylprednisolone	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
MP	MP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
therapy	therapy	NN	B-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
or	or	CC	I-NP	O	O
3	3	CD	I-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pulse	pulse	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
most	most	RBS	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
4	4	CD	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
complaints	complaint	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
substernal	substernal	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Reversal	Reversal	NN	B-NP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
7	7	CD	I-NP	O	O
.	.	.	O	O	O

Electrocardiographic	Electrocardiographic	JJ	B-NP	O	O
registrations	registration	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
sinus	sinus	NN	B-NP	O	B-Disease
bradycardia	bradycardia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
electrolytes	electrolyte	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
MP	MP	NN	I-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
MP	MP	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
contraindicated	contraindicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
known	know	VBN	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
downbeat	downbeat	JJ	B-NP	O	B-Disease
nystagmus	nystagmus	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
oscillopsia	oscillopsia	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Downbeat	Downbeat	NN	B-NP	O	B-Disease
nystagmus	nystagmus	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
often	often	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
structural	structural	JJ	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
craniocervical	craniocervical	JJ	I-NP	O	O
junction	junction	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
has	have	VBZ	B-VP	O	O
occasionally	occasionally	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
manifestation	manifestation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
imbalance	imbalance	NN	I-NP	O	O
or	or	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
intoxication	intoxication	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
recorded	record	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
eye	eye	NN	I-NP	O	O
movements	movement	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
reversible	reversible	JJ	B-NP	O	O
downbeat	downbeat	JJ	I-NP	O	B-Disease
nystagmus	nystagmus	NN	I-NP	O	I-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
nystagmus	nystagmus	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
resolved	resolve	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Neuroradiologic	Neuroradiologic	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
magnetic	magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
scans	scan	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intracranial	intracranial	JJ	B-NP	O	O
abnormality	abnormality	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
downbeat	downbeat	JJ	B-NP	O	B-Disease
nystagmus	nystagmus	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
taking	take	VBG	I-VP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
consideration	consideration	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
before	before	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
.	.	.	O	O	O

Improvement	Improvement	NN	B-NP	O	O
by	by	IN	B-PP	O	O
denopamine	denopamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
TA	TA	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
064	064	CD	I-NP	I	I-Chemical
)	)	)	O	O	O
of	of	IN	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dog	dog	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
lung	lung	NN	I-NP	O	O
preparation	preparation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
denopamine	denopamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
orally	orally	RB	I-NP	O	O
active	active	JJ	I-NP	O	O
beta	beta	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
improving	improve	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
dog	dog	NN	B-NP	O	O
heart	heart	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
lung	lung	NN	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
functions	function	NNS	I-NP	O	O
depressed	depress	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pentobarbital	pentobarbital	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
118	118	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
28	28	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
;	;	:	O	O	O
mean	mean	NN	B-NP	O	O
value	value	NN	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
SD	SD	NN	B-NP	O	O
)	)	)	O	O	O
such	such	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
and	and	CC	O	O	O
maximum	maximum	JJ	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rise	rise	NN	B-NP	O	O
of	of	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
LV	LV	NN	B-NP	B	O
dP	dP	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dt	dt	NN	I-NP	O	O
max	max	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
about	about	RB	B-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
respective	respective	JJ	I-NP	O	O
controls	control	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
improved	improve	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
denopamine	denopamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
300	300	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
100	100	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
denopamine	denopamine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
almost	almost	RB	B-NP	O	O
complete	complete	JJ	I-NP	O	O
restoration	restoration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
performance	performance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
attained	attain	VBN	I-VP	O	O
,	,	,	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
slight	slight	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
these	these	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
denopamine	denopamine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
warrant	warrant	VBP	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
denopamine	denopamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Clonazepam	Clonazepam	NN	B-NP	B	B-Chemical
monotherapy	monotherapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
childhood	childhood	NN	B-NP	O	O
.	.	.	O	O	O

Sixty	Sixty	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
age	age	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
range	range	NN	I-NP	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
to	to	TO	B-PP	O	O
14	14	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
than	than	IN	B-PP	O	O
infantile	infantile	JJ	B-NP	O	B-Disease
spasms	spasm	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
clonazepam	clonazepam	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Disappearance	Disappearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
normalization	normalization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
EEG	EEG	NN	I-NP	O	O
with	with	IN	B-PP	O	O
disappearance	disappearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
recognized	recognize	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
77	77	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Seizures	Seizure	NNS	B-NP	O	B-Disease
disappeared	disappear	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
71	71	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
generalized	generalize	VBN	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
89	89	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
partial	partial	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Improvement	Improvement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
EEG	EEG	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
noticed	notice	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
76	76	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diffuse	diffuse	JJ	B-NP	O	O
paroxysms	paroxysm	NNS	I-NP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
67	67	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
focal	focal	JJ	B-NP	O	O
paroxysms	paroxysm	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
excellent	excellent	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
effective	effective	JJ	I-NP	O	O
dosages	dosage	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
0.086	0.086	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.021	0.021	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
infants	infant	NNS	B-NP	O	O
and	and	CC	O	O	O
0.057	0.057	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.022	0.022	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
schoolchildren	schoolchildren	NN	B-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
statistically	statistically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.005	0.005	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
drowsiness	drowsiness	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
ataxia	ataxia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
only	only	RB	B-NP	O	O
5	5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Postmarketing	Postmarkete	VBG	B-VP	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	B	B-Chemical
antihypertensive	antihypertensive	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
postmarketing	postmarkete	VBG	I-NP	O	O
surveillance	surveillance	NN	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
fixed	fix	VBN	I-NP	O	O
-	-	HYPH	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
maleate	maleate	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
administered	administer	VBN	B-VP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
9,037	9,037	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
collected	collect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
1,455	1,455	CD	B-NP	O	O
participating	participate	VBG	I-NP	O	O
physicians	physician	NNS	I-NP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
25	25	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
and	and	CC	O	O	O
mean	mean	JJ	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
declined	decline	VBD	B-VP	O	O
15	15	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
after	after	IN	B-PP	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
of	of	IN	B-PP	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
,	,	,	O	O	O
both	both	DT	B-NP	O	O
comparisons	comparison	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Age	Age	NN	B-NP	O	O
,	,	,	O	O	O
race	race	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
severe	severe	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
1,453	1,453	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2,658	2,658	CD	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
being	be	VBG	I-NP	O	O
fatigue	fatigue	NN	I-NP	O	B-Disease
,	,	,	O	O	O
dizziness	dizziness	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
weakness	weakness	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
in	in	IN	B-PP	O	O
590	590	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Salicylate	Salicylate	NN	B-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Gunn	Gunn	NNP	I-NP	O	O
rat	rat	NN	I-NP	O	O
:	:	:	O	O	O
potential	potential	JJ	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandins	prostaglandin	NNS	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandins	prostaglandin	NNS	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
analgesic	analgesic	JJ	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Gunn	Gunn	NNP	I-NP	O	O
strain	strain	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
homozygous	homozygous	JJ	I-NP	O	O
Gunn	Gunn	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
unconjugated	unconjugate	VBN	I-VP	O	O
hyperbilirubinemia	hyperbilirubinemia	NN	B-NP	O	B-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucuronyl	glucuronyl	NN	B-NP	O	B-Chemical
transferase	transferase	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
marked	marked	JJ	B-NP	O	O
bilirubin	bilirubin	NN	I-NP	B	B-Chemical
deposition	deposition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
medulla	medulla	NN	I-NP	O	O
and	and	CC	I-NP	O	O
papilla	papilla	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
highly	highly	RB	B-ADJP	O	O
susceptible	susceptible	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
develop	develop	VB	I-VP	O	O
papillary	papillary	JJ	B-NP	O	B-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
analgesic	analgesic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
homozygous	homozygous	JJ	B-ADJP	O	O
(	(	(	O	O	O
jj	jj	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
phenotypically	phenotypically	RB	B-NP	O	O
normal	normal	JJ	I-NP	O	O
heterozygous	heterozygous	JJ	I-NP	O	O
(	(	(	O	O	O
jJ	jJ	NN	B-NP	O	O
)	)	)	O	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
:	:	:	O	O	O
jj	jj	NN	B-NP	O	O
and	and	CC	I-NP	O	O
jJ	jJ	NN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
either	either	CC	B-PP	O	O
with	with	IN	I-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
every	every	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
or	or	CC	I-NP	O	O
sham	sham	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	B-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
one	one	CD	B-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
slices	slice	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cortex	cortex	NN	B-NP	O	O
,	,	,	O	O	O
outer	outer	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
inner	inner	JJ	I-NP	O	O
medulla	medulla	NN	I-NP	O	O
from	from	IN	B-PP	O	O
one	one	CD	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
incubated	incubate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
buffer	buffer	NN	B-NP	O	O
and	and	CC	I-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
radioimmunoassay	radioimmunoassay	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
histologically	histologically	RB	B-ADVP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
corticomedullary	corticomedullary	JJ	I-NP	O	O
gradient	gradient	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

PGE2	PGE2	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
outer	outer	JJ	B-NP	O	O
medulla	medulla	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
cortex	cortex	NN	B-NP	O	O
or	or	CC	O	O	O
inner	inner	JJ	B-NP	O	O
medulla	medulla	NN	I-NP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
jj	jj	NN	B-NP	O	O
(	(	(	O	O	O
38	38	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
mg	mg	NN	I-NP	O	O
prot	prot	NN	I-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
jJ	jJ	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
15	15	CD	O	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
3	3	CD	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
PGE2	PGE2	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
regions	region	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
outer	outer	JJ	B-NP	O	O
medullary	medullary	JJ	I-NP	O	O
PGE2	PGE2	NN	I-NP	B	B-Chemical
remained	remain	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
jj	jj	NN	B-NP	O	O
(	(	(	O	O	O
18	18	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
3	3	CD	I-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
jJ	jJ	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

PGF2	PGF2	NN	B-NP	B	B-Chemical
alpha	alpha	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
outer	outer	JJ	I-NP	O	O
medulla	medulla	NN	I-NP	O	O
of	of	IN	B-PP	O	O
jj	jj	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
and	and	CC	I-PP	O	O
without	without	IN	I-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
jj	jj	NN	I-NP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
jJ	jJ	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
evidenced	evidence	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
:	:	:	O	O	O
increased	increase	VBN	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hematuria	hematuria	NN	B-NP	O	B-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
increased	increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
in	in	IN	B-PP	O	O
outer	outer	JJ	B-NP	O	O
medullary	medullary	JJ	I-NP	O	O
histopathologic	histopathologic	JJ	I-NP	O	O
lesions	lesion	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.005	0.005	CD	B-NP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
either	either	CC	O	O	O
sham	sham	NN	B-NP	O	O
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
jj	jj	NN	I-NP	O	O
or	or	CC	I-NP	O	O
aspirin	aspirin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
jJ	jJ	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
enhanced	enhance	VBN	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
maintenance	maintenance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
morphological	morphological	JJ	B-NP	O	O
integrity	integrity	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
pathological	pathological	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
medullary	medullary	JJ	I-NP	O	I-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
deterioration	deterioration	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
renal	renal	JJ	B-NP	O	I-Disease
function	function	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Prophylactic	Prophylactic	JJ	B-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
seen	see	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
entered	enter	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
randomized	randomize	VBN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
vs	vs	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
sustained	sustained	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
204	204	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
low	low	JJ	B-ADJP	O	O
,	,	,	O	O	O
1.5	1.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Lidocaine	Lidocaine	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
intramuscularly	intramuscularly	RB	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
sustained	sustained	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
warning	warn	VBG	B-VP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	B-Disease
between	between	IN	B-PP	O	O
15	15	CD	B-NP	O	O
and	and	CC	I-NP	O	O
45	45	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
10	10	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
a	a	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
infarction	infarction	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-PP	O	O
blocking	block	VBG	B-NP	O	O
agents	agent	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
no	no	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
from	from	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
not	not	RB	O	O	O
on	on	IN	B-PP	O	O
beta	beta	NN	B-NP	O	O
blocking	block	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
study	study	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
,	,	,	O	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
nine	nine	CD	B-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
four	four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
died	die	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
asystole	asystole	NN	B-NP	O	B-Disease
,	,	,	O	O	O
three	three	CD	B-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
had	have	VBN	I-VP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
cannot	cannot	MD	B-VP	O	O
advocate	advocate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
prophylactically	prophylactically	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Experiments	Experiment	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
tested	test	VBN	B-VP	O	O
previous	previous	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
systems	system	NNS	I-NP	O	O
promotes	promote	VBZ	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
need	need	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
intact	intact	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
full	full	JJ	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Large	Large	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cholinomimetic	cholinomimetic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
could	could	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
when	when	WRB	B-ADVP	O	O
peripheral	peripheral	JJ	B-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
blocked	block	VBN	I-VP	O	O
.	.	.	O	O	O

Low	Low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
muscarinic	muscarinic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
disrupted	disrupt	VBD	B-VP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Intracranial	Intracranial	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acetylcholine	acetylcholine	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
hemicholinium	hemicholinium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
usually	usually	RB	I-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
produced	produce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
neuroleptics	neuroleptic	NNS	B-NP	O	B-Chemical
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
actually	actually	RB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
intrinsic	intrinsic	JJ	B-NP	O	O
central	central	JJ	I-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

Alternatively	Alternatively	RB	B-ADVP	O	O
,	,	,	O	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
promote	promote	VB	I-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
by	by	IN	B-PP	O	O
suppression	suppression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
systems	system	NNS	I-NP	O	O
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
to	to	TO	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
pentobarbital	pentobarbital	NN	I-NP	I	I-Chemical
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
ingestion	ingestion	NN	I-NP	O	O
.	.	.	O	O	O

Barium	Barium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
supplemented	supplement	VBN	B-VP	O	O
Long	Long	NNP	B-NP	O	O
-	-	HYPH	O	O	O
Evans	Evans	NNP	B-NP	O	O
hooded	hood	VBD	B-VP	O	O
rats	rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
persistent	persistent	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
1	1	CD	B-NP	O	O
month	month	NN	I-NP	O	O
of	of	IN	B-PP	O	O
barium	barium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
100	100	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
mineral	mineral	NN	I-NP	O	O
fortified	fortify	VBN	B-VP	O	O
water	water	NN	B-NP	B	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Analysis	Analysis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
excitability	excitability	NN	I-NP	O	O
,	,	,	O	O	O
contractility	contractility	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
metabolic	metabolic	JJ	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
16	16	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
other	other	JJ	B-NP	O	O
significant	significant	JJ	I-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	B-Disease
within	within	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
cardiovascular	cardiovascular	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
distinctive	distinctive	JJ	I-NP	O	O
aspect	aspect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
demonstrated	demonstrate	VBN	I-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
to	to	TO	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
pentobarbital	pentobarbital	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Under	Under	IN	B-PP	O	O
barbiturate	barbiturate	NN	B-NP	B	B-Chemical
anesthesia	anesthesia	NN	I-NP	O	O
,	,	,	O	O	O
virtually	virtually	RB	B-NP	O	O
all	all	DT	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
indices	index	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
depressed	depress	VBN	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
barium	barium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
relative	relative	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
corresponding	correspond	VBG	I-NP	O	O
control	control	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
fed	feed	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
ketamine	ketamine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
xylazine	xylazine	NN	I-NP	B	B-Chemical
anesthesia	anesthesia	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
pentobarbital	pentobarbital	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
barium	barium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
linked	link	VBN	I-VP	O	O
specifically	specifically	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
anesthetic	anesthetic	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
representative	representative	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
generalized	generalize	VBN	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
pathophysiologic	pathophysiologic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
barium	barium	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
manifest	manifest	JJ	B-ADJP	O	O
,	,	,	O	O	O
irrespective	irrespective	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
employed	employ	VBN	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
contractile	contractile	JJ	I-NP	O	O
element	element	NN	I-NP	O	O
shortening	shorten	VBG	B-VP	O	O
velocity	velocity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
fibers	fiber	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
slower	slow	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
barium	barium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
relative	relative	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
irrespective	irrespective	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
significant	significant	JJ	B-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
energy	energy	NN	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
element	element	NN	I-NP	O	O
shortening	shorten	VBG	B-VP	O	O
velocity	velocity	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
excitability	excitability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
system	system	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
depressed	depress	VBN	I-VP	O	O
preferentially	preferentially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
atrioventricular	atrioventricular	JJ	I-NP	O	O
nodal	nodal	JJ	I-NP	O	O
region	region	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hearts	heart	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
barium	barium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
altered	alter	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
contractility	contractility	NN	I-NP	O	O
and	and	CC	I-NP	O	O
excitability	excitability	NN	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	B-Disease
disturbances	disturbance	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
to	to	TO	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
pentobarbital	pentobarbital	NN	I-NP	I	I-Chemical
suggest	suggest	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
existence	existence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
heretofore	heretofore	RB	I-NP	O	O
undescribed	undescribed	JJ	I-NP	O	O
cardiomyopathic	cardiomyopathic	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
represent	represent	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
indication	indication	NN	I-NP	O	O
that	that	IN	B-NP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
long	long	JJ	I-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
ingestion	ingestion	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mammalian	mammalian	JJ	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Propranolol	Propranolol	NN	B-NP	B	B-Chemical
antagonism	antagonism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenylpropanolamine	phenylpropanolamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Phenylpropanolamine	Phenylpropanolamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
overdose	overdose	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
severe	severe	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
,	,	,	O	O	O
intracerebral	intracerebral	JJ	B-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Subjects	Subject	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
either	either	CC	B-PP	O	O
by	by	IN	B-PP	O	O
mouth	mouth	NN	B-NP	O	O
for	for	IN	B-PP	O	O
48	48	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
or	or	CC	B-PP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
after	after	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

PPA	PPA	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
increased	increase	VBN	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
31	31	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
14	14	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
systolic	systolic	JJ	B-ADJP	O	O
,	,	,	O	O	O
20	20	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
diastolic	diastolic	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
antagonized	antagonize	VBD	B-VP	O	O
this	this	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
10	10	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
systolic	systolic	JJ	B-ADJP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
7	7	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
diastolic	diastolic	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
after	after	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
also	also	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Left	Leave	VBN	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
echocardiography	echocardiography	NN	B-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
stroke	stroke	NN	I-NP	O	B-Disease
volume	volume	NN	I-NP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
62.5	62.5	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
20.9	20.9	CD	B-NP	O	O
to	to	TO	B-PP	O	O
80.8	80.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
22.4	22.4	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
64	64	CD	B-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
10	10	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
70	70	CD	I-NP	O	O
%	%	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-ADVP	O	O
-	-	SYM	O	O	O
7	7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
3.6	3.6	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
to	to	TO	B-PP	O	O
4.1	4.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-NP	O	O
1.0	1.0	CD	B-NP	O	O
L	L	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
reversed	reverse	VBD	B-VP	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
1710	1710	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
200	200	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2190	2190	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
700	700	CD	B-NP	O	O
dyne	dyne	NN	I-NP	O	O
X	X	SYM	B-NP	O	O
sec	sec	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
cm5	cm5	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
further	further	RBR	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
to	to	TO	B-PP	O	O
2660	2660	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1200	1200	CD	B-NP	O	O
dyne	dyne	NN	I-NP	O	O
X	X	SYM	B-NP	O	O
sec	sec	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
cm5	cm5	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
increases	increase	VBZ	B-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
systemic	systemic	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
antagonizes	antagonize	VBZ	B-VP	O	O
this	this	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
by	by	IN	B-PP	O	O
reversing	reverse	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
.	.	.	O	O	O

That	That	DT	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
antagonizes	antagonize	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
probably	probably	RB	B-ADVP	O	O
because	because	IN	B-SBAR	O	O
PPA	PPA	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
less	less	JJR	B-NP	O	O
beta	beta	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
activity	activity	NN	I-NP	O	O
than	than	IN	B-SBAR	O	O
does	do	VBZ	O	O	O
norepinephrine	norepinephrine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Mesangial	Mesangial	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
sclerosis	sclerosis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
aminonucleoside	aminonucleoside	NN	B-NP	B	B-Chemical
nephrosis	nephrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
mesangial	mesangial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
sclerosis	sclerosis	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
puromycin	puromycin	NN	I-NP	B	B-Chemical
aminonucleoside	aminonucleoside	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
model	model	NN	B-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
male	male	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
repeated	repeat	VBN	I-VP	O	O
subcutaneous	subcutaneous	JJ	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
;	;	:	O	O	O
five	five	CD	B-NP	O	O
controls	control	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
saline	saline	NN	B-NP	B	O
only	only	RB	B-ADVP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
severely	severely	RB	B-ADJP	O	O
proteinuric	proteinuric	JJ	I-ADJP	O	B-Disease
(	(	(	O	O	O
190	190	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
80	80	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
24	24	CD	B-NP	O	O
hr	hr	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
colloidal	colloidal	JJ	B-NP	B	O
carbon	carbon	NN	I-NP	I	B-Chemical
(	(	(	O	O	O
CC	CC	NN	B-NP	B	O
)	)	)	O	O	O
intravenously	intravenously	RB	B-ADVP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
5	5	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
sclerosis	sclerosis	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
7.6	7.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3.4	3.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glomeruli	glomeruli	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
rats	rat	NNS	I-NP	O	O
;	;	:	O	O	O
glomeruli	glomerulus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
controls	control	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
.	.	.	O	O	O

Glomeruli	Glomerulus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
rats	rat	NNS	I-NP	O	O
contained	contain	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
more	more	JJR	I-NP	O	O
CC	CC	NN	I-NP	B	O
than	than	IN	B-PP	O	O
glomeruli	glomerulus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

Glomeruli	Glomerulus	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
sclerosis	sclerosis	NN	B-NP	O	B-Disease
contained	contain	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
more	more	JJR	I-NP	O	O
CC	CC	NN	I-NP	B	O
than	than	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
sclerotic	sclerotic	JJ	I-NP	O	O
glomeruli	glomerulus	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
.	.	.	O	O	O

CC	CC	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
preferentially	preferentially	RB	I-VP	O	O
localized	localize	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sclerotic	sclerotic	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
affected	affect	VBN	I-NP	O	O
glomeruli	glomerulus	NNS	I-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
mesangial	mesangial	JJ	B-NP	O	O
CC	CC	NN	I-NP	B	O
clearance	clearance	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mesangium	mesangium	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
during	during	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
preferential	preferential	JJ	I-NP	O	O
CC	CC	NN	I-NP	B	O
localization	localization	NN	I-NP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lesions	lesion	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
CC	CC	NN	I-NP	B	O
uptake	uptake	NN	I-NP	O	O
shortly	shortly	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
in	in	IN	B-PP	O	O
apparent	apparent	JJ	B-NP	O	O
vulnerable	vulnerable	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
where	where	WRB	B-ADVP	O	O
sclerosis	sclerosis	NN	B-NP	O	B-Disease
will	will	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
subsequently	subsequently	RB	B-ADVP	O	O
.	.	.	O	O	O

Cluster	Cluster	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
random	random	JJ	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lesions	lesion	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
glomeruli	glomeruli	NN	I-NP	O	O
in	in	IN	B-PP	O	O
concordance	concordance	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
random	random	JJ	I-NP	O	O
localization	localization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mesangial	mesangial	JJ	B-NP	O	O
areas	area	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
dysfunction	dysfunction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Similar	Similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
remnant	remnant	NN	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
model	model	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
nephrosis	nephrosis	NN	I-NP	O	B-Disease
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
sclerosis	sclerosis	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
"	"	``	O	O	O
mesangial	mesangial	JJ	B-NP	O	O
overloading.	overloading.	NN	I-NP	O	O
"	"	''	O	O	O

Relationship	Relationship	NN	B-NP	O	O
between	between	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
nicotinic	nicotinic	JJ	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
controversy	controversy	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
existed	exist	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
years	year	NNS	I-NP	O	O
concerning	concern	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
physiological	physiological	JJ	I-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nicotinic	nicotinic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	O	O
-	-	HYPH	I-NP	O	O
bungarotoxin	bungarotoxin	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

Using	Use	VBG	B-VP	O	O
mice	mouse	NNS	B-NP	O	O
derived	derive	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
classical	classical	JJ	I-NP	O	O
F2	F2	NN	I-NP	B	O
and	and	CC	O	O	O
backcross	backcross	RB	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
design	design	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
alpha	alpha	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
bungarotoxin	bungarotoxin	NN	I-NP	O	O
nicotinic	nicotinic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

Mice	Mouse	NNS	B-NP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
convulsant	convulsant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
greater	great	JJR	B-NP	O	O
alpha	alpha	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
bungarotoxin	bungarotoxin	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
than	than	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
insensitive	insensitive	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
binding	bind	VBG	I-NP	O	O
sites	site	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
sensitive	sensitive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
resistant	resistant	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
equally	equally	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
dithiothreitol	dithiothreitol	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
trypsin	trypsin	NN	I-NP	B	O
or	or	CC	I-NP	O	O
heat	heat	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
sensitive	sensitive	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
insensitive	insensitive	JJ	I-NP	O	O
animals	animal	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
nicotinic	nicotinic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	O	O
-	-	HYPH	I-NP	O	O
bungarotoxin	bungarotoxin	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p	p	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aminophenol	aminophenol	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
:	:	:	O	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bis	bis	NN	B-NP	B	B-Chemical
(	(	(	O	I	I-Chemical
p	p	NN	B-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
nitrophenyl	nitrophenyl	NN	I-NP	I	I-Chemical
)	)	)	O	I	I-Chemical
phosphate	phosphate	NN	B-NP	I	I-Chemical
on	on	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
p	p	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
aminophenol	aminophenol	NN	I-NP	I	I-Chemical
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Fischer	Fischer	NNP	B-NP	O	O
344	344	CD	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Acetaminophen	Acetaminophen	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
produces	produce	VBZ	B-VP	O	O
proximal	proximal	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	B-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Fischer	Fischer	NNP	B-NP	O	O
344	344	CD	I-NP	O	O
(	(	(	O	O	O
F344	F344	NN	B-NP	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
aminophenol	aminophenol	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
known	known	JJ	I-NP	O	O
potent	potent	JJ	I-NP	O	O
nephrotoxicant	nephrotoxicant	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
F344	F344	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
formation	formation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
requisite	requisite	JJ	I-NP	O	O
step	step	NN	I-NP	O	O
in	in	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bis	bis	NN	B-NP	B	B-Chemical
(	(	(	O	I	I-Chemical
p	p	NN	B-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
nitrophenyl	nitrophenyl	NN	I-NP	I	I-Chemical
)	)	)	O	I	I-Chemical
phosphate	phosphate	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
BNPP	BNPP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
acylamidase	acylamidase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
PAP	PAP	NN	I-NP	B	B-Chemical
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

BNPP	BNPP	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
8	8	CD	I-NP	O	O
mM	mM	NN	I-NP	O	O
)	)	)	O	O	O
reduced	reduce	VBD	B-VP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
deacetylation	deacetylation	NN	I-NP	O	O
and	and	CC	O	O	O
covalent	covalent	JJ	B-NP	O	O
binding	binding	NN	I-NP	O	O
in	in	IN	B-PP	O	O
F344	F344	NN	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cortical	cortical	JJ	I-NP	O	O
homogenates	homogenate	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Pretreatment	Pretreatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
BNPP	BNPP	NN	B-NP	B	B-Chemical
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
PAP	PAP	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
marked	marked	JJ	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
900	900	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
result	result	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
altered	altered	JJ	B-NP	O	O
disposition	disposition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
acetylated	acetylate	VBN	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
or	or	CC	O	O	O
renal	renal	JJ	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
.	.	.	O	O	O

Rather	Rather	RB	B-ADVP	O	O
,	,	,	O	O	O
BNPP	BNPP	NN	B-NP	B	B-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
excreted	excrete	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
by	by	IN	B-PP	O	O
64	64	CD	B-NP	O	O
and	and	CC	I-NP	O	O
75	75	CD	I-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
750	750	CD	B-NP	O	O
and	and	CC	I-NP	O	O
900	900	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

BNPP	BNPP	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
the	the	DT	B-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
deacetylated	deacetylate	VBN	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
nor	nor	CC	O	O	O
did	do	VBD	B-VP	O	O
BNPP	BNPP	NN	B-NP	B	B-Chemical
alter	alter	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
150	150	CD	B-NP	O	O
and	and	CC	I-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
BNPP	BNPP	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
deacetylation	deacetylation	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
PAP	PAP	NN	B-NP	B	B-Chemical
formation	formation	NN	I-NP	O	O
,	,	,	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
accounts	account	NNS	B-NP	O	O
,	,	,	O	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
APAP	APAP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Morphine	Morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
newborn	newborn	JJ	B-NP	O	O
infants	infant	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
neonates	neonate	NNS	I-NP	O	O
suffered	suffer	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
generalized	generalize	VBN	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
for	for	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
received	receive	VBD	B-VP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
32	32	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
hr	hr	NN	I-NP	O	O
and	and	CC	I-NP	O	O
40	40	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
hr	hr	NN	B-NP	O	O
larger	large	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
neonates	neonate	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
hr	hr	NN	I-NP	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
neonates	neonate	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
excessive	excessive	JJ	B-ADJP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
and	and	CC	I-NP	O	O
90	90	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
known	known	JJ	I-NP	O	O
reasons	reason	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
ruled	rule	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
stopped	stop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reoccur	reoccur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
8	8	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
should	should	MD	B-VP	O	O
not	not	RB	I-VP	O	O
exceed	exceed	VB	I-VP	O	O
20	20	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rhesus	rhesus	NN	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
,	,	,	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
with	with	IN	B-PP	O	O
0.6	0.6	CD	B-NP	O	O
x	x	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
2.2	2.2	CD	B-NP	O	O
x	x	NN	I-NP	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	O
aeruginosa	aeruginosa	NN	I-NP	O	O
organisms	organism	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	O
illness	illness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
duration	duration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
;	;	:	O	O	O
blood	blood	NN	B-NP	O	O
cultures	culture	NNS	I-NP	O	O
became	become	VBD	B-VP	O	O
negative	negative	JJ	B-ADJP	O	O
3	3	CD	B-NP	O	O
to	to	TO	B-PP	O	O
17	17	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
challenge	challenge	NN	B-NP	O	O
.	.	.	O	O	O

Leukocytosis	Leukocytosis	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
intratracheal	intratracheal	JJ	I-NP	O	O
inoculation	inoculation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2.0	2.0	CD	B-NP	O	O
to	to	TO	I-NP	O	O
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
leukopenia	leukopenia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
4	4	CD	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Intravenous	Intravenous	JJ	B-NP	O	O
inoculation	inoculation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4.2	4.2	CD	B-NP	O	O
x	x	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
7.8	7.8	CD	B-NP	O	O
x	x	NN	I-NP	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
10	10	CD	O	O	O
)	)	)	O	O	O
pyocin	pyocin	NN	B-NP	O	O
type	type	NN	I-NP	O	O
6	6	CD	I-NP	O	O
Pseudomonas	Pseudomonas	NN	I-NP	O	O
organisms	organism	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
monkeys	monkey	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
previously	previously	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
infection	infection	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
of	of	IN	B-PP	O	O
14	14	CD	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
Pseudomonas	Pseudomonas	NNP	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
died	die	VBD	B-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
antimetabolite	antimetabolite	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
leukopenia	leukopenia	NN	I-NP	O	B-Disease
predisposes	predispose	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
Pseudomonas	Pseudomonas	NN	I-NP	O	O
sepsis	sepsis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
such	such	JJ	B-NP	O	O
monkeys	monkey	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
serve	serve	VB	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
for	for	IN	B-PP	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
comparative	comparative	JJ	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antimicrobial	antimicrobial	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Central	Central	JJ	B-NP	O	O
excitatory	excitatory	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
flurazepam	flurazepam	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Toxic	Toxic	JJ	B-NP	O	O
actions	action	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
flurazepam	flurazepam	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
,	,	,	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
central	central	JJ	I-NP	O	O
excitation	excitation	NN	I-NP	O	O
,	,	,	O	O	O
most	most	RBS	B-VP	O	O
clearly	clearly	RB	I-VP	O	O
seen	see	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
clonic	clonic	JJ	B-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
superimposed	superimpose	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
lethal	lethal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
death	death	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
always	always	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

Comparing	Compare	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
central	central	JJ	B-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
excitation	excitation	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
rats	rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
least	least	RBS	B-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	B-NP	O	O
first	first	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
loss	loss	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
consciousness	consciousness	NN	B-NP	O	I-Disease
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
cats	cat	NNS	B-NP	O	O
most	most	RBS	B-ADVP	O	O
clearly	clearly	RB	I-ADVP	O	O
showed	show	VBD	B-VP	O	O
marked	marked	JJ	B-NP	O	O
central	central	JJ	I-NP	O	O
excitatory	excitatory	JJ	I-NP	O	O
actions	action	NNS	I-NP	O	O
.	.	.	O	O	O

Signs	Sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
toxocity	toxocity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
included	include	VBD	B-VP	O	O
excessive	excessive	JJ	B-NP	O	O
salivation	salivation	NN	I-NP	O	B-Disease
,	,	,	O	O	O
extreme	extreme	JJ	B-NP	O	O
apprehensive	apprehensive	JJ	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
,	,	,	O	O	O
retching	retching	NN	B-NP	O	O
,	,	,	O	O	O
muscle	muscle	NN	B-NP	O	B-Disease
tremors	tremor	NNS	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

An	An	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
pentylenetetrazol	pentylenetetrazol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PTZ	PTZ	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pretreating	pretreate	VBG	B-VP	O	O
mice	mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
before	before	IN	B-PP	O	O
PTZ	PTZ	NN	B-NP	B	B-Chemical
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-PP	O	O
a	a	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
,	,	,	O	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
first	first	RB	B-ADVP	O	O
protected	protect	VBD	B-VP	O	O
against	against	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
again	again	RB	B-ADVP	O	O
emerged	emerge	VBD	B-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
were	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
that	that	WDT	B-NP	O	O
would	would	MD	B-VP	O	O
alone	alone	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
relevant	relevant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
FZP	FZP	NN	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
situations	situation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
neural	neural	JJ	B-NP	O	O
excitability	excitability	NN	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
or	or	CC	O	O	O
sedative	sedative	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
hypnotic	hypnotic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptors	adrenoceptor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
atenolol	atenolol	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
cardioselective	cardioselective	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
nonselective	nonselective	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
on	on	IN	B-PP	O	O
both	both	CC	O	O	O
exercise	exercise	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
experiments	experiment	NNS	I-NP	O	O
involving	involve	VBG	B-VP	O	O
nine	nine	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Maximal	Maximal	JJ	B-NP	O	O
exercise	exercise	NN	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
187	187	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4	4	CD	B-NP	O	O
(	(	(	O	O	O
SEM	SEM	NN	B-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
to	to	TO	B-PP	O	O
146	146	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
7	7	CD	B-NP	O	O
bpm	bpm	NN	I-NP	O	O
after	after	IN	B-PP	O	O
atenolol	atenolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
138	138	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
bpm	bpm	NN	I-NP	O	O
after	after	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
tachycardia	tachycardia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.04	0.04	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
IV	IV	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Isoproterenol	Isoproterenol	NN	B-NP	B	B-Chemical
sensitivity	sensitivity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
increased	increase	VBD	B-VP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
by	by	IN	B-PP	O	O
25	25	CD	B-NP	O	O
bpm	bpm	NN	I-NP	O	O
(	(	(	O	O	O
CD25	CD25	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
1.8	1.8	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
0.3	0.3	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
to	to	TO	B-PP	O	O
38.9	38.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
8.3	8.3	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
8.3	8.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
1.7	1.7	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
atenolol	atenolol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
significant	significant	JJ	B-ADJP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
the	the	DT	B-NP	O	O
CD25	CD25	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
2.3	2.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.3	0.3	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
atenolol	atenolol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
7.7	7.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.3	1.3	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
24.8	24.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
5.0	5.0	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
remained	remain	VBD	B-VP	O	O
different	different	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
atenolol	atenolol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
change	change	NN	I-NP	O	O
with	with	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
sensitivity	sensitivity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
Ka	Ka	NNP	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
11.7	11.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.1	2.1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
10.1	10.1	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.5	2.5	CD	B-NP	O	O
ml	ml	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ng	ng	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
exercise	exercise	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
results	result	NNS	I-NP	O	O
largely	largely	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
activation	activation	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
blocked	block	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
both	both	CC	B-NP	O	O
cardioselective	cardioselective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
nonselective	nonselective	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
activates	activate	VBZ	B-VP	O	O
both	both	CC	O	O	O
beta	beta	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
and	and	CC	O	O	O
beta	beta	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
so	so	IN	B-SBAR	O	O
that	that	IN	I-SBAR	O	O
after	after	IN	B-PP	O	O
cardioselective	cardioselective	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
there	there	EX	B-NP	O	O
remains	remain	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
component	component	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
blocked	block	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
nonselective	nonselective	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
beta	beta	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
human	human	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
,	,	,	O	O	O
their	their	PRP$	B-NP	O	O
physiologic	physiologic	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
pathologic	pathologic	JJ	I-NP	O	O
roles	role	NNS	I-NP	O	O
remain	remain	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
defined	define	VBN	I-VP	O	O
.	.	.	O	O	O

Hormones	Hormone	NNS	B-NP	O	O
and	and	CC	O	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
breast	breast	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
reports	report	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
menopausal	menopausal	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
hormonal	hormonal	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
(	(	(	O	O	O
29	29	CD	B-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
surgical	surgical	JJ	B-NP	O	O
menopause	menopause	NN	I-NP	O	O
;	;	:	O	O	O
their	their	PRP$	B-NP	O	O
mean	mean	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
45.7	45.7	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
hypothesized	hypothesize	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
progestins	progestin	NNS	B-NP	B	B-Chemical
could	could	MD	B-VP	O	O
equilibrate	equilibrate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
estrogenic	estrogenic	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mammary	mammary	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
endometrial	endometrial	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
hormonal	hormonal	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
consisted	consist	VBD	B-VP	B	O
of	of	IN	B-PP	O	O
conjugated	conjugate	VBN	B-NP	O	B-Chemical
estrogens	estrogen	NNS	I-NP	B	I-Chemical
(	(	(	O	O	O
Premarin	Premarin	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
1.25	1.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
and	and	CC	O	O	O
Medroxyprogesterone	Medroxyprogesterone	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
month	month	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
18	18	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
up	up	RP	B-PRT	O	O
period	period	NN	B-NP	O	O
,	,	,	O	O	O
attention	attention	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
paid	pay	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
breast	breast	NN	B-NP	O	O
modifications	modification	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
evidenced	evidence	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
symptomatology	symptomatology	NN	B-NP	O	O
,	,	,	O	O	O
physical	physical	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
plate	plate	NN	B-NP	O	O
thermography	thermography	NN	I-NP	O	O
.	.	.	O	O	O

Mastodynia	Mastodynia	NNP	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
21	21	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
physical	physical	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
firmness	firmness	NN	I-NP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
breast	breast	NN	B-NP	O	O
nodularity	nodularity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Themography	Themography	NN	B-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
existence	existence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
excessive	excessive	JJ	I-NP	O	O
breast	breast	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
complained	complain	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
mastodynia	mastodynia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
7	7	CD	I-NP	O	O
women	woman	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
complained	complain	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
mastodynia	mastodynia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Normalization	Normalization	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
halving	halve	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
estrogen	estrogen	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
hormonal	hormonal	JJ	B-NP	O	O
replacement	replacement	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
satisfied	satisfy	VBN	I-VP	O	O
:	:	:	O	O	O
1	1	LS	B-LST	O	O
)	)	)	O	O	O
preliminary	preliminary	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
,	,	,	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
cytologic	cytologic	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mammographic	mammographic	JJ	B-NP	O	O
perspective	perspective	NN	I-NP	O	O
;	;	:	O	O	O
2	2	LS	B-LST	O	O
)	)	)	O	O	O
cyclic	cyclic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
progestative	progestative	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
3	3	LS	B-LST	O	O
)	)	)	O	O	O
periodic	periodic	JJ	B-NP	O	O
complete	complete	JJ	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
accurate	accurate	JJ	B-NP	O	O
thermographic	thermographic	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
breast	breast	NN	I-NP	O	O
target	target	NN	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
.	.	.	O	O	O

Early	Early	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
liver	liver	NN	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
recipients	recipient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
renal	renal	JJ	I-NP	O	O
,	,	,	I-NP	O	O
seventeen	seventeen	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
twenty	twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
four	four	CD	I-NP	O	O
liver	liver	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
infection	infection	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Seventeen	Seventeen	CD	B-NP	O	O
renal	renal	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Aza	Aza	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
prednisone	prednisone	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
immunosuppression	immunosuppression	NN	B-NP	O	O
with	with	IN	B-PP	O	O
21	21	CD	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
-	-	HYPH	I-NP	O	O
prednisone	prednisone	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
renal	renal	JJ	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
others	other	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
prednisone	prednisone	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
Aza	Aza	NN	I-NP	O	B-Chemical
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
more	more	RBR	B-NP	O	O
overall	overall	JJ	I-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
more	more	RBR	B-NP	O	O
nonviral	nonviral	JJ	I-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.02	0.02	CD	B-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	B	B-Chemical
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Heart	Heart	NN	B-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
than	than	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
renal	renal	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
but	but	CC	O	O	O
fewer	few	JJR	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Aza	Aza	NNP	I-NP	O	B-Chemical
renal	renal	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
infectious	infectious	JJ	I-NP	O	O
deaths	death	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
Aza	Aza	NN	I-NP	O	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
infection	infection	NN	B-NP	O	B-Disease
played	play	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
out	out	IN	I-NP	O	O
of	of	IN	I-NP	O	O
6	6	CD	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
8	8	CD	B-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
9	9	CD	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
fewest	few	JJS	I-NP	O	O
bacteremias	bacteremia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Analysis	Analysis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
site	site	NN	B-NP	O	O
of	of	IN	B-PP	O	O
infection	infection	NN	B-NP	O	B-Disease
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
preponderance	preponderance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abdominal	abdominal	JJ	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
intrathoracic	intrathoracic	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	B-Disease
tract	tract	NN	I-NP	O	I-Disease
infections	infection	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Pulmonary	Pulmonary	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
less	less	RBR	B-ADJP	O	O
common	common	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
renal	renal	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
Aza	Aza	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Aza	Aza	NN	B-NP	O	B-Chemical
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
more	more	JJR	I-NP	O	O
staphylococcal	staphylococcal	JJ	I-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
than	than	IN	B-PP	O	O
all	all	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.005	0.005	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
systemic	systemic	JJ	B-NP	O	O
fungal	fungal	JJ	I-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Cytomegalovirus	Cytomegalovirus	NN	B-NP	O	O
(	(	(	O	O	O
CMV	CMV	NN	B-NP	O	O
)	)	)	O	O	O
shedding	shedding	NN	B-NP	O	O
or	or	CC	O	O	O
serological	serological	JJ	B-NP	O	O
rises	rise	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
antibody	antibody	NN	B-NP	O	O
titer	titer	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
78	78	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
76	76	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Aza	Aza	NN	B-NP	O	B-Chemical
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	B	B-Chemical
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
had	have	VBD	O	O	O
symptoms	symptom	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
CMV	CMV	NN	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Serological	Serological	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Epstein	Epstein	NNP	B-NP	O	B-Disease
Barr	Barr	NNP	I-NP	O	I-Disease
Virus	Virus	NNP	I-NP	O	I-Disease
infection	infection	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
65	65	CD	B-NP	O	O
cyclosporine	cyclosporine	NN	I-NP	B	B-Chemical
patients	patient	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
had	have	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
lymphoma	lymphoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Structure	Structure	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effect	effect	NN	I-NP	O	O
relationships	relationship	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
by	by	IN	B-PP	O	O
cholecystokinin	cholecystokinin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
fragments	fragment	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
analogues	analogue	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cholecystokinin	cholecystokinin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Intraperitoneal	Intraperitoneal	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cholecystokinin	cholecystokinin	NN	B-NP	B	B-Chemical
octapeptide	octapeptide	NN	I-NP	O	I-Chemical
sulphate	sulphate	NN	I-NP	B	O
ester	ester	NN	I-NP	B	O
(	(	(	O	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
8	8	CD	B-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
nonsulphated	nonsulphated	JJ	B-NP	O	O
cholecystokinin	cholecystokinin	NN	I-NP	B	B-Chemical
octapeptide	octapeptide	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
8	8	CD	B-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
NS	NS	NN	I-NP	B	O
)	)	)	O	O	O
enhanced	enhance	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
latency	latency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

Experiments	Experiment	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
N	N	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
C	C	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
terminal	terminal	JJ	I-NP	O	O
fragments	fragment	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
terminal	terminal	JJ	I-NP	O	O
tetrapeptide	tetrapeptide	NN	I-NP	O	O
(	(	(	O	O	O
CCK	CCK	NN	B-NP	B	O
-	-	HYPH	O	I	O
5	5	CD	B-NP	I	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
centre	centre	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CCK	CCK	NN	I-NP	O	O
octapeptide	octapeptide	NN	I-NP	O	O
molecule	molecule	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
analogues	analogue	NNS	I-NP	O	O
CCK	CCK	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
and	and	CC	I-NP	O	O
CCK	CCK	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
NS	NS	NN	I-NP	B	O
(	(	(	O	O	O
dose	dose	NN	B-NP	O	O
range	range	NN	I-NP	O	O
0.2	0.2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6.4	6.4	CD	I-NP	O	O
mumol	mumol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
caerulein	caerulein	NN	B-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
range	range	NN	I-NP	O	O
0.1	0.1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
0.8	0.8	CD	I-NP	O	O
mumol	mumol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
bell	bell	NN	B-NP	O	O
-	-	HYPH	O	O	O
shaped	shape	VBN	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effect	effect	NN	I-NP	O	O
curves	curve	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
greatest	great	JJS	I-NP	O	O
maximum	maximum	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
NS	NS	NN	I-NP	B	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
peptide	peptide	NN	I-NP	O	O
CCK	CCK	NN	I-NP	B	O
-	-	HYPH	B-NP	I	O
5	5	CD	I-NP	I	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
had	have	VBD	B-VP	O	O
weak	weak	JJ	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
octapeptides	octapeptide	NNS	I-NP	O	O
,	,	,	O	O	O
3.2	3.2	CD	B-NP	O	O
mumol	mumol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
and	and	CC	O	O	O
larger	large	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reference	reference	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
totally	totally	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peptides	peptide	NNS	I-NP	O	O
tested	test	VBN	B-VP	O	O
was	be	VBD	B-VP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Experiments	Experiment	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
analogues	analogue	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CCK	CCK	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
5	5	CD	I-NP	I	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
alanyl	alanyl	NN	I-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CCK	CCK	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
5	5	CD	I-NP	I	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
equipotent	equipotent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CCK	CCK	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
analogues	analogue	NNS	I-NP	O	O
,	,	,	O	O	O
Ser	Ser	NN	B-NP	B	O
(	(	(	O	O	O
SO3H	SO3H	NN	B-NP	O	O
)	)	)	O	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
Ac	Ac	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
CCK	CCK	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
and	and	CC	I-NP	O	O
Thr	Thr	NN	I-NP	B	O
(	(	(	O	O	O
SO3H	SO3H	NN	B-NP	O	O
)	)	)	O	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
Ac	Ac	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
CCK	CCK	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
and	and	CC	I-NP	O	O
Hyp	Hyp	NN	I-NP	B	O
(	(	(	O	O	O
SO3H	SO3H	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
Ac	Ac	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
CCK	CCK	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
were	be	VBD	B-VP	O	O
slightly	slightly	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
active	active	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
CCK	CCK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
8	8	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	O
SE	SE	NN	I-NP	B	O
.	.	.	O	O	O

Vasopressin	Vasopressin	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
contributor	contributor	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressin	vasopressin	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
process	process	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
.	.	.	O	O	O

Vasopressin	Vasopressin	NN	B-NP	B	B-Chemical
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DOCA	DOCA	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
salt	salt	NN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
substantial	substantial	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
diabetes	diabetes	NN	I-NP	O	B-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
DOCA	DOCA	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
salt	salt	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
DDAVP	DDAVP	NN	B-NP	B	B-Chemical
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
antidiuretic	antidiuretic	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
but	but	CC	O	O	O
minimal	minimal	JJ	B-NP	O	O
vasopressor	vasopressor	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
increase	increase	VB	I-VP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AVP	AVP	NN	B-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pressor	pressor	NN	I-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressin	vasopressin	NN	B-NP	B	B-Chemical
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
important	important	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
since	since	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
enhanced	enhance	VBN	I-NP	O	O
pressor	pressor	NN	I-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
stage	stage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressin	vasopressin	NN	B-NP	B	B-Chemical
from	from	IN	B-PP	O	O
neurohypophysis	neurohypophysis	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
promotes	promote	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pathogenetic	pathogenetic	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

An	An	DT	B-NP	O	O
unproportional	unproportional	JJ	I-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressin	vasopressin	NN	B-NP	B	B-Chemical
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
osmolality	osmolality	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
adjusting	adjust	VBG	I-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
II	II	CD	I-NP	I	O
forming	form	VBG	I-NP	O	O
and	and	CC	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
balance	balance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasopressin	vasopressin	NN	B-NP	B	B-Chemical
remains	remain	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
essential	essential	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Toxic	Toxic	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
disulfiram	disulfiram	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
alcoholic	alcoholic	JJ	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
reversible	reversible	JJ	I-NP	O	O
toxic	toxic	JJ	I-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
damage	damage	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
alcoholic	alcoholic	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
disulfiram	disulfiram	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
causative	causative	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
proven	prove	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
challenge	challenge	NN	B-NP	O	O
.	.	.	O	O	O

Atrial	Atrial	JJ	B-NP	O	B-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
involving	involve	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
of	of	IN	B-PP	O	O
F	F	NN	B-NP	B	O
-	-	HYPH	O	I	O
344	344	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
ingesting	ingest	VBG	B-VP	O	O
quinacrine	quinacrine	NN	B-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Quinacrine	Quinacrine	JJ	B-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
is	be	VBZ	B-VP	O	O
toxic	toxic	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
of	of	IN	B-PP	O	O
F	F	NN	B-NP	B	O
-	-	HYPH	O	I	O
344	344	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
500	500	CD	B-NP	O	O
ppm	ppm	NN	I-NP	O	O
quinacrine	quinacrine	NN	I-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
all	all	DT	O	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
atrial	atrial	JJ	I-NP	O	B-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
dilatation	dilatation	NN	I-NP	O	O
and	and	CC	O	O	O
focal	focal	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
degeneration	degeneration	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
died	die	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
acute	acute	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
congestion	congestion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lungs	lung	NNS	I-NP	O	O
,	,	,	O	O	O
liver	liver	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
organs	organ	NNS	I-NP	O	O
.	.	.	O	O	O

Seventy	Seventy	CD	B-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
given	give	VBN	B-VP	O	O
250	250	CD	B-NP	O	O
ppm	ppm	NN	I-NP	O	O
quinacrine	quinacrine	NN	I-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
1,000	1,000	CD	B-NP	O	O
ppm	ppm	NN	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
nitrite	nitrite	NN	I-NP	I	I-Chemical
simultaneously	simultaneously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diet	diet	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
atria	atria	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
untreated	untreated	JJ	B-NP	O	O
control	control	NN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Sodium	Sodium	NN	B-NP	B	B-Chemical
nitrite	nitrite	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
quinacrine	quinacrine	NN	B-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
no	no	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Alternating	Alternate	VBG	B-VP	O	B-Disease
sinus	sinus	NN	B-NP	O	I-Disease
rhythm	rhythm	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
intermittent	intermittent	JJ	B-NP	O	O
sinoatrial	sinoatrial	JJ	I-NP	O	B-Disease
block	block	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Alternating	Alternate	VBG	B-VP	O	B-Disease
sinus	sinus	NN	B-NP	O	I-Disease
rhythm	rhythm	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
intermittent	intermittent	JJ	B-NP	O	O
sinoatrial	sinoatrial	JJ	I-NP	O	B-Disease
(	(	(	O	O	I-Disease
S	S	NN	B-NP	O	I-Disease
-	-	HYPH	B-NP	O	I-Disease
A	A	NN	I-NP	O	I-Disease
)	)	)	O	O	I-Disease
block	block	NN	B-NP	O	I-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
57	57	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
,	,	,	O	O	O
under	under	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
angina	angina	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
80	80	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
daily	daily	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
alternation	alternation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
short	short	JJ	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
and	and	CC	O	O	O
occasional	occasional	JJ	B-NP	O	O
pauses	pause	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
pauses	pause	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
always	always	RB	I-VP	O	O
preceded	precede	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
usually	usually	RB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
two	two	CD	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
P	P	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
0.92	0.92	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.95	0.95	CD	I-NP	O	O
s	s	NN	I-NP	O	O
representing	represent	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
basic	basic	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
these	these	DT	B-NP	O	O
basic	basic	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
cycles	cycle	NNS	I-NP	O	O
,	,	,	O	O	O
alternating	alternate	VBG	B-VP	O	B-Disease
rhythm	rhythm	NN	B-NP	O	I-Disease
started	start	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
longer	long	JJR	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
ranged	range	VBD	B-VP	O	O
between	between	IN	B-PP	O	O
1.04	1.04	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.12	1.12	CD	I-NP	O	O
s	s	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
0.80	0.80	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.84	0.84	CD	I-NP	O	O
s	s	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pauses	pause	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
equal	equal	JJ	B-ADJP	O	O
or	or	CC	O	O	O
almost	almost	RB	B-ADJP	O	O
equal	equal	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
one	one	CD	B-NP	O	O
short	short	JJ	I-NP	O	O
plus	plus	CC	O	O	O
one	one	CD	B-NP	O	O
long	long	JJ	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
or	or	CC	O	O	O
to	to	TO	B-VP	O	O
twice	twice	VB	I-VP	O	O
the	the	DT	B-NP	O	O
basic	basic	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
recording	record	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
with	with	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
S	S	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
A	A	NN	I-NP	O	I-Disease
block	block	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sinus	sinus	NN	B-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
interrupted	interrupt	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
sudden	sudden	JJ	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
starting	start	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
small	small	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
shape	shape	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
P	P	NN	I-NP	O	O
waves	wave	NNS	I-NP	O	O
and	and	CC	O	O	O
P	P	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
R	R	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

S	S	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
A	A	NN	I-NP	O	O
conduction	conduction	NN	I-NP	O	O
through	through	IN	B-PP	O	O
two	two	CD	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
with	with	IN	B-PP	O	O
2	2	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
block	block	NN	I-NP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
having	have	VBG	B-VP	O	O
0.12	0.12	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.14	0.14	CD	I-NP	O	O
s	s	NN	I-NP	O	O
longer	long	JJR	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
occasional	occasional	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
block	block	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
proposed	propose	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
explanation	explanation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alternating	alternate	VBG	I-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
features	feature	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
.	.	.	O	O	O

Atropine	Atropine	NN	B-NP	B	B-Chemical
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
shortening	shortening	NN	B-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	O	O	O
P	P	NN	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
changing	change	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
abnormal	abnormal	JJ	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
disappeared	disappear	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
restarted	restart	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
1	1	CD	I-NP	O	O
S	S	NN	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
A	A	NN	I-NP	O	I-Disease
block	block	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
accepted	accept	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
being	be	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
conduction	conduction	NN	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Antitumor	Antitumor	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IgM	IgM	NN	I-NP	O	O
solid	solid	JJ	I-NP	O	O
immunocytoma	immunocytoma	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	O
bearing	bear	VBG	B-VP	O	O
LOU	LOU	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
M	M	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
WSL	WSL	NN	I-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Antitumor	Antitumor	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
LOU	LOU	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
M	M	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
WSL	WSL	NN	I-NP	O	O
inbred	inbred	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
each	each	DT	B-NP	O	O
bearing	bear	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
transplantable	transplantable	JJ	I-NP	O	O
solid	solid	JJ	I-NP	O	O
IgM	IgM	NN	I-NP	O	O
immunocytoma	immunocytoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
(	(	(	O	O	O
diameter	diameter	NN	B-NP	O	O
,	,	,	O	O	O
15.8	15.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3.3	3.3	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
iv	iv	NN	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
5	5	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
1	1	CD	B-NP	O	O
weekly	weekly	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
(	(	(	O	O	O
dose	dose	NN	B-NP	O	O
range	range	NN	I-NP	O	O
,	,	,	O	O	O
0.015	0.015	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4.0	4.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
wt	wt	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Tumor	Tumor	NN	B-NP	O	B-Disease
regression	regression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Complete	Complete	JJ	B-NP	O	O
disappearance	disappearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
1.0	1.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Histologic	Histologic	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
scored	score	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
grade	grade	NN	B-NP	O	O
III	III	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1.0	1.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Light	Light	NN	B-NP	O	O
microscopic	microscopic	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
above	above	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
albuminuria	albuminuria	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
very	very	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
serum	serum	NN	I-NP	B	O
albumin	albumin	NN	I-NP	I	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
group	group	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
1.0	1.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	B	O
albumin	albumin	NN	I-NP	I	O
level	level	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
33.6	33.6	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4.1	4.1	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1.5	1.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.5	0.5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
liter	liter	NN	I-NP	O	O
.	.	.	O	O	O

Ascites	Ascites	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
hydrothorax	hydrothorax	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	O
bearing	bear	VBG	B-VP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
no	no	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
antitumor	antitumor	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
LOU	LOU	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
M	M	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
WSL	WSL	NN	I-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Albuminuria	Albuminuria	NNP	B-NP	O	B-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
extremely	extremely	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
serum	serum	NN	I-NP	B	O
albumin	albumin	NN	I-NP	I	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
so	so	IN	O	O	O
ascites	ascite	NNS	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
hydrothorax	hydrothorax	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
necessarily	necessarily	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
consequence	consequence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Intraoperative	Intraoperative	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
eye	eye	NN	I-NP	O	O
drops	drop	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
69	69	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
yr	yr	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
concurrently	concurrently	RB	I-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
nitrate	nitrate	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
maleate	maleate	NN	I-NP	I	I-Chemical
eye	eye	NN	I-NP	O	O
drops	drop	NNS	I-NP	O	O
,	,	,	O	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
became	become	VBD	B-VP	O	O
hypotensive	hypotensive	JJ	B-ADJP	O	B-Disease
during	during	IN	B-PP	O	O
halothane	halothane	NN	B-NP	B	B-Chemical
anaesthesia	anaesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
subsequently	subsequently	RB	I-VP	O	O
identified	identify	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
h	h	NN	I-NP	O	O
collection	collection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
urine	urine	NN	B-NP	O	O
.	.	.	O	O	O

Timolol	Timolol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
sample	sample	NN	I-NP	O	O
of	of	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
removed	remove	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
timolol	timolol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
2.6	2.6	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
ml	ml	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
partial	partial	JJ	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
postulated	postulate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
action	action	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
halothane	halothane	NN	B-NP	B	B-Chemical
anaesthesia	anaesthesia	NN	I-NP	O	O
with	with	IN	B-PP	O	O
resultant	resultant	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Pilocarpine	Pilocarpine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
had	have	VBD	I-VP	O	O
a	a	DT	B-NP	O	O
contributory	contributory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Succinylcholine	Succinylcholine	NN	B-NP	B	B-Chemical
apnoea	apnoea	NN	I-NP	O	B-Disease
:	:	:	O	O	O
attempted	attempt	VBN	B-NP	O	O
reversal	reversal	NN	I-NP	O	O
with	with	IN	B-PP	O	O
anticholinesterases	anticholinesteras	NNS	B-NP	O	O
.	.	.	O	O	O

Anticholinesterases	Anticholinesteras	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
attempt	attempt	NN	I-NP	O	O
to	to	TO	B-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
prolonged	prolonged	JJ	B-NP	O	O
neuromuscular	neuromuscular	JJ	I-NP	O	B-Disease
blockade	blockade	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
later	later	RB	B-ADVP	O	O
found	find	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
homozygous	homozygous	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
atypical	atypical	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
cholinesterase	cholinesterase	NN	I-NP	O	O
.	.	.	O	O	O

Edrophonium	Edrophonium	NN	B-NP	B	B-Chemical
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
74	74	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
train	train	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
of	of	IN	B-PP	O	O
-	-	SYM	B-NP	O	O
four	four	CD	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
characteristic	characteristic	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
phase	phase	NN	B-NP	O	O
II	II	CD	I-NP	O	O
block	block	NN	I-NP	O	O
,	,	,	O	O	O
produced	produce	VBD	B-VP	O	O
partial	partial	JJ	B-NP	O	O
antagonism	antagonism	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
sustained	sustain	VBN	I-VP	O	O
.	.	.	O	O	O

Repeated	Repeat	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
edrophonium	edrophonium	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
70	70	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
neostigmine	neostigmine	NN	I-NP	B	B-Chemical
to	to	TO	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
or	or	CC	I-VP	O	O
augment	augment	VB	I-VP	O	O
the	the	DT	B-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

Spontaneous	Spontaneous	JJ	B-NP	O	O
respiration	respiration	NN	I-NP	O	O
recommenced	recommence	VBD	B-VP	O	O
200	200	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
anticholinesterases	anticholinesteras	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
only	only	RB	B-ADVP	O	O
partially	partially	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
restoring	restore	VBG	B-VP	O	O
neuromuscular	neuromuscular	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
apnoea	apnoea	NN	I-NP	O	B-Disease
despite	despite	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	O
twitch	twitch	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
typical	typical	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
phase	phase	NN	B-NP	O	O
II	II	CD	I-NP	O	O
block	block	NN	I-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
[	[	(	O	O	B-Chemical
omega	omega	SYM	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
I	I	NN	I-NP	B	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
131	131	NN	I-NP	I	I-Chemical
]	]	)	I-NP	O	I-Chemical
heptadecanoic	heptadecanoic	JJ	I-NP	B	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
myocardial	myocardial	JJ	I-NP	O	O
scintigraphy	scintigraphy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
dynamic	dynamic	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
scintigraphy	scintigraphy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
[	[	(	O	O	B-Chemical
omega	omega	SYM	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
I	I	NN	I-NP	B	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
131	131	NN	I-NP	I	I-Chemical
]	]	)	I-NP	O	I-Chemical
heptadecanoic	heptadecanoic	JJ	I-NP	B	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
I	I	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
131	131	CD	B-NP	I	I-Chemical
HA	HA	NN	I-NP	B	I-Chemical
)	)	)	O	O	O
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
on	on	IN	B-PP	O	O
global	global	JJ	B-NP	O	O
left	left	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
determined	determine	VBN	B-VP	O	O
echocardiographically	echocardiographically	RB	B-ADVP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nine	nine	CD	B-NP	O	O
mongrel	mongrel	NN	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
.	.	.	O	O	O

Total	Total	JJ	B-NP	O	O
extractable	extractable	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
postmortem	postmortem	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
and	and	CC	O	O	O
then	then	RB	B-ADVP	O	O
progressive	progressive	JJ	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
global	global	JJ	B-NP	O	O
LV	LV	NN	I-NP	B	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
t1	t1	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
I	I	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
131	131	CD	I-NP	I	I-Chemical
HA	HA	NN	I-NP	B	I-Chemical
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
only	only	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
alteration	alteration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
extractable	extractable	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
lipids	lipid	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
control	control	NN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
alteration	alteration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	O
dynamic	dynamic	JJ	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
with	with	IN	B-PP	O	O
I	I	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
131	131	CD	I-NP	I	I-Chemical
HA	HA	NN	I-NP	B	I-Chemical
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
the	the	DT	B-NP	O	O
initiating	initiate	VBG	I-NP	O	O
factor	factor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Hemodynamics	Hemodynamic	NNS	B-NP	O	O
and	and	CC	O	O	O
myocardial	myocardial	JJ	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
under	under	IN	B-PP	O	O
deliberate	deliberate	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

An	An	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
.	.	.	O	O	O

Coronary	Coronary	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
work	work	NN	I-NP	O	O
and	and	CC	I-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
nitroprusside	nitroprusside	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
SNP	SNP	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
trimetaphan	trimetaphan	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
TMP	TMP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
deliberate	deliberate	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
mean	mean	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
from	from	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Regarding	Regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
on	on	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
,	,	,	O	O	O
aortic	aortic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
(	(	(	O	O	O
pH	pH	NN	B-NP	O	O
,	,	,	O	O	O
pO2	pO2	NN	B-NP	O	O
,	,	,	O	O	O
pCO2	pCO2	NN	B-NP	O	O
)	)	)	O	O	O
we	we	PRP	B-NP	O	O
could	could	MD	B-VP	O	O
confirm	confirm	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
nitroprusside	nitroprusside	NN	B-NP	B	B-Chemical
hypotension	hypotension	NN	I-NP	O	B-Disease
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
mean	mean	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
from	from	IN	B-PP	O	O
control	control	NN	B-NP	O	O
,	,	,	O	O	O
trimetaphan	trimetaphan	NN	B-NP	B	B-Chemical
hypotension	hypotension	NN	I-NP	O	B-Disease
to	to	TO	B-PP	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
mean	mean	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
work	work	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
SNP	SNP	NN	B-NP	O	B-Chemical
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Myocardial	Myocardial	JJ	B-NP	O	O
O2	O2	NN	I-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
and	and	CC	O	O	O
O2	O2	NN	B-NP	B	B-Chemical
availability	availability	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
directly	directly	RB	B-ADJP	O	O
dependent	dependent	JJ	I-ADJP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
invasive	invasive	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
gases	gas	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	O	O
ST	ST	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
T	T	NN	I-NP	O	O
segment	segment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
mandatory	mandatory	JJ	B-ADJP	O	O
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
involvement	involvement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	JJ	I-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
noradrenaline	noradrenaline	NN	I-NP	B	B-Chemical
neurotoxin	neurotoxin	NN	I-NP	O	O
DSP4	DSP4	NN	I-NP	O	B-Chemical
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
amphetamine	amphetamine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
or	or	CC	I-NP	O	O
40	40	CD	I-NP	O	O
mumol	mumol	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
amphetamine	amphetamine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mumol	mumol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
DSP4	DSP4	NN	B-NP	O	B-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
rearings	rearing	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
stereotypies	stereotypy	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
blocked	block	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DSP4	DSP4	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
DSP4	DSP4	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
blocked	block	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
noradrenaline	noradrenaline	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
uptake	uptake	NN	B-NP	O	O
blocking	block	VBG	B-VP	O	O
agent	agent	NN	B-NP	O	O
,	,	,	O	O	O
desipramine	desipramine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
prevents	prevent	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DSP4	DSP4	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
neurones	neurone	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
stimulant	stimulant	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Accelerated	Accelerate	VBN	B-NP	B	B-Disease
junctional	junctional	JJ	I-NP	O	I-Disease
rhythms	rhythm	NNS	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
atrioventricular	atrioventricular	JJ	B-NP	O	O
(	(	(	O	O	O
AV	AV	NN	B-NP	O	O
)	)	)	O	O	O
dissociation	dissociation	NN	B-NP	O	O
and	and	CC	O	O	O
accelerated	accelerate	VBD	B-VP	B	B-Disease
junctional	junctional	JJ	B-NP	O	I-Disease
rhythms	rhythm	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
59	59	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
oral	oral	JJ	B-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Accelerated	Accelerate	VBN	B-NP	B	B-Disease
junctional	junctional	JJ	I-NP	O	I-Disease
rhythms	rhythm	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
AV	AV	NN	B-NP	O	O
dissociation	dissociation	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
frequent	frequent	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
supraventricular	supraventricular	JJ	B-NP	O	B-Disease
tachyarrhythmias	tachyarrhythmia	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
AV	AV	NN	B-NP	O	O
nodal	nodal	JJ	I-NP	O	O
reentry	reentry	NN	I-NP	O	O
.	.	.	O	O	O

Verapamil	Verapamil	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
asymptomatic	asymptomatic	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
junctional	junctional	JJ	I-NP	O	O
pacemakers	pacemaker	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
syndromes	syndrome	NNS	I-NP	O	O
,	,	,	O	O	O
verapamil	verapamil	NN	B-NP	B	B-Chemical
neither	neither	CC	O	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
junctional	junctional	JJ	B-NP	O	O
rhythms	rhythm	NNS	I-NP	O	O
nor	nor	CC	O	O	O
suppressed	suppress	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
role	role	NN	I-NP	O	O
as	as	IN	B-PP	O	O
escape	escape	NN	B-NP	O	O
rhythms	rhythm	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
physiologically	physiologically	RB	B-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
circumstances	circumstance	NNS	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cis	cis	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
platinum	platinum	NN	I-NP	I	I-Chemical
,	,	,	I-NP	O	O
adriamycin	adriamycin	NN	I-NP	B	B-Chemical
,	,	,	I-NP	O	O
cyclophosphamide	cyclophosphamide	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
hexamethylmelamine	hexamethylmelamine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
2	2	CD	I-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cisplatinum	cisplatinum	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CPDD	CPDD	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	B-NP	O	O
,	,	,	O	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
,	,	,	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
m2	m2	NN	B-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
hexamethylmelamine	hexamethylmelamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
HMM	HMM	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
6	6	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
14	14	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
course	course	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
repeated	repeat	VBN	I-VP	O	O
monthly	monthly	RB	B-ADVP	O	O
.	.	.	O	O	O

2	2	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
stage	stage	NN	B-NP	O	O
II	II	CD	I-NP	O	O
,	,	,	O	O	O
14	14	CD	B-NP	O	O
stage	stage	NN	I-NP	O	O
III	III	CD	B-NP	O	O
and	and	CC	I-NP	O	O
22	22	CD	I-NP	O	O
stage	stage	NN	I-NP	O	O
IV	IV	CD	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

14	14	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
38	38	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
previously	previously	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
with	with	IN	B-PP	O	O
radiation	radiation	NN	B-NP	O	O
,	,	,	O	O	O
6	6	CD	B-NP	O	O
with	with	IN	B-PP	O	O
both	both	CC	O	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
radiation	radiation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
17	17	CD	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
any	any	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
before	before	IN	B-PP	O	O
CPDD	CPDD	NN	B-NP	B	B-Chemical
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

31	31	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
38	38	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
(	(	(	O	O	O
81.5	81.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
objective	objective	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
lasting	last	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
responses	response	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
partial	partial	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
19	19	CD	B-NP	O	O
and	and	CC	O	O	O
complete	complete	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Hematologic	Hematologic	JJ	B-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
moderate	moderate	JJ	B-ADJP	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
reversible	reversible	JJ	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
developing	develop	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
71	71	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Gastrointestinal	Gastrointestinal	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
CPDD	CPDD	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
universal	universal	JJ	B-ADJP	O	O
.	.	.	O	O	O

HMM	HMM	NN	B-NP	O	B-Chemical
gastrointestinal	gastrointestinal	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
necessitated	necessitate	VBD	B-VP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Severe	Severe	JJ	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
reversible	reversible	JJ	B-ADJP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
.	.	.	O	O	O

Nontraumatic	Nontraumatic	JJ	B-NP	O	O
dissecting	dissect	VBG	I-NP	O	B-Disease
aneurysm	aneurysm	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basilar	basilar	JJ	I-NP	O	O
artery	artery	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nontraumatic	nontraumatic	JJ	B-NP	O	O
dissecting	dissect	VBG	I-NP	O	B-Disease
aneurysm	aneurysm	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basilar	basilar	JJ	I-NP	O	O
artery	artery	NN	I-NP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
smoke	smoke	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oral	oral	JJ	B-NP	O	B-Chemical
contraceptives	contraceptive	NNS	I-NP	O	I-Chemical
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
young	young	JJ	I-NP	O	O
female	female	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
locked	lock	VBN	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
in	in	IN	B-PP	O	I-Disease
syndrome	syndrome	NN	B-NP	O	I-Disease
.	.	.	O	O	O

Propylthiouracil	Propylthiouracil	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propylthiouracil	propylthiouracil	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
damage	damage	NN	B-NP	O	O
,	,	,	O	O	O
proven	prove	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
rechallenge	rechallenge	NN	B-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
presents	present	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
histologic	histologic	JJ	I-NP	O	O
picture	picture	NN	I-NP	O	O
resembling	resemble	VBG	B-VP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
active	active	JJ	I-NP	O	I-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
remission	remission	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Bepridil	Bepridil	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
active	active	JJ	I-NP	O	O
compound	compound	NN	I-NP	O	O
for	for	IN	B-PP	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anginal	anginal	JJ	B-NP	B	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
induced	induce	VBD	B-VP	O	O
persistent	persistent	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
tachycardial	tachycardial	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
support	support	NN	I-NP	O	O
medium	medium	NN	I-NP	O	O
for	for	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
sino	sino	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
atrial	atrial	JJ	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
from	from	IN	B-PP	O	O
rabbit	rabbit	NN	B-NP	O	O
heart	heart	NN	I-NP	O	O
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
action	action	NN	B-NP	O	O
potential	potential	NN	I-NP	O	O
(	(	(	O	O	O
AP	AP	NN	B-NP	B	O
)	)	)	O	O	O
spike	spike	NN	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
(	(	(	O	O	O
recorded	record	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
KCl	KCl	NN	B-NP	B	B-Chemical
microelectrodes	microelectrode	NNS	I-NP	O	O
)	)	)	O	O	O
starting	start	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
X	X	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
6	6	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
dependent	dependent	JJ	I-ADJP	O	O
up	up	IN	B-PP	O	O
to	to	TO	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
X	X	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
5	5	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
,	,	,	O	O	O
whereupon	whereupon	IN	B-PP	O	O
blockade	blockade	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sinus	sinus	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
set	set	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
.	.	.	O	O	O

Bepridil	Bepridil	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
X	X	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
6	6	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
,	,	,	O	O	O
induced	induce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
AP	AP	NN	B-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
(	(	(	O	O	O
falling	fall	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
71	71	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8	8	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
to	to	TO	B-PP	O	O
47	47	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
maximum	maximum	JJ	B-NP	O	O
systolic	systolic	JJ	I-NP	O	O
depolarization	depolarization	NN	I-NP	O	O
velocity	velocity	NN	I-NP	O	O
(	(	(	O	O	O
phase	phase	NN	B-NP	O	O
0	0	CD	I-NP	O	O
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
fell	fall	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
1.85	1.85	CD	B-NP	O	O
+	+	SYM	B-VP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-NP	O	O
0.35	0.35	CD	I-NP	O	O
V	V	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
s	s	NN	I-NP	O	O
to	to	TO	B-PP	O	O
0.84	0.84	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-NP	O	O
0.28	0.28	CD	I-NP	O	O
V	V	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
s	s	NN	I-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
maximum	maximum	NN	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
depolarization	depolarization	NN	I-NP	O	O
velocity	velocity	NN	I-NP	O	O
(	(	(	O	O	O
phase	phase	NN	B-NP	O	O
4	4	CD	I-NP	O	O
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
fell	fall	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
38	38	CD	B-NP	O	O
+	+	SYM	B-VP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-NP	O	O
3	3	CD	I-NP	O	O
mV	mV	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
s	s	NN	I-NP	O	O
to	to	TO	B-PP	O	O
24	24	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-NP	O	O
5	5	CD	I-NP	O	O
mV	mV	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
s	s	NN	I-NP	O	O
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
into	into	IN	B-PP	O	O
6	6	CD	B-NP	O	O
anaesthetized	anaesthetize	VBN	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
had	have	VBD	B-VP	O	O
undergone	undergo	VBN	I-VP	O	O
ablation	ablation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
extrinsic	extrinsic	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
afferent	afferent	JJ	I-NP	O	O
nerve	nerve	NN	I-NP	O	O
supply	supply	NN	I-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
medullo	medullo	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenalectomy	adrenalectomy	NN	I-NP	O	O
,	,	,	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
fell	fall	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
98.7	98.7	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
4.2	4.2	CD	B-NP	O	O
beats	beat	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
to	to	TO	B-PP	O	O
76	76	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
5.3	5.3	CD	B-NP	O	O
beats	beat	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
sustained	sustain	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
45	45	CD	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
bepridil	bepridil	NN	B-NP	B	B-Chemical
reduces	reduce	VBZ	B-VP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
by	by	IN	B-PP	O	O
acting	act	VBG	B-VP	O	O
directly	directly	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
node	node	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
flattening	flattening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
0	0	CD	I-NP	O	O
and	and	CC	O	O	O
phase	phase	NN	B-NP	O	O
4	4	CD	I-NP	O	O
slope	slope	NN	I-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
longer	long	JJR	I-NP	O	O
AP	AP	NN	I-NP	B	O
duration	duration	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
constants	constant	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
slow	slow	JJ	B-NP	O	O
inward	inward	JJ	I-NP	O	O
ionic	ionic	JJ	I-NP	O	O
currents	current	NNS	I-NP	O	O
(	(	(	O	O	O
already	already	RB	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
elsewhere	elsewhere	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
time	time	NN	I-NP	O	O
constant	constant	NN	I-NP	O	O
for	for	IN	B-PP	O	O
deactivation	deactivation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
outward	outward	JJ	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
current	current	NN	I-NP	O	O
(	(	(	O	O	O
Ip	Ip	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Hepatitis	Hepatitis	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
acidosis	acidosis	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
with	with	IN	B-PP	O	O
methoxyflurane	methoxyflurane	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
69	69	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
operated	operate	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
cholecystitis	cholecystitis	NN	I-NP	O	I-Disease
under	under	IN	B-PP	O	O
methoxyflurane	methoxyflurane	NN	B-NP	B	B-Chemical
anesthesia	anesthesia	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
postoperatively	postoperatively	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
insufficiency	insufficiency	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
acidosis	acidosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Massive	Massive	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
appeared	appear	VBD	B-VP	O	O
during	during	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
which	which	WDT	B-NP	O	O
lasted	last	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
six	six	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Postoperative	Postoperative	JJ	B-NP	O	O
evolution	evolution	NN	I-NP	O	O
under	under	IN	B-PP	O	O
supportive	supportive	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
favourable	favourable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Complete	Complete	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
controls	control	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
year	year	NN	I-NP	O	O
after	after	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
.	.	.	O	O	O

Pituitary	Pituitary	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
luteinizing	luteinize	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
during	during	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
prolactin	prolactin	NN	I-NP	B	O
and	and	CC	O	O	O
luteinizing	luteinize	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
LH	LH	NN	B-NP	B	O
)	)	)	O	O	O
levels	level	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
infusions	infusion	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
LH	LH	NN	B-NP	B	O
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
LH	LH	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
RH	RH	NN	I-NP	I	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
.	.	.	O	O	O

Control	Control	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
infusions	infusion	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
0.9	0.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
NaCl	NaCl	NN	I-NP	B	B-Chemical
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
infusions	infusion	NNS	I-NP	O	O
,	,	,	O	O	O
significant	significant	JJ	B-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
abolished	abolish	VBN	I-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
LH	LH	NN	B-NP	B	O
-	-	HYPH	O	I	O
RH	RH	NN	B-NP	I	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
responses	response	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Antirifampicin	Antirifampicin	NN	B-NP	O	O
antibodies	antibody	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
rifampicin	rifampicin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

5	5	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
3	3	CD	B-NP	O	O
with	with	IN	B-PP	O	O
thrombopenia	thrombopenia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
hemolysis	hemolysis	NN	I-NP	O	B-Disease
)	)	)	O	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reintroduction	reintroduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
correlation	correlation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
taken	take	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
all	all	DT	B-NP	O	O
but	but	CC	I-NP	O	O
1	1	CD	I-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
antirifampicin	antirifampicin	NN	B-NP	O	O
antibodies	antibody	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
.	.	.	O	O	O

Antibodies	Antibody	NNS	B-NP	O	O
suggested	suggest	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IgM	IgM	NN	I-NP	O	O
class	class	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
3	3	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hematological	hematological	JJ	B-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
found	find	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
biopsied	biopsie	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
indistinguishable	indistinguishable	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	O
origin	origin	NN	I-NP	O	O
,	,	,	O	O	O
raised	raise	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
mediated	mediate	VBN	I-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
triggering	trigger	VBG	I-NP	O	O
immunoallergic	immunoallergic	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Cardiovascular	Cardiovascular	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
triphosphate	triphosphate	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
nitroprusside	nitroprusside	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
denervated	denervate	VBN	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
.	.	.	O	O	O

Adenosine	Adenosine	NN	B-NP	B	B-Chemical
triphosphate	triphosphate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
nitroprusside	nitroprusside	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
SNP	SNP	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
and	and	CC	I-VP	O	O
control	control	VB	I-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
.	.	.	O	O	O

SNP	SNP	NN	B-NP	O	B-Chemical
is	be	VBZ	B-VP	O	O
authorized	authorize	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
USA	USA	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
UK	UK	NNP	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
clinically	clinically	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
countries	country	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
Japan	Japan	NNP	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
how	how	WRB	B-ADVP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
act	act	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
whose	whose	WP$	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
denervated	denervate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
devised	devise	VBN	I-VP	O	O
.	.	.	O	O	O

ATP	ATP	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
SNP	SNP	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
reduce	reduce	VB	I-VP	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
by	by	IN	B-PP	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
70	70	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
control	control	NN	B-NP	O	O
.	.	.	O	O	O

Before	Before	IN	B-ADVP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
induced	induce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
measured	measure	VBD	B-VP	O	O
major	major	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
accompanied	accompany	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
central	central	JJ	B-NP	O	O
venous	venous	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
rate	rate	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
product	product	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
all	all	PDT	B-NP	O	O
these	these	DT	I-NP	O	O
variables	variable	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
within	within	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

Cardiac	Cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
SNP	SNP	NN	B-NP	O	B-Chemical
similar	similar	JJ	I-NP	O	O
decreases	decrease	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
central	central	JJ	B-NP	O	O
venous	venous	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
resistance	resistance	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
rate	rate	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
product	product	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
oxygen	oxygen	NN	B-NP	B	B-Chemical
content	content	NN	I-NP	O	O
difference	difference	NN	I-NP	O	O
between	between	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
mixed	mixed	JJ	I-NP	O	O
venous	venous	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
output	output	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
.	.	.	O	O	O

Recoveries	Recovery	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
60	60	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
SNP	SNP	NN	B-NP	O	B-Chemical
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
SNP	SNP	NN	I-NP	O	B-Chemical
should	should	MD	B-VP	O	O
act	act	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
.	.	.	O	O	O

Comparative	Comparative	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
:	:	:	O	O	O
Endografine	Endografine	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
diatrizoate	diatrizoate	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
Vasurix	Vasurix	NN	B-NP	B	B-Chemical
polyvidone	polyvidone	NN	I-NP	B	I-Chemical
(	(	(	O	O	O
acetrizoate	acetrizoate	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
Dimer	Dimer	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
X	X	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
iocarmate	iocarmate	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
Hexabrix	Hexabrix	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ioxaglate	ioxaglate	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
hysterosalpingography	hysterosalpingography	NN	B-NP	O	O
.	.	.	O	O	O

Side	Side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hysterosalpingography	hysterosalpingography	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Dimer	Dimer	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
X	X	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
Hexabrix	Hexabrix	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
Vasurix	Vasurix	NNP	B-NP	B	B-Chemical
polyvidone	polyvidone	NN	I-NP	B	I-Chemical
and	and	CC	I-NP	O	O
Endografine	Endografine	NN	I-NP	O	B-Chemical
in	in	IN	B-PP	O	O
142	142	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
receiving	receive	VBG	B-VP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
four	four	CD	I-NP	O	O
tested	test	VBN	I-NP	O	O
media	medium	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
replies	reply	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
postal	postal	JJ	B-NP	O	O
questionnaires	questionnaire	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Dimer	Dimer	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
X	X	NN	I-NP	I	I-Chemical
group	group	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
dizziness	dizziness	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Endografine	Endografine	NNP	I-NP	O	B-Chemical
group	group	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abdominal	abdominal	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
occur	occur	VBP	B-VP	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
age	age	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
30	30	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Hexabrix	Hexabrix	NNP	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
Vasurix	Vasurix	NNP	I-NP	B	B-Chemical
polyvidone	polyvidone	NN	I-NP	B	I-Chemical
are	be	VBP	B-VP	O	O
considered	consider	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
media	medium	NNS	I-NP	O	I-Chemical
for	for	IN	B-PP	O	O
hysterosalpingography	hysterosalpingography	NN	B-NP	O	O
and	and	CC	O	O	O
perhaps	perhaps	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
low	low	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
Hexabrix	Hexabrix	NNP	I-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
preferred	prefer	VBN	I-VP	B	O
.	.	.	O	O	O

Post	Post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
suxamethonium	suxamethonium	NN	I-NP	B	B-Chemical
pains	pain	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
Nigerian	Nigerian	JJ	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Contrary	Contrary	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
earlier	early	JJR	I-NP	O	O
report	report	NN	I-NP	O	O
by	by	IN	B-PP	O	O
Coxon	Coxon	NNP	B-NP	O	O
,	,	,	O	O	O
scoline	scoline	NN	B-NP	B	B-Chemical
pain	pain	NN	I-NP	O	B-Disease
occurs	occur	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
African	African	JJ	B-NP	O	O
negroes	negro	NNS	I-NP	O	O
.	.	.	O	O	O

Its	Its	PRP$	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
Nigerian	Nigerian	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
out	out	RP	B-PRT	O	O
-	-	HYPH	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
in	in	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

About	About	RB	B-NP	O	O
62	62	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
out	out	RB	I-NP	O	O
-	-	HYPH	O	O	O
patients	patient	NNS	B-NP	O	O
developed	develop	VBD	B-VP	O	O
scoline	scoline	NN	B-NP	B	B-Chemical
pain	pain	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
about	about	RB	B-NP	O	O
26	26	CD	I-NP	O	O
%	%	NN	I-NP	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
in	in	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
abolition	abolition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
muscle	muscle	NN	B-NP	O	O
fasciculations	fasciculation	NNS	I-NP	O	B-Disease
(	(	(	O	O	O
by	by	IN	B-PP	O	O
0.075mg	0.075mg	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fazadinium	Fazadinium	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
scoline	scoline	NN	B-NP	B	B-Chemical
pain	pain	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
the	the	DT	B-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
agent	agent	NN	I-NP	O	O
(	(	(	O	O	O
Althesin	Althesin	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
Thiopentone	Thiopentone	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
nor	nor	CC	O	O	O
the	the	DT	B-NP	O	O
salt	salt	NN	I-NP	O	O
preparation	preparation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
used	use	VBN	B-VP	O	O
(	(	(	O	O	O
chloride	chloride	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
bromide	bromide	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
affected	affect	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
scoline	scoline	NN	B-NP	B	B-Chemical
pain	pain	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Medial	Medial	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
spasm	spasm	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
norepinephrine	norepinephrine	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
media	medium	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
small	small	JJ	B-NP	O	O
arteries	artery	NNS	I-NP	O	O
(	(	(	O	O	O
0.4	0.4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
-	-	SYM	I-NP	O	O
0.2	0.2	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diameter	diameter	NN	B-NP	O	O
)	)	)	O	O	O
previously	previously	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
contain	contain	VB	I-VP	O	O
intracellular	intracellular	JJ	B-NP	O	O
vacuoles	vacuole	NNS	I-NP	O	O
,	,	,	O	O	O
identified	identify	VBN	B-VP	O	O
ultrastructurally	ultrastructurally	RB	B-ADVP	O	O
as	as	IN	B-PP	O	O
herniations	herniation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
one	one	CD	B-NP	O	O
smooth	smooth	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
into	into	IN	B-PP	O	O
another	another	DT	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
intense	intense	JJ	B-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
would	would	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
vacuoles	vacuole	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
tested	test	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
media	medium	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
saphenous	saphenous	JJ	I-NP	O	O
artery	artery	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
distal	distal	JJ	I-NP	O	O
branch	branch	NN	I-NP	O	O
,	,	,	O	O	O
vasoconstriction	vasoconstriction	NN	B-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
norepinephrine	norepinephrine	NN	B-NP	I	I-Chemical
produced	produce	VBD	B-VP	O	O
many	many	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
hernias	hernia	NNS	I-NP	O	B-Disease
within	within	IN	B-PP	O	O
15	15	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
1	1	CD	B-NP	O	O
day	day	NN	I-NP	O	O
their	their	PRP$	B-NP	O	O
number	number	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
about	about	IN	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
10	10	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
original	original	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
vessel	vessel	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
almost	almost	RB	I-VP	O	O
restored	restore	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
.	.	.	O	O	O

Triple	Triple	JJ	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
over	over	IN	B-PP	O	O
1	1	CD	B-NP	O	O
day	day	NN	I-NP	O	O
induced	induce	VBD	B-VP	O	O
more	more	RBR	B-NP	O	O
severe	severe	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
media	medium	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
smooth	smooth	JJ	B-NP	O	O
muscle	muscle	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
damage	damage	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
specific	specific	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
medial	medial	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
instances	instance	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
spasm	spasm	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Endothelial	Endothelial	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
developed	develop	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
described	describe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
paper	paper	NN	I-NP	O	O
.	.	.	O	O	O

Abnormalities	Abnormality	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pupil	pupil	NN	I-NP	O	O
and	and	CC	I-NP	O	O
visual	visual	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
evoked	evoked	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
in	in	IN	B-PP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
amblyopia	amblyopia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Total	Total	JJ	B-NP	O	O
blindness	blindness	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
transient	transient	JJ	I-NP	O	O
tonic	tonic	JJ	I-NP	O	B-Disease
pupillary	pupillary	JJ	I-NP	O	I-Disease
response	response	NN	I-NP	O	O
,	,	,	O	O	O
denervation	denervation	NN	B-NP	O	O
supersensitivity	supersensitivity	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
abnormal	abnormal	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
evoked	evoke	VBN	I-NP	O	O
potentials	potential	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
54	54	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
for	for	IN	B-PP	O	O
leg	leg	NN	B-NP	O	B-Disease
cramps	cramp	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
later	later	RB	B-ADVP	O	O
recovered	recover	VBD	B-VP	O	O
normal	normal	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	O
acuity	acuity	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
transient	transient	JJ	I-NP	O	O
tonic	tonic	JJ	I-NP	O	B-Disease
pupillary	pupillary	JJ	I-NP	O	I-Disease
response	response	NN	I-NP	O	O
,	,	,	O	O	O
denervation	denervation	NN	B-NP	O	O
supersensitivity	supersensitivity	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
abnormal	abnormal	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
evoked	evoke	VBN	I-NP	O	O
potentials	potential	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Suxamethonium	Suxamethonium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
jaw	jaw	NN	I-NP	O	B-Disease
stiffness	stiffness	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
atypical	atypical	JJ	B-NP	O	O
cholinesterase	cholinesterase	NN	I-NP	O	O
:	:	:	O	O	O
case	case	NN	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
11	11	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
boy	boy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
halothane	halothane	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
nitrous	nitrous	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
pancuronium	pancuronium	NN	B-NP	B	B-Chemical
0.4	0.4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
suxamethonium	suxamethonium	NN	I-NP	B	B-Chemical
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
anaesthesia	anaesthesia	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
a	a	DT	I-NP	O	O
marked	marked	JJ	I-NP	O	O
jaw	jaw	NN	I-NP	O	B-Disease
stiffness	stiffness	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
which	which	WDT	B-NP	O	O
lasted	last	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
terminated	terminate	VBN	I-VP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
apnoea	apnoea	NN	B-NP	O	B-Disease
ensued	ensue	VBD	B-VP	O	O
and	and	CC	O	O	O
he	he	PRP	B-NP	O	O
suffered	suffer	VBD	B-VP	O	O
generalized	generalize	VBN	I-VP	O	O
severe	severe	JJ	B-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
lasting	last	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
one	one	CD	B-NP	O	O
week	week	NN	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
atypical	atypical	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
cholinesterase	cholinesterase	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dibucaine	dibucaine	NN	I-NP	B	B-Chemical
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
homozygocity	homozygocity	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
verified	verify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
family	family	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
case	case	NN	I-NP	O	O
shows	show	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
prolonged	prolonged	JJ	B-NP	O	B-Disease
jaw	jaw	NN	I-NP	O	I-Disease
rigidity	rigidity	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
myalgia	myalgia	NN	I-NP	O	B-Disease
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
after	after	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
atypical	atypical	JJ	B-NP	O	O
cholinesterase	cholinesterase	NN	I-NP	O	O
despite	despite	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
pancuronium	pancuronium	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
hyperkalemia	hyperkalemia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
gouty	gouty	NN	B-NP	O	B-Disease
arthritis	arthritis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
severe	severe	JJ	B-NP	O	O
,	,	,	I-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
threatening	threaten	VBG	B-VP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
insufficiency	insufficiency	NN	I-NP	O	I-Disease
developed	develop	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
gouty	gouty	NN	I-NP	O	B-Disease
arthritis	arthritis	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
an	an	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
and	and	CC	O	O	O
consequent	consequent	JJ	B-NP	O	O
hyporeninemic	hyporeninemic	JJ	I-NP	O	B-Disease
hypoaidosteronism	hypoaidosteronism	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
to	to	TO	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
balance	balance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
those	those	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	B-Disease
mellitus	mellitus	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
preexisting	preexisting	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
will	will	MD	B-VP	O	O
help	help	VB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
this	this	DT	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
serious	serious	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
.	.	.	O	O	O

Etomidate	Etomidate	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
a	a	DT	B-NP	O	O
foreshortened	foreshorten	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
outpatient	outpatient	NN	B-NP	O	O
cystoscopy	cystoscopy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
embarked	embark	VBN	I-VP	B	O
upon	upon	IN	B-PP	O	O
.	.	.	O	O	O

Unpremedicated	Unpremedicated	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
fentanyl	fentanyl	NN	B-NP	B	B-Chemical
1	1	CD	I-NP	O	O
microgram	microgram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
etomidate	etomidate	NN	B-NP	B	B-Chemical
0.3	0.3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

Anaesthesia	Anaesthesia	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
etomidate	etomidate	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
interviewed	interview	VBN	I-VP	O	O
personally	personally	RB	B-ADVP	O	O
later	later	RB	B-NP	O	O
the	the	DT	I-NP	O	O
same	same	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
by	by	IN	B-PP	O	O
questionnaire	questionnaire	NN	B-NP	O	O
three	three	CD	I-NP	O	O
to	to	TO	I-NP	O	O
four	four	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
trial	trial	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
20	20	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
an	an	DT	B-NP	O	O
unacceptable	unacceptable	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Venous	Venous	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
68	68	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
redness	redness	NN	B-NP	O	O
,	,	,	O	O	O
pain	pain	NN	B-NP	O	B-Disease
or	or	CC	O	O	O
swelling	swell	VBG	B-VP	O	B-Disease
related	relate	VBN	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
site	site	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
lasting	last	VBG	B-VP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
three	three	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
anaesthesia	anaesthesia	NN	B-NP	O	O
.	.	.	O	O	O

Skeletal	Skeletal	JJ	B-NP	O	O
movements	movement	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
;	;	:	O	O	O
30	30	CD	B-NP	O	O
%	%	NN	I-NP	O	O
experienced	experienced	JJ	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	B-Disease
upset	upset	NN	I-NP	O	I-Disease
,	,	,	O	O	O
one	one	CD	B-NP	O	O
sufficiently	sufficiently	RB	B-ADJP	O	O
severe	severe	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
necessitate	necessitate	VB	I-VP	O	O
abandoning	abandon	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
technique	technique	NN	I-NP	O	O
.	.	.	O	O	O

Nausea	Nausea	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
vomiting	vomiting	NN	I-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
25	25	CD	I-NP	O	O
%	%	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
disturbing	disturbing	JJ	B-NP	O	O
emergence	emergence	NN	I-NP	O	O
psychoses	psychos	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Levodopa	Levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
improved	improve	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
motor	motor	NN	B-NP	O	B-Disease
disability	disability	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
responsive	responsive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
challenge	challenge	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mixed	mixed	JJ	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
agonist	agonist	NN	I-NP	O	O
,	,	,	O	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
11	11	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
47	47	CD	I-NP	O	O
%	%	NN	I-NP	O	O
improvement	improvement	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
without	without	IN	B-PP	O	O
modification	modification	NN	B-NP	O	O
of	of	IN	B-PP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
motor	motor	NN	I-NP	O	B-Disease
disability	disability	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
predominantly	predominantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
limbs	limb	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
and	and	CC	I-NP	O	O
disappearance	disappearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dystonic	dystonic	JJ	B-NP	O	B-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
onset	onset	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
end	end	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
of	of	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
dose	dose	NN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
upper	upper	JJ	I-NP	O	O
limbs	limb	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
choreic	choreic	JJ	B-NP	O	B-Disease
mid	mid	JJ	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
dose	dose	NN	I-NP	O	I-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
increased	increase	VBN	B-NP	O	O
brain	brain	NN	I-NP	O	O
serotoninergic	serotoninergic	JJ	I-NP	O	O
transmission	transmission	NN	I-NP	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
or	or	CC	O	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
agonist	agonist	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
without	without	IN	B-PP	O	O
aggravating	aggravate	VBG	B-VP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
motor	motor	NN	I-NP	O	B-Disease
disability	disability	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
population	population	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
based	base	VBN	I-VP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
trimethoprim	trimethoprim	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
sulfamethoxazole	sulfamethoxazole	NN	B-NP	I	I-Chemical
,	,	,	O	O	O
trimethoprim	trimethoprim	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
cephalexin	cephalexin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
uncommon	uncommon	JJ	B-NP	O	O
serious	serious	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conducted	conduct	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
population	population	NN	I-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-VP	O	O
45	45	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
232,390	232,390	CD	B-NP	O	O
people	people	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
trimethoprim	trimethoprim	AFX	O	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
sulfamethoxazole	sulfamethoxazole	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
TMP	TMP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
SMZ	SMZ	NN	I-NP	O	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
266,951	266,951	CD	B-NP	O	O
prescribed	prescribe	VBN	I-NP	O	O
trimethoprim	trimethoprim	NN	I-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
196,397	196,397	CD	B-NP	O	O
prescribed	prescribed	JJ	I-NP	O	O
cephalexin	cephalexin	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
to	to	TO	B-VP	O	O
estimate	estimate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
,	,	,	O	O	I-Disease
blood	blood	NN	B-NP	O	I-Disease
,	,	,	O	O	I-Disease
skin	skin	NN	B-NP	O	I-Disease
,	,	,	O	O	I-Disease
and	and	CC	O	O	I-Disease
renal	renal	JJ	B-NP	O	I-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
referral	referral	NN	B-NP	O	O
or	or	CC	I-NP	O	O
hospitalization	hospitalization	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
information	information	NN	B-NP	O	O
recorded	record	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
office	office	NN	B-NP	O	O
computers	computer	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
selected	select	VBN	B-NP	O	O
general	general	JJ	I-NP	O	O
practitioners	practitioner	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
Kingdom	Kingdom	NNP	I-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
records	record	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
important	important	JJ	I-NP	O	O
idiopathic	idiopathic	JJ	I-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
for	for	IN	B-SBAR	O	O
persons	person	NNS	B-NP	O	O
prescribed	prescribe	VBD	B-VP	O	O
TMP	TMP	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
SMZ	SMZ	NN	B-NP	O	I-Chemical
(	(	(	O	O	O
5.2	5.2	CD	B-NP	O	O
/	/	SYM	O	O	O
100,000	100,000	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
prescribed	prescribe	VBN	I-NP	O	O
trimethoprim	trimethoprim	NN	I-NP	B	B-Chemical
alone	alone	RB	I-NP	O	O
(	(	(	O	O	O
3.8	3.8	CD	B-NP	O	O
/	/	SYM	O	O	O
100,000	100,000	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
those	those	DT	B-NP	O	O
prescribed	prescribe	VBN	I-NP	O	O
cephalexin	cephalexin	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
somewhat	somewhat	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
(	(	(	O	O	O
2.0	2.0	CD	B-NP	O	O
/	/	SYM	O	O	O
100,000	100,000	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
five	five	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
blood	blood	NN	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
TMP	TMP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
SMZ	SMZ	NN	I-NP	O	I-Chemical
;	;	:	O	O	O
of	of	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
with	with	IN	B-PP	O	O
erythema	erythema	NN	B-NP	O	B-Disease
multiforme	multiforme	JJ	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
Stevens	Stevens	NNP	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
Johnson	Johnson	NNP	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
,	,	,	O	O	O
four	four	CD	B-NP	O	O
were	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
TMP	TMP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
SMZ	SMZ	NN	I-NP	O	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
one	one	CD	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	B-Disease
epidermal	epidermal	JJ	I-NP	O	I-Disease
necrolysis	necrolysis	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
took	take	VBD	B-VP	O	O
cephalexin	cephalexin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Finally	Finally	RB	B-ADVP	O	O
,	,	,	O	O	O
only	only	RB	B-NP	O	O
five	five	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
parenchymal	parenchymal	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
,	,	,	O	O	O
none	none	NN	B-NP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serious	serious	JJ	I-NP	O	O
diseases	disease	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
is	be	VBZ	B-VP	O	O
small	small	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
three	three	CD	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
compares	compare	VBZ	B-VP	O	O
reasonably	reasonably	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
other	other	JJ	I-NP	O	O
antibiotics	antibiotic	NNS	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

STUDY	STUDY	NN	B-NP	O	O
OBJECTIVE	OBJECTIVE	NN	I-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
setting	setting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MI	MI	NN	B-NP	B	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
multicenter	multicenter	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

SETTING	SETTING	NN	B-NP	O	O
:	:	:	O	O	O
Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nine	nine	CD	I-NP	O	O
university	university	NN	I-NP	O	O
,	,	,	O	O	O
university	university	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
affiliated	affiliate	VBN	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
community	community	NN	B-NP	O	O
hospitals	hospital	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
period	period	NN	I-NP	O	O
(	(	(	O	O	O
total	total	NN	B-NP	O	O
of	of	IN	B-PP	O	O
117	117	CD	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
hospital	hospital	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

PARTICIPANTS	PARTICIPANTS	NNS	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
department	department	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Of	Of	IN	B-NP	O	O
29	29	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
setting	setting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
,	,	,	O	O	O
no	no	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
died	die	VBD	B-VP	O	O
;	;	:	O	O	O
exhibited	exhibit	VBN	B-NP	O	O
bradydysrhythmias	bradydysrhythmia	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
or	or	CC	O	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
;	;	:	O	O	O
or	or	CC	O	O	O
experienced	experienced	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Despite	Despite	IN	B-PP	O	O
theoretical	theoretical	JJ	B-NP	O	O
concerns	concern	NNS	I-NP	O	O
that	that	IN	B-NP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
enhance	enhance	VB	I-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	B-Disease
or	or	CC	I-NP	O	I-Disease
central	central	JJ	I-NP	O	I-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Paclitaxel	Paclitaxel	NN	B-NP	B	B-Chemical
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
preliminary	preliminary	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
escalation	escalation	NN	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Paclitaxel	Paclitaxel	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Taxol	Taxol	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
Bristol	Bristol	NNP	B-NP	O	O
-	-	:	O	O	O
Myers	Myers	NNP	B-NP	O	O
Squibb	Squibb	NNP	I-NP	O	O
Company	Company	NNP	I-NP	O	O
,	,	,	O	O	O
Princeton	Princeton	NNP	B-NP	O	O
,	,	,	O	O	O
NJ	NJ	NNP	B-NP	O	O
)	)	)	O	O	O
by	by	IN	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
combined	combine	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
I	I	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
directed	direct	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	O	O	B-Disease
-	-	HYPH	O	O	I-Disease
small	small	JJ	B-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
lung	lung	NN	I-NP	O	I-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Carboplatin	Carboplatin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
fixed	fix	VBN	I-NP	O	O
target	target	NN	I-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6.0	6.0	CD	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Calvert	Calvert	NNP	I-NP	O	O
formula	formula	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
paclitaxel	paclitaxel	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
escalated	escalate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
cohorts	cohort	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
(	(	(	I-NP	O	O
dose	dose	NN	I-NP	O	O
level	level	NN	I-NP	O	O
I	I	CD	I-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
175	175	CD	B-NP	O	O
,	,	,	I-NP	O	O
200	200	CD	I-NP	O	O
,	,	,	I-NP	O	O
225	225	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
225	225	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
m2	m2	NN	I-NP	O	O
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
expanded	expand	VBN	I-VP	B	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
since	since	IN	B-PP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
level	level	NN	I-NP	O	O
achieved	achieve	VBD	B-VP	O	O
(	(	(	O	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
)	)	)	O	O	O
required	require	VBD	B-VP	O	O
modification	modification	NN	B-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
nonhematologic	nonhematologic	JJ	B-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
(	(	(	O	O	O
arthralgia	arthralgia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
sensory	sensory	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Therapeutic	Therapeutic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
all	all	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
objective	objective	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
17	17	CD	B-NP	O	O
(	(	(	O	O	O
two	two	CD	B-NP	O	O
complete	complete	JJ	I-NP	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
partial	partial	JJ	I-NP	O	O
regressions	regression	NNS	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
41	41	CD	B-NP	O	O
previously	previously	RB	I-NP	O	O
untreated	untreated	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Toxicities	Toxicity	NNS	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cohort	cohort	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
I	I	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
identical	identical	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Carboplatin	Carboplatin	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
add	add	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hematologic	hematologic	JJ	I-NP	O	B-Disease
toxicities	toxicity	NNS	I-NP	O	I-Disease
observed	observe	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
/	/	SYM	B-VP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
combination	combination	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
dosed	dose	VBN	I-VP	O	O
every	every	DT	B-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
well	well	RB	B-NP	O	O
compensated	compensate	VBN	I-NP	O	O
cirrhosis	cirrhosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Misoprostol	Misoprostol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
acutely	acutely	RB	I-VP	O	O
counteract	counteract	VB	I-VP	O	O
the	the	DT	B-NP	O	O
indomethacin	indomethacin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
well	well	RB	B-NP	O	O
compensated	compensate	VBN	I-NP	O	O
cirrhotic	cirrhotic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
prophylactic	prophylactic	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
dependent	dependent	JJ	I-ADJP	O	O
.	.	.	O	O	O

Parameters	Parameter	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
hemodynamics	hemodynamic	NNS	I-NP	O	O
and	and	CC	O	O	O
tubular	tubular	JJ	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
water	water	NN	B-NP	B	O
handling	handling	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
clearance	clearance	NN	B-NP	O	O
techniques	technique	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
26	26	CD	B-NP	O	O
well	well	RB	I-NP	O	O
compensated	compensate	VBN	I-NP	O	O
cirrhotic	cirrhotic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
various	various	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
200	200	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
able	able	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
totally	totally	RB	I-VP	O	O
abolish	abolish	VB	I-VP	O	O
the	the	DT	B-NP	O	O
deleterious	deleterious	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
800	800	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
dose	dose	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
worsening	worsening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
hemodynamics	hemodynamic	NNS	I-NP	O	O
and	and	CC	O	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
retention	retention	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
maximal	maximal	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hour	hour	NN	I-NP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
and	and	CC	O	O	O
slowly	slowly	RB	B-VP	O	O
returned	return	VBD	I-VP	O	O
toward	toward	IN	B-PP	O	O
base	base	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
line	line	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
thereafter	thereafter	RB	B-ADVP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
protective	protective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
dependent	dependent	JJ	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
until	until	IN	B-PP	O	O
this	this	DT	B-NP	O	O
apparent	apparent	JJ	I-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
misoprostol	misoprostol	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
prudent	prudent	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cirrhosis	cirrhosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angio	angio	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
oedema	oedema	NN	I-NP	O	I-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
converting	convert	VBG	B-VP	O	I-Chemical
enzyme	enzyme	NN	B-NP	O	I-Chemical
inhibitor	inhibitor	NN	I-NP	O	I-Chemical
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
well	well	RB	I-VP	O	O
recognized	recognize	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
urticaria	urticaria	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
angio	angio	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
oedema	oedema	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Angiotensin	Angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
converting	convert	VBG	B-VP	O	I-Chemical
enzyme	enzyme	NN	B-NP	O	I-Chemical
(	(	(	O	O	I-Chemical
ACE	ACE	NN	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
inhibitors	inhibitor	NNS	B-NP	O	I-Chemical
,	,	,	O	O	O
used	use	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
congestive	congestive	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
introduced	introduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Europe	Europe	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
middle	middle	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
eighties	eighty	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
increased	increase	VBN	I-VP	O	O
progressively	progressively	RB	B-ADVP	O	O
.	.	.	O	O	O

Soon	Soon	RB	B-PP	O	O
after	after	IN	I-PP	O	O
the	the	DT	B-NP	O	O
introduction	introduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-Chemical
inhibitors	inhibitor	NNS	I-NP	O	I-Chemical
,	,	,	O	O	O
acute	acute	JJ	B-NP	O	O
bouts	bout	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
angio	angio	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
oedema	oedema	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
wish	wish	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
draw	draw	VB	I-VP	O	O
attention	attention	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
ACE	ACE	VB	I-VP	O	B-Chemical
inhibitors	inhibitor	NNS	B-NP	O	I-Chemical
after	after	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	B-PP	O	O
existing	exist	VBG	B-NP	O	O
angio	angio	AFX	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
oedema	oedema	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Myoclonus	Myoclonus	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
lorazepam	lorazepam	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
very	very	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
birth	birth	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
weight	weight	NN	I-NP	O	O
infants	infant	NNS	I-NP	O	O
.	.	.	O	O	O

Lorazepam	Lorazepam	NNP	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
being	be	VBG	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
sedative	sedative	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
newborn	newborn	JJ	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
young	young	JJ	I-NP	O	O
infant	infant	NN	I-NP	O	O
.	.	.	O	O	O

Concern	Concern	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
raised	raise	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lorazepam	lorazepam	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
age	age	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
very	very	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
birth	birth	NN	I-NP	O	O
-	-	HYPH	O	O	O
weight	weight	NN	B-NP	O	O
(	(	(	O	O	O
VLBW	VLBW	NN	B-NP	O	O
;	;	:	O	O	O
<	<	SYM	B-NP	O	O
1,500	1,500	CD	I-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
infants	infant	NNS	B-NP	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
young	young	JJ	I-NP	O	O
infants	infant	NNS	I-NP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
birth	birth	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
<	<	SYM	O	O	O
1,500	1,500	CD	B-NP	O	O
g	g	NN	I-NP	O	O
,	,	,	O	O	O
experienced	experience	VBD	B-VP	O	O
myoclonus	myoclonus	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lorazepam	lorazepam	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
(	(	(	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
population	population	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Injectable	Injectable	JJ	B-NP	O	O
lorazepam	lorazepam	NN	I-NP	B	B-Chemical
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
caution	caution	NN	B-NP	O	O
in	in	IN	B-PP	O	O
VLBW	VLBW	NN	B-NP	O	O
infants	infant	NNS	I-NP	O	O
.	.	.	O	O	O

Transvenous	Transvenous	JJ	B-NP	O	O
right	right	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
pacing	pacing	NN	I-NP	O	O
during	during	IN	B-PP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
resuscitation	resuscitation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
cardiopulmonary	cardiopulmonary	JJ	I-NP	O	O
resuscitation	resuscitation	NN	I-NP	O	O
efforts	effort	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
presented	present	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
circulatory	circulatory	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
from	from	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	O
viral	viral	JJ	I-NP	O	O
myocarditis	myocarditis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
one	one	CD	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
acute	acute	JJ	I-NP	O	O
eosinophilic	eosinophilic	JJ	I-NP	O	B-Disease
myocarditis	myocarditis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
had	have	VBD	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
hemosiderosis	hemosiderosis	NN	I-NP	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
cardiogenic	cardiogenic	JJ	I-NP	O	B-Disease
shock	shock	NN	I-NP	O	I-Disease
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
continuously	continuously	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
venous	venous	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
catheters	catheter	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
routine	routine	JJ	B-NP	O	O
noninvasive	noninvasive	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
introducer	introducer	NN	I-NP	O	O
sheath	sheath	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sterile	sterile	JJ	B-NP	O	O
pacing	pacing	NN	I-NP	O	O
wires	wire	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
made	make	VBN	I-VP	O	O
readily	readily	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
should	should	MD	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
arise	arise	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
terminate	terminate	VB	I-VP	O	O
resistant	resistant	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
cardiocirculatory	cardiocirculatory	JJ	B-NP	O	O
arrest	arrest	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
extreme	extreme	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	B-Disease
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
48	48	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
admission	admission	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
(	(	(	O	O	O
PICU	PICU	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Right	Right	RB	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
wires	wire	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
inserted	insert	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
during	during	IN	B-PP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
resuscitation	resuscitation	NN	I-NP	O	O
(	(	(	O	O	O
CPR	CPR	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
four	four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
pacing	pacing	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
temporary	temporary	JJ	I-NP	O	O
captured	captured	JJ	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
and	and	CC	I-NP	O	O
restoration	restoration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
output	output	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
arrest	arrest	NN	I-NP	O	I-Disease
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
death	death	NN	B-NP	O	O
,	,	,	O	O	O
within	within	IN	B-PP	O	O
10	10	CD	B-NP	O	O
to	to	TO	I-NP	O	O
60	60	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
pacing	pacing	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
he	he	PRP	B-NP	O	O
converted	convert	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
by	by	IN	B-PP	O	O
electrical	electrical	JJ	B-NP	O	O
defibrillation	defibrillation	NN	I-NP	O	O
within	within	IN	B-PP	O	O
three	three	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
CPR	CPR	NN	B-NP	B	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
cardiac	cardiac	JJ	B-NP	O	O
pacing	pacing	NN	I-NP	O	O
during	during	IN	B-PP	O	O
resuscitative	resuscitative	JJ	B-NP	O	O
efforts	effort	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
pediatric	pediatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
value	value	NN	I-NP	O	O
in	in	IN	B-PP	O	O
and	and	CC	I-PP	O	O
of	of	IN	I-PP	O	O
itself	itself	PRP	B-NP	O	O
;	;	:	O	O	O
however	however	RB	O	O	O
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
temporary	temporary	JJ	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
stability	stability	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
this	this	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
additional	additional	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
needed	need	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
institute	institute	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
modalities	modality	NNS	I-NP	O	O
.	.	.	O	O	O

Efficacy	Efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
granisetron	granisetron	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxytryptamine	hydroxytryptamine	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
vomiting	vomiting	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antiemetic	antiemetic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
safety	safety	NN	B-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
granisetron	granisetron	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Kytril	Kytril	NNP	B-NP	B	B-Chemical
;	;	:	O	O	O
SmithKline	SmithKline	NNP	B-NP	O	O
Beecham	Beecham	NNP	I-NP	O	O
Pharmaceuticals	Pharmaceutical	NNPS	I-NP	O	O
,	,	,	O	O	O
Philadelphia	Philadelphia	NNP	B-NP	O	O
,	,	,	O	O	O
PA	PA	NNP	B-NP	B	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
administered	administer	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
(	(	(	O	O	O
IV	IV	CD	O	O	O
)	)	)	O	O	O
dose	dose	NN	B-NP	O	O
for	for	IN	B-PP	O	O
prophylaxis	prophylaxis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nausea	nausea	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
vomiting	vomiting	NN	I-NP	O	B-Disease
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
One	One	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
eighty	eighty	CD	I-NP	O	O
-	-	HYPH	O	O	O
four	four	CD	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
-	-	HYPH	O	O	O
naive	naive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
cisplatin	cisplatin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
81	81	CD	B-NP	O	O
to	to	TO	O	O	O
120	120	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
receive	receive	VB	I-VP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
four	four	CD	B-NP	O	O
granisetron	granisetron	NN	I-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
,	,	,	I-NP	O	O
20	20	CD	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
40	40	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
administered	administer	VBN	B-VP	O	O
before	before	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
inpatient	inpatient	JJ	I-NP	O	O
basis	basis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
18	18	CD	B-NP	O	O
to	to	TO	I-NP	O	O
24	24	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
nausea	nausea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
vomiting	vomiting	NN	B-NP	O	B-Disease
,	,	,	O	O	O
retching	retching	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
appetite	appetite	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
.	.	.	O	O	O

Safety	Safety	NN	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
incidence	incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
and	and	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
parameter	parameter	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
After	After	IN	B-PP	O	O
granisetron	granisetron	NN	B-NP	B	B-Chemical
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
,	,	,	I-NP	O	O
20	20	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
40	40	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
(	(	(	O	O	O
<	<	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
two	two	CD	B-NP	O	O
vomiting	vomit	VBG	B-VP	O	B-Disease
or	or	CC	I-VP	O	O
retching	retch	VBG	I-VP	O	O
episodes	episode	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
antiemetic	antiemetic	JJ	I-NP	O	O
rescue	rescue	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
57	57	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
(	(	(	O	O	O
no	no	DT	B-NP	O	O
vomiting	vomiting	NN	I-NP	O	B-Disease
or	or	CC	I-NP	O	O
retching	retching	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
antiemetic	antiemetic	JJ	I-NP	O	O
rescue	rescue	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
41	41	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
47	47	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
longer	long	JJR	I-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
episode	episode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.0015	.0015	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
vomiting	vomiting	NN	B-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.0001	.0001	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
fewer	few	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
additional	additional	JJ	B-NP	O	O
antiemetic	antiemetic	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
granisetron	granisetron	NN	B-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
,	,	,	O	O	O
appetite	appetite	JJ	B-NP	O	O
return	return	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.040	.040	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Headache	Headache	PRP	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
frequently	frequently	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
,	,	,	I-NP	O	O
20	20	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
40	40	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
granisetron	granisetron	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
controlling	control	VBG	B-VP	O	O
vomiting	vomit	VBG	I-VP	O	B-Disease
in	in	IN	B-PP	O	O
57	57	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
60	60	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
81	81	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
and	and	CC	O	O	O
totally	totally	RB	B-VP	O	O
prevented	prevent	VBD	I-VP	O	O
vomiting	vomit	VBG	I-VP	O	B-Disease
in	in	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
47	47	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
efficacy	efficacy	NN	B-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
20	20	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
40	40	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Granisetron	Granisetron	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
all	all	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
two	two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
atrioventricular	atrioventricular	JJ	B-NP	O	B-Disease
(	(	(	O	O	I-Disease
AV	AV	NN	B-NP	O	I-Disease
)	)	)	O	O	I-Disease
block	block	NN	B-NP	O	I-Disease
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
SUMMARIES	SUMMARIES	NNS	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
54	54	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hyperaldosteronism	hyperaldosteronism	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
verapamil	verapamil	NN	B-NP	B	B-Chemical
480	480	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	B-NP	O	O
and	and	CC	I-NP	O	O
spironolactone	spironolactone	NN	I-NP	B	B-Chemical
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
minimal	minimal	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.15	0.15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
complete	complete	JJ	B-NP	O	O
AV	AV	NN	I-NP	O	B-Disease
block	block	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
resolved	resolve	VBD	B-VP	O	O
upon	upon	IN	B-PP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
65	65	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
extended	extend	VBN	B-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
240	240	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
the	the	DT	B-NP	O	O
addition	addition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
0.15	0.15	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
bid	bid	RB	B-ADVP	O	O
she	she	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
complete	complete	JJ	B-NP	O	O
AV	AV	NN	I-NP	O	B-Disease
block	block	NN	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
resolved	resolve	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
all	all	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

DISCUSSION	DISCUSSION	NN	B-NP	O	O
:	:	:	O	O	O
An	An	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
previously	previously	RB	B-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
two	two	CD	B-NP	O	O
such	such	JJ	I-NP	O	O
cases	case	NNS	I-NP	O	O
and	and	CC	O	O	O
discuss	discuss	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
various	various	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
might	might	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
such	such	PDT	B-NP	O	O
an	an	DT	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
.	.	.	O	O	O

Clinicians	Clinician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
acquainted	acquaint	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
possibly	possibly	RB	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
two	two	CD	B-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Caution	Caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combining	combine	VBG	B-VP	O	O
clonidine	clonidine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
verapamil	verapamil	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
even	even	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
sinus	sinus	NN	B-NP	O	O
or	or	CC	I-NP	O	O
AV	AV	NN	I-NP	O	O
node	node	NN	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
act	act	VB	I-VP	O	O
synergistically	synergistically	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
AV	AV	NN	I-NP	O	O
node	node	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
circulation	circulation	NN	I-NP	O	O
.	.	.	O	O	O

Pharmacological	Pharmacological	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
dihydrothienopyridine	dihydrothienopyridine	NN	I-NP	O	B-Chemical
calcium	calcium	NN	I-NP	B	I-Chemical
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
312	312	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
d	d	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

5th	5th	JJ	B-NP	O	O
communication	communication	NN	I-NP	O	O
:	:	:	O	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

S	S	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
312	312	CD	B-NP	O	I-Chemical
,	,	,	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
312	312	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
d	d	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
312	312	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
l	l	NN	I-NP	O	I-Chemical
,	,	,	O	O	O
L	L	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
,	,	,	O	O	O
showed	show	VBD	B-VP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
audiogenic	audiogenic	JJ	I-NP	O	B-Disease
tonic	tonic	JJ	I-NP	O	I-Disease
convulsions	convulsion	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
ED50	ED50	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
18.4	18.4	CD	B-NP	O	O
(	(	(	O	O	O
12.8	12.8	CD	B-NP	O	O
-	-	HYPH	O	O	O
27.1	27.1	CD	O	O	O
)	)	)	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
p.o.	p.o.	FW	B-NP	O	O
and	and	CC	O	O	O
15.0	15.0	CD	B-NP	O	O
(	(	(	O	O	O
10.2	10.2	CD	B-NP	O	O
-	-	HYPH	O	O	O
23.7	23.7	CD	O	O	O
)	)	)	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
p.o.	p.o.	FW	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
flunarizine	flunarizine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
34.0	34.0	CD	B-NP	O	O
(	(	(	O	O	O
26.0	26.0	CD	B-NP	O	O
-	-	HYPH	O	O	O
44.8	44.8	CD	O	O	O
)	)	)	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-VP	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
p.o	p.o	NN	B-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
moderate	moderate	JJ	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
312	312	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
d	d	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clonic	clonic	JJ	I-NP	O	O
convulsions	convulsion	NNS	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
85	85	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c.	s.c.	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
bemegride	bemegride	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
s.c.	s.c.	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
N	N	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
D	D	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
aspartate	aspartate	NN	B-NP	I	I-Chemical
,	,	,	O	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
electroshock	electroshock	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Slc	Slc	NN	B-NP	O	O
:	:	:	O	O	O
ddY	ddY	NN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

S	S	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
312	312	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
d	d	NN	I-NP	O	I-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Transmural	Transmural	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

For	For	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
tightness	tightness	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chest	chest	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
unknown	unknown	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
47	47	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	B	B-Chemical
6	6	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
subcutaneously	subcutaneously	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
cluster	cluster	NN	B-NP	O	B-Disease
headache	headache	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
underlying	underlie	VBG	B-VP	O	O
ischaemic	ischaemic	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
Prinzmetal	Prinzmetal	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
angina	angina	NN	I-NP	O	I-Disease
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
recovered	recover	VBD	B-VP	O	O
without	without	IN	B-PP	O	O
complications	complication	NNS	B-NP	O	O
.	.	.	O	O	O

Flumazenil	Flumazenil	NNP	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mixed	mix	VBN	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
intoxications	intoxication	NNS	I-NP	O	O
.	.	.	O	O	O

STUDY	STUDY	NN	B-NP	O	O
HYPOTHESIS	HYPOTHESIS	NN	I-NP	O	O
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	B	B-Chemical
antagonist	antagonist	NN	I-NP	O	O
flumazenil	flumazenil	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
unmask	unmask	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
mixed	mix	VBN	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
benzodiazepine	benzodiazepine	NN	I-NP	B	B-Chemical
intoxication	intoxication	NN	I-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
Male	Male	NNP	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
IP	IP	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
groups	group	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
challenged	challenge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
vehicle	vehicle	NN	B-NP	O	O
or	or	CC	I-NP	O	O
flumazenil	flumazenil	NN	I-NP	B	B-Chemical
5	5	CD	B-NP	O	O
or	or	CC	I-NP	O	O
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
IP	IP	NN	I-NP	O	O
.	.	.	O	O	O

Animal	Animal	JJ	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
,	,	,	O	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
(	(	(	O	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
and	and	CC	O	O	O
incidence	incidence	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
death	death	NN	B-NP	O	O
(	(	(	O	O	O
time	time	NN	B-NP	O	O
to	to	TO	B-PP	O	O
and	and	CC	O	O	O
incidence	incidence	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
cortical	cortical	JJ	B-NP	O	O
EEG	EEG	NN	I-NP	O	O
tracings	tracing	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
.	.	.	O	O	O

INTERVENTIONS	INTERVENTIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
flumazenil	flumazenil	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
animals	animal	NNS	B-NP	O	O
after	after	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
group	group	NN	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
animals	animal	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
vehicle	vehicle	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
developing	develop	VBG	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

Group	Group	NN	B-NP	O	O
2	2	CD	I-NP	O	O
received	receive	VBD	B-VP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
alone	alone	RB	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
vehicle	vehicle	NN	B-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
became	become	VBD	B-VP	O	O
somnolent	somnolent	JJ	B-ADJP	O	O
and	and	CC	O	O	O
none	none	NN	B-NP	O	O
died	die	VBD	B-VP	O	O
.	.	.	O	O	O

Group	Group	NN	B-NP	O	O
3	3	CD	I-NP	O	O
received	receive	VBD	B-VP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
flumazenil	flumazenil	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
became	become	VBD	B-VP	O	O
somnolent	somnolent	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
then	then	RB	B-ADJP	O	O
active	active	JJ	I-ADJP	O	O
after	after	IN	B-SBAR	O	O
flumazenil	flumazenil	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
group	group	NN	B-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
overt	overt	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
EEG	EEG	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
detectable	detectable	JJ	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

Group	Group	NN	B-NP	O	O
5	5	CD	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
followed	follow	VBD	B-VP	O	O
later	later	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
flumazenil	flumazenil	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.01	.01	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
,	,	,	O	O	O
100	100	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
.01	.01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
group	group	NN	B-NP	O	O
4	4	CD	I-NP	O	O
.	.	.	O	O	O

Group	Group	NN	B-NP	O	O
6	6	CD	I-NP	O	O
received	receive	VBD	B-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
flumazenil	flumazenil	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
also	also	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
.01	.01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
,	,	,	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
.05	.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
group	group	NN	B-NP	O	O
4	4	CD	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Flumazenil	Flumazenil	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
unmask	unmask	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
increase	increase	VB	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
death	death	NN	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combined	combine	VBN	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
diazepam	diazepam	NN	I-NP	B	B-Chemical
intoxications	intoxication	NNS	I-NP	O	O
.	.	.	O	O	O

Mechanisms	Mechanism	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
protective	protective	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
radical	radical	NN	I-NP	O	O
scavengers	scavenger	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
radical	radical	NN	I-NP	O	O
scavengers	scavenger	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
GM	GM	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
GM	GM	NNP	B-NP	O	B-Chemical
at	at	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
sc	sc	NN	I-NP	O	O
for	for	IN	B-PP	O	O
13	13	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
induced	induce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
(	(	(	O	O	O
RBF	RBF	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
inulin	inulin	NN	B-NP	B	O
clearance	clearance	NN	I-NP	O	O
(	(	(	O	O	O
CIn	CIn	NN	B-NP	O	O
)	)	)	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
marked	marked	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
guanosine	guanosine	NN	I-NP	B	B-Chemical
3',5	3',5	CD	I-NP	I	I-Chemical
'	'	SYM	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
cyclic	cyclic	JJ	I-NP	I	I-Chemical
monophosphate	monophosphate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
cGMP	cGMP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
excretion	excretion	NN	B-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
renin	renin	NN	I-NP	O	O
and	and	CC	I-NP	O	O
endothelin	endothelin	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
contents	content	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
GM	GM	NNP	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Superoxide	Superoxide	NN	B-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
(	(	(	O	O	O
SOD	SOD	NN	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
dimethylthiourea	dimethylthiourea	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DMTU	DMTU	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
significantly	significantly	RB	B-VP	O	O
lessened	lessen	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
GM	GM	NNP	I-NP	O	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
decrement	decrement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
CIn	CIn	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
SOD	SOD	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
improvement	improvement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
RBF	RBF	NN	B-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
cGMP	cGMP	NN	I-NP	B	B-Chemical
excretion	excretion	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
renin	renin	NN	I-NP	O	O
and	and	CC	I-NP	O	O
endothelin	endothelin	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
content	content	NN	I-NP	O	O
.	.	.	O	O	O

SOD	SOD	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
DMTU	DMTU	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
peroxidation	peroxidation	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
renal	renal	JJ	B-NP	O	O
hemodynamics	hemodynamic	NNS	I-NP	O	O
and	and	CC	O	O	O
vasoactive	vasoactive	JJ	B-NP	O	O
substances	substance	NNS	I-NP	O	O
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
SOD	SOD	NN	B-NP	O	O
nor	nor	CC	I-NP	O	O
DMTU	DMTU	NN	I-NP	B	B-Chemical
affected	affect	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cortical	cortical	JJ	I-NP	O	O
GM	GM	NNP	I-NP	O	B-Chemical
content	content	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GM	GM	NNP	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
1	1	LS	B-LST	O	O
)	)	)	O	O	O
both	both	CC	O	O	O
SOD	SOD	NN	B-NP	O	O
and	and	CC	I-NP	O	O
DMTU	DMTU	NN	I-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
protective	protective	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
GM	GM	NNP	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
mediated	mediate	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
2	2	LS	B-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
differ	differ	VBP	B-VP	O	O
for	for	IN	B-PP	O	O
SOD	SOD	NN	B-NP	O	O
and	and	CC	I-NP	O	O
DMTU	DMTU	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
3	3	LS	B-LST	O	O
)	)	)	O	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
anions	anion	NNS	I-NP	I	O
play	play	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GM	GM	NNP	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
.	.	.	O	O	O

Assessment	Assessment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
during	during	IN	B-PP	O	O
hypertrophy	hypertrophy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiomyocytes	cardiomyocyte	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
synthesize	synthesize	VB	I-VP	O	O
DNA	DNA	NN	B-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
experimentally	experimentally	RB	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Isoproterenol	Isoproterenol	NN	B-NP	B	B-Chemical
delivered	deliver	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
osmotic	osmotic	JJ	B-NP	O	O
minipump	minipump	NN	I-NP	O	O
implantation	implantation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
C3Heb	C3Heb	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
FeJ	FeJ	NN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
46	46	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
19.3	19.3	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
area	area	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
autoradiographic	autoradiographic	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
or	or	CC	O	O	O
hypertrophic	hypertrophic	JJ	B-NP	O	B-Disease
hearts	heart	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
survey	survey	NN	I-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
independent	independent	JJ	I-NP	O	O
inbred	inbred	JJ	I-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
ventricular	ventricular	JJ	B-NP	O	O
cardiomyocyte	cardiomyocyte	NN	I-NP	O	O
nuclear	nuclear	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
ranged	range	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
3	3	CD	B-NP	O	O
to	to	TO	I-NP	O	O
13	13	CD	I-NP	O	O
%	%	NN	I-NP	O	O
mononucleate	mononucleate	NN	I-NP	O	O
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
terminal	terminal	JJ	I-NP	O	O
differentiation	differentiation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
influenced	influence	VBN	I-VP	O	O
directly	directly	RB	B-ADVP	O	O
or	or	CC	B-ADVP	O	O
indirectly	indirectly	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
genetic	genetic	JJ	B-NP	O	O
background	background	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
capacity	capacity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
reactive	reactive	JJ	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
subject	subject	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
genetic	genetic	JJ	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
strains	strain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
comprising	comprise	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
extremes	extreme	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nuclear	nuclear	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
survey	survey	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
adult	adult	JJ	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
atrial	atrial	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
synthesize	synthesize	VB	I-VP	O	O
DNA	DNA	NN	B-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Central	Central	JJ	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
ANP	ANP	NN	I-NP	O	O
in	in	IN	B-PP	O	O
normotensive	normotensive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
spontaneously	spontaneously	RB	I-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
compare	compare	VB	I-VP	O	O
influence	influence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
arginine	arginine	NN	I-NP	B	B-Chemical
vasopressin	vasopressin	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
of	of	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	B	O
natriuretic	natriuretic	JJ	I-NP	I	O
peptide	peptide	NN	I-NP	I	O
(	(	(	O	O	O
ANP	ANP	NN	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
control	control	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
MAP	MAP	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
HR	HR	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
normotensive	normotensive	JJ	B-NP	O	O
(	(	(	O	O	O
WKY	WKY	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
spontaneously	spontaneously	RB	B-ADJP	O	O
hypertensive	hypertensive	JJ	I-ADJP	O	B-Disease
(	(	(	O	O	O
SHR	SHR	NN	B-NP	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
experiments	experiment	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
30	30	CD	B-NP	O	O
WKY	WKY	NN	I-NP	O	O
and	and	CC	O	O	O
30	30	CD	B-NP	O	O
SHR	SHR	NN	I-NP	O	O
,	,	,	O	O	O
chronically	chronically	RB	B-VP	O	O
instrumented	instrument	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
guide	guide	NN	B-NP	O	O
tubes	tube	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
ventricle	ventricle	NN	I-NP	O	O
(	(	(	O	O	O
LV	LV	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
arterial	arterial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
venous	venous	JJ	I-NP	O	O
catheters	catheter	NNS	I-NP	O	O
.	.	.	O	O	O

MAP	MAP	NN	B-NP	O	O
and	and	CC	I-NP	O	O
HR	HR	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
i.v.	i.v.	JJ	B-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
either	either	CC	O	O	O
vehicle	vehicle	NN	B-NP	O	O
or	or	CC	O	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
25	25	CD	B-NP	O	O
,	,	,	I-NP	O	O
125	125	CD	I-NP	O	O
and	and	CC	I-NP	O	O
500	500	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ANP	ANP	NN	B-NP	O	O
.	.	.	O	O	O

Sensitivity	Sensitivity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
component	component	NN	I-NP	O	O
of	of	IN	B-PP	O	O
baroreflex	baroreflex	NN	B-NP	O	O
(	(	(	O	O	O
CCB	CCB	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
expressed	express	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
slope	slope	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
regression	regression	NN	I-NP	O	O
line	line	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
relationships	relationship	NNS	B-NP	O	O
between	between	IN	B-PP	O	O
systolic	systolic	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
SAP	SAP	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
HR	HR	NN	B-NP	O	O
period	period	NN	I-NP	O	O
(	(	(	O	O	O
HRp	HRp	NN	B-NP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
phenylephrine	phenylephrine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Phe	Phe	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
nitroprusside	nitroprusside	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
SN	SN	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

CCB	CCB	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
either	either	DT	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
,	,	,	O	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
ANP	ANP	NN	B-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
both	both	DT	B-NP	O	O
peptides	peptide	NNS	I-NP	O	O
together	together	RB	B-ADVP	O	O
.	.	.	O	O	O

Increases	Increase	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
MAP	MAP	NN	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-SBAR	O	O
LV	LV	NN	B-NP	B	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
WKY	WKY	NN	B-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
ng	ng	NN	I-NP	O	O
in	in	IN	B-PP	O	O
SHR	SHR	NN	B-NP	O	O
.	.	.	O	O	O

ANP	ANP	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
cause	cause	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
MAP	MAP	NN	B-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
strains	strain	NNS	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
vehicle	vehicle	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
abolished	abolish	VBD	B-VP	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
MAP	MAP	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
WKY	WKY	NN	B-NP	O	O
and	and	CC	I-NP	O	O
SHR	SHR	NN	I-NP	O	O
.	.	.	O	O	O

CCB	CCB	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
WKY	WKY	NN	B-NP	O	O
and	and	CC	I-NP	O	O
SHR	SHR	NN	I-NP	O	O
after	after	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AVP	AVP	NN	B-NP	O	B-Chemical
during	during	IN	B-PP	O	O
SN	SN	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
SHR	SHR	NN	B-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
WKY	WKY	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ANP	ANP	NN	B-NP	O	O
,	,	,	I-NP	O	O
AVP	AVP	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
ANP	ANP	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
AVP	AVP	NN	I-NP	O	B-Chemical
decreased	decrease	VBD	B-VP	O	O
CCB	CCB	NN	B-NP	B	O
during	during	IN	B-PP	O	O
Phe	Phe	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
MAP	MAP	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
centrally	centrally	RB	B-NP	O	O
applied	apply	VBN	I-NP	O	O
AVP	AVP	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
ANP	ANP	NN	I-NP	O	O
exert	exert	VBP	B-VP	O	O
differential	differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
baroreflex	baroreflex	NN	B-NP	O	O
control	control	NN	B-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
WKY	WKY	NN	B-NP	O	O
and	and	CC	I-NP	O	O
SHR	SHR	NN	I-NP	O	O
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
interaction	interaction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
two	two	CD	I-NP	O	O
peptides	peptide	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

Cutaneous	Cutaneous	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	O
causing	cause	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
intracerebral	intracerebral	JJ	I-NP	O	B-Disease
hemorrhage	hemorrhage	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intercerebral	intercerebral	JJ	B-NP	O	O
hematoma	hematoma	NN	I-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
coagulopathy	coagulopathy	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
presented	present	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
39	39	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
spread	spread	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
warfarin	warfarin	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
rat	rat	NN	I-NP	O	O
poison	poison	NN	I-NP	O	O
around	around	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
house	house	NN	I-NP	O	O
weekly	weekly	RB	B-VP	O	O
using	use	VBG	I-VP	O	O
her	her	PRP$	B-NP	O	O
bare	bare	JJ	I-NP	O	O
hands	hand	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
washing	wash	VBG	I-NP	O	O
post	post	NN	I-NP	O	O
application	application	NN	I-NP	O	O
.	.	.	O	O	O

Percutaneous	Percutaneous	JJ	B-NP	O	O
absorption	absorption	NN	I-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
causing	cause	VBG	B-VP	O	O
coagulopathy	coagulopathy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
reported	report	VBD	B-VP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
past	past	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
protective	protective	JJ	B-NP	O	O
measures	measure	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
gloves	glove	NNS	B-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
piroxicam	piroxicam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
she	she	PRP	B-NP	O	O
took	take	VBD	B-VP	O	O
occasionally	occasionally	RB	B-ADVP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
exacerbated	exacerbate	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
coagulopathy	coagulopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Pediatric	Pediatric	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
without	without	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
steroids	steroid	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

From	From	IN	B-PP	O	O
1986	1986	CD	B-NP	O	O
to	to	TO	B-PP	O	O
February	February	NNP	B-NP	O	O
1993	1993	CD	I-NP	O	O
,	,	,	I-NP	O	O
40	40	CD	I-NP	O	O
children	child	NNS	I-NP	O	O
aged	age	VBN	B-VP	O	O
2	2	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
18	18	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
(	(	(	O	O	O
average	average	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
10.4	10.4	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
5.8	5.8	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
underwent	undergo	VBD	B-VP	O	O
heart	heart	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

Indications	Indication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
transplantation	transplantation	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
idiopathic	idiopathic	JJ	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
(	(	(	O	O	O
52	52	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
congenital	congenital	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
35	35	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
and	and	CC	B-PP	O	O
without	without	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
repair	repair	NN	I-NP	O	O
(	(	(	O	O	O
71	71	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
29	29	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
hypertrophic	hypertrophic	JJ	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
(	(	(	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
valvular	valvular	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
3	3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
(	(	(	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
managed	manage	VBN	I-VP	B	O
with	with	IN	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
azathioprine	azathioprine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

No	No	DT	B-NP	O	O
prophylaxis	prophylaxis	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antilymphocyte	antilymphocyte	NN	B-NP	O	O
globulin	globulin	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Steroids	Steroid	NNS	B-NP	O	B-Chemical
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
39	39	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
rejection	rejection	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
weaning	weaning	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
always	always	RB	I-VP	O	O
attempted	attempt	VBN	I-VP	O	O
and	and	CC	O	O	O
generally	generally	RB	B-ADJP	O	O
successful	successful	JJ	I-ADJP	O	O
(	(	(	O	O	O
64	64	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
maintenance	maintenance	NN	B-NP	O	O
steroids	steroid	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
died	die	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
perioperative	perioperative	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
died	die	VBD	B-VP	O	O
4	4	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
deaths	death	NNS	I-NP	O	O
related	relate	VBN	B-ADJP	O	O
to	to	TO	B-PP	O	O
rejection	rejection	NN	B-NP	O	O
or	or	CC	I-NP	O	O
infection	infection	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Average	Average	JJ	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
was	be	VBD	B-VP	O	O
36	36	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
19	19	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
1	1	CD	I-NP	O	O
to	to	TO	I-NP	O	O
65	65	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Cumulative	Cumulative	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
88	88	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
5	5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
7	7	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
rejection	rejection	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
noninvasively	noninvasively	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
postoperative	postoperative	JJ	I-NP	O	O
month	month	NN	I-NP	O	O
,	,	,	O	O	O
89	89	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
rejection	rejection	NN	B-NP	O	O
.	.	.	O	O	O

Freedom	Freedom	NN	B-NP	B	O
from	from	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
infections	infection	NNS	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
83	83	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
month	month	NN	I-NP	O	O
and	and	CC	O	O	O
65	65	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
year	year	NN	I-NP	O	O
.	.	.	O	O	O

Cytomegalovirus	Cytomegalovirus	NN	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
successfully	successfully	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
ganciclovir	ganciclovir	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
growth	growth	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
transplantation	transplantation	NN	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
population	population	NN	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
undergone	undergo	VBN	I-VP	O	O
annual	annual	JJ	B-NP	O	O
catheterizations	catheterization	NNS	I-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
sign	sign	NN	I-NP	O	O
of	of	IN	B-PP	O	O
graft	graft	NN	B-NP	O	O
atherosclerosis	atherosclerosis	NN	I-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Seizures	Seizure	NNS	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
disabled	disabled	JJ	B-ADJP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
lymphoproliferative	lymphoproliferative	JJ	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
observed.	observed.	VBN	I-VP	O	O
(	(	(	O	O	O
ABSTRACT	ABSTRACT	NN	B-NP	O	O
TRUNCATED	TRUNCATED	VBN	B-VP	O	O
AT	AT	IN	B-PP	O	O
250	250	CD	B-NP	O	O
WORDS	WORDS	NNS	I-NP	O	O
)	)	)	O	O	O

Delirium	Delirium	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
correlation	correlation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
tricyclic	tricyclic	JJ	I-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
central	central	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
well	well	RB	I-VP	O	O
established	establish	VBN	I-VP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
a	a	DT	I-NP	O	O
few	few	JJ	I-NP	O	O
reports	report	NNS	I-NP	O	O
exist	exist	VBP	B-VP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
SSRIs	SSRI	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
some	some	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
citalopram	citalopram	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
600	600	CD	B-NP	O	O
nmol	nmol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
somnolence	somnolence	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
movement	movement	NN	I-NP	O	B-Disease
difficulties	difficulty	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Widespread	Widespread	JJ	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
delirium	delirium	NN	B-NP	O	B-Disease
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
linked	link	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
SSRIs	SSRI	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
report	report	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
hyperkinetic	hyperkinetic	JJ	I-NP	O	B-Disease
delirium	delirium	NN	I-NP	O	B-Disease
connected	connect	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
plus	plus	CC	O	O	O
desmethylfluoxetine	desmethylfluoxetine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
concentration	concentration	NN	B-NP	O	O
.	.	.	O	O	O

Pulmonary	Pulmonary	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
shock	shock	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
aracytine	aracytine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
C	C	NN	I-NP	O	I-Chemical
for	for	IN	B-PP	O	O
lymphoma	lymphoma	NN	B-NP	O	B-Disease
;	;	:	O	O	O
possible	possible	JJ	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TNF	TNF	NN	B-NP	B	O
-	-	HYPH	O	O	O
alpha	alpha	SYM	B-NP	O	O
and	and	CC	O	O	O
PAF	PAF	NN	B-NP	B	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
out	out	IN	I-NP	O	O
of	of	IN	I-NP	O	O
23	23	CD	I-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
Ara	Ara	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
C	C	NN	I-NP	I	I-Chemical
for	for	IN	B-PP	O	O
lymphomas	lymphoma	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
institution	institution	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
strikingly	strikingly	RB	I-NP	O	O
similar	similar	JJ	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
perfusion	perfusion	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fever	fever	NN	B-NP	O	B-Disease
,	,	,	O	O	O
diarrhea	diarrhea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
shock	shock	NN	B-NP	O	B-Disease
,	,	,	O	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
,	,	,	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
metabolic	metabolic	JJ	B-NP	O	B-Disease
acidosis	acidosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
weight	weight	NN	B-NP	O	B-Disease
gain	gain	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
leukocytosis	leukocytosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Thorough	Thorough	IN	B-PP	O	O
bacteriological	bacteriological	JJ	B-NP	O	O
screening	screening	NN	I-NP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
provide	provide	VB	I-VP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
infection	infection	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Sequential	Sequential	JJ	B-NP	O	O
biological	biological	JJ	I-NP	O	O
assays	assay	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
IL	IL	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
IL	IL	NN	B-NP	B	O
-	-	HYPH	I-NP	I	O
2	2	CD	I-NP	I	O
,	,	,	I-NP	O	O
TNF	TNF	NN	I-NP	B	O
and	and	CC	I-NP	O	O
PAF	PAF	NN	I-NP	B	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
Ara	Ara	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
C	C	NN	I-NP	I	I-Chemical
infusion	infusion	NN	I-NP	O	O
to	to	TO	B-PP	O	O
ten	ten	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
four	four	CD	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

TNF	TNF	NN	B-NP	O	O
and	and	CC	I-NP	O	O
PAF	PAF	NN	I-NP	B	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
respectively	respectively	RB	B-NP	O	O
two	two	CD	I-NP	O	O
and	and	CC	I-NP	O	O
four	four	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	B-PP	O	O
but	but	CC	I-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
the	the	DT	B-NP	O	O
six	six	CD	I-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
TNF	TNF	NN	B-NP	B	O
and	and	CC	I-NP	O	O
PAF	PAF	NN	I-NP	B	O
are	be	VBP	B-VP	O	O
thought	think	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
septic	septic	JJ	B-NP	O	O
shock	shock	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
adult	adult	JJ	B-NP	O	B-Disease
respiratory	respiratory	JJ	I-NP	O	I-Disease
distress	distress	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
hypothesize	hypothesize	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
Ara	Ara	NN	I-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
C	C	NN	B-NP	I	I-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
cytokine	cytokine	NN	B-NP	O	O
release	release	NN	I-NP	O	O
.	.	.	O	O	O

Protective	Protective	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
against	against	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
1,5	1,5	CD	I-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
benzothiazepine	benzothiazepine	NN	I-NP	O	I-Chemical
calcium	calcium	NN	I-NP	B	B-Chemical
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
week	week	NN	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
,	,	,	O	O	O
16	16	CD	B-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
died	die	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
fibrosis	fibrosis	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
ventricles	ventricle	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
left	leave	VBD	B-VP	O	O
atrial	atrial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
papillary	papillary	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
responses	response	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
or	or	CC	O	O	O
enhanced	enhance	VBN	B-VP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

Left	Leave	VBN	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
alpha	alpha	NN	I-NP	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
densities	density	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
prevented	prevent	VBD	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
death	death	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.05	.05	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
fibrosis	fibrosis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

Left	Leave	VBN	B-NP	O	O
atrial	atrial	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
papillary	papillary	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
contractile	contractile	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
restored	restore	VBD	B-VP	O	O
left	left	JJ	B-NP	O	O
atrial	atrial	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
and	and	CC	O	O	O
enhanced	enhance	VBN	B-VP	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
papillary	papillary	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
clentiazem	clentiazem	NN	I-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-VP	O	O
down	down	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alpha	alpha	NN	B-NP	O	O
and	and	CC	O	O	O
beta	beta	NN	B-NP	O	O
adrenoceptors	adrenoceptor	NNS	I-NP	O	O
.	.	.	O	O	O

Interestingly	Interestingly	RB	B-ADVP	O	O
,	,	,	O	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
infused	infuse	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
densities	density	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
ventricle	ventricle	NN	I-NP	O	O
.	.	.	O	O	O

Clentiazem	Clentiazem	NNP	B-NP	B	B-Chemical
also	also	RB	B-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
enhanced	enhance	VBN	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
partially	partially	RB	B-ADVP	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
maximal	maximal	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
clentiazem	clentiazem	NN	B-NP	B	B-Chemical
attenuated	attenuate	VBD	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
possibly	possibly	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
.	.	.	O	O	O

Cocaine	Cocaine	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
probably	probably	RB	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
spasm	spasm	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
reversed	reverse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
nitroglycerin	nitroglycerin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
blocking	blocking	NN	I-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Doxorubicin	Doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
monitored	monitor	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
in	in	IN	B-PP	O	O
freely	freely	RB	B-ADVP	O	O
moving	move	VBG	B-VP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
to	to	TO	B-VP	O	O
test	test	VB	I-VP	O	O
potential	potential	JJ	B-NP	O	O
protectors	protector	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
laboratory	laboratory	NN	B-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
histology	histology	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
most	most	RBS	B-ADJP	O	O
commonly	commonly	RB	I-ADJP	O	O
used	use	VBN	I-ADJP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
monitoring	monitor	VBG	B-VP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
large	large	JJ	B-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
we	we	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
ECG	ECG	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
freely	freely	RB	B-ADVP	O	O
moving	move	VBG	B-VP	O	O
mice	mouse	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
telemetry	telemetry	NN	B-NP	O	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
this	this	DT	B-NP	O	O
model	model	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	O	O
of	of	IN	B-PP	O	O
freely	freely	RB	B-VP	O	O
moving	move	VBG	I-VP	O	O
BALB	BALB	NN	B-NP	O	O
/	/	SYM	B-VP	O	O
c	c	NN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ICRF	ICRF	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
187	187	CD	I-NP	I	I-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ST	ST	NN	I-NP	B	O
interval	interval	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
widened	widen	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
15.0	15.0	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.5	1.5	CD	B-NP	O	O
to	to	TO	B-PP	O	O
56.8	56.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
11.8	11.8	CD	B-NP	O	O
ms	m	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
week	week	NN	B-NP	O	O
10	10	CD	I-NP	O	O
(	(	(	O	O	O
7	7	CD	B-NP	O	O
weekly	weekly	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
given	give	VBN	B-VP	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
plus	plus	CC	O	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
observation	observation	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ECG	ECG	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
entire	entire	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
sacrifice	sacrifice	NN	B-NP	O	O
the	the	DT	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
enlarged	enlarge	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
atria	atria	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
hypertrophic	hypertrophic	JJ	B-ADJP	O	B-Disease
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
schedule	schedule	NN	I-NP	O	O
exerted	exert	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
than	than	IN	B-SBAR	O	O
needed	need	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
protective	protective	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
protection	protection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ICRF	ICRF	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
187	187	CD	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
using	use	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
with	with	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
general	general	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
(	(	(	O	O	O
6	6	CD	B-NP	O	O
weekly	weekly	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
given	give	VBN	B-VP	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
plus	plus	CC	O	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
observation	observation	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
this	this	DT	B-NP	O	O
schedule	schedule	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
sacrifice	sacrifice	NN	B-NP	O	O
and	and	CC	I-NP	O	O
ICRF	ICRF	NN	I-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
187	187	CD	B-NP	I	I-Chemical
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
given	give	VBN	B-PP	O	O
i.p	i.p	NN	B-NP	O	O
.	.	.	O	O	O

1	1	CD	B-NP	O	O
h	h	NN	I-NP	O	O
before	before	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
provided	provide	VBD	B-VP	O	O
almost	almost	RB	B-NP	O	O
full	full	JJ	I-NP	O	O
protection	protection	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
histology	histology	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
very	very	RB	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
and	and	CC	O	O	O
enables	enable	VBZ	B-VP	O	O
monitoring	monitoring	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
time	time	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
allows	allow	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
testing	testing	NN	I-NP	O	O
of	of	IN	B-PP	O	O
protectors	protector	NNS	B-NP	O	O
against	against	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
as	as	IN	B-SBAR	O	O
demonstrated	demonstrate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protection	protection	NN	I-NP	O	O
provided	provide	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ICRF	ICRF	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
187	187	CD	I-NP	I	I-Chemical
.	.	.	O	O	O

Epinephrine	Epinephrine	NN	B-NP	B	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
subtoxic	subtoxic	JJ	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
both	both	DT	O	O	O
precipitate	precipitate	VB	B-VP	O	O
dysrhythmias	dysrhythmia	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
circulating	circulate	VBG	B-VP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
during	during	IN	B-PP	O	O
regional	regional	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
could	could	MD	B-VP	O	O
potentiate	potentiate	VB	I-VP	O	O
dysrhythmogenic	dysrhythmogenic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
therefore	therefore	RB	B-ADVP	O	O
examined	examine	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
alters	alter	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
dysrhythmogenicity	dysrhythmogenicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
,	,	,	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Forty	Forty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
conscious	conscious	JJ	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
10	10	CD	B-NP	O	O
micrograms.kg	micrograms.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1.min	1.min	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Seventeen	Seventeen	CD	B-NP	O	O
animals	animal	NNS	I-NP	O	O
responded	respond	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
VT	VT	NN	B-NP	O	B-Disease
)	)	)	O	O	O
within	within	IN	B-PP	O	O
3	3	CD	B-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
3	3	CD	B-NP	O	O
h	h	NN	I-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
responders	responder	NNS	I-NP	O	O
randomly	randomly	RB	B-ADVP	O	O
received	receive	VBD	B-VP	O	O
1	1	CD	B-NP	O	O
or	or	CC	I-NP	O	O
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
or	or	CC	O	O	O
saline	saline	NN	B-NP	B	O
over	over	IN	B-PP	O	O
5	5	CD	B-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
10	10	CD	B-NP	O	O
micrograms.kg	micrograms.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1.min	1.min	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
caused	cause	VBD	B-VP	O	O
fewer	few	JJR	B-NP	O	O
prodysrhythmic	prodysrhythmic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
without	without	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

VT	VT	NN	B-NP	O	B-Disease
appeared	appear	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
fewer	few	JJR	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
later	later	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	B-NP	O	O
sinoatrial	sinoatrial	JJ	I-NP	O	O
beats	beat	NNS	I-NP	O	O
and	and	CC	O	O	O
less	less	JJR	B-NP	O	O
ectopies	ectopy	NNS	I-NP	O	O
.	.	.	O	O	O

Epinephrine	Epinephrine	NN	B-NP	B	B-Chemical
shortened	shorten	VBD	B-VP	O	O
QT	QT	NN	B-NP	O	O
less	less	JJR	B-ADVP	O	O
after	after	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
day	day	NN	I-NP	O	O
after	after	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
,	,	,	O	O	O
six	six	CD	B-NP	O	O
additional	additional	JJ	I-NP	O	O
halothane	halothane	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
anesthetized	anesthetize	VBN	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
4	4	CD	B-NP	O	O
micrograms.kg	micrograms.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1.min	1.min	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
until	until	IN	B-SBAR	O	O
VT	VT	NN	B-NP	O	B-Disease
appeared	appear	VBD	B-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
45	45	CD	B-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
over	over	IN	B-PP	O	O
5	5	CD	B-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
again	again	RB	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
4	4	CD	B-NP	O	O
micrograms.kg	micrograms.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1.min	1.min	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
these	these	DT	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prodysrhythmic	prodysrhythmic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
mitigated	mitigate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
preceding	precede	VBG	B-VP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Bupivacaine	Bupivacaine	NN	B-NP	B	B-Chemical
antagonizes	antagonize	VBZ	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
dysrhythmogenicity	dysrhythmogenicity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
VT	VT	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
anesthetized	anesthetize	VBN	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
postinfarct	postinfarct	JJ	I-NP	O	O
dysrhythmias	dysrhythmia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
systemic	systemic	JJ	B-NP	O	O
subtoxic	subtoxic	JJ	I-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
enhances	enhance	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
dysrhythmogenicity	dysrhythmogenicity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Milk	Milk	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
alkali	alkali	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
1,25	1,25	CD	B-NP	O	B-Chemical
(	(	(	O	O	I-Chemical
OH	OH	NN	B-NP	B	I-Chemical
)	)	)	O	O	I-Chemical
2D	2D	NN	B-NP	O	I-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hypoparathyroidism	hypoparathyroidism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Milk	Milk	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
alkali	alkali	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
first	first	RB	I-VP	O	O
described	describe	VBN	I-VP	O	O
70	70	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
ago	ago	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
context	context	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
peptic	peptic	JJ	B-NP	O	B-Disease
ulcer	ulcer	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
amounts	amount	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
alkali	alkali	NN	I-NP	O	B-Chemical
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
with	with	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
ulcer	ulcer	NN	I-NP	O	B-Disease
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
H	H	NN	B-NP	O	O
-	-	HYPH	O	O	O
2	2	CD	B-NP	O	O
blockers	blocker	NNS	I-NP	O	O
,	,	,	O	O	O
omeprazole	omeprazole	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
sucralfate	sucralfate	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
milk	milk	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
alkali	alkali	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
has	have	VBZ	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
classic	classic	JJ	I-NP	B	O
triad	triad	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
alkalosis	alkalosis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
remains	remain	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
hallmark	hallmark	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

Milk	Milk	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
alkali	alkali	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
present	present	VB	I-VP	O	O
serious	serious	JJ	B-ADJP	O	O
and	and	CC	O	O	O
occasionally	occasionally	RB	B-ADVP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
illness	illness	NN	B-NP	O	O
unless	unless	IN	B-SBAR	O	O
diagnosed	diagnose	VBN	B-VP	O	O
and	and	CC	O	O	O
treated	treat	VBN	B-VP	O	O
appropriately	appropriately	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
article	article	NN	I-NP	O	O
presents	present	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hypoparathyroidism	hypoparathyroidism	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
carbonate	carbonate	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
calcitriol	calcitriol	NN	I-NP	B	B-Chemical
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
admissions	admission	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
milk	milk	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
alkali	alkali	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
successfully	successfully	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
pamidronate	pamidronate	NN	I-NP	B	B-Chemical
on	on	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
first	first	JJ	I-NP	O	O
admission	admission	NN	I-NP	O	O
and	and	CC	B-PP	O	O
with	with	IN	B-PP	O	O
hydrocortisone	hydrocortisone	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
illustrates	illustrate	VBZ	B-VP	O	O
intravenous	intravenous	JJ	B-NP	O	O
pamidronate	pamidronate	NN	I-NP	B	B-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
valuable	valuable	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
tool	tool	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
milk	milk	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
alkali	alkali	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
presents	present	VBZ	B-VP	O	O
as	as	IN	B-PP	O	O
hypercalcemic	hypercalcemic	JJ	B-NP	O	B-Disease
emergency	emergency	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Encephalopathy	Encephalopathy	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
amitriptyline	amitriptyline	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
:	:	:	O	O	O
are	be	VBP	B-VP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
spectrum	spectrum	NN	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
?	?	.	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
encephalopathy	encephalopathy	NN	B-NP	O	B-Disease
developed	develop	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amitriptyline	amitriptyline	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
remission	remission	NN	I-NP	O	O
of	of	IN	B-PP	O	O
unipolar	unipolar	JJ	B-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
could	could	MD	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
having	have	VBG	B-VP	O	O
either	either	CC	O	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
NMS	NMS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
or	or	CC	O	O	O
serotonin	serotonin	NN	B-NP	B	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SS	SS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
determinant	determinant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
/	/	SYM	O	O	O
serotonin	serotonin	NN	B-NP	B	B-Chemical
imbalance	imbalance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
NMS	NMS	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
develops	develop	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
NMS	NMS	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
SS	SS	NN	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
spectrum	spectrum	NN	B-NP	O	O
disorders	disorder	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
both	both	CC	B-NP	O	O
antidopaminergic	antidopaminergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Genetic	Genetic	JJ	B-NP	O	O
separation	separation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
growth	growth	NN	I-NP	O	O
and	and	CC	O	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
phenotypes	phenotype	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
estrogen	estrogen	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
Fischer	Fischer	NNP	I-NP	O	O
344	344	CD	I-NP	O	O
(	(	(	O	O	O
F344	F344	NN	B-NP	O	O
)	)	)	O	O	O
rat	rat	NN	B-NP	O	O
induces	induce	VBZ	B-VP	O	O
growth	growth	NN	B-NP	O	O
of	of	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
,	,	,	I-NP	O	O
hemorrhagic	hemorrhagic	JJ	I-NP	O	B-Disease
pituitary	pituitary	JJ	I-NP	O	B-Disease
tumors	tumor	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Ten	Ten	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
diethylstilbestrol	diethylstilbestrol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DES	DES	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
caused	cause	VBD	B-VP	O	O
female	female	JJ	B-NP	O	O
F344	F344	NN	I-NP	O	O
rat	rat	NN	I-NP	O	O
pituitaries	pituitary	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
grow	grow	VB	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
of	of	IN	B-PP	O	O
109.2	109.2	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6.3	6.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
SE	SE	NN	I-NP	B	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
11.3	11.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.4	1.4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
untreated	untreated	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
become	become	VB	I-VP	O	O
highly	highly	RB	B-ADJP	O	O
hemorrhagic	hemorrhagic	JJ	I-ADJP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
DES	DES	NNP	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
growth	growth	NN	I-NP	O	O
(	(	(	O	O	O
8.9	8.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
treated	treat	VBN	B-NP	O	O
females	female	NNS	I-NP	O	O
versus	versus	IN	B-PP	O	O
8.7	8.7	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
1.1	1.1	CD	B-NP	O	O
for	for	IN	B-PP	O	O
untreated	untreated	JJ	B-NP	O	O
females	female	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
morphological	morphological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Brown	Brown	NNP	B-NP	O	O
Norway	Norway	NNP	I-NP	O	O
(	(	(	O	O	O
BN	BN	NN	B-NP	B	O
)	)	)	O	O	O
rat	rat	NN	B-NP	O	O
pituitaries	pituitary	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
F1	F1	NN	I-NP	O	O
hybrid	hybrid	NN	I-NP	O	O
of	of	IN	B-PP	O	O
F344	F344	NN	B-NP	O	O
and	and	CC	I-NP	O	O
BN	BN	NN	I-NP	B	O
exhibited	exhibit	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
growth	growth	NN	I-NP	O	O
after	after	IN	B-PP	O	O
10	10	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DES	DES	NNP	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
mass	mass	NN	I-NP	O	O
of	of	IN	B-PP	O	O
26.3	26.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
8.6	8.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.9	0.9	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
for	for	IN	B-PP	O	O
untreated	untreated	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Surprisingly	Surprisingly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
F1	F1	NN	I-NP	O	O
hybrid	hybrid	JJ	I-NP	O	O
tumors	tumor	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
hemorrhagic	hemorrhagic	JJ	B-ADJP	O	B-Disease
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
hemoglobin	hemoglobin	NN	B-NP	B	O
content	content	NN	I-NP	O	O
and	and	CC	O	O	O
outward	outward	RB	B-ADVP	O	O
appearance	appearance	NN	B-NP	O	O
identical	identical	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
BN	BN	NN	B-NP	B	O
.	.	.	O	O	O

Expression	Expression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
growth	growth	NN	B-NP	O	O
and	and	CC	O	O	O
morphological	morphological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
genes	gene	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
DES	DES	NNP	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
pituitary	pituitary	JJ	I-NP	O	O
growth	growth	NN	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
quantitative	quantitative	JJ	B-NP	O	O
,	,	,	I-NP	O	O
additive	additive	JJ	I-NP	O	O
inheritance	inheritance	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
hemorrhagic	hemorrhagic	JJ	I-NP	O	B-Disease
phenotype	phenotype	NN	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
recessive	recessive	JJ	B-NP	O	O
,	,	,	I-NP	O	O
epistatic	epistatic	JJ	I-NP	O	O
inheritance	inheritance	NN	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
5	5	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
160	160	CD	I-NP	O	O
F2	F2	NN	I-NP	B	O
pituitaries	pituitary	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
hemorrhagic	hemorrhagic	JJ	I-NP	O	B-Disease
phenotype	phenotype	NN	I-NP	O	O
;	;	:	O	O	O
36	36	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
160	160	CD	I-NP	O	O
F2	F2	NN	I-NP	B	O
pituitaries	pituitary	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
F344	F344	NN	I-NP	O	O
range	range	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mass	mass	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
31	31	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
hemorrhagic	hemorrhagic	JJ	B-ADJP	O	B-Disease
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
hemorrhagic	hemorrhagic	JJ	I-NP	O	B-Disease
phenotype	phenotype	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
merely	merely	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
consequence	consequence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extensive	extensive	JJ	B-NP	O	O
growth	growth	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hemorrhagic	hemorrhagic	JJ	I-NP	O	B-Disease
F2	F2	NN	I-NP	B	O
pituitaries	pituitary	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
all	all	DT	O	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
massive	massive	JJ	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
genes	gene	NNS	I-NP	O	O
regulate	regulate	VBP	B-VP	O	O
both	both	DT	B-NP	O	O
phenotypes	phenotype	NNS	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuronal	neuronal	JJ	B-NP	O	O
nitric	nitric	JJ	I-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
synthase	synthase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
afferent	afferent	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
bladder	bladder	NN	I-NP	O	B-Disease
irritation	irritation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Immunocytochemical	Immunocytochemical	JJ	B-NP	O	O
techniques	technique	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
alterations	alteration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuronal	neuronal	JJ	B-NP	O	O
nitric	nitric	JJ	I-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
synthase	synthase	NN	I-NP	O	O
(	(	(	O	O	O
NOS	NOS	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
acute	acute	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
irritation	irritation	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
urinary	urinary	JJ	I-NP	O	I-Disease
tract	tract	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Chemical	Chemical	JJ	B-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
acrolein	acrolein	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
irritant	irritant	JJ	I-NP	O	O
eliminated	eliminate	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
.	.	.	O	O	O

Injection	Injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
,	,	,	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
2	2	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
perfusion	perfusion	NN	B-NP	O	O
(	(	(	O	O	O
acute	acute	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
Fos	Fos	NN	B-NP	O	O
-	-	HYPH	O	O	O
immunoreactivity	immunoreactivity	NN	B-NP	O	O
(	(	(	O	O	O
IR	IR	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dorsal	dorsal	JJ	I-NP	O	O
commissure	commissure	NN	I-NP	O	O
,	,	,	O	O	O
dorsal	dorsal	JJ	B-NP	O	O
horn	horn	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
autonomic	autonomic	JJ	B-NP	O	O
regions	region	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
spinal	spinal	JJ	B-NP	O	O
segments	segment	NNS	I-NP	O	O
(	(	(	O	O	O
L1	L1	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
L2	L2	NN	I-NP	B	O
and	and	CC	I-NP	O	O
L6	L6	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
S1	S1	NN	I-NP	B	O
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
receive	receive	VBP	B-VP	O	O
afferent	afferent	JJ	B-NP	O	O
inputs	input	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
,	,	,	O	O	O
urethra	urethra	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ureter	ureter	NN	B-NP	O	O
.	.	.	O	O	O

Fos	Fos	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
IR	IR	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
cord	cord	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
changed	change	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
chronic	chronic	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
15	15	CD	B-NP	O	O
,	,	,	O	O	O
75	75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
,	,	,	O	O	O
every	every	DT	B-NP	O	O
3rd	3rd	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
control	control	NN	B-NP	O	O
animals	animal	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
acutely	acutely	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
only	only	RB	B-NP	O	O
small	small	JJ	I-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NOS	NOS	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
IR	IR	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.7	0.7	CD	I-NP	O	O
cell	cell	NN	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
sections	section	NNS	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
L6	L6	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
S1	S1	NN	I-NP	B	O
dorsal	dorsal	JJ	I-NP	O	O
root	root	NN	I-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
(	(	(	O	O	O
DRG	DRG	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
.002	.002	CD	B-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
bladder	bladder	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
by	by	IN	B-PP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-VP	O	O
(	(	(	O	O	O
7	7	CD	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
11	11	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NOS	NOS	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
immunoreactive	immunoreactive	JJ	I-NP	O	O
(	(	(	O	O	O
IR	IR	NN	B-NP	O	O
)	)	)	O	O	O
afferent	afferent	JJ	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
L6	L6	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
S1	S1	NN	I-NP	B	O
DRG	DRG	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
small	small	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
L1	L1	NN	I-NP	B	O
DRG	DRG	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
L2	L2	NN	I-NP	B	O
and	and	CC	I-NP	O	O
L5	L5	NN	I-NP	O	O
DRG	DRG	NN	I-NP	O	O
.	.	.	O	O	O

Bladder	Bladder	NN	B-NP	O	O
afferent	afferent	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
L6	L6	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
S1	S1	NN	I-NP	B	O
DRG	DRG	NN	I-NP	O	O
labeled	label	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Fluorogold	Fluorogold	NN	B-NP	B	O
(	(	(	O	O	O
40	40	CD	B-NP	O	O
microliters	microliter	NNS	I-NP	O	O
)	)	)	O	O	O
injected	inject	VBN	B-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
wall	wall	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
NOS	NOS	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
IR	IR	NN	I-NP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
animals	animal	NNS	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
following	follow	VBG	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
CYP	CYP	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
afferent	afferent	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
NOS	NOS	NN	B-NP	O	O
-	-	HYPH	O	O	O
IR	IR	NN	B-NP	O	O
:	:	:	O	O	O
L6	L6	NN	B-NP	O	O
(	(	(	O	O	O
19.8	19.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4.6	4.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
S1	S1	NN	B-NP	B	O
(	(	(	O	O	O
25.3	25.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.9	2.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
neuronal	neuronal	JJ	B-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
visceral	visceral	JJ	B-NP	O	O
sensory	sensory	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
upregulated	upregulate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
chemical	chemical	JJ	B-NP	O	O
irritation	irritation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
afferent	afferent	JJ	B-NP	O	O
receptors	receptor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
that	that	IN	B-SBAR	O	O
pathological	pathological	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
tract	tract	NN	I-NP	O	O
can	can	MD	B-VP	O	O
initiate	initiate	VB	I-VP	O	O
chemical	chemical	JJ	B-NP	O	O
signals	signal	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
alter	alter	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
chemical	chemical	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
visceral	visceral	JJ	B-NP	O	O
afferent	afferent	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
832	832	CD	B-NP	O	I-Chemical
,	,	,	O	O	O
on	on	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
partial	partial	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
stenosis	stenosis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
832	832	CD	B-NP	O	I-Chemical
on	on	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
partial	partial	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
stenosis	stenosis	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
circumflex	circumflex	NN	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
artery	artery	NN	I-NP	O	O
and	and	CC	I-NP	O	O
findings	finding	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
for	for	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
stenosis	stenosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
min	min	NN	I-NP	O	O
periods	period	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intracoronary	intracoronary	JJ	B-NP	O	O
ISO	ISO	NN	I-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
(	(	(	O	O	O
10	10	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
maximal	maximal	JJ	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
rise	rise	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
percentage	percentage	NN	B-NP	O	O
segmental	segmental	JJ	I-NP	O	O
shortening	shortening	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ST	ST	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
segment	segment	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epicardial	epicardial	JJ	I-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
ISO	ISO	NN	I-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
stenosis	stenosis	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
,	,	,	O	O	O
equihypotensive	equihypotensive	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
832	832	CD	B-NP	O	I-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
10	10	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
9	9	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
diltiazem	diltiazem	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
infused	infuse	VBN	I-VP	O	O
5	5	CD	B-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
during	during	IN	I-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
third	third	JJ	I-NP	O	O
ISO	ISO	NN	I-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
CD	CD	NNP	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
832	832	CD	I-NP	O	I-Chemical
and	and	CC	O	O	O
diltiazem	diltiazem	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
significantly	significantly	RB	B-VP	O	O
reduced	reduce	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
to	to	TO	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
832	832	CD	B-NP	O	I-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
percentage	percentage	NN	B-NP	O	O
segmental	segmental	JJ	I-NP	O	O
shortening	shortening	NN	I-NP	O	O
from	from	IN	B-PP	O	O
32	32	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
115	115	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
26	26	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
value	value	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.01	.01	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ST	ST	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
segment	segment	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
from	from	IN	B-PP	O	O
5.6	5.6	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.0	1.0	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
to	to	TO	B-PP	O	O
1.6	1.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.3	1.3	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.01	.01	CD	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
3	3	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
stenosis	stenosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Diltiazem	Diltiazem	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
percentage	percentage	NN	B-NP	O	O
segmental	segmental	JJ	I-NP	O	O
shortening	shortening	NN	I-NP	O	O
from	from	IN	B-PP	O	O
34	34	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
63	63	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
value	value	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.05	.05	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ST	ST	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
segment	segment	NN	I-NP	O	O
elevation	elevation	NN	I-NP	O	O
from	from	IN	B-PP	O	O
4.7	4.7	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
to	to	TO	B-PP	O	O
2.1	2.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
mV	mV	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.01	.01	CD	I-NP	O	O
)	)	)	O	O	O
at	at	IN	B-PP	O	O
3	3	CD	B-NP	O	O
min	min	NN	I-NP	O	O
after	after	IN	B-PP	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
stenosis	stenosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
832	832	CD	B-NP	O	I-Chemical
improves	improve	VBZ	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
ISO	ISO	NN	B-NP	O	B-Chemical
infusion	infusion	NN	I-NP	O	O
with	with	IN	B-PP	O	O
stenosis	stenosis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
chronotropic	chronotropic	JJ	I-NP	O	O
property	property	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
832	832	CD	I-NP	O	I-Chemical
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beneficial	beneficial	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CD	CD	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
832	832	CD	I-NP	O	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
recombinant	recombinant	JJ	B-NP	B	O
human	human	JJ	I-NP	I	O
insulin	insulin	NN	I-NP	I	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
growth	growth	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
on	on	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
puromycin	puromycin	NN	I-NP	B	B-Chemical
aminonucleoside	aminonucleoside	NN	I-NP	I	I-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
recently	recently	RB	B-ADVP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
recombinant	recombinant	JJ	B-NP	O	O
hGH	hGH	NN	I-NP	O	O
exacerbates	exacerbate	VBZ	B-VP	O	O
renal	renal	JJ	B-NP	O	O
functional	functional	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
structural	structural	JJ	I-NP	O	O
injury	injury	NN	I-NP	O	O
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
puromycin	puromycin	NN	I-NP	B	B-Chemical
aminonucleoside	aminonucleoside	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
nephropathy	nephropathy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
an	an	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
recombinant	recombinant	JJ	B-NP	O	O
human	human	JJ	I-NP	O	O
(	(	(	O	O	O
rh	rh	JJ	B-ADJP	O	O
)	)	)	O	O	O
IGF	IGF	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
safer	safe	JJR	I-NP	O	O
alternative	alternative	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
growth	growth	NN	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
glomerulopathy	glomerulopathy	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
seven	seven	CD	B-NP	O	O
serial	serial	JJ	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
over	over	IN	B-PP	O	O
12	12	CD	B-NP	O	O
wk	wk	NN	I-NP	O	O
.	.	.	O	O	O

Experimental	Experimental	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	CD	I-NP	O	O
,	,	,	I-NP	O	O
400	400	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
d	d	NN	B-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
vehicle.	vehicle.	NN	I-NP	O	O
rhIGF	rhIGF	NN	I-NP	O	O
-	-	HYPH	O	O	O
I	I	PRP	B-NP	O	O
improved	improve	VBD	B-VP	O	O
weight	weight	NN	B-NP	O	O
gain	gain	NN	I-NP	O	O
by	by	IN	B-PP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
without	without	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
hematocrit	hematocrit	NN	B-NP	O	O
or	or	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
unaltered	unaltered	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
12	12	CD	B-NP	O	O
wk	wk	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
inulin	inulin	NN	I-NP	B	O
clearance	clearance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	B	O
-	-	HYPH	B-NP	I	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
0.48	0.48	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.08	0.08	CD	B-NP	O	O
versus	versus	IN	B-PP	O	O
0.24	0.24	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.06	0.06	CD	B-NP	O	O
mL	mL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
100	100	CD	I-NP	O	O
g	g	NN	I-NP	O	O
of	of	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
in	in	IN	B-PP	O	O
untreated	untreated	JJ	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
0.05	0.05	CD	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GFR	GFR	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
glomerular	glomerular	JJ	I-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
increased	increase	VBN	B-NP	O	O
segmental	segmental	JJ	I-NP	O	O
glomerulosclerosis	glomerulosclerosis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
tubulointerstitial	tubulointerstitial	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
or	or	CC	O	O	O
renal	renal	JJ	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
malondialdehyde	malondialdehyde	NN	I-NP	B	B-Chemical
content	content	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	O	O	O
I	I	PRP	B-NP	O	O
increased	increase	VBD	B-VP	O	O
IGF	IGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
and	and	CC	I-NP	O	O
GH	GH	NN	I-NP	B	O
receptor	receptor	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
,	,	,	O	O	O
without	without	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IGF	IGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
,	,	,	O	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
alter	alter	VB	I-VP	O	O
weight	weight	NN	B-NP	O	O
gain	gain	NN	I-NP	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
,	,	,	O	O	O
GFR	GFR	NN	B-NP	O	O
,	,	,	O	O	O
glomerular	glomerular	JJ	B-NP	O	O
planar	planar	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
,	,	,	O	O	O
renal	renal	JJ	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
malondialdehyde	malondialdehyde	NN	I-NP	B	B-Chemical
content	content	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
glomerular	glomerular	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
tubulointerstitial	tubulointerstitial	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
untreated	untreated	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
steady	steady	JJ	I-NP	O	O
state	state	NN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
IGF	IGF	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
I	I	NN	I-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
level	level	NN	I-NP	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
modify	modify	VB	I-VP	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IGF	IGF	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
or	or	CC	I-NP	O	O
GH	GH	NN	I-NP	B	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
:	:	:	O	O	O
1	1	LS	B-LST	O	O
)	)	)	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
improves	improve	VBZ	B-VP	O	O
growth	growth	NN	B-NP	O	O
and	and	CC	I-NP	O	O
GFR	GFR	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
2	2	LS	B-LST	O	O
)	)	)	O	O	O
unlike	unlike	IN	B-PP	O	O
rhGH	rhGH	NN	B-NP	O	O
,	,	,	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rhIGF	rhIGF	NN	B-NP	O	O
-	-	HYPH	O	O	O
I	I	PRP	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
worsen	worsen	VBN	I-VP	O	O
renal	renal	JJ	B-NP	O	O
functional	functional	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
structural	structural	JJ	I-NP	O	O
injury	injury	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
disease	disease	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Nefiracetam	Nefiracetam	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DM	DM	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
9384	9384	CD	I-NP	I	I-Chemical
)	)	)	O	O	O
reverses	reverse	VBZ	B-VP	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
response	response	NN	I-NP	O	O
:	:	:	O	O	O
delayed	delay	VBN	B-NP	O	O
emergence	emergence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
memory	memory	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Nefiracetam	Nefiracetam	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
pyrrolidone	pyrrolidone	NN	I-NP	B	B-Chemical
derivative	derivative	NN	I-NP	O	O
which	which	WDT	B-NP	O	O
attenuates	attenuate	VBZ	B-VP	O	O
scopolamine	scopolamine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
learning	learning	NN	I-NP	O	B-Disease
and	and	CC	O	O	I-Disease
post	post	AFX	O	O	I-Disease
-	-	HYPH	O	O	I-Disease
training	train	VBG	B-VP	O	I-Disease
consolidation	consolidation	NN	B-NP	O	I-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Given	Give	VBN	B-VP	O	O
that	that	IN	B-SBAR	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
inhibits	inhibit	VBZ	B-VP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
retention	retention	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
training	training	NN	B-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
defined	define	VBN	I-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
12h	12h	CD	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
training	training	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nefiracetam	nefiracetam	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
amnesia	amnesia	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
agonism	agonism	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
step	step	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
down	down	RB	B-ADVP	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
paradigm	paradigm	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
employed	employ	VBN	I-VP	O	O
and	and	CC	O	O	O
nefiracetam	nefiracetam	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
during	during	IN	B-PP	O	O
training	training	NN	B-NP	O	O
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
12h	12h	CD	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
training	training	NN	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
consolidation	consolidation	NN	B-NP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nefiracetam	nefiracetam	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
apomorphine	apomorphine	NN	I-NP	B	B-Chemical
during	during	IN	B-PP	O	O
training	training	NN	B-NP	O	O
or	or	CC	I-NP	O	O
10h	10h	NN	I-NP	O	O
thereafter	thereafter	RB	B-VP	O	O
produced	produce	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
amnesic	amnesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nefiracetam	nefiracetam	NN	B-NP	B	B-Chemical
during	during	IN	B-PP	O	O
training	training	NN	B-NP	O	O
completely	completely	RB	B-ADVP	O	O
reversed	reverse	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
amnesia	amnesia	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
10h	10h	CD	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
training	training	NN	I-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
converse	converse	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
true	true	JJ	B-ADJP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
as	as	IN	B-PP	O	O
nefiracetam	nefiracetam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
at	at	IN	B-PP	O	O
millimolar	millimolar	JJ	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
,	,	,	O	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
displace	displace	VB	I-VP	O	O
either	either	CC	O	O	O
[	[	(	O	O	O
3H	3H	NN	B-NP	O	O
]	]	)	O	O	O
SCH	SCH	NN	B-NP	B	B-Chemical
23390	23390	CD	I-NP	I	I-Chemical
or	or	CC	O	O	O
[	[	(	O	O	O
3H	3H	NN	B-NP	O	O
]	]	)	I-NP	O	O
spiperone	spiperone	NN	I-NP	B	B-Chemical
binding	binding	NN	I-NP	O	O
from	from	IN	B-PP	O	O
D1	D1	NN	B-NP	O	O
or	or	CC	I-NP	O	O
D2	D2	NN	I-NP	B	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
subtypes	subtype	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
nefiracetam	nefiracetam	NN	B-NP	B	B-Chemical
augments	augment	VBZ	B-VP	O	O
molecular	molecular	JJ	B-NP	O	O
processes	process	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
stages	stage	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
events	event	NNS	B-NP	O	O
which	which	WDT	B-NP	O	O
ultimately	ultimately	RB	B-ADVP	O	O
lead	lead	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
consolidation	consolidation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
memory	memory	NN	B-NP	O	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
corticotropin	corticotropin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
and	and	CC	I-NP	O	O
thyrotropin	thyrotropin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
modulate	modulate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
hypercapnic	hypercapnic	JJ	I-NP	O	B-Disease
ventilatory	ventilatory	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

Human	Human	JJ	B-NP	O	O
corticotropin	corticotropin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
hCRH	hCRH	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
thyrotropin	thyrotropin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
releasing	release	VBG	B-VP	O	O
hormone	hormone	NN	B-NP	O	O
(	(	(	O	O	O
TRH	TRH	NN	B-NP	B	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
stimulate	stimulate	VB	I-VP	O	O
ventilation	ventilation	NN	B-NP	O	O
after	after	IN	B-SBAR	O	O
i.v.	i.v.	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
controlled	control	VBN	I-NP	O	O
,	,	,	I-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
clarify	clarify	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
peptides	peptide	NNS	I-NP	O	O
act	act	VBP	B-VP	O	O
by	by	IN	B-PP	O	O
altering	alter	VBG	B-VP	O	O
central	central	JJ	B-NP	O	O
chemosensitivity	chemosensitivity	NN	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
CO2	CO2	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
rebreathing	rebreathe	VBG	B-NP	O	O
tests	test	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
young	young	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
0.9	0.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
NaCl	NaCl	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
;	;	:	O	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
test	test	NN	I-NP	O	O
200	200	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hCRH	hCRH	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
400	400	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TRH	TRH	NN	B-NP	B	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
i.v	i.v	JJ	B-ADJP	O	O
.	.	.	O	O	O

Nine	Nine	CD	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
0.9	0.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
NaCl	NaCl	NN	I-NP	B	B-Chemical
i.v.	i.v.	JJ	B-ADJP	O	O
during	during	IN	B-PP	O	O
both	both	CC	O	O	O
rebreathing	rebreathe	VBG	B-VP	O	O
manoeuvres	manoeuvre	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
CO2	CO2	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
response	response	NN	B-NP	O	O
curves	curve	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
tests	test	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
subject	subject	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hCRH	hCRH	NN	I-NP	O	O
group	group	NN	I-NP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
parallel	parallel	JJ	I-NP	O	O
shift	shift	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CO2	CO2	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
response	response	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
hCRH	hCRH	NN	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
following	follow	VBG	I-VP	O	O
TRH	TRH	NN	B-NP	B	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
less	less	RBR	B-ADJP	O	O
striking	striking	JJ	I-ADJP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O
hCRH	hCRH	NN	B-NP	O	O
and	and	CC	I-NP	O	O
TRH	TRH	NN	I-NP	B	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CO2	CO2	NN	I-NP	B	B-Chemical
threshold	threshold	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
CO2	CO2	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
response	response	NN	B-NP	O	O
curves	curve	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
nearly	nearly	RB	B-ADJP	O	O
identical	identical	JJ	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
additive	additive	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
releasing	release	VBG	I-NP	O	O
hormones	hormone	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hypercapnic	hypercapnic	JJ	I-NP	O	B-Disease
ventilatory	ventilatory	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
presumably	presumably	RB	B-ADJP	O	O
independent	independent	JJ	I-ADJP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
chemosensitivity	chemosensitivity	NN	I-NP	O	O
.	.	.	O	O	O

Lamivudine	Lamivudine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
suppressing	suppress	VBG	B-VP	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	O
DNA	DNA	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Chinese	Chinese	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Chemical
B	B	NN	I-NP	O	I-Chemical
surface	surface	NN	I-NP	O	I-Chemical
antigen	antigen	NN	I-NP	O	I-Chemical
carriers	carrier	NNS	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Lamivudine	Lamivudine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
2',3	2',3	CD	I-NP	O	B-Chemical
'	'	SYM	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
dideoxy	dideoxy	NN	I-NP	O	I-Chemical
cytosine	cytosine	NN	I-NP	B	I-Chemical
analogue	analogue	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
potent	potent	JJ	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	O
replication	replication	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
study	study	NN	I-NP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Chinese	Chinese	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Chemical
B	B	NN	I-NP	O	I-Chemical
surface	surface	NN	I-NP	O	I-Chemical
antigen	antigen	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
HBsAg	HBsAg	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
carriers	carrier	NNS	B-NP	O	O
.	.	.	O	O	O

Forty	Forty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
two	two	CD	I-NP	O	O
Chinese	Chinese	JJ	I-NP	O	O
HBsAg	HBsAg	NN	I-NP	O	B-Chemical
carriers	carrier	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
receive	receive	VB	I-VP	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
orally	orally	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
dosages	dosage	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
daily	daily	JJ	B-ADJP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
each	each	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
closely	closely	RB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
clinically	clinically	RB	B-ADVP	O	O
,	,	,	O	O	O
biochemically	biochemically	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
serologically	serologically	RB	B-ADVP	O	O
up	up	IN	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
36	36	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	O
(	(	(	O	O	O
HBV	HBV	NN	B-NP	O	O
)	)	)	O	O	O
DNA	DNA	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
>	>	JJR	B-NP	O	O
90	90	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
.001	.001	CD	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
slightly	slightly	RB	B-ADJP	O	O
less	less	RBR	I-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.011	.011	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
300	300	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.005	.005	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
still	still	RB	B-ADVP	O	O
induced	induce	VBD	B-VP	O	O
94	94	CD	B-NP	O	O
%	%	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HBV	HBV	NN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
fourth	fourth	JJ	I-NP	O	O
week	week	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

HBV	HBV	NN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
e	e	NN	I-NP	O	O
antigen	antigen	NN	I-NP	O	O
status	status	NN	I-NP	O	O
or	or	CC	B-PP	O	O
in	in	IN	B-PP	O	O
aminotransferase	aminotransferase	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
serious	serious	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
safe	safe	JJ	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
suppression	suppression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
HBV	HBV	NN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Chinese	Chinese	JJ	B-NP	O	O
HBsAg	HBsAg	NN	I-NP	O	B-Chemical
carriers	carrier	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
>	>	JJR	B-NP	O	O
90	90	CD	I-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	O	O	O
reversible	reversible	JJ	B-ADJP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
lamivudine	lamivudine	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
prolonged	prolonged	JJ	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HBV	HBV	NN	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
achieved	achieve	VBN	I-VP	O	O
.	.	.	O	O	O

Population	Population	NN	B-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-VP	O	O
study	study	NN	B-NP	O	O
of	of	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
venous	venous	JJ	B-NP	O	B-Disease
thromboembolism	thromboembolism	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	B-Chemical
contraceptives	contraceptive	NNS	I-NP	O	I-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Four	Four	CD	B-NP	O	O
studies	study	NNS	I-NP	O	O
published	publish	VBN	B-VP	O	O
since	since	IN	B-PP	O	O
December	December	NNP	B-NP	O	O
,	,	,	O	O	O
1995	1995	CD	B-NP	O	O
,	,	,	O	O	O
reported	report	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
venous	venous	JJ	B-NP	O	B-Disease
thromboembolism	thromboembolism	NN	I-NP	O	I-Disease
(	(	(	O	O	O
VTE	VTE	NN	B-NP	O	B-Disease
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
used	use	VBD	B-VP	O	O
oral	oral	JJ	B-NP	O	B-Chemical
contraceptives	contraceptive	NNS	I-NP	O	I-Chemical
(	(	(	O	O	O
OCs	OC	NNS	B-NP	O	B-Chemical
)	)	)	O	O	O
containing	contain	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
progestagens	progestagen	NNS	I-NP	O	B-Chemical
gestodene	gestodene	NN	I-NP	B	B-Chemical
or	or	CC	I-NP	O	O
desogestrel	desogestrel	NN	I-NP	B	B-Chemical
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
OCs	OC	NNS	B-NP	O	B-Chemical
containing	contain	VBG	B-VP	O	O
second	second	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
progestagens	progestagen	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
confounding	confound	VBG	B-NP	O	O
and	and	CC	I-NP	O	O
bias	bias	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
design	design	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
re	re	VB	I-VP	O	O
-	-	HYPH	O	O	O
examine	examine	VB	B-VP	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
OC	OC	NN	I-NP	O	B-Chemical
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
design	design	NN	I-NP	O	O
and	and	CC	O	O	O
analysis	analysis	NN	B-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bias	bias	NN	I-NP	O	O
and	and	CC	O	O	O
confounding	confound	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
earlier	early	JJR	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
computer	computer	NN	B-NP	O	O
records	record	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
143	143	CD	B-NP	O	O
general	general	JJ	I-NP	O	O
practices	practice	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
UK	UK	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
based	base	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
records	record	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
about	about	IN	B-NP	O	O
540,000	540,000	CD	I-NP	O	O
women	woman	NNS	I-NP	O	O
born	bear	VBN	B-VP	O	O
between	between	IN	B-PP	O	O
1941	1941	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1981	1981	CD	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
women	woman	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
recorded	record	VBN	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deep	deep	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
vein	vein	NN	I-NP	O	I-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
venous	venous	JJ	B-NP	O	B-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
not	not	RB	B-VP	O	O
otherwise	otherwise	RB	I-VP	O	O
specified	specify	VBN	I-VP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
embolus	embolus	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
cohort	cohort	JJ	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
to	to	TO	B-VP	O	O
estimate	estimate	VB	I-VP	O	O
and	and	CC	I-VP	O	O
compare	compare	VB	I-VP	O	O
incidence	incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
OC	OC	NN	I-NP	O	B-Chemical
preparations	preparation	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
nested	nest	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
to	to	TO	B-VP	O	O
calculate	calculate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
odds	odd	NNS	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
OC	OC	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
after	after	IN	B-PP	O	O
adjustment	adjustment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
confounding	confound	VBG	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
matched	match	VBD	B-VP	B	O
cases	case	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
by	by	IN	B-PP	O	O
exact	exact	JJ	B-NP	O	O
year	year	NN	I-NP	O	O
of	of	IN	B-PP	O	O
birth	birth	NN	B-NP	O	O
,	,	,	O	O	O
practice	practice	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
current	current	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
OCs	OC	NNS	B-NP	O	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
logistic	logistic	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
model	model	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
body	body	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
mass	mass	NN	I-NP	O	O
index	index	NN	I-NP	O	O
,	,	,	O	O	O
number	number	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cycles	cycle	NNS	B-NP	O	O
,	,	,	O	O	O
change	change	NN	B-NP	O	O
in	in	IN	B-PP	O	O
type	type	NN	B-NP	O	O
of	of	IN	B-PP	O	O
OC	OC	NN	B-NP	O	B-Chemical
prescribed	prescribe	VBN	B-VP	O	O
within	within	IN	B-PP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
event	event	NN	I-NP	O	O
,	,	,	O	O	O
previous	previous	JJ	B-NP	O	O
pregnancy	pregnancy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
concurrent	concurrent	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

FINDINGS	FINDINGS	NNS	B-NP	O	O
:	:	:	O	O	O
85	85	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
met	meet	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
inclusion	inclusion	NN	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
VTE	VTE	NNP	B-NP	O	B-Disease
,	,	,	O	O	O
two	two	CD	B-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
progestagen	progestagen	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
only	only	JJ	B-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
83	83	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
,	,	,	O	O	O
43	43	CD	B-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
deep	deep	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
vein	vein	NN	I-NP	O	I-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
35	35	CD	B-NP	O	O
as	as	IN	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
thrombosis	thrombosis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
five	five	CD	B-NP	O	O
as	as	IN	B-SBAR	O	O
venous	venous	JJ	B-NP	O	B-Disease
thrombosis	thrombosis	NN	I-NP	O	I-Disease
not	not	RB	B-VP	O	O
otherwise	otherwise	RB	I-VP	O	O
specified	specify	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
crude	crude	JJ	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
per	per	IN	B-PP	O	O
10,000	10,000	CD	B-NP	O	O
woman	woman	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
years	year	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
4.10	4.10	CD	B-NP	O	O
in	in	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
OC	OC	NN	I-NP	O	B-Chemical
,	,	,	O	O	O
3.10	3.10	CD	B-NP	O	O
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
second	second	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
4.96	4.96	CD	B-NP	O	O
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
third	third	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
adjustment	adjustment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
third	third	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
second	second	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
1.68	1.68	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
1.04	1.04	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
2.75	2.75	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Logistic	Logistic	JJ	B-NP	O	O
regression	regression	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
between	between	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
third	third	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
second	second	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
third	third	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
progestagens	progestagen	NNS	I-NP	O	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VTE	VTE	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
desogestrel	desogestrel	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
20	20	CD	B-NP	O	O
g	g	NN	I-NP	O	O
ethinyloestradiol	ethinyloestradiol	NN	I-NP	B	B-Chemical
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
gestodene	gestodene	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
desogestrel	desogestrel	NN	I-NP	B	B-Chemical
with	with	IN	B-PP	O	O
30	30	CD	B-NP	O	O
g	g	NN	I-NP	O	O
ethinyloestradiol	ethinyloestradiol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

With	With	IN	B-PP	O	O
all	all	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reference	reference	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
odds	odd	NNS	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
VTE	VTE	NNP	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
3.49	3.49	CD	B-NP	O	O
(	(	(	O	O	O
1.21	1.21	CD	B-NP	O	O
-	-	HYPH	O	O	O
10.12	10.12	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
desogestrel	desogestrel	NN	B-NP	B	B-Chemical
plus	plus	CC	O	O	O
20	20	CD	B-NP	O	O
g	g	NN	I-NP	O	O
ethinyloestradiol	ethinyloestradiol	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
1.18	1.18	CD	B-NP	O	O
(	(	(	O	O	O
0.66	0.66	CD	B-NP	O	O
-	-	HYPH	O	O	O
2.17	2.17	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
third	third	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
progestagens	progestagen	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

INTERPRETATION	INTERPRETATION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
odds	odd	NNS	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
third	third	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
OCs	OC	NNS	I-NP	O	B-Chemical
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
second	second	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
generation	generation	NN	I-NP	O	O
products	product	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
residual	residual	JJ	B-NP	O	O
confounding	confounding	NN	I-NP	O	O
by	by	IN	B-PP	O	O
age	age	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
odds	odd	NNS	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
products	product	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
20	20	CD	B-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
ethinyloestradiol	ethinyloestradiol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
desogestrel	desogestrel	NN	I-NP	B	B-Chemical
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
30	30	CD	I-NP	O	O
micrograms	microgram	NNS	I-NP	O	O
product	product	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
biologically	biologically	RB	B-ADJP	O	O
implausible	implausible	JJ	I-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
preferential	preferential	JJ	B-NP	O	O
prescribing	prescribing	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
,	,	,	O	O	O
confounding	confound	VBG	B-VP	O	O
.	.	.	O	O	O

MK	MK	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
801	801	CD	I-NP	O	I-Chemical
augments	augment	NNS	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
electrographic	electrographic	JJ	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
but	but	CC	O	O	O
protects	protect	VBZ	B-VP	O	O
against	against	IN	B-PP	O	O
brain	brain	NN	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
anticonvulsant	anticonvulsant	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
801	801	CD	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
model	model	NN	I-NP	O	O
.	.	.	O	O	O

Intraperitoneal	Intraperitoneal	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
tonic	tonic	JJ	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
clonic	clonic	JJ	I-NP	O	I-Disease
seizure	seizure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Scopolamine	Scopolamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
pentobarbital	pentobarbital	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
prevented	prevent	VBD	B-VP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
but	but	CC	I-NP	O	O
MK	MK	NN	I-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
801	801	CD	B-NP	I	I-Chemical
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	O	O	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
electrical	electrical	JJ	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
measured	measure	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
EEG	EEG	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Scopolamine	Scopolamine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
pentobarbital	pentobarbital	NN	I-NP	B	B-Chemical
blocked	block	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
electrographic	electrographic	JJ	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
,	,	,	O	O	O
MK	MK	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
801	801	CD	B-NP	I	I-Chemical
treatment	treatment	NN	I-NP	O	O
augmented	augment	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
electrographic	electrographic	JJ	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

Brain	Brain	NN	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
examining	examine	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
microscopically	microscopically	RB	B-ADVP	O	O
.	.	.	O	O	O

Pilocarpine	Pilocarpine	NN	B-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
neuronal	neuronal	JJ	B-NP	O	B-Disease
death	death	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
showed	show	VBD	B-VP	O	O
pyknotic	pyknotic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

Pentobarbital	Pentobarbital	NN	B-NP	B	B-Chemical
,	,	,	I-NP	O	O
scopolamine	scopolamine	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
MK	MK	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
801	801	CD	I-NP	I	I-Chemical
protected	protect	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
MK	MK	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
801	801	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	O	O
treated	treat	VBN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pyramidal	pyramidal	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hippocampus	hippocampus	NN	B-NP	O	O
appeared	appear	VBD	B-VP	O	O
darker	darker	RBR	B-ADVP	O	O
than	than	IN	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
all	all	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
,	,	,	O	O	O
granule	granule	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dentate	dentate	NN	I-NP	O	O
gyrus	gyrus	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cholinergic	cholinergic	JJ	B-NP	O	O
overstimulation	overstimulation	NN	I-NP	O	O
and	and	CC	O	O	O
propagated	propagate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
glutamatergic	glutamatergic	JJ	B-NP	O	O
transmission	transmission	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
brain	brain	NN	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
through	through	IN	B-PP	O	O
an	an	DT	B-NP	O	O
excitatory	excitatory	JJ	I-NP	O	O
NMDA	NMDA	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
mediated	mediate	VBN	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
.	.	.	O	O	O

Paclitaxel	Paclitaxel	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
folinic	folinic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
:	:	:	O	O	O
BRE	BRE	NN	B-NP	O	O
-	-	HYPH	O	O	O
26	26	CD	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Fluorouracil	Fluorouracil	NN	I-NP	I	I-Chemical
plus	plus	CC	O	O	O
folinic	folinic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
paclitaxel	paclitaxel	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Taxol	Taxol	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
Bristol	Bristol	NNP	B-NP	O	O
-	-	:	O	O	O
Myers	Myers	NNP	B-NP	O	O
Squibb	Squibb	NNP	I-NP	O	O
Company	Company	NNP	I-NP	O	O
,	,	,	O	O	O
Princeton	Princeton	NNP	B-NP	O	O
,	,	,	O	O	O
NJ	NJ	NNP	B-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
effective	effective	JJ	B-NP	O	O
salvage	salvage	NN	I-NP	O	O
therapies	therapy	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Paclitaxel	Paclitaxel	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
have	have	VBP	B-VP	O	O
additive	additive	JJ	B-NP	O	O
cytotoxicity	cytotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
MCF	MCF	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
7	7	CD	I-NP	O	O
cell	cell	NN	I-NP	O	O
lines	line	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	B	B-Chemical
175	175	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
over	over	IN	B-PP	O	O
3	3	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
I	I	CD	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
folinic	folinic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
over	over	IN	B-PP	O	O
1	1	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
before	before	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
350	350	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
every	every	DT	B-NP	O	O
28	28	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
TFL	TFL	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Analysis	Analysis	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
37	37	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
minimum	minimum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
192	192	CD	B-NP	O	O
cycles	cycle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TFL	TFL	NN	B-NP	O	O
:	:	:	O	O	O
nine	nine	CD	B-NP	O	O
cycles	cycle	NNS	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
grade	grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
4	4	CD	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
;	;	:	O	O	O
seven	seven	CD	B-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
cycles	cycle	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
required	require	VBD	B-VP	O	O
granulocyte	granulocyte	NN	B-NP	O	B-Chemical
colony	colony	NN	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
stimulating	stimulate	VBG	B-VP	O	I-Chemical
factor	factor	NN	B-NP	O	I-Chemical
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
neutropenia	neutropenia	NN	B-NP	O	B-Disease
;	;	:	O	O	O
no	no	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
required	require	VBD	B-VP	O	O
platelet	platelet	NN	B-NP	O	O
transfusions	transfusion	NNS	I-NP	O	O
.	.	.	O	O	O

Grade	Grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
4	4	CD	I-NP	O	O
nonhematologic	nonhematologic	JJ	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
uncommon	uncommon	JJ	B-ADJP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
34	34	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
evaluable	evaluable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
response	response	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
three	three	CD	B-NP	O	O
complete	complete	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
18	18	CD	B-NP	O	O
partial	partial	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
(	(	(	O	O	O
53	53	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
19	19	CD	I-NP	O	O
evaluable	evaluable	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
,	,	,	O	O	O
11	11	CD	B-NP	O	O
(	(	(	O	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
responded	respond	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
nine	nine	CD	B-NP	O	O
of	of	IN	B-PP	O	O
15	15	CD	B-NP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
without	without	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
completion	completion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paclitaxel	paclitaxel	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
19	19	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

TFL	TFL	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
,	,	,	I-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
tolerated	tolerate	VBN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
in	in	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
breast	breast	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Efficacy	Efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
proarrhythmia	proarrhythmia	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
for	for	IN	B-PP	O	O
sustained	sustained	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachyarrhythmias	tachyarrhythmia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
prospectively	prospectively	RB	B-ADVP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
presumable	presumable	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
for	for	IN	B-PP	O	O
sustained	sustained	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachyarrhythmias	tachyarrhythmia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
54	54	CD	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
20	20	CD	B-NP	O	O
with	with	IN	B-PP	O	O
dilated	dilated	JJ	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
)	)	)	O	O	O
with	with	IN	B-PP	O	O
inducible	inducible	JJ	B-NP	O	O
sustained	sustained	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
received	receive	VBD	B-VP	O	O
oral	oral	JJ	B-NP	O	O
d,l	d,l	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachyarrhythmia	tachyarrhythmia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

During	During	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
loading	loading	NN	I-NP	O	O
with	with	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
continuous	continuous	JJ	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
(	(	(	O	O	O
ECG	ECG	NN	B-NP	O	O
)	)	)	O	O	O
monitoring	monitoring	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

Those	Those	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
d,l	d,l	NN	O	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
sotalol	sotalol	NN	B-NP	I	I-Chemical
prevented	prevent	VBD	B-VP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
discharged	discharge	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
followed	follow	VBD	B-VP	O	O
up	up	RP	B-PRT	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
outpatient	outpatient	NN	I-NP	O	O
basis	basis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
21	21	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
18	18	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachyarrhythmia	tachyarrhythmia	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
prevented	prevent	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
d,l	d,l	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
35	35	CD	B-NP	O	O
(	(	(	O	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachyarrhythmia	tachyarrhythmia	NN	I-NP	O	I-Disease
remained	remain	VBD	B-VP	O	O
inducible	inducible	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
40	40	CD	B-NP	O	O
(	(	(	O	O	O
49	49	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
two	two	CD	B-NP	O	O
(	(	(	O	O	O
2.5	2.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
tolerate	tolerate	VB	I-VP	O	O
even	even	RB	B-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
ECG	ECG	NN	B-NP	O	O
[	[	(	O	O	O
sinus	sinus	NN	B-NP	O	O
-	-	HYPH	O	O	O
cycle	cycle	NN	B-NP	O	O
length	length	NN	I-NP	O	O
(	(	(	O	O	O
SCL	SCL	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
QT	QT	NN	B-NP	O	O
or	or	CC	O	O	O
QTc	QTc	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
U	U	NN	B-NP	O	O
wave	wave	NN	I-NP	O	O
]	]	)	O	O	O
nor	nor	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
identified	identify	VBD	B-VP	O	O
patients	patient	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
for	for	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
(	(	(	O	O	O
200	200	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
46	46	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

328	328	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
53	53	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.0017	0.0017	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	I-NP	O	I-Disease
pointes	pointe	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
U	U	NN	I-NP	O	O
wave	wave	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.049	0.049	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
female	female	JJ	B-NP	O	O
gender	gender	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.015	0.015	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
significant	significant	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
corrected	correct	VBN	I-NP	O	O
changes	change	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
SCL	SCL	NN	B-NP	O	O
,	,	,	O	O	O
QT	QT	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
QTc	QTc	NN	B-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
,	,	,	O	O	O
seven	seven	CD	B-NP	O	O
(	(	(	O	O	O
20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
nonfatal	nonfatal	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
recurrence	recurrence	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
two	two	CD	B-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
died	die	VBD	B-VP	O	O
suddenly	suddenly	RB	B-ADVP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
had	have	VBD	B-VP	O	O
recurrent	recurrent	JJ	B-NP	O	O
torsades	torsade	NNS	I-NP	O	B-Disease
de	de	IN	I-NP	O	I-Disease
pointes	pointe	NNS	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
successful	successful	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Torsades	Torsades	NNP	B-NP	O	B-Disease
de	de	IN	I-NP	O	I-Disease
pointes	pointe	NNS	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
early	early	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
even	even	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
d,l	d,l	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Pronounced	Pronounce	VBN	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
surface	surface	NN	I-NP	O	O
ECG	ECG	NN	I-NP	O	O
(	(	(	O	O	O
cycle	cycle	NN	B-NP	O	O
length	length	NN	I-NP	O	O
,	,	,	O	O	O
QT	QT	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
QTc	QTc	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
d,l	d,l	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
might	might	MD	B-VP	O	O
identify	identify	VB	I-VP	O	O
a	a	DT	B-NP	O	O
subgroup	subgroup	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
ECG	ECG	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
sotalol	sotalol	NN	B-NP	I	I-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
identify	identify	VB	I-VP	O	O
patients	patient	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
.	.	.	O	O	O

Recurrence	Recurrence	NN	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachyarrhythmias	tachyarrhythmia	NNS	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
high	high	JJ	B-ADJP	O	O
despite	despite	IN	B-PP	O	O
complete	complete	JJ	B-NP	O	O
suppression	suppression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
programmed	program	VBN	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-NP	O	O
programmed	program	VBN	I-NP	O	O
electrical	electrical	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d,l	d,l	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
sotalol	sotalol	NN	I-NP	I	I-Chemical
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
limited	limited	JJ	B-NP	O	O
prognostic	prognostic	JJ	I-NP	O	O
value	value	NN	I-NP	O	O
.	.	.	O	O	O

Chronic	Chronic	JJ	B-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
neurons	neuron	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
tuberoinfundibular	tuberoinfundibular	JJ	I-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
(	(	(	O	O	O
TIDA	TIDA	NN	B-NP	O	O
)	)	)	O	O	O
system	system	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
prolactin	prolactin	NN	B-NP	B	O
(	(	(	O	O	O
PRL	PRL	NN	B-NP	O	O
)	)	)	O	O	O
secretion	secretion	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
this	this	DT	B-NP	O	O
system	system	NN	I-NP	O	O
responds	respond	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
acute	acute	JJ	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
PRL	PRL	NN	I-NP	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
responsiveness	responsiveness	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
lost	lose	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
aging	age	VBG	B-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chronically	chronically	RB	B-NP	O	O
high	high	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
PRL	PRL	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
extended	extend	VBN	B-NP	O	O
periods	period	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
time	time	NN	B-NP	O	O
and	and	CC	O	O	O
examine	examine	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
systems	system	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

Hyperprolactinemia	Hyperprolactinemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Palkovits	Palkovits	NNP	B-NP	O	O
'	'	POS	B-NP	O	O
microdissection	microdissection	NN	I-NP	O	O
technique	technique	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
performance	performance	NN	I-NP	O	O
liquid	liquid	NN	I-NP	O	O
chromatography	chromatography	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
neurotransmitter	neurotransmitter	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
areas	area	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DA	DA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
concentrations	concentration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
median	median	NN	I-NP	O	O
eminence	eminence	NN	I-NP	O	O
(	(	(	O	O	O
ME	ME	NN	B-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
84	84	CD	B-NP	O	O
%	%	NN	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Nine	Nine	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
produced	produce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
DA	DA	NN	B-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ME	ME	NN	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
DA	DA	NN	B-NP	B	B-Chemical
response	response	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lost	lose	VBN	I-VP	O	O
if	if	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
9	9	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
long	long	JJ	I-NP	O	O
haloperidol	haloperidol	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperprolactinemia	hyperprolactinemia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
month	month	NN	I-NP	O	O
-	-	HYPH	O	O	O
long	long	RB	B-NP	O	O
extremely	extremely	RB	I-NP	O	O
high	high	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
PRL	PRL	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
implantation	implantation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MMQ	MMQ	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
capsule	capsule	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DA	DA	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
norepinephrine	norepinephrine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
NE	NE	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
serotonin	serotonin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
their	their	PRP$	B-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
arcuate	arcuate	JJ	I-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
(	(	(	O	O	O
AN	AN	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
medial	medial	JJ	B-NP	O	O
preoptic	preoptic	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
(	(	(	O	O	O
MPA	MPA	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
caudate	caudate	JJ	B-NP	O	O
putamen	putaman	NNS	I-NP	O	O
(	(	(	O	O	O
CP	CP	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
substantia	substantia	NN	B-NP	O	O
nigra	nigra	NN	I-NP	O	O
(	(	(	O	O	O
SN	SN	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
zona	zona	NN	B-NP	O	O
incerta	incerta	NN	I-NP	O	O
(	(	(	O	O	O
ZI	ZI	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxyindoleacetic	hydroxyindoleacetic	JJ	I-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
HIAA	HIAA	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AN	AN	NN	I-NP	O	O
after	after	IN	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
DA	DA	NN	B-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
AN	AN	NN	I-NP	O	O
after	after	IN	B-PP	O	O
9	9	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
specifically	specifically	RB	B-ADVP	O	O
affects	affect	VBZ	B-VP	O	O
TIDA	TIDA	NN	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
and	and	CC	O	O	O
these	these	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
vary	vary	VBP	B-VP	O	O
,	,	,	O	O	O
depending	depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperprolactinemia	hyperprolactinemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
age	age	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
related	relate	VBN	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hypothalamic	hypothalamic	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
function	function	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
PRL	PRL	NN	B-NP	O	O
secretion	secretion	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-VP	O	O
disseminated	disseminate	VBN	I-VP	O	O
necrotizing	necrotize	VBG	B-VP	O	O
leukoencephalopathy	leukoencephalopathy	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
characteristic	characteristic	JJ	B-NP	O	O
contrast	contrast	NN	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
white	white	JJ	I-NP	O	O
matter	matter	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
unique	unique	JJ	B-NP	O	O
contrast	contrast	NN	I-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
white	white	JJ	I-NP	O	O
matter	matter	NN	I-NP	O	O
on	on	IN	B-PP	O	O
T1	T1	NN	B-NP	O	O
-	-	HYPH	O	O	O
weighted	weight	VBN	B-VP	O	O
magnetic	magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
images	image	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
disseminated	disseminate	VBN	B-NP	O	O
necrotizing	necrotize	VBG	I-NP	O	O
leukoencephalopathy	leukoencephalopathy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
developed	develop	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
methotrexate	methotrexate	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
near	near	IN	B-PP	O	O
the	the	DT	B-NP	O	O
base	base	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
than	than	IN	B-PP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vertex	vertex	NN	I-NP	B	O
.	.	.	O	O	O

Necropsy	Necropsy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
loss	loss	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
myelination	myelination	NN	B-NP	O	I-Disease
and	and	CC	I-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
white	white	JJ	I-NP	O	O
matter	matter	NN	I-NP	O	O
.	.	.	O	O	O

Possible	Possible	JJ	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
causing	cause	VBG	B-VP	O	O
such	such	JJ	B-NP	O	O
a	a	DT	I-NP	O	O
leukoencephalopathy	leukoencephalopathy	NN	I-NP	O	B-Disease
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Thrombotic	Thrombotic	JJ	B-NP	O	B-Disease
complications	complication	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
promyelocytic	promyelocytic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
all	all	DT	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
trans	trans	AFX	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
retinoic	retinoic	JJ	B-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
due	due	IN	B-PP	O	O
to	to	TO	I-PP	O	O
occlusion	occlusion	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
renal	renal	JJ	B-NP	O	I-Disease
vessels	vessel	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
promyelocytic	promyelocytic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
APL	APL	NN	B-NP	O	B-Disease
)	)	)	O	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
all	all	DT	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
trans	trans	AFX	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
retinoic	retinoic	JJ	B-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
recently	recently	RB	B-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
APL	APL	NN	I-NP	O	B-Disease
patient	patient	NN	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
further	further	RBR	B-ADVP	O	O
supports	support	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
concern	concern	NN	I-NP	O	O
about	about	IN	B-PP	O	O
thromboembolic	thromboembolic	JJ	B-NP	O	B-Disease
complications	complication	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
APL	APL	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
43	43	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
,	,	,	O	O	O
presented	present	VBD	B-VP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
signs	sign	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
APL	APL	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
protocol	protocol	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

After	After	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
completely	completely	RB	B-ADJP	O	O
reversible	reversible	JJ	I-ADJP	O	O
after	after	IN	B-PP	O	O
complete	complete	JJ	B-NP	O	O
remission	remission	NN	I-NP	O	O
of	of	IN	B-PP	O	O
APL	APL	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
and	and	CC	O	O	O
therapy	therapy	NN	B-NP	O	O
discontinued	discontinue	VBN	B-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ATRA	ATRA	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
valid	valid	JJ	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
choice	choice	NN	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
APL	APL	NN	B-NP	O	B-Disease
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
procoagulant	procoagulant	JJ	I-NP	O	O
tendency	tendency	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
completely	completely	RB	B-ADJP	O	O
corrected	correct	VBN	I-ADJP	O	O
.	.	.	O	O	O

Thrombotic	Thrombotic	JJ	B-NP	O	B-Disease
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Pupillary	Pupillary	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stimulant	stimulant	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
mania	mania	NN	I-NP	O	B-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
30	30	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
subject	subject	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
study	study	NN	I-NP	O	O
evaluating	evaluate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
anticraving	anticrave	VBG	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
stimulant	stimulant	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
diethylpropion	diethylpropion	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
DEP	DEP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
became	become	VBD	B-VP	O	O
manic	manic	JJ	B-ADJP	O	B-Disease
during	during	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
second	second	JJ	I-NP	O	O
week	week	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Pupillometric	Pupillometric	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
while	while	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
DEP	DEP	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
power	power	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pupillary	pupillary	JJ	B-NP	O	B-Disease
oscillation	oscillation	NN	I-NP	O	I-Disease
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
dramatically	dramatically	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
eight	eight	CD	I-NP	O	O
other	other	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
become	become	VB	I-VP	O	O
manic	manic	JJ	B-ADJP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
power	power	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pupillary	pupillary	JJ	B-NP	O	B-Disease
oscillation	oscillation	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
became	become	VBD	B-VP	O	O
fully	fully	RB	B-ADJP	O	O
manic	manic	JJ	I-ADJP	O	B-Disease
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
power	power	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pupillary	pupillary	JJ	B-NP	O	B-Disease
oscillation	oscillation	NN	I-NP	O	I-Disease
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
utility	utility	NN	B-NP	O	O
in	in	IN	B-PP	O	O
identifying	identify	VBG	B-VP	O	O
persons	person	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
for	for	IN	B-PP	O	O
manic	manic	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	O
like	like	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychomotor	psychomotor	NN	B-NP	O	O
stimulants	stimulant	NNS	I-NP	O	O
or	or	CC	O	O	O
sympathomimetic	sympathomimetic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
mucosal	mucosal	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
:	:	:	O	O	O
separating	separate	VBG	B-VP	O	O
central	central	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
man	man	NN	B-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
wanted	want	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
test	test	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
assessment	assessment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	O	O	O
a	a	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
-	-	HYPH	B-VP	O	O
related	relate	VBN	B-NP	O	O
signal	signal	NN	I-NP	O	O
(	(	(	O	O	O
chemo	chemo	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
somatosensory	somatosensory	JJ	I-NP	O	O
evoked	evoke	VBN	I-NP	O	O
potential	potential	NN	I-NP	O	O
,	,	,	I-NP	O	O
CSSEP	CSSEP	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
concomitantly	concomitantly	RB	I-NP	O	O
recorded	record	VBN	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
signal	signal	NN	I-NP	O	O
(	(	(	O	O	O
negative	negative	JJ	B-NP	O	O
mucosal	mucosal	JJ	I-NP	O	O
potential	potential	NN	I-NP	O	O
,	,	,	O	O	O
NMP	NMP	NN	B-NP	B	O
)	)	)	O	O	O
allows	allow	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
separation	separation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
central	central	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
this	this	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
,	,	,	O	O	O
experimental	experimental	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
created	create	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
previously	previously	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
effects	effect	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
phasic	phasic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
tonic	tonic	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
by	by	IN	B-PP	O	O
either	either	CC	B-NP	O	O
central	central	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
According	Accord	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	O	O	O
randomised	randomise	VBN	B-VP	O	O
,	,	,	O	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
threefold	threefold	RB	B-ADVP	O	O
cross	cross	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
over	over	IN	B-PP	O	O
design	design	NN	B-NP	O	O
,	,	,	O	O	O
18	18	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
11	11	CD	B-NP	O	O
males	male	NNS	I-NP	O	O
,	,	,	O	O	O
7	7	CD	B-NP	O	O
females	female	NNS	I-NP	O	O
;	;	:	O	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
26	26	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
either	either	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
,	,	,	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
ibuprofen	ibuprofen	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
ibuprofen	ibuprofen	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Phasic	Phasic	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
applied	apply	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
short	short	JJ	B-NP	O	O
pulses	pulse	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CO2	CO2	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
nasal	nasal	JJ	I-NP	O	O
mucosa	mucosa	NN	I-NP	O	O
(	(	(	O	O	O
stimulus	stimulus	NN	B-NP	O	O
duration	duration	NN	I-NP	O	O
500	500	CD	B-NP	O	O
ms	ms	NN	I-NP	O	O
,	,	,	O	O	O
interval	interval	NN	B-NP	O	O
approximately	approximately	RB	B-NP	O	O
60	60	CD	I-NP	O	O
s	s	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
tonic	tonic	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nasal	nasal	JJ	I-NP	O	O
cavity	cavity	NN	I-NP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
dry	dry	JJ	B-NP	O	O
air	air	NN	I-NP	O	O
of	of	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
temperature	temperature	NN	I-NP	O	O
,	,	,	I-NP	O	O
humidity	humidity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
flow	flow	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
22	22	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
C	C	NN	I-NP	O	O
,	,	,	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
relative	relative	JJ	I-NP	O	O
humidity	humidity	NN	I-NP	O	O
,	,	,	O	O	O
145	145	CD	B-NP	O	O
ml.s	ml.	NNS	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
CSSEPs	CSSEP	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
central	central	JJ	B-ADJP	O	O
and	and	CC	O	O	O
NMPs	NMP	NNS	B-NP	B	O
as	as	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
correlates	correlate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
pain	pain	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
CO2	CO2	NN	I-NP	B	B-Chemical
stimuli	stimulus	NNS	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
rated	rat	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	CC	B-NP	O	O
phasic	phasic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
tonic	tonic	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
analogue	analogue	NN	I-NP	O	O
scales	scale	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
As	As	IN	B-SBAR	O	O
described	describe	VBN	B-VP	O	O
earlier	earlier	RBR	B-ADVP	O	O
,	,	,	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
tonic	tonic	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
but	but	CC	O	O	O
-	-	HYPH	B-NP	O	O
relative	relative	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
placebo	placebo	AFX	O	O	O
-	-	HYPH	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
correlates	correlate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
phasic	phasic	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
stimuli	stimulus	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
these	these	DT	B-NP	O	O
special	special	JJ	I-NP	O	O
experimental	experimental	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CSSEP	CSSEP	NN	B-NP	O	O
and	and	CC	I-NP	O	O
NMP	NMP	NN	I-NP	B	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
process	process	NN	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
localised	localise	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
periphery	periphery	NN	I-NP	O	O
.	.	.	O	O	O

By	By	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
recording	recording	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interrelated	interrelated	JJ	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
central	central	JJ	I-NP	O	O
electrophysiologic	electrophysiologic	JJ	I-NP	O	O
correlates	correlate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nociception	nociception	NN	B-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
possible	possible	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
separate	separate	VB	I-VP	O	O
central	central	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
NSAID	NSAID	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
advantage	advantage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
model	model	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
obtaining	obtain	VBG	B-VP	O	O
peripheral	peripheral	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
-	-	HYPH	B-VP	O	O
related	relate	VBN	B-NP	O	O
activity	activity	NN	I-NP	O	O
directly	directly	RB	B-VP	O	O
using	use	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
invasive	invasive	JJ	I-NP	O	O
technique	technique	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
severe	severe	JJ	I-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
peri	peri	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
ondansetron	ondansetron	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
41	41	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	B-Disease
nausea	nausea	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
vomiting	vomiting	NN	I-NP	O	I-Disease
presented	present	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
abdominal	abdominal	JJ	B-NP	O	O
hysterectomy	hysterectomy	NN	I-NP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
anaesthetic	anaesthetic	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
ondansetron	ondansetron	NN	B-NP	B	B-Chemical
prophylaxis	prophylaxis	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
developed	develop	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
acute	acute	JJ	I-NP	O	O
major	major	JJ	I-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
disorder	disorder	NN	I-NP	O	I-Disease
almost	almost	RB	B-ADVP	O	O
immediately	immediately	RB	I-ADVP	O	O
thereafter	thereafter	RB	I-ADVP	O	O
,	,	,	O	O	O
possibly	possibly	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
antagonist	antagonist	NN	I-NP	O	O
.	.	.	O	O	O

Nine	Nine	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
before	before	IN	B-SBAR	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
self	self	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
limited	limit	VBN	B-NP	O	O
puerperal	puerperal	JJ	I-NP	O	O
depressive	depressive	JJ	I-NP	O	B-Disease
episode	episode	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Anaesthesia	Anaesthesia	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serotonin	serotonin	NN	B-NP	B	B-Chemical
antagonists	antagonist	NNS	I-NP	O	O
provided	provide	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
nausea	nausea	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
postoperative	postoperative	JJ	I-NP	O	O
course	course	NN	I-NP	O	O
without	without	IN	B-PP	O	O
exacerbation	exacerbation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Hypertensive	Hypertensive	JJ	B-NP	O	B-Disease
response	response	NN	I-NP	O	O
during	during	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
stress	stress	NN	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
3,129	3,129	CD	B-NP	O	O
dobutamine	dobutamine	NN	I-NP	B	B-Chemical
stress	stress	NN	I-NP	O	O
echocardiographic	echocardiographic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
response	response	NN	I-NP	O	O
,	,	,	O	O	O
defined	define	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
systolic	systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
BP	BP	NN	B-NP	B	O
)	)	)	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
220	220	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
diastolic	diastolic	JJ	B-NP	O	O
BP	BP	NN	I-NP	B	O
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
110	110	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
,	,	,	O	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
30	30	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
response	response	NN	I-NP	O	O
more	more	RBR	B-ADVP	O	O
often	often	RB	I-ADVP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
higher	high	JJR	B-NP	O	O
resting	rest	VBG	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
BP	BP	NN	I-NP	B	O
before	before	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
.	.	.	O	O	O

Continuously	Continuously	RB	B-NP	O	O
nebulized	nebulize	VBN	I-NP	O	O
albuterol	albuterol	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
exacerbations	exacerbation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-VP	O	O
analysis	analysis	NN	B-NP	O	O
comparing	compare	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
exacerbations	exacerbation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
continuously	continuously	RB	I-VP	O	O
nebulized	nebulize	VBN	I-VP	O	O
albuterol	albuterol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CNA	CNA	NN	B-NP	B	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
albuterol	albuterol	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
INA	INA	NN	B-NP	B	O
)	)	)	O	O	O
treatments	treatment	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Forty	Forty	CD	B-NP	O	O
matched	match	VBN	I-NP	B	O
pairs	pair	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
asthma	asthma	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
compared	compare	VBN	I-VP	O	O
.	.	.	O	O	O

CNA	CNA	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	NN	I-NP	O	O
of	of	IN	B-PP	O	O
11	11	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
10	10	CD	B-NP	O	O
hr	hr	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
dysrhythmias	dysrhythmia	NNS	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
.	.	.	O	O	O

Symptomatic	Symptomatic	JJ	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	B-Disease
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

CNA	CNA	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
higher	high	JJR	B-NP	O	O
heart	heart	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
reflect	reflect	VB	I-VP	O	O
severity	severity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
illness	illness	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intubation	intubation	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
CNA	CNA	NN	B-NP	B	O
and	and	CC	I-NP	O	O
INA	INA	NN	I-NP	B	O
demonstrated	demonstrate	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
profiles	profile	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
safety	safety	NN	B-NP	O	O
,	,	,	O	O	O
morbidity	morbidity	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mortality	mortality	NN	B-NP	O	O
.	.	.	O	O	O

Hyperosmolar	Hyperosmolar	JJ	B-NP	O	B-Disease
nonketotic	nonketotic	JJ	I-NP	O	I-Disease
coma	coma	NN	I-NP	O	I-Disease
precipitated	precipitate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
nephrogenic	nephrogenic	JJ	I-NP	O	B-Disease
diabetes	diabetes	NN	I-NP	O	I-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
45	45	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
manic	manic	JJ	B-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
hyperosmolar	hyperosmolar	JJ	B-NP	O	B-Disease
,	,	,	I-NP	O	I-Disease
nonketotic	nonketotic	JJ	I-NP	O	I-Disease
coma	coma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
gave	give	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
five	five	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
polyuria	polyuria	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
polydipsia	polydipsia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
during	during	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
time	time	NN	B-NP	O	O
urinalysis	urinalysis	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
negative	negative	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

After	After	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
from	from	IN	B-PP	O	O
hyperglycaemia	hyperglycaemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
remained	remain	VBD	B-VP	O	O
polyuric	polyuric	JJ	B-ADJP	O	B-Disease
despite	despite	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
;	;	:	O	O	O
water	water	NN	B-NP	B	O
deprivation	deprivation	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
nephrogenic	nephrogenic	JJ	B-NP	O	B-Disease
diabetes	diabetes	NN	I-NP	O	I-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
,	,	,	O	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
hypothesize	hypothesize	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
when	when	WRB	B-ADVP	O	O
this	this	DT	B-NP	O	O
man	man	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
type	type	NN	B-NP	O	B-Disease
2	2	CD	I-NP	O	I-Disease
diabetes	diabete	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
chronic	chronic	JJ	B-NP	O	O
polyuria	polyuria	NNS	I-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
nephrogenic	nephrogenic	JJ	B-NP	O	B-Disease
diabetes	diabetes	NN	I-NP	O	I-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
precipitate	precipitate	VB	I-VP	O	O
hyperosmolar	hyperosmolar	JJ	B-NP	O	O
dehydration	dehydration	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intracoronary	intracoronary	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
large	large	JJ	I-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
profound	profound	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
left	left	JJ	B-NP	O	I-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
(	(	(	O	O	I-Disease
LV	LV	NN	B-NP	B	I-Disease
)	)	)	I-NP	O	I-Disease
systolic	systolic	JJ	I-NP	O	I-Disease
function	function	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
done	do	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
intracoronary	intracoronary	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
systolic	systolic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
20	20	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
and	and	CC	O	O	O
6	6	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
aged	age	VBN	B-ADJP	O	O
39	39	CD	B-NP	O	O
to	to	TO	I-NP	O	O
72	72	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
referred	refer	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
catheterization	catheterization	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chest	chest	NN	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
measured	measure	VBD	B-VP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
systemic	systemic	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
LV	LV	NN	B-NP	B	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
first	first	JJ	I-NP	O	O
derivative	derivative	NN	I-NP	O	O
(	(	(	O	O	O
dP	dP	NN	B-NP	O	O
/	/	SYM	O	O	O
dt	dt	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
LV	LV	NN	B-NP	B	O
volumes	volume	NNS	I-NP	O	O
and	and	CC	O	O	O
ejection	ejection	NN	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
during	during	IN	I-PP	O	O
the	the	DT	B-NP	O	O
final	final	JJ	I-NP	O	O
2	2	CD	I-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
15	15	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
minute	minute	JJ	I-NP	O	O
intracoronary	intracoronary	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
,	,	,	O	O	O
control	control	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
min	min	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
variable	variable	JJ	I-NP	O	O
changed	change	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
.	.	.	O	O	O

With	With	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
obtained	obtain	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
3.0	3.0	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.4	0.4	CD	B-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
SD	SD	NN	I-NP	O	O
)	)	)	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
,	,	,	O	O	O
similar	similar	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
magnitude	magnitude	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
abusers	abuser	NNS	B-NP	O	O
dying	die	VBG	B-VP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
intoxication	intoxication	NN	I-NP	O	O
.	.	.	O	O	O

Cocaine	Cocaine	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
LV	LV	NN	B-NP	B	O
dP	dP	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dt	dt	NN	I-NP	O	O
(	(	(	O	O	O
positive	positive	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
negative	negative	JJ	I-ADJP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
LV	LV	NN	B-NP	B	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
volume	volume	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
caused	cause	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
systolic	systolic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
mean	mean	JJ	I-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressures	pressure	NNS	I-NP	O	O
,	,	,	O	O	O
LV	LV	NN	B-NP	B	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
LV	LV	NN	B-NP	B	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
systolic	systolic	JJ	I-NP	O	O
volume	volume	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
intracoronary	intracoronary	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
sufficient	sufficient	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
amount	amount	NN	B-NP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
deterioration	deterioration	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
LV	LV	NN	B-NP	B	I-Disease
systolic	systolic	JJ	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
diastolic	diastolic	JJ	I-NP	O	I-Disease
performance	performance	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
paradoxical	paradoxical	JJ	B-NP	O	O
thromboembolism	thromboembolism	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
several	several	JJ	B-NP	O	O
new	new	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
development	development	NN	B-NP	O	O
,	,	,	O	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
remains	remain	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
of	of	IN	B-PP	O	O
choice	choice	NN	B-NP	O	O
for	for	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
needs	need	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
meritorious	meritorious	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
exist	exist	VB	I-VP	O	O
.	.	.	O	O	O

Important	Important	JJ	B-NP	O	O
untoward	untoward	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
osteoporosis	osteoporosis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
eosinophilia	eosinophilia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
skin	skin	NN	B-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
allergic	allergic	JJ	B-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
alopecia	alopecia	NN	I-NP	O	B-Disease
will	will	MD	B-VP	O	O
be	be	VB	I-VP	O	O
discussed	discuss	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
article	article	NN	I-NP	O	O
.	.	.	O	O	O

Nonopaque	Nonopaque	JJ	B-NP	O	O
crystal	crystal	JJ	I-NP	O	O
deposition	deposition	NN	I-NP	O	O
causing	cause	VBG	B-VP	O	O
ureteric	ureteric	JJ	B-NP	O	B-Disease
obstruction	obstruction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
unique	unique	JJ	I-NP	O	O
CT	CT	NN	I-NP	B	O
features	feature	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ureteric	ureteric	JJ	B-NP	O	B-Disease
calculi	calculus	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
six	six	CD	B-NP	O	O
HIV	HIV	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
infected	infect	VBN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
commonly	commonly	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
HIV	HIV	NN	I-NP	O	O
protease	protease	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
urolithiasis	urolithiasis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Ureteric	Ureteric	JJ	B-NP	O	B-Disease
obstruction	obstruction	NN	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
precipitated	precipitate	VBN	B-NP	O	O
indinavir	indinavir	NN	I-NP	B	B-Chemical
crystals	crystal	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
difficult	difficult	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
diagnose	diagnose	VB	I-VP	O	O
with	with	IN	B-PP	O	O
unenhanced	unenhanced	JJ	B-NP	O	O
CT	CT	NN	I-NP	B	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
calculi	calculus	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
opaque	opaque	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
secondary	secondary	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
obstruction	obstruction	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
absent	absent	JJ	B-ADJP	O	O
or	or	CC	I-ADJP	O	O
minimal	minimal	JJ	I-ADJP	O	O
and	and	CC	O	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
sought	seek	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
.	.	.	O	O	O

Images	Image	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
need	need	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
obtained	obtain	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
i.v.	i.v.	JJ	B-NP	O	O
contrast	contrast	NN	I-NP	O	O
material	material	NN	I-NP	O	O
to	to	TO	B-VP	O	O
enable	enable	VB	I-VP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ureteric	ureteric	JJ	B-NP	O	B-Disease
stones	stone	NNS	I-NP	O	I-Disease
or	or	CC	O	O	I-Disease
obstruction	obstruction	NN	B-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
receive	receive	VBP	B-VP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Ischemic	Ischemic	JJ	B-NP	O	B-Disease
colitis	colitis	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
sumatriptan	sumatriptan	NN	I-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Sumatriptan	Sumatriptan	NNP	B-NP	B	B-Chemical
succinate	succinate	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxytryptamine	hydroxytryptamine	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
receptor	receptor	NN	B-NP	O	O
agonist	agonist	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
antimigraine	antimigraine	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
act	act	VB	I-VP	O	O
by	by	IN	B-PP	O	O
selectively	selectively	RB	B-VP	O	O
constricting	constrict	VBG	I-VP	O	O
intracranial	intracranial	JJ	B-NP	O	O
arteries	artery	NNS	I-NP	O	O
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
,	,	,	O	O	O
vasopressor	vasopressor	NN	B-NP	O	O
responses	response	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
distinct	distinct	JJ	B-ADJP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cranial	cranial	JJ	I-NP	O	O
circulation	circulation	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
coronary	coronary	JJ	B-NP	O	O
circulations	circulation	NNS	I-NP	O	O
.	.	.	O	O	O

Cases	Case	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
published	publish	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
vasospasm	vasospasm	NN	I-NP	O	I-Disease
,	,	,	O	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
occurring	occur	VBG	B-VP	O	O
after	after	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
8	8	CD	B-NP	O	O
serious	serious	JJ	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
colitis	colitis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
migraine	migraine	NN	B-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
sumatriptan	sumatriptan	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Pallidotomy	Pallidotomy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
gamma	gamma	NN	I-NP	O	O
knife	knife	NN	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
.	.	.	O	O	O

51	51	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
medically	medically	RB	O	O	O
refractory	refractory	JJ	O	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
underwent	undergo	VBD	B-VP	O	O
stereotactic	stereotactic	JJ	B-NP	O	O
posteromedial	posteromedial	JJ	I-NP	O	O
pallidotomy	pallidotomy	NN	I-NP	O	O
between	between	IN	B-PP	O	O
August	August	NNP	B-NP	O	O
1993	1993	CD	I-NP	O	O
and	and	CC	O	O	O
February	February	NNP	B-NP	O	O
1997	1997	CD	I-NP	O	O
for	for	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bradykinesia	bradykinesia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
rigidity	rigidity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
DOPA	DOPA	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
29	29	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pallidotomies	pallidotomy	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Leksell	Leksell	NNP	I-NP	O	O
Gamma	Gamma	NNP	I-NP	O	O
Knife	Knife	NNP	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
22	22	CD	B-NP	O	O
they	they	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
radiofrequency	radiofrequency	NN	I-NP	O	O
(	(	(	O	O	O
RF	RF	NN	B-NP	O	O
)	)	)	O	O	O
method	method	NN	B-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
assessment	assessment	NN	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
blinded	blinded	JJ	B-NP	O	O
ratings	rating	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Unified	Unified	NNP	B-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
Disease	Disease	NN	I-NP	O	I-Disease
Rating	Rating	NN	I-NP	O	O
Scale	Scale	NN	I-NP	O	O
(	(	(	O	O	O
UPDRS	UPDRS	NN	B-NP	O	O
)	)	)	O	O	O
scores	score	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
pre	pre	AFX	O	O	O
-	-	HYPH	O	O	O
and	and	CC	O	O	O
postoperatively	postoperatively	RB	B-ADVP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
time	time	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
20.6	20.6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
48	48	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
except	except	IN	B-PP	O	O
4	4	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
followed	follow	VBN	I-VP	O	O
more	more	RBR	B-NP	O	O
than	than	IN	I-NP	O	O
one	one	CD	I-NP	O	O
year	year	NN	I-NP	O	O
.	.	.	O	O	O

85	85	CD	B-NP	O	O
percent	percent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
dyskinesias	dyskinesia	NNS	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
relieved	relieve	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
,	,	,	O	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pallidotomies	pallidotomy	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Gamma	Gamma	NN	I-NP	O	O
Knife	Knife	NN	I-NP	O	O
or	or	CC	I-NP	O	O
radiofrequency	radiofrequency	NN	I-NP	O	O
methods	method	NNS	I-NP	O	O
.	.	.	O	O	O

About	About	IN	B-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
Gamma	Gamma	NN	B-NP	O	O
Knife	Knife	NN	I-NP	O	O
and	and	CC	I-NP	O	O
radiofrequency	radiofrequency	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
improvements	improvement	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
bradykinesia	bradykinesia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
rigidity	rigidity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
when	when	WRB	B-ADVP	O	O
considered	consider	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
neither	neither	CC	O	O	O
the	the	DT	B-NP	O	O
Gamma	Gamma	NNP	I-NP	O	O
Knife	Knife	NNP	I-NP	O	O
nor	nor	CC	O	O	O
the	the	DT	B-NP	O	O
radiofrequency	radiofrequency	NN	I-NP	O	O
group	group	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
statistically	statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
improvements	improvement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
UPDRS	UPDRS	NN	B-NP	O	O
scores	score	NNS	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Gamma	Gamma	NN	I-NP	O	O
Knife	Knife	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
3.4	3.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
homonymous	homonymous	JJ	I-NP	O	B-Disease
hemianopsia	hemianopsia	NN	I-NP	O	I-Disease
9	9	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
27.7	27.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
radiofrequency	radiofrequency	NN	I-NP	O	O
group	group	NN	I-NP	O	O
became	become	VBD	B-VP	O	O
transiently	transiently	RB	B-ADJP	O	O
confused	confuse	VBN	I-ADJP	O	O
postoperatively	postoperatively	RB	B-ADVP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

Gamma	Gamma	NN	B-NP	O	O
Knife	Knife	NN	I-NP	O	O
pallidotomy	pallidotomy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
as	as	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
as	as	IN	B-PP	O	O
radiofrequency	radiofrequency	NN	B-NP	O	O
pallidotomy	pallidotomy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
controlling	control	VBG	B-VP	O	O
certain	certain	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
practical	practical	JJ	I-NP	O	O
technique	technique	NN	I-NP	O	O
available	available	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
those	those	DT	B-NP	O	O
who	who	WP	B-NP	O	O
take	take	VBP	B-VP	O	O
anticoagulants	anticoagulant	NNS	B-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
bleeding	bleed	VBG	I-VP	O	B-Disease
diatheses	diathes	NNS	B-NP	O	O
or	or	CC	O	O	O
serious	serious	JJ	B-NP	O	O
systemic	systemic	JJ	I-NP	O	O
medical	medical	JJ	I-NP	O	O
illnesses	illness	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
viable	viable	JJ	I-NP	O	O
option	option	NN	I-NP	O	O
for	for	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
as	as	RB	B-ADVP	O	O
well	well	RB	I-ADVP	O	O
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
methylphenidate	methylphenidate	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
female	female	JJ	I-NP	O	O
presented	present	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
probably	probably	RB	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
methylphenidate	methylphenidate	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
defects	defect	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
supratentorial	supratentorial	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
basal	basal	JJ	I-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
striatum	striatum	NN	I-NP	O	O
(	(	(	O	O	O
multicystic	multicystic	JJ	B-NP	O	B-Disease
encephalomalacia	encephalomalacia	NN	I-NP	O	I-Disease
)	)	)	O	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
severe	severe	VB	I-VP	O	O
perinatal	perinatal	JJ	B-NP	O	O
hypoxic	hypoxic	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
ischemic	ischemic	JJ	I-NP	O	I-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
predisposing	predispose	VBG	I-NP	O	O
factor	factor	NN	I-NP	O	O
causing	cause	VBG	B-VP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
generally	generally	RB	B-ADVP	O	O
is	be	VBZ	B-VP	O	O
accepted	accept	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
methylphenidate	methylphenidate	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
agonist	agonist	NN	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
uptake	uptake	NN	B-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
therefore	therefore	RB	B-ADVP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
systems	system	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brainstem	brainstem	NN	I-NP	O	O
(	(	(	O	O	O
mainly	mainly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
midbrain	midbrain	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
cord	cord	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
unlikely	unlikely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
participate	participate	VB	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
gamma	gamma	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	B-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
ergic	ergic	JJ	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
might	might	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
because	because	IN	B-SBAR	O	O
diazepam	diazepam	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
gamma	gamma	SYM	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminobutyric	aminobutyric	JJ	B-NP	I	I-Chemical
acid	acid	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
mimetic	mimetic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
strikingly	strikingly	RB	B-ADJP	O	O
effective	effective	JJ	I-ADJP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
reported	report	VBN	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
probably	probably	RB	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
methylphenidate	methylphenidate	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Differential	Differential	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
17alpha	17alpha	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
ethinylestradiol	ethinylestradiol	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neutral	neutral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bile	bile	NN	B-NP	B	B-Chemical
salt	salt	NN	I-NP	I	I-Chemical
synthesis	synthesis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
17alpha	17alpha	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
ethinylestradiol	ethinylestradiol	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
EE	EE	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neutral	neutral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
biosynthetic	biosynthetic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bile	bile	NN	B-NP	B	B-Chemical
salt	salt	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
BS	BS	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
synthesis	synthesis	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
intact	intact	JJ	I-NP	O	O
enterohepatic	enterohepatic	JJ	I-NP	O	O
circulation	circulation	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
bile	bile	NN	I-NP	O	O
diversion	diversion	NN	I-NP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
BS	BS	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
this	this	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
,	,	,	O	O	O
bile	bile	NN	B-NP	B	B-Chemical
salt	salt	NN	I-NP	I	I-Chemical
pool	pool	NN	I-NP	O	O
composition	composition	NN	I-NP	O	O
,	,	,	O	O	O
synthesis	synthesis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
BS	BS	NN	I-NP	B	B-Chemical
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
,	,	,	O	O	O
hepatic	hepatic	JJ	B-NP	O	O
activities	activity	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
expression	expression	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cholesterol	cholesterol	NN	B-NP	B	B-Chemical
7alpha	7alpha	NN	I-NP	O	O
-	-	HYPH	O	O	O
hydroxylase	hydroxylase	NN	B-NP	O	O
(	(	(	O	O	O
CYP7A	CYP7A	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sterol	sterol	NN	B-NP	B	B-Chemical
27	27	CD	I-NP	O	O
-	-	HYPH	O	O	O
hydroxylase	hydroxylase	NN	B-NP	O	O
(	(	(	O	O	O
CYP27	CYP27	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
BS	BS	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
vehicle	vehicle	NN	I-NP	O	O
.	.	.	O	O	O

BS	BS	NN	B-NP	O	B-Chemical
pool	pool	NN	I-NP	O	O
size	size	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
but	but	CC	O	O	O
total	total	JJ	B-NP	O	O
BS	BS	NN	I-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Synthesis	Synthesis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cholate	cholate	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
68	68	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
chenodeoxycholate	chenodeoxycholate	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
recently	recently	RB	I-NP	O	O
identified	identify	VBN	I-NP	O	O
Delta22	Delta22	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
isomer	isomer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	O	O	O
-	-	HYPH	O	O	O
muricholate	muricholate	NN	B-NP	B	O
contributed	contribute	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
5.4	5.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
18.3	18.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
pool	pool	NN	I-NP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
and	and	CC	I-NP	O	O
EE	EE	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
could	could	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
bile	bile	NN	B-NP	O	O
after	after	IN	B-PP	O	O
exhaustion	exhaustion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pool	pool	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
clear	clear	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BS	BS	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
bile	bile	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
diverted	divert	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
yet	yet	RB	B-NP	O	O
biliary	biliary	JJ	I-NP	O	O
BS	BS	NNP	I-NP	B	B-Chemical
composition	composition	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
only	only	RB	I-VP	O	O
minimally	minimally	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

Activity	Activity	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP7A	CYP7A	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
intact	intact	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
bile	bile	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diverted	divert	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CYP27	CYP27	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
.	.	.	O	O	O

Hepatic	Hepatic	JJ	B-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CYP7A	CYP7A	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
bile	bile	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
diverted	divert	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
only	only	RB	B-ADVP	O	O
;	;	:	O	O	O
CYP27	CYP27	NN	B-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
mRNA	mRNA	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sterol	sterol	NN	B-NP	B	B-Chemical
12alpha	12alpha	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
hydroxylase	hydroxylase	NN	I-NP	O	O
and	and	CC	I-NP	O	O
lithocholate	lithocholate	NN	I-NP	B	O
6beta	6beta	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
hydroxylase	hydroxylase	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
bile	bile	NN	B-NP	O	O
diversion	diversion	NN	I-NP	O	O
and	and	CC	O	O	O
suppressed	suppress	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
shows	show	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
17alpha	17alpha	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
ethinylestradiol	ethinylestradiol	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
EE	EE	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
intrahepatic	intrahepatic	JJ	I-NP	O	B-Disease
cholestasis	cholestasis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neutral	neutral	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bile	bile	NN	B-NP	B	B-Chemical
salt	salt	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
BS	BS	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
synthesis	synthesis	NN	B-NP	O	O
.	.	.	O	O	O

Simultaneous	Simultaneous	JJ	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
BS	BS	NNP	I-NP	B	B-Chemical
biosynthetic	biosynthetic	JJ	I-NP	O	O
pathways	pathway	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
overall	overall	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
EE	EE	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
BS	BS	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
.	.	.	O	O	O

Glibenclamide	Glibenclamide	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
helodermin	helodermin	NN	B-NP	B	B-Chemical
assessed	assess	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
helodermin	helodermin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
basic	basic	JJ	I-NP	O	O
35	35	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
amino	amino	NN	I-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
peptide	peptide	NN	I-NP	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
venom	venom	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lizard	lizard	NN	I-NP	O	O
salivary	salivary	JJ	I-NP	O	O
gland	gland	NN	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
,	,	,	O	O	O
focusing	focus	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
sensitive	sensitive	JJ	I-NP	O	O
K	K	NN	I-NP	B	B-Chemical
+	+	SYM	B-NP	I	O
(	(	(	O	O	O
K	K	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
)	)	)	O	O	O
channels	channel	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
responses	response	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
vasoactive	vasoactive	JJ	B-NP	B	O
intestinal	intestinal	JJ	I-NP	I	O
polypeptide	polypeptide	NN	I-NP	I	O
(	(	(	O	O	O
VIP	VIP	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

Helodermin	Helodermin	NN	B-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
with	with	IN	B-PP	O	O
approximately	approximately	RB	B-NP	O	O
similar	similar	JJ	I-NP	O	O
potency	potency	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
VIP	VIP	NN	B-NP	B	O
.	.	.	O	O	O

Hypotension	Hypotension	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
both	both	DT	B-NP	O	O
peptides	peptide	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
attenuated	attenuate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
glibenclamide	glibenclamide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
abolished	abolish	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
levcromakalim	levcromakalim	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
produced	produce	VBN	B-VP	O	O
decrease	decrease	NN	B-NP	O	O
in	in	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
.	.	.	O	O	O

Oxyhemoglobin	Oxyhemoglobin	NN	B-NP	B	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
helodermin	helodermin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
it	it	PRP	B-NP	O	O
shortened	shorten	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acetylcholine	acetylcholine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ACh	ACh	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
produced	produce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
helodermin	helodermin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
produced	produce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
partly	partly	RB	B-ADJP	O	O
attributable	attributable	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
activation	activation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glibenclamide	glibenclamide	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
K	K	NN	I-NP	B	B-Chemical
+	+	SYM	O	I	O
channels	channel	NNS	B-NP	O	O
(	(	(	O	O	O
K	K	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
channels	channel	NNS	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
presumably	presumably	RB	B-ADVP	O	O
exist	exist	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
smooth	smooth	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

EDRF	EDRF	NN	B-NP	B	O
(	(	(	O	O	O
endothelium	endothelium	NN	B-NP	O	O
-	-	HYPH	O	O	O
derived	derive	VBN	B-NP	O	O
relaxing	relaxing	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
nitric	nitric	JJ	I-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
seem	seem	VB	I-VP	O	O
to	to	TO	I-VP	O	O
play	play	VB	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peptide	peptide	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
produced	produce	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
event	event	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
sustained	sustained	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
tablets	tablet	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
psoriasis	psoriasis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Thirteen	Thirteen	CD	B-NP	O	O
psoriatic	psoriatic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
therapy	therapy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
25	25	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
sustained	sustain	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Seven	Seven	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
13	13	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
exhibited	exhibit	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
subclinical	subclinical	JJ	I-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
state	state	NN	I-NP	O	O
before	before	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
systolic	systolic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressures	pressure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
13	13	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nifedipine	nifedipine	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
range	range	NN	I-NP	O	O
thereafter	thereafter	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
25	25	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	B	B-Chemical
included	include	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
blood	blood	NN	B-NP	O	B-Chemical
urea	urea	NN	I-NP	B	I-Chemical
nitrogen	nitrogen	NN	I-NP	B	I-Chemical
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
9	9	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
13	13	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gingival	gingival	JJ	B-NP	O	B-Disease
hyperplasia	hyperplasia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
13	13	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
sustained	sustained	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
release	release	NN	I-NP	O	O
nifedipine	nifedipine	NN	I-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
useful	useful	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	B-Disease
psoriatic	psoriatic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
under	under	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cyclosporin	cyclosporin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
gingival	gingival	JJ	B-NP	O	B-Disease
hyperplasia	hyperplasia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Torsade	Torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
intermittent	intermittent	JJ	I-NP	O	O
dobutamine	dobutamine	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
dilated	dilated	JJ	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
congestive	congestive	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
56	56	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
,	,	,	I-NP	O	O
severe	severe	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
dilated	dilate	VBN	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
arrhythmias	arrhythmia	NNS	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
one	one	CD	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
low	low	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
2.5	2.5	CD	B-NP	O	O
mcg	mcg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
min	min	NN	B-NP	O	O
)	)	)	O	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
intermittent	intermittent	JJ	B-NP	O	O
dobutamine	dobutamine	NN	I-NP	B	B-Chemical
supports	support	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
unpredictable	unpredictable	JJ	B-NP	O	O
fatal	fatal	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	B-Disease
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
even	even	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
disturbances	disturbance	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
proarrhythmic	proarrhythmic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Dubutamine	Dubutamine	NN	B-NP	O	B-Chemical
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Positive	Positive	JJ	B-NP	O	O
skin	skin	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
late	late	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
radiographic	radiographic	JJ	B-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
media	medium	NNS	I-NP	O	I-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
few	few	JJ	I-NP	O	O
years	year	NNS	I-NP	O	O
delayed	delay	VBD	B-VP	O	O
reactions	reaction	NNS	B-NP	O	O
several	several	JJ	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
radiographic	radiographic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
materials	material	NNS	I-NP	O	I-Chemical
(	(	(	O	O	O
PRC	PRC	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
report	report	VBP	B-VP	O	O
two	two	CD	B-NP	O	O
observations	observation	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
intradermoreactions	intradermoreaction	NNS	B-NP	O	O
(	(	(	O	O	O
IDR	IDR	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
patch	patch	NN	B-NP	O	O
tests	test	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ionic	ionic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
non	non	JJ	I-NP	O	O
ionic	ionic	JJ	I-NP	O	O
PRC	PRC	NN	I-NP	O	B-Chemical
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
angiography	angiography	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
venous	venous	JJ	I-NP	O	O
route	route	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
n	n	NN	I-NP	O	O
degree	degree	NN	I-NP	O	O
1	1	CD	I-NP	O	O
a	a	DT	B-NP	O	O
biphasic	biphasic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
immediate	immediate	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
(	(	(	O	O	O
dyspnea	dyspnea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
loss	loss	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
consciousness	consciousness	NN	B-NP	O	I-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
delayed	delay	VBN	B-VP	O	O
macro	macro	AFX	O	O	B-Disease
-	-	HYPH	O	O	I-Disease
papular	papular	JJ	B-NP	O	I-Disease
rash	rash	NN	I-NP	O	I-Disease
appeared	appear	VBD	B-VP	O	O
,	,	,	O	O	O
whilst	whilst	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
n	n	NN	I-NP	O	O
degree	degree	NN	I-NP	O	O
2	2	CD	I-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
generalised	generalise	VBN	I-NP	O	O
sensation	sensation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heat	heat	NN	B-NP	O	O
,	,	,	O	O	O
persistent	persistent	JJ	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
site	site	NN	I-NP	O	O
of	of	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
immediately	immediately	RB	B-ADVP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
generalised	generalise	VBN	I-NP	O	O
macro	macro	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
papular	papular	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
after	after	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
skin	skin	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
positive	positive	JJ	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	O	O	O
48	48	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
IDR	IDR	NN	B-NP	O	O
and	and	CC	I-NP	O	O
patch	patch	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
only	only	RB	B-NP	O	O
some	some	DT	I-NP	O	O
PRC	PRC	NN	I-NP	O	B-Chemical
with	with	IN	B-PP	O	O
common	common	JJ	B-NP	O	O
chains	chain	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
structures	structure	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
skin	skin	NN	I-NP	O	O
tests	test	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
favour	favour	NN	B-NP	O	O
of	of	IN	B-PP	O	O
immunological	immunological	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
and	and	CC	O	O	O
may	may	MD	B-VP	O	O
help	help	VB	I-VP	O	O
in	in	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
allergy	allergy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
hyperammonemic	hyperammonemic	JJ	I-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dehydration	dehydration	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
infection	infection	NN	I-NP	O	B-Disease
.	.	.	O	O	O

From	From	IN	B-PP	O	O
1986	1986	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1998	1998	CD	B-NP	O	O
,	,	,	O	O	O
29	29	CD	B-NP	O	O
cancer	cancer	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
32	32	CD	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
hyperammonemic	hyperammonemic	JJ	I-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

None	None	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
decompensated	decompensate	VBN	I-VP	O	O
liver	liver	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Onset	Onset	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hyperammonemic	hyperammonemic	JJ	B-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
varied	vary	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
to	to	TO	I-NP	O	O
5	5	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
:	:	:	O	O	O
2.6	2.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
1.3	1.3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
ammonium	ammonium	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
ranged	range	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
248	248	CD	B-NP	O	O
to	to	TO	I-NP	O	O
2387	2387	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
:	:	:	O	O	O
626	626	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
431	431	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
32	32	CD	I-NP	O	O
episodes	episode	NNS	I-NP	O	O
,	,	,	O	O	O
26	26	CD	B-NP	O	O
(	(	(	O	O	O
81	81	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
various	various	JJ	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
azotemia	azotemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
18	18	CD	B-NP	O	O
(	(	(	O	O	O
56	56	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
occurred	occur	VBD	B-VP	O	O
during	during	IN	B-PP	O	O
bacterial	bacterial	JJ	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
14	14	CD	B-NP	O	O
(	(	(	O	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
without	without	IN	B-PP	O	O
infection	infection	NN	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
during	during	IN	B-PP	O	O
periods	period	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
dehydration	dehydration	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Higher	High	JJR	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
ammonium	ammonium	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
more	more	RBR	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperammonemia	hyperammonemia	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
18	18	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
bacterial	bacterial	JJ	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.003	0.003	CD	B-NP	O	O
and	and	CC	I-NP	O	O
0.0006	0.0006	CD	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
nine	nine	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
high	high	JJ	B-NP	O	O
daily	daily	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
2600	2600	CD	B-NP	O	O
or	or	CC	I-NP	O	O
1800	1800	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m2	m2	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.0001	0.0001	CD	B-NP	O	O
and	and	CC	O	O	O
<	<	SYM	B-NP	O	O
0.0001	0.0001	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
25	25	CD	B-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
32	32	CD	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
(	(	(	O	O	O
78	78	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
plasma	plasma	NN	B-NP	O	O
ammonium	ammonium	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
within	within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
management	management	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
hyperammonemic	hyperammonemic	JJ	B-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Azotemia	Azotemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
body	body	NN	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
insufficiency	insufficiency	NN	I-NP	O	O
and	and	CC	O	O	O
bacterial	bacterial	JJ	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
frequently	frequently	RB	I-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
therefore	therefore	RB	B-ADVP	O	O
important	important	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
recognize	recognize	VB	I-VP	O	O
this	this	DT	B-NP	O	O
condition	condition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
4	4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminopyridine	aminopyridine	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
conditioned	condition	VBN	B-NP	O	O
place	place	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
and	and	CC	O	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
unselective	unselective	JJ	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
K	K	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	O	O	O
)	)	)	O	O	O
channel	channel	NN	B-NP	O	O
blockers	blocker	NNS	I-NP	O	O
,	,	,	O	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
12.5	12.5	CD	B-NP	O	O
,	,	,	I-NP	O	O
25	25	CD	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
4	4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminopyridine	aminopyridine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
conditioned	condition	VBN	B-NP	O	O
place	place	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
and	and	CC	O	O	O
biphasic	biphasic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Wistar	Wistar	NNP	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Quinine	Quinine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
block	block	VB	I-VP	O	O
voltage	voltage	NN	B-NP	O	O
-	-	HYPH	B-ADVP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
ATP	ATP	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channels	channel	NNS	I-NP	O	O
while	while	IN	B-SBAR	O	O
4	4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminopyridine	aminopyridine	NN	I-NP	I	I-Chemical
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
block	block	VB	I-VP	O	O
voltage	voltage	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channels	channel	NNS	I-NP	O	O
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
counterbalanced	counterbalanced	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
,	,	,	O	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
attenuated	attenuate	VBD	B-VP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
place	place	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
4	4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminopyridine	aminopyridine	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
ineffective	ineffective	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
motor	motor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
test	test	NN	I-NP	O	O
measured	measure	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
Animex	Animex	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
activity	activity	NN	I-NP	O	O
meter	meter	NN	I-NP	O	O
neither	neither	CC	B-PP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channel	channel	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
affected	affect	VBD	B-VP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypoactivity	hypoactivity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
both	both	CC	O	O	O
K	K	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channel	channel	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
prevented	prevent	VBD	B-VP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
secondary	secondary	JJ	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
4	4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminopyridine	aminopyridine	NN	I-NP	I	I-Chemical
-	-	HYPH	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channels	channel	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
reward	reward	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
K	K	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channels	channel	NNS	I-NP	O	O
sensitive	sensitive	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
blockers	blocker	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypoactivity	hypoactivity	NN	I-NP	O	B-Disease
whereas	whereas	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
connected	connect	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
both	both	CC	O	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
4	4	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
aminopyridine	aminopyridine	NN	I-NP	I	I-Chemical
-	-	HYPH	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
channels	channel	NNS	I-NP	O	O
.	.	.	O	O	O

Nociceptin	Nociceptin	NN	B-NP	B	B-Chemical
/	/	SYM	I-NP	O	O
orphanin	orphanin	NN	I-NP	B	B-Chemical
FQ	FQ	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
nocistatin	nocistatin	NN	I-NP	O	B-Chemical
on	on	IN	B-PP	O	O
learning	learning	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
impairment	impairment	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
scopolamine	scopolamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

Nociceptin	Nociceptin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
also	also	RB	B-VP	O	O
known	know	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
orphanin	orphanin	NN	B-NP	B	B-Chemical
FQ	FQ	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
endogenous	endogenous	JJ	I-NP	O	O
ligand	ligand	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
orphan	orphan	NN	I-NP	B	O
opioid	opioid	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
like	like	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
ORL1	ORL1	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
involves	involve	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
functions	function	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
nocistatin	nocistatin	NN	B-NP	O	B-Chemical
is	be	VBZ	B-VP	O	O
recently	recently	RB	I-VP	O	O
isolated	isolate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
precursor	precursor	NN	I-NP	O	O
as	as	IN	B-PP	O	O
nociceptin	nociceptin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
blocks	block	VBZ	B-VP	O	O
nociceptin	nociceptin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
allodynia	allodynia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
hyperalgesia	hyperalgesia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

2	2	LS	B-LST	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
ORL1	ORL1	NN	B-NP	O	O
receptors	receptor	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
display	display	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sequence	sequence	NN	B-NP	O	O
homology	homology	NN	I-NP	O	O
with	with	IN	B-PP	O	O
classical	classical	JJ	B-NP	O	O
opioid	opioid	JJ	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
abundant	abundant	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
,	,	,	O	O	O
little	little	JJ	B-NP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
regarding	regard	VBG	I-VP	O	O
their	their	PRP$	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
.	.	.	O	O	O

3	3	LS	B-LST	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
nociceptin	nociceptin	NN	B-NP	B	B-Chemical
/	/	SYM	I-NP	O	O
orphanin	orphanin	NN	I-NP	B	B-Chemical
FQ	FQ	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
nocistatin	nocistatin	NN	I-NP	O	B-Chemical
could	could	MD	B-VP	O	O
modulate	modulate	VB	I-VP	O	O
impairment	impairment	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
learning	learning	NN	B-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
scopolamine	scopolamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
muscarinic	muscarinic	JJ	I-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Y	Y	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
maze	maze	NN	I-NP	O	O
and	and	CC	I-NP	O	O
step	step	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
down	down	RP	B-PRT	O	O
type	type	NN	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
tasks	task	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

4	4	LS	B-LST	O	O
.	.	.	O	O	O

While	While	IN	B-SBAR	O	O
nocistatin	nocistatin	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5.0	5.0	CD	I-NP	O	O
nmol	nmol	NN	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
i.c.v.	i.c.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
administered	administer	VBN	B-VP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
training	training	NN	I-NP	O	O
session	session	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
task	task	NN	I-NP	O	O
,	,	,	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
or	or	CC	O	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
behaviours	behaviour	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	O	O	O
lower	low	JJR	O	O	O
per	per	IN	B-PP	O	O
cent	cent	NN	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
and	and	CC	O	O	O
shorter	short	JJR	B-NP	O	O
median	median	JJ	I-NP	O	O
step	step	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
down	down	RP	B-PRT	O	O
latency	latency	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
retention	retention	NN	I-NP	O	O
test	test	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
nociceptin	nociceptin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
5.0	5.0	CD	B-NP	O	O
nmol	nmol	NN	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
i.c.v.	i.c.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
normal	normal	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

5	5	LS	B-LST	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nocistatin	nocistatin	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
5.0	5.0	CD	B-NP	O	O
nmol	nmol	NN	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
i.c.v.	i.c.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
performance	performance	NN	I-NP	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
training	training	NN	I-NP	O	O
session	session	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
passive	passive	JJ	I-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
task	task	NN	I-NP	O	O
,	,	,	O	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
scopolamine	scopolamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
and	and	CC	O	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
behaviours	behaviour	NNS	I-NP	O	O
.	.	.	O	O	O

6	6	CD	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
nocistatin	nocistatin	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
biologically	biologically	RB	I-NP	O	O
active	active	JJ	I-NP	O	O
peptide	peptide	NN	I-NP	O	O
,	,	,	O	O	O
ameliorates	ameliorate	VBZ	B-VP	O	O
impairments	impairment	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
alternation	alternation	NN	I-NP	O	O
and	and	CC	O	O	O
passive	passive	JJ	B-NP	O	O
avoidance	avoidance	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
scopolamine	scopolamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
suggested	suggest	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
peptides	peptide	NNS	I-NP	O	O
play	play	VBP	B-VP	O	O
opposite	opposite	JJ	B-NP	O	O
roles	role	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
.	.	.	O	O	O

Meloxicam	Meloxicam	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
female	female	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
rheumatoid	rheumatoid	JJ	B-NP	O	B-Disease
arthritis	arthritis	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	O
cytolytic	cytolytic	JJ	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
introduced	introduce	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
Belgium	Belgium	NN	B-NP	O	O
,	,	,	O	O	O
meloxicam	meloxicam	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	O
antiinflammatory	antiinflammatory	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
with	with	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inducible	inducible	JJ	I-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclooxygenase	cyclooxygenase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
cytolytic	cytolytic	JJ	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
after	after	IN	B-SBAR	O	O
meloxicam	meloxicam	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antinuclear	antinuclear	JJ	B-NP	O	O
antibodies	antibody	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
mechanism	mechanism	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
meloxicam	meloxicam	NN	B-NP	B	B-Chemical
related	related	JJ	I-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
demonstrates	demonstrate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
hepatic	hepatic	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
by	by	IN	B-PP	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
metabolites	metabolite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HL60	HL60	NN	B-NP	O	O
and	and	CC	I-NP	O	O
CD34	CD34	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
CD19	CD19	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
human	human	JJ	I-NP	O	O
bone	bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
progenitor	progenitor	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
:	:	:	O	O	O
potential	potential	JJ	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
aplastic	aplastic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
[	[	(	O	O	O
(	(	(	O	O	B-Chemical
S	S	NN	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
(	(	(	O	O	I-Chemical
-	-	SYM	O	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
3	3	CD	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
bromo	bromo	AFX	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
N	N	NN	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
[	[	(	O	O	I-Chemical
(	(	(	O	O	I-Chemical
1	1	CD	B-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
ethyl	ethyl	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
pyrrolidinyl	pyrrolidinyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
methyl	methyl	NN	B-NP	B	I-Chemical
]	]	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2,6	2,6	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
dimethoxybenz	dimethoxybenz	NN	I-NP	O	I-Chemical
amide	amide	NN	I-NP	B	I-Chemical
]	]	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
acquired	acquire	VBN	B-NP	O	O
aplastic	aplastic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
examined	examine	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
three	three	CD	B-NP	O	O
pyrrolidine	pyrrolidine	NN	I-NP	B	B-Chemical
ring	ring	NN	I-NP	I	O
metabolites	metabolite	NNS	I-NP	O	O
and	and	CC	O	O	O
five	five	CD	B-NP	O	O
aromatic	aromatic	JJ	I-NP	O	O
ring	ring	NN	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parent	parent	NN	I-NP	O	O
compound	compound	NN	I-NP	O	O
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
HL60	HL60	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	O	O	O
human	human	JJ	B-NP	O	O
bone	bone	NN	I-NP	O	O
marrow	marrow	NN	I-NP	O	O
progenitor	progenitor	NN	I-NP	O	O
(	(	(	O	O	O
HBMP	HBMP	NN	B-NP	O	O
)	)	)	O	O	O
cells	cell	NNS	B-NP	O	O
.	.	.	O	O	O

Cells	Cell	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
24	24	CD	I-NP	O	O
h	h	NN	I-NP	O	O
with	with	IN	B-PP	O	O
each	each	DT	B-NP	O	O
compound	compound	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
200	200	CD	I-NP	O	O
microM	microM	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Apoptosis	Apoptosis	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
fluorescence	fluorescence	NN	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Hoechst	Hoechst	NNP	B-NP	B	B-Chemical
33342	33342	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
propidium	propidium	NN	I-NP	B	B-Chemical
iodide	iodide	NN	I-NP	I	I-Chemical
stained	stain	VBD	B-VP	O	O
cell	cell	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
.	.	.	O	O	O

Results	Result	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
determination	determination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
internucleosomal	internucleosomal	JJ	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
fragmentation	fragmentation	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
gel	gel	NN	B-NP	O	O
electrophoresis	electrophoresis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
HL60	HL60	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
samples	sample	NNS	I-NP	O	O
and	and	CC	O	O	O
terminal	terminal	JJ	B-NP	O	O
deoxynucleotidyl	deoxynucleotidyl	NN	I-NP	O	O
transferase	transferase	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HBMP	HBMP	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
catechol	catechol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
hydroquinone	hydroquinone	NN	I-NP	B	B-Chemical
metabolites	metabolite	NNS	I-NP	O	O
,	,	,	O	O	O
NCQ436	NCQ436	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
NCQ344	NCQ344	NN	I-NP	O	B-Chemical
,	,	,	O	O	O
induced	induce	VBD	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
HL60	HL60	NN	B-NP	O	O
and	and	CC	I-NP	O	O
HBMP	HBMP	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
time	time	NN	I-NP	O	O
-	-	HYPH	O	O	O
and	and	CC	O	O	O
concentration	concentration	NN	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
phenols	phenol	NNS	I-NP	B	B-Chemical
,	,	,	O	O	O
NCR181	NCR181	NN	B-NP	O	O
,	,	,	O	O	O
FLA873	FLA873	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
FLA797	FLA797	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
derivatives	derivative	NNS	I-NP	O	O
formed	form	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
oxidation	oxidation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pyrrolidine	pyrrolidine	NN	I-NP	B	B-Chemical
ring	ring	NN	I-NP	I	O
,	,	,	O	O	O
FLA838	FLA838	NN	B-NP	O	O
,	,	,	O	O	O
NCM001	NCM001	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
NCL118	NCL118	NN	B-NP	O	O
,	,	,	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cells	cell	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
NCQ436	NCQ436	NN	B-NP	O	B-Chemical
but	but	CC	O	O	O
NCQ344	NCQ344	NN	B-NP	O	B-Chemical
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
biphasic	biphasic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
types	type	NNS	I-NP	O	O
,	,	,	O	O	O
inducing	induce	VBG	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
at	at	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
and	and	CC	O	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
at	at	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
catechol	catechol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
hydroquinone	hydroquinone	NN	I-NP	B	B-Chemical
metabolites	metabolite	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
direct	direct	JJ	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
HL60	HL60	NN	B-NP	O	O
and	and	CC	I-NP	O	O
HBMP	HBMP	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
phenol	phenol	NN	I-NP	B	B-Chemical
metabolites	metabolite	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
inactive	inactive	JJ	B-ADJP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
benzene	benzene	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
derived	derive	VBN	I-NP	O	O
catechol	catechol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
hydroquinone	hydroquinone	NN	I-NP	B	B-Chemical
,	,	,	B-NP	O	O
but	but	CC	I-NP	O	O
not	not	RB	I-NP	O	O
phenol	phenol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
induce	induce	VBP	B-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
HBMP	HBMP	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
[	[	(	O	O	O
Moran	Moran	NNP	B-NP	O	O
et	et	FW	I-NP	O	O
al.	al.	FW	I-NP	O	O
,	,	,	O	O	O
Mol	Mol	NNP	B-NP	O	O
.	.	.	O	O	O

Pharmacol.	Pharmacol.	NNP	B-NP	O	O
,	,	,	O	O	O
50	50	CD	B-NP	O	O
(	(	(	O	O	O
1996	1996	CD	B-NP	O	O
)	)	)	O	O	O
610	610	CD	B-NP	O	O
-	-	HYPH	O	O	O
615	615	CD	B-NP	O	O
]	]	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
propose	propose	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
benzene	benzene	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
aplastic	aplastic	JJ	B-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
via	via	IN	B-PP	O	O
production	production	NN	B-NP	O	O
of	of	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
reactive	reactive	JJ	I-NP	O	O
metabolites	metabolite	NNS	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
ability	ability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NCQ436	NCQ436	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
NCQ344	NCQ344	NN	I-NP	O	B-Chemical
to	to	TO	B-VP	O	O
induce	induce	VB	I-VP	O	O
apoptosis	apoptosis	NN	B-NP	O	O
in	in	IN	B-PP	O	O
HBMP	HBMP	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
underlying	underlie	VBG	B-VP	O	O
acquired	acquire	VBN	I-VP	O	O
aplastic	aplastic	JJ	B-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
remoxipride	remoxipride	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Synthesis	Synthesis	NN	B-NP	O	O
and	and	CC	O	O	O
preliminary	preliminary	JJ	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
investigations	investigation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	B-Chemical
-	-	HYPH	B-ADJP	O	I-Chemical
(	(	(	O	O	I-Chemical
1,2	1,2	CD	O	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
dihydro	dihydro	AFX	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
acenaphthylenyl	acenaphthylenyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
piperazine	piperazine	NN	B-NP	B	I-Chemical
derivatives	derivative	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
research	research	NN	B-NP	O	O
towards	towards	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
new	new	JJ	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
strategy	strategy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
modulated	modulate	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
manipulation	manipulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
and	and	CC	I-NP	O	O
preliminary	preliminary	JJ	I-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
structure	structure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	B-Chemical
-	-	HYPH	B-ADJP	O	I-Chemical
(	(	(	O	O	I-Chemical
1,2	1,2	CD	O	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
dihydro	dihydro	AFX	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
acenaphthylenyl	acenaphthylenyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
piperazine	piperazine	NN	B-NP	B	I-Chemical
(	(	(	O	O	O
7	7	CD	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Compound	Compound	NN	B-NP	O	O
7e	7e	CD	I-NP	O	O
,	,	,	I-NP	O	O
5	5	CD	I-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
{	{	SYM	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
[	[	(	B-NP	O	I-Chemical
4	4	CD	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
(	(	(	O	O	I-Chemical
1,2	1,2	CD	O	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
dihydro	dihydro	AFX	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
acenaphthylenyl	acenaphthylenyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
piperazinyl	piperazinyl	NN	B-NP	O	I-Chemical
]	]	)	O	O	I-Chemical
ethyl	ethyl	NN	B-NP	B	I-Chemical
}	}	AFX	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2,3	2,3	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
dihy	dihy	JJ	I-NP	O	I-Chemical
dro	dro	AFX	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
1H	1H	NN	I-NP	B	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
indol	indol	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
one	one	CD	I-NP	O	I-Chemical
,	,	,	O	O	O
from	from	IN	B-PP	O	O
this	this	DT	B-NP	O	O
series	series	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
affinities	affinity	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
HT1A	HT1A	NN	I-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
HT2A	HT2A	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
and	and	CC	O	O	O
moderate	moderate	JJ	B-NP	O	O
affinity	affinity	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
D2	D2	NN	I-NP	B	O
receptor	receptor	NN	I-NP	O	O
.	.	.	O	O	O

7e	7e	NN	B-NP	O	O
exhibits	exhibit	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
reversal	reversal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
indicating	indicate	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
nature	nature	NN	I-NP	O	O
.	.	.	O	O	O

Sub	Sub	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nitric	nitric	JJ	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
oxide	oxide	NN	I-NP	B	I-Chemical
synthesis	synthesis	NN	I-NP	O	O
modifies	modify	VBZ	B-VP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NADPH	NADPH	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
diaphorase	diaphorase	NN	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

RATIONALE	RATIONALE	NN	B-NP	O	O
:	:	:	O	O	O
NG	NG	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
nitro	nitro	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
L	L	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
arginine	arginine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
L	L	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
NOARG	NOARG	NN	B-NP	B	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nitric	nitric	JJ	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
oxide	oxide	NN	I-NP	B	I-Chemical
synthase	synthase	NN	I-NP	O	O
(	(	(	O	O	O
NOS	NOS	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
induces	induce	VBZ	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
undergoes	undergo	VBZ	B-VP	O	O
rapid	rapid	JJ	B-NP	O	O
tolerance	tolerance	NN	I-NP	O	O
,	,	,	O	O	O
showing	show	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
after	after	IN	B-PP	O	O
2	2	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sub	sub	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
chronic	chronic	JJ	B-NP	O	O
L	L	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
NOARG	NOARG	NN	I-NP	B	I-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Nitric	Nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
NO	NO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
influence	influence	VB	I-VP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
neurotransmission	neurotransmission	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
striatum	striatum	NN	I-NP	O	O
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
block	block	VBP	B-VP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
,	,	,	O	O	O
also	also	RB	B-ADVP	O	O
cause	cause	VBP	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
rodents	rodent	NNS	B-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
subchronic	subchronic	JJ	B-NP	O	O
L	L	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
NOARG	NOARG	NN	I-NP	B	I-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NOS	NOS	NN	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
areas	area	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
motor	motor	NN	B-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Male	Male	JJ	B-NP	O	O
albino	albino	JJ	I-NP	O	O
Swiss	Swiss	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
sub	sub	AFX	O	O	O
-	-	HYPH	O	O	O
chronically	chronically	RB	B-ADVP	O	O
(	(	(	O	O	O
twice	twice	RB	B-NP	O	O
a	a	DT	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
L	L	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
NOARG	NOARG	NN	B-NP	B	I-Chemical
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Catalepsy	Catalepsy	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beginning	beginning	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
end	end	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
nicotinamide	nicotinamide	NN	I-NP	B	B-Chemical
adenine	adenine	NN	I-NP	I	I-Chemical
dinucleotide	dinucleotide	NN	I-NP	I	I-Chemical
phosphate	phosphate	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
diaphorase	diaphorase	NN	I-NP	O	O
(	(	(	O	O	O
NADPH	NADPH	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
d	d	NN	I-NP	O	O
)	)	)	O	O	O
histochemistry	histochemistry	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
visualize	visualize	VB	I-VP	O	O
NOS	NOS	NN	B-NP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
index	index	NN	I-NP	O	O
of	of	IN	B-PP	O	O
enzyme	enzyme	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
brain	brain	NN	I-NP	O	O
regions	region	NNS	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
motor	motor	NN	B-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
L	L	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
NOARG	NOARG	NN	I-NP	B	I-Chemical
sub	sub	AFX	O	O	O
-	-	HYPH	O	O	O
chronic	chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
tolerance	tolerance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
NOARG	NOARG	NN	I-NP	B	I-Chemical
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
induced	induce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NADPH	NADPH	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
d	d	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dorsal	dorsal	JJ	I-NP	O	O
part	part	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caudate	caudate	NN	I-NP	O	O
and	and	CC	O	O	O
accumbens	accumben	VBZ	B-VP	O	O
nuclei	nucleus	NNS	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pedunculopontine	pedunculopontine	JJ	I-NP	O	O
tegmental	tegmental	JJ	I-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NADPH	NADPH	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
d	d	JJ	I-NP	O	O
neuron	neuron	NN	I-NP	O	O
number	number	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
substantia	substantia	NN	I-NP	O	O
nigra	nigra	NN	I-NP	O	O
,	,	,	O	O	O
pars	par	NNS	B-NP	O	O
compacta	compacta	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	B-VP	O	O
and	and	CC	O	O	O
L	L	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
NOARG	NOARG	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
give	give	VBP	B-VP	O	O
further	further	JJ	B-NP	O	O
support	support	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
NO	NO	NN	B-NP	O	B-Chemical
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
control	control	VBP	B-VP	O	O
and	and	CC	I-VP	O	O
suggest	suggest	VBP	I-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
take	take	VB	I-VP	O	O
part	part	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
synaptic	synaptic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
antipsychotic	antipsychotic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Prolonged	Prolong	VBN	B-VP	O	O
left	leave	VBD	B-VP	O	B-Disease
ventricular	ventricular	JJ	B-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
occurs	occur	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
after	after	IN	B-SBAR	O	O
both	both	CC	O	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
exercise	exercise	NN	B-NP	O	O
induced	induce	VBD	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
ischaemia	ischaemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
but	but	CC	I-NP	O	O
reversible	reversible	JJ	I-NP	O	O
left	left	JJ	I-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
seen	see	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
randomised	randomise	VBN	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systolic	systolic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
after	after	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
and	and	CC	I-NP	O	O
dobutamine	dobutamine	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
ischaemia	ischaemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

SUBJECTS	SUBJECTS	NNS	B-NP	O	O
:	:	:	O	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	B-Disease
angina	angina	NN	I-NP	O	I-Disease
,	,	,	O	O	O
angiographically	angiographically	RB	B-NP	O	O
proven	prove	VBN	I-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
normal	normal	JJ	B-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

INTERVENTIONS	INTERVENTIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Treadmill	Treadmill	NN	B-NP	O	O
exercise	exercise	NN	I-NP	O	O
and	and	CC	O	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
stress	stress	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Quantitative	Quantitative	JJ	B-NP	O	O
assessment	assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systolic	systolic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
transthoracic	transthoracic	JJ	B-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
and	and	CC	B-PP	O	O
at	at	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
intervals	interval	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
each	each	DT	B-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Both	Both	DT	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
stress	stress	NN	B-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
but	but	CC	I-NP	O	O
reversible	reversible	JJ	I-NP	O	O
systolic	systolic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
double	double	JJ	I-NP	O	O
product	product	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.53	0.53	CD	B-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
ST	ST	NN	B-NP	B	O
depression	depression	NN	I-NP	O	B-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.63	0.63	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
form	form	NN	B-NP	O	O
of	of	IN	B-PP	O	O
stress	stress	NN	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
,	,	,	O	O	O
ejection	ejection	NN	B-NP	O	O
fraction	fraction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
15	15	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
(	(	(	O	O	O
SEM	SEM	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
-	-	HYPH	O	O	O
5.6	5.6	CD	B-NP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
-	-	SYM	O	O	O
6.1	6.1	CD	B-NP	O	O
(	(	(	O	O	O
2.2	2.2	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
0	0	CD	B-NP	O	O
.	.	.	O	O	O

01	01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
and	and	CC	I-NP	O	O
45	45	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
-	-	SYM	O	O	O
10.8	10.8	CD	B-NP	O	O
(	(	(	O	O	O
1.8	1.8	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
and	and	CC	O	O	O
-	-	SYM	B-NP	O	O
5	5	CD	I-NP	O	O
.	.	.	O	O	O

5	5	CD	B-NP	O	O
(	(	(	O	O	O
1.8	1.8	CD	O	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
,	,	,	O	O	O
both	both	CC	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Regional	Regional	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
worst	worst	JJS	I-NP	O	O
affected	affect	VBN	I-NP	O	O
segment	segment	NN	I-NP	O	O
15	15	CD	I-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
27.9	27.9	CD	B-NP	O	O
(	(	(	O	O	O
7.2	7.2	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
and	and	CC	O	O	O
-	-	SYM	B-NP	O	O
28.6	28.6	CD	I-NP	O	O
(	(	(	O	O	O
5.7	5.7	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
,	,	,	O	O	O
both	both	CC	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
-	-	SYM	O	O	O
32	32	CD	B-NP	O	O
(	(	(	O	O	O
5.3	5.3	CD	B-NP	O	O
)	)	)	O	O	O
%	%	NN	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
isovolumic	isovolumic	JJ	I-NP	O	O
relaxation	relaxation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
prolonged	prolonged	JJ	B-ADJP	O	O
45	45	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
each	each	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stress	stress	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
dobutamine	dobutamine	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
ischaemia	ischaemia	NN	B-NP	O	B-Disease
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
reversible	reversible	JJ	I-NP	O	O
left	left	JJ	I-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
,	,	,	O	O	O
presumed	presume	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
myocardial	myocardial	JJ	B-ADJP	O	B-Disease
stunning	stunning	JJ	B-ADJP	O	I-Disease
,	,	,	O	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
seen	see	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
exercise	exercise	NN	B-NP	O	O
.	.	.	O	O	O

Dobutamine	Dobutamine	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
ischaemia	ischaemia	NN	B-NP	O	B-Disease
could	could	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
pathophysiology	pathophysiology	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
phenomenon	phenomenon	NN	I-NP	O	O
further	further	RBR	B-ADVP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Anorexigens	Anorexigen	NNS	B-NP	O	O
and	and	CC	O	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	State	NNPS	I-NP	O	O
:	:	:	O	O	O
results	result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
surveillance	surveillance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
North	North	JJ	B-NP	O	O
American	American	JJ	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
appetite	appetite	JJ	B-NP	O	O
suppressants	suppressant	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Europe	Europe	NNP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	B-Disease
pulmonary	pulmonary	JJ	I-NP	O	I-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PPH	PPH	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
,	,	,	O	O	O
fenfluramine	fenfluramine	NN	B-NP	B	B-Chemical
appetite	appetite	NN	I-NP	O	O
suppressants	suppressant	NNS	I-NP	O	O
became	become	VBD	B-VP	O	O
widely	widely	RB	B-ADJP	O	O
used	use	VBN	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	State	NNPS	I-NP	O	O
but	but	CC	O	O	O
were	be	VBD	B-VP	O	O
withdrawn	withdraw	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
September	September	NNP	B-NP	O	O
1997	1997	CD	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
concerns	concern	NNS	B-NP	O	O
over	over	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

MATERIALS	MATERIALS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
conducted	conduct	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
surveillance	surveillance	NN	I-NP	O	O
study	study	NN	I-NP	O	O
on	on	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
diagnosed	diagnose	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
12	12	CD	B-NP	O	O
large	large	JJ	I-NP	O	O
referral	referral	JJ	I-NP	O	O
centers	center	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
North	North	NNP	B-NP	O	O
America	America	NNP	I-NP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
collected	collect	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
seen	see	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
September	September	NNP	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
1996	1996	CD	I-NP	O	O
,	,	,	O	O	O
to	to	TO	B-PP	O	O
December	December	NNP	B-NP	O	O
31	31	CD	I-NP	O	O
,	,	,	I-NP	O	O
1997	1997	CD	I-NP	O	O
,	,	,	O	O	O
included	include	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
severity	severity	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
identifiable	identifiable	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
classed	class	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
PPH	PPH	NN	B-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
special	special	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antidepressants	antidepressant	NNS	B-NP	O	O
,	,	,	O	O	O
anorexigens	anorexigen	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
amphetamines	amphetamine	NNS	B-NP	B	B-Chemical
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Five	Five	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
seventy	seventy	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
nine	nine	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
,	,	,	O	O	O
205	205	CD	B-NP	O	O
with	with	IN	B-PP	O	O
PPH	PPH	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
374	374	CD	B-NP	O	O
with	with	IN	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
from	from	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
causes	cause	NNS	I-NP	O	O
(	(	(	O	O	O
secondary	secondary	JJ	B-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
[	[	(	O	O	O
SPH	SPH	NN	B-NP	B	O
]	]	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anorexigens	anorexigen	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
common	common	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
surveyed	survey	VBN	B-VP	O	O
,	,	,	O	O	O
only	only	RB	B-NP	O	O
the	the	DT	I-NP	O	O
fenfluramines	fenfluramine	NNS	I-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
preferential	preferential	JJ	I-NP	O	O
association	association	NN	I-NP	O	O
with	with	IN	B-PP	O	O
PPH	PPH	NN	B-NP	O	B-Disease
as	as	IN	B-PP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
SPH	SPH	NN	B-NP	B	O
(	(	(	O	O	O
adjusted	adjust	VBN	B-NP	O	O
odds	odd	NNS	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
for	for	IN	B-PP	O	O
use	use	NN	B-NP	O	O
>	>	SYM	O	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
7.5	7.5	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
,	,	,	O	O	O
1.7	1.7	CD	B-NP	O	O
to	to	TO	B-PP	O	O
32.4	32.4	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
association	association	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
stronger	strong	JJR	B-ADJP	O	O
with	with	IN	B-PP	O	O
longer	long	JJR	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
shorter	short	JJR	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
pronounced	pronounced	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
recent	recent	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
remote	remote	JJ	B-NP	O	O
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
unexpectedly	unexpectedly	RB	I-NP	O	O
high	high	JJ	I-NP	O	O
(	(	(	O	O	O
11.4	11.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
number	number	NN	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
SPH	SPH	NN	B-NP	B	O
had	have	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
anorexigens	anorexigen	NNS	B-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
with	with	IN	B-PP	O	O
PPH	PPH	NN	B-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
association	association	NN	B-NP	O	O
with	with	IN	B-PP	O	O
increasing	increase	VBG	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
specificity	specificity	NN	I-NP	O	O
for	for	IN	B-PP	O	O
fenfluramines	fenfluramine	NNS	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
fenfluramines	fenfluramine	NNS	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
causally	causally	RB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
PPH	PPH	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anorexigen	anorexigen	NN	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
SPH	SPH	NN	B-NP	B	O
also	also	RB	B-ADVP	O	O
raises	raise	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
precipitate	precipitate	VBP	B-VP	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
underlying	underlie	VBG	B-VP	O	O
conditions	condition	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
SPH	SPH	NN	B-NP	B	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
aspects	aspect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
thrombosis	thrombosis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
first	first	RB	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clotting	clotting	NN	I-NP	O	O
of	of	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
clinically	clinically	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
for	for	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
50	50	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
several	several	JJ	B-NP	O	O
new	new	JJ	I-NP	O	O
anticoagulant	anticoagulant	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
development	development	NN	B-NP	O	O
,	,	,	O	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
remains	remain	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
anticoagulant	anticoagulant	NN	I-NP	O	O
of	of	IN	B-PP	O	O
choice	choice	NN	B-NP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
acute	acute	JJ	B-NP	O	O
thrombotic	thrombotic	JJ	I-NP	O	B-Disease
episodes	episode	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
meritorious	meritorious	JJ	B-ADJP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
exist	exist	VB	I-VP	O	O
.	.	.	O	O	O

Bleeding	Bleeding	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
untoward	untoward	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Major	Major	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
concern	concern	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
additional	additional	JJ	B-NP	O	O
important	important	JJ	I-NP	O	O
untoward	untoward	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
include	include	VBP	B-VP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
osteoporosis	osteoporosis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
eosinophilia	eosinophilia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
skin	skin	NN	B-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
allergic	allergic	JJ	B-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
alopecia	alopecia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
transaminasemia	transaminasemia	NN	B-NP	O	O
,	,	,	O	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
hypoaldosteronism	hypoaldosteronism	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
priapism	priapism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
side	side	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
relatively	relatively	RB	B-ADJP	O	O
rare	rare	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
given	give	VBN	I-NP	O	O
individual	individual	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
extremely	extremely	RB	I-NP	O	O
widespread	widespread	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
some	some	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
quite	quite	RB	B-ADJP	O	O
common	common	JJ	I-ADJP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
HITT	HITT	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
osteoporosis	osteoporosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
reasonable	reasonable	JJ	B-NP	O	O
incidences	incidence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
side	side	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
"	"	``	O	O	O
softly	softly	RB	B-ADVP	O	O
"	"	''	O	O	O
deduced	deduce	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
dealing	deal	VBG	B-VP	O	O
with	with	IN	B-PP	O	O
unfractionated	unfractionated	JJ	B-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
at	at	IN	B-PP	O	O
present	present	JJ	B-ADJP	O	O
the	the	DT	B-NP	O	O
incidences	incidence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
side	side	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
newer	new	JJR	B-NP	O	O
low	low	JJ	I-NP	O	O
molecular	molecular	JJ	I-NP	O	O
weight	weight	NN	I-NP	O	O
heparins	heparin	NNS	I-NP	B	B-Chemical
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
much	much	RB	B-ADJP	O	O
less	less	RBR	I-ADJP	O	O
common	common	JJ	I-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
only	only	RB	B-NP	O	O
longer	long	JJR	I-NP	O	O
experience	experience	NN	I-NP	O	O
will	will	MD	B-VP	O	O
more	more	RBR	I-VP	O	O
clearly	clearly	RB	I-VP	O	O
define	define	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
weight	weight	NN	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
optic	optic	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
on	on	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
FK506	FK506	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
therapy	therapy	NN	B-NP	O	O
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
optic	optic	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
FK	FK	NN	B-NP	B	B-Chemical
506	506	CD	I-NP	I	I-Chemical
,	,	,	O	O	O
Prograf	Prograf	NNP	B-NP	B	O
;	;	:	O	O	O
Fujisawa	Fujisawa	NNP	B-NP	B	O
USA	USA	NNP	I-NP	O	O
,	,	,	O	O	O
Inc	Inc	NNP	B-NP	O	O
,	,	,	O	O	O
Deerfield	Deerfield	NNP	B-NP	O	O
,	,	,	O	O	O
Illinois	Illinois	NNP	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
immunosuppression	immunosuppression	NN	B-NP	O	O
after	after	IN	B-PP	O	O
orthotropic	orthotropic	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
Case	Case	NN	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
58	58	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
after	after	IN	B-PP	O	O
orthotropic	orthotropic	JJ	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
,	,	,	O	O	O
serial	serial	JJ	B-NP	O	O
neuro	neuro	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
ophthalmologic	ophthalmologic	JJ	I-NP	O	O
examinations	examination	NNS	I-NP	O	O
and	and	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
episodic	episodic	JJ	B-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vision	vision	NN	B-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
features	feature	NNS	I-NP	O	O
resembling	resemble	VBG	B-VP	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
optic	optic	JJ	I-NP	O	I-Disease
neuropathies	neuropathy	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Deterioration	Deterioration	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
vision	vision	NN	B-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
despite	despite	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tacrolimus	tacrolimus	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Tacrolimus	Tacrolimus	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
optic	optic	JJ	B-NP	O	B-Disease
nerve	nerve	NN	I-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Hypercalcemia	Hypercalcemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
arrhythmia	arrhythmia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
mood	mood	NN	B-NP	O	O
stabilizers	stabilizer	NNS	I-NP	O	O
.	.	.	O	O	O

Recent	Recent	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
patient	patient	NN	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
maintenance	maintenance	NN	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
severe	severe	JJ	B-NP	O	O
bradyarrhythmia	bradyarrhythmia	NN	I-NP	O	B-Disease
prompted	prompt	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
conduct	conduct	VB	I-VP	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
printout	printout	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	B-Disease
that	that	WDT	B-NP	O	O
presented	present	VBD	B-VP	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
generated	generate	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
eliminating	eliminate	VBG	B-VP	O	O
spurious	spurious	JJ	B-NP	O	O
hypercalcemias	hypercalcemia	NNS	I-NP	O	B-Disease
or	or	CC	O	O	O
those	those	DT	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
fluids	fluid	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
identified	identify	VBD	B-VP	O	O
18	18	CD	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hypercalcemias	hypercalcemia	NNS	B-NP	O	B-Disease
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
malignancies	malignancy	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
(	(	(	O	O	O
group	group	NN	B-NP	O	O
A	A	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
group	group	NN	B-NP	O	O
B	B	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
group	group	NN	B-NP	O	O
B	B	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
group	group	NN	B-NP	O	O
A	A	NN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
latter	latter	JJ	I-NP	O	O
were	be	VBD	B-VP	O	O
medically	medically	RB	I-VP	O	O
compromised	compromise	VBN	I-VP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
multiple	multiple	JJ	B-NP	O	O
pharmacotherapies	pharmacotherapy	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
two	two	CD	B-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
generated	generate	VBN	I-VP	O	O
:	:	:	O	O	O
group	group	NN	B-NP	O	O
C1	C1	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
age	age	NN	B-NP	O	O
-	-	HYPH	O	O	O
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	O
-	-	HYPH	O	O	O
comparable	comparable	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
normocalcemic	normocalcemic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
group	group	NN	B-NP	O	O
C2	C2	NN	I-NP	B	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
normocalcemic	normocalcemic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
anticonvulsant	anticonvulsant	JJ	B-NP	O	O
mood	mood	NN	I-NP	O	O
stabilizers	stabilizer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
(	(	(	O	O	O
ECG	ECG	NN	B-NP	O	O
)	)	)	O	O	O
findings	finding	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
group	group	NN	B-NP	O	O
B	B	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
C1	C1	NN	I-NP	O	O
and	and	CC	I-NP	O	O
C2	C2	NN	I-NP	B	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
overall	overall	JJ	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
conduction	conduction	NN	B-NP	O	O
defects	defect	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hypercalcemia	hypercalcemia	NN	B-NP	O	B-Disease
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
medical	medical	JJ	B-NP	O	O
diseases	disease	NNS	I-NP	O	O
and	and	CC	O	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	B-Disease
had	have	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
higher	high	JJR	I-NP	O	O
frequencies	frequency	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
conduction	conduction	NN	B-NP	O	O
defects	defect	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
group	group	NN	B-NP	O	O
A	A	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
at	at	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
(	(	(	O	O	O
28	28	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
to	to	TO	B-PP	O	O
zero	zero	CD	B-NP	O	O
mortality	mortality	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
three	three	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
implications	implication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Attenuation	Attenuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
nanosphere	nanosphere	NN	I-NP	O	O
(	(	(	O	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
718	718	CD	I-NP	O	O
)	)	)	O	O	O
incorporating	incorporate	VBG	B-VP	O	O
amphotericin	amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

NS	NS	NN	B-NP	O	O
-	-	HYPH	O	O	O
718	718	CD	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
nanosphere	nanosphere	NN	I-NP	O	O
incorporating	incorporate	VBG	B-VP	O	O
amphotericin	amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
against	against	IN	B-PP	O	O
pathogenic	pathogenic	JJ	B-NP	O	O
fungi	fungus	NNS	I-NP	O	O
and	and	CC	O	O	O
has	have	VBZ	B-VP	O	O
low	low	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	O	O	O
718	718	CD	B-NP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
Fungizone	Fungizone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
amphotericin	amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
sodium	sodium	NN	I-NP	B	I-Chemical
deoxycholate	deoxycholate	NN	I-NP	I	I-Chemical
;	;	:	O	O	O
D	D	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
AmB	AmB	NN	B-NP	B	I-Chemical
)	)	)	O	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
using	use	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
cultures	culture	NNS	I-NP	O	O
and	and	CC	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
by	by	IN	B-PP	O	O
biochemical	biochemical	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
,	,	,	O	O	O
histopathological	histopathological	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
following	follow	VBG	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
formulation	formulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Incubation	Incubation	NN	B-NP	O	O
with	with	IN	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
718	718	CD	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
significantly	significantly	RB	B-NP	O	O
less	less	JJR	I-NP	O	O
damage	damage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cultured	culture	VBN	B-NP	O	O
human	human	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
proximal	proximal	JJ	I-NP	O	O
tubular	tubular	JJ	I-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
D	D	NN	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
AmB	AmB	NN	I-NP	B	I-Chemical
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
blood	blood	NN	I-NP	O	O
urea	urea	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
given	give	VBN	B-PP	O	O
an	an	DT	B-NP	O	O
iv	iv	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
D	D	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
AmB	AmB	NN	B-NP	B	I-Chemical
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
kg	kg	NN	B-NP	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
those	those	DT	B-NP	O	O
given	give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
718	718	CD	I-NP	O	O
.	.	.	O	O	O

Histopathological	Histopathological	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
tubular	tubular	JJ	B-NP	O	B-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
D	D	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
AmB	AmB	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
718	718	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Amphotericin	Amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
718	718	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
D	D	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
AmB	AmB	NN	I-NP	B	I-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
in	in	FW	I-NP	O	O
vitro	vitro	FW	I-NP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
incorporation	incorporation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
into	into	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
nanospheres	nanosphere	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
718	718	CD	I-NP	O	O
attenuates	attenuate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
amphotericin	amphotericin	NN	B-NP	B	B-Chemical
B	B	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Patterns	Pattern	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sulfadiazine	sulfadiazine	NN	B-NP	B	B-Chemical
acute	acute	JJ	I-NP	O	B-Disease
nephrotoxicity	nephrotoxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Sulfadiazine	Sulfadiazine	NN	B-NP	B	B-Chemical
acute	acute	JJ	I-NP	O	B-Disease
nephrotoxicity	nephrotoxicity	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
reviving	revive	VBG	I-VP	O	O
specially	specially	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
toxoplasmosis	toxoplasmosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
4	4	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
person	person	NN	I-NP	O	O
.	.	.	O	O	O

Under	Under	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
sulfadiazine	sulfadiazine	NN	B-NP	B	B-Chemical
they	they	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
oliguria	oliguria	NN	B-NP	O	B-Disease
,	,	,	O	O	O
abdominal	abdominal	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
showed	show	VBD	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
radiolucent	radiolucent	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
calculi	calculus	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
echography	echography	NN	B-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
recovered	recover	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
previous	previous	JJ	I-NP	O	O
normal	normal	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
after	after	IN	B-PP	O	O
adequate	adequate	JJ	B-NP	O	O
hydration	hydration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
alcalinization	alcalinization	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
nephrostomy	nephrostomy	NN	I-NP	O	O
tube	tube	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
placed	place	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
ureteral	ureteral	JJ	B-NP	O	B-Disease
lithiasis	lithiasis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
functional	functional	JJ	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
.	.	.	O	O	O

None	None	NN	B-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
needed	need	VBD	B-VP	O	O
dialysis	dialysis	NN	B-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
benign	benign	JJ	I-NP	O	O
course	course	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
sulfadiazine	sulfadiazine	NN	B-NP	B	B-Chemical
requires	require	VBZ	B-VP	O	O
exquisite	exquisite	NN	B-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
water	water	NN	B-NP	B	O
ingestion	ingestion	NN	I-NP	O	O
and	and	CC	O	O	O
possibly	possibly	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
alcalinization	alcalinization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
communicate	communicate	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
person	person	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
fact	fact	NN	I-NP	O	O
not	not	RB	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recent	recent	JJ	I-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

Probably	Probably	RB	B-NP	O	O
many	many	JJ	I-NP	O	O
more	more	JJR	I-NP	O	O
cases	case	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
think	think	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
.	.	.	O	O	O

Downbeat	Downbeat	NN	B-NP	O	B-Disease
nystagmus	nystagmus	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
controlled	control	VBN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

IMPLICATIONS	IMPLICATIONS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
documents	document	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
dizziness	dizziness	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
downbeating	downbeate	VBG	B-VP	O	B-Disease
nystagmus	nystagmus	NN	B-NP	O	I-Disease
while	while	IN	B-SBAR	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
large	large	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IV	IV	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
case	case	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epidural	epidural	JJ	B-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
previously	previously	RB	I-VP	O	O
documented	document	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
IV	IV	CD	B-NP	O	O
or	or	CC	O	O	O
patient	patient	NN	B-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Hemodynamic	Hemodynamic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
antiadrenergic	antiadrenergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dronedarone	dronedarone	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
amiodarone	amiodarone	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
healed	healed	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
antiadrenergic	antiadrenergic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dronedarone	dronedarone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
noniodinated	noniodinated	JJ	I-NP	O	O
compound	compound	NN	I-NP	O	O
structurally	structurally	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
after	after	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
oral	oral	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
both	both	CC	B-PP	O	O
at	at	IN	I-PP	O	O
rest	rest	NN	B-NP	O	O
and	and	CC	O	O	O
during	during	IN	B-PP	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
healed	healed	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

All	All	DT	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
randomly	randomly	RB	B-VP	O	O
received	receive	VBD	I-VP	O	O
orally	orally	RB	B-NP	O	O
dronedarone	dronedarone	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
washout	washout	NN	I-NP	O	O
between	between	IN	B-PP	O	O
consecutive	consecutive	JJ	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
.	.	.	O	O	O

Heart	Heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
HR	HR	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
MBP	MBP	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
positive	positive	JJ	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
increase	increase	NN	B-NP	O	O
of	of	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
LVdP	LVdP	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dt	dt	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
echocardiographically	echocardiographically	RB	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
(	(	(	O	O	O
LVEF	LVEF	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
fractional	fractional	JJ	B-NP	O	O
shortening	shortening	NN	I-NP	O	O
(	(	(	O	O	O
FS	FS	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
chronotropic	chronotropic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
exercise	exercise	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
under	under	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
and	and	CC	I-NP	O	O
posttreatment	posttreatment	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

Resting	Rest	VBG	B-VP	O	O
values	value	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
LVEF	LVEF	NN	B-NP	O	O
,	,	,	O	O	O
FS	FS	NN	B-NP	B	O
,	,	,	O	O	O
+	+	SYM	B-NP	O	O
LVdP	LVdP	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dt	dt	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
MBP	MBP	NN	B-NP	B	O
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
whatever	whatever	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dosing	dosing	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	B-PP	O	O
resting	rest	VBG	B-NP	O	O
HR	HR	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
and	and	CC	O	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	O	O	O
dependently	dependently	RB	B-VP	O	O
lowered	lower	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
dronedarone	dronedarone	NN	B-NP	B	B-Chemical
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
lesser	less	JJR	I-NP	O	O
extent	extent	NN	I-NP	O	O
after	after	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Both	Both	CC	O	O	O
dronedarone	dronedarone	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
amiodarone	amiodarone	NN	I-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
exercise	exercise	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
tachycardia	tachycardia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
dronedarone	dronedarone	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
amiodarone	amiodarone	NN	I-NP	B	B-Chemical
displayed	display	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antiadrenergic	antiadrenergic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
impair	impair	VB	I-VP	O	O
the	the	DT	B-NP	O	O
resting	resting	NN	I-NP	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Consequently	Consequently	RB	B-ADVP	O	O
,	,	,	O	O	O
dronedarone	dronedarone	NN	B-NP	B	B-Chemical
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
suitable	suitable	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
and	and	CC	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
without	without	IN	B-PP	O	O
compromising	compromise	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Phase	Phase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
(	(	(	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
platinum	platinum	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
refractory	refractory	JJ	I-NP	O	O
ovarian	ovarian	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
fallopian	fallopian	JJ	I-NP	O	I-Disease
tube	tube	NN	I-NP	O	I-Disease
cancers	cancer	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
primary	primary	JJ	B-NP	O	O
carcinoma	carcinoma	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
peritoneum	peritoneum	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Several	Several	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
(	(	(	O	O	O
Doxil	Doxil	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
antineoplastic	antineoplastic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
in	in	IN	B-PP	O	O
platinum	platinum	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
ovarian	ovarian	JJ	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
limiting	limit	VBG	B-VP	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
dosing	dosing	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
(	(	(	O	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
q	q	NN	B-NP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
being	be	VBG	B-VP	O	O
severe	severe	JJ	B-NP	O	O
erythrodysesthesia	erythrodysesthesia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
"	"	``	O	O	O
hand	hand	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
foot	foot	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
"	"	''	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
stomatitis	stomatitis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
wished	wish	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
develop	develop	VB	I-VP	O	O
a	a	DT	B-NP	O	O
more	more	RBR	I-NP	O	O
tolerable	tolerable	JJ	I-NP	O	O
liposomal	liposomal	JJ	I-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
treatment	treatment	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
and	and	CC	O	O	O
document	document	VB	B-VP	O	O
its	its	PRP$	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
defined	define	VBN	I-NP	O	O
patient	patient	NN	I-NP	O	O
population	population	NN	I-NP	O	O
with	with	IN	B-PP	O	O
platinum	platinum	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
refractory	refractory	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
MATERIALS	MATERIALS	NNS	I-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ovarian	ovarian	JJ	B-NP	O	B-Disease
or	or	CC	I-NP	O	I-Disease
fallopian	fallopian	JJ	I-NP	O	I-Disease
tube	tube	NN	I-NP	O	I-Disease
cancers	cancer	NNS	I-NP	O	I-Disease
or	or	CC	O	O	O
primary	primary	JJ	B-NP	O	O
peritoneal	peritoneal	JJ	I-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
platinum	platinum	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
refractory	refractory	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
(	(	(	O	O	O
stable	stable	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
progressive	progressive	JJ	I-NP	O	O
disease	disease	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
or	or	CC	O	O	O
previous	previous	JJ	B-NP	O	O
objective	objective	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
<	<	SYM	B-NP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
duration	duration	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
q	q	NN	B-NP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
49	49	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
median	median	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
:	:	:	O	O	O
60	60	CD	B-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
41	41	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
81	81	CD	I-NP	O	O
)	)	)	O	O	O
entered	enter	VBD	B-VP	O	O
this	this	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
2	2	CD	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
regimens	regimen	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
2	2	CD	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
:	:	:	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Six	Six	CD	B-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
4	4	CD	B-NP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
experienced	experience	VBD	B-VP	O	O
grade	grade	NN	B-NP	O	O
2	2	CD	I-NP	O	O
hand	hand	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
foot	foot	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
stomatitis	stomatitis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
(	(	(	O	O	O
no	no	DT	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
grade	grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
grade	grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
diarrhea	diarrhea	NN	I-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
for	for	IN	B-PP	O	O
hydration	hydration	NN	B-NP	O	O
.	.	.	O	O	O

Six	Six	CD	B-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
individuals	individual	NNS	B-NP	O	O
required	require	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
courses	course	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
administered	administer	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
this	this	DT	B-NP	O	O
protocol	protocol	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
2	2	CD	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
:	:	:	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
12	12	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
of	of	IN	B-PP	O	O
44	44	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
evaluable	evaluable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
response	response	NN	B-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
objective	objective	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
subjective	subjective	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antineoplastic	antineoplastic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
modified	modify	VBN	I-NP	O	O
liposomal	liposomal	JJ	I-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
regimen	regimen	NN	I-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
(	(	(	O	O	O
stomatitis	stomatitis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
hand	hand	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
foot	foot	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
)	)	)	O	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
FDA	FDA	NN	I-NP	B	O
-	-	HYPH	B-VP	O	O
approved	approve	VBN	B-NP	O	O
dose	dose	NN	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
.	.	.	O	O	O

Definite	Definite	NN	B-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
limited	limited	JJ	B-NP	O	O
,	,	,	I-NP	O	O
antineoplastic	antineoplastic	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
well	well	RB	B-ADVP	O	O
-	-	HYPH	I-ADVP	O	O
defined	define	VBN	B-NP	O	O
platinum	platinum	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
refractory	refractory	JJ	I-NP	O	O
ovarian	ovarian	JJ	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Efficacy	Efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
mania	mania	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Olanzipine	Olanzipine	NNP	I-NP	O	B-Chemical
HGGW	HGGW	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
Group	Group	NNP	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
vs	vs	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
mania	mania	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Four	Four	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
randomized	randomize	VBN	B-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
parallel	parallel	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
115	115	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
DSM	DSM	NN	I-NP	B	O
-	-	HYPH	O	O	O
IV	IV	CD	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
,	,	,	O	O	O
manic	manic	JJ	B-ADJP	O	B-Disease
or	or	CC	I-ADJP	O	O
mixed	mixed	JJ	I-ADJP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
5	5	CD	B-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
d	d	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
55	55	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
60	60	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
measure	measure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Young	Young	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Mania	Mania	NNP	I-NP	O	B-Disease
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
(	(	(	O	O	O
Y	Y	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
MRS	MRS	NN	I-NP	O	O
)	)	)	I-NP	O	O
total	total	JJ	I-NP	O	O
score	score	NN	I-NP	O	O
.	.	.	O	O	O

Response	Response	NN	B-NP	O	O
and	and	CC	I-NP	O	O
euthymia	euthymia	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
priori	priori	NNS	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
a	a	DT	B-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
improvement	improvement	NN	I-NP	O	O
from	from	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
to	to	TO	B-VP	O	O
end	end	VB	I-VP	O	O
point	point	NN	B-NP	O	O
and	and	CC	B-PP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
score	score	NN	I-NP	O	O
of	of	IN	B-PP	O	O
no	no	DT	B-NP	O	O
less	less	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
12	12	CD	I-NP	O	O
at	at	IN	B-PP	O	O
end	end	NN	B-NP	O	O
point	point	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Y	Y	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
MRS	MRS	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
score	score	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Safety	Safety	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
Extrapyramidal	Extrapyramidal	NNP	B-NP	O	B-Disease
Symptom	Symptom	NNP	I-NP	O	I-Disease
(	(	(	O	O	O
EPS	EPS	NNP	O	O	B-Disease
)	)	)	O	O	O
rating	rating	NN	B-NP	O	O
scales	scale	NNS	I-NP	O	O
,	,	,	O	O	O
laboratory	laboratory	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
,	,	,	O	O	O
electrocardiograms	electrocardiogram	NNS	B-NP	O	O
,	,	,	O	O	O
vital	vital	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
weight	weight	NN	B-NP	O	O
change	change	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Olanzapine	Olanzapine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
greater	great	JJR	I-NP	O	O
mean	mean	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	HYPH	B-NP	O	O
SD	SD	NN	I-NP	O	O
)	)	)	O	O	O
improvement	improvement	NN	B-NP	O	O
in	in	IN	B-PP	O	O
Y	Y	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MRS	MRS	NN	I-NP	O	O
total	total	JJ	I-NP	O	O
score	score	NN	I-NP	O	O
than	than	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
14.8	14.8	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
12.5	12.5	CD	B-NP	O	O
and	and	CC	O	O	O
-	-	SYM	B-NP	O	O
8.1	8.1	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
12.7	12.7	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.001	.001	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
postbaseline	postbaseline	NN	I-NP	O	O
observation	observation	NN	I-NP	O	O
1	1	CD	I-NP	O	O
week	week	NN	I-NP	O	O
after	after	IN	B-PP	O	O
randomization	randomization	NN	B-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
last	last	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
carried	carry	VBD	B-VP	O	O
forward	forward	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
(	(	(	O	O	O
65	65	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.02	.02	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
euthymia	euthymia	NN	B-NP	O	O
(	(	(	O	O	O
61	61	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
36	36	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	JJ	I-NP	O	O
.	.	.	O	O	O

01	01	LS	B-LST	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
EPSs	EPS	NNS	B-NP	O	B-Disease
between	between	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
greater	great	JJR	I-NP	O	O
mean	mean	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	O	O	O
-	-	HYPH	B-NP	O	O
SD	SD	NN	I-NP	O	O
)	)	)	O	O	O
weight	weight	NN	B-NP	O	B-Disease
gain	gain	NN	I-NP	O	I-Disease
than	than	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
2.1	2.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.8	2.8	CD	B-NP	O	O
vs	vs	IN	B-PP	O	O
0.45	0.45	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
2.3	2.3	CD	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
also	also	RB	B-ADVP	O	O
experienced	experience	VBD	B-VP	O	O
more	more	JJR	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
-	-	HYPH	O	O	O
emergent	emergent	NN	B-NP	O	O
somnolence	somnolence	NN	I-NP	O	B-Disease
(	(	(	O	O	O
21	21	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
[	[	(	O	O	O
38.2	38.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
]	]	)	O	O	O
vs	vs	IN	B-PP	O	O
5	5	CD	B-NP	O	O
[	[	(	O	O	O
8.3	8.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Olanzapine	Olanzapine	NN	B-NP	B	B-Chemical
demonstrated	demonstrate	VBD	B-VP	O	O
greater	great	JJR	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
than	than	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
mania	mania	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
generally	generally	RB	I-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pupil	pupil	NN	B-NP	O	B-Disease
dilation	dilation	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
tropicamide	tropicamide	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
vision	vision	NN	B-NP	O	O
and	and	CC	O	O	O
driving	drive	VBG	B-VP	O	O
simulator	simulator	NN	B-NP	O	O
performance	performance	NN	I-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pupil	pupil	NN	B-NP	O	B-Disease
dilation	dilation	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
vision	vision	NN	B-NP	O	O
and	and	CC	O	O	O
driving	drive	VBG	B-VP	O	O
ability	ability	NN	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
series	series	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tests	test	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
driving	drive	VBG	B-VP	O	O
simulator	simulator	NN	B-NP	O	O
performance	performance	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
12	12	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
drivers	driver	NNS	I-NP	O	O
,	,	,	O	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
pupil	pupil	NN	B-NP	O	B-Disease
dilation	dilation	NN	I-NP	O	I-Disease
using	use	VBG	B-VP	O	O
guttae	gutta	NNS	B-NP	O	O
tropicamide	tropicamide	NN	I-NP	B	B-Chemical
1	1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
driving	drive	VBG	I-NP	O	O
simulator	simulator	NN	I-NP	O	O
(	(	(	O	O	O
Transport	Transport	NNP	B-NP	O	O
Research	Research	NNP	I-NP	O	O
Laboratory	Laboratory	NNP	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
reaction	reaction	NN	B-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
RT	RT	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
speed	speed	NN	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
steering	steering	NN	I-NP	O	O
accuracy	accuracy	NN	I-NP	O	O
.	.	.	O	O	O

Tests	Test	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
basic	basic	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
included	include	VBD	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
contrast	contrast	NN	I-NP	O	O
visual	visual	JJ	I-NP	O	O
acuity	acuity	NN	I-NP	O	O
(	(	(	O	O	O
HCVA	HCVA	NN	B-NP	O	O
and	and	CC	O	O	O
LCVA	LCVA	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
Pelli	Pelli	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Robson	Robson	NNP	I-NP	O	O
contrast	contrast	NN	I-NP	O	O
threshold	threshold	NN	I-NP	O	O
(	(	(	O	O	O
CT	CT	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
Goldmann	Goldmann	NNP	B-NP	O	O
perimetry	perimetry	NN	I-NP	O	O
(	(	(	O	O	O
FIELDS	FIELDS	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Useful	Useful	NNP	B-NP	O	O
Field	Field	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
View	View	NNP	B-NP	O	O
(	(	(	O	O	O
UFOV	UFOV	NN	B-NP	O	O
-	-	HYPH	B-ADJP	O	O
-	-	:	O	O	O
a	a	DT	B-NP	O	O
test	test	NN	I-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
dilatation	dilatation	NN	I-NP	O	O
measurements	measurement	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
statistical	statistical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
95	95	CD	I-NP	O	O
%	%	NN	I-NP	O	O
level	level	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
tail	tail	NN	I-NP	O	O
paired	paired	JJ	I-NP	O	O
t	t	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
tests	test	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Pupillary	Pupillary	JJ	B-NP	O	B-Disease
dilation	dilation	NN	I-NP	O	I-Disease
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
CT	CT	NN	B-NP	B	O
and	and	CC	I-NP	O	O
HCVA	HCVA	NN	I-NP	O	O
only	only	RB	B-ADVP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
drivers	driver	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
exhibited	exhibit	VBD	B-VP	O	O
deterioration	deterioration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
LCVA	LCVA	NN	B-NP	O	O
,	,	,	I-NP	O	O
CT	CT	NN	I-NP	B	O
and	and	CC	I-NP	O	O
RT	RT	NN	I-NP	B	O
.	.	.	O	O	O

Little	Little	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
emerged	emerge	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
deterioration	deterioration	NN	B-NP	O	O
in	in	IN	B-PP	O	O
FIELDS	FIELDS	NN	B-NP	O	O
and	and	CC	I-NP	O	O
UFOV	UFOV	NN	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
7	7	CD	B-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
drivers	driver	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
adjust	adjust	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
driving	driving	NN	I-NP	O	O
behaviour	behaviour	NN	I-NP	O	O
by	by	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
speed	speed	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
driving	drive	VBG	I-NP	O	O
simulator	simulator	NN	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
improved	improve	VBN	B-NP	O	O
steering	steering	NN	I-NP	O	O
accuracy	accuracy	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Pupillary	Pupillary	JJ	B-NP	O	B-Disease
dilation	dilation	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
vision	vision	NN	B-NP	O	O
and	and	CC	I-NP	O	O
daylight	daylight	NN	I-NP	O	O
driving	drive	VBG	B-VP	O	O
performance	performance	NN	B-NP	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
people	people	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
larger	large	JJR	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
broader	broad	JJR	I-NP	O	O
spectrum	spectrum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
before	before	IN	B-SBAR	O	O
guidelines	guideline	NNS	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isotretinoin	isotretinoin	NN	B-NP	B	B-Disease
embryopathy	embryopathy	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
anotia	anotia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
Taussig	Taussig	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
Bing	Be	VBG	B-VP	O	I-Disease
malformation	malformation	NN	B-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
newborn	newborn	JJ	I-NP	O	O
infant	infant	NN	I-NP	O	O
with	with	IN	B-PP	O	O
multiple	multiple	JJ	B-NP	O	O
congenital	congenital	JJ	I-NP	O	O
anomalies	anomaly	NNS	I-NP	O	O
(	(	(	O	O	O
anotia	anotia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
Taussig	Taussig	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
Bing	Be	VBG	B-VP	O	I-Disease
malformation	malformation	NN	B-NP	O	I-Disease
)	)	)	O	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
isotretinoin	isotretinoin	NN	B-NP	B	B-Chemical
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
trimester	trimester	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
aim	aim	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
draw	draw	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
fact	fact	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
caution	caution	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
prescribing	prescribe	VBG	B-VP	O	O
vitamin	vitamin	NN	B-NP	B	B-Chemical
A	A	NN	I-NP	I	I-Chemical
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
drugs	drug	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
women	woman	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
childbearing	childbeare	VBG	B-VP	O	O
years	year	NNS	B-NP	O	O
.	.	.	O	O	O

Effect	Effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
methoxamine	methoxamine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
maximum	maximum	JJ	B-NP	O	O
urethral	urethral	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
genuine	genuine	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	B-Disease
incontinence	incontinence	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
double	double	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
crossover	crossover	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
alpha1	alpha1	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	B-Disease
stress	stress	NN	I-NP	O	I-Disease
incontinence	incontinence	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
randomised	randomise	VBN	I-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
crossover	crossover	NN	B-NP	O	O
study	study	NN	I-NP	O	O
design	design	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
employed	employ	VBN	I-VP	O	O
.	.	.	O	O	O

Half	Half	NN	B-NP	O	O
log	log	NN	I-NP	O	O
incremental	incremental	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
methoxamine	methoxamine	NN	I-NP	B	B-Chemical
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
(	(	(	O	O	O
saline	saline	NN	B-NP	B	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
genuine	genuine	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	B-Disease
incontinence	incontinence	NN	I-NP	O	I-Disease
while	while	IN	B-SBAR	O	O
measuring	measure	VBG	B-VP	O	O
maximum	maximum	JJ	B-NP	O	O
urethral	urethral	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
MUP	MUP	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
symptomatic	symptomatic	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Methoxamine	Methoxamine	NN	B-NP	B	B-Chemical
evoked	evoke	VBD	B-VP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
MUP	MUP	NN	B-NP	O	O
and	and	CC	O	O	O
diastolic	diastolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
but	but	CC	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	B-Disease
significant	significant	JJ	I-NP	O	I-Disease
rise	rise	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	I-Disease
systolic	systolic	JJ	B-NP	O	I-Disease
blood	blood	NN	I-NP	O	I-Disease
pressure	pressure	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
significant	significant	JJ	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
at	at	IN	B-PP	O	O
maximum	maximum	JJ	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
piloerection	piloerection	NN	B-NP	O	O
,	,	,	O	O	O
headache	headache	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
cold	cold	JJ	B-NP	O	O
extremities	extremity	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
experienced	experience	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
usefulness	usefulness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
direct	direct	JJ	B-NP	O	O
,	,	,	O	O	O
peripherally	peripherally	RB	B-VP	O	O
acting	act	VBG	I-VP	O	O
sub	sub	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
selective	selective	JJ	I-NP	O	O
alpha1	alpha1	NN	I-NP	O	O
-	-	HYPH	O	O	O
adrenoceptor	adrenoceptor	NN	B-NP	O	O
agonists	agonist	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stress	stress	NN	B-NP	O	B-Disease
incontinence	incontinence	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
limited	limit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
associated	associate	VBN	B-NP	O	O
piloerection	piloerection	NN	I-NP	O	O
and	and	CC	O	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Toleration	Toleration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
converting	convert	VBG	B-VP	O	I-Chemical
enzyme	enzyme	NN	B-NP	O	I-Chemical
inhibitors	inhibitor	NNS	I-NP	O	I-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
:	:	:	O	O	O
results	result	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ATLAS	ATLAS	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Assessment	Assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
Lisinopril	Lisinopril	NNP	B-NP	B	B-Chemical
and	and	CC	O	O	O
Survival	Survival	NN	B-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
converting	convert	VBG	B-VP	O	I-Chemical
enzyme	enzyme	NN	B-NP	O	I-Chemical
(	(	(	O	O	I-Chemical
ACE	ACE	NN	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
inhibitors	inhibitor	NNS	B-NP	O	I-Chemical
reduces	reduce	VBZ	B-VP	O	O
mortality	mortality	NN	B-NP	O	O
and	and	CC	I-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CHF	CHF	NN	B-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
most	most	JJS	B-VP	O	O
affected	affect	VBN	I-VP	O	O
patients	patient	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
receiving	receive	VBG	I-VP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
or	or	CC	O	O	O
are	be	VBP	B-VP	O	O
being	be	VBG	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
found	find	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
efficacious	efficacious	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
trials	trial	NNS	B-NP	O	O
,	,	,	O	O	O
primarily	primarily	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
concerns	concern	NNS	B-NP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
examines	examine	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
lisinopril	lisinopril	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
CHF	CHF	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
Assessment	Assessment	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Lisinopril	Lisinopril	NNP	B-NP	B	B-Chemical
and	and	CC	O	O	O
Survival	Survival	NN	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
multicenter	multicenter	NN	I-NP	O	O
,	,	,	O	O	O
randomized	randomize	VBN	B-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-Chemical
inhibitor	inhibitor	NN	I-NP	O	I-Chemical
treatment	treatment	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
stabilized	stabilize	VBN	I-VP	O	O
receiving	receive	VBG	B-VP	O	O
medium	medium	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
lisinopril	lisinopril	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
12.5	12.5	CD	B-NP	O	O
or	or	CC	I-NP	O	O
15.0	15.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
[	[	(	O	O	O
OD	OD	NN	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
to	to	TO	I-NP	O	O
4	4	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	O	O	O
then	then	RB	B-VP	O	O
randomized	randomize	VBD	I-VP	O	O
to	to	TO	B-PP	O	O
high	high	JJ	O	O	O
-	-	HYPH	O	O	O
(	(	(	O	O	O
35.0	35.0	CD	B-NP	O	O
or	or	CC	I-NP	O	O
32.5	32.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
OD	OD	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
5.0	5.0	CD	B-NP	O	O
or	or	CC	I-NP	O	O
2.5	2.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
OD	OD	NN	I-NP	O	O
)	)	)	O	O	O
groups	group	NNS	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
New	New	NNP	B-NP	O	O
York	York	NNP	I-NP	O	O
Heart	Heart	NNP	I-NP	O	O
Association	Association	NNP	I-NP	O	O
classes	class	NNS	I-NP	O	O
II	II	CD	I-NP	O	O
to	to	TO	I-NP	O	O
IV	IV	CD	I-NP	O	O
CHF	CHF	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
ejection	ejection	NN	I-NP	O	O
fractions	fraction	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
no	no	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
0.30	0.30	CD	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
3164	3164	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
and	and	CC	O	O	O
followed	follow	VBN	B-VP	O	O
up	up	RP	B-PRT	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	NN	I-NP	O	O
of	of	IN	B-PP	O	O
46	46	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
and	and	CC	I-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
focus	focus	NN	I-NP	O	O
on	on	IN	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Of	Of	IN	B-PP	O	O
405	405	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
not	not	RB	O	O	O
previously	previously	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
an	an	DT	B-NP	O	O
ACE	ACE	NN	I-NP	O	B-Chemical
inhibitor	inhibitor	NN	I-NP	O	I-Chemical
,	,	,	O	O	O
doses	dose	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
only	only	RB	B-NP	O	O
4.2	4.2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
could	could	MD	B-VP	O	O
not	not	RB	I-VP	O	O
be	be	VB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
medium	medium	NN	I-NP	O	O
doses	dose	NNS	I-NP	O	O
required	require	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
randomization	randomization	NN	B-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
possibly	possibly	RB	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
(	(	(	O	O	O
2.0	2.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
2.3	2.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Doses	Dose	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
90	90	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
randomized	randomize	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
assigned	assign	VBN	I-NP	O	O
target	target	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
blinded	blinded	JJ	B-NP	O	O
medication	medication	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
remained	remain	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
throughout	throughout	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Withdrawals	Withdrawal	NNS	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
27.1	27.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	O	O	O
30.7	30.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Subgroups	Subgroup	NNS	B-NP	O	O
presumed	presume	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ACE	ACE	NN	B-NP	O	B-Chemical
inhibitor	inhibitor	NN	I-NP	O	I-Chemical
intolerance	intolerance	NN	I-NP	O	O
(	(	(	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
<	<	SYM	B-NP	O	O
120	120	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
;	;	:	O	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
132.6	132.6	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
[	[	(	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
1.5	1.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
]	]	)	O	O	O
;	;	:	O	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
70	70	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	B-Disease
)	)	)	O	O	O
generally	generally	RB	B-ADVP	O	O
tolerated	tolerate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
strategy	strategy	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
ACE	ACE	NN	B-NP	O	B-Chemical
inhibitor	inhibitor	NN	I-NP	O	I-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
CHF	CHF	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
successfully	successfully	RB	I-VP	O	O
titrated	titrate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
and	and	CC	O	O	O
maintained	maintain	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
more	more	RBR	B-NP	O	O
aggressive	aggressive	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

Cocaine	Cocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
ethanol	ethanol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
cocaethylene	cocaethylene	NN	B-NP	B	B-Chemical
cardiotoxity	cardiotoxity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Disease
and	and	CC	I-NP	O	I-Disease
ethanol	ethanol	NN	I-NP	B	I-Disease
abuse	abuse	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
Simultaneous	Simultaneous	JJ	B-NP	O	O
abuse	abuse	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
cocaine	cocaine	NN	B-NP	B	I-Disease
and	and	CC	I-NP	O	I-Disease
ethanol	ethanol	NN	I-NP	B	I-Disease
affects	affect	VBZ	B-VP	O	O
12	12	CD	B-NP	O	O
million	million	CD	I-NP	O	O
Americans	American	NNPS	I-NP	O	O
annually	annually	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
substances	substance	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
substantially	substantially	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Their	Their	PRP$	B-NP	O	O
combined	combined	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
independent	independent	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
cocaethylene	cocaethylene	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CE	CE	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
metabolite	metabolite	NN	I-NP	O	O
formed	form	VBN	B-VP	O	O
only	only	RB	B-PP	O	O
in	in	IN	I-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
delineate	delineate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CE	CE	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
ethanol	ethanol	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
simulating	simulate	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
abuse	abuse	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
three	three	CD	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
either	either	CC	O	O	O
1	1	CD	B-NP	O	O
)	)	)	O	O	O
three	three	CD	B-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
(	(	(	O	O	O
IV	IV	CD	O	O	O
)	)	)	O	O	O
boluses	bolus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
7.5	7.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ethanol	ethanol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
IV	IV	CD	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
(	(	(	O	O	O
C	C	NN	B-NP	O	O
+	+	SYM	O	O	O
E	E	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
three	three	CD	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
boluses	bolus	NNS	I-NP	O	O
only	only	RB	B-ADVP	O	O
(	(	(	O	O	O
C	C	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	JJ	B-VP	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
3	3	LS	B-LST	O	O
)	)	)	O	O	O
ethanol	ethanol	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
only	only	RB	B-ADVP	O	O
(	(	(	O	O	O
E	E	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
5	5	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
4	4	CD	O	O	O
)	)	)	O	O	O
placebo	placebo	NN	B-NP	O	O
boluses	bolus	NNS	I-NP	O	O
and	and	CC	O	O	O
infusion	infusion	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Hemodynamic	Hemodynamic	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
,	,	,	O	O	O
electrocardiograms	electrocardiogram	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
serum	serum	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
then	then	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
fixed	fix	VBN	B-NP	O	O
time	time	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
each	each	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Two	Two	CD	B-NP	O	O
of	of	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
E	E	NN	I-NP	O	O
group	group	NN	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
collapse	collapse	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
dramatic	dramatic	JJ	I-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
after	after	IN	B-SBAR	O	O
each	each	DT	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
bolus	bolus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
+	+	SYM	B-VP	O	O
E	E	NN	B-NP	O	O
and	and	CC	I-NP	O	O
C	C	NN	I-NP	O	O
only	only	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
persistent	persistent	JJ	B-NP	O	O
hemodynamic	hemodynamic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
E	E	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Peak	Peak	JJ	B-NP	O	O
CE	CE	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
45	45	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
SD	SD	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
69	69	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
decrease	decrease	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
cardiac	cardiac	JJ	B-NP	O	I-Disease
output	output	NN	I-NP	O	I-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
56	56	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
SD	SD	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
32	32	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
80	80	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
decrease	decrease	NN	B-NP	O	O
in	in	IN	B-PP	O	O
dP	dP	NN	B-NP	O	O
/	/	SYM	O	O	O
dt	dt	NN	B-NP	O	O
(	(	(	O	O	O
max	max	NN	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.006	.006	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
23	23	CD	I-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
SD	SD	NN	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
49	49	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
decrease	decrease	NN	B-NP	O	O
in	in	IN	B-PP	O	O
SVO	SVO	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
0.025	0.025	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Ventricular	Ventricular	JJ	B-NP	O	B-Disease
arrhythmias	arrhythmia	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
primarily	primarily	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
E	E	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
four	four	CD	B-NP	O	O
of	of	IN	I-NP	O	O
eight	eight	CD	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Cocaine	Cocaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
ethanol	ethanol	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
toxic	toxic	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
either	either	DT	B-NP	O	O
substance	substance	NN	I-NP	O	O
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Co	Co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
dysrhythmogenic	dysrhythmogenic	JJ	B-ADJP	O	O
.	.	.	O	O	O

Peak	Peak	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
cocaethylene	cocaethylene	NN	I-NP	B	B-Chemical
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Worsening	Worsening	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Parkinsonism	Parkinsonism	NNP	B-NP	O	B-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
veralipride	veralipride	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
menopause	menopause	NN	B-NP	O	O
:	:	:	O	O	O
case	case	NN	B-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
female	female	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
worsening	worsening	NN	I-NP	O	O
of	of	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
motor	motor	NN	I-NP	O	O
functions	function	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
menopause	menopause	NN	B-NP	O	O
related	relate	VBN	B-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
veralipride	veralipride	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
back	back	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
emphasize	emphasize	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
veralipride	veralipride	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Viracept	Viracept	JJ	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
irregular	irregular	JJ	I-NP	O	B-Disease
heartbeat	heartbeat	NN	I-NP	O	I-Disease
warning	warning	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doctors	doctor	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
Boston	Boston	NNP	B-NP	O	O
warn	warn	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
protease	protease	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
Viracept	Viracept	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
an	an	DT	B-NP	O	O
irregular	irregular	JJ	I-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
beat	beat	NN	I-NP	O	I-Disease
,	,	,	O	O	O
known	know	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
in	in	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
.	.	.	O	O	O

Bradycardia	Bradycardia	NNP	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
45	45	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
was	be	VBD	B-VP	O	O
Viracept	Viracept	VBN	I-VP	B	B-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
HIV	HIV	NN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
ceased	cease	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
another	another	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
.	.	.	O	O	O

Frequency	Frequency	NN	B-NP	O	O
of	of	IN	B-PP	O	O
appearance	appearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
myeloperoxidase	myeloperoxidase	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
antineutrophil	antineutrophil	NN	I-NP	O	O
cytoplasmic	cytoplasmic	JJ	I-NP	O	O
antibody	antibody	NN	I-NP	O	O
(	(	(	O	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
Graves	Graves	NN	B-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
propylthiouracil	propylthiouracil	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Myeloperoxidase	Myeloperoxidase	NN	B-NP	O	O
antineutrophil	antineutrophil	NN	I-NP	O	O
cytoplasmic	cytoplasmic	JJ	I-NP	O	O
antibody	antibody	NN	I-NP	O	O
(	(	(	O	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
positive	positive	JJ	I-NP	O	O
vasculitis	vasculitis	NN	I-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Graves	Graves	NN	B-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
propylthiouracil	propylthiouracil	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
suspected	suspect	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
titres	titre	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
decreased	decrease	VBD	B-VP	O	O
when	when	WRB	B-ADVP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
no	no	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
temporal	temporal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
and	and	CC	I-NP	O	O
vasculitis	vasculitis	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
in	in	IN	B-PP	O	O
untreated	untreated	JJ	B-NP	O	O
Graves	Graves	NN	I-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
sought	seek	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
address	address	VB	I-VP	O	O
these	these	DT	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Graves	Graves	NN	B-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
102	102	CD	B-NP	O	O
untreated	untreated	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O	B-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Graves	Graves	NN	B-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
,	,	,	O	O	O
and	and	CC	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
vasculitis	vasculitis	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nine	nine	CD	I-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
later	later	RB	I-VP	O	O
excluded	exclude	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
3	3	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
remaining	remain	VBG	I-NP	O	O
73	73	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
55	55	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
and	and	CC	O	O	O
18	18	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
3	3	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
adopted	adopt	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
23.6	23.6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
:	:	:	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
37	37	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

MEASUREMENTS	MEASUREMENTS	NNS	B-NP	O	O
:	:	:	O	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
intervals	interval	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Before	Before	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
MPO	MPO	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
titres	titre	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
102	102	CD	I-NP	O	O
untreated	untreated	JJ	I-NP	O	O
Graves	Graves	NN	I-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
reference	reference	NN	I-NP	O	O
range	range	NN	I-NP	O	O
(	(	(	O	O	O
below	below	IN	B-PP	O	O
10	10	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
(	(	(	O	O	O
4.1	4.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
73	73	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
at	at	IN	B-PP	O	O
13	13	CD	B-NP	O	O
,	,	,	I-NP	O	O
16	16	CD	I-NP	O	O
and	and	CC	I-NP	O	O
17	17	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
start	start	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
two	two	CD	B-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
MPO	MPO	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
titres	titre	NNS	I-NP	O	O
transiently	transiently	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
12.8	12.8	CD	B-NP	O	O
and	and	CC	I-NP	O	O
15.0	15.0	CD	I-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	O	O	O
ml	ml	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
continued	continue	VBN	B-NP	O	O
PTU	PTU	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
vasculitic	vasculitic	JJ	I-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
developed	develop	VBD	B-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
MPO	MPO	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
titre	titre	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
204	204	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
and	and	CC	O	O	O
she	she	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
fever	fever	NN	I-NP	O	B-Disease
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	B-Disease
ulcers	ulcer	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
polyarthralgia	polyarthralgia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
resolved	resolve	VBD	B-VP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
stopping	stop	VBG	B-VP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
MPO	MPO	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
titre	titre	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
20.7	20.7	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	O	O	O
ml	ml	NN	B-NP	O	O
by	by	IN	B-PP	O	O
4	4	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
,	,	,	O	O	O
but	but	CC	O	O	O
MPO	MPO	NN	B-NP	O	O
-	-	HYPH	O	O	O
ANCA	ANCA	NN	B-NP	B	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
closely	closely	RB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
vasculitis	vasculitis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Prevalence	Prevalence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
asymptomatic	asymptomatic	JJ	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
outpatient	outpatient	NN	B-NP	O	O
young	young	JJ	I-NP	O	O
asymptomatic	asymptomatic	JJ	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
35	35	CD	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
and	and	CC	O	O	O
32	32	CD	B-NP	O	O
age	age	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
matched	match	VBN	I-NP	B	O
controls	control	NNS	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
resting	rest	VBG	I-VP	O	O
and	and	CC	O	O	O
exercise	exercise	NN	B-NP	O	O
electrocardiography	electrocardiography	NN	I-NP	O	O
(	(	(	O	O	O
ECG	ECG	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Doppler	Doppler	NN	B-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
.	.	.	O	O	O

Findings	Finding	NNS	B-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
(	(	(	O	O	O
34	34	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
(	(	NN	I-NP	O	O
9	9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
controls	control	NNS	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Decreased	Decrease	VBN	B-VP	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
systolic	systolic	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
in	in	IN	B-PP	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
controls	control	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.055	0.055	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Finally	Finally	RB	B-ADVP	O	O
,	,	,	O	O	O
resting	rest	VBG	B-NP	O	O
and	and	CC	I-NP	O	O
peak	peak	JJ	I-NP	O	O
exercise	exercise	NN	I-NP	O	O
abnormal	abnormal	JJ	I-NP	O	B-Disease
left	left	JJ	I-NP	O	I-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
filling	filling	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
38	38	CD	B-NP	O	O
and	and	CC	I-NP	O	O
35	35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
19	19	CD	B-NP	O	O
and	and	CC	I-NP	O	O
9	9	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.11	0.11	CD	B-NP	O	O
and	and	CC	I-NP	O	O
0.02	0.02	CD	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
or	or	CC	O	O	I-Disease
myocardial	myocardial	JJ	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
common	common	JJ	B-ADJP	O	O
(	(	(	O	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
young	young	JJ	B-NP	O	O
asymptomatic	asymptomatic	JJ	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
screening	screen	VBG	B-VP	O	O
ECG	ECG	NN	B-NP	O	O
and	and	CC	I-NP	O	O
echocardiography	echocardiography	NN	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warranted	warrant	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Cardioprotective	Cardioprotective	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Picrorrhiza	Picrorrhiza	NNP	B-NP	O	O
kurroa	kurroa	NN	I-NP	O	O
against	against	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cardioprotective	cardioprotective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ethanol	ethanol	NN	I-NP	B	B-Chemical
extract	extract	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Picrorrhiza	Picrorrhiza	NNP	B-NP	O	O
kurroa	kurroa	NN	I-NP	O	O
rhizomes	rhizome	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
roots	root	NNS	I-NP	O	O
(	(	(	O	O	O
PK	PK	NN	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	O	O	O
pre	pre	AFX	O	O	O
-	-	HYPH	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PK	PK	NN	B-NP	O	O
(	(	(	O	O	O
80	80	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
day	day	NN	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
15	15	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
significantly	significantly	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
maintained	maintain	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
near	near	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
.	.	.	O	O	O

Phase	Phase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
early	early	JJ	I-NP	O	O
afterdepolarization	afterdepolarization	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
trigger	trigger	NN	I-NP	O	O
of	of	IN	B-PP	O	O
polymorphic	polymorphic	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
acquired	acquire	VBN	B-NP	O	O
long	long	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
QT	QT	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
:	:	:	O	O	O
direct	direct	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
from	from	IN	B-PP	O	O
intracellular	intracellular	JJ	B-NP	O	O
recordings	recording	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
intact	intact	JJ	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
wall	wall	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phase	phase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
early	early	JJ	I-NP	O	O
afterdepolarization	afterdepolarization	NN	I-NP	O	O
(	(	(	O	O	O
EAD	EAD	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
producing	produce	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
trigger	trigger	NN	I-NP	O	O
to	to	TO	B-VP	O	O
initiate	initiate	VB	I-VP	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
(	(	(	O	O	O
TdP	TdP	NN	B-NP	O	B-Disease
)	)	)	O	O	O
with	with	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
dl	dl	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sotalol	sotalol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
azimilide	azimilide	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transmural	transmural	JJ	B-NP	O	O
dispersion	dispersion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
repolarization	repolarization	NN	B-NP	O	O
(	(	(	O	O	O
TDR	TDR	NN	B-NP	B	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
transmural	transmural	JJ	B-NP	O	O
propagation	propagation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EAD	EAD	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
maintenance	maintenance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
Transmembrane	Transmembrane	NN	B-NP	O	O
action	action	NN	I-NP	O	O
potentials	potential	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
epicardium	epicardium	NN	B-NP	O	O
,	,	,	O	O	O
midmyocardium	midmyocardium	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
endocardium	endocardium	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
transmural	transmural	JJ	I-NP	O	O
ECG	ECG	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
arterially	arterially	RB	B-NP	O	O
perfused	perfuse	VBN	I-NP	O	O
canine	canine	NN	I-NP	O	O
and	and	CC	I-NP	O	O
rabbit	rabbit	NN	I-NP	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
preparations.	preparations.	JJ	I-NP	O	O
dl	dl	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Sotalol	Sotalol	NN	I-NP	B	B-Chemical
preferentially	preferentially	RB	B-ADVP	O	O
prolonged	prolong	VBD	B-VP	O	O
action	action	NN	B-NP	O	O
potential	potential	NN	I-NP	O	O
duration	duration	NN	I-NP	O	O
(	(	(	O	O	O
APD	APD	NN	B-NP	B	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
M	M	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
dependently	dependently	RB	B-ADVP	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
to	to	TO	O	O	O
100	100	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
TDR	TDR	NN	B-NP	B	O
.	.	.	O	O	O

Azimilide	Azimilide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
significantly	significantly	RB	B-VP	O	O
prolonged	prolong	VBD	I-VP	O	O
APD	APD	NN	B-NP	B	O
and	and	CC	I-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
0.1	0.1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
L	L	NN	I-NP	O	O
but	but	CC	O	O	O
shortened	shorten	VBD	B-VP	O	O
them	them	PRP	B-NP	O	O
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

Unlike	Unlike	IN	B-PP	O	O
dl	dl	NN	B-NP	O	O
-	-	HYPH	O	O	O
sotalol	sotalol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
azimilide	azimilide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
3	3	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
epicardial	epicardial	JJ	B-NP	O	O
APD	APD	NN	I-NP	B	O
markedly	markedly	RB	B-ADVP	O	O
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
diminished	diminished	JJ	I-NP	O	O
TDR	TDR	NN	I-NP	B	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
both	both	CC	O	O	O
dl	dl	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sotalol	sotalol	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
azimilide	azimilide	NN	I-NP	B	B-Chemical
rarely	rarely	RB	B-ADVP	O	O
induced	induce	VBD	B-VP	O	O
EADs	EAD	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
canine	canine	JJ	B-NP	O	O
left	left	JJ	I-NP	O	O
ventricles	ventricle	NNS	I-NP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
produced	produce	VBD	B-VP	O	O
frequent	frequent	JJ	B-NP	O	O
EADs	EAD	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rabbits	rabbit	NNS	B-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
more	more	RBR	B-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
QT	QT	NN	I-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
TDR	TDR	NN	B-NP	B	O
by	by	IN	B-PP	O	O
dl	dl	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sotalol	sotalol	NN	I-NP	B	B-Chemical
facilitated	facilitate	VBD	B-VP	O	O
transmural	transmural	JJ	B-NP	O	O
propagation	propagation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
EADs	EAD	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
initiated	initiate	VBD	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
TdP	TdP	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
rabbit	rabbit	NN	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricles	ventricle	NNS	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
note	note	NN	B-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
azimilide	azimilide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3	3	CD	B-NP	O	O
to	to	TO	I-NP	O	O
10	10	CD	I-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
L	L	NN	I-NP	O	O
)	)	)	O	O	O
increased	increase	VBD	B-VP	O	O
APD	APD	NN	B-NP	B	O
more	more	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
dl	dl	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
sotalol	sotalol	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
EADs	EAD	NNS	I-NP	O	O
often	often	RB	B-ADVP	O	O
failed	fail	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
propagate	propagate	VB	I-VP	O	O
transmurally	transmurally	RB	B-ADVP	O	O
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
diminished	diminished	JJ	I-NP	O	O
TDR	TDR	NN	I-NP	B	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
provides	provide	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
direct	direct	JJ	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
from	from	IN	B-PP	O	O
intracellular	intracellular	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
recordings	recording	NNS	I-NP	O	O
that	that	IN	B-SBAR	O	O
phase	phase	NN	B-NP	O	O
2	2	CD	I-NP	O	O
EAD	EAD	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
generated	generate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
intact	intact	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
wall	wall	NN	I-NP	O	O
and	and	CC	O	O	O
produce	produce	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
trigger	trigger	NN	I-NP	O	O
to	to	TO	B-VP	O	O
initiate	initiate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TdP	TdP	NN	B-NP	O	B-Disease
under	under	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Prenatal	Prenatal	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
cranial	cranial	JJ	B-NP	O	O
sonographic	sonographic	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
preterm	preterm	JJ	B-NP	O	B-Disease
infants	infant	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
Prenatal	Prenatal	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
linked	link	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
subependymal	subependymal	JJ	B-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cysts	cyst	NNS	B-NP	O	B-Disease
that	that	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
detectable	detectable	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
cranial	cranial	JJ	B-NP	O	O
sonography	sonography	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neonates	neonate	NNS	B-NP	O	O
born	bear	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
term	term	NN	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
sought	seek	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
prenatal	prenatal	JJ	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subependymal	subependymal	JJ	B-NP	O	B-Disease
cysts	cyst	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
preterm	preterm	JJ	B-NP	O	B-Disease
infants	infant	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
reviewed	review	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
records	record	NNS	I-NP	O	O
and	and	CC	O	O	O
cranial	cranial	JJ	B-NP	O	O
sonograms	sonogram	NNS	I-NP	O	O
obtained	obtain	VBN	B-VP	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
period	period	NN	I-NP	O	O
on	on	IN	B-PP	O	O
122	122	CD	B-NP	O	O
premature	premature	JJ	I-NP	O	B-Disease
(	(	(	O	O	I-Disease
<	<	SYM	O	O	I-Disease
36	36	CD	B-NP	O	I-Disease
weeks	week	NNS	I-NP	O	I-Disease
of	of	IN	B-PP	O	I-Disease
gestation	gestation	NN	B-NP	O	I-Disease
)	)	)	O	O	I-Disease
infants	infant	NNS	B-NP	O	I-Disease
.	.	.	O	O	O

Infants	Infant	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
categorized	categorize	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
1	1	CD	B-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
those	those	DT	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
not	not	RB	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Infants	Infant	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
exposed	expose	VBN	B-NP	O	O
group	group	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
maternal	maternal	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
or	or	CC	O	O	O
if	if	IN	B-SBAR	O	O
maternal	maternal	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
neonatal	neonatal	JJ	I-NP	O	O
urine	urine	NN	I-NP	O	O
toxicology	toxicology	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
delivery	delivery	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Five	Five	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
122	122	CD	I-NP	O	O
infants	infant	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
excluded	exclude	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
insufficient	insufficient	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
drug	drug	NN	I-NP	O	O
histories	history	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subependymal	subependymal	JJ	B-NP	O	B-Disease
cysts	cyst	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
117	117	CD	I-NP	O	O
remaining	remain	VBG	I-NP	O	O
infants	infant	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
16	16	CD	B-NP	O	O
of	of	IN	B-PP	O	O
117	117	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subependymal	subependymal	JJ	B-NP	O	B-Disease
cysts	cyst	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
infants	infant	NNS	B-NP	O	O
exposed	expose	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
prenatally	prenatally	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
44	44	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
of	of	IN	B-PP	O	O
18	18	CD	B-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
8	8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
of	of	IN	B-PP	O	O
99	99	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unexposed	unexposed	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
subependymal	subependymal	JJ	B-NP	O	B-Disease
cyst	cyst	NN	I-NP	O	I-Disease
formation	formation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
preterm	preterm	JJ	B-NP	O	B-Disease
infants	infant	NNS	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
prenatally	prenatally	RB	B-ADVP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
result	result	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
results	result	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
term	term	NN	B-NP	O	O
infants	infant	NNS	I-NP	O	O
.	.	.	O	O	O

Thalidomide	Thalidomide	NN	B-NP	B	B-Chemical
neuropathy	neuropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
prospectively	prospectively	RB	B-ADVP	O	O
evaluated	evaluate	VBD	B-VP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	B-Disease
using	use	VBG	B-VP	O	O
electrodiagnostic	electrodiagnostic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

Sixty	Sixty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
seven	seven	CD	I-NP	O	O
men	man	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
androgen	androgen	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
independent	independent	JJ	I-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
thalidomide	thalidomide	NN	I-NP	B	B-Chemical
underwent	undergo	VBD	B-VP	O	O
neurologic	neurologic	JJ	B-NP	O	O
examinations	examination	NNS	I-NP	O	O
and	and	CC	O	O	O
nerve	nerve	NN	B-NP	O	O
conduction	conduction	NN	I-NP	O	O
studies	study	NNS	I-NP	O	O
(	(	(	O	O	O
NCS	NCS	NNS	B-NP	B	O
)	)	)	O	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
and	and	CC	B-PP	O	O
at	at	IN	I-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

NCS	NCS	NN	B-NP	O	O
included	include	VBD	B-VP	O	O
recording	recording	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sensory	sensory	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
action	action	NN	I-NP	O	O
potentials	potential	NNS	I-NP	O	O
(	(	(	O	O	O
SNAPs	SNAP	NNS	B-NP	B	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
median	median	JJ	B-NP	O	O
,	,	,	I-NP	O	O
radial	radial	JJ	I-NP	O	O
,	,	,	I-NP	O	O
ulnar	ulnar	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sural	sural	JJ	B-NP	O	O
nerves	nerve	NNS	I-NP	O	O
.	.	.	O	O	O

SNAP	SNAP	NN	B-NP	B	O
amplitudes	amplitude	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
each	each	DT	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
expressed	express	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
percentage	percentage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
baseline	baseline	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
four	four	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
termed	term	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
SNAP	SNAP	NN	I-NP	B	O
index	index	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
40	40	CD	I-NP	O	O
%	%	NN	I-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SNAP	SNAP	NN	I-NP	B	O
index	index	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
clinically	clinically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
.	.	.	O	O	O

Thalidomide	Thalidomide	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
55	55	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
lack	lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
67	67	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
initially	initially	RB	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
,	,	,	O	O	O
24	24	CD	B-NP	O	O
remained	remain	VBD	B-VP	O	O
on	on	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
8	8	CD	B-NP	O	O
remained	remain	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
remained	remain	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
9	9	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

Six	Six	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
neuropathy	neuropathy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SNAP	SNAP	NN	I-NP	B	O
index	index	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Older	Old	JJR	B-NP	O	O
age	age	NN	I-NP	O	O
and	and	CC	O	O	O
cumulative	cumulative	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
possible	possible	JJ	B-NP	O	O
contributing	contribute	VBG	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Neuropathy	Neuropathy	NN	B-NP	O	B-Disease
may	may	MD	B-VP	O	O
thus	thus	RB	I-VP	O	O
be	be	VB	I-VP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
SNAP	SNAP	NN	I-NP	B	O
index	index	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	B-PP	O	O
for	for	IN	I-PP	O	O
early	early	JJ	B-NP	O	O
detection	detection	NN	I-NP	O	O
.	.	.	O	O	O

Overexpression	Overexpression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
copper	copper	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
zinc	zinc	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
superoxide	superoxide	NN	I-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
protects	protect	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
kanamycin	kanamycin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hearing	hearing	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
participation	participation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reactive	reactive	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
species	specie	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ototoxicity	ototoxicity	NN	I-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
deduced	deduce	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
observations	observation	NNS	B-NP	O	O
that	that	IN	B-SBAR	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
iron	iron	NN	B-NP	B	B-Chemical
complexes	complex	NNS	I-NP	I	O
catalyze	catalyze	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
radicals	radical	NNS	I-NP	I	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
antioxidants	antioxidant	NNS	B-NP	O	O
attenuate	attenuate	VBP	B-VP	O	O
ototoxicity	ototoxicity	NN	B-NP	O	B-Disease
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
therefore	therefore	RB	B-ADVP	O	O
hypothesized	hypothesize	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
overexpression	overexpression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Cu	Cu	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
Zn	Zn	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
(	(	(	O	O	O
h	h	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
SOD1	SOD1	NN	I-NP	O	O
)	)	)	O	O	O
should	should	MD	B-VP	O	O
protect	protect	VB	I-VP	O	O
transgenic	transgenic	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
ototoxicity	ototoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Immunocytochemistry	Immunocytochemistry	NN	B-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
expression	expression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
h	h	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
SOD1	SOD1	NN	I-NP	O	O
in	in	IN	B-PP	O	O
inner	inner	JJ	B-NP	O	O
ear	ear	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
transgenic	transgenic	JJ	B-NP	O	O
C57BL	C57BL	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
TgN	TgN	NN	I-NP	O	O
[	[	(	I-NP	O	O
SOD1	SOD1	NN	I-NP	O	O
]	]	)	I-NP	O	O
3Cje	3Cje	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Transgenic	Transgenic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
nontransgenic	nontransgenic	JJ	I-NP	O	O
littermates	littermate	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
kanamycin	kanamycin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
400	400	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
beginning	begin	VBG	B-VP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
10	10	CD	I-NP	O	O
after	after	IN	B-PP	O	O
birth	birth	NN	B-NP	O	O
.	.	.	O	O	O

Auditory	Auditory	JJ	B-NP	O	O
thresholds	threshold	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
evoked	evoke	VBN	B-NP	O	O
auditory	auditory	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
stem	stem	NN	I-NP	O	O
responses	response	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
month	month	NN	I-NP	O	O
after	after	IN	B-PP	O	O
birth	birth	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
nontransgenic	nontransgenic	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kanamycin	kanamycin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
45	45	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
50	50	CD	I-NP	O	O
dB	dB	NN	I-NP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
injected	inject	VBN	I-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
transgenic	transgenic	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
kanamycin	kanamycin	NN	B-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
by	by	IN	B-PP	O	O
only	only	RB	B-NP	O	O
15	15	CD	I-NP	O	O
dB	dB	NN	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
respective	respective	JJ	I-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
at	at	IN	B-PP	O	O
12	12	CD	B-NP	O	O
and	and	CC	I-NP	O	O
24	24	CD	I-NP	O	O
kHz	kHz	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
protection	protection	NN	I-NP	O	O
by	by	IN	B-PP	O	O
overexpression	overexpression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
supports	support	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
oxidant	oxidant	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
aminoglycoside	aminoglycoside	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ototoxicity	ototoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
transgenic	transgenic	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
suitable	suitable	JJ	B-NP	O	O
models	model	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
strategies	strategy	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
prevention	prevention	NN	B-NP	O	O
.	.	.	O	O	O

Prednisone	Prednisone	NN	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
glial	glial	JJ	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
prednisone	prednisone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PDN	PDN	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
produces	produce	VBZ	B-VP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
cerebral	cerebral	JJ	B-NP	O	O
glial	glial	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Male	Male	NNP	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
formed	form	VBN	I-VP	O	O
(	(	(	O	O	O
8	8	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
group	group	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
PDN	PDN	NN	I-NP	O	B-Chemical
released	release	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subcutaneous	subcutaneous	JJ	I-NP	O	O
implant	implant	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
implants	implant	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
PDN	PDN	NN	B-NP	O	B-Chemical
equivalent	equivalent	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
60	60	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
applied	apply	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
implants	implant	NNS	I-NP	O	O
contained	contain	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
PDN	PDN	NN	I-NP	O	B-Chemical
.	.	.	O	O	O

Anxiety	Anxiety	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
using	use	VBG	I-VP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
and	and	CC	O	O	O
elevated	elevate	VBN	B-VP	B	O
plus	plus	CC	O	O	O
-	-	HYPH	B-NP	O	O
maze	maze	NN	I-NP	O	O
devices	device	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cells	cell	NNS	B-NP	O	O
and	and	CC	O	O	O
cytoplasmic	cytoplasmic	JJ	B-NP	O	O
transformation	transformation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
astrocytes	astrocyte	NNS	B-NP	O	O
and	and	CC	O	O	O
microglia	microglia	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
immunohistochemical	immunohistochemical	JJ	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Anxiety	Anxiety	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
PDN	PDN	NN	B-NP	O	B-Chemical
treated	treat	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
magnitude	magnitude	NN	I-NP	O	O
of	of	IN	B-PP	O	O
transformation	transformation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
microglia	microglia	NNS	I-NP	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intersections	intersection	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PDN	PDN	NN	I-NP	O	B-Chemical
groups	group	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prefrontal	prefrontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
(	(	(	O	O	O
moderate	moderate	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
24.1	24.1	CD	B-NP	O	O
;	;	:	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
23.6	23.6	CD	B-NP	O	O
;	;	:	O	O	O
controls	control	VBZ	B-VP	O	O
18.7	18.7	CD	B-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
striatum	striatum	NN	B-NP	O	O
(	(	(	O	O	O
moderate	moderate	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
25.6	25.6	CD	I-NP	O	O
;	;	:	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	B-NP	O	O
26.3	26.3	CD	I-NP	O	O
;	;	:	O	O	O
controls	control	VBZ	B-VP	O	O
18.9	18.9	CD	B-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
hippocampus	hippocampus	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stained	stain	VBN	B-NP	O	O
microglia	microglia	NNS	I-NP	O	O
cells	cell	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PDN	PDN	NN	I-NP	O	B-Chemical
treated	treat	VBN	B-VP	O	O
groups	group	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prefrontal	prefrontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
(	(	(	O	O	O
moderate	moderate	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
29.1	29.1	CD	B-NP	O	O
;	;	:	O	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
28.4	28.4	CD	B-NP	O	O
;	;	:	O	O	O
control	control	NN	B-NP	O	O
,	,	,	O	O	O
17.7	17.7	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
per	per	IN	B-PP	O	O
field	field	NN	B-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Stained	Stain	VBN	B-NP	O	O
microglia	microglia	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
more	more	RBR	B-NP	O	O
numerous	numerous	JJ	I-NP	O	O
striatum	striatum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Subacute	Subacute	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
PDN	PDN	NN	B-NP	O	B-Chemical
induced	induce	VBD	B-VP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
reactivity	reactivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
microglia	microglia	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
relevance	relevance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
features	feature	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
using	use	VBG	B-VP	O	O
PDN	PDN	NN	B-NP	O	B-Chemical
remains	remain	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
elucidated	elucidate	VBN	I-VP	O	O
.	.	.	O	O	O

Phase	Phase	NN	B-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
squamous	squamous	JJ	I-NP	O	B-Disease
cell	cell	NN	I-NP	O	I-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
cervix	cervix	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
was	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Phase	Phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
cervical	cervical	JJ	I-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
area	area	NN	B-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
curve	curve	NN	I-NP	O	O
[	[	(	O	O	O
AUC	AUC	NN	B-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
(	(	(	O	O	O
Doxil	Doxil	NNP	B-NP	B	B-Chemical
;	;	:	O	O	O
starting	start	VBG	B-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
intravenously	intravenously	RB	B-NP	O	O
every	every	DT	I-NP	O	O
28	28	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
37	37	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
squamous	squamous	JJ	I-NP	O	B-Disease
cell	cell	NN	I-NP	O	I-Disease
cervical	cervical	JJ	I-NP	O	I-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
antitumor	antitumor	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
profile	profile	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nine	nine	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assessable	assessable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
response	response	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
35	35	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assessable	assessable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
38	38	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
response	response	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
10	10	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
26	26	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
37	37	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
myelosuppression	myelosuppression	NN	B-NP	O	B-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
Grade	Grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
and	and	CC	I-NP	O	O
4	4	CD	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
16	16	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
anemia	anemia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
11	11	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
neutropenic	neutropenic	JJ	B-NP	O	B-Disease
fever	fever	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
five	five	CD	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Grade	Grade	NN	B-NP	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
nonhematologic	nonhematologic	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
included	include	VBD	B-VP	O	O
nausea	nausea	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
17	17	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
emesis	emesis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
14	14	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
fatigue	fatigue	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
9	9	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
mucositis	mucositis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
stomatitis	stomatitis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
8	8	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
constipation	constipation	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
weight	weight	NN	B-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
hand	hand	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
foot	foot	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
skin	skin	NN	B-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carboplatin	carboplatin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
liposomal	liposomal	JJ	B-NP	B	O
doxorubicin	doxorubicin	NN	I-NP	I	B-Chemical
has	have	VBZ	B-VP	O	O
modest	modest	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
recurrent	recurrent	JJ	B-NP	O	O
cervical	cervical	JJ	I-NP	O	B-Disease
carcinoma	carcinoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Antimicrobial	Antimicrobial	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
mania	mania	NN	I-NP	O	B-Disease
(	(	(	O	O	O
antibiomania	antibiomania	NN	B-NP	O	B-Disease
)	)	)	O	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
reviewed	review	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
cases	case	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
antibiotic	antibiotic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
manic	manic	JJ	I-NP	O	B-Disease
episodes	episode	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
means	mean	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
MEDLINE	MEDLINE	NNP	I-NP	O	O
and	and	CC	I-NP	O	O
PsychLit	PsychLit	NNP	I-NP	O	O
search	search	NN	I-NP	O	O
for	for	IN	B-PP	O	O
reports	report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
antibiotic	antibiotic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
mania	mania	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Unpublished	Unpublished	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
requested	request	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
World	World	NNP	I-NP	O	O
Health	Health	NNP	I-NP	O	O
Organization	Organization	NNP	I-NP	O	O
(	(	(	O	O	O
WHO	WHO	WP	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Food	Food	NNP	I-NP	O	O
and	and	CC	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Administration	Administration	NNP	I-NP	O	O
(	(	(	O	O	O
FDA	FDA	NNP	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
one	one	CD	I-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antimicrobial	antimicrobial	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
mania	mania	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
6	6	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
implicating	implicate	VBG	B-VP	O	O
clarithromycin	clarithromycin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
13	13	CD	B-NP	O	O
implicating	implicate	VBG	I-NP	O	O
isoniazid	isoniazid	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
case	case	NN	I-NP	O	O
each	each	DT	B-NP	O	O
implicating	implicate	VBG	I-NP	O	O
erythromycin	erythromycin	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
amoxicillin	amoxicillin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
WHO	WHO	NNP	I-NP	O	O
reported	report	VBD	B-VP	O	O
82	82	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
,	,	,	O	O	O
clarithromycin	clarithromycin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
23	23	CD	B-NP	O	O
(	(	(	O	O	O
27.6	27.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
cases	case	NNS	B-NP	O	O
,	,	,	O	O	O
ciprofloxacin	ciprofloxacin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
(	(	(	O	O	O
14.4	14.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
cases	case	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ofloxacin	ofloxacin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
cases	case	NNS	B-NP	O	O
.	.	.	O	O	O

Cotrimoxazole	Cotrimoxazole	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
metronidazole	metronidazole	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
erythromycin	erythromycin	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
15	15	CD	B-NP	O	O
reported	report	VBD	B-VP	O	O
manic	manic	JJ	B-NP	O	B-Disease
episodes	episode	NNS	I-NP	O	O
.	.	.	O	O	O

Cases	Case	NNS	B-NP	O	O
reported	report	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
FDA	FDA	NNP	I-NP	B	O
showed	show	VBD	B-VP	O	O
clarithromycin	clarithromycin	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
ciprofloxacin	ciprofloxacin	NN	I-NP	B	B-Chemical
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
frequently	frequently	RB	I-NP	O	O
associated	associate	VBN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mania	mania	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Statistical	Statistical	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
statistical	statistical	JJ	I-NP	O	O
correlative	correlative	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
not	not	RB	I-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
mania	mania	NN	B-NP	O	B-Disease
while	while	IN	B-SBAR	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
antimicrobials	antimicrobial	NNS	B-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
and	and	CC	I-NP	O	O
reversibility	reversibility	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
clearly	clearly	RB	B-ADVP	O	O
is	be	VBZ	B-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antimicrobial	antimicrobial	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
mania	mania	NN	I-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
antimicrobial	antimicrobial	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
induced	induce	VBN	I-NP	O	O
manic	manic	JJ	I-NP	O	B-Disease
episode	episode	NN	I-NP	O	O
among	among	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
demographic	demographic	JJ	I-NP	O	O
populations	population	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
continue	continue	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
persistent	persistent	JJ	B-NP	O	O
affective	affective	JJ	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
once	once	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
episode	episode	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
while	while	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
taking	take	VBG	I-VP	O	O
antibiotics	antibiotic	NNS	B-NP	O	O
,	,	,	O	O	O
subsides	subside	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
elected	elect	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
name	name	VB	I-VP	O	O
this	this	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
"	"	``	O	O	O
antibiomania	antibiomania	NN	B-NP	O	B-Disease
.	.	.	O	O	O
"	"	''	O	O	O

Levodopa	Levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ocular	ocular	JJ	I-NP	O	B-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Levodopa	Levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ocular	ocular	JJ	I-NP	O	B-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
very	very	RB	B-ADJP	O	O
uncommon	uncommon	JJ	I-ADJP	O	O
.	.	.	O	O	O

Usually	Usually	RB	B-ADVP	O	O
they	they	PRP	B-NP	O	O
occur	occur	VBP	B-VP	O	O
simultaneously	simultaneously	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
limb	limb	NN	B-NP	O	O
peak	peak	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dose	dose	NN	I-NP	O	O
choreatic	choreatic	JJ	I-NP	O	B-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
leftward	leftward	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
upward	upward	JJ	I-NP	O	O
deviations	deviation	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
gaze	gaze	NN	B-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
hypothesize	hypothesize	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
denervation	denervation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caudate	caudate	JJ	I-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
needed	need	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induce	induce	VBP	B-VP	O	O
ocular	ocular	JJ	B-NP	O	B-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glyceryl	glyceryl	NN	B-NP	B	B-Chemical
trinitrate	trinitrate	NN	I-NP	I	I-Chemical
with	with	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
dysmenorrhea	dysmenorrhea	NN	I-NP	O	B-Disease
:	:	:	O	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
,	,	,	O	O	O
randomized	randomize	VBN	B-VP	O	O
,	,	,	O	O	O
cross	cross	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
over	over	IN	B-PP	O	O
trial	trial	NN	B-NP	O	O
.	.	.	O	O	O

Primary	Primary	JJ	B-NP	O	O
dysmenorrhea	dysmenorrhea	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
syndrome	syndrome	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
painful	painful	JJ	B-NP	O	O
uterine	uterine	JJ	I-NP	O	O
contractility	contractility	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
hypersecretion	hypersecretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endometrial	endometrial	JJ	B-NP	O	O
prostaglandins	prostaglandin	NNS	I-NP	B	B-Chemical
;	;	:	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
choice	choice	NN	I-NP	O	O
for	for	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
and	and	CC	O	O	O
in	in	FW	B-NP	O	O
vitro	vitro	FW	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
myometrial	myometrial	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	B-ADVP	O	O
targets	target	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
relaxant	relaxant	JJ	I-NP	B	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nitric	nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
NO	NO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glyceryl	glyceryl	NN	B-NP	B	B-Chemical
trinitrate	trinitrate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
NO	NO	NN	I-NP	O	B-Chemical
donor	donor	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
resolution	resolution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
dysmenorrhea	dysmenorrhea	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
diclofenac	diclofenac	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DCF	DCF	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
24	24	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
primary	primary	JJ	I-NP	O	O
dysmenorrhea	dysmenorrhea	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
two	two	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
menstrual	menstrual	JJ	I-NP	O	O
cycles	cycle	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
,	,	,	O	O	O
cross	cross	AFX	O	O	O
-	-	HYPH	B-VP	O	O
over	over	RP	B-PRT	O	O
,	,	,	O	O	O
controlled	control	VBN	B-VP	O	O
design	design	NN	B-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
either	either	CC	O	O	O
DCF	DCF	NN	B-NP	B	B-Chemical
per	per	IN	B-PP	O	O
os	o	NNS	B-NP	O	O
or	or	CC	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
patches	patch	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
menses	mens	NNS	B-NP	O	O
,	,	,	O	O	O
when	when	WRB	B-ADVP	O	O
menstrual	menstrual	JJ	B-NP	O	O
cramps	cramp	NNS	I-NP	O	O
became	become	VBD	B-VP	O	O
unendurable	unendurable	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
doses	dose	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
DCF	DCF	NN	I-NP	B	B-Chemical
or	or	CC	O	O	O
2.5	2.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
transdermal	transdermal	JJ	I-NP	O	O
GTN	GTN	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
3	3	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
their	their	PRP$	B-NP	O	O
needs	need	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
participants	participant	NNS	I-NP	O	O
recorded	record	VBD	B-VP	O	O
menstrual	menstrual	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
and	and	CC	O	O	O
possible	possible	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
effects	effect	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
,	,	,	I-NP	O	O
30	30	CD	I-NP	O	O
,	,	,	I-NP	O	O
60	60	CD	I-NP	O	O
,	,	,	I-NP	O	O
120	120	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medication	medication	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pain	pain	NN	B-NP	O	B-Disease
intensity	intensity	NN	I-NP	O	O
score	score	NN	I-NP	O	O
(	(	(	O	O	O
DPI	DPI	NN	B-NP	B	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
variable	variable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
reduced	reduce	VBD	B-VP	O	O
DPI	DPI	NN	B-NP	B	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
30th	30th	JJ	I-NP	O	O
minute	minute	NN	I-NP	O	O
(	(	(	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
12.8	12.8	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
17.9	17.9	CD	B-NP	O	O
;	;	:	O	O	O
DCF	DCF	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
18.9	18.9	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
16.6	16.6	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
DCF	DCF	NN	B-NP	B	B-Chemical
continued	continue	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
reducing	reduce	VBG	B-VP	O	O
pelvic	pelvic	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
for	for	IN	B-PP	O	O
two	two	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
scores	score	NNS	I-NP	O	O
remained	remain	VBD	B-VP	O	O
more	more	RBR	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
less	less	RBR	B-ADJP	O	O
stable	stable	JJ	I-ADJP	O	O
after	after	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
and	and	CC	O	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
for	for	IN	B-PP	O	O
DFC	DFC	NN	B-NP	O	O
(	(	(	O	O	O
after	after	IN	B-PP	O	O
one	one	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
:	:	:	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
12.8	12.8	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
17.9	17.9	CD	B-NP	O	O
;	;	:	O	O	O
DFC	DFC	NN	B-NP	O	O
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
18.9	18.9	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
16.6	16.6	CD	B-NP	O	O
and	and	CC	O	O	O
after	after	IN	B-PP	O	O
two	two	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
:	:	:	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
23.7	23.7	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
20.5	20.5	CD	B-NP	O	O
;	;	:	O	O	O
DFC	DFC	NN	B-NP	O	O
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
59.7	59.7	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
17.9	17.9	CD	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.0001	0.0001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Low	Low	JJ	B-NP	O	B-Disease
back	back	JJ	I-NP	O	I-Disease
pain	pain	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
relieved	relieve	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
both	both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Headache	Headache	PRP	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
by	by	IN	I-PP	O	O
DCF	DCF	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Eight	Eight	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
stopped	stop	VBD	B-VP	O	O
using	use	VBG	I-VP	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
because	because	IN	B-SBAR	O	O
headache	headache	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
-	-	HYPH	I-NP	O	O
attributed	attribute	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
-	-	HYPH	O	O	O
-	-	SYM	B-NP	O	O
became	become	VBD	B-VP	O	O
intolerable	intolerable	JJ	B-ADJP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
by	by	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DCF	DCF	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
dysmenorrhea	dysmenorrhea	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Temocapril	Temocapril	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
long	long	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	B-VP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
SH	SH	NN	I-NP	B	O
group	group	NN	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
converting	convert	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
modulates	modulate	VBZ	B-VP	O	O
glomerular	glomerular	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
puromycin	puromycin	NN	I-NP	B	B-Chemical
aminonucleoside	aminonucleoside	NN	I-NP	I	I-Chemical
nephrosis	nephrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
chronic	chronic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temocapril	temocapril	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
long	long	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	B-VP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
SH	SH	NN	I-NP	B	O
group	group	NN	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
converting	convert	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
(	(	(	O	O	O
ACE	ACE	NN	B-NP	O	O
)	)	)	O	O	O
inhibitor	inhibitor	NN	B-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBN	B-VP	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
,	,	,	O	O	O
inhibited	inhibit	VBD	B-VP	O	O
glomerular	glomerular	JJ	B-NP	O	O
hypertrophy	hypertrophy	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
prevented	prevent	VBD	B-VP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
puromycin	puromycin	NN	I-NP	B	B-Chemical
aminonucleoside	aminonucleoside	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
nephrotic	nephrotic	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Nephrosis	Nephrosis	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
15mg	15mg	NN	B-NP	O	O
/	/	SYM	O	O	O
100g	100g	NN	B-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
(	(	(	O	O	O
SD	SD	NNP	B-NP	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
,	,	,	O	O	O
i	i	LS	B-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ii	ii	LS	B-LST	O	O
)	)	)	O	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
/	/	SYM	O	O	O
temocapril	temocapril	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
13	13	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
iii	iii	LS	B-LST	O	O
)	)	)	O	O	O
temocapril	temocapril	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
14	14	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
iv	iv	NN	B-NP	O	O
)	)	)	O	O	O
untreated	untreated	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
(	(	(	O	O	O
15	15	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Temocapril	Temocapril	NNP	B-NP	B	B-Chemical
(	(	(	O	O	O
8	8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
weeks	week	NNS	B-NP	O	O
4	4	CD	I-NP	O	O
,	,	,	I-NP	O	O
14	14	CD	I-NP	O	O
or	or	CC	I-NP	O	O
20	20	CD	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
each	each	DT	B-NP	O	O
time	time	NN	I-NP	O	O
point	point	NN	I-NP	O	O
,	,	,	O	O	O
systolic	systolic	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
BP	BP	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
urinary	urinary	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	O
histopathological	histopathological	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
morphometric	morphometric	JJ	B-NP	O	O
image	image	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
done	do	VBN	I-VP	O	O
.	.	.	O	O	O

Systolic	Systolic	JJ	B-NP	O	O
BP	BP	NN	I-NP	B	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
high	high	JJ	I-ADJP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
,	,	,	I-NP	O	O
14	14	CD	I-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
temocapril	temocapril	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Urinary	Urinary	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
,	,	,	O	O	O
peaking	peak	VBG	B-VP	O	O
at	at	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
then	then	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
rose	rise	VBD	B-VP	O	O
again	again	RB	B-ADVP	O	O
significantly	significantly	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
14	14	CD	B-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Temocapril	Temocapril	NNP	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
at	at	IN	B-PP	O	O
8	8	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
markedly	markedly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
it	it	PRP	B-NP	O	O
from	from	IN	B-PP	O	O
weeks	week	NNS	B-NP	O	O
4	4	CD	B-NP	O	O
to	to	TO	B-PP	O	O
20	20	CD	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
glomerulosclerosis	glomerulosclerosis	NN	I-NP	O	B-Disease
index	index	NN	I-NP	O	O
(	(	(	O	O	O
GSI	GSI	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
6.21	6.21	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	O	O	O
respectively	respectively	RB	B-NP	O	O
25.35	25.35	CD	I-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
30.49	30.49	CD	B-NP	O	O
%	%	NN	I-NP	O	O
at	at	IN	B-PP	O	O
14	14	CD	B-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
correlation	correlation	NN	I-NP	O	O
between	between	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
and	and	CC	O	O	O
GSI	GSI	NN	B-NP	O	O
(	(	(	O	O	O
r	r	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.808	0.808	CD	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.0001	0.0001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerular	glomerular	JJ	B-NP	O	O
tuft	tuft	NN	I-NP	O	O
area	area	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
area	area	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Bowman	Bowman	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
capsules	capsule	NNS	I-NP	O	O
(	(	(	O	O	O
GT	GT	NN	B-NP	B	O
/	/	SYM	B-NP	O	O
BC	BC	NN	I-NP	B	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PAN	PAN	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
temocapril	temocapril	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
temocapril	temocapril	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
retarding	retard	VBG	B-VP	B	O
renal	renal	JJ	B-NP	O	O
progression	progression	NN	I-NP	O	O
and	and	CC	O	O	O
protected	protect	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PAN	PAN	NN	B-NP	B	B-Chemical
neprotic	neprotic	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Pulmonary	Pulmonary	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
prophylaxis	prophylaxis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
very	very	RB	B-NP	O	O
preterm	preterm	JJ	I-NP	O	O
infants	infant	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
three	three	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
hypoxaemia	hypoxaemia	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
during	during	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomised	randomise	VBN	I-NP	O	O
controlled	control	VBN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patent	patent	NN	B-NP	O	B-Disease
ductus	ductus	NN	I-NP	O	I-Disease
arteriosus	arteriosus	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
premature	premature	JJ	B-NP	O	O
infants	infant	NNS	I-NP	O	O
born	bear	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
28	28	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
gestation	gestation	NN	B-NP	O	O
.	.	.	O	O	O

Echocardiography	Echocardiography	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
severely	severely	RB	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
.	.	.	O	O	O

Hypoxaemia	Hypoxaemia	NN	B-NP	O	B-Disease
resolved	resolve	VBD	B-VP	O	O
quickly	quickly	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
inhaled	inhale	VBN	B-NP	O	O
nitric	nitric	JJ	I-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
investigators	investigator	NNS	B-NP	O	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
pay	pay	VBP	B-VP	O	O
close	close	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
to	to	TO	B-PP	O	O
pulmonary	pulmonary	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
hypoxaemia	hypoxaemia	NN	B-NP	O	B-Disease
occurs	occur	VBZ	B-VP	O	O
after	after	IN	B-SBAR	O	O
prophylactic	prophylactic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Hyponatremia	Hyponatremia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
syndrome	syndrome	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
inappropriate	inappropriate	JJ	B-NP	O	I-Disease
anti	anti	AFX	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
diuretic	diuretic	JJ	I-NP	O	I-Disease
hormone	hormone	NN	I-NP	O	I-Disease
reported	report	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vincristine	Vincristine	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
an	an	DT	B-NP	O	O
over	over	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
representation	representation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Asians	Asian	NNPS	B-NP	O	O
?	?	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
used	use	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
pharmaceutical	pharmaceutical	JJ	I-NP	O	O
company	company	NN	I-NP	O	O
's	's	POS	B-NP	O	O
global	global	JJ	I-NP	O	O
safety	safety	NN	I-NP	O	O
database	database	NN	I-NP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
reporting	reporting	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyponatremia	hyponatremia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
syndrome	syndrome	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
inappropriate	inappropriate	JJ	B-NP	O	I-Disease
secretion	secretion	NN	I-NP	O	I-Disease
of	of	IN	B-PP	O	I-Disease
anti	anti	AFX	B-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
diuretic	diuretic	JJ	I-NP	O	I-Disease
hormone	hormone	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
)	)	)	O	O	O
among	among	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
explore	explore	VB	I-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
risk	risk	NN	I-NP	O	O
population	population	NN	I-NP	O	O
subgroups	subgroup	NNS	I-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
searched	search	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
Eli	Eli	NNP	I-NP	O	O
Lilly	Lilly	NNP	I-NP	O	O
and	and	CC	O	O	O
Company	Company	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
computerized	computerized	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
database	database	NN	I-NP	O	O
for	for	IN	B-PP	O	O
all	all	DT	B-NP	O	O
reported	report	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyponatremia	hyponatremia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
as	as	IN	B-PP	O	O
of	of	IN	B-PP	O	O
1	1	CD	B-NP	O	O
November	November	NNP	I-NP	O	O
1999	1999	CD	I-NP	O	O
that	that	WDT	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
76	76	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hyponatremia	hyponatremia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
reporting	reporting	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
1.3	1.3	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
100,000	100,000	CD	I-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
35.6	35.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
28.3	28.3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
males	male	NNS	B-NP	O	O
.	.	.	O	O	O

Approximately	Approximately	RB	B-NP	O	O
75	75	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
leukemia	leukemia	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
lymphoma	lymphoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
39	39	CD	I-NP	O	O
reports	report	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
information	information	NN	B-NP	O	O
on	on	IN	B-PP	O	O
race	race	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
racial	racial	JJ	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
:	:	:	O	O	O
1	1	CD	B-NP	O	O
Black	Black	NN	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
Caucasian	Caucasian	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
35	35	CD	B-NP	O	O
Asian	Asian	JJ	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
Asian	Asian	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyponatremia	hyponatremia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
reported	report	VBN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
SIADH	SIADH	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
vincristine	vincristine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
very	very	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
caring	care	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
Asian	Asian	JJ	B-NP	O	O
oncology	oncology	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
serious	serious	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
reversible	reversible	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
.	.	.	O	O	O

Delayed	Delay	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
and	and	CC	O	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
describes	describe	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
severe	severe	JJ	I-NP	O	O
bladder	bladder	NN	I-NP	O	O
pathology	pathology	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
susceptible	susceptible	JJ	I-NP	O	O
strain	strain	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
(	(	(	O	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
but	but	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
a	a	DT	B-NP	O	O
resistant	resistant	JJ	I-NP	O	O
strain	strain	NN	I-NP	O	O
(	(	(	O	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
when	when	WRB	B-ADVP	O	O
both	both	DT	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CY	CY	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Inbred	Inbreed	VBN	B-NP	O	O
DBA	DBA	NN	I-NP	B	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
and	and	CC	O	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
CY	CY	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
100	100	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
light	light	NN	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
different	different	JJ	B-NP	O	O
staining	staining	NN	I-NP	O	O
procedures	procedure	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
after	after	IN	B-PP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
electron	electron	NN	I-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
.	.	.	O	O	O

Early	Early	JJ	B-NP	O	O
CY	CY	NN	I-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
haemorrhagic	haemorrhagic	JJ	I-NP	O	B-Disease
cystitis	cystitis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
strains	strain	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
completely	completely	RB	I-VP	O	O
repaired	repair	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
about	about	RB	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CY	CY	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
ulcerous	ulcerous	JJ	B-ADJP	O	O
and	and	CC	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
ulcerous	ulcerous	JJ	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
appeared	appear	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
86	86	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
but	but	CC	O	O	O
only	only	RB	B-PP	O	O
in	in	IN	I-PP	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Delayed	Delay	VBN	B-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
infiltration	infiltration	NN	B-NP	O	O
and	and	CC	O	O	O
transepithelial	transepithelial	JJ	B-NP	O	O
passage	passage	NN	I-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lumen	lumen	NN	I-NP	B	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
by	by	IN	B-PP	O	O
frequent	frequent	JJ	B-NP	O	O
exfoliation	exfoliation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urothelium	urothelium	NN	I-NP	O	O
.	.	.	O	O	O

Mast	Mast	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
connective	connective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
muscular	muscular	JJ	I-NP	O	O
layers	layer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
much	much	RB	I-NP	O	O
higher	high	JJR	I-NP	O	O
number	number	NN	I-NP	O	O
in	in	IN	B-PP	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
or	or	CC	O	O	O
untreated	untreated	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

Electron	Electron	NN	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
disclosed	disclose	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
discoidal	discoidal	JJ	I-NP	O	O
vesicles	vesicle	NNS	I-NP	O	O
normally	normally	RB	B-ADJP	O	O
present	present	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytoplasm	cytoplasm	NN	I-NP	O	O
of	of	IN	B-PP	O	O
surface	surface	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

Instead	Instead	RB	B-ADVP	O	O
,	,	,	O	O	O
numerous	numerous	JJ	B-NP	O	O
abnormal	abnormal	JJ	I-NP	O	O
vesicles	vesicle	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
one	one	CD	B-NP	O	O
or	or	CC	O	O	O
several	several	JJ	B-NP	O	O
dark	dark	JJ	I-NP	O	O
granules	granule	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cytoplasm	cytoplasm	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cells	cell	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
layers	layer	NNS	I-NP	O	O
.	.	.	O	O	O

Delayed	Delay	VBN	B-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
still	still	RB	B-ADVP	O	O
persisted	persist	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
DBA	DBA	NN	B-NP	B	O
/	/	SYM	O	O	O
2	2	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
100	100	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
delayed	delay	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
CY	CY	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
DBA	DBA	NN	I-NP	B	O
/	/	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
pathology	pathology	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
C57BL	C57BL	NN	B-NP	O	O
/	/	SYM	O	O	O
6	6	CD	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
pathology	pathology	NN	I-NP	O	O
resembles	resemble	VBZ	B-VP	O	O
interstitial	interstitial	JJ	B-NP	O	B-Disease
cystitis	cystitis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
and	and	CC	O	O	O
could	could	MD	B-VP	O	O
perhaps	perhaps	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
for	for	IN	B-PP	O	O
studies	study	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	B-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
/	/	SYM	B-NP	O	O
folinic	folinic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
three	three	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
weekly	weekly	JJ	I-NP	O	O
mitomycin	mitomycin	NN	I-NP	B	B-Chemical
C	C	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
gastric	gastric	JJ	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
continuous	continuous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
folinic	folinic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
FA	FA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
new	new	JJ	I-NP	O	O
multidrug	multidrug	JJ	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
gastric	gastric	JJ	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AGC	AGC	NN	B-NP	B	B-Disease
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
effective	effective	JJ	B-ADJP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
weekly	weekly	JJ	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
FA	FA	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
mitomycin	mitomycin	NN	B-NP	B	B-Chemical
C	C	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
MMC	MMC	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
we	we	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
response	response	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
regimens	regimen	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
ELF	ELF	NN	B-NP	O	O
,	,	,	I-NP	O	O
FAM	FAM	NN	I-NP	B	O
or	or	CC	I-NP	O	O
FAMTX	FAMTX	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
promising	promising	JJ	I-NP	O	O
median	median	JJ	I-NP	O	O
overall	overall	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
improve	improve	VB	I-VP	O	O
this	this	DT	B-NP	O	O
MMC	MMC	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
schedule	schedule	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
initiated	initiate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	B-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
/	/	SYM	B-NP	O	O
FA	FA	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
weekly	weekly	JJ	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
MMC	MMC	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
From	From	IN	B-PP	O	O
February	February	NNP	B-NP	O	O
,	,	,	O	O	O
1998	1998	CD	B-NP	O	O
to	to	TO	B-PP	O	O
September	September	NNP	B-NP	O	O
,	,	,	O	O	O
2000	2000	CD	B-NP	O	O
we	we	PRP	B-NP	O	O
recruited	recruit	VBD	B-VP	B	O
33	33	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
AGC	AGC	NN	B-NP	B	B-Disease
to	to	TO	B-VP	O	O
receive	receive	VB	I-VP	O	O
weekly	weekly	RB	B-NP	O	O
24	24	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	B-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
2,600	2,600	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
preceded	precede	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
hour	hour	NN	I-NP	O	O
FA	FA	NN	I-NP	B	B-Chemical
500	500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
rest	rest	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

Bolus	Bolus	NN	B-NP	O	O
MMC	MMC	NN	I-NP	B	B-Chemical
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
added	add	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
weekly	weekly	JJ	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
given	give	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
outpatient	outpatient	NN	I-NP	O	O
basis	basis	NN	I-NP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
portable	portable	JJ	B-NP	O	O
pump	pump	NN	I-NP	O	O
systems	system	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
repeated	repeat	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
57	57	CD	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
male	male	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
female	female	JJ	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
20	20	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
13	13	CD	I-NP	O	O
;	;	:	O	O	O
median	median	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
57	57	CD	I-NP	O	O
(	(	(	O	O	O
27	27	CD	B-NP	O	O
-	-	HYPH	O	O	O
75	75	CD	O	O	O
)	)	)	O	O	O
years	year	NNS	B-NP	O	O
;	;	:	O	O	O
median	median	JJ	B-NP	O	O
WHO	WHO	NN	I-NP	O	O
status	status	NN	I-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

18	18	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
AGC	AGC	NN	I-NP	B	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
15	15	CD	B-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
relapsed	relapsed	JJ	I-NP	O	O
AGC	AGC	NN	I-NP	B	B-Disease
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
was	be	VBD	B-VP	O	O
11.8	11.8	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
of	of	IN	B-PP	O	O
those	those	DT	B-NP	O	O
surviving	survive	VBG	B-VP	O	O
:	:	:	O	O	O
2.7	2.7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
11.8	11.8	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
32	32	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluable	evaluable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
response	response	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
complete	complete	JJ	I-NP	O	O
remission	remission	NN	I-NP	O	O
9.1	9.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
partial	partial	JJ	B-NP	O	O
remission	remission	NN	I-NP	O	O
45.5	45.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
15	15	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
27.3	27.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
9	9	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
progressive	progressive	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
15.1	15.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
5	5	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
overall	overall	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
10.2	10.2	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
CI	CI	NN	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
8.7	8.7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
11.6	11.6	CD	I-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
median	median	JJ	B-NP	O	O
progression	progression	NN	I-NP	O	O
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
survival	survival	NN	I-NP	O	O
time	time	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
7.6	7.6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
4.4	4.4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10.9	10.9	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
worst	worst	JJS	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
(	(	(	O	O	O
%	%	NN	B-NP	O	O
)	)	)	O	O	O
observed	observe	VBN	B-VP	O	O
were	be	VBD	B-VP	O	O
(	(	(	O	O	O
CTC	CTC	NN	B-NP	B	O
-	-	HYPH	O	O	O
NCI	NCI	NN	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
3	3	CD	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
leukopenia	leukopenia	SYM	B-NP	O	B-Disease
45.5	45.5	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
18.2	18.2	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
6.1	6.1	CD	I-NP	O	O
,	,	,	O	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
33.3	33.3	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
9.1	9.1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
6.1	6.1	CD	I-NP	O	O
,	,	,	O	O	O
vomitus	vomitus	NN	B-NP	O	B-Disease
24.2	24.2	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
9.1	9.1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
0	0	CD	I-NP	O	O
,	,	,	O	O	O
diarrhea	diarrhea	NN	B-NP	O	B-Disease
36.4	36.4	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
6.1	6.1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
3.0	3.0	CD	I-NP	O	O
,	,	,	O	O	O
stomatitis	stomatitis	NN	B-NP	O	B-Disease
18.2	18.2	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
9.1	9.1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
0	0	CD	I-NP	O	O
,	,	,	O	O	O
hand	hand	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
foot	foot	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
12.1	12.1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
0	0	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
0	0	CD	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
hemolytic	hemolytic	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
uremic	uremic	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
HUS	HUS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
High	High	JJ	O	O	O
-	-	HYPH	O	O	O
dose	dose	NN	B-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
/	/	SYM	B-NP	O	O
FA	FA	NN	I-NP	B	B-Chemical
/	/	SYM	O	O	O
MMC	MMC	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	B-VP	O	O
tolerated	tolerate	VBN	B-NP	O	O
outpatient	outpatient	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
for	for	IN	B-PP	O	O
AGC	AGC	NN	B-NP	B	B-Disease
(	(	(	O	O	O
objective	objective	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
54.6	54.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
serve	serve	VB	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
alternative	alternative	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
regimens	regimen	NNS	B-NP	O	O
;	;	:	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
possibly	possibly	RB	B-NP	O	O
HUS	HUS	NNS	I-NP	O	B-Disease
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
.	.	.	O	O	O

Persistent	Persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
function	function	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	B-Disease
immunodeficiency	immunodeficiency	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	I-Disease
type	type	NN	I-NP	O	I-Disease
1	1	CD	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
infected	infect	VBN	I-NP	O	I-Disease
children	child	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Prolonged	Prolonged	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
documented	document	VBN	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
restricted	restrict	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
potent	potent	JJ	I-NP	O	O
protease	protease	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
to	to	TO	B-VP	O	O
monitor	monitor	VB	I-VP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cohort	cohort	NN	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
human	human	JJ	I-NP	O	B-Disease
immunodeficiency	immunodeficiency	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	I-Disease
type	type	NN	I-NP	O	I-Disease
1	1	CD	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
infected	infect	VBN	I-NP	O	I-Disease
children	child	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Urinary	Urinary	JJ	B-NP	O	O
pH	pH	NN	I-NP	O	O
,	,	,	O	O	O
albumin	albumin	NN	B-NP	O	O
,	,	,	O	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erythrocytes	erythrocyte	NNS	B-NP	O	O
,	,	,	I-NP	O	O
leukocytes	leukocyte	NNS	I-NP	O	O
,	,	,	I-NP	O	O
bacteria	bacteria	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
crystals	crystal	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
culture	culture	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
every	every	DT	B-NP	O	O
3	3	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
96	96	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
routinely	routinely	RB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
.	.	.	O	O	O

Steady	Steady	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
state	state	NN	I-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
done	do	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
week	week	NN	B-NP	O	O
4	4	CD	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
75	75	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	O	O	O
micro	micro	NN	B-NP	O	O
L	L	NN	I-NP	O	O
in	in	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
visits	visit	NNS	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
96	96	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
53	53	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Persistent	Persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
frequently	frequently	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mild	mild	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
albumin	albumin	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
ratio	ratio	NN	I-NP	O	O
and	and	CC	B-PP	O	O
by	by	IN	B-PP	O	O
microscopic	microscopic	JJ	B-NP	O	O
hematuria	hematuria	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
>	>	SYM	B-NP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
above	above	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
was	be	VBD	B-VP	O	O
33	33	CD	B-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
96	96	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Children	Child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
had	have	VBD	B-VP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
above	above	IN	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
children	child	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
younger	young	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
5.6	5.6	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
frequent	frequent	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
children	child	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
>	>	JJR	B-NP	O	O
19	19	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
x	x	SYM	B-NP	O	O
h	h	NN	B-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
>	>	SYM	O	O	O
12	12	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
4	4	CD	B-NP	O	O
children	child	NNS	I-NP	O	O
,	,	,	O	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
nephrotoxicity	nephrotoxicity	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Subsequently	Subsequently	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
urine	urine	NN	I-NP	O	O
albumin	albumin	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
ratios	ratio	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
zero	zero	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
disappeared	disappear	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Children	Child	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Children	Child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
>	>	SYM	B-NP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
above	above	IN	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
.	.	.	O	O	O

Younger	Younger	NN	B-NP	O	O
children	child	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
additional	additional	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
impairment	impairment	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
function	function	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
children	child	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nephrolithiasis	nephrolithiasis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Indinavir	Indinavir	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
associated	associate	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
persistent	persistent	JJ	B-NP	O	O
sterile	sterile	JJ	I-NP	O	O
leukocyturia	leukocyturia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
age	age	NN	B-NP	O	O
<	<	SYM	O	O	O
5.6	5.6	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
area	area	NN	I-NP	O	O
under	under	IN	B-PP	O	O
the	the	DT	B-NP	O	O
curve	curve	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indinavir	indinavir	NN	B-NP	B	B-Chemical
>	>	SYM	O	O	O
19	19	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
x	x	SYM	O	O	O
h	h	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
C	C	NN	I-NP	O	O
(	(	(	O	O	O
max	max	NN	B-NP	O	O
)	)	)	O	O	O
>	>	SYM	O	O	O
12	12	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

Utility	Utility	NN	B-NP	O	O
of	of	IN	B-PP	O	O
troponin	troponin	NN	B-NP	O	O
I	I	CD	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Baseline	Baseline	NN	B-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
and	and	CC	O	O	O
market	market	NN	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
not	not	RB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
necrosis	necrosis	NN	I-NP	O	I-Disease
make	make	VBP	B-VP	O	O
accurate	accurate	JJ	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MI	MI	NN	B-NP	B	B-Disease
)	)	)	O	O	O
difficult	difficult	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Troponin	Troponin	NN	B-NP	O	O
sampling	sampling	NN	I-NP	O	O
may	may	MD	B-VP	O	O
offer	offer	VB	I-VP	O	O
greater	great	JJR	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
utility	utility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
outcomes	outcome	NNS	B-NP	O	O
based	base	VBN	B-PP	O	O
on	on	IN	B-PP	O	O
troponin	troponin	NN	B-NP	O	O
positivity	positivity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
admitted	admit	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
exclusion	exclusion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
MI	MI	NN	B-NP	B	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Outcomes	Outcome	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
admitted	admit	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
possible	possible	JJ	B-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
after	after	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
rule	rule	NN	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
in	in	IN	B-PP	O	O
protocol	protocol	NN	B-NP	O	O
that	that	WDT	B-NP	O	O
included	include	VBD	B-VP	O	O
serial	serial	JJ	B-NP	O	O
sampling	sampling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
creatine	creatine	NN	B-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
(	(	(	O	O	O
CK	CK	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MB	MB	NN	I-NP	B	O
,	,	,	O	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
troponin	troponin	NN	I-NP	O	O
I	I	CD	I-NP	O	O
(	(	(	O	O	O
cTnI	cTnI	NN	B-NP	O	O
)	)	)	O	O	O
over	over	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Outcomes	Outcome	NNS	B-NP	O	O
included	include	VBD	B-VP	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	O	O	O
MB	MB	NN	B-NP	B	O
MI	MI	NN	I-NP	B	B-Disease
(	(	(	O	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MB	MB	NN	I-NP	B	O
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
8	8	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
relative	relative	JJ	I-NP	O	O
index	index	NN	I-NP	O	O
[	[	(	O	O	O
(	(	(	O	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MB	MB	NN	I-NP	B	O
x	x	SYM	I-NP	O	O
100	100	CD	I-NP	O	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
total	total	JJ	B-NP	O	O
CK	CK	NN	I-NP	O	O
]	]	)	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
4	4	CD	B-NP	O	O
,	,	,	O	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
death	death	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
significant	significant	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
246	246	CD	I-NP	O	O
admitted	admit	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
34	34	CD	B-NP	O	O
(	(	(	O	O	O
14	14	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
met	meet	VBD	B-VP	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MB	MB	NN	I-NP	B	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
MI	MI	NN	B-NP	B	B-Disease
and	and	CC	O	O	O
38	38	CD	B-NP	O	O
(	(	(	O	O	O
16	16	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
cTnI	cTnI	NN	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
.	.	.	O	O	O

Angiography	Angiography	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
29	29	CD	B-NP	O	O
of	of	IN	B-PP	O	O
38	38	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
cTnI	cTnI	NN	B-NP	O	O
-	-	HYPH	O	O	O
positive	positive	JJ	B-ADJP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
25	25	CD	B-NP	O	O
(	(	(	O	O	O
86	86	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
four	four	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
cTnI	cTnI	NN	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
met	meet	VBD	B-VP	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	O	O	O
MB	MB	NN	B-NP	B	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
MI	MI	NN	B-NP	B	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
peak	peak	JJ	I-NP	O	O
CK	CK	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
MB	MB	NN	I-NP	B	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
13	13	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
.	.	.	O	O	O

Sensitivities	Sensitivity	NNS	B-NP	O	O
,	,	,	O	O	O
specificities	specificity	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
positive	positive	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
negative	negative	JJ	I-NP	O	O
likelihood	likelihood	NN	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
predicting	predict	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
death	death	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
significant	significant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
high	high	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
both	both	CC	O	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MB	MB	NN	I-NP	B	O
MI	MI	NN	I-NP	B	B-Disease
and	and	CC	I-NP	O	O
cTnI	cTnI	NN	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	O	O	O
significantly	significantly	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Most	Most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cTnI	cTnI	NN	B-NP	O	O
elevations	elevation	NNS	I-NP	O	O
meet	meet	VBP	B-VP	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
MB	MB	NN	I-NP	B	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
MI	MI	NN	B-NP	B	B-Disease
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
have	have	VB	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
underlying	underlie	VBG	B-VP	O	O
significant	significant	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
.	.	.	O	O	O

Troponin	Troponin	NN	B-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
equivalent	equivalent	JJ	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
accuracy	accuracy	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
CK	CK	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
MB	MB	NN	I-NP	B	O
for	for	IN	B-PP	O	O
diagnosing	diagnose	VBG	B-VP	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
suspected	suspect	VBN	B-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	B-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
nicergoline	nicergoline	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Sermion	Sermion	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	B-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AIN	AIN	NN	B-NP	O	B-Disease
)	)	)	O	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
nicergoline	nicergoline	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Sermion	Sermion	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
50	50	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
fever	fever	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Before	Before	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
taking	take	VBG	I-VP	O	O
nicergoline	nicergoline	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
bendazac	bendazac	NN	I-NP	B	B-Chemical
lysine	lysine	NN	I-NP	I	I-Chemical
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
retinal	retinal	JJ	B-NP	O	B-Disease
vein	vein	NN	I-NP	O	I-Disease
occlusion	occlusion	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
ophthalmologic	ophthalmologic	JJ	B-NP	O	O
department	department	NN	I-NP	O	O
.	.	.	O	O	O

Thereafter	Thereafter	RB	B-ADVP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
experienced	experience	VBD	B-VP	O	O
intermittent	intermittent	JJ	B-NP	O	O
fever	fever	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
skin	skin	NN	I-NP	O	B-Disease
rash	rash	NN	I-NP	O	I-Disease
.	.	.	O	O	O

On	On	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
,	,	,	O	O	O
clinical	clinical	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-ADJP	O	O
.	.	.	O	O	O

arthralgia	arthralgia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
fever	fever	NN	I-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
laboratory	laboratory	NN	B-NP	O	O
findings	finding	NNS	I-NP	O	O
(	(	(	O	O	O
i.e	i.e	JJ	B-ADJP	O	O
.	.	.	O	O	O

eosinophilia	eosinophilia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
)	)	)	O	O	O
suggested	suggest	VBD	B-VP	O	O
AIN	AIN	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pathologic	pathologic	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
lymphocyte	lymphocyte	NN	I-NP	O	O
transformation	transformation	NN	I-NP	O	O
test	test	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
result	result	NN	I-NP	O	O
against	against	IN	B-PP	O	O
nicergoline	nicergoline	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
consisted	consist	VBN	I-VP	B	O
of	of	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nicergoline	nicergoline	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
intravenous	intravenous	JJ	B-NP	O	O
methylprednisolone	methylprednisolone	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
his	his	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
completely	completely	RB	I-VP	O	O
recovered	recover	VBN	I-VP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nicergoline	nicergoline	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
AIN	AIN	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Neuroleptic	Neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
complicated	complicate	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
massive	massive	JJ	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CRF	CRF	NN	B-NP	B	B-Disease
)	)	)	O	O	O
developed	develop	VBD	B-VP	O	O
neuroleptic	neuroleptic	JJ	B-NP	O	B-Disease
malignant	malignant	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
NMS	NMS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
levomepromazine	levomepromazine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
typical	typical	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NMS	NMS	NN	B-NP	O	B-Disease
,	,	,	O	O	O
massive	massive	JJ	B-NP	O	O
intestinal	intestinal	JJ	I-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
episode	episode	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
report	report	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
NMS	NMS	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
CRF	CRF	NN	B-NP	B	B-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
complicated	complicate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
intestinal	intestinal	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
needs	need	VBZ	B-VP	O	O
special	special	JJ	B-NP	O	O
caution	caution	NN	I-NP	O	O
for	for	IN	B-PP	O	O
this	this	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
in	in	IN	B-PP	O	O
right	right	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	O	O	O
left	leave	VBN	B-VP	O	O
-	-	HYPH	O	O	O
pawed	paw	VBN	B-VP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
staining	staining	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
asymmetrical	asymmetrical	JJ	I-NP	O	O
breakdown	breakdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
(	(	(	O	O	O
BBB	BBB	NN	B-NP	B	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Paw	Paw	NN	B-NP	O	O
preference	preference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
food	food	NN	I-NP	O	O
reaching	reach	VBG	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Adrenaline	Adrenaline	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
destroy	destroy	VB	I-VP	O	O
the	the	DT	B-NP	O	O
BBB	BBB	NN	I-NP	B	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
using	use	VBG	I-VP	O	O
triphenyltetrazolium	triphenyltetrazolium	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
TTC	TTC	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
staining	staining	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
slices	slice	NNS	I-NP	O	O
just	just	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
giving	give	VBG	B-VP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
30	30	CD	B-NP	O	O
s	s	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
whole	whole	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
sections	section	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
complete	complete	JJ	B-NP	O	O
staining	staining	NN	I-NP	O	O
with	with	IN	B-PP	O	O
TTC	TTC	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

After	After	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
for	for	IN	B-PP	O	O
30	30	CD	B-NP	O	O
s	s	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
large	large	JJ	B-NP	O	O
unstained	unstained	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
in	in	IN	B-PP	O	O
right	right	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
pawed	paw	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
vice	vice	NN	B-NP	O	O
versa	versa	NN	I-NP	O	O
in	in	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
pawed	paw	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

Similar	Similar	JJ	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
seizure	seizure	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
breakdown	breakdown	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BBB	BBB	NN	B-NP	B	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
explained	explain	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
asymmetric	asymmetric	JJ	I-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
flow	flow	NN	I-NP	O	O
depending	depend	VBG	B-VP	O	O
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
paw	paw	NN	I-NP	O	O
preference	preference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
contralateral	contralateral	JJ	B-NP	O	O
motor	motor	NN	I-NP	O	O
control	control	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
important	important	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
determining	determine	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dominant	dominant	JJ	I-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
hemisphere	hemisphere	NN	I-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

Carvedilol	Carvedilol	NN	B-NP	B	B-Chemical
protects	protect	VBZ	B-VP	O	O
against	against	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
cytopathic	cytopathic	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
mediate	mediate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-VP	O	O
cumulative	cumulative	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
irreversible	irreversible	JJ	I-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Recent	Recent	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
and	and	CC	O	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
key	key	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenic	pathogenic	JJ	I-NP	O	O
process	process	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
test	test	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-NP	O	O
carvedilol	carvedilol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
nonselective	nonselective	JJ	I-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
with	with	IN	B-PP	O	O
potent	potent	JJ	B-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
,	,	,	O	O	O
protects	protect	VBZ	B-VP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
bioenergetic	bioenergetic	JJ	I-NP	O	O
dysfunction	dysfunction	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
subchronic	subchronic	JJ	B-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Heart	Heart	NN	B-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
isolated	isolate	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
sc	sc	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
carvedilol	carvedilol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
ip	ip	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

Heart	Heart	NN	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
depressed	depressed	JJ	B-NP	O	O
rates	rate	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
state	state	NN	B-NP	O	O
3	3	CD	I-NP	O	O
respiration	respiration	NN	I-NP	O	O
(	(	(	O	O	O
336	336	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
26	26	CD	B-NP	O	O
versus	versus	IN	B-PP	O	O
425	425	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
53	53	CD	B-NP	O	O
natom	natom	NN	I-NP	O	O
O	O	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
mg	mg	NN	I-NP	O	O
protein	protein	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
(	(	(	O	O	O
RCR	RCR	NN	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
4.3	4.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
versus	versus	IN	B-PP	O	O
5.8	5.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.4	0.4	CD	B-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
isolated	isolate	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Mitochondrial	Mitochondrial	JJ	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
loading	load	VBG	B-VP	O	O
capacity	capacity	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NADH	NADH	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
dehydrogenase	dehydrogenase	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
suppressed	suppress	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Doxorubicin	Doxorubicin	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
RCR	RCR	NN	B-NP	O	O
for	for	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
(	(	(	O	O	O
3.9	3.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.9	0.9	CD	B-NP	O	O
versus	versus	IN	B-PP	O	O
5.6	5.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
0.7	0.7	CD	B-NP	O	O
for	for	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
cytochrome	cytochrome	NN	I-NP	O	O
oxidase	oxidase	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Coadministration	Coadministration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cellular	cellular	JJ	B-NP	O	O
vacuolization	vacuolization	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
myocytes	myocyte	NNS	I-NP	O	O
and	and	CC	O	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
respiration	respiration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
heart	heart	NN	B-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
.	.	.	O	O	O

Carvedilol	Carvedilol	NN	B-NP	B	B-Chemical
also	also	RB	B-ADVP	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
2	2	CD	B-NP	I	O
+	+	SYM	O	I	O
)	)	)	O	I	O
loading	load	VBG	B-VP	O	O
capacity	capacity	NN	B-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
complexes	complex	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Carvedilol	Carvedilol	NN	B-NP	B	B-Chemical
by	by	IN	B-PP	O	O
itself	itself	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
parameters	parameter	NNS	I-NP	O	O
measured	measure	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
or	or	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
protection	protection	NN	I-NP	O	O
by	by	IN	B-PP	O	O
carvedilol	carvedilol	NN	B-NP	B	B-Chemical
against	against	IN	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
structural	structural	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
damage	damage	NN	I-NP	O	O
may	may	MD	B-VP	O	O
afford	afford	VB	I-VP	O	O
significant	significant	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
advantage	advantage	NN	I-NP	O	O
in	in	IN	B-PP	O	O
minimizing	minimize	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	O	O	O
limiting	limit	VBG	B-VP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
accompanies	accompany	VBZ	B-VP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Cocaine	Cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
more	more	RBR	B-ADJP	O	O
influenced	influence	VBN	I-ADJP	O	O
by	by	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	B-Disease
the	the	DT	B-NP	O	I-Disease
locomotor	locomotor	NN	I-NP	O	I-Disease
activity	activity	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
dependent	dependent	JJ	B-ADJP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
seems	seem	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
A1	A1	NN	I-NP	O	O
and	and	CC	I-NP	O	O
A2	A2	NN	I-NP	B	O
receptors	receptor	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
:	:	:	O	O	O
2	2	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
p	p	NN	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
(	(	(	O	O	I-Chemical
2	2	CD	B-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
carboxyethyl	carboxyethyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
phenethylamino	phenethylamino	AFX	O	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
5	5	CD	B-NP	B	I-Chemical
'	'	SYM	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
N	N	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
ethylcarboxamidoadenosine	ethylcarboxamidoadenosine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
CGS	CGS	NN	B-NP	B	B-Chemical
21680	21680	CD	I-NP	I	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
A2A	A2A	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
,	,	,	O	O	O
N6	N6	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
cyclopentyladenosine	cyclopentyladenosine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
CPA	CPA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
A1	A1	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	B	B-Chemical
'	'	SYM	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
N	N	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
ethylcarboxamidoadenosine	ethylcarboxamidoadenosine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
NECA	NECA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
A2	A2	NN	B-NP	B	O
/	/	SYM	B-NP	O	O
A1	A1	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
and	and	CC	O	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
dependently	dependently	RB	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
cocaine	cocaine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

CPA	CPA	NN	B-NP	O	B-Chemical
reduced	reduce	VBD	B-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
action	action	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
motility	motility	NN	B-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
CGS	CGS	NN	B-NP	B	B-Chemical
21680	21680	CD	I-NP	I	I-Chemical
and	and	CC	O	O	O
NECA	NECA	NNP	B-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
,	,	,	O	O	O
given	give	VBN	B-PP	O	O
alone	alone	RB	B-ADVP	O	O
,	,	,	O	O	O
decreased	decrease	VBN	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
both	both	DT	B-NP	O	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
although	although	IN	B-SBAR	O	O
agonists	agonist	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
A1	A1	NN	B-NP	O	O
receptors	receptor	NNS	I-NP	O	O
seem	seem	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
stronger	strong	JJR	B-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
it	it	PRP	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
A2	A2	NN	B-NP	B	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
by	by	IN	B-PP	O	O
DMPX	DMPX	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3,7	3,7	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
dimethyl	dimethyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
1	1	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
propargylxanthine	propargylxanthine	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
significantly	significantly	RB	B-ADVP	O	O
enhanced	enhance	VBD	B-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
action	action	NN	I-NP	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
significant	significant	JJ	B-ADJP	O	O
.	.	.	O	O	O

CPT	CPT	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
8	8	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
cyclopentyltheophylline	cyclopentyltheophylline	NN	I-NP	O	I-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
-	-	HYPH	B-NP	O	O
A1	A1	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
any	any	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
all	all	DT	B-NP	O	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
doses	dose	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
active	active	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
A2	A2	NN	B-NP	B	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
(	(	(	O	O	O
DMPX	DMPX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
selective	selective	JJ	I-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
(	(	(	O	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
action	action	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
all	all	DT	B-NP	O	O
adenosine	adenosine	NN	I-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
(	(	(	O	O	O
A1	A1	NN	B-NP	O	O
and	and	CC	O	O	O
A2	A2	NN	B-NP	B	O
)	)	)	O	O	O
reduce	reduce	VBP	B-VP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
amphetamine	amphetamine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
locomotor	locomotor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
more	more	RBR	B-ADJP	O	O
influenced	influence	VBN	I-ADJP	O	O
by	by	IN	B-PP	O	O
adenosine	adenosine	NN	B-NP	B	B-Chemical
receptor	receptor	NN	I-NP	O	O
agonists	agonist	NNS	I-NP	O	O
(	(	(	O	O	O
particularly	particularly	RB	B-NP	O	O
A1	A1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
)	)	)	O	O	O
than	than	IN	B-SBAR	O	O
amphetamine	amphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hyperactivity	hyperactivity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bradyarrhythmia	bradyarrhythmia	NN	B-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
permanent	permanent	JJ	B-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
prior	prior	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AF	AF	NN	B-NP	B	B-Disease
)	)	)	O	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bradyarrhythmia	bradyarrhythmia	NN	B-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
permanent	permanent	JJ	I-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Reports	Report	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
bradyarrhythmia	bradyarrhythmia	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
infrequent	infrequent	JJ	B-ADJP	O	O
and	and	CC	O	O	O
limited	limited	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
studies	study	NNS	B-NP	O	O
assessing	assess	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
's	's	POS	B-NP	O	O
use	use	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
arrhythmias	arrhythmia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
study	study	NN	I-NP	O	O
cohort	cohort	NN	I-NP	O	O
of	of	IN	B-PP	O	O
8,770	8,770	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
age	age	NN	I-NP	O	O
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
65	65	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
AF	AF	NN	B-NP	B	B-Disease
was	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
provincewide	provincewide	JJ	I-NP	O	O
database	database	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Quebec	Quebec	NNP	B-NP	O	O
residents	resident	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MI	MI	NN	B-NP	B	B-Disease
)	)	)	O	O	O
between	between	IN	B-PP	O	O
1991	1991	CD	B-NP	O	O
and	and	CC	I-NP	O	O
1999	1999	CD	I-NP	O	O
.	.	.	O	O	O

Using	Use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
nested	nest	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
design	design	NN	I-NP	O	O
,	,	,	O	O	O
477	477	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bradyarrhythmia	bradyarrhythmia	NN	B-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
permanent	permanent	JJ	I-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
matched	match	VBN	I-VP	B	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
:	:	:	O	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
1,908	1,908	CD	B-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

Multivariable	Multivariable	JJ	B-NP	O	O
logistic	logistic	JJ	I-NP	O	O
regression	regression	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
estimate	estimate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
odds	odd	NNS	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
pacemaker	pacemaker	NN	B-NP	O	O
insertion	insertion	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
,	,	,	O	O	O
controlling	control	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
and	and	CC	O	O	O
exposure	exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
sotalol	sotalol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
Class	Class	NN	B-NP	O	O
I	I	CD	I-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-VP	O	O
blockers	blocker	NNS	B-NP	O	O
,	,	,	O	O	O
calcium	calcium	NN	B-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
blockers	blocker	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
digoxin	digoxin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pacemaker	pacemaker	NN	B-NP	O	O
insertion	insertion	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
:	:	:	O	O	O
2.14	2.14	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
]	]	)	O	O	O
:	:	:	O	O	O
1.30	1.30	CD	B-NP	O	O
to	to	TO	B-PP	O	O
3.54	3.54	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
modified	modify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
gender	gender	NN	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
risk	risk	NN	I-NP	O	O
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
versus	versus	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
:	:	:	O	O	O
3.86	3.86	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
1.70	1.70	CD	B-NP	O	O
to	to	TO	I-NP	O	O
8.75	8.75	CD	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

OR	OR	NN	B-NP	O	O
:	:	:	O	O	O
1.52	1.52	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
0.80	0.80	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.89	2.89	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Digoxin	Digoxin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
other	other	JJ	I-NP	O	O
medication	medication	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pacemaker	pacemaker	NN	B-NP	O	O
insertion	insertion	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
:	:	:	O	O	O
1.78	1.78	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
1.37	1.37	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.31	2.31	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
AF	AF	NN	B-NP	B	B-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
MI	MI	NN	I-NP	B	B-Disease
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bradyarrhythmia	bradyarrhythmia	NN	B-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
permanent	permanent	JJ	I-NP	O	O
pacemaker	pacemaker	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
augmented	augmented	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pacemaker	pacemaker	NN	B-NP	O	O
insertion	insertion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
requires	require	VBZ	B-VP	O	O
further	further	JJ	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
.	.	.	O	O	O

Indomethacin	Indomethacin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
morphologic	morphologic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
urinary	urinary	JJ	I-NP	O	O
bladder	bladder	NN	I-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
morphologic	morphologic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
urothelium	urothelium	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Nonsteroidal	Nonsteroidal	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
poorly	poorly	RB	I-NP	O	O
recognized	recognize	VBN	I-NP	O	O
and	and	CC	O	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
reported	report	VBN	I-NP	O	O
condition	condition	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
tiaprofenic	tiaprofenic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
condition	condition	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Three	Three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
established	establish	VBN	I-VP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
one	one	CD	B-NP	O	O
intraperitoneal	intraperitoneal	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
indomethacin	indomethacin	NN	B-NP	B	B-Chemical
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
10	10	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
oral	oral	JJ	B-NP	O	O
indomethacin	indomethacin	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
3.25	3.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
then	then	RB	I-VP	O	O
killed	kill	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
bladders	bladder	NNS	I-NP	O	O
removed	remove	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
light	light	NN	B-NP	O	O
and	and	CC	I-NP	O	O
electron	electron	NN	I-NP	O	O
microscopic	microscopic	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
light	light	NN	I-NP	O	O
microscopic	microscopic	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
some	some	DT	B-NP	O	O
focal	focal	JJ	I-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
degeneration	degeneration	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
prominent	prominent	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
both	both	DT	B-NP	O	O
indomethacin	indomethacin	NN	I-NP	B	B-Chemical
groups	group	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
statistically	statistically	RB	B-NP	O	O
increased	increase	VBN	I-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mast	mast	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mucosa	mucosa	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.0001	0.0001	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
penetration	penetration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
lanthanum	lanthanum	NN	B-NP	B	B-Chemical
nitrate	nitrate	NN	I-NP	I	I-Chemical
through	through	IN	B-PP	O	O
intercellular	intercellular	JJ	B-NP	O	O
areas	area	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mast	mast	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
statistically	statistically	RB	B-ADJP	O	O
significant	significant	JJ	I-ADJP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.0001	0.0001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Indomethacin	Indomethacin	NN	B-NP	B	B-Chemical
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
histopathologic	histopathologic	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
typical	typical	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
interstitial	interstitial	JJ	B-NP	O	B-Disease
cystitis	cystitis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
leaky	leaky	JJ	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
epithelium	epithelium	NN	I-NP	O	O
and	and	CC	O	O	O
mucosal	mucosal	JJ	B-NP	O	O
mastocytosis	mastocytosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
true	true	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nonsteroidal	nonsteroidal	JJ	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
humans	human	NNS	B-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
clarified	clarify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
prospective	prospective	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
phase	phase	NN	I-NP	O	O
II	II	CD	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
thalidomide	thalidomide	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
androgen	androgen	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
independent	independent	JJ	I-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antiangiogenic	antiangiogenic	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
assessed	assess	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
solid	solid	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
haematological	haematological	JJ	I-NP	O	B-Disease
malignancies	malignancy	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Thalidomide	Thalidomide	NN	B-NP	B	B-Chemical
blocks	block	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
angiogenic	angiogenic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
including	include	VBG	B-PP	O	O
bFGF	bFGF	NN	B-NP	O	O
,	,	,	I-NP	O	O
VEGF	VEGF	NN	I-NP	O	O
and	and	CC	I-NP	O	O
IL	IL	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
6	6	CD	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
undertook	undertake	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
study	study	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
thalidomide	thalidomide	IN	B-NP	B	B-Chemical
100	100	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
once	once	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
6	6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
20	20	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
androgen	androgen	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
independent	independent	JJ	I-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
study	study	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
109	109	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
(	(	(	O	O	O
median	median	NN	B-NP	O	O
107	107	CD	I-NP	O	O
,	,	,	O	O	O
range	range	NN	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	O	O	O
184	184	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
regular	regular	JJ	B-NP	O	O
measurement	measurement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prostate	prostate	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
antigen	antigen	NN	I-NP	O	O
(	(	(	O	O	O
PSA	PSA	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
urea	urea	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
electrolytes	electrolyte	NNS	I-NP	O	O
,	,	,	O	O	O
serum	serum	NN	B-NP	O	O
bFGF	bFGF	NN	I-NP	O	O
and	and	CC	I-NP	O	O
VEGF	VEGF	NN	I-NP	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
(	(	(	O	O	O
15	15	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
PSA	PSA	NN	I-NP	O	O
of	of	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
sustained	sustain	VBN	B-VP	O	O
throughout	throughout	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
16	16	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
2	2	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
six	six	CD	B-NP	O	O
(	(	(	O	O	O
37.5	37.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
absolute	absolute	JJ	B-NP	O	O
PSA	PSA	NN	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	NN	I-NP	O	O
of	of	IN	B-PP	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Increasing	Increase	VBG	B-VP	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
bFGF	bFGF	NN	I-NP	O	O
and	and	CC	I-NP	O	O
VEGF	VEGF	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
progressive	progressive	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
;	;	:	O	O	O
five	five	CD	B-NP	O	O
of	of	IN	I-NP	O	O
six	six	CD	I-NP	O	O
men	man	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
PSA	PSA	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decline	decline	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bFGF	bFGF	NN	B-NP	O	O
and	and	CC	I-NP	O	O
VEGF	VEGF	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
three	three	CD	B-NP	O	O
of	of	IN	I-NP	O	O
four	four	CD	I-NP	O	O
men	man	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rising	rise	VBG	I-NP	O	O
PSA	PSA	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
growth	growth	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
constipation	constipation	NN	B-NP	O	B-Disease
,	,	,	O	O	O
morning	morning	NN	B-NP	O	O
drowsiness	drowsiness	NN	I-NP	O	B-Disease
,	,	,	O	O	O
dizziness	dizziness	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
rash	rash	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
withdrawal	withdrawal	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
by	by	IN	B-PP	O	O
three	three	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
.	.	.	O	O	O

Evidence	Evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
sensory	sensory	JJ	I-NP	O	I-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
nine	nine	CD	B-NP	O	O
of	of	IN	B-PP	O	O
13	13	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
seven	seven	CD	I-NP	O	O
men	man	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
completed	complete	VBD	B-VP	O	O
six	six	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
subclinical	subclinical	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
four	four	CD	B-NP	O	O
before	before	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
seven	seven	CD	I-NP	O	O
at	at	IN	B-PP	O	O
repeat	repeat	NN	B-NP	O	O
testing	testing	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
option	option	NN	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
failed	fail	VBN	I-VP	O	O
other	other	JJ	B-NP	O	O
forms	form	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
therapy	therapy	NN	B-NP	O	O
,	,	,	O	O	O
provided	provide	VBN	B-VP	O	O
close	close	RB	B-ADVP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
is	be	VBZ	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Central	Central	JJ	B-NP	O	B-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
lumbar	lumbar	NN	B-NP	O	O
plexus	plexus	NN	I-NP	O	O
block	block	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
OBJECTIVES	OBJECTIVES	NNS	I-NP	O	O
:	:	:	O	O	O
Central	Central	JJ	B-NP	O	B-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
and	and	CC	O	O	I-Disease
cardiac	cardiac	JJ	B-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
recognized	recognize	VBN	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
regional	regional	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Levobupivacaine	Levobupivacaine	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
pure	pure	JJ	I-NP	O	O
S	S	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
enantiomer	enantiomer	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
developed	develop	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
improve	improve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
safety	safety	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
2	2	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
grand	grand	JJ	B-NP	O	B-Disease
mal	mal	JJ	I-NP	B	I-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
accidental	accidental	JJ	B-NP	O	O
intravascular	intravascular	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
REPORT	REPORT	NN	I-NP	O	O
:	:	:	O	O	O
Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
presenting	present	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
elective	elective	JJ	B-NP	O	O
orthopedic	orthopedic	JJ	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
limb	limb	NN	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
blockade	blockade	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lumbar	lumbar	JJ	I-NP	O	O
plexus	plexus	NN	I-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
posterior	posterior	JJ	I-NP	O	O
approach	approach	NN	I-NP	O	O
.	.	.	O	O	O

Immediately	Immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
0.5	0.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
with	with	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
2.5	2.5	CD	I-NP	O	O
microgram	microgram	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
grand	grand	JJ	B-NP	O	B-Disease
mal	mal	JJ	I-NP	B	I-Disease
seizures	seizure	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
despite	despite	IN	B-PP	O	O
negative	negative	JJ	B-NP	O	O
aspiration	aspiration	NN	I-NP	O	O
for	for	IN	B-PP	O	O
blood	blood	NN	B-NP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
epinephrine	epinephrine	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
successfully	successfully	RB	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
thiopental	thiopental	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
succinylcholine	succinylcholine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

Neither	Neither	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
signs	sign	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
preoperatively	preoperatively	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
adrenergic	adrenergic	JJ	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
masked	mask	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unintentional	unintentional	JJ	I-NP	O	O
intravascular	intravascular	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
safer	safe	JJR	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
profile	profile	NN	I-NP	O	O
than	than	IN	B-PP	O	O
racemic	racemic	JJ	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
if	if	IN	B-SBAR	O	O
adequate	adequate	JJ	B-NP	O	O
amounts	amount	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
levobupivacaine	levobupivacaine	NN	B-NP	B	B-Chemical
reach	reach	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
circulation	circulation	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
will	will	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
sufficient	sufficient	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
central	central	JJ	B-NP	O	B-Disease
nervous	nervous	JJ	I-NP	O	I-Disease
system	system	NN	I-NP	O	I-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
manifestations	manifestation	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
2	2	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Anaesthetic	Anaesthetic	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
myotonia	myotonia	NN	B-NP	O	B-Disease
congenita	congenita	NN	I-NP	O	I-Disease
:	:	:	O	O	O
case	case	NN	B-NP	O	O
study	study	NN	I-NP	O	O
and	and	CC	O	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
myotonic	myotonic	JJ	I-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Myotonia	Myotonia	NN	B-NP	O	B-Disease
congenita	congenita	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MC	MC	NN	B-NP	B	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
defect	defect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
skeletal	skeletal	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
chloride	chloride	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
sustained	sustained	JJ	B-NP	O	B-Disease
membrane	membrane	NN	I-NP	O	I-Disease
depolarisation	depolarisation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
previously	previously	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
32	32	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
muscle	muscle	NN	B-NP	O	B-Disease
spasm	spasm	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
secondary	secondary	JJ	B-NP	O	O
ventilation	ventilation	NN	I-NP	O	O
difficulties	difficulty	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
preoperative	preoperative	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
suxamethonium	suxamethonium	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
muscle	muscle	NN	I-NP	O	B-Disease
spasms	spasm	NNS	I-NP	O	I-Disease
disappeared	disappear	VBD	B-VP	O	O
spontaneously	spontaneously	RB	B-ADVP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
proceeded	proceed	VBD	B-VP	O	O
without	without	IN	B-PP	O	O
further	further	JJ	B-NP	O	O
problems	problem	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
subsequently	subsequently	RB	B-VP	O	O
questioned	question	VBN	I-VP	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
reported	report	VBD	B-VP	O	O
minor	minor	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
myotonic	myotonic	JJ	I-NP	O	B-Disease
condition	condition	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Myotonia	Myotonia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
and	and	CC	I-NP	O	O
EMG	EMG	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
MC	MC	NN	I-NP	B	B-Disease
was	be	VBD	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
genetically	genetically	RB	B-ADVP	O	O
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
nor	nor	CC	O	O	O
the	the	DT	B-NP	O	O
anaesthetist	anaesthetist	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
before	before	IN	B-PP	O	O
this	this	DT	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
lethal	lethal	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
give	give	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
brief	brief	JJ	I-NP	O	O
overview	overview	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ion	ion	NN	B-NP	O	B-Disease
channel	channel	NN	I-NP	O	I-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
including	include	VBG	B-PP	O	O
malignant	malignant	JJ	B-NP	O	B-Disease
hyperthermia	hyperthermia	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
anaesthetic	anaesthetic	JJ	I-NP	O	O
considerations	consideration	NNS	I-NP	O	O
.	.	.	O	O	O

Respiratory	Respiratory	JJ	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
Apnea	Apnea	NNP	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
occur	occur	VB	I-VP	O	O
during	during	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
systematic	systematic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ictal	ictal	JJ	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
few	few	JJ	B-ADJP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
regarding	regard	VBG	B-PP	O	O
respiratory	respiratory	JJ	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
defects	defect	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
interictal	interictal	JJ	B-NP	O	O
periods	period	NNS	I-NP	O	O
also	also	RB	B-ADVP	O	O
are	be	VBP	B-VP	O	O
scarce	scarce	JJ	B-ADJP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
we	we	PRP	B-NP	O	O
sought	seek	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
generate	generate	VB	I-VP	O	O
information	information	NN	B-NP	O	O
with	with	IN	B-PP	O	O
regard	regard	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
interictal	interictal	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Twelve	Twelve	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
six	six	CD	B-NP	O	O
chronically	chronically	RB	I-NP	O	O
epileptic	epileptic	JJ	I-NP	O	B-Disease
animals	animal	NNS	I-NP	O	O
and	and	CC	O	O	O
six	six	CD	B-NP	O	O
controls	control	NNS	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
anesthetized	anesthetize	VBN	I-VP	O	O
,	,	,	O	O	O
given	give	VBN	B-NP	O	O
tracheotomies	tracheotomy	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
subjected	subject	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
hyperventilation	hyperventilation	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
hypoventilation	hypoventilation	NN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

Breathing	Breathing	NN	B-NP	O	O
movements	movement	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
thoracic	thoracic	JJ	B-NP	O	O
volume	volume	NN	I-NP	O	O
and	and	CC	O	O	O
forced	force	VBN	B-NP	O	O
air	air	NN	I-NP	O	O
to	to	TO	B-VP	O	O
flow	flow	VB	I-VP	O	O
tidally	tidally	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pneumotachograph	pneumotachograph	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
flow	flow	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
differential	differential	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
transducer	transducer	NN	I-NP	O	O
,	,	,	O	O	O
passed	pass	VBN	B-VP	O	O
through	through	IN	B-PP	O	O
a	a	DT	B-NP	O	O
polygraph	polygraph	NN	I-NP	O	O
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
from	from	IN	B-PP	O	O
this	this	DT	B-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
computer	computer	NN	I-NP	O	O
with	with	IN	B-PP	O	O
custom	custom	NN	B-NP	O	O
software	software	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
derived	derive	VBD	B-VP	O	O
ventilation	ventilation	NN	B-NP	O	O
(	(	(	O	O	O
VE	VE	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
tidal	tidal	JJ	B-NP	O	O
volume	volume	NN	I-NP	O	O
(	(	(	O	O	O
VT	VT	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
inspiratory	inspiratory	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
TI	TI	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
expiratory	expiratory	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
TE	TE	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
breathing	breathing	NN	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
(	(	(	O	O	O
f	f	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
mean	mean	JJ	B-NP	O	O
inspiratory	inspiratory	JJ	I-NP	O	O
flow	flow	NN	I-NP	O	O
(	(	(	O	O	O
VT	VT	NN	B-NP	O	O
/	/	SYM	O	O	O
TI	TI	NN	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
breath	breath	NN	I-NP	O	O
-	-	HYPH	B-ADJP	O	O
by	by	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
breath	breath	NN	I-NP	O	O
basis	basis	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
hyperventilation	hyperventilation	NN	I-NP	O	B-Disease
maneuver	maneuver	NN	I-NP	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
spontaneous	spontaneous	JJ	B-NP	O	O
ventilation	ventilation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
and	and	CC	O	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
VE	VE	NN	B-NP	B	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epileptic	epileptic	JJ	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
VE	VE	NN	B-NP	B	O
was	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
(	(	(	O	O	O
p	p	NN	O	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	O	O	O
)	)	)	O	O	O
increase	increase	NN	B-NP	O	O
in	in	IN	B-PP	O	O
TE	TE	NN	B-NP	B	O
peak	peak	NN	I-NP	O	O
in	in	IN	B-PP	O	O
relation	relation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hypoventilation	hypoventilation	NN	I-NP	O	O
maneuver	maneuver	NN	I-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
Paco2	Paco2	NN	I-NP	O	O
,	,	,	O	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
VE	VE	NN	B-NP	B	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
epileptic	epileptic	JJ	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
VE	VE	NN	B-NP	B	O
was	be	VBD	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
(	(	(	O	O	O
p	p	NN	O	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	O	O	O
)	)	)	O	O	O
decrease	decrease	NN	B-NP	O	O
in	in	IN	B-PP	O	O
TE	TE	NN	B-NP	B	O
peak	peak	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
KCN	KCN	NN	B-NP	B	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
peripheral	peripheral	JJ	B-NP	O	O
chemoreception	chemoreception	NN	I-NP	O	O
activation	activation	NN	I-NP	O	O
on	on	IN	B-PP	O	O
ventilation	ventilation	NN	B-NP	O	O
,	,	,	O	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
VE	VE	NN	B-NP	B	O
for	for	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
altered	altered	JJ	I-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
react	react	VB	I-VP	O	O
to	to	TO	B-PP	O	O
(	(	(	O	O	O
or	or	CC	O	O	O
compensate	compensate	VB	B-VP	O	O
for	for	IN	B-PP	O	O
)	)	)	O	O	O
blood	blood	NN	B-NP	O	O
gas	gas	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
ventilation	ventilation	NN	B-NP	O	O
and	and	CC	O	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
centrally	centrally	RB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
speculate	speculate	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
relation	relation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
treating	treat	VBG	B-VP	O	O
different	different	JJ	B-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
serum	serum	NN	I-NP	O	O
soluble	soluble	JJ	I-NP	O	O
Fas	Fas	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
paracetamol	paracetamol	NN	B-NP	B	B-Chemical
overdose	overdose	NN	I-NP	O	B-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
AIMS	AIMS	NNS	I-NP	O	O
:	:	:	O	O	O
Experimental	Experimental	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
apoptosis	apoptosis	NN	B-NP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Fas	Fas	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
Fas	Fas	NN	I-NP	O	O
Ligand	Ligand	NN	I-NP	O	O
signaling	signaling	NN	I-NP	O	O
system	system	NN	I-NP	O	O
may	may	MD	B-VP	O	O
play	play	VB	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
soluble	soluble	JJ	I-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fas	Fas	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODOLOGY	METHODOLOGY	NN	B-NP	O	O
:	:	:	O	O	O
Serum	Serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
sFas	sFas	NN	B-NP	O	O
(	(	(	O	O	O
soluble	soluble	JJ	B-NP	O	O
Fas	Fas	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ELISA	ELISA	NN	B-NP	O	O
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
normal	normal	JJ	I-NP	O	O
control	control	NN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tumor	tumor	NN	B-NP	B	B-Disease
necrosis	necrosis	NN	I-NP	I	B-Disease
factor	factor	NN	I-NP	I	O
-	-	HYPH	O	I	O
alpha	alpha	SYM	B-NP	I	O
and	and	CC	O	O	O
interferon	interferon	NN	B-NP	B	O
-	-	HYPH	O	I	O
gamma	gamma	SYM	B-NP	I	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
ELISA	ELISA	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Serum	Serum	NN	B-NP	O	O
sFas	sFas	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
median	median	NN	B-NP	O	O
,	,	,	O	O	O
26.8	26.8	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
6.9	6.9	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
52.7	52.7	CD	I-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
controls	control	NNS	I-NP	O	O
(	(	(	O	O	O
median	median	NN	B-NP	O	O
,	,	,	O	O	O
8.6	8.6	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
6.5	6.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
12.0	12.0	CD	I-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.0001	0.0001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Levels	Level	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
paracetamol	paracetamol	NN	B-NP	B	B-Chemical
overdose	overdose	NN	I-NP	O	B-Disease
(	(	(	O	O	O
median	median	NN	B-NP	O	O
,	,	,	O	O	O
28.7	28.7	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
12.8	12.8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
52.7	52.7	CD	I-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
17	17	CD	B-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
A	A	NN	I-NP	O	O
to	to	TO	B-PP	O	O
E	E	NN	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
(	(	(	O	O	O
median	median	NN	B-NP	O	O
,	,	,	O	O	O
12.5	12.5	CD	B-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
;	;	:	O	O	O
range	range	NN	B-NP	O	O
,	,	,	O	O	O
6.9	6.9	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
46.0	46.0	CD	I-NP	O	O
U	U	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7	7	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sFas	sFas	NN	B-NP	O	O
to	to	TO	B-PP	O	O
eventual	eventual	JJ	B-NP	O	O
outcome	outcome	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
correlation	correlation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
sFas	sFas	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
aspartate	aspartate	NN	B-NP	B	B-Chemical
aminotransferase	aminotransferase	NN	I-NP	O	O
(	(	(	O	O	O
r	r	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.613	0.613	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sFas	sFas	NN	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
reflect	reflect	VB	I-VP	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Fas	Fas	NN	B-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-NP	O	O
apoptosis	apoptosis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
together	together	NN	I-NP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
tumor	tumor	NN	I-NP	B	B-Disease
necrosis	necrosis	NN	I-NP	I	B-Disease
factor	factor	NN	I-NP	I	O
-	-	HYPH	O	I	O
alpha	alpha	SYM	B-NP	I	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	O
subthalamic	subthalamic	JJ	I-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

High	High	JJ	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subthalamic	subthalamic	JJ	I-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
(	(	(	O	O	O
STN	STN	NN	B-NP	B	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
ameliorate	ameliorate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
advanced	advance	VBN	B-VP	B	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

AIM	AIM	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
STN	STN	NN	I-NP	B	O
stimulation	stimulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
23	23	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
Twenty	Twenty	CD	B-NP	O	O
-	-	HYPH	O	O	O
three	three	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
suffering	suffer	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
Stages	Stage	NNS	B-NP	O	O
III	III	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
V	V	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Hoehn	Hoehn	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Yahr	Yahr	NNP	I-NP	O	O
scale	scale	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
bradykinesia	bradykinesia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
rigidity	rigidity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
underwent	undergo	VBD	B-VP	O	O
bilateral	bilateral	JJ	B-NP	O	O
implantation	implantation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
electrodes	electrode	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STN	STN	NN	I-NP	B	O
.	.	.	O	O	O

Preoperative	Preoperative	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
postoperative	postoperative	JJ	I-NP	O	O
assessments	assessment	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	I-NP	O	O
6	6	CD	I-NP	O	O
and	and	CC	I-NP	O	O
12	12	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
"	"	``	O	O	O
on	on	IN	B-PP	O	O
"	"	''	O	O	O
and	and	CC	O	O	O
"	"	``	O	O	O
off	off	RP	B-PRT	O	O
"	"	''	O	O	O
drug	drug	NN	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
using	use	VBG	B-VP	O	O
Unified	Unified	NNP	B-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
Disease	Disease	NNP	I-NP	O	I-Disease
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
,	,	,	O	O	O
Hoehn	Hoehn	NNP	B-NP	O	O
and	and	CC	O	O	O
Yahr	Yahr	NNP	B-NP	O	O
staging	staging	NN	I-NP	O	O
,	,	,	O	O	O
England	England	NNP	B-NP	O	O
activities	activity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
living	living	NN	I-NP	O	O
score	score	NN	I-NP	O	O
and	and	CC	I-NP	O	O
video	video	NN	I-NP	O	O
recordings	recording	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
After	After	IN	B-PP	O	O
one	one	CD	B-NP	O	O
year	year	NN	I-NP	O	O
of	of	IN	B-PP	O	O
electrical	electrical	JJ	B-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STN	STN	NN	I-NP	B	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
'	'	POS	B-NP	O	O
scores	score	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
activities	activity	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
living	living	NN	I-NP	O	O
and	and	CC	I-NP	O	O
motor	motor	NN	I-NP	O	O
examination	examination	NN	I-NP	O	O
scores	score	NNS	I-NP	O	O
(	(	(	O	O	O
Unified	Unified	NNP	B-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
Disease	Disease	NN	I-NP	O	I-Disease
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
parts	part	NNS	I-NP	O	O
II	II	CD	I-NP	O	O
and	and	CC	I-NP	O	O
III	III	CD	I-NP	O	O
)	)	)	O	O	O
off	off	IN	B-PP	O	O
medication	medication	NN	B-NP	O	O
improved	improve	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
62	62	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
61	61	CD	B-NP	O	O
%	%	NN	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
0.0005	0.0005	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
subscores	subscore	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
akinesia	akinesia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
rigidity	rigidity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
tremor	tremor	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
gait	gait	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
improved	improve	VBD	B-VP	O	O
.	.	.	O	O	O

(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
0.0005	0.0005	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
813	813	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
to	to	TO	B-PP	O	O
359	359	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	O
functions	function	NNS	I-NP	O	O
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
developed	develop	VBD	B-VP	O	O
device	device	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
complications	complication	NNS	I-NP	O	O
and	and	CC	O	O	O
two	two	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
abnormal	abnormal	JJ	B-NP	O	O
weight	weight	NN	I-NP	O	O
gain	gain	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Bilateral	Bilateral	JJ	B-NP	O	O
subthalamic	subthalamic	JJ	I-NP	O	O
nucleus	nucleus	NN	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
advanced	advanced	JJ	B-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
"	"	``	B-NP	O	O
off	off	JJ	I-NP	O	O
"	"	''	I-NP	O	O
phase	phase	NN	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
,	,	,	O	O	O
improves	improve	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
axial	axial	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
and	and	CC	O	O	O
reduces	reduce	VBZ	B-VP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
requirements	requirement	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
useful	useful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
controlling	control	VBG	B-VP	O	O
drug	drug	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
induced	induce	VBN	I-NP	O	I-Disease
dyskinesias	dyskinesia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Ocular	Ocular	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
changes	change	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
subtenon	subtenon	NN	B-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
chemotherapy	chemotherapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
retinoblastoma	retinoblastoma	NN	B-NP	O	B-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Focal	Focal	JJ	B-NP	O	O
subtenon	subtenon	NN	I-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
recently	recently	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
presumably	presumably	RB	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
adjunct	adjunct	NN	I-NP	O	O
to	to	TO	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
intraocular	intraocular	JJ	B-NP	O	O
retinoblastoma	retinoblastoma	NN	I-NP	O	B-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
our	our	PRP$	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
experience	experience	NN	I-NP	O	O
with	with	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	B-Disease
ocular	ocular	JJ	I-NP	O	I-Disease
motility	motility	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
subtenon	subtenon	NN	B-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
noted	note	VBD	B-VP	O	O
abnormal	abnormal	JJ	B-NP	O	B-Disease
ocular	ocular	JJ	I-NP	O	I-Disease
motility	motility	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
retinoblastoma	retinoblastoma	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
subtenon	subtenon	NN	B-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

During	During	IN	B-PP	O	O
ocular	ocular	JJ	B-NP	O	O
manipulation	manipulation	NN	I-NP	O	O
under	under	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
assessed	assess	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
eyes	eye	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
forced	force	VBN	B-NP	O	O
duction	duction	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
,	,	,	O	O	O
comparing	compare	VBG	B-VP	O	O
ocular	ocular	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
after	after	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
control	control	NN	I-NP	O	O
with	with	IN	B-PP	O	O
ocular	ocular	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
at	at	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
.	.	.	O	O	O

Eyes	Eye	NNS	B-NP	O	O
subsequently	subsequently	RB	B-VP	O	O
enucleated	enucleate	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
treatment	treatment	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
4	4	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
histologically	histologically	RB	B-ADVP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Limitation	Limitation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ocular	ocular	JJ	B-NP	O	O
motility	motility	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
12	12	CD	I-NP	O	O
eyes	eye	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
intraocular	intraocular	JJ	B-NP	O	O
retinoblastoma	retinoblastoma	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
6	6	CD	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
subtenon	subtenon	NN	B-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
multimodality	multimodality	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Histopathological	Histopathological	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
many	many	JJ	B-NP	O	O
lipophages	lipophage	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
periorbital	periorbital	JJ	I-NP	O	O
fat	fat	NN	I-NP	O	O
surrounding	surround	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
optic	optic	JJ	I-NP	O	O
nerve	nerve	NN	I-NP	O	O
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
eye	eye	NN	I-NP	O	O
,	,	,	O	O	O
indicative	indicative	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
phagocytosis	phagocytosis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
previously	previously	RB	B-NP	O	O
existing	exist	VBG	I-NP	O	O
fat	fat	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	O	O	O
suggesting	suggest	VBG	B-VP	O	O
prior	prior	JJ	B-NP	O	O
fat	fat	NN	I-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
enucleations	enucleation	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
technically	technically	RB	B-ADJP	O	O
difficult	difficult	JJ	I-ADJP	O	O
and	and	CC	I-ADJP	O	O
hazardous	hazardous	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
globe	globe	NN	B-NP	O	O
rupture	rupture	NN	I-NP	O	B-Disease
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
extensive	extensive	JJ	B-NP	O	O
orbital	orbital	JJ	I-NP	O	O
soft	soft	JJ	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
adhesions	adhesion	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Subtenon	Subtenon	NN	B-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
chemotherapy	chemotherapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
orbital	orbital	JJ	B-NP	O	O
soft	soft	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
mechanical	mechanical	JJ	B-NP	O	O
restriction	restriction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eye	eye	NN	B-NP	O	O
movements	movement	NNS	I-NP	O	O
and	and	CC	O	O	O
making	make	VBG	B-VP	O	O
subsequent	subsequent	JJ	B-NP	O	O
enucleation	enucleation	NN	I-NP	O	O
difficult	difficult	JJ	B-ADJP	O	O
.	.	.	O	O	O

Subtenon	Subtenon	NN	B-NP	O	O
carboplatin	carboplatin	NN	I-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
free	free	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
best	well	RBS	B-ADJP	O	O
restricted	restricted	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
specific	specific	JJ	B-NP	O	O
indications	indication	NNS	I-NP	O	O
.	.	.	O	O	O

Ethambutol	Ethambutol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
optic	optic	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
optic	optic	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
Thirteen	Thirteen	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
optic	optic	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
tuberculosis	tuberculosis	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
lung	lung	NN	I-NP	O	I-Disease
or	or	CC	I-NP	O	I-Disease
lymph	lymph	NN	I-NP	O	I-Disease
node	node	NN	I-NP	O	I-Disease
at	at	IN	B-PP	O	O
Siriraj	Siriraj	NNP	B-NP	O	O
Hospital	Hospital	NNP	I-NP	O	O
between	between	IN	B-PP	O	O
1997	1997	CD	B-NP	O	O
and	and	CC	I-NP	O	O
2001	2001	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
retrospectively	retrospectively	RB	I-VP	O	O
reviewed	review	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
and	and	CC	O	O	O
initial	initial	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
final	final	JJ	I-NP	O	O
visual	visual	JJ	I-NP	O	O
acuity	acuity	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
visual	visual	JJ	B-NP	O	O
outcome	outcome	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
optic	optic	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
between	between	IN	B-PP	O	O
1	1	CD	B-NP	O	O
to	to	TO	I-NP	O	O
6	6	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
2.9	2.9	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
starting	start	VBG	B-VP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dosage	dosage	NN	I-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
13	13	CD	B-NP	O	O
to	to	TO	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
17	17	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Seven	Seven	CD	B-NP	O	O
(	(	(	O	O	O
54	54	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
13	13	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
visual	visual	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
after	after	IN	B-PP	O	O
stopping	stop	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
irreversible	irreversible	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
,	,	,	O	O	O
4	4	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
diabetes	diabetes	NN	B-NP	O	B-Disease
mellitus	mellitus	NN	I-NP	O	I-Disease
,	,	,	O	O	O
glaucoma	glaucoma	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heavy	heavy	JJ	B-NP	O	O
smoking	smoking	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Early	Early	JJ	B-NP	O	O
recognition	recognition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
optic	optic	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ethambutol	ethambutol	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	O	O	O
prompt	prompt	JJ	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
individuals	individual	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
diabetes	diabetes	NN	B-NP	O	B-Disease
mellitus	mellitus	NN	I-NP	O	I-Disease
,	,	,	O	O	O
glaucoma	glaucoma	NN	B-NP	O	B-Disease
or	or	CC	O	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
heavy	heavy	JJ	B-NP	O	O
smokers	smoker	NNS	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
compensatory	compensatory	JJ	B-NP	O	O
gustatory	gustatory	JJ	I-NP	O	B-Disease
hyperhidrosis	hyperhidrosis	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
topical	topical	JJ	B-NP	O	O
glycopyrrolate	glycopyrrolate	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Gustatory	Gustatory	JJ	B-NP	O	B-Disease
hyperhidrosis	hyperhidrosis	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
facial	facial	JJ	B-NP	O	O
sweating	sweating	NN	I-NP	O	B-Disease
usually	usually	RB	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
eating	eating	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hot	hot	JJ	B-NP	O	O
spicy	spicy	NN	I-NP	O	O
food	food	NN	I-NP	O	O
or	or	CC	O	O	O
even	even	RB	B-ADVP	O	O
smelling	smell	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
food	food	NN	I-NP	O	O
.	.	.	O	O	O

Current	Current	JJ	B-NP	O	O
options	option	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
include	include	VBP	B-VP	O	O
oral	oral	JJ	B-NP	O	O
anticholinergic	anticholinergic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
topical	topical	JJ	I-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anticholinergics	anticholinergic	NNS	B-NP	O	O
or	or	CC	O	O	O
aluminum	aluminum	NN	B-NP	B	B-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
botulinum	botulinum	NN	B-NP	O	O
toxin	toxin	NN	I-NP	O	O
.	.	.	O	O	O

Thirteen	Thirteen	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
date	date	NN	B-NP	O	O
with	with	IN	B-PP	O	O
1.5	1.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
or	or	CC	I-NP	O	O
2	2	CD	I-NP	O	O
%	%	NN	I-NP	O	O
topical	topical	JJ	I-NP	O	O
glycopyrrolate	glycopyrrolate	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
gustatory	gustatory	JJ	B-NP	O	B-Disease
hyperhidrosis	hyperhidrosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
interfered	interfere	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
social	social	JJ	I-NP	O	O
activities	activity	NNS	I-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
transthroacic	transthroacic	JJ	B-NP	O	O
endoscopic	endoscopic	JJ	I-NP	O	O
sympathectomy	sympathectomy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
compensatory	compensatory	JJ	B-NP	O	O
focal	focal	JJ	I-NP	O	O
hyperhidrosis	hyperhidrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
applying	apply	VBG	B-VP	O	O
topical	topical	JJ	B-NP	O	O
glycopyrrolate	glycopyrrolate	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
subjective	subjective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
excellent	excellent	JJ	B-ADJP	O	O
(	(	(	O	O	O
no	no	DT	B-NP	O	O
sweating	sweating	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
eating	eat	VBG	B-VP	O	O
hot	hot	JJ	B-NP	O	O
spicy	spicy	NN	I-NP	O	O
food	food	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
77	77	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
fair	fair	JJ	B-ADJP	O	O
(	(	(	O	O	O
clearly	clearly	RB	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
sweating	sweating	NN	B-NP	O	B-Disease
)	)	)	O	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
23	23	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
had	have	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
incidents	incident	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
very	very	RB	B-ADJP	O	O
embarrassed	embarrassed	JJ	I-ADJP	O	O
whilst	whilst	IN	B-PP	O	O
eating	eat	VBG	B-VP	O	O
hot	hot	JJ	B-NP	O	O
spicy	spicy	NN	I-NP	O	O
foods	food	NNS	I-NP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
included	include	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
mildly	mildly	RB	I-NP	O	O
dry	dry	JJ	I-NP	O	B-Disease
mouth	mouth	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
sore	sore	JJ	I-NP	O	B-Disease
throat	throat	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
glycopyrrolate	glycopyrrolate	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
light	light	JJ	I-NP	O	O
headache	headache	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
glycopyrrolate	glycopyrrolate	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
topical	topical	JJ	I-NP	O	O
application	application	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
glycopyrrolate	glycopyrrolate	NN	I-NP	B	B-Chemical
pad	pad	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
safe	safe	JJ	B-ADJP	O	O
,	,	,	O	O	O
efficacious	efficacious	JJ	B-ADJP	O	O
,	,	,	O	O	O
well	well	RB	B-ADJP	O	O
tolerated	tolerate	VBN	I-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
convenient	convenient	JJ	I-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
moderate	moderate	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
severe	severe	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
gustatory	gustatory	JJ	B-NP	O	B-Disease
hyperhidrosis	hyperhidrosis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
post	post	NN	B-NP	O	O
transthoracic	transthoracic	JJ	I-NP	O	O
endoscopic	endoscopic	JJ	I-NP	O	O
sympathectomy	sympathectomy	NN	I-NP	O	O
or	or	CC	I-NP	O	O
sympathicotomy	sympathicotomy	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
few	few	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Pharmacological	Pharmacological	JJ	B-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
and	and	CC	O	O	O
side	side	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
galenic	galenic	JJ	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
without	without	IN	B-PP	O	O
soyabean	soyabean	JJ	B-NP	O	O
oil	oil	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
pharmacokinetics	pharmacokinetic	NNS	I-NP	O	O
,	,	,	O	O	O
pharmacodynamics	pharmacodynamic	NNS	B-NP	O	O
and	and	CC	O	O	O
safety	safety	NN	B-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
galenic	galenic	JJ	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
AM149	AM149	NN	B-NP	O	O
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
contain	contain	VB	I-VP	O	O
soyabean	soyabean	JJ	B-NP	O	O
oil	oil	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
standard	standard	JJ	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Disoprivan	Disoprivan	NN	B-NP	B	B-Chemical
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomised	randomise	VBN	I-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	O	O	O
cross	cross	AFX	O	O	O
-	-	HYPH	O	O	O
over	over	IN	B-PP	O	O
study	study	NN	B-NP	O	O
,	,	,	O	O	O
30	30	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
mg.kg	mg.kg	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
propofol	propofol	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
drug	drug	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
and	and	CC	O	O	O
evaluated	evaluate	VBD	B-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
three	three	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
compartment	compartment	NN	I-NP	O	O
model	model	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
assessed	assess	VBN	B-VP	O	O
included	include	VBD	B-VP	O	O
induction	induction	NN	B-NP	O	O
and	and	CC	O	O	O
emergence	emergence	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
,	,	,	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
pain	pain	NN	B-NP	O	B-Disease
on	on	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
side	side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Owing	Owe	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombophlebitis	thrombophlebitis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
terminated	terminate	VBN	I-VP	O	O
prematurely	prematurely	RB	B-ADVP	O	O
and	and	CC	O	O	O
only	only	RB	B-NP	O	O
the	the	DT	I-NP	O	O
data	datum	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
parallel	parallel	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
15	15	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
group	group	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
analysed	analyse	VBN	I-VP	O	O
.	.	.	O	O	O

Plasma	Plasma	NN	B-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
formulations	formulation	NNS	I-NP	O	O
.	.	.	O	O	O

Anaesthesia	Anaesthesia	NN	B-NP	O	O
induction	induction	NN	I-NP	O	O
and	and	CC	O	O	O
emergence	emergence	NN	B-NP	O	O
times	time	NNS	I-NP	O	O
,	,	,	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
variables	variable	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Pain	Pain	NN	B-NP	O	B-Disease
on	on	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
(	(	(	O	O	O
80	80	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

20	20	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
thrombophlebitis	thrombophlebitis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
93.3	93.3	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

6.6	6.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
occurred	occur	VBD	B-VP	O	O
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
with	with	IN	B-PP	O	O
AM149	AM149	NN	B-NP	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
Disoprivan	Disoprivan	NNP	B-NP	B	B-Chemical
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
both	both	DT	B-NP	O	O
formulations	formulation	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
pharmacodynamic	pharmacodynamic	JJ	I-NP	O	O
profiles	profile	NNS	I-NP	O	O
the	the	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
formulation	formulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
suitable	suitable	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombophlebitis	thrombophlebitis	NN	B-NP	O	B-Disease
produced	produce	VBN	B-VP	O	O
.	.	.	O	O	O

Vinorelbine	Vinorelbine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
meta	meta	JJ	I-NP	B	O
-	-	HYPH	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
randomized	randomize	VBN	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
vinorelbine	vinorelbine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
quantify	quantify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
meta	meta	JJ	I-NP	B	O
-	-	HYPH	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
comparing	compare	VBG	B-VP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
malignancies	malignancy	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Randomized	Randomize	VBN	B-VP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
comparing	compare	VBG	B-VP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cancer	cancer	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
searched	search	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Medline	Medline	NN	B-NP	O	O
,	,	,	O	O	O
Embase	Embase	NN	B-NP	O	O
,	,	,	O	O	O
Evidence	Evidence	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
based	base	VBN	B-NP	O	O
Medicine	Medicine	NN	I-NP	O	O
Reviews	Reviews	NNP	I-NP	O	O
databases	database	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Cochrane	Cochrane	NN	I-NP	O	O
library	library	NN	I-NP	O	O
from	from	IN	B-PP	O	O
1987	1987	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2002	2002	CD	B-NP	O	O
.	.	.	O	O	O

Outcomes	Outcome	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
interest	interest	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
severe	severe	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
toxic	toxic	JJ	B-NP	O	O
deaths	death	NNS	I-NP	O	O
and	and	CC	O	O	O
cardiac	cardiac	JJ	B-NP	O	O
event	event	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
deaths	death	NNS	I-NP	O	O
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
publication	publication	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
19	19	CD	B-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
involving	involve	VBG	B-VP	O	O
2441	2441	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
2050	2050	CD	B-NP	O	O
control	control	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
1.19	1.19	CD	B-NP	O	O
%	%	NN	I-NP	O	O
[	[	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
(	(	(	O	O	O
CI	CI	NN	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
0.75	0.75	CD	B-NP	O	O
;	;	:	O	O	O
1.67	1.67	CD	B-NP	O	O
)	)	)	O	O	O
]	]	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
[	[	(	O	O	O
odds	odd	NNS	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
:	:	:	O	O	O
0.92	0.92	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
(	(	(	O	O	O
0.54	0.54	CD	B-NP	O	O
;	;	:	O	O	O
1.55	1.55	CD	B-NP	O	O
)	)	)	O	O	O
]	]	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
cardiac	cardiac	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
vindesine	vindesine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VDS	VDS	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
cardiotoxic	cardiotoxic	JJ	I-NP	O	B-Disease
drugs	drug	NNS	I-NP	O	O
[	[	(	O	O	O
fluorouracil	fluorouracil	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
anthracyclines	anthracycline	NNS	B-NP	O	B-Chemical
,	,	,	O	O	O
gemcitabine	gemcitabine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
GEM	GEM	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
em	em	NN	B-NP	O	O
leader	leader	NN	I-NP	B	O
]	]	)	O	O	O
.	.	.	O	O	O

Even	Even	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
it	it	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reach	reach	VB	I-VP	O	O
statistical	statistical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
few	few	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cases	case	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
trials	trial	NNS	B-NP	O	O
excluding	exclude	VBG	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
history	history	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
seemed	seem	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
trials	trial	NNS	B-NP	O	O
including	include	VBG	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	B-PP	O	O
existing	exist	VBG	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Vinorelbine	Vinorelbine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
concern	concern	NN	I-NP	O	O
about	about	IN	B-NP	O	O
1	1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treated	treat	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
VNR	VNR	NN	B-NP	O	B-Chemical
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
indications	indication	NNS	I-NP	O	O
.	.	.	O	O	O

MRI	MRI	NN	B-NP	O	O
findings	finding	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypoxic	hypoxic	JJ	B-NP	O	O
cortical	cortical	JJ	I-NP	O	O
laminar	laminar	JJ	I-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
child	child	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hemolytic	hemolytic	JJ	B-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
crisis	crisis	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
present	present	VBP	B-VP	O	O
magnetic	magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
findings	finding	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
girl	girl	NN	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
rapidly	rapidly	RB	I-NP	O	O
installing	instal	VBG	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
crisis	crisis	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
trimethoprim	trimethoprim	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
sulfomethoxazole	sulfomethoxazole	NN	I-NP	O	I-Chemical
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
anoxia	anoxia	NN	I-NP	O	I-Disease
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
permanent	permanent	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

Magnetic	Magnetic	JJ	B-NP	O	O
Resonance	Resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
cortical	cortical	JJ	B-NP	O	O
laminar	laminar	JJ	I-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	O
border	border	NN	I-NP	O	O
zones	zone	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
hemispheres	hemisphere	NNS	I-NP	O	O
,	,	,	O	O	O
ischemic	ischemic	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
subcortical	subcortical	JJ	B-NP	O	O
white	white	JJ	I-NP	O	O
matter	matter	NN	I-NP	O	O
of	of	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	O
hemisphere	hemisphere	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
putamen	putaman	NNS	I-NP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
cortical	cortical	JJ	B-NP	O	O
laminar	laminar	JJ	I-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
classic	classic	JJ	I-NP	B	O
entity	entity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adulthood	adulthood	NN	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
conditions	condition	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
energy	energy	NN	B-NP	O	O
depletions	depletion	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
few	few	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
available	available	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
wide	wide	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
presented	present	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
natural	natural	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vigabatrin	Vigabatrin	NN	B-NP	B	B-Chemical
associated	associated	JJ	I-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
electing	elect	VBG	B-VP	O	O
to	to	TO	I-VP	O	O
continue	continue	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natural	natural	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
Vigabatrin	Vigabatrin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
changes	change	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
elected	elect	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
continue	continue	VB	I-VP	O	O
the	the	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
good	good	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
control	control	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
Vigabatrin	Vigabatrin	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
other	other	JJ	B-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
5	5	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
12	12	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
entered	enter	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
a	a	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	O
surveillance	surveillance	NN	I-NP	O	O
programme	programme	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
followed	follow	VBN	I-VP	O	O
up	up	RP	B-PRT	O	O
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
monthly	monthly	JJ	I-NP	O	O
intervals	interval	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
not	not	RB	B-NP	O	O
less	less	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
18	18	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
18	18	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
43	43	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
all	all	DT	B-NP	O	O
,	,	,	O	O	O
16	16	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
unequivocal	unequivocal	JJ	B-NP	O	O
defects	defect	NNS	I-NP	O	O
continued	continue	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-VP	O	O
already	already	RB	I-VP	O	O
published	publish	VBN	I-VP	O	O
methodology	methodology	NN	B-NP	O	O
(	(	(	O	O	O
Eye	Eye	NN	B-NP	O	O
2002	2002	CD	I-NP	O	O
;	;	:	O	O	O
16	16	CD	B-NP	O	O
;	;	:	O	O	O
567	567	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
571	571	CD	I-NP	O	O
)	)	)	O	O	O
monocular	monocular	JJ	B-NP	O	O
mean	mean	JJ	I-NP	O	O
radial	radial	JJ	I-NP	O	O
degrees	degree	NNS	I-NP	O	O
(	(	(	O	O	O
MRDs	MRD	NNS	B-NP	O	O
)	)	)	O	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
I	I	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
4e	4e	NN	I-NP	O	O
isopter	isopter	NN	I-NP	O	O
on	on	IN	B-PP	O	O
Goldmann	Goldmann	NNP	B-NP	O	O
perimetry	perimetry	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
right	right	JJ	I-NP	O	O
eye	eye	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
discovery	discovery	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
defect	defect	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
again	again	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
not	not	RB	B-NP	O	O
less	less	JJR	I-NP	O	O
than	than	IN	I-NP	O	O
18	18	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Mean	Mean	JJ	B-NP	O	O
right	right	JJ	I-NP	O	O
eye	eye	NN	I-NP	O	O
MRD	MRD	NN	I-NP	O	O
at	at	IN	B-PP	O	O
presentation	presentation	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
36.98	36.98	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
22.25	22.25	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
51.0	51.0	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
38.40	38.40	CD	B-NP	O	O
degrees	degree	NNS	I-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
22.5	22.5	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
49.75	49.75	CD	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-SBAR	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
up	up	RP	B-PRT	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.338	0.338	CD	B-NP	O	O
unpaired	unpaired	JJ	I-NP	O	O
t	t	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
patient	patient	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
deterioration	deterioration	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
visual	visual	JJ	B-NP	O	I-Disease
field	field	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
period	period	NN	I-NP	O	O
and	and	CC	O	O	O
discontinued	discontinue	VBN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Established	Establish	VBN	B-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
presumed	presume	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
Vigabatrin	Vigabatrin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
usually	usually	RB	I-VP	O	O
progress	progress	VBP	I-VP	O	O
in	in	IN	B-PP	O	O
spite	spite	NN	B-NP	O	O
of	of	IN	B-PP	O	O
continuing	continue	VBG	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
give	give	VBP	B-VP	O	O
support	support	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Vigabatrin	Vigabatrin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
idiosyncratic	idiosyncratic	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
rather	rather	RB	B-CONJP	O	O
than	than	IN	I-CONJP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Induction	Induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rosaceiform	rosaceiform	JJ	B-NP	O	O
dermatitis	dermatitis	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
facial	facial	JJ	B-NP	O	B-Disease
inflammatory	inflammatory	JJ	I-NP	O	I-Disease
dermatoses	dermatos	NNS	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
ointment	ointment	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Tacrolimus	Tacrolimus	NN	B-NP	B	B-Chemical
ointment	ointment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increasingly	increasingly	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensitive	sensitive	JJ	B-NP	O	O
areas	area	NNS	I-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
the	the	DT	B-NP	O	O
face	face	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
recent	recent	JJ	B-NP	O	O
observations	observation	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
steroid	steroid	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
aggravated	aggravate	VBN	I-NP	O	O
rosacea	rosacea	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
perioral	perioral	JJ	I-NP	O	B-Disease
dermatitis	dermatitis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
rosaceiform	rosaceiform	NN	B-NP	O	O
dermatitis	dermatitis	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
ointment	ointment	NN	I-NP	O	O
.	.	.	O	O	O

OBSERVATIONS	OBSERVATIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Six	Six	CD	B-NP	O	O
adult	adult	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	B-Disease
facial	facial	JJ	I-NP	O	I-Disease
dermatoses	dermatos	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
ointment	ointment	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
ineffectiveness	ineffectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
standard	standard	JJ	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
.	.	.	O	O	O

Within	Within	IN	B-PP	O	O
2	2	CD	B-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
initially	initially	RB	B-NP	O	O
effective	effective	JJ	I-NP	O	O
and	and	CC	O	O	O
well	well	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
tolerated	tolerate	VBN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rosacea	rosacea	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acne	acne	NN	B-NP	O	B-Disease
experienced	experience	VBD	B-VP	O	O
sudden	sudden	JJ	B-NP	O	O
worsening	worsen	VBG	I-NP	O	O
with	with	IN	B-PP	O	O
pustular	pustular	JJ	B-NP	O	O
rosaceiform	rosaceiform	NN	I-NP	O	O
lesions	lesion	NNS	I-NP	O	O
.	.	.	O	O	O

Biopsy	Biopsy	NN	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
abundance	abundance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Demodex	Demodex	NN	B-NP	O	O
mites	mite	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
eyelid	eyelid	JJ	B-NP	O	O
eczema	eczema	NN	I-NP	O	B-Disease
,	,	,	O	O	O
rosaceiform	rosaceiform	VBP	B-VP	O	O
periocular	periocular	JJ	B-NP	O	B-Disease
dermatitis	dermatitis	NN	I-NP	O	I-Disease
gradually	gradually	RB	B-ADVP	O	O
appeared	appear	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
3	3	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
atopic	atopic	JJ	B-NP	O	B-Disease
dermatitis	dermatitis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
telangiectatic	telangiectatic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
papular	papular	JJ	I-NP	O	B-Disease
rosacea	rosacea	NN	I-NP	O	I-Disease
insidiously	insidiously	RB	B-ADVP	O	O
appeared	appear	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
5	5	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
observations	observation	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
spectrum	spectrum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rosaceiform	rosaceiform	JJ	B-NP	O	O
dermatitis	dermatitis	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
ointment	ointment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
heterogeneous	heterogeneous	JJ	B-ADJP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
factors	factor	NNS	B-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
vasoactive	vasoactive	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
proliferation	proliferation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Demodex	Demodex	NN	B-NP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
local	local	JJ	B-NP	O	O
immunosuppression	immunosuppression	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
occlusive	occlusive	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ointment	ointment	NN	I-NP	O	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
observed	observe	VBN	I-NP	O	O
phenomena	phenomenon	NNS	I-NP	O	O
.	.	.	O	O	O

Future	Future	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
individual	individual	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Structural	Structural	JJ	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brains	brain	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
use	use	VBP	B-VP	O	O
methamphetamine	methamphetamine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
visualize	visualize	VBP	B-VP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
profile	profile	NN	I-NP	O	O
of	of	IN	B-PP	O	O
structural	structural	JJ	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
human	human	JJ	I-NP	O	I-Disease
brain	brain	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
MA	MA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
abuse	abuse	NN	B-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
MA	MA	NN	B-NP	B	B-Chemical
chronically	chronically	RB	B-ADVP	O	O
have	have	VBP	B-VP	O	O
revealed	reveal	VBN	I-VP	O	O
deficits	deficit	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
systems	system	NNS	I-NP	O	O
and	and	CC	O	O	O
cerebral	cerebral	JJ	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Using	Use	VBG	B-VP	O	O
magnetic	magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
(	(	(	O	O	O
MRI	MRI	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
new	new	JJ	B-NP	O	O
computational	computational	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
-	-	HYPH	O	O	O
mapping	map	VBG	B-VP	O	O
techniques	technique	NNS	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
determined	determine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
structural	structural	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
alterations	alteration	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
MA	MA	JJ	I-NP	B	B-Chemical
abuse	abuse	NN	I-NP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	O	O	O
related	relate	VBN	B-VP	O	O
these	these	DT	B-NP	O	O
deficits	deficit	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
resolution	resolution	NN	I-NP	O	O
MRI	MRI	NN	I-NP	O	O
and	and	CC	I-NP	O	O
surface	surface	NN	I-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-VP	O	O
computational	computational	JJ	B-NP	O	O
image	image	NN	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
map	map	VB	I-VP	O	O
regional	regional	JJ	B-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
cortex	cortex	NN	I-NP	O	I-Disease
,	,	,	O	O	I-Disease
hippocampus	hippocampus	NN	B-NP	O	I-Disease
,	,	,	O	O	I-Disease
white	white	JJ	B-NP	O	I-Disease
matter	matter	NN	I-NP	O	I-Disease
,	,	,	O	O	I-Disease
and	and	CC	O	O	I-Disease
ventricles	ventricle	NNS	B-NP	O	I-Disease
in	in	IN	B-PP	O	O
22	22	CD	B-NP	O	O
human	human	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
used	use	VBD	B-VP	O	O
MA	MA	JJ	B-ADJP	B	B-Chemical
and	and	CC	O	O	O
21	21	CD	B-NP	O	O
age	age	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
matched	match	VBN	I-VP	B	O
,	,	,	O	O	O
healthy	healthy	JJ	B-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

Cortical	Cortical	JJ	B-NP	O	O
maps	map	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
severe	severe	JJ	B-NP	O	O
gray	gray	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
matter	matter	NN	I-NP	O	O
deficits	deficit	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cingulate	cingulate	NN	I-NP	O	O
,	,	,	O	O	O
limbic	limbic	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
paralimbic	paralimbic	JJ	B-NP	O	O
cortices	cortex	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MA	MA	JJ	B-NP	B	B-Chemical
abusers	abuser	NNS	I-NP	O	O
(	(	(	O	O	O
averaging	average	VBG	B-VP	O	O
11.3	11.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
below	below	IN	B-PP	O	O
control	control	NN	B-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
average	average	NN	B-NP	O	O
,	,	,	O	O	O
MA	MA	JJ	B-NP	B	B-Chemical
abusers	abuser	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
7.8	7.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
smaller	small	JJR	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
volumes	volume	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
control	control	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
;	;	:	O	O	O
left	leave	VBN	B-VP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
;	;	:	O	O	O
right	right	NN	B-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.05	0.05	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
significant	significant	JJ	B-NP	O	O
white	white	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
matter	matter	NN	I-NP	O	O
hypertrophy	hypertrophy	NN	I-NP	O	B-Disease
(	(	(	O	O	O
7.0	7.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Hippocampal	Hippocampal	JJ	B-NP	O	O
deficits	deficit	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
mapped	map	VBN	I-VP	O	O
and	and	CC	O	O	O
correlated	correlate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
memory	memory	NN	B-NP	O	O
performance	performance	NN	I-NP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
word	word	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
recall	recall	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

MRI	MRI	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
maps	map	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
chronic	chronic	JJ	B-NP	O	O
methamphetamine	methamphetamine	NN	I-NP	B	B-Chemical
abuse	abuse	NN	I-NP	O	O
causes	cause	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
selective	selective	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
impaired	impaired	JJ	B-NP	O	B-Disease
memory	memory	NN	I-NP	O	I-Disease
performance	performance	NN	I-NP	O	I-Disease
.	.	.	O	O	O

MA	MA	NN	B-NP	O	B-Chemical
may	may	MD	B-VP	O	O
selectively	selectively	RB	I-VP	O	O
damage	damage	VB	I-VP	O	O
the	the	DT	B-NP	O	O
medial	medial	JJ	I-NP	O	O
temporal	temporal	JJ	I-NP	O	O
lobe	lobe	NN	I-NP	O	O
and	and	CC	O	O	O
,	,	,	O	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
cingulate	cingulate	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
limbic	limbic	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
,	,	,	O	O	O
inducing	induce	VBG	B-VP	O	O
neuroadaptation	neuroadaptation	NN	B-NP	O	O
,	,	,	O	O	O
neuropil	neuropil	NN	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
cell	cell	NN	B-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

Prominent	Prominent	JJ	B-NP	O	O
white	white	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
matter	matter	NN	I-NP	O	O
hypertrophy	hypertrophy	NN	I-NP	O	B-Disease
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
altered	alter	VBN	B-NP	O	O
myelination	myelination	NN	I-NP	O	O
and	and	CC	O	O	O
adaptive	adaptive	JJ	B-NP	O	O
glial	glial	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
gliosis	gliosis	NN	B-NP	O	B-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
neuronal	neuronal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
substrates	substrate	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
help	help	VB	I-VP	O	O
account	account	VB	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MA	MA	JJ	B-NP	B	B-Chemical
abuse	abuse	NN	I-NP	O	O
,	,	,	O	O	O
providing	provide	VBG	B-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
targets	target	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
brain	brain	NN	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Disruption	Disruption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
homeostasis	homeostasis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
after	after	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
peroxisome	peroxisome	NN	B-NP	O	O
proliferator	proliferator	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
activated	activate	VBN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
alpha	alpha	SYM	I-NP	O	O
target	target	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
activation	activation	NN	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
efficacious	efficacious	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
widely	widely	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
hepatotoxicity	hepatotoxicity	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
gain	gain	VB	I-VP	O	O
insight	insight	NN	B-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
unwanted	unwanted	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
mice	mouse	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
various	various	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
examined	examine	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
histology	histology	NN	I-NP	O	O
and	and	CC	I-NP	O	O
gene	gene	NN	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
hepatomegaly	hepatomegaly	RB	B-ADVP	O	B-Disease
,	,	,	O	O	O
hepatocyte	hepatocyte	NN	B-NP	O	O
microvesicular	microvesicular	JJ	I-NP	O	O
lipid	lipid	NN	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
triglycerides	triglyceride	NNS	I-NP	B	B-Chemical
and	and	CC	O	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Northern	Northern	NN	B-NP	O	O
blot	blot	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
RNA	RNA	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
genes	gene	NNS	B-NP	O	O
critical	critical	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
fatty	fatty	JJ	B-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
oxidation	oxidation	NN	I-NP	O	O
,	,	,	O	O	O
lipoprotein	lipoprotein	NN	B-NP	O	O
assembly	assembly	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
lipid	lipid	NN	B-NP	O	O
transport	transport	NN	I-NP	O	O
.	.	.	O	O	O

Many	Many	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
genes	gene	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
regulated	regulate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peroxisome	peroxisome	NN	I-NP	O	O
proliferator	proliferator	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
activated	activate	VBN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
-	-	HYPH	O	O	O
alpha	alpha	SYM	B-NP	O	O
(	(	(	O	O	O
PPARalpha	PPARalpha	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
ligand	ligand	NN	I-NP	O	O
-	-	HYPH	O	O	O
activated	activate	VBN	B-VP	O	O
nuclear	nuclear	JJ	B-NP	O	O
hormone	hormone	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
transcription	transcription	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
genes	gene	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
hepatomegaly	hepatomegaly	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
PPARalpha	PPARalpha	NN	B-NP	O	O
knockout	knockout	NN	I-NP	O	O
[	[	(	O	O	O
PPARalpha	PPARalpha	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
]	]	)	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
indicated	indicate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
dependent	dependent	JJ	B-ADJP	O	O
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
functional	functional	JJ	I-NP	O	O
PPARalpha	PPARalpha	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
.	.	.	O	O	O

Compared	Compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
wild	wild	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
PPARalpha	PPARalpha	NN	B-NP	O	O
-	-	HYPH	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
mice	mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
total	total	JJ	B-NP	O	O
body	body	NN	I-NP	O	O
weight	weight	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
inability	inability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
to	to	TO	B-VP	O	O
directly	directly	RB	I-VP	O	O
activate	activate	VB	I-VP	O	O
either	either	CC	O	O	O
human	human	JJ	O	O	O
or	or	CC	O	O	O
mouse	mouse	NN	B-NP	O	O
PPARalpha	PPARalpha	NN	I-NP	O	O
transiently	transiently	RB	B-VP	O	O
expressed	express	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
HepG2	HepG2	NN	I-NP	O	O
hepatoma	hepatoma	NN	I-NP	O	B-Disease
cells	cell	NNS	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
indirect	indirect	JJ	B-ADJP	O	O
.	.	.	O	O	O

Based	Base	VBN	B-VP	O	O
upon	upon	IN	B-PP	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
disrupts	disrupt	VBZ	B-VP	O	O
hepatic	hepatic	JJ	B-NP	O	O
lipid	lipid	NN	I-NP	O	O
homeostasis	homeostasis	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PPARalpha	PPARalpha	NN	B-NP	O	O
target	target	NN	I-NP	O	O
genes	gene	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
provide	provide	VBP	B-VP	O	O
important	important	JJ	B-NP	O	O
new	new	JJ	I-NP	O	O
mechanistic	mechanistic	JJ	I-NP	O	O
information	information	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
hepatotoxic	hepatotoxic	JJ	I-NP	O	B-Disease
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
PPARalpha	PPARalpha	NN	B-NP	O	O
protects	protect	VBZ	B-VP	O	O
against	against	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Safety	Safety	NN	B-NP	O	O
and	and	CC	I-NP	O	O
compliance	compliance	NN	I-NP	O	O
with	with	IN	B-PP	O	O
once	once	RB	B-ADVP	O	O
-	-	HYPH	I-ADVP	O	O
daily	daily	JJ	B-NP	O	O
niacin	niacin	NN	I-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
release	release	NN	I-NP	O	I-Chemical
/	/	SYM	B-NP	O	I-Chemical
lovastatin	lovastatin	NN	I-NP	B	I-Chemical
as	as	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Impact	Impact	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Medical	Medical	NNP	B-NP	O	O
Subspecialty	Subspecialty	NNP	I-NP	O	O
on	on	IN	B-PP	O	O
Patient	Patient	NNP	B-NP	O	O
Compliance	Compliance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
Treatment	Treatment	NN	B-NP	O	O
(	(	(	O	O	O
IMPACT	IMPACT	NN	B-NP	O	O
)	)	)	O	O	O
study	study	NN	B-NP	O	O
.	.	.	O	O	O

Niacin	Niacin	NN	B-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
release	release	NN	I-NP	O	I-Chemical
/	/	SYM	B-NP	O	I-Chemical
lovastatin	lovastatin	NN	I-NP	B	I-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
combination	combination	NN	I-NP	O	O
product	product	NN	I-NP	O	O
approved	approve	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
hypercholesterolemia	hypercholesterolemia	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
mixed	mixed	JJ	B-NP	O	O
dyslipidemia	dyslipidemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
labeled	label	VBN	B-VP	O	O
,	,	,	O	O	O
multicenter	multicenter	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
bedtime	bedtime	NN	B-NP	O	O
niacin	niacin	NN	I-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
release	release	NN	I-NP	O	I-Chemical
/	/	SYM	B-NP	O	I-Chemical
lovastatin	lovastatin	NN	I-NP	B	I-Chemical
when	when	WRB	B-ADVP	O	O
dosed	dose	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
patient	patient	NN	B-NP	O	O
compliance	compliance	NN	I-NP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
in	in	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
practice	practice	NN	I-NP	O	O
settings	setting	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
4,499	4,499	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
dyslipidemia	dyslipidemia	NN	B-NP	O	B-Disease
requiring	require	VBG	B-VP	O	O
drug	drug	NN	B-NP	O	O
intervention	intervention	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
1,081	1,081	CD	B-NP	O	O
sites	site	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
1	1	CD	B-NP	O	O
tablet	tablet	NN	I-NP	O	O
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
niacin	niacin	NN	B-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
release	release	NN	I-NP	O	O
/	/	SYM	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lovastatin	lovastatin	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
once	once	RB	B-ADVP	O	O
nightly	nightly	RB	I-ADVP	O	O
for	for	IN	B-PP	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	O	O	O
then	then	RB	O	O	O
2	2	CD	B-NP	O	O
tablets	tablet	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
8	8	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
also	also	RB	B-ADVP	O	O
received	receive	VBD	B-VP	O	O
dietary	dietary	JJ	B-NP	O	O
counseling	counseling	NN	I-NP	O	O
,	,	,	O	O	O
educational	educational	JJ	B-NP	O	O
materials	material	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
reminders	reminder	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
call	call	VB	I-VP	O	O
a	a	DT	B-NP	O	O
toll	toll	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
provided	provide	VBD	B-VP	O	O
further	further	JJ	B-NP	O	O
education	education	NN	I-NP	O	O
about	about	IN	B-PP	O	O
dyslipidemia	dyslipidemia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
niacin	niacin	NN	I-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
release	release	NN	I-NP	O	I-Chemical
/	/	SYM	B-NP	O	I-Chemical
lovastatin	lovastatin	NN	I-NP	B	I-Chemical
.	.	.	O	O	O

Primary	Primary	JJ	B-NP	O	O
end	end	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
study	study	NN	B-NP	O	O
compliance	compliance	NN	I-NP	O	O
,	,	,	O	O	O
increases	increase	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transaminases	transaminase	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
>	>	SYM	B-NP	O	O
3	3	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
myopathy	myopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Final	Final	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
status	status	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
available	available	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
4,217	4,217	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
94	94	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Compliance	Compliance	NN	B-NP	O	O
to	to	TO	B-PP	O	O
niacin	niacin	NN	B-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
release	release	NN	I-NP	O	I-Chemical
/	/	SYM	B-NP	O	I-Chemical
lovastatin	lovastatin	NN	I-NP	B	I-Chemical
was	be	VBD	B-VP	O	O
77	77	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
3,245	3,245	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
completing	complete	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
southeast	southeast	NN	I-NP	O	O
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
enrolled	enrol	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
endocrinologists	endocrinologist	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
lowest	low	JJS	I-NP	O	O
compliance	compliance	NN	I-NP	O	O
and	and	CC	O	O	O
highest	high	JJS	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
.	.	.	O	O	O

Flushing	Flushing	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
,	,	,	O	O	O
reported	report	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
and	and	CC	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
by	by	IN	B-PP	O	O
6	6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Incidence	Incidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
aspartate	aspartate	NN	I-NP	B	B-Chemical
aminotransferase	aminotransferase	NN	I-NP	O	O
and	and	CC	O	O	O
/	/	SYM	B-NP	O	O
or	or	CC	O	O	O
alanine	alanine	NN	B-NP	B	B-Chemical
aminotransferase	aminotransferase	NN	I-NP	O	O
>	>	SYM	B-VP	O	O
3	3	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
was	be	VBD	B-VP	O	O
<	<	JJR	B-NP	O	O
0.3	0.3	CD	I-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
creatine	creatine	NN	B-NP	B	B-Chemical
phosphokinase	phosphokinase	NN	I-NP	O	O
to	to	TO	B-PP	O	O
>	>	SYM	B-NP	O	O
5	5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
the	the	DT	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limit	limit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
0.24	0.24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myopathy	myopathy	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Niacin	Niacin	NN	B-NP	B	B-Chemical
extended	extend	VBN	B-VP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
release	release	NN	I-NP	O	I-Chemical
/	/	SYM	B-VP	O	I-Chemical
lovastatin	lovastatin	NN	B-NP	B	I-Chemical
1,000	1,000	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
,	,	,	O	O	O
dosed	dose	VBN	B-VP	O	O
as	as	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
good	good	JJ	B-NP	O	O
compliance	compliance	NN	I-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
very	very	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
incidences	incidence	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
.	.	.	O	O	O

Protective	Protective	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Terminalia	Terminalia	NNP	B-NP	O	B-Chemical
chebula	chebula	NN	I-NP	O	I-Chemical
against	against	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Cardioprotective	Cardioprotective	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ethanolic	ethanolic	JJ	B-NP	O	B-Chemical
extract	extract	NN	I-NP	O	I-Chemical
of	of	IN	B-PP	O	I-Chemical
Terminalia	Terminalia	NNP	B-NP	O	I-Chemical
chebula	chebula	NN	I-NP	O	I-Chemical
fruits	fruit	NNS	I-NP	O	I-Chemical
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
wt	wt	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
body	body	NN	I-NP	O	O
wt	wt	NN	I-NP	O	O
)	)	)	O	O	O
induced	induce	VBD	B-VP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
administered	administer	VBN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
peroxides	peroxide	NNS	I-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
.	.	.	O	O	O

Histopathological	Histopathological	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
to	to	TO	B-VP	O	O
confirm	confirm	VB	I-VP	O	O
the	the	DT	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	O
necrosis	necrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

T.	T.	NN	B-NP	O	B-Chemical
chebula	chebula	NN	I-NP	O	I-Chemical
extract	extract	NN	I-NP	O	I-Chemical
pretreatment	pretreatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
ameliorate	ameliorate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
isoproterenol	isoproterenol	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
peroxide	peroxide	NN	I-NP	B	B-Chemical
formation	formation	NN	I-NP	O	O
and	and	CC	O	O	O
retained	retain	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
activities	activity	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
postoperative	postoperative	JJ	B-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
low	low	JJ	B-NP	O	O
dose	dose	NN	I-NP	O	O
droperidol	droperidol	NN	I-NP	B	B-Chemical
used	use	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
patient	patient	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
controlled	control	VBN	I-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
multiparous	multiparous	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
in	in	IN	B-PP	O	O
good	good	JJ	B-NP	O	O
psychological	psychological	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
urgent	urgent	JJ	B-NP	O	O
caesarean	caesarean	JJ	I-NP	O	O
section	section	NN	I-NP	O	O
in	in	IN	B-PP	O	O
labour	labour	NN	B-NP	O	O
.	.	.	O	O	O

Postoperatively	Postoperatively	RB	B-ADVP	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
-	-	HYPH	O	O	O
controlled	control	VBN	B-NP	O	O
analgesia	analgesia	NN	I-NP	O	O
device	device	NN	I-NP	O	O
delivering	deliver	VBG	B-VP	O	O
boluses	bolus	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
diamorphine	diamorphine	NN	B-NP	B	B-Chemical
0.5	0.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
droperidol	droperidol	NN	I-NP	B	B-Chemical
0.025	0.025	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
.	.	.	O	O	O

Whilst	Whilst	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
device	device	NN	I-NP	O	O
she	she	PRP	B-NP	O	O
gradually	gradually	RB	B-ADVP	O	O
became	become	VBD	B-VP	O	O
anxious	anxious	JJ	B-ADJP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
feeling	feeling	NN	I-NP	O	O
worsening	worsen	VBG	B-VP	O	O
after	after	IN	B-SBAR	O	O
each	each	DT	B-NP	O	O
bolus	bolus	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
droperidol	droperidol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
psychological	psychological	JJ	I-NP	O	B-Disease
disturbance	disturbance	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
made	make	VBN	I-VP	O	O
straight	straight	RB	B-ADVP	O	O
away	away	RB	I-ADVP	O	O
although	although	IN	B-SBAR	O	O
on	on	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
close	close	NN	I-NP	O	O
questioning	question	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
gave	give	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
very	very	RB	I-NP	O	O
clear	clear	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-SBAR	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
only	only	RB	B-NP	O	O
0.9	0.9	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
droperidol	droperidol	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
syringe	syringe	NN	I-NP	O	O
containing	contain	VBG	B-VP	O	O
diamorphine	diamorphine	NN	B-NP	B	B-Chemical
only	only	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
substituted	substitute	VBN	I-VP	O	O
and	and	CC	O	O	O
her	her	PRP$	B-NP	O	O
unease	unease	NN	I-NP	O	O
resolved	resolve	VBD	B-VP	O	O
completely	completely	RB	B-ADVP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
feel	feel	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
dramatic	dramatic	JJ	I-NP	O	O
extrapyramidal	extrapyramidal	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
antiemetics	antiemetic	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
well	well	RB	I-VP	O	O
known	know	VBN	I-VP	O	O
,	,	,	O	O	O
more	more	RBR	B-NP	O	O
subtle	subtle	JJ	I-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
easily	easily	RB	I-VP	O	O
be	be	VB	I-VP	O	O
overlooked	overlook	VBN	I-VP	O	O
.	.	.	O	O	O

Accurate	Accurate	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
history	history	NN	I-NP	O	O
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
differentiating	differentiate	VBG	B-VP	O	O
diabetes	diabete	NNS	B-NP	O	B-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
study	study	NN	I-NP	O	O
highlights	highlight	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nursing	nursing	NN	B-NP	O	O
in	in	IN	B-PP	O	O
obtaining	obtain	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
accurate	accurate	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
history	history	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
case	case	NN	I-NP	O	O
discussed	discuss	VBD	B-VP	O	O
herein	herein	RB	B-ADVP	O	O
initially	initially	RB	B-ADVP	O	O
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
neurogenic	neurogenic	JJ	B-NP	O	B-Disease
diabetes	diabetes	NN	I-NP	O	I-Disease
insipidus	insipidus	NN	I-NP	O	I-Disease
(	(	(	O	O	O
DI	DI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
traumatic	traumatic	JJ	I-NP	O	B-Disease
brain	brain	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
nursing	nursing	NN	I-NP	O	O
staff	staff	NN	I-NP	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
reviewing	review	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
health	health	NN	I-NP	O	O
history	history	NN	I-NP	O	O
with	with	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
family	family	NN	I-NP	O	O
,	,	,	O	O	O
discovered	discover	VBD	B-VP	B	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
polydipsia	polydipsia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
long	long	RB	B-ADVP	O	O
-	-	HYPH	O	O	O
standing	stand	VBG	B-VP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrogenic	nephrogenic	JJ	I-NP	O	B-Disease
DI	DI	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
because	because	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
received	receive	VBN	I-VP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
since	since	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
,	,	,	O	O	O
his	his	PRP$	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
changed	change	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
focus	focus	VB	I-VP	O	O
on	on	IN	B-PP	O	O
nephrogenic	nephrogenic	JJ	B-NP	O	B-Disease
DI	DI	NNP	I-NP	O	I-Disease
.	.	.	O	O	O

By	By	IN	B-PP	O	O
combining	combine	VBG	B-VP	O	O
information	information	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
history	history	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
physical	physical	JJ	I-NP	O	O
examination	examination	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
radiologic	radiologic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
laboratory	laboratory	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
team	team	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
self	self	AFX	B-ADJP	O	O
-	-	HYPH	O	O	O
treating	treat	VBG	B-VP	O	O
his	his	PRP$	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
nephrogenic	nephrogenic	JJ	I-NP	O	B-Disease
DI	DI	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
developed	develop	VBD	B-VP	O	O
neurogenic	neurogenic	JJ	B-NP	O	B-Disease
DI	DI	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
brain	brain	NN	B-NP	O	B-Disease
trauma	trauma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Thus	Thus	RB	B-NP	O	O
successful	successful	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
required	require	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
nephrogenic	nephrogenic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neurogenic	neurogenic	JJ	I-NP	O	B-Disease
DI	DI	NN	I-NP	O	I-Disease
be	be	VB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
.	.	.	O	O	O

Factors	Factor	NNS	B-NP	O	O
contributing	contribute	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
AIM	AIM	NN	I-NP	O	O
:	:	:	O	O	O
Interferon	Interferon	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
ribavirin	ribavirin	NN	I-NP	B	B-Chemical
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
C	C	NN	I-NP	O	I-Disease
produces	produce	VBZ	B-VP	O	O
hemolytic	hemolytic	JJ	B-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
identify	identify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
factors	factor	NNS	I-NP	O	O
contributing	contribute	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	O	O	O
eight	eight	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
C	C	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
interferon	interferon	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
alpha	alpha	SYM	O	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
2b	2b	NN	B-NP	O	I-Chemical
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
MU	MU	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
intramuscularly	intramuscularly	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
24	24	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	B	B-Chemical
administered	administer	VBN	B-VP	O	O
orally	orally	RB	B-ADVP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
600	600	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	O	O	O
800	800	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
participated	participate	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
hemoglobin	hemoglobin	NN	I-NP	B	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
<	<	SYM	B-NP	O	O
10	10	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
ribavirin	ribavirin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Ribavirin	Ribavirin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
18	18	CD	B-NP	O	O
(	(	(	O	O	O
20.5	20.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
2	2	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hemoglobin	hemoglobin	NN	B-NP	B	O
concentrations	concentration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
anemia	anemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
week	week	NN	B-NP	O	O
2	2	CD	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
start	start	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hemoglobin	hemoglobin	NN	I-NP	B	O
concentration	concentration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
at	at	IN	B-PP	O	O
week	week	NN	B-NP	O	O
2	2	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
lower	low	JJR	I-ADJP	O	O
even	even	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
week	week	NN	B-NP	O	O
2	2	CD	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
<	<	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hemoglobin	hemoglobin	NN	B-NP	B	O
concentrations	concentration	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
week	week	NN	B-NP	O	O
2	2	CD	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anemia	anemia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
factors	factor	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
sex	sex	NN	B-NP	O	O
(	(	(	O	O	O
female	female	JJ	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
age	age	NN	B-NP	O	O
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
60	60	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
old	old	JJ	B-ADJP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
ribavirin	ribavirin	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
by	by	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
significant	significant	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
univariate	univariate	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Careful	Careful	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
necessary	necessary	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
60	60	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
old	old	JJ	B-ADJP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
female	female	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
ribavirin	ribavirin	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
experience	experience	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hemoglobin	hemoglobin	NN	B-NP	B	O
concentrations	concentration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
2	2	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
at	at	IN	B-PP	O	O
week	week	NN	B-NP	O	O
2	2	CD	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
start	start	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
particular	particular	JJ	B-NP	O	O
care	care	NN	I-NP	O	O
.	.	.	O	O	O

Oxidative	Oxidative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
precedes	precede	VBZ	B-VP	O	O
nitrative	nitrative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
elevated	elevated	JJ	B-NP	O	O
reactive	reactive	JJ	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
ROS	ROS	NN	B-NP	B	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
nitrogen	nitrogen	NN	I-NP	B	B-Chemical
species	specie	NNS	I-NP	O	O
(	(	(	O	O	O
RNS	RNS	NNS	B-NP	B	O
)	)	)	O	O	O
reported	report	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
actually	actually	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
oxidative	oxidative	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
nitrative	nitrative	JJ	I-NP	O	O
damage	damage	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
quantitatively	quantitatively	RB	I-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
course	course	NN	I-NP	O	O
and	and	CC	O	O	O
subcellular	subcellular	JJ	B-NP	O	O
localization	localization	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
postulated	postulate	VBN	I-NP	O	O
damage	damage	NN	I-NP	O	O
products	product	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
approach	approach	NN	I-NP	O	O
.	.	.	O	O	O

B6C3	B6C3	NN	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
ADR	ADR	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Ultrastructural	Ultrastructural	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
and	and	CC	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
4	4	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxy	hydroxy	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
2	2	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
nonenal	nonenal	JJ	I-NP	I	I-Chemical
(	(	(	O	O	O
4HNE	4HNE	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
protein	protein	NN	I-NP	O	O
adducts	adduct	NNS	I-NP	O	O
and	and	CC	O	O	O
3	3	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
nitrotyrosine	nitrotyrosine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
3NT	3NT	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
.	.	.	O	O	O

Quantitative	Quantitative	JJ	B-NP	O	O
ultrastructural	ultrastructural	JJ	I-NP	O	O
damage	damage	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
computerized	computerized	JJ	B-NP	O	O
image	image	NN	I-NP	O	O
techniques	technique	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	O
injury	injury	NN	I-NP	O	O
as	as	RB	B-ADVP	O	O
early	early	RB	I-ADVP	O	O
as	as	IN	B-PP	O	O
3	3	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
mitochondria	mitochondrion	NNS	B-NP	O	O
being	be	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
extensively	extensively	RB	I-NP	O	O
and	and	CC	O	O	O
progressively	progressively	RB	B-NP	O	O
injured	injure	VBN	I-NP	O	O
subcellular	subcellular	JJ	I-NP	O	O
organelle	organelle	NN	I-NP	O	O
.	.	.	O	O	O

Analysis	Analysis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
4HNE	4HNE	NN	B-NP	O	B-Chemical
protein	protein	NN	I-NP	O	O
adducts	adduct	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
immunogold	immunogold	NN	B-NP	O	O
electron	electron	NN	I-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
appearance	appearance	NN	B-NP	O	O
of	of	IN	B-PP	O	O
4HNE	4HNE	NN	B-NP	O	B-Chemical
protein	protein	NN	I-NP	O	O
adducts	adduct	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mitochondria	mitochondrion	NNS	B-NP	O	O
as	as	RB	B-ADVP	O	O
early	early	RB	I-ADVP	O	O
as	as	IN	B-PP	O	O
3	3	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
peak	peak	NN	I-NP	O	O
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	O	O	O
subsequent	subsequent	JJ	B-NP	O	O
decline	decline	NN	I-NP	O	O
at	at	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

3NT	3NT	NN	B-NP	O	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
subcellular	subcellular	JJ	I-NP	O	O
compartments	compartment	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	O	O	O
subsequently	subsequently	RB	B-VP	O	O
declined	decline	VBD	I-VP	O	O
at	at	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
induced	induced	JJ	I-NP	O	O
4HNE	4HNE	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
protein	protein	NN	I-NP	O	O
adducts	adduct	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mitochondria	mitochondrion	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
point	point	NN	I-NP	O	O
as	as	IN	B-PP	O	O
when	when	WRB	B-ADVP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
initially	initially	RB	B-ADVP	O	O
appeared	appear	VBD	B-VP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
document	document	VBP	B-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vivo	vivo	FW	I-ADVP	O	O
that	that	IN	B-SBAR	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
oxidative	oxidative	JJ	I-NP	O	I-Disease
damage	damage	NN	I-NP	O	I-Disease
precedes	precede	VBZ	B-VP	O	O
nitrative	nitrative	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
nature	nature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
mitochondria	mitochondrion	NNS	B-NP	O	O
,	,	,	B-NP	O	O
not	not	RB	I-NP	O	O
other	other	JJ	B-NP	O	O
subcellular	subcellular	JJ	I-NP	O	O
organelles	organelle	NNS	I-NP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
site	site	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intracellular	intracellular	JJ	B-NP	O	O
injury	injury	NN	I-NP	O	O
.	.	.	O	O	O

Sotalol	Sotalol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
spasm	spasm	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
dilated	dilated	JJ	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
sustained	sustained	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
54	54	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
dilated	dilate	VBN	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
referred	refer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
for	for	IN	B-PP	O	O
symptomatic	symptomatic	JJ	B-NP	O	O
incessant	incessant	NN	I-NP	O	O
sustained	sustain	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
VT	VT	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

After	After	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nifekalant	nifekalant	JJ	B-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
sustained	sustained	JJ	B-NP	O	O
VT	VT	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
terminated	terminate	VBN	I-VP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
alternate	alternate	JJ	I-NP	O	O
class	class	NN	I-NP	O	O
III	III	CD	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
sotalol	sotalol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
effective	effective	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VT	VT	NN	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
month	month	NN	I-NP	O	O
after	after	IN	B-PP	O	O
switching	switch	VBG	B-VP	O	O
over	over	IN	B-PP	O	O
nifekalant	nifekalant	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
sotalol	sotalol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ST	ST	JJ	B-NP	B	O
elevation	elevation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
ECG	ECG	NN	B-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
at	at	IN	B-PP	O	O
almost	almost	RB	B-NP	O	O
the	the	DT	I-NP	O	O
same	same	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
for	for	IN	B-PP	O	O
three	three	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

ST	ST	JJ	B-NP	O	O
elevation	elevation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
chest	chest	NN	B-NP	O	O
discomfort	discomfort	NN	I-NP	O	O
disappeared	disappear	VBD	B-VP	O	O
since	since	IN	B-SBAR	O	O
he	he	PRP	B-NP	O	O
began	begin	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
acting	act	VBG	I-NP	O	O
diltiazem	diltiazem	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Coronary	Coronary	JJ	B-NP	O	B-Disease
vasospasm	vasospasm	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
selective	selective	JJ	I-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
blocking	block	VBG	B-VP	O	O
properties	property	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
sotalol	sotalol	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Effects	Effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	O
trazodone	trazodone	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2A	2A	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
2C	2C	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
behaviors	behavior	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

RATIONALE	RATIONALE	NN	B-NP	O	O
:	:	:	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Hydroxytryptamine	Hydroxytryptamine	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
via	via	IN	B-PP	O	O
stimulation	stimulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2C	2C	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
,	,	,	O	O	O
exerts	exert	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
tonic	tonic	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
neurotransmission	neurotransmission	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2A	2A	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
enhances	enhance	VBZ	B-VP	O	O
stimulated	stimulate	VBN	I-VP	O	O
DAergic	DAergic	JJ	B-NP	O	O
neurotransmission	neurotransmission	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	O
trazodone	trazodone	NN	I-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2A	2A	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
2C	2C	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
trazodone	trazodone	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
behaviors	behavior	NNS	B-NP	O	O
dependent	dependent	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
functional	functional	JJ	I-NP	O	O
status	status	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nigrostriatal	nigrostriatal	JJ	I-NP	O	O
DAergic	DAergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
trazodone	trazodone	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
dexamphetamine	dexamphetamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
apomorphine	apomorphine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
oral	oral	JJ	I-NP	O	B-Disease
stereotypies	stereotypy	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
on	on	IN	B-PP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
apomorphine	apomorphine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
ergometrine	ergometrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
wet	wet	JJ	I-NP	O	O
dog	dog	NN	I-NP	O	O
shake	shake	NN	I-NP	O	O
(	(	(	O	O	O
WDS	WDS	NN	B-NP	O	O
)	)	)	O	O	O
behavior	behavior	NN	B-NP	O	O
and	and	CC	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
penile	penile	JJ	I-NP	O	O
erections	erection	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
investigated	investigate	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
trazodone	trazodone	NN	B-NP	B	B-Chemical
induces	induce	VBZ	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Trazodone	Trazodone	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
antagonize	antagonize	VB	I-VP	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
and	and	CC	I-NP	O	O
3	3	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
stereotypy	stereotypy	NN	B-NP	O	O
and	and	CC	O	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
catalepsy	catalepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
i.p	i.p	NN	I-NP	O	O
.	.	.	O	O	O

trazodone	trazodone	NN	B-NP	B	B-Chemical
enhanced	enhance	VBD	B-VP	O	O
dexamphetamine	dexamphetamine	NN	B-NP	B	B-Chemical
stereotypy	stereotypy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
antagonized	antagonize	VBD	B-VP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
catalepsy	catalepsy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
ergometrine	ergometrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
WDS	WDS	NN	I-NP	O	O
behavior	behavior	NN	I-NP	O	O
and	and	CC	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
penile	penile	JJ	I-NP	O	O
erections	erection	NNS	I-NP	O	O
.	.	.	O	O	O

Trazodone	Trazodone	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
40	40	CD	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
induced	induce	VBD	B-VP	O	O
catalepsy	catalepsy	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
antagonized	antagonize	VBD	B-VP	O	O
apomorphine	apomorphine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dexamphetamine	dexamphetamine	NN	I-NP	B	B-Chemical
stereotypies	stereotypy	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
trazodone	trazodone	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
block	block	VB	I-VP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
postsynaptic	postsynaptic	JJ	I-NP	O	O
striatal	striatal	JJ	I-NP	O	O
D2	D2	NN	I-NP	B	O
DA	DA	NN	I-NP	B	O
receptors	receptor	NNS	I-NP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
at	at	IN	B-PP	O	O
30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
40	40	CD	I-NP	O	O
and	and	CC	I-NP	O	O
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
it	it	PRP	B-NP	O	O
blocks	block	VBZ	B-VP	O	O
postsynaptic	postsynaptic	JJ	B-NP	O	O
striatal	striatal	JJ	I-NP	O	O
D2	D2	NN	I-NP	B	O
DA	DA	NN	I-NP	B	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
5	5	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
trazodone	trazodone	NN	B-NP	B	B-Chemical
blocks	block	NNS	I-NP	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2A	2A	NN	I-NP	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2C	2C	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
trazodone	trazodone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
,	,	,	I-NP	O	O
10	10	CD	I-NP	O	O
and	and	CC	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
by	by	IN	B-PP	O	O
blocking	block	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
5	5	CD	I-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
2C	2C	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
,	,	,	O	O	O
releases	release	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
nigrostriatal	nigrostriatal	JJ	I-NP	O	O
DAergic	DAergic	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
tonic	tonic	JJ	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
5	5	CD	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
HT	HT	NN	I-NP	B	I-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
thereby	thereby	RB	B-VP	O	O
potentiates	potentiate	VBZ	I-VP	O	O
dexamphetamine	dexamphetamine	NN	B-NP	B	B-Chemical
stereotypy	stereotypy	NN	I-NP	O	O
and	and	CC	O	O	O
antagonizes	antagonize	VBZ	B-VP	O	O
haloperidol	haloperidol	NN	B-NP	B	B-Chemical
catalepsy	catalepsy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Swallowing	Swallow	VBG	B-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
dyskinesia	dyskinesia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Gastrointestinal	Gastrointestinal	JJ	B-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PD	PD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
known	know	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
almost	almost	RB	B-NP	O	O
two	two	CD	I-NP	O	O
centuries	century	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
many	many	JJ	B-NP	O	O
aspects	aspect	NNS	I-NP	O	O
concerning	concern	VBG	B-VP	O	O
their	their	PRP$	B-NP	O	O
pathophysiology	pathophysiology	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
completely	completely	RB	B-ADJP	O	O
clarified	clarify	VBN	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
characterize	characterize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
oropharyngeal	oropharyngeal	JJ	I-NP	O	O
dynamics	dynamic	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
and	and	CC	I-PP	O	O
without	without	IN	I-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
dyskinesia	dyskinesia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Fifteen	Fifteen	CD	B-NP	O	O
dyskinetic	dyskinetic	JJ	I-NP	O	B-Disease
,	,	,	O	O	O
12	12	CD	B-NP	O	O
nondyskinetic	nondyskinetic	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
asked	ask	VBN	I-VP	O	O
about	about	IN	B-PP	O	O
dysphagia	dysphagia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
evaluated	evaluate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Unified	Unified	NNP	I-NP	O	O
Parkinson	Parkinson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
Disease	Disease	NNP	I-NP	O	I-Disease
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
Parts	Parts	NNP	I-NP	O	O
II	II	CD	I-NP	O	O
and	and	CC	I-NP	O	O
III	III	CD	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Hoehn	Hoehn	NNP	I-NP	O	O
and	and	CC	O	O	O
Yahr	Yahr	NN	B-NP	O	O
scale	scale	NN	I-NP	O	O
.	.	.	O	O	O

Deglutition	Deglutition	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
modified	modify	VBN	B-NP	O	O
barium	barium	NN	I-NP	B	B-Chemical
swallow	swallow	NN	I-NP	O	O
with	with	IN	B-PP	O	O
videofluoroscopy	videofluoroscopy	NN	B-NP	O	O
.	.	.	O	O	O

Nondyskinetic	Nondyskinetic	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
the	the	DT	B-NP	O	O
dyskinetic	dyskinetic	JJ	I-NP	O	B-Disease
ones	one	NNS	I-NP	O	O
,	,	,	O	O	O
showed	show	VBD	B-VP	O	O
less	less	RBR	B-NP	O	O
oropharyngeal	oropharyngeal	JJ	I-NP	O	O
swallowing	swallow	VBG	I-NP	O	O
efficiency	efficiency	NN	I-NP	O	O
(	(	(	O	O	O
OPSE	OPSE	NN	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
liquid	liquid	JJ	B-NP	O	O
food	food	NN	I-NP	O	O
than	than	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
(	(	(	O	O	O
Dunnett	Dunnett	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.02	0.02	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Dyskinetic	Dyskinetic	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
tended	tend	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
OPSE	OPSE	NN	I-NP	O	O
than	than	IN	B-PP	O	O
nondyskinetic	nondyskinetic	JJ	B-NP	O	O
(	(	(	O	O	O
Dunnett	Dunnett	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.06	0.06	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
using	use	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
OPSE	OPSE	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
trend	trend	NN	I-NP	O	O
toward	toward	IN	B-PP	O	O
a	a	DT	B-NP	O	O
smaller	small	JJR	I-NP	O	O
oral	oral	JJ	I-NP	O	O
transit	transit	NN	I-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
Pearson	Pearson	NNP	B-NP	O	O
's	's	POS	B-NP	O	O
correlation	correlation	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
and	and	CC	I-NP	O	O
0.08	0.08	CD	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
the	the	DT	B-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dysphagia	dysphagia	NN	B-NP	O	B-Disease
nor	nor	CC	O	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PD	PD	NN	I-NP	O	B-Disease
severity	severity	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
correlated	correlate	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
videofluoroscopic	videofluoroscopic	JJ	I-NP	O	O
variables	variable	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
dyskinetic	dyskinetic	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
performed	perform	VBN	B-VP	O	O
better	well	RBR	B-ADVP	O	O
in	in	IN	B-PP	O	O
swallowing	swallow	VBG	B-VP	O	O
function	function	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
explained	explain	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
phase	phase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deglutition	deglutition	NN	B-NP	O	O
and	and	CC	O	O	O
confirm	confirm	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
dysphagia	dysphagia	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
a	a	DT	B-NP	O	O
good	good	JJ	I-NP	O	O
predictor	predictor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
deglutition	deglutition	NN	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Inhibition	Inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nuclear	nuclear	JJ	B-NP	O	O
factor	factor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
kappaB	kappaB	NN	I-NP	O	O
activation	activation	NN	I-NP	O	O
attenuates	attenuate	VBZ	B-VP	O	O
tubulointerstitial	tubulointerstitial	JJ	B-NP	O	B-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Animals	Animal	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
show	show	VB	I-VP	O	O
residual	residual	JJ	B-NP	O	O
areas	area	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
interstitial	interstitial	JJ	B-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nuclear	nuclear	JJ	B-NP	O	O
factor	factor	NN	I-NP	O	O
-	-	HYPH	O	O	O
kappaB	kappaB	NN	B-NP	O	O
(	(	(	O	O	O
NF	NF	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
kappaB	kappaB	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
mitogen	mitogen	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
activated	activate	VBN	B-NP	O	O
protein	protein	NN	I-NP	O	O
(	(	(	O	O	O
MAP	MAP	NN	B-NP	O	O
)	)	)	O	O	O
kinases	kinase	NNS	B-NP	O	O
and	and	CC	O	O	O
macrophages	macrophage	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
and	and	CC	O	O	O
structural	structural	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
functional	functional	JJ	I-NP	O	O
renal	renal	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
gentamicin	gentamicin	NN	I-NP	B	B-Chemical
+	+	SYM	O	O	O
pyrrolidine	pyrrolidine	NN	B-NP	B	B-Chemical
dithiocarbamate	dithiocarbamate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
PDTC	PDTC	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
NF	NF	NN	I-NP	B	O
-	-	HYPH	I-NP	O	O
kappaB	kappaB	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
38	38	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
40	40	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
twice	twice	RB	B-NP	O	O
a	a	DT	I-NP	O	O
day	day	NN	I-NP	O	O
for	for	IN	B-PP	O	O
9	9	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
38	38	CD	B-NP	O	O
with	with	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
+	+	SYM	I-NP	O	O
PDTC	PDTC	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
28	28	CD	B-NP	O	O
with	with	IN	B-PP	O	O
0.15	0.15	CD	B-NP	O	O
M	M	NN	I-NP	O	O
NaCl	NaCl	NN	I-NP	B	B-Chemical
solution	solution	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
5	5	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
these	these	DT	B-NP	O	O
injections	injection	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
removed	remove	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
histological	histological	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
immunohistochemical	immunohistochemical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immunohistochemical	immunohistochemical	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
scored	score	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
staining	staining	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
fractional	fractional	JJ	I-NP	O	O
interstitial	interstitial	JJ	I-NP	O	O
area	area	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
morphometry	morphometry	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Gentamicin	Gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
presented	present	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
transitory	transitory	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-VP	O	O
ED	ED	VBN	B-VP	B	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
MAP	MAP	NN	B-NP	O	O
kinases	kinase	NNS	I-NP	O	O
and	and	CC	O	O	O
NF	NF	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
kappaB	kappaB	NN	I-NP	O	O
staining	staining	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
from	from	IN	B-PP	O	O
all	all	DT	B-NP	O	O
gentamicin	gentamicin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
control	control	NN	B-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
killed	kill	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
30	30	CD	I-NP	O	O
also	also	RB	B-VP	O	O
presented	present	VBN	I-VP	O	O
fibrosis	fibrosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
despite	despite	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
PDTC	PDTC	NN	B-NP	B	B-Chemical
reduced	reduce	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
functional	functional	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
structural	structural	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
NF	NF	NN	B-NP	B	O
-	-	HYPH	O	O	O
kappaB	kappaB	NN	B-NP	O	O
activation	activation	NN	I-NP	O	O
attenuates	attenuate	VBZ	B-VP	O	O
tubulointerstitial	tubulointerstitial	JJ	B-NP	O	B-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Glucose	Glucose	NN	B-NP	B	B-Chemical
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
atypical	atypical	JJ	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
frequently	frequently	RB	I-NP	O	O
sampled	sample	VBN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
tolerance	tolerance	NN	I-NP	O	O
test	test	NN	I-NP	O	O
and	and	CC	O	O	O
minimal	minimal	JJ	B-NP	O	O
model	model	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
While	While	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
new	new	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
onset	onset	NN	I-NP	O	O
diabetes	diabetes	NN	I-NP	O	B-Disease
mellitus	mellitus	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increasing	increase	VBG	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
certain	certain	JJ	B-NP	O	O
atypical	atypical	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
remains	remain	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
atypical	atypical	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
directly	directly	RB	I-VP	O	O
affecting	affect	VBG	I-VP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
metabolism	metabolism	NN	I-NP	O	O
or	or	CC	O	O	O
simply	simply	RB	B-VP	O	O
increasing	increase	VBG	I-VP	O	O
known	know	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
diabetes	diabete	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
most	most	RBS	B-VP	O	O
clearly	clearly	RB	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
frequently	frequently	RB	I-NP	O	O
sampled	sample	VBN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
tolerance	tolerance	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
cross	cross	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
sectional	sectional	JJ	I-NP	O	O
design	design	NN	I-NP	O	O
in	in	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
,	,	,	O	O	O
treated	treat	VBN	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
evaluated	evaluate	VBN	B-VP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
frequently	frequently	RB	I-NP	O	O
sampled	sample	VBN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
tolerance	tolerance	NN	I-NP	O	O
test	test	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Bergman	Bergman	NNP	I-NP	O	O
minimal	minimal	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

SETTING	SETTING	NN	B-NP	O	O
:	:	:	O	O	O
Subjects	Subject	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
recruited	recruit	VBN	I-VP	B	O
from	from	IN	B-PP	O	O
an	an	DT	B-NP	O	O
urban	urban	JJ	I-NP	O	O
community	community	NN	I-NP	O	O
mental	mental	JJ	I-NP	O	O
health	health	NN	I-NP	O	O
clinic	clinic	NN	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
general	general	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
research	research	NN	I-NP	O	O
center	center	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
Fifty	Fifty	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
signed	sign	VBD	B-VP	O	O
informed	inform	VBN	B-NP	O	O
consent	consent	NN	I-NP	O	O
and	and	CC	O	O	O
41	41	CD	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
frequently	frequently	RB	I-NP	O	O
sampled	sample	VBN	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
tolerance	tolerance	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Thirty	Thirty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
six	six	CD	I-NP	O	O
nonobese	nonobese	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
or	or	CC	O	O	O
schizoaffective	schizoaffective	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
,	,	,	O	O	O
matched	match	VBN	B-VP	B	O
by	by	IN	B-PP	O	O
body	body	NN	B-NP	O	O
mass	mass	NN	I-NP	O	O
index	index	NN	I-NP	O	O
and	and	CC	O	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
or	or	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

MAIN	MAIN	NNP	B-NP	O	O
OUTCOME	OUTCOME	NNP	I-NP	O	O
MEASURES	MEASURES	NNP	I-NP	O	O
:	:	:	O	O	O
Fasting	Fast	VBG	B-VP	O	O
plasma	plasma	NN	B-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
fasting	fast	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
insulin	insulin	NN	B-NP	B	B-Disease
sensitivity	sensitivity	NN	I-NP	O	I-Disease
index	index	NN	I-NP	O	O
,	,	,	O	O	O
homeostasis	homeostasis	NN	B-NP	O	O
model	model	NN	I-NP	O	O
assessment	assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
effectiveness	effectiveness	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
mean	mean	NN	I-NP	O	O
+	+	SYM	B-VP	O	O
/	/	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
SD	SD	NN	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
identified	identify	VBN	I-NP	O	O
atypical	atypical	JJ	I-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
68.3	68.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
28.9	28.9	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
29.5	29.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
17.5	17.5	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
40.9	40.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
33.7	33.7	CD	B-NP	O	O
(	(	(	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Fasting	Fast	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
concentrations	concentration	NNS	I-NP	O	O
differed	differ	VBD	B-VP	O	O
among	among	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
(	(	(	O	O	O
F	F	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
3.35	3.35	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.047	.047	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
>	>	SYM	B-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
>	>	SYM	I-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
2.32	2.32	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.03	.03	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
2.15	2.15	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.04	.04	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
in	in	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	B-Disease
sensitivity	sensitivity	NN	I-NP	O	I-Disease
index	index	NN	I-NP	O	O
among	among	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
(	(	(	O	O	O
F	F	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
10.66	10.66	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.001	.001	CD	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
<	<	SYM	B-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
<	<	SYM	I-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
exhibiting	exhibit	VBG	B-VP	O	O
significant	significant	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
vs	vs	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-ADJP	O	O
4.29	4.29	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-ADJP	O	O
.001	.001	CD	B-NP	O	O
;	;	:	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
vs	vs	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-ADJP	O	O
3.62	3.62	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.001	.001	CD	B-NP	O	O
[	[	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.001	.001	CD	I-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
homeostasis	homeostasis	NN	I-NP	O	O
model	model	NN	I-NP	O	O
assessment	assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
also	also	RB	B-ADVP	O	O
differed	differ	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
among	among	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
(	(	(	O	O	O
F	F	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
4.92	4.92	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.01	.01	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
>	>	SYM	B-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
>	>	SYM	I-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
vs	vs	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
2.94	2.94	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.006	.006	CD	B-NP	O	O
;	;	:	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
vs	vs	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
33	33	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
2.42	2.42	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.02	.02	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
among	among	IN	B-PP	O	O
groups	group	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
effectiveness	effectiveness	NN	I-NP	O	O
(	(	(	O	O	O
F	F	NN	B-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
4.18	4.18	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.02	.02	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
<	<	SYM	B-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
<	<	SYM	I-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
with	with	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-ADJP	O	O
2.59	2.59	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.02	.02	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
t	t	NN	B-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
-	-	SYM	B-NP	O	O
2.34	2.34	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.03	.03	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Both	Both	CC	O	O	O
nonobese	nonobese	JJ	B-NP	O	O
clozapine	clozapine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
and	and	CC	I-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
treated	treat	VBN	I-NP	O	O
groups	group	NNS	I-NP	O	O
displayed	display	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
insulin	insulin	NN	I-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
impairment	impairment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
effectiveness	effectiveness	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
clozapine	clozapine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
examined	examine	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
consequences	consequence	NNS	I-NP	O	O
.	.	.	O	O	O

Focal	Focal	JJ	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
:	:	:	O	O	O
effect	effect	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phenylephrine	phenylephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
during	during	IN	B-PP	O	O
reperfusion	reperfusion	NN	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
180	180	CD	B-NP	O	O
min	min	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temporary	temporary	JJ	B-NP	O	O
middle	middle	JJ	I-NP	O	B-Disease
cerebral	cerebral	JJ	I-NP	O	I-Disease
artery	artery	NN	I-NP	O	I-Disease
occlusion	occlusion	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
spontaneously	spontaneously	RB	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
phenylephrine	phenylephrine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
on	on	IN	B-PP	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
brain	brain	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
permeability	permeability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
manipulated	manipulate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
schedules	schedule	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
120	120	CD	B-NP	O	O
min	min	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reperfusion	reperfusion	NN	B-NP	O	O
:	:	:	O	O	O
Control	Control	NN	B-NP	O	O
,	,	,	O	O	O
normotensive	normotensive	JJ	B-NP	O	O
reperfusion	reperfusion	NN	I-NP	O	O
;	;	:	O	O	O
90	90	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
(	(	(	O	O	O
90	90	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
35	35	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
90	90	CD	I-NP	O	O
min	min	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reperfusion	reperfusion	NN	B-NP	O	O
only	only	RB	B-ADVP	O	O
;	;	:	O	O	O
15	15	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
(	(	(	O	O	O
15	15	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
normotensive	normotensive	JJ	B-NP	O	O
reperfusion	reperfusion	NN	I-NP	O	O
for	for	IN	B-PP	O	O
30	30	CD	B-NP	O	O
min	min	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
15	15	CD	B-NP	O	O
min	min	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
75	75	CD	B-NP	O	O
min	min	NN	I-NP	O	O
of	of	IN	B-PP	O	O
normotension	normotension	NN	B-NP	O	O
.	.	.	O	O	O

Part	Part	NNP	B-NP	O	O
A	A	NNP	I-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
group	group	NN	I-NP	O	O
brain	brain	NN	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
staining	stain	VBG	B-VP	O	O
tissue	tissue	NN	B-NP	O	O
using	use	VBG	B-VP	O	O
2,3,5	2,3,5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
triphenyltetrazolium	triphenyltetrazolium	NN	I-NP	I	I-Chemical
chloride	chloride	NN	I-NP	I	I-Chemical
and	and	CC	I-NP	O	O
edema	edema	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
microgravimetry	microgravimetry	NN	B-NP	O	O
.	.	.	O	O	O

Part	Part	NNP	B-NP	O	O
B	B	NNP	I-NP	O	O
,	,	,	O	O	O
for	for	IN	B-PP	O	O
eight	eight	CD	B-NP	O	O
different	different	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
each	each	DT	B-NP	O	O
group	group	NN	I-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
permeability	permeability	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
measuring	measure	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
and	and	CC	I-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extravasation	extravasation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Evans	Evans	NNP	B-NP	B	O
Blue	Blue	NNP	I-NP	I	O
dye	dye	NN	I-NP	O	O
.	.	.	O	O	O

Brain	Brain	NN	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
(	(	(	O	O	O
percentage	percentage	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
hemisphere	hemisphere	NN	I-NP	O	I-Disease
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
less	less	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
15	15	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
(	(	(	O	O	O
16	16	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
,	,	,	O	O	O
mean	mean	NN	B-NP	O	O
+	+	SYM	B-VP	O	O
/	/	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
SD	SD	NN	I-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
the	the	DT	B-NP	O	O
90	90	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
(	(	(	O	O	O
30	30	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
42	42	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
5	5	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Specific	Specific	JJ	B-NP	O	O
gravity	gravity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
15	15	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
(	(	(	O	O	O
1.043	1.043	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.002	0.002	CD	B-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
the	the	DT	B-NP	O	O
90	90	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
(	(	(	O	O	O
1.036	1.036	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.003	0.003	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
control	control	NN	B-NP	O	O
(	(	(	O	O	O
1.037	1.037	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.003	0.003	CD	O	O	O
)	)	)	O	O	O
groups	group	NNS	B-NP	O	O
.	.	.	O	O	O

Evans	Evans	NNP	B-NP	B	B-Chemical
Blue	Blue	NNP	I-NP	I	I-Chemical
(	(	(	O	O	O
mug	mug	NN	B-NP	O	O
g	g	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
of	of	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
90	90	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
(	(	(	O	O	O
24.4	24.4	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6.0	6.0	CD	B-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
12.3	12.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4.1	4.1	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
15	15	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
HTN	HTN	NN	I-NP	O	B-Disease
group	group	NN	I-NP	O	O
(	(	(	O	O	O
7.3	7.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3.2	3.2	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
supports	support	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
that	that	IN	B-NP	O	O
during	during	IN	B-PP	O	O
reperfusion	reperfusion	NN	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
short	short	JJ	I-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
decreases	decrease	VBZ	B-VP	O	O
brain	brain	NN	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
edema	edema	NN	I-NP	O	B-Disease
;	;	:	O	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
sustained	sustained	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vasogenic	vasogenic	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
.	.	.	O	O	O

People	People	NNS	B-NP	O	O
aged	age	VBN	B-VP	O	O
over	over	IN	B-PP	O	O
75	75	CD	B-NP	O	O
in	in	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
stroke	stroke	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
500	500	CD	I-NP	O	O
patient	patient	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
stroke	stroke	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
aged	age	VBN	B-VP	O	O
76	76	CD	B-NP	O	O
and	and	CC	O	O	O
older	old	JJR	B-ADJP	O	O
with	with	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
adjusted	adjust	VBN	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
warfarin	warfarin	NN	I-NP	B	B-Chemical
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
recently	recently	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
hospital	hospital	NN	B-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
observational	observational	JJ	I-NP	O	O
cohort	cohort	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

SETTING	SETTING	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
healthcare	healthcare	NN	I-NP	O	O
network	network	NN	I-NP	O	O
involving	involve	VBG	B-VP	O	O
four	four	CD	B-NP	O	O
tertiary	tertiary	JJ	I-NP	O	O
hospitals	hospital	NNS	I-NP	O	O
.	.	.	O	O	O

PARTICIPANTS	PARTICIPANTS	NNS	B-NP	O	O
:	:	:	O	O	O
Two	Two	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
thirty	thirty	CD	I-NP	O	O
-	-	HYPH	O	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
aged	age	VBN	B-ADJP	O	O
76	76	CD	B-NP	O	O
and	and	CC	O	O	O
older	old	JJR	B-ADJP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
healthcare	healthcare	NN	I-NP	O	O
network	network	NN	I-NP	O	O
between	between	IN	B-PP	O	O
July	July	NNP	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
2001	2001	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
June	June	NNP	B-NP	O	O
30	30	CD	I-NP	O	O
,	,	,	I-NP	O	O
2002	2002	CD	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
.	.	.	O	O	O

MEASUREMENTS	MEASUREMENTS	NNS	B-NP	O	O
:	:	:	O	O	O
Information	Information	NN	B-NP	O	O
regarding	regard	VBG	B-PP	O	O
major	major	JJ	B-NP	O	O
bleeding	bleed	VBG	I-NP	O	B-Disease
episodes	episode	NNS	I-NP	O	O
,	,	,	O	O	O
strokes	stroke	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
obtained	obtain	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
relatives	relative	NNS	B-NP	O	O
,	,	,	O	O	O
primary	primary	JJ	B-NP	O	O
physicians	physician	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
medical	medical	JJ	B-NP	O	O
records	record	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Two	Two	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
twenty	twenty	CD	I-NP	O	O
-	-	HYPH	O	O	O
eight	eight	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
42	42	CD	B-NP	O	O
%	%	NN	I-NP	O	O
men	man	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
81.1	81.1	CD	B-NP	O	O
(	(	(	O	O	O
range	range	NN	B-NP	O	O
76	76	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
94	94	CD	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

Total	Total	JJ	B-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
530	530	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
28	28	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
53	53	CD	B-NP	O	O
major	major	JJ	I-NP	O	O
hemorrhages	hemorrhage	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
for	for	IN	B-PP	O	O
an	an	DT	B-NP	O	O
annual	annual	JJ	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10.0	10.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
24	24	CD	B-NP	O	O
(	(	(	O	O	O
45.3	45.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
and	and	CC	O	O	O
five	five	CD	B-NP	O	O
(	(	(	O	O	O
9.4	9.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
fatal	fatal	JJ	B-NP	O	O
bleeds	bleed	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
annual	annual	JJ	I-NP	O	O
stroke	stroke	NN	I-NP	O	B-Disease
rate	rate	NN	I-NP	O	O
after	after	IN	B-PP	O	O
initiation	initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
2.6	2.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
hemorrhage	hemorrhage	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
high	high	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
old	old	JJ	I-NP	O	O
,	,	,	I-NP	O	O
frail	frail	NN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
excluding	exclude	VBG	B-PP	O	O
fatalities	fatality	NNS	B-NP	O	O
,	,	,	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
no	no	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
sequelae	sequela	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
stroke	stroke	NN	I-NP	O	B-Disease
rate	rate	NN	I-NP	O	O
on	on	IN	B-PP	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
low	low	JJ	B-ADJP	O	O
,	,	,	O	O	O
demonstrating	demonstrate	VBG	B-VP	O	O
how	how	WRB	B-ADVP	O	O
effective	effective	JJ	B-NP	O	O
warfarin	warfarin	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
.	.	.	O	O	O

Safety	Safety	NN	B-NP	O	O
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
skin	skin	NN	I-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
to	to	TO	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
paracetamol	paracetamol	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
nimesulide	nimesulide	NN	B-NP	B	B-Chemical
associated	associate	VBN	B-VP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
with	with	IN	B-PP	O	O
common	common	JJ	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Acetaminophen	Acetaminophen	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
paracetamol	paracetamol	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
-	-	HYPH	B-NP	O	O
P	P	NN	I-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
Nimesulide	Nimesulide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
N	N	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
widely	widely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
analgesic	analgesic	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
antipyretic	antipyretic	JJ	I-NP	O	O
/	/	SYM	O	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	B-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
generally	generally	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contrary	contrary	JJ	I-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
commonly	commonly	RB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
such	such	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

Celecoxib	Celecoxib	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CE	CE	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
selectivity	selectivity	NN	I-NP	O	O
and	and	CC	O	O	O
affinity	affinity	NN	B-NP	O	O
for	for	IN	B-PP	O	O
COX	COX	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CE	CE	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
documented	document	VBN	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
cutaneous	cutaneous	JJ	I-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
to	to	TO	B-PP	O	O
P	P	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
N	N	NN	I-NP	O	B-Chemical
associated	associate	VBN	B-VP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
to	to	TO	B-PP	O	O
classic	classic	JJ	B-NP	B	O
NSAIDs	NSAID	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
9	9	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
hypersensitivity	hypersensitivity	NN	B-NP	O	B-Disease
to	to	TO	B-PP	O	O
P	P	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
N	N	NN	I-NP	O	B-Chemical
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
associated	associated	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
classic	classic	JJ	B-NP	B	O
NSAIDs	NSAID	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
P	P	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
N	N	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
skin	skin	NN	I-NP	O	B-Disease
reactions	reaction	NNS	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
based	base	VBN	I-VP	O	O
in	in	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
placebo	placebo	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
blindly	blindly	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beginning	beginning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
three	three	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
dosage	dosage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CE	CE	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
refracted	refracted	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
3	3	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
each	each	DT	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
controlled	control	VBN	B-VP	O	O
again	again	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
exclude	exclude	VB	I-VP	O	O
delayed	delayed	JJ	B-NP	O	O
reactions	reaction	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
positive	positive	JJ	B-ADJP	O	O
if	if	IN	B-SBAR	O	O
one	one	CD	B-NP	O	O
or	or	CC	I-NP	O	O
more	more	JJR	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	following	NN	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
:	:	:	O	O	O
erythema	erythema	NN	B-NP	O	B-Disease
,	,	,	I-NP	O	O
rush	rush	NN	I-NP	O	O
or	or	CC	I-NP	O	O
urticaria	urticaria	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	O
angioedema	angioedema	NN	I-NP	O	B-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
No	No	DT	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
and	and	CC	O	O	O
eight	eight	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
88.8	88.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
tolerated	tolerate	VBD	B-VP	O	O
CE	CE	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Only	Only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
moderate	moderate	JJ	I-NP	O	O
angioedema	angioedema	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lips	lip	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Only	Only	RB	B-NP	O	O
one	one	CD	I-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
CE	CE	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
among	among	IN	B-PP	O	O
9	9	CD	B-NP	O	O
P	P	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
N	N	NN	I-NP	O	B-Chemical
-	-	HYPH	O	O	O
highly	highly	RB	B-ADVP	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
intolerant	intolerant	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
CE	CE	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
reasonably	reasonably	RB	I-NP	O	O
safe	safe	JJ	I-NP	O	O
alternative	alternative	NN	I-NP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
subjects	subject	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
tolerate	tolerate	VB	I-VP	O	O
P	P	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
N	N	NN	I-NP	O	B-Chemical
.	.	.	O	O	O

Case	Case	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
of	of	IN	B-PP	O	O
regular	regular	JJ	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
and	and	CC	I-NP	O	O
end	end	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Studies	Study	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
nonsteroidal	nonsteroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
end	end	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ESRD	ESRD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
have	have	VBP	B-VP	O	O
given	give	VBN	I-VP	O	O
conflicting	conflict	VBG	I-VP	O	O
results	result	NNS	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
examine	examine	VB	I-VP	O	O
this	this	DT	B-NP	O	O
association	association	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
with	with	IN	B-PP	O	O
incident	incident	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ESRD	ESRD	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
entering	enter	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
local	local	JJ	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
program	program	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
ESRD	ESRD	NNP	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
area	area	NN	I-NP	O	O
between	between	IN	B-PP	O	O
June	June	NNP	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
1995	1995	CD	I-NP	O	O
and	and	CC	O	O	O
November	November	NNP	B-NP	O	O
30	30	CD	I-NP	O	O
,	,	,	I-NP	O	O
1997	1997	CD	I-NP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
classified	classify	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
underlying	underlie	VBG	I-NP	O	O
disease	disease	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
had	have	VBD	B-VP	O	O
presumably	presumably	RB	I-VP	O	O
led	lead	VBN	I-VP	O	O
them	them	PRP	B-NP	O	O
to	to	TO	B-PP	O	O
ESRD	ESRD	NNP	B-NP	O	B-Disease
.	.	.	O	O	O

Controls	Control	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
patients	patient	NNS	B-NP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
hospitals	hospital	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
where	where	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
arose	arise	VBD	B-VP	O	O
,	,	,	O	O	O
also	also	RB	B-ADVP	O	O
matched	match	VBN	B-VP	B	O
by	by	IN	B-PP	O	O
age	age	NN	B-NP	O	O
and	and	CC	I-NP	O	O
sex	sex	NN	I-NP	O	O
.	.	.	O	O	O

Odds	Odd	NNS	B-NP	O	O
ratios	ratio	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
calculated	calculate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
conditional	conditional	JJ	I-NP	O	O
logistic	logistic	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
potential	potential	JJ	B-NP	O	O
confounding	confound	VBG	I-NP	O	O
factors	factor	NNS	I-NP	O	O
,	,	,	O	O	O
both	both	DT	B-PP	O	O
for	for	IN	I-PP	O	O
the	the	DT	B-NP	O	O
whole	whole	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
population	population	NN	I-NP	O	O
and	and	CC	B-PP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
various	various	JJ	I-NP	O	O
underlying	underlie	VBG	I-NP	O	O
diseases	disease	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Five	Five	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
and	and	CC	I-NP	O	O
eighty	eighty	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
three	three	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
and	and	CC	O	O	O
1190	1190	CD	B-NP	O	O
controls	control	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
analgesic	analgesic	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
odds	odd	NNS	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1.22	1.22	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
0.89	0.89	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.66	1.66	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
specific	specific	JJ	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
1.56	1.56	CD	B-NP	O	O
(	(	(	O	O	O
1.05	1.05	CD	B-NP	O	O
-	-	HYPH	O	O	O
2.30	2.30	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
1.03	1.03	CD	B-NP	O	O
(	(	(	O	O	O
0.60	0.60	CD	B-NP	O	O
-	-	HYPH	O	O	O
1.76	1.76	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
pyrazolones	pyrazolone	NNS	B-NP	B	B-Chemical
,	,	,	O	O	O
0.80	0.80	CD	B-NP	O	O
(	(	(	O	O	O
0.39	0.39	CD	B-NP	O	O
-	-	HYPH	O	O	O
1.63	1.63	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
paracetamol	paracetamol	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
0.94	0.94	CD	B-NP	O	O
(	(	(	O	O	O
0.57	0.57	CD	B-NP	O	O
-	-	HYPH	O	O	O
1.56	1.56	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
nonaspirin	nonaspirin	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ESRD	ESRD	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cumulated	cumulate	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
use	use	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
particularly	particularly	RB	B-ADJP	O	O
high	high	JJ	I-ADJP	O	O
among	among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
vascular	vascular	JJ	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
underlying	underlie	VBG	B-VP	O	O
disease	disease	NN	B-NP	O	O
[	[	(	O	O	O
2.35	2.35	CD	B-NP	O	O
(	(	(	O	O	O
1.17	1.17	CD	B-NP	O	O
-	-	HYPH	O	O	O
4.72	4.72	CD	B-NP	O	O
)	)	)	O	O	O
]	]	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nonaspirin	nonaspirin	JJ	B-NP	O	O
analgesic	analgesic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ESRD	ESRD	NNP	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
chronic	chronic	JJ	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ESRD	ESRD	NNP	B-NP	O	B-Disease
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
amisulpride	amisulpride	NN	B-NP	B	B-Chemical
overdose	overdose	NN	I-NP	O	B-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
for	for	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	B-Disease
QT	QT	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
deliberate	deliberate	JJ	B-NP	O	O
self	self	NN	I-NP	O	O
-	-	HYPH	O	O	O
poisoning	poison	VBG	B-VP	O	B-Disease
with	with	IN	B-PP	O	O
5	5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
and	and	CC	O	O	O
3.6	3.6	CD	B-NP	O	O
g	g	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amisulpride	amisulpride	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
hypocalcaemia	hypocalcaemia	NN	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
QT	QT	NN	I-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
appeared	appear	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
respond	respond	VB	I-VP	O	O
to	to	TO	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
i.v	i.v	NN	B-NP	O	O
.	.	.	O	O	O

calcium	calcium	NN	B-NP	B	B-Chemical
gluconate	gluconate	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Growth	Growth	NN	B-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
protein	protein	NN	B-NP	O	O
43	43	CD	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
molecular	molecular	JJ	I-NP	O	O
layer	layer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
epileptic	epileptic	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
cycloheximide	cycloheximide	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
GAP43	GAP43	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
thought	think	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
linked	link	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
mossy	mossy	NN	B-NP	O	O
fiber	fiber	NN	I-NP	O	O
sprouting	sprouting	NN	I-NP	O	O
(	(	(	O	O	O
MFS	MFS	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

To	To	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
how	how	WRB	B-ADVP	O	O
GAP43	GAP43	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
(	(	(	O	O	O
GAP43	GAP43	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ir	ir	NN	I-NP	O	O
)	)	)	O	O	O
correlates	correlate	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
MFS	MFS	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
assessed	assess	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
(	(	(	O	O	O
densitometry	densitometry	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
extension	extension	NN	B-NP	O	O
(	(	(	O	O	O
width	width	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
GAP43	GAP43	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ir	ir	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inner	inner	JJ	I-NP	O	O
molecular	molecular	JJ	I-NP	O	O
layer	layer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dentate	dentate	NN	I-NP	O	O
gyrus	gyrus	NN	I-NP	O	O
(	(	(	O	O	O
IML	IML	NN	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
subject	subject	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Pilo	Pilo	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
previously	previously	RB	B-VP	O	O
injected	inject	VBN	I-VP	O	O
or	or	CC	O	O	O
not	not	RB	O	O	O
with	with	IN	B-PP	O	O
cycloheximide	cycloheximide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CHX	CHX	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
MFS	MFS	NN	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
CHX	CHX	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Pilo	Pilo	NNP	I-NP	O	B-Chemical
injection	injection	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
Pilo	Pilo	NNP	I-NP	O	B-Chemical
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
except	except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
CHX	CHX	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
30	30	CD	B-NP	O	O
and	and	CC	I-NP	O	O
60	60	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
brain	brain	NN	B-NP	O	O
sections	section	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
processed	process	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
GAP43	GAP43	NN	B-NP	O	O
immunohistochemistry	immunohistochemistry	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Densitometry	Densitometry	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
difference	difference	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
GAP43	GAP43	NN	B-NP	O	O
-	-	HYPH	O	O	O
ir	ir	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IML	IML	NNP	I-NP	O	O
between	between	IN	B-PP	O	O
Pilo	Pilo	NNP	B-NP	O	B-Chemical
,	,	,	O	O	O
CHX	CHX	NNP	B-NP	O	B-Chemical
+	+	SYM	B-VP	O	O
Pilo	Pilo	NNP	B-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
control	control	NN	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
width	width	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
GAP43	GAP43	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
ir	ir	NN	I-NP	O	O
band	band	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IML	IML	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
CHX	CHX	NN	B-NP	O	B-Chemical
+	+	CC	I-NP	O	O
Pilo	Pilo	NN	I-NP	O	B-Chemical
and	and	CC	I-NP	O	O
control	control	NN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
larger	large	JJR	I-NP	O	O
band	band	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.03	0.03	CD	B-NP	O	O
)	)	)	O	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Pilo	Pilo	NNP	I-NP	O	B-Chemical
group	group	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
current	current	JJ	I-NP	O	O
finding	finding	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
animals	animal	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CHX	CHX	NNP	I-NP	O	B-Chemical
+	+	SYM	I-NP	O	O
Pilo	Pilo	NNP	I-NP	O	B-Chemical
group	group	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
GAP43	GAP43	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
ir	ir	NN	I-NP	O	O
band	band	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
IML	IML	NN	I-NP	O	O
,	,	,	O	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
,	,	,	O	O	O
reinforces	reinforce	VBZ	B-VP	O	O
prior	prior	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MFS	MFS	NN	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
GAP43	GAP43	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ir	ir	NN	I-NP	O	O
present	present	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
Pilo	Pilo	NNP	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
thinning	thinning	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
band	band	NN	I-NP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
very	very	RB	I-NP	O	O
narrow	narrow	JJ	I-NP	O	O
layer	layer	NN	I-NP	O	O
just	just	RB	B-PP	O	O
above	above	IN	I-PP	O	O
the	the	DT	B-NP	O	O
granule	granule	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
layer	layer	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
likely	likely	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hilar	hilar	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
projections	projection	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
express	express	VBP	B-VP	O	O
GAP	GAP	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
43	43	CD	I-NP	O	O
.	.	.	O	O	O

Nicotine	Nicotine	NN	B-NP	B	B-Chemical
antagonizes	antagonize	VBZ	B-VP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-ADJP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

RATIONALE	RATIONALE	NN	B-NP	O	O
:	:	:	O	O	O
Nicotine	Nicotine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
widely	widely	RB	I-VP	O	O
consumed	consume	VBN	I-VP	O	O
licit	licit	NN	B-NP	O	O
psychoactive	psychoactive	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
worldwide	worldwide	RB	B-ADVP	O	O
.	.	.	O	O	O

Epidemiological	Epidemiological	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
they	they	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
generally	generally	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
concurrently	concurrently	RB	B-ADVP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
some	some	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
experimental	experimental	JJ	B-NP	O	O
animals	animal	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
clear	clear	JJ	B-NP	O	O
pharmacological	pharmacological	JJ	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
on	on	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
responses	response	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
investigates	investigate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
another	another	DT	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
elevated	elevated	JJ	I-NP	O	O
plus	plus	CC	I-NP	O	O
-	-	HYPH	I-NP	O	O
maze	maze	NN	I-NP	O	O
(	(	(	O	O	O
EPM	EPM	NN	B-NP	B	O
)	)	)	O	O	O
test	test	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Adult	Adult	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
Swiss	Swiss	JJ	I-NP	O	O
Webster	Webster	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
32	32	CD	I-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.25	0.25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
s.c.	s.c.	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
saline	saline	NN	B-NP	B	O
10	10	CD	I-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
70	70	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
15	15	CD	B-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
injections	injection	NNS	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
15	15	CD	B-NP	O	O
min	min	NN	I-NP	O	O
,	,	,	O	O	O
mice	mouse	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
closed	close	VBN	I-NP	O	O
-	-	HYPH	I-NP	O	O
arm	arm	NN	I-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	O	O	O
entries	entry	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
EPM	EPM	NN	I-NP	B	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
min	min	NN	I-NP	O	O
session	session	NN	I-NP	O	O
.	.	.	O	O	O

Locomotor	Locomotor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
recorded	record	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
groups	group	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
protocol	protocol	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
EPM	EPM	NN	I-NP	B	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Nicotine	Nicotine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.05	0.05	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
0.25	0.25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
itself	itself	PRP	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
any	any	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
EPM	EPM	NN	I-NP	B	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
70	70	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
produced	produce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
anxiogenic	anxiogenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
apparent	apparent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
decreases	decrease	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
open	open	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
arm	arm	NN	I-NP	O	O
time	time	NN	I-NP	O	O
and	and	CC	I-NP	O	O
entry	entry	NN	I-NP	O	O
.	.	.	O	O	O

Nicotine	Nicotine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.25	0.25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
blocked	block	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
pentylenetetrazole	pentylenetetrazole	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
each	each	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
combinations	combination	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
produce	produce	VB	I-VP	O	O
any	any	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
locomotor	locomotor	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
antagonistic	antagonistic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
specific	specific	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
instead	instead	RB	B-PP	O	O
of	of	IN	I-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	I-NP	O	O
anxiolytic	anxiolytic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
extend	extend	VB	I-VP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
findings	finding	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
nicotine	nicotine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
term	term	NN	I-NP	O	O
hormone	hormone	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
perimenopausal	perimenopausal	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
postmenopausal	postmenopausal	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Hormone	Hormone	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
HT	HT	NN	B-NP	B	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
widely	widely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
controlling	control	VBG	B-VP	O	O
menopausal	menopausal	JJ	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
also	also	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
and	and	CC	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
osteoporosis	osteoporosis	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
dementia	dementia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
women	woman	NNS	I-NP	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
supporting	support	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
indications	indication	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
largely	largely	RB	B-ADJP	O	O
observational	observational	JJ	I-ADJP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
HT	HT	NN	I-NP	B	O
on	on	IN	B-PP	O	O
mortality	mortality	NN	B-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
venous	venous	JJ	B-NP	O	B-Disease
thromboembolism	thromboembolism	NN	I-NP	O	I-Disease
,	,	,	O	O	O
stroke	stroke	NN	B-NP	O	B-Disease
,	,	,	O	O	O
transient	transient	JJ	B-NP	O	B-Disease
ischaemic	ischaemic	JJ	I-NP	O	I-Disease
attacks	attack	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
breast	breast	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
,	,	,	O	O	O
colorectal	colorectal	JJ	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
,	,	,	O	O	O
ovarian	ovarian	JJ	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
,	,	,	O	O	O
endometrial	endometrial	JJ	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
,	,	,	O	O	O
gallbladder	gallbladder	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
cognitive	cognitive	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
,	,	,	O	O	O
dementia	dementia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
fractures	fracture	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
quality	quality	NN	B-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
.	.	.	O	O	O

SEARCH	SEARCH	NN	B-NP	O	O
STRATEGY	STRATEGY	NN	I-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
searched	search	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
databases	database	NNS	I-NP	O	O
up	up	RB	B-PP	O	O
to	to	TO	B-PP	O	O
November	November	NNP	B-NP	O	O
2004	2004	CD	I-NP	O	O
:	:	:	O	O	O
the	the	DT	B-NP	O	O
Cochrane	Cochrane	NNP	I-NP	O	O
Menstrual	Menstrual	NNP	I-NP	O	O
Disorders	Disorders	NNP	I-NP	O	O
and	and	CC	O	O	O
Subfertility	Subfertility	NNP	B-NP	O	O
Group	Group	NNP	I-NP	O	O
Trials	Trials	NNP	I-NP	O	O
Register	Register	NNP	I-NP	O	O
,	,	,	O	O	O
Cochrane	Cochrane	NNP	B-NP	O	O
Central	Central	NNP	I-NP	O	O
Register	Register	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Controlled	Controlled	NNP	B-NP	O	O
Trials	Trials	NNP	I-NP	O	O
(	(	(	O	O	O
CENTRAL	CENTRAL	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
MEDLINE	MEDLINE	NNP	B-NP	O	O
,	,	,	O	O	O
EMBASE	EMBASE	NNP	B-NP	O	O
,	,	,	O	O	O
Biological	Biological	NNP	B-NP	O	O
Abstracts	Abstract	NNPS	I-NP	O	O
.	.	.	O	O	O

Relevant	Relevant	JJ	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
indexed	indexed	JJ	I-NP	O	O
journals	journal	NNS	I-NP	O	O
and	and	CC	O	O	O
conference	conference	NN	B-NP	O	O
abstracts	abstract	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
searched	search	VBN	I-VP	O	O
.	.	.	O	O	O

SELECTION	SELECTION	NN	B-NP	O	O
CRITERIA	CRITERIA	NN	I-NP	O	O
:	:	:	O	O	O
Randomised	Randomise	VBN	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HT	HT	NN	B-NP	B	O
(	(	(	O	O	O
oestrogens	oestrogen	NNS	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
progestogens	progestogen	NNS	B-NP	O	B-Chemical
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
,	,	,	O	O	O
taken	take	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
one	one	CD	I-NP	O	O
year	year	NN	I-NP	O	O
by	by	IN	B-PP	O	O
perimenopausal	perimenopausal	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
postmenopausal	postmenopausal	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

DATA	DATA	NNP	B-NP	O	O
COLLECTION	COLLECTION	NNP	I-NP	O	O
AND	AND	CC	O	O	O
ANALYSIS	ANALYSIS	NNP	B-NP	O	O
:	:	:	O	O	O
Fifteen	Fifteen	CD	B-NP	O	O
RCTs	RCT	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
.	.	.	O	O	O

Trials	Trial	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
quality	quality	NN	B-NP	O	O
and	and	CC	O	O	O
two	two	CD	B-NP	O	O
review	review	NN	I-NP	O	O
authors	author	NNS	I-NP	O	O
extracted	extract	VBD	B-VP	O	O
data	datum	NNS	B-NP	O	O
independently	independently	RB	B-ADVP	O	O
.	.	.	O	O	O

They	They	PRP	B-NP	O	O
calculated	calculate	VBD	B-VP	O	O
risk	risk	NN	B-NP	O	O
ratios	ratio	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
dichotomous	dichotomous	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
and	and	CC	O	O	O
weighted	weight	VBD	B-VP	O	O
mean	mean	JJ	B-NP	O	O
differences	difference	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
heterogeneity	heterogeneity	NN	I-NP	O	O
precluded	preclude	VBD	B-VP	O	O
meta	meta	JJ	B-NP	B	O
-	-	HYPH	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
most	most	JJS	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

MAIN	MAIN	NN	B-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
All	All	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
derived	derive	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
biggest	big	JJS	I-NP	O	O
trials	trial	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
relatively	relatively	RB	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
,	,	,	O	O	O
combined	combined	JJ	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
HT	HT	NN	I-NP	B	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
venous	venous	JJ	B-NP	O	B-Disease
thromboembolism	thromboembolism	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
coronary	coronary	JJ	B-NP	O	O
event	event	NN	I-NP	O	O
(	(	(	O	O	O
after	after	IN	B-PP	O	O
one	one	CD	B-NP	O	O
year	year	NN	I-NP	O	O
's	's	POS	B-NP	O	O
use	use	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
stroke	stroke	NN	B-NP	O	B-Disease
(	(	(	O	O	O
after	after	IN	B-PP	O	O
3	3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
breast	breast	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
(	(	(	O	O	O
after	after	IN	B-PP	O	O
5	5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
gallbladder	gallbladder	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
oestrogen	oestrogen	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
only	only	RB	B-NP	O	O
HT	HT	NN	I-NP	B	O
also	also	RB	B-ADVP	O	O
significantly	significantly	RB	B-VP	O	O
increased	increase	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
stroke	stroke	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
gallbladder	gallbladder	NN	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
only	only	RB	I-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HT	HT	NN	B-NP	B	O
were	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fractures	fracture	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
colon	colon	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
relatively	relatively	RB	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
women	woman	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
65	65	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
combined	combine	VBN	I-NP	O	O
HT	HT	NN	I-NP	B	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
statistically	statistically	RB	I-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dementia	dementia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combined	combined	JJ	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
HT	HT	NN	I-NP	B	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
venous	venous	JJ	B-NP	O	B-Disease
thromboembolism	thromboembolism	NN	I-NP	O	I-Disease
.	.	.	O	O	O

No	No	DT	B-NP	O	O
trials	trial	NNS	I-NP	O	O
focussed	focusse	VBD	B-VP	O	O
specifically	specifically	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
younger	young	JJR	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
trial	trial	NN	I-NP	O	O
analysed	analyse	VBN	B-VP	O	O
subgroups	subgroup	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
2839	2839	CD	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
healthy	healthy	JJ	I-NP	O	O
50	50	CD	I-NP	O	O
to	to	TO	I-NP	O	O
59	59	CD	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
taking	take	VBG	B-VP	O	O
combined	combined	JJ	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
HT	HT	NN	I-NP	B	O
and	and	CC	O	O	O
1637	1637	CD	B-NP	O	O
taking	take	VBG	I-NP	O	O
oestrogen	oestrogen	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
only	only	RB	B-NP	O	O
HT	HT	NN	I-NP	B	O
,	,	,	O	O	O
versus	versus	IN	B-PP	O	O
similar	similar	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
sized	sized	JJ	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
only	only	RB	I-NP	O	O
significantly	significantly	RB	I-ADVP	O	O
increased	increase	VBD	B-VP	O	O
risk	risk	NN	B-NP	O	O
reported	report	VBN	B-VP	O	O
was	be	VBD	B-VP	O	O
for	for	IN	B-PP	O	O
venous	venous	JJ	B-NP	O	B-Disease
thromboembolism	thromboembolism	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
combined	combined	JJ	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
HT	HT	NN	I-NP	B	O
;	;	:	O	O	O
their	their	PRP$	B-NP	O	O
absolute	absolute	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
very	very	RB	B-ADJP	O	O
low	low	JJ	I-ADJP	O	O
.	.	.	O	O	O

AUTHORS	AUTHORS	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
CONCLUSIONS	CONCLUSIONS	NNS	I-NP	O	O
:	:	:	O	O	O
HT	HT	NN	B-NP	B	O
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
indicated	indicate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
routine	routine	JJ	I-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
need	need	VBP	B-VP	O	O
more	more	JJR	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HT	HT	NN	B-NP	B	O
for	for	IN	B-PP	O	O
menopausal	menopausal	JJ	B-NP	O	O
symptom	symptom	NN	I-NP	O	O
control	control	NN	I-NP	O	O
,	,	,	O	O	O
though	though	IN	B-SBAR	O	O
short	short	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
use	use	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
relatively	relatively	RB	B-ADJP	O	O
safe	safe	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
younger	young	JJR	I-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	B-Disease
-	-	HYPH	B-PP	O	I-Disease
induced	induce	VBN	B-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
:	:	:	O	O	O
an	an	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
461	461	CD	B-NP	O	O
incidences	incidence	NNS	I-NP	O	O
submitted	submit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
Spanish	Spanish	JJ	I-NP	O	O
registry	registry	NN	I-NP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
&	&	CC	I-NP	O	O
AIMS	AIMS	NNS	I-NP	O	O
:	:	:	O	O	O
Progress	Progress	NNP	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
understanding	understanding	NN	I-NP	O	O
of	of	IN	B-PP	O	O
susceptibility	susceptibility	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
drug	drug	NN	B-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
induced	induce	VBN	B-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
(	(	(	O	O	O
DILI	DILI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
outcome	outcome	NN	B-NP	O	O
predictability	predictability	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
hampered	hamper	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
systematic	systematic	JJ	B-NP	O	O
programs	program	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
detect	detect	VB	I-VP	O	O
bona	bona	NN	B-NP	B	O
fide	fide	NN	I-NP	O	O
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
cooperative	cooperative	JJ	I-NP	O	O
network	network	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
created	create	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
1994	1994	CD	B-NP	O	O
in	in	IN	B-PP	O	O
Spain	Spain	NNP	B-NP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
all	all	DT	B-NP	O	O
suspicions	suspicion	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
DILI	DILI	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
structured	structure	VBN	I-NP	O	O
report	report	NN	I-NP	O	O
form	form	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
liver	liver	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	O
,	,	,	I-NP	O	O
cholestatic	cholestatic	JJ	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
mixed	mixed	JJ	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
to	to	TO	B-PP	O	O
histologic	histologic	JJ	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
available	available	JJ	B-ADJP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
causality	causality	NN	B-NP	O	O
assessment	assessment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
centrally	centrally	RB	I-VP	O	O
performed	perform	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Since	Since	IN	B-PP	O	O
April	April	NNP	B-NP	O	O
1994	1994	CD	I-NP	O	O
to	to	TO	B-PP	O	O
August	August	NNP	B-NP	O	O
2004	2004	CD	I-NP	O	O
,	,	,	I-NP	O	O
461	461	CD	I-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
570	570	CD	B-NP	O	O
submitted	submit	VBN	I-NP	O	O
cases	case	NNS	I-NP	O	O
,	,	,	O	O	O
involving	involve	VBG	B-VP	O	O
505	505	CD	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
deemed	deem	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
DILI	DILI	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antiinfective	antiinfective	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	O	O	O
more	more	RBR	B-ADVP	O	O
frequently	frequently	RB	I-ADVP	O	O
incriminated	incriminate	VBN	B-VP	O	O
,	,	,	O	O	O
amoxicillin	amoxicillin	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
clavulanate	clavulanate	NN	I-NP	B	I-Chemical
accounting	accounting	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
12.8	12.8	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
whole	whole	JJ	I-NP	O	O
series	series	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hepatocellular	hepatocellular	JJ	I-NP	O	O
pattern	pattern	NN	I-NP	O	O
of	of	IN	B-PP	O	O
damage	damage	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
(	(	(	O	O	O
58	58	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
inversely	inversely	RB	I-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
age	age	NN	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.0001	.0001	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
worst	worst	JJS	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
(	(	(	O	O	O
Cox	Cox	NNP	B-NP	O	O
regression	regression	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
.034	.034	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Indeed	Indeed	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
death	death	NN	I-NP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
11.7	11.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
jaundice	jaundice	NN	B-NP	O	B-Disease
at	at	IN	B-PP	O	O
presentation	presentation	NN	B-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
corresponding	correspond	VBG	I-NP	O	O
figure	figure	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
3.8	3.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
nonjaundiced	nonjaundiced	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.04	.04	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Factors	Factor	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
hepatic	hepatic	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
female	female	JJ	B-NP	O	O
sex	sex	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
25	25	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
4.1	4.1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
151	151	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.0001	.0001	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
hepatocellular	hepatocellular	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
7.9	7.9	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
1.6	1.6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
37	37	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.009	.009	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
higher	high	JJR	B-NP	O	O
baseline	baseline	NN	I-NP	O	O
plasma	plasma	NN	I-NP	O	O
bilirubin	bilirubin	NN	I-NP	B	B-Chemical
value	value	NN	I-NP	O	O
(	(	(	O	O	O
OR	OR	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1.15	1.15	CD	B-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
:	:	:	O	O	O
1.09	1.09	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.22	1.22	CD	I-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.0001	.0001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hepatocellular	hepatocellular	JJ	I-NP	O	O
jaundice	jaundice	NNS	I-NP	O	B-Disease
have	have	VBP	B-VP	O	O
11.7	11.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
chance	chance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progressing	progress	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
death	death	NN	B-NP	O	O
or	or	CC	I-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

Amoxicillin	Amoxicillin	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
clavulanate	clavulanate	NN	I-NP	B	I-Chemical
stands	stand	VBZ	B-VP	O	O
out	out	RP	B-PRT	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
DILI	DILI	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Morphological	Morphological	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
ribose	ribose	NN	B-NP	I	I-Chemical
on	on	IN	B-PP	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
evoked	evoke	VBN	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
ribose	ribose	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
myocardiopathy	myocardiopathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
studied	study	VBN	I-VP	O	O
.	.	.	O	O	O

Adriamycin	Adriamycin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cumulative	cumulative	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
25	25	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
evoked	evoke	VBD	B-VP	O	O
fully	fully	RB	I-VP	O	O
developed	develop	VBN	I-VP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
.	.	.	O	O	O

D	D	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
ribose	ribose	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
multiple	multiple	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
influence	influence	VB	I-VP	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	FW	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
evidences	evidence	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pathogenesis	pathogenesis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
:	:	:	O	O	O
protection	protection	NN	B-NP	O	O
by	by	IN	B-PP	O	O
erdosteine	erdosteine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aims	aim	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
examine	examine	VB	I-VP	O	O
vancomycin	vancomycin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VCM	VCM	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
promotes	promote	VBZ	B-VP	O	O
production	production	NN	B-NP	O	O
of	of	IN	B-PP	O	O
reactive	reactive	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
species	specie	NNS	I-NP	O	O
(	(	(	O	O	O
ROS	ROS	NNS	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
erdosteine	erdosteine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
expectorant	expectorant	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
also	also	RB	B-ADVP	O	O
antioxidant	antioxidant	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
,	,	,	O	O	O
on	on	IN	B-PP	O	O
kidney	kidney	NN	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
VCM	VCM	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
three	three	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
sham	sham	NN	B-NP	O	O
,	,	,	I-NP	O	O
VCM	VCM	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
VCM	VCM	NN	I-NP	B	B-Chemical
plus	plus	CC	I-NP	O	O
erdosteine	erdosteine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

VCM	VCM	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
administrated	administrate	VBN	I-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
(	(	(	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
200mgkg	200mgkg	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Erdosteine	Erdosteine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
orally	orally	RB	B-ADVP	O	O
.	.	.	O	O	O

VCM	VCM	NN	B-NP	O	B-Chemical
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	O
malondialdehyde	malondialdehyde	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
MDA	MDA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
N	N	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
acetyl	acetyl	NN	I-NP	B	O
-	-	HYPH	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
d	d	NN	I-NP	O	O
-	-	HYPH	O	O	O
glucosaminidase	glucosaminidase	NN	B-NP	O	O
(	(	(	O	O	O
NAG	NAG	NN	B-NP	B	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
marker	marker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
tubular	tubular	JJ	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
)	)	)	O	O	O
excretion	excretion	NN	B-NP	O	O
but	but	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
(	(	(	O	O	O
SOD	SOD	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
catalase	catalase	NN	B-NP	O	O
(	(	(	O	O	O
CAT	CAT	NN	B-NP	O	O
)	)	)	O	O	O
activities	activity	NNS	B-NP	O	O
.	.	.	O	O	O

Erdosteine	Erdosteine	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
VCM	VCM	NN	B-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
renal	renal	JJ	I-NP	O	O
MDA	MDA	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
urinary	urinary	JJ	B-NP	O	O
NAG	NAG	NN	I-NP	B	O
excretion	excretion	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
SOD	SOD	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
CAT	CAT	NN	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
tissue	tissue	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
VCM	VCM	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Erdosteine	Erdosteine	NN	B-NP	B	B-Chemical
showed	show	VBD	B-VP	O	O
histopathological	histopathological	JJ	B-NP	O	O
protection	protection	NN	I-NP	O	O
against	against	IN	B-PP	O	O
VCM	VCM	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
dilatation	dilatation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
lumens	lumen	NNS	I-NP	B	O
,	,	,	O	O	O
extensive	extensive	JJ	B-NP	O	O
epithelial	epithelial	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
vacuolization	vacuolization	NN	I-NP	O	O
,	,	,	O	O	O
atrophy	atrophy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
desquamation	desquamation	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
VCM	VCM	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
more	more	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
erdosteine	erdosteine	NN	I-NP	B	B-Chemical
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Erdosteine	Erdosteine	NN	B-NP	B	B-Chemical
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
concluded	conclude	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
oxidative	oxidative	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
damage	damage	NN	I-NP	O	O
plays	play	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
VCM	VCM	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
modulation	modulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
with	with	IN	B-PP	O	O
erdosteine	erdosteine	NN	B-NP	B	B-Chemical
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
VCM	VCM	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
kidney	kidney	NN	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
both	both	CC	B-PP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
histological	histological	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Does	Do	VBZ	O	O	O
domperidone	domperidone	NN	B-NP	B	B-Chemical
potentiate	potentiate	NN	I-NP	O	O
mirtazapine	mirtazapine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
restless	restless	JJ	I-NP	O	B-Disease
legs	leg	NNS	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
?	?	.	O	O	O

There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
now	now	RB	B-ADVP	O	O
evidence	evidence	NN	B-NP	O	O
to	to	TO	B-VP	O	O
suggest	suggest	VB	I-VP	O	O
a	a	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
in	in	IN	B-PP	O	O
restless	restless	JJ	B-NP	O	B-Disease
legs	leg	NNS	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
RLS	RLS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
example	example	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
dramatically	dramatically	RB	I-VP	O	O
improved	improve	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
agonists	agonist	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
central	central	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
D2	D2	NN	I-NP	B	O
receptor	receptor	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
induce	induce	VB	I-VP	O	O
or	or	CC	I-VP	O	O
aggravate	aggravate	VB	I-VP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
report	report	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
domperidone	domperidone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
peripheral	peripheral	JJ	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
D2	D2	NN	I-NP	B	O
receptor	receptor	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
can	can	MD	B-VP	O	O
also	also	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
or	or	CC	I-VP	O	O
aggravate	aggravate	VB	I-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Mirtazapine	Mirtazapine	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
noradrenergic	noradrenergic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
specific	specific	JJ	I-NP	O	O
serotonergic	serotonergic	JJ	I-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	O
(	(	(	O	O	O
NaSSA	NaSSA	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
recent	recent	JJ	I-NP	O	O
publications	publication	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
report	report	VBP	B-VP	O	O
here	here	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
depressed	depressed	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
comorbid	comorbid	NN	I-NP	O	O
with	with	IN	B-PP	O	O
postprandial	postprandial	JJ	B-NP	O	B-Disease
dyspepsia	dyspepsia	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
after	after	IN	B-SBAR	O	O
mirtazapine	mirtazapine	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
added	add	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
his	his	PRP$	B-NP	O	O
domperidone	domperidone	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
started	start	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
symptoms	symptom	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
only	only	RB	B-ADVP	O	O
after	after	IN	B-SBAR	O	O
he	he	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
his	his	PRP$	B-NP	O	O
RLS	RLS	NN	I-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	O
resolved	resolve	VBD	B-VP	O	O
completely	completely	RB	B-ADVP	O	O
upon	upon	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
mirtazapine	mirtazapine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Such	Such	PDT	B-NP	O	O
a	a	DT	I-NP	O	O
temporal	temporal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
support	support	VB	I-VP	O	O
a	a	DT	B-NP	O	O
potentiating	potentiating	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
domperione	domperione	NN	B-NP	O	B-Chemical
on	on	IN	B-PP	O	O
mirtazapine	mirtazapine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
RLS	RLS	NN	I-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
physicians	physician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
mirtazapine	mirtazapine	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
RLS	RLS	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
some	some	DT	B-NP	O	O
individuals	individual	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
those	those	DT	B-NP	O	O
receiving	receive	VBG	I-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
D2	D2	NN	I-NP	B	O
receptor	receptor	NN	I-NP	O	O
antagonists	antagonist	NNS	I-NP	O	O
.	.	.	O	O	O

Antiandrogenic	Antiandrogenic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
arterial	arterial	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

AIM	AIM	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
study	study	VB	I-VP	O	O
the	the	DT	B-NP	O	O
change	change	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lipid	lipid	NN	B-NP	O	O
metabolism	metabolism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
antiandrogen	antiandrogen	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
prostate	prostate	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
.	.	.	O	O	O

MATERIALS	MATERIALS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2.5	2.5	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
the	the	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
plasma	plasma	NN	B-NP	O	O
cholesterols	cholesterol	NNS	I-NP	B	B-Chemical
(	(	(	O	O	O
C	C	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
triglycerides	triglyceride	NNS	B-NP	B	B-Chemical
(	(	(	O	O	O
TG	TG	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
lipoproteins	lipoprotein	NNS	B-NP	O	O
(	(	(	O	O	O
LP	LP	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
apolipoproteins	apolipoprotein	NNS	B-NP	O	O
(	(	(	O	O	O
Apo	Apo	NN	B-NP	O	O
)	)	)	O	O	O
B	B	NN	B-NP	O	O
-	-	HYPH	O	O	O
100	100	CD	B-NP	O	O
,	,	,	O	O	O
A	A	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
A	A	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
II	II	CD	I-NP	O	O
pro	pro	JJ	I-NP	O	O
fi	fi	NN	I-NP	O	O
les	le	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
24	24	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
60	60	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
prostate	prostate	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
(	(	(	O	O	O
stage	stage	NN	B-NP	O	O
:	:	:	O	O	O
T1cN0M0	T1cN0M0	NN	B-NP	O	O
,	,	,	O	O	O
Gleason	Gleason	NNP	B-NP	O	O
score	score	NN	I-NP	O	O
:	:	:	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
cyproterone	cyproterone	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
CPA	CPA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
without	without	IN	B-PP	O	O
surgical	surgical	JJ	B-NP	O	O
management	management	NN	I-NP	O	O
or	or	CC	I-NP	O	O
radiation	radiation	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Significant	Significant	JJ	B-NP	O	O
decreases	decrease	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HDL	HDL	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
C	C	NN	I-NP	O	O
,	,	,	O	O	O
Apo	Apo	IN	B-PP	O	O
A	A	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	CD	I-NP	O	O
and	and	CC	O	O	O
Apo	Apo	NNP	B-NP	O	O
A	A	NNP	I-NP	O	O
-	-	:	O	O	O
II	II	CD	B-NP	O	O
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
triglyceride	triglyceride	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
VLDL	VLDL	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CPA	CPA	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

After	After	IN	B-PP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
2.5	2.5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
CPA	CPA	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
four	four	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
out	out	IN	B-PP	O	O
of	of	IN	B-PP	O	O
twenty	twenty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
four	four	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Ischaemic	Ischaemic	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	B-Disease
arteriosclerosis	arteriosclerosis	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
16.6	16.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
CPA	CPA	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
mediated	mediate	VBN	I-VP	O	O
through	through	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
HDL	HDL	NN	B-NP	O	O
cholesterol	cholesterol	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
Apo	Apo	IN	B-PP	O	O
A	A	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
I	I	CD	I-NP	O	O
and	and	CC	O	O	O
Apo	Apo	NNP	B-NP	O	O
A	A	NNP	I-NP	O	O
-	-	HYPH	B-NP	O	O
II	II	CD	I-NP	O	O
pro	pro	JJ	I-NP	O	O
fi	fi	NN	I-NP	O	O
les	le	NNS	I-NP	O	O
,	,	,	O	O	O
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
well	well	RB	I-NP	O	O
-	-	HYPH	I-NP	O	O
known	know	VBN	I-NP	O	O
hyperglyceridemic	hyperglyceridemic	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
estrogen	estrogen	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
Fluorouracil	Fluorouracil	NN	I-NP	I	I-Chemical
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
fluoro	fluoro	SYM	O	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
beta	beta	SYM	B-NP	I	I-Chemical
-	-	HYPH	B-VP	I	I-Chemical
alanine	alanine	NN	B-NP	I	I-Chemical
.	.	.	O	O	O

Cardiotoxicity	Cardiotoxicity	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
occurring	occur	VBG	B-VP	O	O
during	during	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
malignancies	malignancy	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
herein	herein	RB	B-ADVP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
70	70	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alpha	alpha	SYM	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
fluoro	fluoro	SYM	O	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
beta	beta	SYM	O	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
alanine	alanine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
FBAL	FBAL	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
unresectable	unresectable	JJ	B-NP	O	O
colon	colon	NN	I-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
metastases	metastasis	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	I-NP	O	O
lung	lung	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
referred	refer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
us	us	PRP	B-NP	O	O
for	for	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
from	from	IN	B-PP	O	O
an	an	DT	B-NP	O	O
affiliated	affiliated	JJ	I-NP	O	O
hospital	hospital	NN	I-NP	O	O
;	;	:	O	O	O
he	he	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
continuous	continuous	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
infusion	infusion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
1000	1000	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
precordial	precordial	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
right	right	JJ	B-NP	O	B-Disease
bundle	bundle	NN	I-NP	O	I-Disease
branch	branch	NN	I-NP	O	I-Disease
block	block	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
concomitantly	concomitantly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
serum	serum	NN	I-NP	O	O
FBAL	FBAL	NN	I-NP	O	B-Chemical
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1955	1955	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	CC	O	O	O
the	the	DT	B-NP	O	O
precordial	precordial	JJ	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
electrocardiographic	electrocardiographic	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
disappeared	disappear	VBD	B-VP	O	O
spontaneously	spontaneously	RB	B-ADVP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
discontinuation	discontinuation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
precordial	precordial	JJ	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
abandoned	abandon	VBN	I-VP	O	O
.	.	.	O	O	O

Instead	Instead	RB	B-ADVP	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
1	1	CD	I-NP	I	O
(	(	(	O	O	O
a	a	DT	B-NP	O	O
derivative	derivative	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
instituted	institute	VBN	I-VP	O	O
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
S	S	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
1	1	CD	I-NP	I	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
inhibitory	inhibitory	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
dihydropyrimidine	dihydropyrimidine	NN	B-NP	O	B-Chemical
dehydrogenase	dehydrogenase	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
catalyzes	catalyze	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
degradative	degradative	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
into	into	IN	B-PP	O	O
FBAL	FBAL	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
FBAL	FBAL	NN	I-NP	O	B-Chemical
concentration	concentration	NN	I-NP	O	O
subsequently	subsequently	RB	B-ADVP	O	O
decreased	decrease	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
352	352	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
value	value	NN	I-NP	O	O
measured	measure	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
of	of	IN	B-PP	O	O
S	S	NN	B-NP	B	O
-	-	HYPH	B-NP	I	O
1	1	CD	I-NP	I	O
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

Thereafter	Thereafter	RB	B-ADVP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
achieved	achieve	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
partial	partial	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initiation	initiation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
S	S	NN	I-NP	B	O
-	-	HYPH	B-NP	I	O
1	1	CD	I-NP	I	O
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
experience	experience	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
,	,	,	O	O	O
together	together	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
,	,	,	O	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
FBAL	FBAL	NN	B-NP	O	B-Chemical
is	be	VBZ	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

S	S	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
safely	safely	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
influence	influence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
between	between	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
protection	protection	NN	I-NP	O	O
against	against	IN	B-PP	O	O
doxorubicin	doxorubicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
Despite	Despite	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
well	well	NN	I-NP	O	O
-	-	HYPH	B-VP	O	O
known	know	VBN	I-VP	O	O
cardiotoxicity	cardiotoxicity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
anthracyclin	anthracyclin	NN	I-NP	O	O
doxorubicin	doxorubicin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
continues	continue	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
widely	widely	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
.	.	.	O	O	O

DOX	DOX	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
presumably	presumably	RB	B-ADVP	O	O
results	result	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
radicals	radical	NNS	I-NP	O	O
by	by	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Reactive	Reactive	JJ	B-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
species	specie	NNS	I-NP	O	O
particularly	particularly	RB	B-ADVP	O	O
affect	affect	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
myocytes	myocyte	NNS	I-NP	O	O
because	because	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
cells	cell	NNS	I-NP	O	O
seem	seem	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
poor	poor	JJ	I-NP	O	O
antioxidant	antioxidant	JJ	I-NP	O	O
defense	defense	NN	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
semisynthetic	semisynthetic	JJ	I-NP	O	O
flavonoid	flavonoid	NN	I-NP	O	B-Chemical
monohydroxyethylrutoside	monohydroxyethylrutoside	NN	I-NP	O	B-Chemical
(	(	(	O	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
showed	show	VBD	B-VP	O	O
cardioprotection	cardioprotection	NN	B-NP	O	O
against	against	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
through	through	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
radical	radical	JJ	I-NP	O	O
scavenging	scavenging	NN	I-NP	O	O
and	and	CC	I-NP	O	O
iron	iron	NN	I-NP	B	B-Chemical
chelating	chelating	NN	I-NP	O	O
properties	property	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
the	the	DT	B-NP	O	O
relatively	relatively	RB	I-NP	O	O
short	short	JJ	I-NP	O	O
final	final	JJ	I-NP	O	O
half	half	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
life	life	NN	I-NP	O	O
of	of	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
about	about	RB	B-NP	O	O
30	30	CD	I-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
expected	expect	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
between	between	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
DOX	DOX	NN	I-NP	B	B-Chemical
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
of	of	IN	B-PP	O	O
influence	influence	NN	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardioprotective	cardioprotective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
this	this	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Six	Six	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
6	6	CD	B-NP	O	O
BALB	BALB	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
c	c	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
,	,	,	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.v.	i.v.	JJ	B-ADJP	O	O
)	)	)	O	O	O
preceded	precede	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
,	,	,	I-NP	O	O
30	30	CD	I-NP	O	O
,	,	,	I-NP	O	O
60	60	CD	I-NP	O	O
or	or	CC	I-NP	O	O
120	120	CD	I-NP	O	O
min	min	NN	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
a	a	DT	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
period	period	NN	I-NP	O	O
and	and	CC	O	O	O
additional	additional	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
sacrificed	sacrifice	VBN	I-VP	O	O
.	.	.	O	O	O

Their	Their	PRP$	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
tissues	tissue	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
processed	process	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
light	light	JJ	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
cardiomyocyte	cardiomyocyte	NN	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
Billingham	Billingham	NNP	B-NP	O	O
(	(	(	O	O	O
in	in	IN	B-PP	O	O
Cancer	Cancer	NNP	B-NP	O	B-Disease
Treat	Treat	NNP	I-NP	O	O
Rep	Rep	NNP	I-NP	O	O
62	62	CD	I-NP	O	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
865	865	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
872	872	CD	I-NP	O	O
,	,	,	I-NP	O	O
1978	1978	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Microscopic	Microscopic	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
induced	induce	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
saline	saline	NN	I-NP	B	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
damaged	damage	VBN	B-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
9.6	9.6	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
4.4	4.4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
21.0	21.0	CD	I-NP	O	O
)	)	)	O	O	O
higher	high	JJR	B-ADJP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
in	in	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aberrant	aberrant	JJ	B-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
preceded	precede	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
ranged	range	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
1.6	1.6	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.8	2.8	CD	B-NP	O	O
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
2.2	2.2	CD	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
1.2	1.2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4.1	4.1	CD	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.019	0.019	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
by	by	IN	B-PP	O	O
adding	add	VBG	B-VP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
before	before	IN	B-SBAR	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
4.4	4.4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
fold	fold	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-ADJP	O	O
0.001	0.001	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
2.3	2.3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
8.2	8.2	CD	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
abnormal	abnormal	JJ	B-NP	O	O
cardiomyocytes	cardiomyocyte	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
protective	protective	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
depend	depend	VB	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
between	between	IN	B-PP	O	O
monoHER	monoHER	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.345	0.345	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
outpatient	outpatient	NN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
setting	set	VBG	I-NP	O	O
monoHER	monoHER	NN	I-NP	O	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
shortly	shortly	RB	B-ADVP	O	O
before	before	IN	B-PP	O	O
DOX	DOX	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
bepridil	bepridil	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
flutter	flutter	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Bepridil	Bepridil	NN	B-NP	B	B-Chemical
hydrochloride	hydrochloride	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
Bpd	Bpd	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
attracted	attract	VBN	I-VP	O	O
attention	attention	NN	B-NP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
for	for	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AF	AF	NN	B-NP	B	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
flutter	flutter	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AFL	AFL	NN	B-NP	B	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
serious	serious	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
torsade	torsade	FW	B-NP	O	B-Disease
de	de	FW	I-NP	O	I-Disease
pointes	pointes	FW	I-NP	O	I-Disease
(	(	(	O	O	O
Tdp	Tdp	NN	B-NP	O	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
RESULTS	RESULTS	NNS	I-NP	O	O
:	:	:	O	O	O
Adverse	Adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Bpd	Bpd	NN	B-NP	O	B-Chemical
requiring	require	VBG	B-VP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Bpd	Bpd	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
459	459	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
361	361	CD	B-NP	O	O
males	male	NNS	I-NP	O	O
,	,	,	O	O	O
63	63	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
12	12	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
old	old	JJ	B-ADJP	O	O
)	)	)	O	O	O
comprising	comprise	VBG	B-VP	O	O
378	378	CD	B-NP	O	O
AF	AF	NN	I-NP	B	B-Disease
and	and	CC	O	O	O
81	81	CD	B-NP	O	O
AFL	AFL	NN	I-NP	B	B-Disease
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Mean	Mean	NNP	B-NP	O	O
left	leave	VBD	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	O
ejection	ejection	NN	I-NP	O	O
fraction	fraction	NN	I-NP	O	O
and	and	CC	O	O	O
atrial	atrial	JJ	B-NP	O	O
dimension	dimension	NN	I-NP	O	O
(	(	(	O	O	O
LAD	LAD	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
66	66	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
11	11	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
40	40	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
6	6	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Adverse	Adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
19	19	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
during	during	IN	B-PP	O	O
an	an	DT	B-NP	O	O
average	average	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
20	20	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
marked	marked	JJ	B-NP	O	O
QT	QT	NN	I-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
greater	great	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
0.55	0.55	CD	I-NP	O	O
s	s	NN	I-NP	O	O
in	in	IN	B-PP	O	O
13	13	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
bradycardia	bradycardia	NN	B-NP	O	B-Disease
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
40	40	CD	I-NP	O	O
beats	beat	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
dizziness	dizziness	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
general	general	JJ	B-NP	O	O
fatigue	fatigue	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
1	1	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
each	each	DT	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
4	4	CD	B-NP	O	O
of	of	IN	B-PP	O	O
13	13	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
,	,	,	O	O	O
Tdp	Tdp	NN	B-NP	O	B-Disease
occurred	occur	VBD	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
triggering	triggering	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Tdp	Tdp	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
sudden	sudden	JJ	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
backgrounds	background	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
and	and	CC	B-PP	O	O
without	without	IN	B-PP	O	O
Tdp	Tdp	NN	B-NP	O	B-Disease
other	other	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
LAD	LAD	NN	B-NP	O	O
and	and	CC	I-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
larger	large	JJR	B-ADJP	O	O
and	and	CC	I-ADJP	O	O
older	old	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
Tdp	Tdp	NN	B-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Careful	Careful	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
ECG	ECG	NN	I-NP	O	O
should	should	MD	B-VP	O	O
always	always	RB	I-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
Bpd	Bpd	NN	B-NP	O	B-Chemical
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
particularly	particularly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Enhanced	Enhance	VBN	B-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
transgenic	transgenic	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
angiotensinogen	angiotensinogen	NN	I-NP	B	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
permanent	permanent	JJ	I-NP	O	O
deficiency	deficiency	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
renin	renin	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
system	system	NN	I-NP	O	O
(	(	(	O	O	O
RAS	RAS	NN	B-NP	B	O
)	)	)	O	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
the	the	DT	B-NP	O	O
sensitivity	sensitivity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
baroreflex	baroreflex	NN	I-NP	O	O
control	control	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
at	at	IN	B-PP	O	O
studying	study	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
RAS	RAS	NN	I-NP	B	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
reactivity	reactivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
adrenoceptor	adrenoceptor	NN	I-NP	O	O
(	(	(	O	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
AR	AR	NN	I-NP	O	O
)	)	)	O	O	O
agonist	agonist	NN	B-NP	O	O
isoproterenol	isoproterenol	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
Iso	Iso	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Transgenic	Transgenic	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
angiotensinogen	angiotensinogen	NN	I-NP	B	O
(	(	(	O	O	O
TGR	TGR	NN	B-NP	B	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
hearts	heart	NNS	I-NP	O	O
,	,	,	O	O	O
Iso	Iso	NNP	B-NP	O	B-Chemical
induced	induce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
greater	great	JJR	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
left	left	JJ	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
(	(	(	O	O	O
LV	LV	NN	B-NP	B	O
)	)	)	O	O	O
pressure	pressure	NN	B-NP	O	O
and	and	CC	O	O	O
maximal	maximal	JJ	B-NP	O	O
contraction	contraction	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
dP	dP	NN	I-NP	O	O
/	/	SYM	O	O	O
dt	dt	NN	B-NP	O	O
(	(	(	O	O	O
max	max	NN	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TGR	TGR	NN	I-NP	B	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Sprague	Sprague	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
(	(	(	O	O	O
SD	SD	NNP	B-NP	O	O
)	)	)	O	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

LV	LV	NN	B-NP	O	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Iso	Iso	NN	B-NP	O	B-Chemical
treatment	treatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
TGR	TGR	NN	B-NP	B	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
SD	SD	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
in	in	IN	B-PP	O	O
g	g	NN	B-NP	O	O
LV	LV	NN	I-NP	B	O
wt	wt	NN	I-NP	O	O
/	/	SYM	O	O	O
100	100	CD	B-NP	O	O
g	g	NN	I-NP	O	O
body	body	NN	I-NP	O	O
wt	wt	NN	I-NP	O	O
,	,	,	O	O	O
0.28	0.28	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
0.004	0.004	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

0.24	0.24	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.004	0.004	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
LV	LV	NN	I-NP	B	B-Disease
hypertrophy	hypertrophy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
TGR	TGR	NN	B-NP	B	O
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
pronounced	pronounced	JJ	I-NP	O	O
downregulation	downregulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	I-NP	O	O
AR	AR	NN	I-NP	O	O
and	and	CC	I-NP	O	O
upregulation	upregulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
beta	beta	SYM	O	O	O
-	-	HYPH	O	O	O
AR	AR	NN	B-NP	O	O
kinase	kinase	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
SD	SD	NNP	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
HR	HR	NN	B-NP	O	O
)	)	)	O	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
AR	AR	NN	I-NP	O	O
antagonist	antagonist	NN	I-NP	O	O
metoprolol	metoprolol	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
attenuated	attenuate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
TGR	TGR	NN	B-NP	B	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
SD	SD	NNP	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
9.9	9.9	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.7	1.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

-	-	SYM	O	O	O
18.1	18.1	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.5	1.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
parasympathetic	parasympathetic	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
by	by	IN	B-PP	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
HR	HR	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	DT	B-NP	O	O
strains	strain	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
TGR	TGR	NN	B-NP	B	O
are	be	VBP	B-VP	O	O
more	more	RBR	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	O	O	O
AR	AR	NN	B-NP	O	O
agonist	agonist	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
inotropic	inotropic	JJ	I-NP	O	I-Disease
response	response	NN	I-NP	O	O
and	and	CC	I-NP	O	O
hypertrophy	hypertrophy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
possibly	possibly	RB	B-ADJP	O	O
due	due	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
chronically	chronically	RB	B-NP	O	O
low	low	JJ	I-NP	O	O
sympathetic	sympathetic	JJ	I-NP	O	O
outflow	outflow	NN	I-NP	O	O
directed	direct	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
heart	heart	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
long	long	JJ	I-NP	O	B-Disease
QT	QT	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
high	high	JJ	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hospitalized	hospitalize	VBN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
and	and	CC	O	O	O
risk	risk	NN	B-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Drug	Drug	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
long	long	JJ	I-NP	O	B-Disease
QT	QT	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
serious	serious	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Methadone	Methadone	NN	B-NP	B	B-Chemical
prolongs	prolong	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
QT	QT	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
in	in	FW	B-ADVP	O	O
vitro	vitro	FW	I-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inpatient	inpatient	NN	I-NP	O	O
setting	setting	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
interval	interval	NN	I-NP	O	I-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
dose	dose	NN	I-NP	O	O
dependence	dependence	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
importance	importance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cofactors	cofactor	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
remain	remain	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
performed	perform	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
systematic	systematic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
comparing	compare	VBG	B-VP	O	O
active	active	JJ	B-NP	O	O
or	or	CC	I-NP	O	O
former	former	JJ	I-NP	O	O
intravenous	intravenous	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
those	those	DT	B-NP	O	O
not	not	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
among	among	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
hospitalized	hospitalize	VBD	B-VP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
5	5	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
period	period	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tertiary	tertiary	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
hospital	hospital	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
167	167	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
fulfilled	fulfil	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
inclusion	inclusion	NN	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
80	80	CD	B-NP	O	O
injection	injection	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
not	not	RB	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
15	15	CD	B-NP	O	O
demographic	demographic	JJ	I-NP	O	O
,	,	,	I-NP	O	O
biological	biological	JJ	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
pharmacological	pharmacological	JJ	B-NP	O	O
variables	variable	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Among	Among	IN	B-NP	O	O
167	167	CD	I-NP	O	O
methadone	methadone	NN	I-NP	B	B-Chemical
maintenance	maintenance	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
to	to	TO	B-PP	O	O
0.50	0.50	CD	B-NP	O	O
second	second	JJ	I-NP	O	O
(	(	(	O	O	O
(	(	(	O	O	O
1	1	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
longer	long	JJR	B-NP	O	O
was	be	VBD	B-VP	O	O
16.2	16.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
80	80	CD	B-NP	O	O
control	control	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Six	Six	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
3.6	3.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
methadone	methadone	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
presented	present	VBD	B-VP	O	O
torsades	torsade	NNS	B-NP	O	B-Disease
de	de	IN	B-PP	O	I-Disease
pointes	pointe	NNS	B-NP	O	I-Disease
.	.	.	O	O	O

QTc	QTc	NN	B-NP	O	O
length	length	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
weakly	weakly	RB	B-VP	O	O
but	but	CC	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
daily	daily	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
Spearman	Spearman	NN	B-NP	O	O
rank	rank	NN	I-NP	O	O
correlation	correlation	NN	I-NP	O	O
coefficient	coefficient	NN	I-NP	O	O
,	,	,	O	O	O
0.20	0.20	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
.01	.01	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Multivariate	Multivariate	JJ	B-NP	O	O
regression	regression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
allowed	allow	VBD	B-VP	O	O
attribution	attribution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
31.8	31.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
QTc	QTc	NN	B-NP	O	O
variability	variability	NN	I-NP	O	O
to	to	TO	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
cytochrome	cytochrome	NN	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
450	450	CD	I-NP	O	O
3A4	3A4	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
drug	drug	NN	I-NP	O	O
interactions	interaction	NNS	I-NP	O	O
,	,	,	O	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
altered	alter	VBD	B-VP	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
QT	QT	NN	B-NP	O	B-Disease
interval	interval	NN	I-NP	O	I-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
maintenance	maintenance	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
hospitalized	hospitalize	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tertiary	tertiary	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
center	center	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
finding	finding	NN	I-NP	O	O
.	.	.	O	O	O

Methadone	Methadone	NN	B-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
presence	presence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cytochrome	cytochrome	NN	B-NP	O	O
P	P	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
450	450	CD	I-NP	O	O
3A4	3A4	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
level	level	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
liver	liver	NN	B-NP	O	O
function	function	NN	I-NP	O	O
contribute	contribute	VBP	B-VP	O	O
to	to	TO	B-PP	O	O
QT	QT	NN	B-NP	O	B-Disease
prolongation	prolongation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	B-Disease
QT	QT	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Mechanisms	Mechanism	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
nitric	nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
NO	NO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
deficiency	deficiency	NN	B-NP	O	O
:	:	:	O	O	O
focus	focus	NN	B-NP	O	O
on	on	IN	B-PP	O	O
venous	venous	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Loss	Loss	NN	B-NP	O	O
of	of	IN	B-PP	O	O
endothelial	endothelial	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	O	O	O
derived	derive	VBN	B-VP	O	O
nitric	nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
NO	NO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
hallmark	hallmark	NN	I-NP	O	O
of	of	IN	B-PP	O	O
arterial	arterial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Experimental	Experimental	JJ	B-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
created	create	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
removal	removal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NO	NO	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
involves	involve	VBZ	B-VP	O	O
mechanisms	mechanism	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
vasodilator	vasodilator	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
include	include	VBP	B-VP	O	O
augmented	augmented	JJ	B-NP	O	O
endothelin	endothelin	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
(	(	(	O	O	O
ET	ET	NN	O	O	O
-	-	HYPH	O	O	O
1	1	CD	O	O	O
)	)	)	O	O	O
release	release	NN	B-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
elevated	elevate	VBD	B-VP	B	O
tissue	tissue	NN	B-NP	O	O
oxidative	oxidative	JJ	I-NP	O	O
stress	stress	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
hypothesized	hypothesize	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
increased	increase	VBN	B-NP	O	O
venous	venous	JJ	I-NP	O	O
smooth	smooth	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
(	(	(	O	O	O
venomotor	venomotor	NN	B-NP	O	O
)	)	)	O	O	O
tone	tone	NN	B-NP	O	O
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Nomega	Nomega	NNP	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
nitro	nitro	AFX	O	B	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
L	L	NN	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
arginine	arginine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
through	through	IN	B-PP	O	O
these	these	DT	B-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
NO	NO	NN	I-NP	O	B-Chemical
synthase	synthase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
LNNA	LNNA	NN	I-NP	O	B-Chemical
(	(	(	O	O	O
0.5	0.5	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
in	in	IN	B-PP	O	O
drinking	drinking	NN	B-NP	O	O
water	water	NN	I-NP	B	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
conscious	conscious	JJ	B-NP	O	O
rats	rat	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
119	119	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
and	and	CC	O	O	O
194	194	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
5	5	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Carotid	Carotid	JJ	B-NP	O	O
arteries	artery	NNS	I-NP	O	O
and	and	CC	O	O	O
vena	vena	NN	B-NP	O	O
cava	cava	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
removed	remove	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
isometric	isometric	JJ	B-NP	O	O
contraction	contraction	NN	I-NP	O	O
.	.	.	O	O	O

Maximal	Maximal	JJ	B-NP	O	O
contraction	contraction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
modestly	modestly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
arteries	artery	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
whereas	whereas	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
contraction	contraction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
ET	ET	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
(	(	(	O	O	O
54	54	CD	B-NP	O	O
%	%	NN	I-NP	O	O
control	control	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Maximum	Maximum	JJ	B-NP	O	O
contraction	contraction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vena	vena	NN	B-NP	O	O
cava	cava	NN	I-NP	O	O
to	to	TO	B-PP	O	O
norepinephrine	norepinephrine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
37	37	CD	B-NP	O	O
%	%	NN	I-NP	O	O
control	control	NN	I-NP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
response	response	NN	B-NP	O	O
to	to	TO	B-PP	O	O
ET	ET	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
circulatory	circulatory	JJ	I-NP	O	O
filling	filling	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
measure	measure	NN	I-NP	O	O
of	of	IN	B-PP	O	O
venomotor	venomotor	NN	B-NP	O	O
tone	tone	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
elevated	elevate	VBN	I-VP	B	O
in	in	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
hypertension	hypertension	NN	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
1	1	CD	B-NP	O	O
or	or	CC	I-NP	O	O
2	2	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
superoxide	superoxide	NN	I-NP	B	B-Chemical
scavenger	scavenger	NN	I-NP	O	O
tempol	tempol	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
100	100	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
300	300	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
kg	kg	NN	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
IV	IV	CD	B-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
change	change	VB	I-VP	O	O
arterial	arterial	JJ	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
but	but	CC	O	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
18	18	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8	8	CD	B-NP	O	O
,	,	,	O	O	O
-	-	SYM	B-NP	O	O
26	26	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-NP	O	O
15	15	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
-	-	SYM	B-NP	O	O
54	54	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
11	11	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
ganglionic	ganglionic	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hexamethonium	hexamethonium	NN	B-NP	B	B-Chemical
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
greater	great	JJR	I-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
76	76	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
9	9	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
)	)	)	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
35	35	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
10	10	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Carotid	Carotid	JJ	B-NP	O	O
arteries	artery	NNS	I-NP	O	O
,	,	,	O	O	O
vena	vena	NN	B-NP	O	O
cava	cava	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
LNNA	LNNA	NN	B-NP	O	B-Chemical
rats	rat	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
higher	high	JJR	B-NP	O	O
basal	basal	JJ	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
from	from	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
while	while	IN	B-SBAR	O	O
NO	NO	NN	B-NP	O	B-Chemical
deficiency	deficiency	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
and	and	CC	O	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
venous	venous	JJ	I-NP	O	O
vessels	vessel	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
impact	impact	NN	I-NP	O	O
on	on	IN	B-PP	O	O
veins	vein	NNS	B-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
make	make	VB	I-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
contribution	contribution	NN	I-NP	O	O
to	to	TO	B-PP	O	O
this	this	DT	B-NP	O	O
form	form	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Association	Association	NN	B-NP	O	O
of	of	IN	B-PP	O	O
DRD2	DRD2	NN	B-NP	O	O
polymorphisms	polymorphism	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
chlorpromazine	chlorpromazine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
extrapyramidal	extrapyramidal	JJ	I-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Chinese	Chinese	JJ	B-NP	O	O
schizophrenic	schizophrenic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

AIM	AIM	NN	B-NP	O	O
:	:	:	O	O	O
Extrapyramidal	Extrapyramidal	JJ	B-NP	O	B-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
EPS	EPS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
most	most	RBS	I-VP	O	O
commonly	commonly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
typical	typical	JJ	B-NP	O	O
antipsychotic	antipsychotic	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
affinity	affinity	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
D2	D2	NN	I-NP	B	O
receptor	receptor	NN	I-NP	O	O
.	.	.	O	O	O

Recently	Recently	RB	B-ADVP	O	O
,	,	,	O	O	O
many	many	JJ	B-NP	O	O
research	research	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
variations	variation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DRD2	DRD2	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
therapeutic	therapeutic	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
in	in	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
variations	variation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
in	in	IN	B-PP	O	O
modulating	modulate	VBG	B-VP	O	O
receptor	receptor	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
evaluate	evaluate	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
DRD2	DRD2	NN	I-NP	O	O
plays	play	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
EPS	EPS	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
schizophrenic	schizophrenic	JJ	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
identified	identify	VBD	B-VP	O	O
seven	seven	CD	B-NP	O	O
SNP	SNP	NN	I-NP	O	O
(	(	(	O	O	O
single	single	JJ	B-NP	O	O
nucleotide	nucleotide	NN	I-NP	O	O
polymorphism	polymorphism	NN	I-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
141Cins	141Cins	NN	I-NP	O	O
>	>	SYM	I-NP	O	O
del	del	NN	I-NP	O	O
,	,	,	O	O	O
TaqIB	TaqIB	NN	B-NP	O	O
,	,	,	O	O	O
TaqID	TaqID	NN	B-NP	O	O
,	,	,	O	O	O
Ser311Cys	Ser311Cys	NN	B-NP	O	O
,	,	,	O	O	O
rs6275	rs6275	NN	B-NP	O	O
,	,	,	O	O	O
rs6277	rs6277	NN	B-NP	O	O
and	and	CC	O	O	O
TaqIA	TaqIA	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DRD2	DRD2	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
in	in	IN	B-PP	O	O
146	146	CD	B-NP	O	O
schizophrenic	schizophrenic	JJ	I-NP	O	B-Disease
inpatients	inpatient	NNS	I-NP	O	O
(	(	(	O	O	O
59	59	CD	B-NP	O	O
with	with	IN	B-PP	O	O
EPS	EPS	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
87	87	CD	B-NP	O	O
without	without	IN	B-PP	O	O
EPS	EPS	NN	B-NP	O	B-Disease
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
Simpson	Simpson	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Angus	Angus	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
)	)	)	O	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	B	B-Chemical
after	after	IN	B-PP	O	O
8	8	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
alleles	allele	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
loci	locus	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
PCR	PCR	NN	B-NP	O	O
(	(	(	O	O	O
polymerase	polymerase	NN	B-NP	O	O
chain	chain	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Polymorphisms	Polymorphism	NNS	B-NP	O	O
TaqID	TaqID	NN	I-NP	O	O
,	,	,	I-NP	O	O
Ser311Cys	Ser311Cys	NN	I-NP	O	O
and	and	CC	I-NP	O	O
rs6277	rs6277	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	B-ADJP	O	O
polymorphic	polymorphic	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
population	population	NN	I-NP	O	O
recruited	recruit	VBN	B-VP	B	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
statistical	statistical	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
allele	allele	NN	I-NP	O	O
distribution	distribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
-	-	SYM	B-NP	O	O
141Cins	141Cins	NN	I-NP	O	O
>	>	SYM	B-NP	O	O
del	del	NN	I-NP	O	O
,	,	,	I-NP	O	O
TaqIB	TaqIB	NN	I-NP	O	O
,	,	,	I-NP	O	O
rs6275	rs6275	NN	I-NP	O	O
and	and	CC	I-NP	O	O
TaqIA	TaqIA	NN	I-NP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
estimated	estimate	VBN	I-NP	O	O
haplotypes	haplotype	NNS	I-NP	O	O
(	(	(	O	O	O
constituted	constitute	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
TaqIB	TaqIB	NN	B-NP	O	O
,	,	,	O	O	O
rs6275	rs6275	NN	B-NP	O	O
and	and	CC	O	O	O
TaqIA	TaqIA	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
linkage	linkage	NN	B-NP	O	O
disequilibrium	disequilibrium	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
lend	lend	VB	I-VP	O	O
strong	strong	JJ	B-NP	O	O
support	support	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
view	view	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
genetic	genetic	JJ	I-NP	O	O
variation	variation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
DRD2	DRD2	NN	I-NP	O	O
gene	gene	NN	I-NP	O	O
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
major	major	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
individually	individually	RB	I-NP	O	O
variable	variable	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
chlorpromazine	chlorpromazine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
in	in	IN	B-PP	O	O
Chinese	Chinese	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
schizophrenia	schizophrenia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
DRD2	DRD2	NN	B-NP	O	O
and	and	CC	I-NP	O	O
EPS	EPS	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
Caucasians	Caucasian	NNPS	B-NP	O	O
.	.	.	O	O	O

Physical	Physical	JJ	B-NP	O	O
training	training	NN	I-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
susceptibility	susceptibility	NN	B-NP	O	O
to	to	TO	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Regular	Regular	JJ	B-NP	O	O
motor	motor	NN	I-NP	O	O
activity	activity	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
many	many	JJ	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
physical	physical	JJ	I-NP	O	O
condition	condition	NN	I-NP	O	O
but	but	CC	O	O	O
its	its	PRP$	B-NP	O	O
implications	implication	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
still	still	RB	B-ADVP	O	O
controversial	controversial	JJ	B-ADJP	O	O
.	.	.	O	O	O

In	In	IN	B-SBAR	O	O
order	order	NN	O	O	O
to	to	TO	B-VP	O	O
elucidate	elucidate	VB	I-VP	O	O
this	this	DT	B-NP	O	O
problem	problem	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
studied	study	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
physical	physical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
on	on	IN	B-PP	O	O
susceptibility	susceptibility	NN	B-NP	O	O
to	to	TO	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Male	Male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
subjected	subject	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
training	training	NN	I-NP	O	O
sessions	session	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
treadmill	treadmill	NN	I-NP	O	O
and	and	CC	I-NP	O	O
swimming	swimming	NN	I-NP	O	O
pool	pool	NN	I-NP	O	O
.	.	.	O	O	O

Thereafter	Thereafter	RB	B-ADVP	O	O
,	,	,	O	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
trained	trained	JJ	O	O	O
and	and	CC	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	O	O	O
trained	train	VBN	B-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
measured	measure	VBD	B-VP	O	O
:	:	:	O	O	O
(	(	(	B-LST	O	O
1	1	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
latency	latency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
motor	motor	NN	I-NP	O	O
sign	sign	NN	I-NP	O	O
,	,	,	O	O	O
(	(	(	B-LST	O	O
2	2	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
intensity	intensity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
(	(	(	B-LST	O	O
3	3	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
occurred	occur	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
the	the	DT	B-NP	O	O
6	6	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
h	h	NN	I-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
(	(	(	B-LST	O	O
4	4	LS	I-LST	O	O
)	)	)	O	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
ended	end	VBN	B-VP	O	O
.	.	.	O	O	O

All	All	PDT	B-NP	O	O
these	these	DT	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
statistically	statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
regular	regular	JJ	B-NP	O	O
physical	physical	JJ	I-NP	O	O
exercises	exercise	NNS	I-NP	O	O
decrease	decrease	VBP	B-VP	O	O
susceptibility	susceptibility	NN	B-NP	O	O
to	to	TO	B-PP	O	O
subsequently	subsequently	RB	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
and	and	CC	O	O	O
ameliorate	ameliorate	VB	B-VP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
experimentally	experimentally	RB	B-NP	O	O
induced	induce	VBN	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Tonic	Tonic	JJ	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
impairs	impair	VBZ	B-VP	O	B-Disease
associative	associative	JJ	B-NP	O	I-Disease
learning	learning	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

Endogenous	Endogenous	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
salience	salience	NN	B-NP	O	O
coding	coding	NN	I-NP	O	O
during	during	IN	B-PP	O	O
associative	associative	JJ	B-NP	O	O
learning	learning	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
precursor	precursor	NN	I-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
enhances	enhance	VBZ	B-VP	O	O
learning	learning	NN	B-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	O	O	O
stroke	stroke	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
increases	increase	VBZ	B-VP	O	O
both	both	CC	O	O	O
phasic	phasic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
tonic	tonic	JJ	I-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
neurotransmission	neurotransmission	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
mediating	mediate	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
enhancement	enhancement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
unresolved	unresolved	JJ	B-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
here	here	RB	B-ADVP	O	O
probed	probe	VBD	B-VP	O	O
how	how	WRB	B-ADVP	O	O
selective	selective	JJ	B-NP	O	O
tonic	tonic	JJ	I-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
stimulation	stimulation	NN	I-NP	O	O
affects	affect	VBZ	B-VP	O	O
associative	associative	JJ	B-NP	O	O
learning	learning	NN	I-NP	O	O
.	.	.	O	O	O

Forty	Forty	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
trained	train	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
vocabulary	vocabulary	NN	I-NP	O	O
of	of	IN	B-PP	O	O
45	45	CD	B-NP	O	O
concrete	concrete	JJ	I-NP	O	O
nouns	noun	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
training	training	NN	I-NP	O	O
days	day	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
randomized	randomize	VBN	I-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	B-NP	O	O
design	design	NN	I-NP	O	O
.	.	.	O	O	O

Subjects	Subject	NNS	B-NP	O	O
received	receive	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
tonically	tonically	RB	I-NP	O	O
stimulating	stimulate	VBG	I-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
agonist	agonist	NN	I-NP	O	O
pergolide	pergolide	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
vs	vs	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
120	120	CD	I-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
training	training	NN	B-NP	O	O
on	on	IN	B-PP	O	O
each	each	DT	B-NP	O	O
training	training	NN	I-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
agonist	agonist	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
impaired	impair	VBD	B-VP	O	B-Disease
novel	novel	JJ	B-NP	O	I-Disease
word	word	NN	I-NP	O	I-Disease
learning	learning	NN	I-NP	O	I-Disease
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
learning	learn	VBG	I-NP	O	O
decrement	decrement	NN	I-NP	O	O
persisted	persist	VBD	B-VP	O	O
up	up	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
last	last	JJ	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
4	4	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
training	training	NN	B-NP	O	O
.	.	.	O	O	O

Subjects	Subject	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
pergolide	pergolide	NN	B-NP	B	B-Chemical
also	also	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
restricted	restricted	JJ	B-NP	O	O
emotional	emotional	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
PLACEBO	PLACEBO	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
extent	extent	NN	I-NP	O	O
of	of	IN	B-PP	O	O
'	'	``	O	O	O
flattened	flatten	VBN	B-VP	O	O
'	'	POS	B-NP	O	O
affect	affect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
pergolide	pergolide	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
related	relate	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
degree	degree	NN	I-NP	O	O
of	of	IN	B-PP	O	O
learning	learn	VBG	B-VP	O	O
inhibition	inhibition	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
tonic	tonic	JJ	B-NP	O	O
occupation	occupation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
receptors	receptor	NNS	I-NP	O	O
impairs	impair	VBZ	B-VP	O	O
learning	learning	NN	B-NP	O	O
by	by	IN	B-PP	O	O
competition	competition	NN	B-NP	O	O
with	with	IN	B-PP	O	O
phasic	phasic	JJ	B-NP	O	O
dopamine	dopamine	NN	I-NP	B	B-Chemical
signals	signal	NNS	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
phasic	phasic	JJ	B-NP	O	O
signaling	signaling	NN	I-NP	O	O
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
critical	critical	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
by	by	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
enhances	enhance	VBZ	B-VP	O	O
associative	associative	JJ	B-NP	O	O
learning	learning	NN	I-NP	O	O
in	in	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
and	and	CC	O	O	O
stroke	stroke	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Minocycline	Minocycline	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
vasculitis	vasculitis	NN	I-NP	O	B-Disease
fulfilling	fulfil	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
polyarteritis	polyarteritis	NN	B-NP	O	B-Disease
nodosa	nodosa	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
47	47	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
man	man	NN	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
taking	take	VBG	I-VP	O	O
minocycline	minocycline	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
palmoplantar	palmoplantar	JJ	B-NP	O	B-Disease
pustulosis	pustulosis	NN	I-NP	O	I-Disease
developed	develop	VBD	B-VP	O	O
fever	fever	NN	B-NP	O	B-Disease
,	,	,	O	O	O
myalgias	myalgia	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
polyneuropathy	polyneuropathy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
testicular	testicular	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
elevated	elevate	VBN	B-NP	B	O
C	C	NN	I-NP	B	O
-	-	HYPH	O	I	O
reactive	reactive	JJ	B-NP	I	O
protein	protein	NN	I-NP	I	O
(	(	(	O	O	O
CRP	CRP	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

Neither	Neither	CC	O	O	O
myeloperoxidase	myeloperoxidase	NN	B-NP	O	O
-	-	HYPH	O	O	O
nor	nor	CC	O	O	O
proteinase	proteinase	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
antineutrophil	antineutrophil	NN	I-NP	O	O
cytoplasmic	cytoplasmic	JJ	I-NP	O	O
antibody	antibody	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
met	meet	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
American	American	NNP	I-NP	O	O
College	College	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Rheumatology	Rheumatology	NNP	B-NP	O	O
1990	1990	CD	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
classification	classification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
polyarteritis	polyarteritis	NN	B-NP	O	B-Disease
nodosa	nodosa	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Stopping	Stop	VBG	B-NP	O	O
minocycline	minocycline	NN	I-NP	B	B-Chemical
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
amelioration	amelioration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
and	and	CC	O	O	O
normalization	normalization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CRP	CRP	NN	B-NP	B	O
level	level	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
minocycline	minocycline	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
vasculitis	vasculitis	NN	I-NP	O	B-Disease
satisfying	satisfy	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
.	.	.	O	O	O

Differential	Differential	JJ	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
for	for	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
disease	disease	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
invaluable	invaluable	JJ	B-ADJP	O	O
even	even	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
classical	classical	JJ	B-NP	O	O
polyarteritis	polyarteritis	NN	I-NP	O	B-Disease
nodosa	nodosa	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Intramuscular	Intramuscular	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
immune	immune	JJ	I-NP	B	O
globulin	globulin	NN	I-NP	I	O
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
prevention	prevention	NN	B-NP	O	O
of	of	IN	B-PP	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
recurrence	recurrence	NN	I-NP	O	O
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Combined	Combine	VBN	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
immune	immune	JJ	I-NP	B	O
globulin	globulin	NN	I-NP	I	O
(	(	(	O	O	O
HBIg	HBIg	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
prophylaxis	prophylaxis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
improved	improve	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
survival	survival	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HBsAg	HBsAg	NN	B-NP	O	B-Chemical
positive	positive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
undertaken	undertake	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	O
(	(	(	O	O	O
HBV	HBV	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
chart	chart	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
review	review	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
organ	organ	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
database	database	NN	I-NP	O	O
identified	identify	VBD	B-VP	O	O
51	51	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
43	43	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
and	and	CC	O	O	O
8	8	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
)	)	)	O	O	O
transplanted	transplant	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
benign	benign	JJ	B-NP	O	O
HBV	HBV	NN	I-NP	O	O
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
cirrhotic	cirrhotic	JJ	I-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
between	between	IN	B-PP	O	O
June	June	NNP	B-NP	O	O
2002	2002	CD	I-NP	O	O
and	and	CC	O	O	O
December	December	NNP	B-NP	O	O
2004	2004	CD	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
survived	survive	VBN	I-VP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
3	3	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

HBIg	HBIg	NN	B-NP	B	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
intravenously	intravenously	RB	B-ADVP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
week	week	NN	I-NP	O	O
and	and	CC	O	O	O
intramuscularly	intramuscularly	RB	B-ADVP	O	O
thereafter	thereafter	RB	I-ADVP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
At	At	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
14.1	14.1	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
51	51	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
3.9	3.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
/	/	SYM	O	O	O
51	51	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
patient	patient	NN	I-NP	O	O
survival	survival	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
88.3	88.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
82.4	82.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
after	after	IN	B-PP	O	O
1	1	CD	B-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
daily	daily	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
lamivudine	lamivudine	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
before	before	IN	B-PP	O	O
transplantation	transplantation	NN	B-NP	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
enabled	enable	VBD	B-VP	O	O
57.1	57.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
7	7	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
62.5	62.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
5	5	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
8	8	CD	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
HBV	HBV	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
DNA	DNA	NN	I-NP	O	O
and	and	CC	I-NP	O	O
HBeAg	HBeAg	NN	I-NP	O	B-Chemical
positive	positive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
respectively	respectively	RB	B-ADVP	O	O
to	to	TO	B-VP	O	O
convert	convert	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
negative	negative	JJ	B-ADJP	O	O
.	.	.	O	O	O

Intramuscular	Intramuscular	JJ	B-NP	O	O
HBIg	HBIg	NN	I-NP	B	O
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Lamivudine	Lamivudine	NN	B-NP	B	B-Chemical
combined	combine	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
intramuscular	intramuscular	JJ	B-NP	O	O
HBIg	HBIg	NN	I-NP	B	O
can	can	MD	B-VP	O	O
effectively	effectively	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
allograft	allograft	NN	B-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HBV	HBV	NN	B-NP	O	O
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
.	.	.	O	O	O

Anticonvulsant	Anticonvulsant	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
eslicarbazepine	eslicarbazepine	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
BIA	BIA	NN	B-NP	B	B-Chemical
2	2	CD	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
093	093	CD	I-NP	I	I-Chemical
)	)	)	O	O	O
on	on	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
microperfusion	microperfusion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
of	of	IN	B-PP	O	O
freely	freely	RB	B-ADVP	O	O
moving	move	VBG	B-VP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Eslicarbazepine	Eslicarbazepine	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
BIA	BIA	NN	B-NP	B	B-Chemical
2	2	CD	I-NP	I	I-Chemical
-	-	HYPH	O	I	I-Chemical
093	093	CD	B-NP	I	I-Chemical
,	,	,	O	O	O
S	S	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
(	(	(	O	O	I-Chemical
-	-	SYM	O	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
10	10	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
acetoxy	acetoxy	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
10,11	10,11	CD	I-NP	O	I-Chemical
-	-	HYPH	O	O	I-Chemical
dihydro	dihydro	AFX	O	B	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
5H	5H	NN	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
dibenzo	dibenzo	NN	I-NP	O	I-Chemical
/	/	SYM	I-NP	O	I-Chemical
b,f	b,f	NN	I-NP	O	I-Chemical
/	/	SYM	B-NP	O	I-Chemical
azepine	azepine	NN	I-NP	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
5	5	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
carboxamide	carboxamide	NN	I-NP	O	I-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
now	now	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
Phase	Phase	NN	B-NP	O	O
III	III	CD	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
,	,	,	O	O	O
designed	design	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
improving	improve	VBG	B-VP	O	O
efficacy	efficacy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
safety	safety	NN	I-NP	O	O
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
structurally	structurally	RB	I-NP	O	O
related	relate	VBN	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
CBZ	CBZ	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
oxcarbazepine	oxcarbazepine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
OXC	OXC	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
studied	study	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
eslicarbazepine	eslicarbazepine	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
whole	whole	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
partial	partial	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
elicited	elicit	VBN	I-VP	O	O
repeatedly	repeatedly	RB	B-ADVP	O	O
on	on	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
days	day	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
threshold	threshold	NN	B-NP	O	O
or	or	CC	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
patterns	pattern	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
animals	animal	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
threshold	threshold	NN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
average	average	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
2.3	2.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.2	1.2	CD	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
average	average	JJ	B-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
duration	duration	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
39.5	39.5	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
8.4s	8.4	NNS	B-NP	O	O
.	.	.	O	O	O

Pre	Pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
2h	2h	NN	I-NP	O	O
before	before	IN	B-PP	O	O
picrotoxin	picrotoxin	NN	B-NP	B	B-Chemical
microperfusion	microperfusion	NN	I-NP	O	O
prevented	prevent	VBD	B-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
75	75	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Lower	Low	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
and	and	CC	I-NP	O	O
10mg	10mg	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
suppress	suppress	VB	I-VP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
10mg	10mg	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
significant	significant	JJ	B-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
duration	duration	NN	I-NP	O	O
(	(	(	O	O	O
24.3	24.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	B-NP	O	O
6.8s	6.8	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
seizure	seizure	NN	B-NP	O	B-Disease
number	number	NN	I-NP	O	O
(	(	(	O	O	O
1.6	1.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.34	0.34	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
eslicarbazepine	eslicarbazepine	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
EEG	EEG	NN	B-NP	O	O
patterns	pattern	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
sleep	sleep	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
wakefulness	wakefulness	NN	I-NP	O	O
cycle	cycle	NN	I-NP	O	O
,	,	,	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
studied	study	VBN	B-VP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
prolonged	prolonged	JJ	B-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
slimming	slimme	VBG	B-VP	O	O
pills	pill	NNS	B-NP	O	O
containing	contain	VBG	B-VP	O	O
anthraquinones	anthraquinone	NNS	B-NP	B	B-Chemical
.	.	.	O	O	O

Chinese	Chinese	JJ	B-NP	O	B-Chemical
herbal	herbal	JJ	I-NP	O	I-Chemical
medicine	medicine	NN	I-NP	O	O
preparations	preparation	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
widely	widely	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
and	and	CC	O	O	O
often	often	RB	B-VP	O	O
regarded	regard	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
public	public	NN	I-NP	O	O
as	as	IN	B-PP	O	O
natural	natural	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
safe	safe	JJ	I-NP	O	O
remedies	remedy	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
medical	medical	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
.	.	.	O	O	O

Nephropathy	Nephropathy	NN	B-NP	O	B-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Chinese	Chinese	JJ	B-NP	O	B-Chemical
herbs	herb	NNS	I-NP	O	I-Chemical
has	have	VBZ	B-VP	O	O
previously	previously	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
usually	usually	RB	B-ADVP	O	O
involving	involve	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aristolochic	aristolochic	JJ	B-NP	B	B-Chemical
acids	acid	NNS	I-NP	I	I-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
23	23	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
prolonged	prolong	VBN	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
proprietary	proprietary	JJ	I-NP	O	O
Chinese	Chinese	JJ	I-NP	O	B-Chemical
herbal	herbal	JJ	I-NP	O	I-Chemical
slimming	slimming	JJ	I-NP	O	O
pill	pill	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
contained	contain	VBD	B-VP	O	O
anthraquinone	anthraquinone	NN	B-NP	B	B-Chemical
derivatives	derivative	NNS	I-NP	O	O
,	,	,	O	O	O
extracted	extract	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
Rhizoma	Rhizoma	NNP	B-NP	O	O
Rhei	Rhei	NNP	I-NP	O	O
(	(	(	O	O	O
rhubarb	rhubarb	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
probably	probably	RB	I-VP	O	O
aggravated	aggravate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
concomitant	concomitant	JJ	I-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Renal	Renal	JJ	B-NP	O	O
pathology	pathology	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
of	of	IN	B-PP	O	O
hypocellular	hypocellular	JJ	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Spontaneous	Spontaneous	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
upon	upon	IN	B-PP	O	O
cessation	cessation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
slimming	slimming	JJ	I-NP	O	O
pills	pill	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
mild	mild	JJ	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
tubular	tubular	JJ	B-NP	O	O
atrophy	atrophy	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
still	still	RB	B-ADVP	O	O
evident	evident	JJ	B-NP	O	O
histologically	histologically	RB	I-NP	O	O
4	4	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
causal	causal	JJ	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
anthraquinone	anthraquinone	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
containing	contain	VBG	B-VP	O	O
herbal	herbal	JJ	B-NP	O	O
agent	agent	NN	I-NP	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
remains	remain	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
proven	prove	VBN	I-VP	O	O
,	,	,	O	O	O
phytotherapy	phytotherapy	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
present	present	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
unexplained	unexplained	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Chloroacetaldehyde	Chloroacetaldehyde	NN	B-NP	B	B-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
sulfhydryl	sulfhydryl	NN	I-NP	O	B-Chemical
reagent	reagent	NN	I-NP	O	O
:	:	:	O	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
critical	critical	JJ	B-NP	O	O
thiol	thiol	NN	I-NP	O	B-Chemical
groups	group	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
ifosfamide	ifosfamide	NN	B-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Chloroacetaldehyde	Chloroacetaldehyde	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
metabolite	metabolite	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
alkylating	alkylate	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
ifosfamide	ifosfamide	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
putatively	putatively	RB	B-ADJP	O	O
responsible	responsible	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Depletion	Depletion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
sulfhydryl	sulfhydryl	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
SH	SH	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
groups	group	NNS	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
culture	culture	NN	I-NP	O	O
,	,	,	O	O	O
animal	animal	NN	B-NP	O	O
and	and	CC	O	O	O
clinical	clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
work	work	NN	I-NP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
proximal	proximal	JJ	I-NP	O	O
tubule	tubule	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
culture	culture	NN	I-NP	O	O
(	(	(	O	O	O
hRPTEC	hRPTEC	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
.	.	.	O	O	O

Toxicity	Toxicity	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
protein	protein	NN	B-NP	O	O
content	content	NN	I-NP	O	O
,	,	,	O	O	O
cell	cell	NN	B-NP	O	O
number	number	NN	I-NP	O	O
,	,	,	O	O	O
LDH	LDH	NN	B-NP	O	O
release	release	NN	I-NP	O	O
,	,	,	O	O	O
trypan	trypan	NN	B-NP	B	B-Chemical
blue	blue	JJ	I-NP	I	I-Chemical
exclusion	exclusion	NN	I-NP	O	O
assay	assay	NN	I-NP	O	O
and	and	CC	I-NP	O	O
caspase	caspase	NN	I-NP	O	O
-	-	HYPH	O	O	O
3	3	CD	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

Free	Free	JJ	B-NP	O	O
thiols	thiol	NNS	I-NP	O	B-Chemical
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
method	method	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Ellman	Ellman	NNP	B-NP	O	O
.	.	.	O	O	O

CAA	CAA	NN	B-NP	O	B-Chemical
reduced	reduce	VBD	B-VP	O	O
hRPTEC	hRPTEC	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
number	number	NN	I-NP	O	O
and	and	CC	O	O	O
protein	protein	NN	B-NP	O	O
,	,	,	O	O	O
induced	induce	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
loss	loss	NN	I-NP	O	O
in	in	IN	B-PP	O	O
free	free	JJ	B-NP	O	O
intracellular	intracellular	JJ	I-NP	O	O
thiols	thiol	NNS	I-NP	O	B-Chemical
and	and	CC	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
markers	marker	NNS	I-NP	O	O
.	.	.	O	O	O

CAA	CAA	NN	B-NP	O	B-Chemical
but	but	CC	B-NP	O	O
not	not	RB	I-NP	O	O
acrolein	acrolein	NN	B-NP	B	B-Chemical
inhibited	inhibit	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
cysteine	cysteine	NN	I-NP	B	B-Chemical
proteases	protease	VBZ	B-VP	O	O
caspase	caspase	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
,	,	,	O	O	O
caspase	caspase	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
8	8	CD	I-NP	O	O
and	and	CC	I-NP	O	O
cathepsin	cathepsin	NN	I-NP	O	O
B	B	NN	I-NP	O	O
.	.	.	O	O	O

Caspase	Caspase	NN	B-NP	O	O
activation	activation	NN	I-NP	O	O
by	by	IN	B-PP	O	O
cisplatin	cisplatin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
cells	cell	NNS	B-NP	O	O
stained	stain	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fluorescent	fluorescent	JJ	B-NP	O	O
dyes	dye	NNS	I-NP	O	O
targeting	target	VBG	B-VP	O	O
lysosomes	lysosome	NNS	B-NP	O	O
,	,	,	O	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
lysosomal	lysosomal	JJ	B-NP	O	O
size	size	NN	I-NP	O	O
and	and	CC	I-NP	O	O
lysosomal	lysosomal	JJ	I-NP	O	O
leakage	leakage	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
cysteine	cysteine	NN	B-NP	B	B-Chemical
protease	protease	NN	I-NP	O	O
activities	activity	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
thiols	thiol	NNS	I-NP	O	B-Chemical
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reproduced	reproduce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
lysate	lysate	NN	I-NP	O	O
.	.	.	O	O	O

Acidification	Acidification	NN	B-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
slowed	slow	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
thiol	thiol	NN	B-NP	O	B-Chemical
donors	donor	NNS	I-NP	O	O
,	,	,	O	O	O
could	could	MD	B-VP	O	O
also	also	RB	I-VP	O	O
attenuate	attenuate	VB	I-VP	O	O
effects	effect	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
necrosis	necrosis	NN	B-NP	O	B-Disease
markers	marker	NNS	I-NP	O	O
,	,	,	O	O	O
thiol	thiol	NN	B-NP	O	B-Chemical
depletion	depletion	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cysteine	cysteine	NN	I-NP	B	B-Chemical
protease	protease	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
in	in	IN	B-PP	O	O
living	live	VBG	B-VP	O	O
cells	cell	NNS	B-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
CAA	CAA	NN	B-NP	B	B-Chemical
directly	directly	RB	B-ADVP	O	O
reacts	react	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
cellular	cellular	JJ	B-NP	O	O
protein	protein	NN	I-NP	O	O
and	and	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
protein	protein	NN	I-NP	O	O
thiols	thiol	NNS	I-NP	O	B-Chemical
,	,	,	O	O	O
mediating	mediate	VBG	B-VP	O	O
its	its	PRP$	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
on	on	IN	B-PP	O	O
hRPTEC	hRPTEC	NN	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
acidification	acidification	NN	B-NP	O	O
.	.	.	O	O	O

Therefore	Therefore	RB	B-ADVP	O	O
,	,	,	O	O	O
urinary	urinary	JJ	B-NP	O	O
acidification	acidification	NN	I-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
option	option	NN	I-NP	O	O
to	to	TO	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
IFO	IFO	NN	B-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

Stereological	Stereological	JJ	B-NP	O	O
methods	method	NNS	I-NP	O	O
reveal	reveal	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
robust	robust	JJ	I-NP	O	O
size	size	NN	I-NP	O	O
and	and	CC	I-NP	O	O
stability	stability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ectopic	ectopic	JJ	B-NP	O	O
hilar	hilar	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adult	adult	JJ	I-NP	O	O
rat	rat	NN	I-NP	O	O
.	.	.	O	O	O

Following	Follow	VBG	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
,	,	,	O	O	O
dentate	dentate	NN	B-NP	O	O
granule	granule	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
neurogenesis	neurogenesis	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
greatly	greatly	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
many	many	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
appear	appear	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
develop	develop	VB	I-VP	O	O
ectopically	ectopically	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hilar	hilar	JJ	I-NP	O	O
region	region	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
formation	formation	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
ectopic	ectopic	JJ	I-NP	O	O
hilar	hilar	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
could	could	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
spontaneous	spontaneous	JJ	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
ultimately	ultimately	RB	B-ADVP	O	O
develop	develop	VBP	B-VP	O	O
after	after	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
population	population	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
never	never	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
quantified	quantify	VBN	I-VP	O	O
,	,	,	O	O	O
so	so	IN	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
substantial	substantial	JJ	B-ADJP	O	O
enough	enough	RB	I-ADJP	O	O
to	to	TO	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
strong	strong	JJ	I-NP	O	O
influence	influence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
epileptogenesis	epileptogenesis	NN	B-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
quantify	quantify	VB	I-VP	O	O
this	this	DT	B-NP	O	O
population	population	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
total	total	JJ	I-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ectopic	ectopic	JJ	B-NP	O	O
hilar	hilar	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
unbiased	unbiased	JJ	B-NP	O	O
stereology	stereology	NN	I-NP	O	O
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hilar	hilar	JJ	B-NP	O	O
neurons	neuron	NNS	I-NP	O	O
immunoreactive	immunoreactive	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
Prox	Prox	NNP	B-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
granule	granule	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
using	use	VBG	I-VP	O	O
the	the	DT	B-NP	O	O
optical	optical	JJ	I-NP	O	O
fractionator	fractionator	NN	I-NP	O	O
method	method	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
size	size	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hilar	hilar	JJ	I-NP	O	O
ectopic	ectopic	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
population	population	NN	I-NP	O	O
after	after	IN	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
substantial	substantial	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
stable	stable	JJ	B-ADJP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
.	.	.	O	O	O

Interestingly	Interestingly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
size	size	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
population	population	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
correlated	correlate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
behavioral	behavioral	JJ	B-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
because	because	IN	B-SBAR	O	O
animals	animal	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
more	more	RBR	B-NP	O	O
ectopic	ectopic	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hilus	hilus	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
more	more	RBR	B-NP	O	O
frequent	frequent	JJ	I-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hilar	hilar	JJ	I-NP	O	O
ectopic	ectopic	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cell	cell	NN	I-NP	O	O
population	population	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
appear	appear	VB	I-VP	O	O
to	to	TO	I-VP	O	O
vary	vary	VB	I-VP	O	O
systematically	systematically	RB	B-ADVP	O	O
across	across	IN	B-PP	O	O
the	the	DT	B-NP	O	O
septotemporal	septotemporal	JJ	I-NP	O	O
axis	axis	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
volume	volume	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hilus	hilus	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
provide	provide	VBP	B-VP	O	O
new	new	JJ	B-NP	O	O
insight	insight	NN	I-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ectopic	ectopic	JJ	B-NP	O	O
hilar	hilar	JJ	I-NP	O	O
granule	granule	NN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temporal	temporal	JJ	B-NP	O	B-Disease
lobe	lobe	NN	I-NP	O	I-Disease
epilepsy	epilepsy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
,	,	,	I-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galantamine	galantamine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
autistic	autistic	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
Post	Post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
mortem	mortem	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
reported	report	VBN	I-VP	O	O
abnormalities	abnormality	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cholinergic	cholinergic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
in	in	IN	B-PP	O	O
autism	autism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galantamine	galantamine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
acetylcholinesterase	acetylcholinesterase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
and	and	CC	O	O	O
nicotinic	nicotinic	JJ	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
modulator	modulator	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interfering	interfere	VBG	B-VP	O	O
behaviors	behavior	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
autism	autism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Thirteen	Thirteen	CD	B-NP	O	O
medication	medication	NN	I-NP	O	O
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
children	child	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
autism	autism	NN	B-NP	O	B-Disease
(	(	(	O	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
8.8	8.8	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
3.5	3.5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
participated	participate	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
12	12	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
open	open	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galantamine	galantamine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
rated	rat	VBN	I-VP	O	O
monthly	monthly	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
parents	parent	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Aberrant	Aberrant	NNP	I-NP	O	O
Behavior	Behavior	NNP	I-NP	O	O
Checklist	Checklist	NNP	I-NP	O	O
(	(	(	O	O	O
ABC	ABC	NNP	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Conners	Conner	NNPS	I-NP	O	O
'	'	POS	B-NP	O	O
Parent	Parent	NNP	I-NP	O	O
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
-	-	HYPH	O	O	O
Revised	Revise	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
physician	physician	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
Children	Children	NNP	I-NP	O	O
's	's	POS	B-NP	O	O
Psychiatric	Psychiatric	NNP	I-NP	O	O
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
Clinical	Clinical	NNP	I-NP	O	O
Global	Global	NNP	I-NP	O	O
Impressions	Impressions	NNP	I-NP	O	O
scale	scale	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
parent	parent	NN	B-NP	O	O
-	-	HYPH	B-PP	O	O
rated	rat	VBN	B-NP	O	O
irritability	irritability	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
social	social	JJ	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ABC	ABC	NNP	I-NP	B	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
significant	significant	JJ	B-NP	O	O
improvements	improvement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
emotional	emotional	JJ	B-NP	O	O
lability	lability	NN	I-NP	O	O
and	and	CC	I-NP	O	O
inattention	inattention	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Conners	Conner	NNPS	I-NP	O	O
'	'	POS	B-NP	O	O
Parent	Parent	NNP	I-NP	O	O
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
-	-	HYPH	O	O	O
-	-	HYPH	B-NP	O	O
Revised	Revise	VBN	B-VP	O	O
.	.	.	O	O	O

Similarly	Similarly	RB	B-ADVP	O	O
,	,	,	O	O	O
clinician	clinician	JJ	B-NP	O	O
ratings	rating	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
reductions	reduction	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
anger	anger	NN	I-NP	O	O
subscale	subscale	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Children	Children	NNP	I-NP	O	O
's	's	POS	B-NP	O	O
Psychiatric	Psychiatric	NNP	I-NP	O	O
Rating	Rating	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
.	.	.	O	O	O

Eight	Eight	CD	B-NP	O	O
of	of	IN	B-PP	O	O
13	13	CD	B-NP	O	O
participants	participant	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
rated	rat	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
responders	responder	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
improvement	improvement	NN	I-NP	O	O
scores	score	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Clinical	Clinical	NNP	I-NP	O	O
Global	Global	NNP	I-NP	O	O
Impressions	Impressions	NNP	I-NP	O	O
scale	scale	NN	I-NP	O	O
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
galantamine	galantamine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
well	well	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
apart	apart	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
headaches	headache	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
one	one	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
,	,	,	O	O	O
galantamine	galantamine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
well	well	RB	B-VP	O	O
-	-	HYPH	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
and	and	CC	O	O	O
appeared	appear	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
beneficial	beneficial	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
interfering	interfere	VBG	B-VP	O	O
behaviors	behavior	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
autism	autism	NN	B-NP	O	B-Disease
,	,	,	O	O	O
particularly	particularly	RB	B-NP	O	O
aggression	aggression	NN	I-NP	O	B-Disease
,	,	,	O	O	O
behavioral	behavioral	JJ	B-NP	O	B-Disease
dyscontrol	dyscontrol	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
inattention	inattention	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
controlled	controlled	JJ	I-NP	O	O
trials	trial	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

Randomized	Randomize	VBN	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
versus	versus	CC	I-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
episode	episode	NN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	B-Disease
:	:	:	O	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
authors	author	NNS	I-NP	O	O
compared	compare	VBD	B-VP	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
outcomes	outcome	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
versus	versus	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
episode	episode	NN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	B-Disease
spectrum	spectrum	NN	I-NP	O	O
disorders	disorder	NNS	I-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
One	One	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
twelve	twelve	CD	I-NP	O	O
subjects	subject	NNS	I-NP	O	O
(	(	(	O	O	O
70	70	CD	B-NP	O	O
%	%	NN	I-NP	O	O
male	male	NN	I-NP	O	O
;	;	:	O	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
23.3	23.3	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
[	[	(	O	O	O
SD	SD	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
5.1	5.1	CD	B-NP	O	O
]	]	)	O	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
first	first	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
episode	episode	NN	I-NP	O	O
schizophrenia	schizophrenia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
schizophreniform	schizophreniform	NN	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
17	17	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
schizoaffective	schizoaffective	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
8	8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
2.5	2.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
20	20	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
1	1	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6	6	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Response	Response	NN	B-NP	O	O
rates	rate	NNS	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
differ	differ	VBP	I-VP	O	O
between	between	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
43.7	43.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
28.8	28.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
58.6	58.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
54.3	54.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
39.9	39.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
68.7	68.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
those	those	DT	B-NP	O	O
responding	respond	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
more	more	JJR	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
olanzapine	olanzapine	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
(	(	(	O	O	O
40.9	40.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
16.8	16.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
65.0	65.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
risperidone	risperidone	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
(	(	(	O	O	O
18.9	18.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
39.2	39.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
subsequent	subsequent	JJ	B-NP	O	O
ratings	rating	NNS	I-NP	O	O
not	not	RB	B-VP	O	O
meeting	meet	VBG	I-VP	O	O
response	response	NN	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
.	.	.	O	O	O

Negative	Negative	JJ	B-NP	O	O
symptom	symptom	NN	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
measures	measure	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
parkinsonism	parkinsonism	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
akathisia	akathisia	NN	I-NP	O	B-Disease
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
differ	differ	VB	I-VP	O	O
between	between	IN	B-PP	O	O
medications	medication	NNS	B-NP	O	O
.	.	.	O	O	O

Extrapyramidal	Extrapyramidal	JJ	B-NP	O	B-Disease
symptom	symptom	NN	I-NP	O	I-Disease
severity	severity	NN	I-NP	O	O
scores	score	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
1.4	1.4	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.2	1.2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.6	1.6	CD	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
1.2	1.2	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
1.0	1.0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.4	1.4	CD	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Significantly	Significantly	RB	B-NP	O	O
more	more	JJR	I-NP	O	O
weight	weight	NN	I-NP	O	B-Disease
gain	gain	NN	I-NP	O	I-Disease
occurred	occur	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
weight	weight	NN	B-NP	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
relative	relative	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
17.3	17.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
14.2	14.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
20.5	20.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
11.3	11.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
8.4	8.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
14.3	14.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Body	Body	JJ	B-NP	O	O
mass	mass	NN	I-NP	O	O
index	index	NN	I-NP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
and	and	CC	O	O	O
at	at	IN	B-PP	O	O
4	4	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
24.3	24.3	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
22.8	22.8	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
25.7	25.7	CD	I-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
28.2	28.2	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
26.7	26.7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
29.7	29.7	CD	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
23.9	23.9	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
22.5	22.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
25.3	25.3	CD	I-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
26.7	26.7	CD	B-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
=	=	SYM	B-VP	O	O
25.2	25.2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
28.2	28.2	CD	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
risperidone	risperidone	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
equal	equal	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
response	response	NN	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
more	more	RBR	B-ADJP	O	O
stable	stable	JJ	I-ADJP	O	O
.	.	.	O	O	O

Olanzapine	Olanzapine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
an	an	DT	B-NP	O	O
advantage	advantage	NN	I-NP	O	O
for	for	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
medications	medication	NNS	I-NP	O	O
caused	cause	VBD	B-VP	O	O
substantial	substantial	JJ	B-NP	O	O
rapid	rapid	JJ	I-NP	O	O
weight	weight	NN	I-NP	O	B-Disease
gain	gain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
weight	weight	NN	B-NP	O	B-Disease
gain	gain	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
with	with	IN	B-PP	O	O
olanzapine	olanzapine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Early	Early	RB	B-NP	O	O
paracentral	paracentral	JJ	I-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
loss	loss	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
review	review	VB	I-VP	O	O
the	the	DT	B-NP	O	O
natural	natural	JJ	I-NP	O	O
history	history	NN	I-NP	O	O
and	and	CC	O	O	O
ocular	ocular	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
systemic	systemic	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	B	B-Chemical
sulfate	sulfate	NN	I-NP	I	I-Chemical
who	who	WP	B-NP	O	O
attended	attend	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
ophthalmic	ophthalmic	JJ	I-NP	O	O
screening	screening	NN	I-NP	O	O
program	program	NN	I-NP	O	O
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
Retrospective	Retrospective	JJ	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Records	Record	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
262	262	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
screened	screen	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Department	Department	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Ophthalmology	Ophthalmology	NNP	B-NP	O	O
were	be	VBD	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
262	262	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
14	14	CD	B-NP	O	O
(	(	(	O	O	O
18	18	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
76	76	CD	B-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
treatment	treatment	NN	B-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
documented	document	VBN	I-VP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
8	8	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
10.5	10.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ocular	ocular	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
5	5	CD	B-NP	O	O
(	(	(	O	O	O
6.5	6.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Thirty	Thirty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
five	five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
13.4	13.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
visual	visual	JJ	B-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
4	4	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
4	4	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
6.5	6.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
normal	normal	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
liver	liver	NN	I-NP	O	O
function	function	NN	I-NP	O	O
test	test	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
used	use	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
protocol	protocol	NN	I-NP	O	O
of	of	IN	B-PP	O	O
visual	visual	JJ	B-NP	O	O
acuity	acuity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
color	color	NN	I-NP	O	O
vision	vision	NN	I-NP	O	O
assessment	assessment	NN	I-NP	O	O
,	,	,	O	O	O
funduscopy	funduscopy	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Humphrey	Humphrey	NNP	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
visual	visual	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
and	and	CC	O	O	O
shows	show	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
visual	visual	JJ	B-NP	O	B-Disease
field	field	NN	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
appeared	appear	VBD	B-VP	O	O
before	before	IN	B-SBAR	O	O
any	any	DT	B-NP	O	O
corresponding	correspond	VBG	I-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
tested	test	VBN	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
;	;	:	O	O	O
the	the	DT	B-NP	O	O
defects	defect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reproducible	reproducible	JJ	B-ADJP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reliable	reliable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
taking	take	VBG	B-VP	O	O
hydroxychloroquine	hydroxychloroquine	NN	B-NP	B	B-Chemical
can	can	MD	B-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
a	a	DT	B-NP	O	O
toxic	toxic	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
retina	retina	NN	I-NP	O	O
despite	despite	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
factors	factor	NNS	I-NP	O	O
.	.	.	O	O	O

Screening	Screening	NN	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
Humphrey	Humphrey	NNP	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
visual	visual	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
assessment	assessment	NN	I-NP	O	O
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
recommended	recommended	JJ	B-NP	O	O
2	2	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
initial	initial	JJ	I-NP	O	O
baseline	baseline	NN	I-NP	O	O
and	and	CC	O	O	O
yearly	yearly	RB	B-ADVP	O	O
thereafter	thereafter	RB	I-ADVP	O	O
.	.	.	O	O	O

Peri	Peri	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
atrioventricular	atrioventricular	JJ	I-NP	O	B-Disease
block	block	NN	I-NP	O	I-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
result	result	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
with	with	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
paclitaxel	paclitaxel	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
47	47	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
presented	present	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
mastectomy	mastectomy	NN	B-NP	O	O
and	and	CC	O	O	O
immediate	immediate	JJ	B-NP	O	O
latissimus	latissimus	JJ	I-NP	O	O
dorsi	dorsi	NN	I-NP	O	O
flap	flap	NN	I-NP	O	O
reconstruction	reconstruction	NN	I-NP	O	O
having	have	VBG	B-VP	O	O
been	be	VBN	I-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
carcinoma	carcinoma	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
the	the	DT	B-NP	O	I-Disease
breast	breast	NN	I-NP	O	I-Disease
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
previously	previously	RB	B-ADVP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
preceding	precede	VBG	I-NP	O	O
months	month	NNS	I-NP	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
neo	neo	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
adjuvant	adjuvant	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
epirubicin	epirubicin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
paclitaxel	paclitaxel	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
Taxol	Taxol	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
apparently	apparently	RB	I-VP	O	O
uncomplicated	uncomplicate	VBN	I-VP	O	O
and	and	CC	O	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
remarkably	remarkably	RB	I-NP	O	O
high	high	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
physical	physical	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
.	.	.	O	O	O

She	She	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
bradycardic	bradycardic	JJ	B-ADJP	O	B-Disease
at	at	IN	B-PP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
assessment	assessment	NN	I-NP	O	O
but	but	CC	O	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Second	Second	NNP	B-NP	O	O
degree	degree	VBP	B-VP	O	O
Mobitz	Mobitz	NNP	B-NP	O	O
type	type	NN	I-NP	O	O
II	II	CD	I-NP	O	O
atrioventricular	atrioventricular	JJ	I-NP	O	B-Disease
block	block	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
electrocardiogram	electrocardiogram	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
temporary	temporary	JJ	B-NP	O	O
transvenous	transvenous	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
pacing	pacing	NN	I-NP	O	O
instituted	institute	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
peri	peri	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
discuss	discuss	VBP	B-VP	O	O
how	how	WRB	B-ADVP	O	O
evidence	evidence	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
guidelines	guideline	NNS	I-NP	O	O
would	would	MD	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
been	be	VBN	I-VP	O	O
helpful	helpful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
how	how	WRB	B-ADVP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
can	can	MD	B-VP	O	O
exhibit	exhibit	VB	I-VP	O	O
substantial	substantial	JJ	B-NP	O	O
cardiotoxicity	cardiotoxicity	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
develop	develop	VB	I-VP	O	O
over	over	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
received	receive	VBN	I-VP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
at	at	IN	B-PP	O	O
any	any	DT	B-NP	O	O
time	time	NN	I-NP	O	O
should	should	MD	B-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
operative	operative	JJ	I-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
even	even	RB	B-SBAR	O	O
if	if	IN	I-SBAR	O	O
they	they	PRP	B-NP	O	O
are	be	VBP	B-VP	O	O
asymptomatic	asymptomatic	JJ	B-ADJP	O	O
.	.	.	O	O	O

Risks	Risk	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
COX	COX	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
2	2	CD	B-NP	O	I-Chemical
inhibitors	inhibitor	NNS	I-NP	O	I-Chemical
vs	vs	CC	O	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
selective	selective	JJ	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
:	:	:	O	O	O
does	do	VBZ	B-VP	O	O
their	their	PRP$	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
exceed	exceed	VBP	B-VP	O	O
their	their	PRP$	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
benefit	benefit	NN	I-NP	O	O
?	?	.	O	O	O

A	A	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
cohort	cohort	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
myocardial	myocardial	JJ	I-NP	O	I-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AMI	AMI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
with	with	IN	B-PP	O	O
COX	COX	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	I-Chemical
2	2	CD	B-NP	O	I-Chemical
inhibitors	inhibitor	NNS	I-NP	O	I-Chemical
may	may	MD	B-VP	O	O
offset	offset	VB	I-VP	O	O
their	their	PRP$	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	O
(	(	(	O	O	O
GI	GI	NN	B-NP	O	O
)	)	)	O	O	O
benefit	benefit	NN	B-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
selective	selective	JJ	I-NP	O	O
(	(	(	O	O	O
NS	NS	NN	B-NP	B	O
)	)	)	O	O	O
non	non	AFX	O	O	B-Chemical
-	-	HYPH	O	O	I-Chemical
steroidal	steroidal	JJ	B-NP	O	I-Chemical
anti	anti	AFX	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
inflammatory	inflammatory	JJ	I-NP	O	I-Chemical
drugs	drug	NNS	I-NP	O	I-Chemical
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
compare	compare	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
for	for	IN	B-PP	O	O
AMI	AMI	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
GI	GI	NN	I-NP	O	B-Disease
bleeding	bleeding	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
COX	COX	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
2	2	CD	I-NP	O	I-Chemical
inhibitors	inhibitor	NNS	I-NP	O	I-Chemical
,	,	,	O	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
conducted	conduct	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
retrospective	retrospective	JJ	I-NP	O	O
cohort	cohort	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
administrative	administrative	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
65	65	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
age	age	NN	B-NP	O	O
who	who	WP	B-NP	O	O
filled	fill	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
prescription	prescription	NN	I-NP	O	O
for	for	IN	B-PP	O	O
NSAID	NSAID	NN	B-NP	O	O
or	or	CC	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
during	during	IN	B-PP	O	O
1999	1999	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2002	2002	CD	I-NP	O	O
.	.	.	O	O	O

Outcomes	Outcome	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
Cox	Cox	NNP	B-NP	O	O
regression	regression	NN	I-NP	O	O
models	model	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
time	time	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
exposures	exposure	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Person	Person	NNP	B-NP	O	O
-	-	HYPH	B-NP	O	O
years	year	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
among	among	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
users	user	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
75,761	75,761	CD	B-NP	O	O
to	to	TO	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
42,671	42,671	CD	B-NP	O	O
to	to	TO	B-VP	O	O
rofecoxib	rofecoxib	VB	I-VP	B	B-Chemical
65,860	65,860	CD	B-NP	O	O
to	to	TO	B-VP	O	O
celecoxib	celecoxib	VB	I-VP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
37,495	37,495	CD	B-NP	O	O
to	to	TO	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
14,671	14,671	CD	B-NP	O	O
to	to	TO	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
22,875	22,875	CD	B-NP	O	O
to	to	TO	B-VP	O	O
celecoxib	celecoxib	VB	I-VP	B	B-Chemical
,	,	,	O	O	O
9,832	9,832	CD	B-NP	O	O
to	to	TO	B-PP	O	O
NS	NS	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
and	and	CC	O	O	O
38,048	38,048	CD	B-NP	O	O
to	to	TO	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
users	user	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
adjusted	adjust	VBN	I-NP	O	O
hazard	hazard	NN	I-NP	O	O
ratios	ratio	NNS	I-NP	O	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
hospitalization	hospitalization	NN	B-NP	O	O
for	for	IN	B-PP	O	O
AMI	AMI	NN	B-NP	O	B-Disease
/	/	SYM	B-NP	O	O
GI	GI	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
aspirin	aspirin	NN	I-NP	B	B-Chemical
)	)	)	O	O	O
group	group	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
rofecoxib	rofecoxib	NN	B-NP	B	B-Chemical
1.27	1.27	CD	I-NP	O	O
(	(	(	O	O	O
1.13	1.13	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.42	1.42	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
celecoxib	celecoxib	NN	B-NP	B	B-Chemical
0.93	0.93	CD	I-NP	O	O
(	(	(	O	O	O
0.83	0.83	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.03	1.03	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	B	B-Chemical
1.59	1.59	CD	I-NP	O	O
(	(	(	O	O	O
1.31	1.31	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.93	1.93	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	B	B-Chemical
1.17	1.17	CD	I-NP	O	O
(	(	(	O	O	O
0.99	0.99	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.38	1.38	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
1.05	1.05	CD	I-NP	O	O
(	(	(	O	O	O
0.74	0.74	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.51	1.51	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
rofecoxib	rofecoxib	NN	B-NP	B	B-Chemical
1.73	1.73	CD	I-NP	O	O
(	(	(	O	O	O
1.52	1.52	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.98	1.98	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
celecoxib	celecoxib	NN	B-NP	B	B-Chemical
1.34	1.34	CD	I-NP	O	O
(	(	(	O	O	O
1.19	1.19	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.52	1.52	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
1.51	1.51	CD	I-NP	O	O
(	(	(	O	O	O
0.95	0.95	CD	B-NP	O	O
,	,	,	I-NP	O	O
2.41	2.41	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
diclofenac	diclofenac	NN	B-NP	B	B-Chemical
1.69	1.69	CD	I-NP	O	O
(	(	(	O	O	O
1.35	1.35	CD	B-NP	O	O
,	,	,	I-NP	O	O
2.10	2.10	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	B	B-Chemical
1.35	1.35	CD	I-NP	O	O
(	(	(	O	O	O
0.97	0.97	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.88	1.88	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
1.29	1.29	CD	I-NP	O	O
(	(	(	O	O	O
1.17	1.17	CD	B-NP	O	O
,	,	,	I-NP	O	O
1.42	1.42	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Among	Among	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
naproxen	naproxen	NN	B-NP	B	B-Chemical
seemed	seem	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
carry	carry	VB	I-VP	O	O
the	the	DT	B-NP	O	O
highest	high	JJS	I-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
AMI	AMI	NN	B-NP	O	B-Disease
/	/	SYM	B-NP	O	O
GI	GI	NN	I-NP	O	B-Disease
bleeding	bleeding	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
AMI	AMI	NN	I-NP	O	B-Disease
/	/	SYM	B-VP	O	O
GI	GI	NN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
celecoxib	celecoxib	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
seemed	seem	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
better	good	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
of	of	IN	B-PP	O	O
rofecoxib	rofecoxib	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
NS	NS	NN	I-NP	B	O
-	-	HYPH	B-NP	O	O
NSAIDs	NSAID	NNS	I-NP	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
users	user	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
both	both	CC	O	O	O
celecoxib	celecoxib	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
naproxen	naproxen	NN	I-NP	B	B-Chemical
seemed	seem	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
least	least	JJS	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
.	.	.	O	O	O

Quinine	Quinine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	B-Disease
malaria	malaria	NN	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	B-Disease
malaria	malaria	NN	I-NP	O	I-Disease
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
jaundice	jaundice	NN	B-NP	O	B-Disease
who	who	WP	B-NP	O	O
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
arrhythmia	arrhythmia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
premature	premature	JJ	B-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
contraction	contraction	NN	I-NP	O	I-Disease
)	)	)	O	O	O
while	while	IN	B-SBAR	O	O
getting	get	VBG	B-VP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
man	man	NN	I-NP	O	O
,	,	,	O	O	O
25	25	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
old	old	JJ	B-ADJP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
hospital	hospital	NN	B-NP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
fever	fever	NN	I-NP	O	B-Disease
,	,	,	O	O	O
chill	chill	NN	B-NP	O	B-Disease
,	,	,	O	O	O
vomiting	vomiting	NN	B-NP	O	B-Disease
,	,	,	O	O	O
jaundice	jaundice	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
fully	fully	RB	B-ADJP	O	O
conscious	conscious	JJ	I-ADJP	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
120	120	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
80	80	CD	I-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
,	,	,	O	O	O
pulse	pulse	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
100	100	CD	I-NP	O	O
x	x	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
minute	minute	NN	I-NP	O	O
,	,	,	O	O	O
regular	regular	JJ	B-ADJP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
,	,	,	O	O	O
laboratory	laboratory	NN	B-NP	O	O
examination	examination	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
Plasmodium	Plasmodium	NN	B-NP	O	O
falciparum	falciparum	NN	I-NP	O	O
(	(	(	O	O	O
+	+	SYM	B-NP	O	O
+	+	SYM	O	O	O
+	+	SYM	B-NP	O	O
+	+	SYM	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
total	total	JJ	B-NP	B	O
bilirubin	bilirubin	NN	I-NP	I	B-Chemical
8.25	8.25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
,	,	,	O	O	O
conjugated	conjugate	VBD	B-VP	O	O
bilirubin	bilirubin	NN	B-NP	B	B-Chemical
4.36	4.36	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
,	,	,	O	O	O
unconjugated	unconjugated	JJ	B-NP	O	O
bilirubin	bilirubin	NN	I-NP	B	B-Chemical
3.89	3.89	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
dL	dL	NN	B-NP	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
3.52	3.52	CD	I-NP	O	O
meq	meq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
Patient	Patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
severe	severe	JJ	B-NP	O	B-Disease
malaria	malaria	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
jaundice	jaundice	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
got	get	VBD	B-VP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dextrose	dextrose	NN	B-NP	B	B-Chemical
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
500	500	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
8	8	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
vomitus	vomitus	NN	B-NP	O	B-Disease
,	,	,	O	O	O
diarrhea	diarrhea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
tinnitus	tinnitus	NN	B-NP	O	B-Disease
,	,	,	O	O	O
loss	loss	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
hearing	hearing	NN	B-NP	O	I-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
30	30	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
quinine	quinine	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
felt	feel	VBD	B-VP	O	O
palpitation	palpitation	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
electrocardiography	electrocardiography	NN	B-NP	O	O
(	(	(	O	O	O
ECG	ECG	NN	B-NP	O	O
)	)	)	O	O	O
recording	recording	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
premature	premature	JJ	B-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
contraction	contraction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PVC	PVC	NN	B-NP	B	B-Disease
)	)	)	O	O	O
>	>	SYM	O	O	O
5	5	CD	B-NP	O	O
x	x	NN	I-NP	O	O
/	/	SYM	B-VP	O	O
minute	minute	NN	B-NP	O	O
,	,	,	O	O	O
trigemini	trigemini	NN	B-NP	O	O
,	,	,	O	O	O
constant	constant	JJ	B-NP	O	O
type	type	NN	I-NP	O	O
-	-	HYPH	O	O	O
-	-	HYPH	B-NP	O	O
sinoatrial	sinoatrial	JJ	I-NP	O	B-Disease
block	block	NN	I-NP	O	I-Disease
,	,	,	O	O	O
positive	positive	JJ	B-NP	O	O
U	U	NN	I-NP	O	O
wave	wave	NN	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lidocaine	lidocaine	NN	B-NP	B	B-Chemical
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
intravenously	intravenously	RB	B-VP	O	O
followed	follow	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
infusion	infusion	NN	B-NP	O	O
1500	1500	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
dextrose	dextrose	NN	B-NP	B	B-Chemical
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
24	24	CD	B-NP	O	O
hour	hour	NN	I-NP	O	O
and	and	CC	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
aspartate	aspartate	NN	I-NP	I	I-Chemical
tablet	tablet	NN	I-NP	O	O
.	.	.	O	O	O

Quinine	Quinine	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
changed	change	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
sulfate	sulfate	NN	B-NP	B	O
quinine	quinine	NN	I-NP	I	B-Chemical
tablets	tablet	NNS	I-NP	O	O
.	.	.	O	O	O

Three	Three	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
felt	feel	VBD	B-VP	O	O
better	well	RBR	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PVC	PVC	NN	B-NP	B	B-Disease
reduced	reduce	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
4	4	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
x	x	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
minute	minute	NN	I-NP	O	O
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
ECG	ECG	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
,	,	,	O	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
3.34	3.34	CD	B-NP	O	O
meq	meq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
discharged	discharge	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
7th	7th	JJ	B-NP	O	O
day	day	NN	I-NP	O	O
in	in	IN	B-PP	O	O
good	good	JJ	B-NP	O	O
condition	condition	NN	I-NP	O	O
.	.	.	O	O	O

Quinine	Quinine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
like	like	IN	B-PP	O	O
quinidine	quinidine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
chincona	chincona	NN	I-NP	O	O
alkaloid	alkaloid	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
arrhythmic	arrhythmic	JJ	I-NP	O	B-Disease
property	property	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
pro	pro	AFX	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
arrhythmic	arrhythmic	JJ	I-ADJP	O	B-Disease
that	that	WDT	B-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
various	various	JJ	B-NP	O	O
arrhythmias	arrhythmia	NNS	I-NP	O	B-Disease
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
severe	severe	JJ	B-NP	O	O
arrhythmia	arrhythmia	NN	I-NP	O	B-Disease
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
multiple	multiple	JJ	B-NP	O	O
PVC	PVC	NN	I-NP	B	B-Disease
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
parenteral	parenteral	JJ	B-NP	O	O
quinine	quinine	NN	I-NP	B	B-Chemical
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
done	do	VBN	I-VP	O	O
carefully	carefully	RB	B-ADVP	O	O
and	and	CC	O	O	O
with	with	IN	B-PP	O	O
good	good	JJ	B-NP	O	O
observation	observation	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
its	its	PRP$	B-NP	O	O
pro	pro	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
arrhythmic	arrhythmic	JJ	I-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
older	old	JJR	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
heart	heart	NN	B-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
or	or	CC	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
electrolyte	electrolyte	NN	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
frequently	frequently	RB	B-ADVP	O	O
occurs	occur	VBZ	B-VP	O	O
due	due	IN	B-PP	O	O
to	to	TO	B-PP	O	O
vomiting	vomiting	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
or	or	CC	O	O	O
diarrhea	diarrhea	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
malaria	malaria	NN	B-NP	O	B-Disease
cases	case	NNS	I-NP	O	O
.	.	.	O	O	O

Penicillamine	Penicillamine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
related	relate	VBN	B-NP	O	O
lichenoid	lichenoid	NN	I-NP	O	B-Disease
dermatitis	dermatitis	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
utility	utility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
zinc	zinc	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Wilson	Wilson	NNP	I-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
presentation	presentation	NN	I-NP	O	O
,	,	,	O	O	O
anxiety	anxiety	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
SPECT	SPECT	NN	I-NP	O	O
abnormalities	abnormality	NNS	I-NP	O	O
.	.	.	O	O	O

Wilson	Wilson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
autosomal	autosomal	JJ	I-NP	O	O
recessive	recessive	JJ	I-NP	O	O
disorder	disorder	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
copper	copper	NN	I-NP	B	B-Chemical
metabolism	metabolism	NN	I-NP	O	O
with	with	IN	B-PP	O	O
consequent	consequent	JJ	B-NP	O	O
copper	copper	NN	I-NP	B	B-Chemical
accumulation	accumulation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
tissues	tissue	NNS	I-NP	O	O
and	and	CC	O	O	O
consequent	consequent	JJ	B-NP	O	O
hepatic	hepatic	JJ	I-NP	O	B-Disease
,	,	,	I-NP	O	I-Disease
neurologic	neurologic	JJ	I-NP	O	I-Disease
and	and	CC	I-NP	O	I-Disease
psychiatric	psychiatric	JJ	I-NP	O	I-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Wilson	Wilson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
;	;	:	O	O	O
moreover	moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
presenting	present	VBG	B-VP	O	O
also	also	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
state	state	NN	B-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
without	without	IN	B-PP	O	O
depression	depression	NN	B-NP	O	B-Disease
,	,	,	O	O	O
99mTc	99mTc	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
ECD	ECD	NN	I-NP	O	O
-	-	HYPH	O	O	O
SPECT	SPECT	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
cortical	cortical	JJ	B-NP	O	O
hypoperfusion	hypoperfusion	NN	I-NP	O	O
in	in	IN	B-PP	O	O
frontal	frontal	JJ	B-NP	O	O
lobes	lobe	NNS	I-NP	O	O
,	,	,	O	O	O
more	more	JJR	B-NP	O	O
marked	marked	JJ	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
frontal	frontal	JJ	I-NP	O	O
lobe	lobe	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
follow	follow	VB	I-NP	O	O
-	-	HYPH	B-VP	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
,	,	,	O	O	O
penicillamine	penicillamine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
interrupted	interrupt	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lichenoid	lichenoid	JJ	I-NP	O	B-Disease
dermatitis	dermatitis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
zinc	zinc	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
permitted	permit	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
continue	continue	VB	I-VP	O	O
the	the	DT	B-NP	O	O
successful	successful	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
without	without	IN	B-PP	O	O
side	side	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
effects	effect	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
case	case	NN	I-NP	O	O
the	the	DT	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
zinc	zinc	NN	B-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
represented	represent	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Wilson	Wilson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
patient	patient	NN	I-NP	O	O
in	in	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
penicillamine	penicillamine	NN	B-NP	B	B-Chemical
-	-	HYPH	I-NP	O	O
related	relate	VBN	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
appeared	appear	VBD	B-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
zinc	zinc	NN	I-NP	B	B-Chemical
acetate	acetate	NN	I-NP	I	I-Chemical
allowed	allow	VBD	B-VP	O	O
us	us	PRP	B-NP	O	O
to	to	TO	B-VP	O	O
avoid	avoid	VB	I-VP	O	O
other	other	JJ	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
toxic	toxic	JJ	I-NP	O	O
chelating	chelate	VBG	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
;	;	:	O	O	O
this	this	DT	B-NP	O	O
observation	observation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
line	line	NN	B-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
growing	grow	VBG	I-NP	O	O
evidence	evidence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Wilson	Wilson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Since	Since	IN	B-SBAR	O	O
most	most	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
Wilson	Wilson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
penicillamine	penicillamine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
seem	seem	VB	I-VP	O	O
to	to	TO	I-VP	O	O
develop	develop	VB	I-VP	O	O
this	this	DT	B-NP	O	O
skin	skin	NN	I-NP	O	B-Disease
lesion	lesion	NN	I-NP	O	I-Disease
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
conceivable	conceivable	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
genetic	genetic	JJ	I-NP	O	O
factor	factor	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
needed	need	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
better	good	JJR	I-NP	O	O
clarification	clarification	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Wilson	Wilson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
differentiate	differentiate	VB	I-VP	O	O
specific	specific	JJ	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
Wilson	Wilson	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
phenotypes	phenotype	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
dramatic	dramatic	JJ	I-NP	O	O
drop	drop	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
blood	blood	NN	B-NP	O	I-Disease
pressure	pressure	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
prehospital	prehospital	NN	B-NP	O	O
GTN	GTN	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
male	male	NN	I-NP	O	O
in	in	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
sixties	sixty	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
awoke	awoke	NN	I-NP	O	O
with	with	IN	B-PP	O	O
chest	chest	NN	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
following	follow	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
afternoon	afternoon	NN	I-NP	O	O
sleep	sleep	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
self	self	VB	I-VP	O	O
medicate	medicate	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
observations	observation	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
within	within	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
limits	limit	NNS	I-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
oxygen	oxygen	NN	B-NP	B	B-Chemical
via	via	IN	B-PP	O	O
a	a	DT	B-NP	O	O
face	face	NN	I-NP	O	O
mask	mask	NN	I-NP	O	O
and	and	CC	O	O	O
glyceryl	glyceryl	NN	B-NP	B	B-Chemical
trinitrate	trinitrate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
GTN	GTN	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
GTN	GTN	NN	I-NP	B	B-Chemical
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
sudden	sudden	JJ	I-NP	O	O
drop	drop	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
blood	blood	NN	B-NP	O	I-Disease
pressure	pressure	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
was	be	VBD	B-VP	O	O
rectified	rectify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
atropine	atropine	NN	B-NP	B	B-Chemical
sulphate	sulphate	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
condition	condition	NN	I-NP	O	O
during	during	IN	B-PP	O	O
transport	transport	NN	B-NP	O	O
to	to	TO	B-PP	O	O
hospital	hospital	NN	B-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
very	very	RB	B-NP	O	O
few	few	JJ	I-NP	O	O
documented	document	VBN	I-NP	O	O
case	case	NN	I-NP	O	O
like	like	IN	B-PP	O	O
this	this	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prehospital	prehospital	NN	I-NP	O	O
scientific	scientific	JJ	I-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
appears	appear	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
the	the	DT	B-NP	O	O
Bezold	Bezold	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Jarish	Jarish	JJ	I-NP	O	O
reflex	reflex	NN	I-NP	O	O
,	,	,	O	O	O
stimulation	stimulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
walls	wall	NNS	I-NP	O	O
which	which	WDT	B-NP	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
decreases	decrease	VBZ	B-VP	O	O
sympathetic	sympathetic	JJ	B-NP	O	O
outflow	outflow	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
vasomotor	vasomotor	NN	I-NP	O	O
centre	centre	NN	I-NP	O	O
.	.	.	O	O	O

Prehospital	Prehospital	NN	B-NP	O	O
care	care	NN	I-NP	O	O
providers	provider	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
managing	manage	VBG	I-VP	B	O
any	any	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
syncopal	syncopal	JJ	I-NP	O	B-Disease
episode	episode	NN	I-NP	O	I-Disease
that	that	WDT	B-NP	O	O
fails	fail	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
recover	recover	VB	I-VP	O	O
within	within	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reasonable	reasonable	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
frame	frame	NN	I-NP	O	O
should	should	MD	B-VP	O	O
consider	consider	VB	I-VP	O	O
the	the	DT	B-NP	O	O
Bezold	Bezold	NNP	I-NP	O	O
-	-	HYPH	I-NP	O	O
Jarisch	Jarisch	NNP	I-NP	O	O
reflex	reflex	NN	I-NP	O	O
as	as	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
and	and	CC	O	O	O
manage	manage	VB	B-VP	B	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
accordingly	accordingly	RB	B-ADVP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
vasospasm	vasospasm	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
multiagent	multiagent	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
including	include	VBG	B-PP	O	O
PEG	PEG	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
asparaginase	asparaginase	NN	I-NP	B	I-Chemical
and	and	CC	O	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
cytarabine	cytarabine	NN	I-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
7	7	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
girl	girl	NN	I-NP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
unusual	unusual	JJ	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
to	to	TO	B-PP	O	O
induction	induction	NN	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
precursor	precursor	NN	B-NP	O	O
B	B	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
lymphoblastic	lymphoblastic	JJ	I-NP	O	I-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ALL	ALL	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
evidenced	evidence	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
behavioral	behavioral	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
,	,	,	O	O	O
aphasia	aphasia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
incontinence	incontinence	NN	B-NP	O	B-Disease
,	,	,	O	O	O
visual	visual	JJ	B-NP	O	B-Disease
hallucinations	hallucination	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
right	right	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
sided	sided	JJ	I-NP	O	O
weakness	weakness	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
diffuse	diffuse	JJ	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	B-Disease
vasospasm	vasospasm	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
magnetic	magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
angiography	angiography	NN	I-NP	O	O
after	after	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intrathecal	intrathecal	JJ	B-NP	O	O
cytarabine	cytarabine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Vincristine	Vincristine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
dexamethasone	dexamethasone	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
polyethylene	polyethylene	NN	B-NP	B	B-Chemical
glycol	glycol	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
asparaginase	asparaginase	NN	I-NP	B	I-Chemical
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
administered	administer	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
the	the	DT	B-NP	O	O
episode	episode	NN	I-NP	O	O
as	as	IN	B-PP	O	O
part	part	NN	B-NP	O	O
of	of	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Neurologic	Neurologic	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
within	within	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
magnetic	magnetic	JJ	B-NP	O	O
resonance	resonance	NN	I-NP	O	O
angiography	angiography	NN	I-NP	O	O
findings	finding	NNS	I-NP	O	O
returned	return	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-NP	O	O
4	4	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

Comparison	Comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
valsartan	valsartan	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	I-NP	B	B-Chemical
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
at	at	IN	B-PP	O	O
doses	dose	NNS	B-NP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
320	320	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
versus	versus	IN	B-PP	O	O
monotherapy	monotherapy	NN	B-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
controlled	control	VBN	I-NP	O	O
study	study	NN	I-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
combination	combination	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
hypertensive	hypertensive	JJ	B-NP	O	B-Disease
adults	adult	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
One	One	CD	B-NP	O	O
third	third	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
attain	attain	NN	I-NP	O	O
adequate	adequate	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
BP	BP	NN	B-NP	B	O
)	)	)	O	O	O
control	control	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
multidrug	multidrug	JJ	B-NP	O	O
regimens	regimen	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
often	often	RB	I-VP	O	O
required	require	VBN	I-VP	O	O
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
lifelong	lifelong	JJ	I-NP	O	O
nature	nature	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
need	need	NN	I-NP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
therapies	therapy	NNS	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valsartan	valsartan	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
or	or	CC	O	O	O
hydrochlorothiazide	hydrochlorothiazide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
monotherapy	monotherapy	NN	I-NP	O	O
and	and	CC	O	O	O
higher	high	JJR	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
combinations	combination	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
essential	essential	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
part	part	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
multicenter	multicenter	NN	B-NP	O	O
,	,	,	O	O	O
randomized	randomize	VBN	B-NP	O	O
,	,	,	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
,	,	,	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
controlled	control	VBN	B-VP	O	O
,	,	,	O	O	O
parallel	parallel	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
group	group	NN	I-NP	O	O
trial	trial	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
essential	essential	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
(	(	(	O	O	O
mean	mean	NN	B-NP	O	O
sitting	sit	VBG	B-VP	O	O
diastolic	diastolic	JJ	B-NP	O	O
BP	BP	NN	I-NP	B	O
[	[	(	O	O	O
MSDBP	MSDBP	NN	B-NP	O	O
]	]	)	O	O	O
,	,	,	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
95	95	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
and	and	CC	O	O	O
<	<	SYM	B-NP	O	O
110	110	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
1	1	CD	B-NP	O	O
of	of	IN	B-PP	O	O
8	8	CD	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
160	160	CD	B-NP	O	O
or	or	CC	I-NP	O	O
320	320	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
;	;	:	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
12.5	12.5	CD	I-NP	O	O
or	or	CC	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
;	;	:	O	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
160	160	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
12.5	12.5	CD	I-NP	O	O
,	,	,	I-NP	O	O
320	320	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
12.5	12.5	CD	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
320	320	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
;	;	:	O	O	O
or	or	CC	O	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
MSDBP	MSDBP	NN	B-NP	O	O
and	and	CC	I-NP	O	O
mean	mean	NN	I-NP	O	O
sitting	sit	VBG	B-VP	O	O
systolic	systolic	JJ	B-NP	O	O
BP	BP	NN	I-NP	B	O
(	(	(	O	O	O
MSSBP	MSSBP	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
analyzed	analyze	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
core	core	NN	I-NP	O	O
study	study	NN	I-NP	O	O
end	end	NN	I-NP	O	O
point	point	NN	I-NP	O	O
.	.	.	O	O	O

VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
320	320	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
12.5	12.5	CD	I-NP	O	O
and	and	CC	I-NP	O	O
320	320	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
further	further	RB	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
54	54	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
,	,	,	O	O	O
open	open	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
label	label	NN	I-NP	O	O
extension	extension	NN	I-NP	O	O
.	.	.	O	O	O

Response	Response	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
MSDBP	MSDBP	NN	B-NP	O	O
<	<	SYM	O	O	O
90	90	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
>	>	SYM	I-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-NP	O	O
10	10	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
.	.	.	O	O	O

Control	Control	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
defined	define	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
MSDBP	MSDBP	NN	B-NP	O	O
<	<	SYM	O	O	O
90	90	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
.	.	.	O	O	O

Tolerability	Tolerability	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
assessed	assess	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
monitoring	monitor	VBG	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
randomization	randomization	NN	B-NP	O	O
and	and	CC	O	O	O
all	all	DT	B-NP	O	O
subsequent	subsequent	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
visits	visit	NNS	I-NP	O	O
and	and	CC	O	O	O
regular	regular	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hematology	hematology	NN	B-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
chemistry	chemistry	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1346	1346	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomized	randomize	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
core	core	NN	I-NP	O	O
study	study	NN	I-NP	O	O
(	(	(	O	O	O
734	734	CD	B-NP	O	O
men	man	NNS	I-NP	O	O
,	,	,	O	O	O
612	612	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
;	;	:	O	O	O
924	924	CD	B-NP	O	O
white	white	JJ	I-NP	O	O
,	,	,	O	O	O
291	291	CD	B-NP	O	O
black	black	JJ	I-NP	O	O
,	,	,	O	O	O
23	23	CD	B-NP	O	O
Asian	Asian	NNP	I-NP	O	O
,	,	,	O	O	O
108	108	CD	B-NP	O	O
other	other	JJ	I-NP	O	O
;	;	:	O	O	O
mean	mean	NN	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
52.7	52.7	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
;	;	:	O	O	O
mean	mean	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
,	,	,	O	O	O
92.6	92.6	CD	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
active	active	JJ	I-NP	O	O
treatments	treatment	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significantly	significantly	RB	B-NP	O	O
reduced	reduce	VBN	I-NP	O	O
MSSBP	MSSBP	NN	I-NP	O	O
and	and	CC	I-NP	O	O
MSDBP	MSDBP	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
core	core	NN	I-NP	O	O
8	8	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
each	each	DT	B-NP	O	O
monotherapy	monotherapy	NN	I-NP	O	O
significantly	significantly	RB	B-VP	O	O
contributing	contribute	VBG	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
and	and	CC	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Each	Each	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significantly	significantly	RB	B-NP	O	O
greater	great	JJR	I-NP	O	O
reductions	reduction	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
MSSBP	MSSBP	NN	B-NP	O	O
and	and	CC	I-NP	O	O
MSDBP	MSDBP	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
monotherapies	monotherapy	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
(	(	(	O	O	O
all	all	DT	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MSSBP	MSSBP	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
MSDBP	MSDBP	NN	I-NP	O	O
with	with	IN	B-PP	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
320	320	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
24.7	24.7	CD	B-NP	O	O
/	/	SYM	B-NP	O	O
16.6	16.6	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
5.9	5.9	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
7.0	7.0	CD	I-NP	O	O
mm	mm	NN	I-NP	O	O
Hg	Hg	NN	I-NP	O	O
with	with	IN	B-PP	O	O
placebo	placebo	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
MSSBP	MSSBP	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
with	with	IN	B-PP	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
320	320	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
25	25	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	O	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
160	160	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
12.5	12.5	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
0.002	0.002	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Rates	Rate	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
response	response	NN	B-NP	O	O
and	and	CC	I-NP	O	O
BP	BP	NN	I-NP	B	O
control	control	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
combination	combination	NN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
monotherapy	monotherapy	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypokalemia	hypokalemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
with	with	IN	B-PP	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	B-NP	O	O
HCTZ	HCTZ	NN	I-NP	B	B-Chemical
combinations	combination	NNS	I-NP	O	O
(	(	(	O	O	O
1.8	1.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
6.1	6.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
than	than	IN	B-PP	O	O
with	with	IN	B-PP	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
monotherapies	monotherapy	NNS	I-NP	O	O
(	(	(	O	O	O
7.1	7.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
-	-	HYPH	O	O	O
13.3	13.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
majority	majority	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
core	core	NN	I-NP	O	O
study	study	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
mild	mild	JJ	B-NP	O	O
to	to	TO	B-PP	O	O
moderate	moderate	JJ	B-NP	O	O
severity	severity	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
and	and	CC	I-NP	O	O
tolerability	tolerability	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	B-NP	O	O
HCTZ	HCTZ	NN	I-NP	B	B-Chemical
combinations	combination	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
extension	extension	NN	I-NP	O	O
(	(	(	O	O	O
797	797	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
population	population	NN	I-NP	O	O
,	,	,	O	O	O
combination	combination	NN	B-NP	O	O
therapies	therapy	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
VAL	VAL	NN	B-NP	O	B-Chemical
/	/	SYM	B-NP	O	O
HCTZ	HCTZ	NN	I-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
significantly	significantly	RB	B-NP	O	O
greater	great	JJR	I-NP	O	O
BP	BP	NN	I-NP	B	O
reductions	reduction	NNS	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
monotherapy	monotherapy	NN	B-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
less	less	JJR	B-NP	O	O
hypokalemia	hypokalemia	NN	I-NP	O	B-Disease
than	than	IN	B-PP	O	O
HCTZ	HCTZ	NN	B-NP	B	B-Chemical
alone	alone	RB	B-ADVP	O	O
.	.	.	O	O	O

Succimer	Succimer	NN	B-NP	B	B-Chemical
chelation	chelation	NN	I-NP	O	O
improves	improve	VBZ	B-VP	O	O
learning	learning	NN	B-NP	O	O
,	,	,	O	O	O
attention	attention	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
arousal	arousal	JJ	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
lead	lead	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
but	but	CC	O	O	O
produces	produce	VBZ	B-VP	O	O
lasting	last	VBG	I-VP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lead	lead	NN	B-NP	O	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
growing	grow	VBG	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
for	for	IN	B-SBAR	O	O
clinicians	clinician	NNS	B-NP	O	O
to	to	TO	B-VP	O	O
prescribe	prescribe	VB	I-VP	O	O
chelation	chelation	NN	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
at	at	IN	B-PP	O	O
only	only	RB	B-NP	O	O
slightly	slightly	RB	I-NP	O	O
elevated	elevated	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
lead	lead	NN	I-NP	O	B-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
very	very	RB	B-NP	O	O
few	few	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
chelation	chelation	NN	B-NP	O	O
improves	improve	VBZ	B-VP	O	O
cognitive	cognitive	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
children	child	NNS	I-NP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
whether	whether	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
affect	affect	VB	I-VP	O	O
brain	brain	NN	B-NP	O	O
development	development	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
answer	answer	VB	I-VP	O	O
these	these	DT	B-NP	O	O
questions	question	NNS	I-NP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
rodent	rodent	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
childhood	childhood	NN	I-NP	O	O
Pb	Pb	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
succimer	succimer	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
widely	widely	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
chelating	chelate	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Disease
poisoning	poisoning	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
produced	produce	VBD	B-VP	O	O
lasting	last	VBG	I-VP	O	O
impairments	impairment	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	I-Disease
learning	learning	NN	B-NP	O	I-Disease
,	,	,	O	O	I-Disease
attention	attention	NN	B-NP	O	I-Disease
,	,	,	O	O	I-Disease
inhibitory	inhibitory	JJ	B-NP	O	I-Disease
control	control	NN	I-NP	O	I-Disease
,	,	,	O	O	I-Disease
and	and	CC	O	O	I-Disease
arousal	arousal	JJ	B-NP	O	I-Disease
regulation	regulation	NN	I-NP	O	I-Disease
,	,	,	O	O	O
paralleling	parallel	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
areas	area	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
dysfunction	dysfunction	NN	B-NP	O	O
seen	see	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
children	child	NNS	I-NP	O	O
.	.	.	O	O	O

Succimer	Succimer	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Pb	Pb	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
improved	improve	VBD	B-VP	O	O
learning	learning	NN	B-NP	O	O
,	,	,	O	O	O
attention	attention	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
arousal	arousal	JJ	B-NP	O	O
regulation	regulation	NN	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
varied	vary	VBD	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
function	function	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Pb	Pb	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
level	level	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
functional	functional	JJ	I-NP	O	O
deficit	deficit	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
succimer	succimer	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
not	not	RB	B-VP	O	O
previously	previously	RB	I-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
produced	produce	VBD	B-VP	O	O
lasting	lasting	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
pervasive	pervasive	JJ	I-NP	O	O
cognitive	cognitive	JJ	I-NP	O	B-Disease
and	and	CC	I-NP	O	I-Disease
affective	affective	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
comparable	comparable	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
magnitude	magnitude	NN	B-NP	O	O
to	to	TO	B-PP	O	O
that	that	DT	B-NP	O	O
produced	produce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
higher	high	JJR	I-NP	O	O
Pb	Pb	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
,	,	,	O	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
,	,	,	O	O	O
to	to	TO	B-VP	O	O
show	show	VB	I-VP	O	O
that	that	IN	B-SBAR	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
chelating	chelate	VBG	I-NP	O	O
agent	agent	NN	I-NP	O	O
can	can	MD	B-VP	O	O
alleviate	alleviate	VB	I-VP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
possible	possible	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
a	a	DT	B-NP	O	O
succimer	succimer	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
protocol	protocol	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
improves	improve	VBZ	B-VP	O	O
cognitive	cognitive	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
children	child	NNS	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
they	they	PRP	B-NP	O	O
also	also	RB	B-ADVP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
succimer	succimer	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
strongly	strongly	RB	I-VP	O	O
discouraged	discourage	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
children	child	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
have	have	VB	I-VP	O	O
elevated	elevate	VBN	I-VP	B	O
tissue	tissue	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
Pb	Pb	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
heavy	heavy	JJ	I-NP	O	O
metals	metal	NNS	I-NP	O	O
.	.	.	O	O	O

Caffeine	Caffeine	NN	B-NP	B	B-Chemical
challenge	challenge	NN	I-NP	O	O
test	test	NN	I-NP	O	O
in	in	IN	B-PP	O	O
panic	panic	NN	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
depression	depression	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
panic	panic	NN	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
aim	aim	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
observe	observe	VB	I-VP	O	O
if	if	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
panic	panic	NN	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PD	PD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
major	major	JJ	B-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
panic	panic	JJ	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
MDP	MDP	NN	B-NP	B	B-Disease
)	)	)	O	O	O
(	(	(	O	O	O
Diagnostic	Diagnostic	NNP	B-NP	O	O
and	and	CC	O	O	O
Statistical	Statistical	NNP	B-NP	O	O
Manual	Manual	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Mental	Mental	NNP	B-NP	O	B-Disease
Disorders	Disorders	NNP	I-NP	O	I-Disease
,	,	,	O	O	O
Fourth	Fourth	NNP	B-NP	O	O
Edition	Edition	NNP	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
)	)	)	O	O	O
respond	respond	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
similar	similar	JJ	I-NP	O	O
way	way	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
induction	induction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
panic	panic	NN	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
by	by	IN	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
challenge	challenge	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
randomly	randomly	RB	B-ADVP	O	O
selected	select	VBD	B-VP	O	O
29	29	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
,	,	,	O	O	O
27	27	CD	B-NP	O	O
with	with	IN	B-PP	O	O
MDP	MDP	NN	B-NP	B	B-Disease
,	,	,	O	O	O
25	25	CD	B-NP	O	O
with	with	IN	B-PP	O	O
major	major	JJ	B-NP	O	B-Disease
depression	depression	NN	I-NP	O	I-Disease
without	without	IN	B-PP	O	O
panic	panic	JJ	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
(	(	(	O	O	O
MD	MD	NN	B-NP	B	B-Disease
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
28	28	CD	B-NP	O	O
healthy	healthy	JJ	I-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
psychotropic	psychotropic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
a	a	DT	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
randomized	randomize	VBN	I-NP	O	O
double	double	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
blind	blind	JJ	I-NP	O	O
experiment	experiment	NN	I-NP	O	O
performed	perform	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
occasions	occasion	NNS	I-NP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
apart	apart	RB	B-ADVP	O	O
,	,	,	O	O	O
480	480	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
free	free	JJ	O	O	O
(	(	(	O	O	O
placebo	placebo	NN	B-NP	O	O
)	)	)	O	O	O
solution	solution	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
coffee	coffee	NN	I-NP	O	O
form	form	NN	I-NP	O	O
and	and	CC	I-NP	O	O
anxiety	anxiety	NN	I-NP	O	B-Disease
scales	scale	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
applied	apply	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	I-PP	O	O
each	each	DT	B-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
58.6	58.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
17	17	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
,	,	,	O	O	O
44.4	44.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
MDP	MDP	NN	B-NP	B	B-Disease
,	,	,	O	O	O
12.0	12.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
MD	MD	NN	B-NP	B	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
7.1	7.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
control	control	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
panic	panic	JJ	I-NP	O	B-Disease
attack	attack	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
480	480	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
mg	mg	NN	I-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
challenge	challenge	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
chi	chi	NN	B-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
(	(	(	O	O	O
3	3	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
16.22	16.22	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.001	.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
MDP	MDP	NN	I-NP	B	B-Disease
were	be	VBD	B-VP	O	O
more	more	RBR	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
caffeine	caffeine	NN	B-NP	B	B-Chemical
than	than	IN	B-SBAR	O	O
were	be	VBD	B-VP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
MD	MD	NN	B-NP	B	B-Disease
and	and	CC	O	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

No	No	DT	B-NP	O	O
panic	panic	NN	I-NP	O	B-Disease
attack	attack	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
solution	solution	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
MD	MD	NN	B-NP	B	B-Disease
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
heart	heart	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
test	test	NN	I-NP	O	O
than	than	IN	B-SBAR	O	O
all	all	PDT	B-NP	O	O
the	the	DT	I-NP	O	O
other	other	JJ	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
variance	variance	NN	B-NP	O	O
,	,	,	O	O	O
group	group	NN	B-NP	O	O
by	by	IN	B-PP	O	O
time	time	NN	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Greenhouse	Greenhouse	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
Geisser	Geisser	NN	I-NP	O	O
correction	correction	NN	I-NP	O	O
:	:	:	O	O	O
F	F	NN	B-NP	O	O
(	(	(	O	O	O
3,762	3,762	CD	B-NP	O	O
)	)	)	O	O	O
=	=	SYM	B-VP	O	O
2.85	2.85	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
.026	.026	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
panic	panic	JJ	B-NP	O	B-Disease
attacks	attack	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
no	no	DT	B-NP	O	O
matter	matter	NN	I-NP	O	O
if	if	IN	B-SBAR	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
or	or	CC	I-NP	O	O
MDP	MDP	NN	I-NP	B	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
hyperreactivity	hyperreactivity	NN	B-NP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
caffeine	caffeine	NN	I-NP	B	B-Chemical
challenge	challenge	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Mitral	Mitral	JJ	B-NP	O	O
annuloplasty	annuloplasty	NN	I-NP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
restoration	restoration	NN	I-NP	O	O
method	method	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
failing	fail	VBG	I-NP	O	B-Disease
left	left	JJ	I-NP	O	I-Disease
ventricle	ventricle	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
pilot	pilot	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
AIM	AIM	NN	I-NP	O	O
OF	OF	IN	B-PP	O	O
THE	THE	DT	B-NP	O	O
STUDY	STUDY	NN	I-NP	O	O
:	:	:	O	O	O
Undersized	Undersized	JJ	B-NP	O	O
mitral	mitral	JJ	I-NP	O	O
annuloplasty	annuloplasty	NN	I-NP	O	O
(	(	(	O	O	O
MAP	MAP	NN	B-NP	O	O
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
dilated	dilate	VBN	B-NP	O	B-Disease
cardiomyopathy	cardiomyopathy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
functional	functional	JJ	B-NP	O	O
mitral	mitral	JJ	I-NP	O	B-Disease
regurgitation	regurgitation	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MR	MR	NN	B-NP	O	B-Disease
)	)	)	O	O	O
since	since	IN	B-SBAR	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
addressing	address	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
MR	MR	NN	I-NP	O	B-Disease
,	,	,	O	O	O
the	the	DT	B-NP	O	O
MAP	MAP	NN	I-NP	O	O
may	may	MD	B-VP	O	O
also	also	RB	I-VP	O	O
reshape	reshape	VB	I-VP	O	O
the	the	DT	B-NP	O	O
dilated	dilated	JJ	I-NP	O	O
left	left	JJ	I-NP	O	O
ventricular	ventricular	JJ	I-NP	O	O
(	(	(	O	O	O
LV	LV	NN	B-NP	B	O
)	)	)	O	O	O
base	base	NN	B-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
benefits	benefit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
reshaping	reshaping	NN	I-NP	O	O
on	on	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
underlying	underlie	VBG	B-VP	O	O
MR	MR	NN	B-NP	O	B-Disease
remain	remain	VBP	B-VP	O	O
incompletely	incompletely	RB	B-ADJP	O	O
understood	understand	VBN	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
aim	aim	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
these	these	DT	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
canine	canine	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Six	Six	CD	B-NP	O	O
dogs	dog	NNS	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
MAP	MAP	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
prosthetic	prosthetic	JJ	I-NP	O	O
band	band	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
posterior	posterior	JJ	I-NP	O	O
mitral	mitral	JJ	I-NP	O	O
annulus	annulus	NN	I-NP	O	O
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
four	four	CD	B-NP	O	O
mattress	mattress	NN	I-NP	O	O
sutures	suture	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
sutures	suture	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
passed	pass	VBN	I-VP	O	O
individually	individually	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
four	four	CD	B-NP	O	O
tourniquets	tourniquet	NNS	I-NP	O	O
and	and	CC	O	O	O
exteriorized	exteriorize	VBN	B-VP	O	O
untied	untied	JJ	B-ADJP	O	O
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
atriotomy	atriotomy	NN	I-NP	O	O
.	.	.	O	O	O

Sonomicrometry	Sonomicrometry	NN	B-NP	O	O
crystals	crystal	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
implanted	implant	VBN	I-VP	O	O
around	around	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mitral	mitral	JJ	I-NP	O	O
annulus	annulus	NN	I-NP	O	O
and	and	CC	O	O	O
left	leave	VBD	B-VP	O	O
ventricle	ventricle	NN	B-NP	O	O
to	to	TO	B-VP	O	O
measure	measure	VB	I-VP	O	O
geometry	geometry	NN	B-NP	O	O
and	and	CC	I-NP	O	O
regional	regional	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
volume	volume	NN	I-NP	O	O
loading	loading	NN	I-NP	O	O
after	after	IN	B-PP	O	O
weaning	wean	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
cardiopulmonary	cardiopulmonary	JJ	B-NP	O	O
bypass	bypass	NN	I-NP	O	O
;	;	:	O	O	O
an	an	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MR	MR	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
confirmed	confirm	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
echocardiography	echocardiography	NN	B-NP	O	O
.	.	.	O	O	O

MAP	MAP	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
accomplished	accomplish	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
cinching	cinch	VBG	B-VP	B	O
the	the	DT	B-NP	O	O
tourniquets	tourniquet	NNS	I-NP	O	O
.	.	.	O	O	O

Data	Datum	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
acquired	acquire	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	B-PP	O	O
and	and	CC	I-PP	O	O
after	after	IN	B-PP	O	O
MAP	MAP	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
MAP	MAP	NN	B-NP	O	O
decreased	decrease	VBD	B-VP	O	O
mitral	mitral	JJ	B-NP	O	O
annular	annular	JJ	I-NP	O	O
dimensions	dimension	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
commissure	commissure	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
commissure	commissure	NN	B-NP	O	O
and	and	CC	O	O	O
septal	septal	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
lateral	lateral	JJ	I-NP	O	O
directions	direction	NNS	I-NP	O	O
.	.	.	O	O	O

Concomitantly	Concomitantly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
diameter	diameter	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LV	LV	NN	I-NP	B	O
base	base	NN	I-NP	O	O
and	and	CC	O	O	O
LV	LV	NN	B-NP	B	O
sphericity	sphericity	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
(	(	(	O	O	O
i.e.	i.e.	FW	O	O	O
,	,	,	O	O	O
improved	improve	VBN	B-VP	O	O
)	)	)	O	O	O
from	from	IN	B-PP	O	O
37.4	37.4	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
9.3	9.3	CD	B-NP	O	O
to	to	TO	B-PP	O	O
35.9	35.9	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
10	10	CD	B-NP	O	O
mm	mm	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.063	0.063	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	B-PP	O	O
from	from	IN	B-PP	O	O
67.9	67.9	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
18.6	18.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
65.3	65.3	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
18.9	18.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.016	0.016	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Decreases	Decrease	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
evident	evident	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
LV	LV	NN	B-NP	B	O
end	end	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
17	17	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
7	7	CD	B-NP	O	O
to	to	TO	B-PP	O	O
15	15	CD	B-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
6	6	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.0480	0.0480	CD	B-NP	O	O
and	and	CC	O	O	O
Tau	Tau	NNP	B-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
48	48	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8	8	CD	B-NP	O	O
to	to	TO	B-PP	O	O
45	45	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
8	8	CD	B-NP	O	O
ms	ms	NN	I-NP	O	O
,	,	,	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.01	0.01	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
fractional	fractional	JJ	B-NP	O	O
shortening	shortening	NN	I-NP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
LV	LV	NN	I-NP	B	O
base	base	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
7.7	7.7	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4.5	4.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	B-PP	O	O
9.4	9.4	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
4.5	4.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.045	0.045	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
MAP	MAP	NN	B-NP	O	O
,	,	,	O	O	O
increases	increase	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
output	output	NN	I-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
1.54	1.54	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.57	0.57	CD	B-NP	O	O
to	to	TO	B-PP	O	O
1.65	1.65	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.57	0.57	CD	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
Emax	Emax	NN	B-NP	O	O
(	(	(	O	O	O
from	from	IN	B-PP	O	O
1.86	1.86	CD	B-NP	O	O
+	+	SYM	B-ADJP	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.9	0.9	CD	B-NP	O	O
to	to	TO	B-PP	O	O
2.41	2.41	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.31	1.31	CD	B-NP	O	O
mmHg	mmHg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
acquired	acquire	VBN	B-VP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
isolated	isolate	VBN	B-NP	O	O
MAP	MAP	NN	I-NP	O	O
may	may	MD	B-VP	O	O
have	have	VB	I-VP	O	O
certain	certain	JJ	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
LV	LV	NN	B-NP	B	O
dimension	dimension	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
function	function	NN	I-NP	O	O
in	in	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
even	even	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MR	MR	NN	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
further	further	JJ	B-NP	O	O
investigations	investigation	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Piperacillin	Piperacillin	NN	B-NP	B	B-Chemical
/	/	SYM	I-NP	I	I-Chemical
tazobactam	tazobactam	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizure	seizure	NN	I-NP	O	B-Disease
rapidly	rapidly	RB	B-VP	O	O
reversed	reverse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
flux	flux	NN	I-NP	O	O
hemodialysis	hemodialysis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
on	on	IN	B-PP	O	O
peritoneal	peritoneal	JJ	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
popular	popular	JJ	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
the	the	DT	B-NP	O	O
dire	dire	JJ	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B	B-Chemical
still	still	RB	B-ADVP	O	O
goes	go	VBZ	B-VP	O	O
unrecognized	unrecognized	JJ	B-ADJP	O	O
,	,	,	O	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
delay	delay	NN	I-NP	O	O
in	in	IN	B-PP	O	O
appropriate	appropriate	JJ	B-NP	O	O
management	management	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
57	57	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
end	end	NN	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
receiving	receive	VBG	B-VP	O	O
continuous	continuous	JJ	B-NP	O	O
ambulatory	ambulatory	JJ	I-NP	O	O
peritoneal	peritoneal	JJ	I-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
(	(	(	O	O	O
CAPD	CAPD	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
slurred	slur	VBN	I-VP	O	O
speech	speech	NN	B-NP	O	O
,	,	,	O	O	O
tremor	tremor	NN	B-NP	O	B-Disease
,	,	,	O	O	O
bizarre	bizarre	JJ	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
,	,	,	O	O	O
progressive	progressive	JJ	B-NP	O	O
mental	mental	JJ	I-NP	O	O
confusion	confusion	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
2	2	CD	B-NP	O	O
episodes	episode	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
generalized	generalize	VBN	B-NP	O	O
tonic	tonic	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
clonic	clonic	JJ	I-NP	O	I-Disease
seizure	seizure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
GTCS	GTCS	NN	B-NP	O	B-Disease
)	)	)	O	O	O
after	after	IN	B-PP	O	O
5	5	CD	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	I	I-Chemical
tazobactam	tazobactam	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
2	2	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
250	250	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
bronchiectasis	bronchiectasis	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
secondary	secondary	JJ	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
laboratory	laboratory	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
normal	normal	JJ	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
electrolyte	electrolyte	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ammonia	ammonia	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
but	but	CC	O	O	O
leukocytosis	leukocytosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Neurologic	Neurologic	JJ	B-NP	O	O
examinations	examination	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
dysarthria	dysarthria	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
Babinski	Babinski	NNP	I-NP	O	O
sign	sign	NN	I-NP	O	O
.	.	.	O	O	O

Computed	Compute	VBN	B-NP	O	O
tomography	tomography	NN	I-NP	O	O
of	of	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
and	and	CC	I-NP	O	O
electroencephalogram	electroencephalogram	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
unremarkable	unremarkable	JJ	B-ADJP	O	O
.	.	.	O	O	O

Despite	Despite	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antiepileptic	antiepileptic	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
,	,	,	O	O	O
another	another	DT	B-NP	O	O
GTCS	GTCS	NN	I-NP	O	B-Disease
episode	episode	NN	I-NP	O	O
recurred	recur	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sixth	sixth	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
piperacillin	piperacillin	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	I	I-Chemical
tazobactam	tazobactam	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Brain	Brain	NN	B-NP	O	O
magnetic	magnetic	JJ	I-NP	O	O
resonance	resonance	NN	I-NP	O	O
imaging	imaging	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
demonstrate	demonstrate	VB	I-VP	O	O
acute	acute	JJ	B-NP	O	O
infarction	infarction	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
organic	organic	JJ	B-NP	O	B-Disease
brain	brain	NN	I-NP	O	I-Disease
lesions	lesion	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Initiation	Initiation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
flux	flux	NN	I-NP	O	O
hemodialysis	hemodialysis	NN	I-NP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
reversed	reverse	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
neurologic	neurologic	JJ	I-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
within	within	IN	B-PP	O	O
4	4	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

Piperacillin	Piperacillin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
uremic	uremic	JJ	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
unexplained	unexplained	JJ	B-NP	O	O
neurological	neurological	JJ	I-NP	O	O
manifestations	manifestation	NNS	I-NP	O	O
.	.	.	O	O	O

CAPD	CAPD	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
inefficient	inefficient	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
removing	remove	VBG	B-VP	O	O
piperacillin	piperacillin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
hemodialysis	hemodialysis	NN	B-NP	O	O
can	can	MD	B-VP	O	O
rapidly	rapidly	RB	I-VP	O	O
terminate	terminate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
piperacillin	piperacillin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
encephalopathy	encephalopathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Frequency	Frequency	NN	B-NP	O	O
of	of	IN	B-PP	O	O
transient	transient	JJ	B-NP	O	O
ipsilateral	ipsilateral	JJ	I-NP	O	O
vocal	vocal	JJ	I-NP	O	B-Disease
cord	cord	NN	I-NP	O	I-Disease
paralysis	paralysis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
carotid	carotid	NN	B-NP	O	O
endarterectomy	endarterectomy	NN	I-NP	O	O
under	under	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Especially	Especially	RB	B-ADVP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
improvements	improvement	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
neurologic	neurologic	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
,	,	,	O	O	O
carotid	carotid	NN	B-NP	O	O
endarterectomy	endarterectomy	NN	I-NP	O	O
done	do	VBN	B-VP	O	O
under	under	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
become	become	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
technique	technique	NN	I-NP	O	O
of	of	IN	B-PP	O	O
choice	choice	NN	B-NP	O	O
in	in	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
centers	center	NNS	I-NP	O	O
.	.	.	O	O	O

Temporary	Temporary	JJ	B-NP	O	O
ipsilateral	ipsilateral	JJ	I-NP	O	O
vocal	vocal	JJ	I-NP	O	B-Disease
nerve	nerve	NN	I-NP	O	I-Disease
palsies	palsy	NNS	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
described	describe	VBN	I-VP	O	O
,	,	,	O	O	O
however	however	RB	B-ADVP	O	O
.	.	.	O	O	O

Such	Such	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
most	most	RBS	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
situations	situation	NNS	B-NP	O	O
where	where	WRB	B-ADVP	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
existing	exist	VBG	I-NP	O	O
contralateral	contralateral	JJ	I-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
therefore	therefore	RB	B-ADVP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
on	on	IN	B-PP	O	O
vocal	vocal	JJ	B-NP	O	O
cord	cord	NN	I-NP	O	O
function	function	NN	I-NP	O	O
to	to	TO	B-VP	O	O
better	well	RBR	I-VP	O	O
understand	understand	VB	I-VP	O	O
its	its	PRP$	B-NP	O	O
possible	possible	JJ	I-NP	O	O
consequences	consequence	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
prospective	prospective	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
included	include	VBD	B-VP	O	O
28	28	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
carotid	carotid	NN	B-NP	O	O
endarterectomy	endarterectomy	NN	I-NP	O	O
under	under	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
.	.	.	O	O	O

Vocal	Vocal	JJ	B-NP	O	O
cord	cord	NN	I-NP	O	O
function	function	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
before	before	IN	B-ADVP	O	O
,	,	,	O	O	O
during	during	IN	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
after	after	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
(	(	(	O	O	O
postoperative	postoperative	JJ	B-NP	O	O
day	day	NN	I-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
using	use	VBG	B-VP	O	O
flexible	flexible	JJ	B-NP	O	O
laryngoscopy	laryngoscopy	NN	I-NP	O	O
.	.	.	O	O	O

Anesthesia	Anesthesia	NNP	B-NP	O	O
was	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
injecting	inject	VBG	B-VP	O	O
20	20	CD	B-NP	O	O
to	to	TO	I-NP	O	O
40	40	CD	I-NP	O	O
mL	mL	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mixture	mixture	NN	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	O	O	O
-	-	HYPH	O	O	O
acting	act	VBG	B-VP	O	O
(	(	(	O	O	O
ropivacaine	ropivacaine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
short	short	JJ	B-ADJP	O	O
-	-	HYPH	O	O	O
acting	act	VBG	B-VP	O	O
(	(	(	O	O	O
prilocaine	prilocaine	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
anesthetic	anesthetic	JJ	B-ADJP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
normal	normal	JJ	B-NP	O	O
vocal	vocal	JJ	I-NP	O	O
cord	cord	NN	I-NP	O	O
function	function	NN	I-NP	O	O
preoperatively	preoperatively	RB	B-ADVP	O	O
.	.	.	O	O	O

Twelve	Twelve	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
intraoperative	intraoperative	JJ	B-NP	O	O
ipsilateral	ipsilateral	JJ	I-NP	O	O
vocal	vocal	JJ	I-NP	O	B-Disease
cord	cord	NN	I-NP	O	I-Disease
paralysis	paralysis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
resolved	resolve	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
cases	case	NNS	I-NP	O	O
<	<	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
24	24	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
operating	operating	NN	B-NP	O	O
time	time	NN	I-NP	O	O
or	or	CC	O	O	O
volume	volume	NN	B-NP	O	O
or	or	CC	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
anesthetic	anesthetic	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
temporary	temporary	JJ	B-NP	O	O
vocal	vocal	JJ	I-NP	O	B-Disease
cord	cord	NN	I-NP	O	I-Disease
paralysis	paralysis	NN	I-NP	O	I-Disease
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
those	those	DT	B-NP	O	O
without	without	IN	B-PP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Local	Local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
temporary	temporary	JJ	B-NP	O	O
ipsilateral	ipsilateral	JJ	I-NP	O	O
vocal	vocal	JJ	I-NP	O	B-Disease
cord	cord	NN	I-NP	O	I-Disease
paralysis	paralysis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
almost	almost	RB	B-NP	O	O
half	half	NN	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	B-PP	O	O
existing	exist	VBG	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
relevant	relevant	JJ	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
(	(	(	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
3	3	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
preoperative	preoperative	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
vocal	vocal	JJ	B-NP	O	O
cord	cord	NN	I-NP	O	O
function	function	NN	I-NP	O	O
before	before	IN	B-PP	O	O
carotid	carotid	NN	B-NP	O	O
endarterectomy	endarterectomy	NN	I-NP	O	O
under	under	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
recommended	recommend	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
avoid	avoid	VB	I-VP	O	O
intraoperative	intraoperative	JJ	B-NP	O	O
bilateral	bilateral	JJ	I-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
preoperative	preoperative	JJ	B-NP	O	O
contralateral	contralateral	JJ	I-NP	O	O
vocal	vocal	JJ	I-NP	O	B-Disease
cord	cord	NN	I-NP	O	I-Disease
paralysis	paralysis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
surgery	surgery	NN	B-NP	O	O
under	under	IN	B-PP	O	O
general	general	JJ	B-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Neuroprotective	Neuroprotective	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
melatonin	melatonin	NN	B-NP	B	B-Chemical
upon	upon	IN	B-PP	O	O
the	the	DT	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
cerebellar	cerebellar	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cortical	cortical	JJ	I-NP	O	B-Disease
dysplasia	dysplasia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Cortical	Cortical	JJ	B-NP	O	B-Disease
dysplasia	dysplasia	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
malformation	malformation	NN	I-NP	O	O
characterized	characterize	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
defects	defect	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
proliferation	proliferation	NN	B-NP	O	O
,	,	,	I-NP	O	O
migration	migration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
maturation	maturation	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
designed	design	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
offspring	offspre	VBG	B-VP	O	O
rat	rat	NN	B-NP	O	O
cerebellum	cerebellum	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
maternal	maternal	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
carmustine	carmustine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
[	[	(	B-NP	O	O
1,3	1,3	CD	I-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
bis	bis	NN	I-NP	O	I-Chemical
(	(	(	O	O	I-Chemical
2	2	CD	B-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
chloroethyl	chloroethyl	NN	I-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
-	-	HYPH	B-NP	O	I-Chemical
1	1	CD	I-NP	O	I-Chemical
-	-	HYPH	I-NP	O	I-Chemical
nitrosoure	nitrosoure	NN	I-NP	O	I-Chemical
]	]	)	O	O	O
(	(	(	O	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
exogenous	exogenous	JJ	B-NP	O	O
melatonin	melatonin	NN	I-NP	B	B-Chemical
upon	upon	IN	B-PP	O	O
cerebellar	cerebellar	JJ	B-NP	O	O
BCNU	BCNU	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cortical	cortical	JJ	I-NP	O	B-Disease
dysplasia	dysplasia	NN	I-NP	O	I-Disease
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
histological	histological	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
analyses	analysis	NNS	I-NP	O	O
.	.	.	O	O	O

Pregnant	Pregnant	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
assigned	assign	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
five	five	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
intact	intact	JJ	B-ADJP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
,	,	,	O	O	O
saline	saline	NN	B-NP	B	O
-	-	HYPH	O	O	O
control	control	NN	B-NP	O	O
,	,	,	O	O	O
melatonin	melatonin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-VP	O	O
,	,	,	O	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
exposed	expose	VBN	B-VP	O	O
and	and	CC	O	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
exposed	expose	VBN	B-VP	O	O
plus	plus	CC	O	O	O
melatonin	melatonin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Rats	Rat	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
embryonic	embryonic	JJ	B-NP	O	O
day	day	NN	I-NP	O	O
15	15	CD	I-NP	O	O
and	and	CC	O	O	O
melatonin	melatonin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
until	until	IN	B-PP	O	O
delivery	delivery	NN	B-NP	O	O
.	.	.	O	O	O

Immuno	Immuno	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
histochemistry	histochemistry	NN	I-NP	O	O
and	and	CC	I-NP	O	O
electron	electron	NN	I-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
offspring	offspring	NN	I-NP	O	O
cerebellum	cerebellum	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
levels	level	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
malondialdehyde	malondialdehyde	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
superoxide	superoxide	NN	I-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Histopathologically	Histopathologically	RB	B-ADVP	O	O
,	,	,	O	O	O
typical	typical	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerebella	cerebella	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
embryonic	embryonic	JJ	I-NP	O	O
development	development	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
exposed	expose	VBN	B-NP	O	O
cortical	cortical	JJ	I-NP	O	B-Disease
dysplasia	dysplasia	NN	I-NP	O	I-Disease
group	group	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
marked	marked	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
TUNEL	TUNEL	NN	B-NP	O	O
positive	positive	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
and	and	CC	O	O	O
nestin	nestin	NN	B-NP	O	O
positive	positive	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
immunoreactivity	immunoreactivity	NN	I-NP	O	O
to	to	TO	B-PP	O	O
glial	glial	JJ	B-NP	O	O
fibrillary	fibrillary	JJ	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
,	,	,	O	O	O
synaptophysin	synaptophysin	NN	B-NP	O	O
and	and	CC	O	O	O
transforming	transform	VBG	B-NP	O	O
growth	growth	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
beta1	beta1	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
delayed	delay	VBN	I-NP	O	O
maturation	maturation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
melatonin	melatonin	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
reversed	reverse	VBD	B-VP	O	O
these	these	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
.	.	.	O	O	O

Malondialdehyde	Malondialdehyde	NN	B-NP	B	B-Chemical
level	level	NN	I-NP	O	O
in	in	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
exposed	expose	VBN	I-NP	O	O
group	group	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
groups	group	NNS	I-NP	O	O
and	and	CC	O	O	O
melatonin	melatonin	NN	B-NP	B	B-Chemical
decreased	decrease	VBD	B-VP	O	O
malondialdehyde	malondialdehyde	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
group	group	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
superoxide	superoxide	NN	I-NP	B	B-Chemical
dismutase	dismutase	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
between	between	IN	B-PP	O	O
these	these	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
exposure	exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
during	during	IN	B-PP	O	O
pregnancy	pregnancy	NN	B-NP	O	O
leads	lead	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
delayed	delay	VBN	B-NP	O	O
maturation	maturation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
offspring	offspring	NN	B-NP	O	O
cerebellum	cerebellum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
melatonin	melatonin	NN	I-NP	B	B-Chemical
protects	protect	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
cerebellum	cerebellum	NN	I-NP	O	O
against	against	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Myo	Myo	AFX	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
inositol	inositol	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
1	1	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
phosphate	phosphate	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
MIP	MIP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
synthase	synthase	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
:	:	:	O	O	O
in	in	FW	B-PP	O	O
-	-	HYPH	B-NP	O	O
vivo	vivo	FW	I-NP	O	O
study	study	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
valproate	valproate	NN	I-NP	B	B-Chemical
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
prototypic	prototypic	JJ	I-NP	O	O
mood	mood	NN	I-NP	O	O
stabilizers	stabilizer	NNS	I-NP	O	O
and	and	CC	O	O	O
have	have	VBP	B-VP	O	O
diverse	diverse	JJ	B-NP	O	O
structures	structure	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
targets	target	NNS	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
influence	influence	VBP	B-VP	O	O
inositol	inositol	NN	B-NP	B	B-Chemical
metabolism	metabolism	NN	I-NP	O	O
.	.	.	O	O	O

Lithium	Lithium	NN	B-NP	B	B-Chemical
inhibits	inhibit	VBZ	B-VP	O	O
IMPase	IMPase	NN	B-NP	O	O
and	and	CC	I-NP	O	O
valproate	valproate	NN	I-NP	B	B-Chemical
inhibits	inhibit	VBZ	B-VP	O	O
MIP	MIP	NN	B-NP	B	B-Chemical
synthase	synthase	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
shows	show	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
MIP	MIP	NN	B-NP	B	B-Chemical
synthase	synthase	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
replicate	replicate	VB	I-VP	O	O
or	or	CC	I-VP	O	O
augment	augment	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inositol	inositol	NN	I-NP	B	B-Chemical
sensitive	sensitive	JJ	I-NP	O	O
pilocarpine	pilocarpine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
seizures	seizure	NNS	I-NP	O	B-Disease
model	model	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
effects	effect	NNS	B-NP	O	O
may	may	MD	B-VP	O	O
stem	stem	VB	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
contribution	contribution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
de	de	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
novo	novo	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cellular	cellular	JJ	B-NP	O	O
inositol	inositol	NN	I-NP	B	B-Chemical
supply	supply	NN	I-NP	O	O
or	or	CC	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
de	de	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
novo	novo	NN	I-NP	O	O
synthesis	synthesis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
itself	itself	PRP	B-NP	O	O
.	.	.	O	O	O

Non	Non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-VP	O	O
acute	acute	JJ	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	B-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
granular	granular	JJ	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
basement	basement	NN	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
deposits	deposit	NNS	I-NP	O	O
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	B-Disease
tubulo	tubulo	AFX	I-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
interstitial	interstitial	JJ	I-NP	O	I-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ATIN	ATIN	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
resulting	result	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
insults	insult	NNS	B-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
immune	immune	JJ	B-NP	O	O
complex	complex	NN	I-NP	O	O
-	-	HYPH	O	O	O
mediated	mediate	VBN	B-VP	O	O
tubulo	tubulo	AFX	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
interstitial	interstitial	JJ	B-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
drugs	drug	NNS	B-NP	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
steroidal	steroidal	JJ	I-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
drugs	drug	NNS	I-NP	O	O
(	(	(	O	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
a	a	DT	O	O	O
far	far	RB	B-ADVP	O	O
more	more	RBR	I-ADVP	O	O
frequent	frequent	JJ	B-NP	O	O
cause	cause	NN	I-NP	O	O
.	.	.	O	O	O

Overall	Overall	RB	B-ADVP	O	O
,	,	,	O	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
entity	entity	NN	I-NP	O	O
,	,	,	O	O	O
ATIN	ATIN	NN	B-NP	O	B-Disease
remains	remain	VBZ	B-VP	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
diagnosed	diagnose	VBN	I-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
symptoms	symptom	NNS	B-NP	O	O
resolve	resolve	VBP	B-VP	O	O
spontaneously	spontaneously	RB	B-ADVP	O	O
if	if	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
medication	medication	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
stopped	stop	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
on	on	IN	B-PP	O	O
a	a	DT	B-NP	O	O
14	14	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
boy	boy	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
aortic	aortic	JJ	B-NP	O	O
valve	valve	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
put	put	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
following	follow	VBG	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
and	and	CC	O	O	O
took	take	VBD	B-VP	O	O
ibuprofen	ibuprofen	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
fever	fever	NN	B-NP	O	B-Disease
for	for	IN	B-PP	O	O
nearly	nearly	RB	B-NP	O	O
a	a	DT	I-NP	O	O
week	week	NN	I-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
presentation	presentation	NN	B-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
then	then	RB	B-ADVP	O	O
presented	present	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
department	department	NN	I-NP	O	O
feeling	feel	VBG	B-VP	O	O
quite	quite	RB	B-ADVP	O	O
ill	ill	RB	I-ADVP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
blood	blood	NN	I-NP	O	B-Chemical
urea	urea	NN	I-NP	B	I-Chemical
nitrogen	nitrogen	NN	I-NP	B	I-Chemical
(	(	(	O	O	O
BUN	BUN	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
concentration	concentration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
of	of	IN	B-PP	O	O
147	147	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
dl	dl	NN	B-NP	O	O
,	,	,	O	O	O
creatinine	creatinine	NN	B-NP	B	B-Chemical
of	of	IN	B-PP	O	O
15.3	15.3	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	B-NP	O	O
and	and	CC	I-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
of	of	IN	B-PP	O	O
8.7	8.7	CD	B-NP	O	O
mEq	mEq	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
l	l	NN	I-NP	O	O
.	.	.	O	O	O

Dialysis	Dialysis	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
immediately	immediately	RB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
biopsy	biopsy	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
infiltrate	infiltrate	NN	I-NP	O	O
consistent	consistent	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
ATIN	ATIN	NN	B-NP	O	B-Disease
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
tubular	tubular	JJ	I-NP	O	O
basement	basement	NN	I-NP	O	O
membrane	membrane	NN	I-NP	O	O
(	(	(	O	O	O
TBM	TBM	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
very	very	RB	B-NP	O	O
intense	intense	JJ	I-NP	O	O
granular	granular	JJ	I-NP	O	O
deposits	deposit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
polyclonal	polyclonal	JJ	B-NP	O	O
IgG	IgG	NN	I-NP	O	O
and	and	CC	I-NP	O	O
C3	C3	NN	I-NP	B	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
needed	need	VBD	B-VP	O	O
dialysis	dialysis	NN	B-NP	O	O
for	for	IN	B-PP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
successfully	successfully	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
steroids	steroid	NNS	B-NP	O	B-Chemical
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

His	His	PRP$	B-NP	O	O
renal	renal	JJ	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
and	and	CC	I-NP	O	O
disappearance	disappearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
took	take	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
year	year	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
report	report	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NSAIDs	NSAID	NNS	B-NP	O	O
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
ATIN	ATIN	NN	I-NP	O	B-Disease
,	,	,	O	O	O
showing	show	VBG	B-VP	O	O
deposits	deposit	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
granular	granular	JJ	B-NP	O	O
immune	immune	JJ	I-NP	O	O
complex	complex	NN	I-NP	O	O
present	present	VBP	B-VP	O	O
only	only	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
TBM	TBM	NN	I-NP	B	O
and	and	CC	B-PP	O	O
not	not	RB	B-PP	O	O
in	in	IN	I-PP	O	O
the	the	DT	B-NP	O	O
glomeruli	glomerulus	NNS	I-NP	O	O
.	.	.	O	O	O

Rifampicin	Rifampicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
associated	associate	VBN	B-NP	O	O
segmental	segmental	JJ	I-NP	O	O
necrotizing	necrotize	VBG	I-NP	O	O
glomerulonephritis	glomerulonephritis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
staphylococcal	staphylococcal	JJ	B-NP	O	B-Disease
endocarditis	endocarditis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Segmental	Segmental	JJ	B-NP	O	O
necrotising	necrotising	NN	I-NP	O	O
glomerulonephritis	glomerulonephritis	NN	I-NP	O	B-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
complication	complication	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
tuberculosis	tuberculosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Changing	Change	VBG	B-VP	O	O
epidemiology	epidemiology	NN	B-NP	O	O
of	of	IN	B-PP	O	O
infections	infection	NNS	B-NP	O	B-Disease
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
infective	infective	JJ	B-NP	O	B-Disease
endocarditis	endocarditis	NN	I-NP	O	I-Disease
(	(	(	O	O	O
IE	IE	NN	B-NP	O	B-Disease
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
led	lead	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
Staphylococcal	Staphylococcal	JJ	B-NP	O	B-Disease
infections	infection	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Staphylococcal	Staphylococcal	JJ	B-NP	O	B-Disease
IE	IE	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
segmental	segmental	JJ	I-NP	O	O
necrotising	necrotise	VBG	I-NP	O	O
glomerulonephritis	glomerulonephritis	NN	I-NP	O	B-Disease
while	while	IN	B-SBAR	O	O
being	be	VBG	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
review	review	VB	B-VP	O	O
the	the	DT	B-NP	O	O
literature	literature	NN	I-NP	O	O
regarding	regard	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rifampicin	rifampicin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Rate	Rate	NN	B-NP	O	O
of	of	IN	B-PP	O	O
YMDD	YMDD	NN	B-NP	O	O
motif	motif	NN	I-NP	O	O
mutants	mutant	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
untreated	untreated	JJ	I-NP	O	O
Iranian	Iranian	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	I-Disease
infection	infection	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Lamivudine	Lamivudine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Recent	Recent	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
YMDD	YMDD	NN	I-NP	O	O
motif	motif	NN	I-NP	O	O
mutants	mutant	NNS	I-NP	O	O
(	(	(	O	O	O
resistant	resistant	JJ	B-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
B	B	NN	I-NP	O	I-Disease
virus	virus	NN	I-NP	O	O
)	)	)	O	O	O
occur	occur	VBP	B-VP	O	O
as	as	IN	B-PP	O	O
natural	natural	JJ	B-NP	O	O
genome	genome	NN	I-NP	O	O
variability	variability	NN	I-NP	O	O
in	in	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
untreated	untreated	JJ	I-NP	O	O
chronic	chronic	JJ	I-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
YMDD	YMDD	NN	B-NP	O	O
motif	motif	NN	I-NP	O	O
mutants	mutant	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
untreated	untreated	JJ	I-NP	O	O
chronic	chronic	JJ	I-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
Iran	Iran	NNP	B-NP	O	O
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
77	77	CD	B-NP	O	O
chronic	chronic	JJ	I-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Serum	Serum	NN	B-NP	O	O
samples	sample	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
polymerase	polymerase	NN	B-NP	O	O
chain	chain	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
restriction	restriction	NN	I-NP	O	O
fragment	fragment	NN	I-NP	O	O
length	length	NN	I-NP	O	O
polymorphism	polymorphism	NN	I-NP	O	O
(	(	(	O	O	O
PCR	PCR	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
RFLP	RFLP	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
detection	detection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
YMDD	YMDD	NN	B-NP	O	O
motif	motif	NN	I-NP	O	O
mutants	mutant	NNS	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
tested	test	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
enzymes	enzyme	NNS	I-NP	O	O
,	,	,	O	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
HCV	HCV	NN	B-NP	O	O
,	,	,	O	O	O
HBeAg	HBeAg	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
HBe	HBe	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Of	Of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
77	77	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
enrolled	enrol	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
73	73	CD	B-NP	O	O
%	%	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
male	male	JJ	B-ADJP	O	O
and	and	CC	O	O	O
27	27	CD	B-NP	O	O
%	%	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
female	female	JJ	B-ADJP	O	O
.	.	.	O	O	O

Mean	Mean	JJ	B-NP	O	O
ALT	ALT	NN	I-NP	O	O
and	and	CC	I-NP	O	O
AST	AST	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
124.4	124.4	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
73.4	73.4	CD	B-NP	O	O
and	and	CC	I-NP	O	O
103.1	103.1	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
81	81	CD	B-NP	O	O
IU	IU	NN	I-NP	O	O
/	/	SYM	O	O	O
l	l	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

HBeAg	HBeAg	NN	B-NP	O	B-Chemical
was	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
HBe	HBe	NN	I-NP	O	O
in	in	IN	B-PP	O	O
60	60	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Anti	Anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
HCV	HCV	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
negative	negative	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
all	all	DT	B-NP	O	O
of	of	IN	B-PP	O	O
them	them	PRP	B-NP	O	O
.	.	.	O	O	O

YMDD	YMDD	NN	B-NP	O	O
motif	motif	NN	I-NP	O	O
mutants	mutant	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
despite	despite	IN	B-PP	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
enzyme	enzyme	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HBeAg	HBeAg	NN	B-NP	O	B-Chemical
or	or	CC	O	O	O
anti	anti	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
HBe	HBe	NN	B-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
natural	natural	JJ	I-NP	O	O
occurrence	occurrence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
YMDD	YMDD	NN	B-NP	O	O
motif	motif	NN	I-NP	O	O
mutants	mutant	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
lamivudine	lamivudine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
untreated	untreated	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
mutants	mutant	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
detected	detect	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Iranian	Iranian	JJ	B-NP	O	O
lamivudine	lamivudine	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
untreated	untreated	JJ	I-NP	O	O
chronic	chronic	JJ	I-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
B	B	NN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Branch	Branch	NN	B-NP	O	O
retinal	retinal	JJ	I-NP	O	B-Disease
vein	vein	NN	I-NP	O	I-Disease
occlusion	occlusion	NN	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
fluoxetine	fluoxetine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
branch	branch	NN	B-NP	O	O
retinal	retinal	NN	I-NP	O	B-Disease
vein	vein	NN	I-NP	O	I-Disease
occlusion	occlusion	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fluoxetine	fluoxetine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
secondary	secondary	JJ	I-NP	O	O
hypertension	hypertension	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
described	describe	VBN	I-VP	O	O
.	.	.	O	O	O

Although	Although	IN	B-SBAR	O	O
an	an	DT	B-NP	O	O
infrequent	infrequent	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
selective	selective	JJ	B-NP	O	O
serotonin	serotonin	NN	I-NP	B	B-Chemical
reuptake	reuptake	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
important	important	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
ophthalmologists	ophthalmologist	NNS	B-NP	O	O
are	be	VBP	B-VP	O	O
aware	aware	JJ	B-ADJP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
agents	agent	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
hypertension	hypertension	NN	B-NP	O	B-Disease
because	because	IN	B-SBAR	O	O
this	this	DT	B-NP	O	O
class	class	NN	I-NP	O	O
of	of	IN	B-PP	O	O
drugs	drug	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
widely	widely	RB	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
differential	differential	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
on	on	IN	B-PP	O	O
prostaglandin	prostaglandin	NN	B-NP	B	B-Chemical
E2	E2	NN	I-NP	I	I-Chemical
release	release	NN	I-NP	O	O
,	,	,	O	O	O
cyclooxygenase	cyclooxygenase	NN	B-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
and	and	CC	O	O	O
pain	pain	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
model	model	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
blocking	block	VBG	B-VP	O	O
nociceptive	nociceptive	JJ	B-NP	O	O
input	input	NN	I-NP	O	O
from	from	IN	B-PP	O	O
surgical	surgical	JJ	B-NP	O	O
sites	site	NNS	I-NP	O	O
,	,	,	O	O	O
long	long	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
acting	act	VBG	B-VP	O	O
local	local	JJ	B-NP	O	O
anesthetics	anesthetic	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
directly	directly	RB	I-VP	O	O
modulate	modulate	VB	I-VP	O	O
inflammation	inflammation	NN	B-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
describe	describe	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
proinflammatory	proinflammatory	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
local	local	JJ	B-NP	O	O
prostaglandin	prostaglandin	NN	I-NP	B	B-Chemical
E2	E2	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
PGE2	PGE2	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
production	production	NN	B-NP	O	O
and	and	CC	O	O	O
cyclooxygenase	cyclooxygenase	NN	B-NP	O	O
(	(	(	O	O	O
COX	COX	NN	B-NP	B	O
)	)	)	O	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
increases	increase	VBZ	B-VP	O	O
postoperative	postoperative	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
subjects	subject	NNS	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Subjects	Subject	NNS	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
114	114	CD	B-NP	O	O
)	)	)	O	O	O
undergoing	undergo	VBG	B-VP	O	O
extraction	extraction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
impacted	impacted	JJ	B-NP	O	O
third	third	JJ	I-NP	O	O
molars	molar	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
either	either	CC	O	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
or	or	CC	O	O	O
0.5	0.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
before	before	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
and	and	CC	O	O	O
either	either	CC	O	O	O
rofecoxib	rofecoxib	NN	B-NP	B	B-Chemical
50	50	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
or	or	CC	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
orally	orally	RB	B-NP	O	O
90	90	CD	I-NP	O	O
min	min	NN	I-NP	O	O
before	before	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
and	and	CC	B-PP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
48	48	CD	I-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
mucosal	mucosal	JJ	I-NP	O	O
biopsies	biopsy	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
and	and	CC	O	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
extraction	extraction	NN	B-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
microdialysis	microdialysis	NN	I-NP	O	O
probe	probe	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
placed	place	VBN	I-VP	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
site	site	NN	I-NP	O	O
for	for	IN	B-PP	O	O
PGE2	PGE2	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
thromboxane	thromboxane	NN	B-NP	B	B-Chemical
B2	B2	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
TXB2	TXB2	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
measurements	measurement	NNS	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
/	/	SYM	B-NP	O	O
rofecoxib	rofecoxib	NN	I-NP	B	B-Chemical
group	group	NN	I-NP	O	O
reported	report	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
less	less	JJR	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
assessed	assess	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	O
analog	analog	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
,	,	,	O	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
three	three	CD	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
4	4	CD	I-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
/	/	SYM	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
group	group	NN	I-NP	O	O
reported	report	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
more	more	JJR	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
at	at	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
and	and	CC	I-NP	O	O
PGE2	PGE2	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
4	4	CD	I-NP	O	O
h	h	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
three	three	CD	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
COX	COX	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
at	at	IN	B-PP	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
as	as	IN	B-PP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lidocaine	lidocaine	NN	I-NP	B	B-Chemical
/	/	SYM	I-NP	O	O
placebo	placebo	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Thromboxane	Thromboxane	NN	B-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
significantly	significantly	RB	I-VP	O	O
affected	affect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
any	any	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatments	treatment	NNS	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
were	be	VBD	B-VP	O	O
attributable	attributable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
inhibition	inhibition	NN	B-NP	O	O
of	of	IN	B-PP	O	O
COX	COX	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
not	not	RB	O	O	O
COX	COX	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
bupivacaine	bupivacaine	NN	B-NP	B	B-Chemical
stimulates	stimulate	VBZ	B-VP	O	O
COX	COX	NN	B-NP	B	O
-	-	HYPH	I-NP	O	O
2	2	CD	I-NP	O	O
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
after	after	IN	B-PP	O	O
tissue	tissue	NN	B-NP	O	B-Disease
injury	injury	NN	I-NP	O	I-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
PGE2	PGE2	NN	I-NP	B	B-Chemical
production	production	NN	I-NP	O	O
and	and	CC	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
local	local	JJ	I-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
dissipates	dissipate	NNS	I-NP	O	O
.	.	.	O	O	O

p75NTR	p75NTR	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
bladder	bladder	NN	I-NP	O	O
sensory	sensory	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
and	and	CC	O	O	O
spinal	spinal	JJ	B-NP	O	O
cord	cord	NN	I-NP	O	O
with	with	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

A	A	DT	B-NP	O	O
role	role	NN	I-NP	O	O
for	for	IN	B-PP	O	O
nerve	nerve	NN	B-NP	B	O
growth	growth	NN	I-NP	I	O
factor	factor	NN	I-NP	I	O
(	(	(	O	O	O
NGF	NGF	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
contributing	contribute	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
increased	increase	VBN	B-NP	O	O
voiding	void	VBG	I-NP	O	O
frequency	frequency	NN	I-NP	O	O
and	and	CC	O	O	O
altered	altered	JJ	B-NP	O	O
sensation	sensation	NN	I-NP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
urinary	urinary	JJ	I-NP	O	O
bladder	bladder	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
.	.	.	O	O	O

Previous	Previous	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
examined	examine	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	B-NP	O	O
and	and	CC	O	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tyrosine	tyrosine	NN	B-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
(	(	(	O	O	O
Trks	Trk	NNS	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
micturition	micturition	NN	B-NP	O	O
reflexes	reflex	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
urinary	urinary	JJ	B-NP	O	B-Disease
bladder	bladder	NN	I-NP	O	I-Disease
inflammation	inflammation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
studies	study	NNS	I-NP	O	O
examine	examine	VBP	B-VP	O	O
the	the	DT	O	O	O
expression	expression	NN	B-NP	O	O
and	and	CC	O	O	O
regulation	regulation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
another	another	DT	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
known	know	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
bind	bind	VB	I-VP	O	O
NGF	NGF	NN	B-NP	O	O
,	,	,	O	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
after	after	IN	B-PP	O	O
various	various	JJ	B-NP	O	O
durations	duration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	B-Disease
inflammation	inflammation	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
cyclophosphamide	cyclophosphamide	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

CYP	CYP	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
increased	increase	VBD	B-VP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
expression	expression	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
superficial	superficial	JJ	I-NP	O	O
lateral	lateral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
medial	medial	JJ	I-NP	O	O
dorsal	dorsal	JJ	I-NP	O	O
horn	horn	NN	I-NP	O	O
in	in	IN	B-PP	O	O
L1	L1	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
L2	L2	NN	I-NP	B	O
and	and	CC	I-NP	O	O
L6	L6	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
S1	S1	NN	I-NP	B	O
spinal	spinal	JJ	I-NP	O	O
segments	segment	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	O	O	O
immunoreactive	immunoreactive	JJ	B-ADJP	O	O
(	(	(	O	O	O
-	-	HYPH	B-NP	O	O
IR	IR	NN	I-NP	O	O
)	)	)	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lumbosacral	lumbosacral	JJ	I-NP	O	O
dorsal	dorsal	JJ	I-NP	O	O
root	root	NN	I-NP	O	O
ganglia	ganglia	NNS	I-NP	O	O
(	(	(	O	O	O
DRG	DRG	NN	B-NP	O	O
)	)	)	O	O	O
also	also	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
CYP	CYP	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
(	(	(	O	O	O
acute	acute	JJ	B-ADJP	O	O
,	,	,	O	O	O
intermediate	intermediate	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
chronic	chronic	JJ	B-ADJP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Quantitative	Quantitative	JJ	B-NP	O	O
,	,	,	I-NP	O	O
real	real	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
time	time	NN	I-NP	O	O
polymerase	polymerase	NN	I-NP	O	O
chain	chain	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
also	also	RB	B-ADVP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
increases	increase	NNS	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
mRNA	mRNA	NN	B-NP	O	O
in	in	IN	B-PP	O	O
DRG	DRG	NN	B-NP	O	O
with	with	IN	B-PP	O	O
intermediate	intermediate	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
chronic	chronic	JJ	I-NP	O	O
CYP	CYP	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cystitis	cystitis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Retrograde	Retrograde	NN	B-NP	O	O
dye	dye	NN	I-NP	O	O
-	-	HYPH	O	O	O
tracing	trace	VBG	B-VP	O	O
techniques	technique	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Fastblue	Fastblue	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
presumptive	presumptive	JJ	B-NP	O	O
bladder	bladder	NN	I-NP	O	O
afferent	afferent	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lumbosacral	lumbosacral	JJ	I-NP	O	O
DRG	DRG	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	O
afferent	afferent	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
DRG	DRG	NN	B-NP	O	O
,	,	,	O	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
IR	IR	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
cystitis	cystitis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
increases	increase	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
IR	IR	NN	I-NP	O	O
in	in	IN	B-PP	O	O
DRG	DRG	NN	B-NP	O	O
cell	cell	NN	I-NP	O	O
bodies	body	NNS	I-NP	O	O
,	,	,	O	O	O
increases	increase	NNS	B-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
pericellular	pericellular	JJ	B-ADJP	O	O
(	(	(	O	O	O
encircling	encircle	VBG	B-VP	O	O
DRG	DRG	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
)	)	)	O	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
IR	IR	NN	I-NP	O	O
in	in	IN	B-PP	O	O
DRG	DRG	NN	B-NP	O	O
also	also	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
.	.	.	O	O	O

Confocal	Confocal	JJ	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
pericellular	pericellular	JJ	B-NP	O	O
p75	p75	NN	I-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
IR	IR	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
colocalized	colocalize	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
glial	glial	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
,	,	,	O	O	O
glial	glial	JJ	B-NP	O	O
fibrillary	fibrillary	JJ	I-NP	O	O
acidic	acidic	JJ	I-NP	O	O
protein	protein	NN	I-NP	O	O
(	(	(	O	O	O
GFAP	GFAP	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
expression	expression	NN	B-NP	O	O
in	in	IN	B-PP	O	O
micturition	micturition	NN	B-NP	O	O
reflexes	reflex	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
present	present	JJ	B-ADJP	O	O
constitutively	constitutively	RB	B-ADVP	O	O
and	and	CC	O	O	O
modified	modify	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
bladder	bladder	NN	B-NP	O	B-Disease
inflammation	inflammation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
functional	functional	JJ	I-NP	O	O
significance	significance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
p75	p75	NN	B-NP	B	O
(	(	(	O	O	O
NTR	NTR	NN	B-NP	O	O
)	)	)	O	O	O
expression	expression	NN	B-NP	O	O
in	in	IN	B-PP	O	O
micturition	micturition	NN	B-NP	O	O
reflexes	reflex	NNS	I-NP	O	O
remains	remain	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Azathioprine	Azathioprine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
suicidal	suicidal	JJ	I-NP	O	O
erythrocyte	erythrocyte	NN	I-NP	O	O
death	death	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Azathioprine	Azathioprine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
widely	widely	RB	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
side	side	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
include	include	VBP	B-VP	O	O
anemia	anemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
attributed	attribute	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
bone	bone	NN	B-NP	O	O
marrow	marrow	NN	I-NP	O	O
suppression	suppression	NN	I-NP	O	O
.	.	.	O	O	O

Alternatively	Alternatively	RB	B-ADVP	O	O
,	,	,	O	O	O
anemia	anemia	NN	B-NP	O	B-Disease
could	could	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
accelerated	accelerate	VBN	B-NP	B	O
suicidal	suicidal	JJ	I-NP	O	O
erythrocyte	erythrocyte	NN	I-NP	O	O
death	death	NN	I-NP	O	O
or	or	CC	I-NP	O	O
eryptosis	eryptosis	NN	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
exposure	exposure	NN	B-NP	O	O
of	of	IN	B-PP	O	O
phosphatidylserine	phosphatidylserine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PS	PS	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
at	at	IN	B-PP	O	O
the	the	DT	B-NP	O	O
erythrocyte	erythrocyte	NN	I-NP	O	O
surface	surface	NN	I-NP	O	O
and	and	CC	B-PP	O	O
by	by	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
shrinkage	shrinkage	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
experiments	experiment	NNS	I-NP	O	O
explored	explore	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
influences	influence	VBZ	B-VP	O	O
eryptosis	eryptosis	NN	B-NP	O	O
.	.	.	O	O	O

According	Accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
annexin	annexin	NN	B-NP	O	O
V	V	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
,	,	,	O	O	O
erythrocytes	erythrocyte	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
indeed	indeed	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PS	PS	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
within	within	IN	B-PP	O	O
1	1	CD	B-NP	O	O
week	week	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
a	a	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
series	series	NN	I-NP	O	O
,	,	,	O	O	O
cytosolic	cytosolic	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	B	B-Chemical
2	2	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
activity	activity	NN	I-NP	O	O
(	(	(	O	O	O
Fluo3	Fluo3	NN	B-NP	O	B-Chemical
fluorescence	fluorescence	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
cell	cell	NN	B-NP	O	O
volume	volume	NN	I-NP	O	O
(	(	(	O	O	O
forward	forward	JJ	B-NP	O	O
scatter	scatter	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
PS	PS	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
exposure	exposure	NN	B-NP	O	O
(	(	(	O	O	O
annexin	annexin	NN	B-NP	O	O
V	V	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
FACS	FACS	NN	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
in	in	IN	B-PP	O	O
erythrocytes	erythrocyte	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
healthy	healthy	JJ	B-NP	O	O
volunteers	volunteer	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Exposure	Exposure	NN	B-NP	O	O
to	to	TO	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
48	48	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
cytosolic	cytosolic	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	B	B-Chemical
2	2	CD	I-NP	O	O
+	+	SYM	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
annexin	annexin	NN	I-NP	O	O
V	V	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
forward	forward	RB	B-ADJP	O	O
scatter	scatt	JJR	I-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
both	both	CC	O	O	O
annexin	annexin	NN	B-NP	O	O
V	V	NN	I-NP	O	O
binding	binding	NN	I-NP	O	O
and	and	CC	O	O	O
forward	forward	JJ	B-NP	O	O
scatter	scatter	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
blunted	blunt	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
nominal	nominal	JJ	I-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
extracellular	extracellular	JJ	B-NP	O	O
Ca	Ca	NN	I-NP	B	B-Chemical
2	2	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Azathioprine	Azathioprine	NN	B-NP	B	B-Chemical
triggers	trigger	VBZ	B-VP	O	O
suicidal	suicidal	JJ	B-NP	O	O
erythrocyte	erythrocyte	NN	I-NP	O	O
death	death	NN	I-NP	O	O
,	,	,	O	O	O
an	an	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
presumably	presumably	RB	B-VP	O	O
contributing	contribute	VBG	I-VP	O	O
to	to	TO	B-PP	O	O
azathioprine	azathioprine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
comparison	comparison	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiorespiratory	cardiorespiratory	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
unilateral	unilateral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
conventional	conventional	JJ	I-NP	O	O
spinal	spinal	JJ	I-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Spinal	Spinal	JJ	B-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
widely	widely	RB	I-VP	O	O
employed	employ	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
clinical	clinical	JJ	B-NP	O	O
practice	practice	NN	I-NP	O	O
but	but	CC	O	O	O
has	have	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
drawback	drawback	NN	I-NP	O	O
of	of	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
spinal	spinal	JJ	I-NP	O	O
block	block	NN	I-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Efforts	Effort	NNS	B-NP	O	O
must	must	MD	B-VP	O	O
therefore	therefore	RB	I-VP	O	O
continue	continue	VB	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
made	make	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
obviate	obviate	VB	I-VP	O	O
this	this	DT	B-NP	O	O
setback	setback	NN	I-NP	O	O
OBJECTIVE	OBJECTIVE	NN	I-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
evaluate	evaluate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
changes	change	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
unilateral	unilateral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
conventional	conventional	JJ	I-NP	O	O
spinal	spinal	JJ	I-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
With	With	IN	B-PP	O	O
ethical	ethical	JJ	B-NP	O	O
approval	approval	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
74	74	CD	B-NP	O	O
American	American	NNP	I-NP	O	O
Society	Society	NNP	I-NP	O	O
of	of	IN	B-PP	O	O
Anesthesiologists	Anesthesiologist	NNS	B-NP	O	O
(	(	(	O	O	O
ASA	ASA	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
physical	physical	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
class	class	NN	I-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
scheduled	schedule	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
elective	elective	JJ	B-NP	O	O
unilateral	unilateral	JJ	I-NP	O	O
lower	low	JJR	I-NP	O	O
limb	limb	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
allocated	allocate	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
two	two	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
lateral	lateral	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
conventional	conventional	JJ	I-NP	O	O
spinal	spinal	JJ	I-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
position	position	NN	I-NP	O	O
with	with	IN	B-PP	O	O
operative	operative	JJ	B-NP	O	O
side	side	NN	I-NP	O	O
down	down	RP	B-PRT	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
recived	recive	VBD	B-VP	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
(	(	(	O	O	O
2mls	2ml	NNS	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
0.5	0.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
hyperbaric	hyperbaric	JJ	I-NP	O	O
bupivacaine	bupivacaine	NN	I-NP	B	B-Chemical
through	through	IN	B-PP	O	O
a	a	DT	B-NP	O	O
25	25	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
gauge	gauge	NN	I-NP	O	O
spinal	spinal	JJ	I-NP	O	O
needle	needle	NN	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unilateral	unilateral	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
maintained	maintain	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
lateral	lateral	JJ	I-NP	O	O
position	position	NN	I-NP	O	O
for	for	IN	B-PP	O	O
15	15	CD	B-NP	O	O
minutes	minute	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
spinal	spinal	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
while	while	IN	B-SBAR	O	O
those	those	DT	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conventional	conventional	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
turned	turn	VBN	I-VP	O	O
supine	supine	NN	B-NP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
heart	heart	NN	B-NP	O	O
rate	rate	NN	I-NP	O	O
,	,	,	O	O	O
respiratory	respiratory	JJ	B-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
saturation	saturation	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
monitored	monitor	VBN	I-VP	O	O
over	over	IN	B-NP	O	O
1	1	CD	I-NP	O	O
hour	hour	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Three	Three	CD	B-NP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
8.1	8.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unilateral	unilateral	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
and	and	CC	O	O	O
5	5	CD	B-NP	O	O
(	(	(	O	O	O
13.5	13.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conventional	conventional	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.71	0.71	CD	B-NP	O	O
.	.	.	O	O	O

Four	Four	CD	B-NP	O	O
(	(	(	O	O	O
10.8	10.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conventional	conventional	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
and	and	CC	O	O	O
1	1	CD	B-NP	O	O
(	(	(	O	O	O
2.7	2.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
unilateral	unilateral	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.17	0.17	CD	B-NP	O	O
required	require	VBD	B-VP	O	O
epinephrine	epinephrine	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
to	to	TO	B-VP	O	O
treat	treat	VB	I-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
conventional	conventional	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
statistically	statistically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
greater	great	JJR	I-NP	O	O
fall	fall	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
systolic	systolic	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
pressures	pressure	NNS	I-NP	O	O
at	at	IN	B-PP	O	O
15	15	CD	B-NP	O	O
,	,	,	I-NP	O	O
30	30	CD	I-NP	O	O
and	and	CC	I-NP	O	O
45	45	CD	I-NP	O	O
minutes	minute	NNS	I-NP	O	O
when	when	WRB	B-ADVP	O	O
compared	compare	VBN	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
baseline	baseline	NN	I-NP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.003	0.003	CD	B-NP	O	O
,	,	,	O	O	O
0.001	0.001	CD	B-NP	O	O
and	and	CC	I-NP	O	O
0.004	0.004	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
saturations	saturation	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
similar	similar	JJ	B-ADJP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Compared	Compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
,	,	,	O	O	O
unilateral	unilateral	JJ	B-NP	O	O
spinal	spinal	JJ	I-NP	O	O
anaesthesia	anaesthesia	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
fewer	few	JJR	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
perturbations	perturbation	NNS	I-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
spinal	spinal	JJ	B-NP	O	O
block	block	NN	I-NP	O	O
instituted	institute	VBN	B-VP	O	O
affected	affect	VBD	B-VP	O	O
neither	neither	CC	O	O	O
the	the	DT	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	O
rate	rate	NN	I-NP	O	O
nor	nor	CC	O	O	O
the	the	DT	B-NP	O	O
arterial	arterial	JJ	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
saturation	saturation	NN	I-NP	O	O
.	.	.	O	O	O

Spectrum	Spectrum	NN	B-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
generic	generic	JJ	B-NP	O	O
HAART	HAART	NN	I-NP	O	O
in	in	IN	B-PP	O	O
southern	southern	JJ	B-NP	O	O
Indian	Indian	JJ	I-NP	O	O
HIV	HIV	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
infected	infect	VBN	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
clinically	clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
,	,	,	O	O	O
fixed	fix	VBN	B-VP	O	O
-	-	HYPH	B-NP	O	O
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
generic	generic	JJ	B-NP	O	O
highly	highly	RB	I-NP	O	O
active	active	JJ	I-NP	O	O
antiretroviral	antiretroviral	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
HAART	HAART	NN	B-NP	O	O
)	)	)	O	O	O
use	use	NN	B-NP	O	O
among	among	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
-	-	HYPH	O	O	I-Disease
infected	infect	VBN	B-VP	O	I-Disease
individuals	individual	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
South	South	NNP	B-NP	O	O
India	India	NNP	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
3154	3154	CD	B-NP	O	O
HIV	HIV	NN	I-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
infected	infect	VBN	I-NP	O	I-Disease
individuals	individual	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
minimum	minimum	NN	I-NP	O	O
of	of	IN	B-PP	O	O
3	3	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
generic	generic	JJ	B-NP	O	O
HAART	HAART	NN	I-NP	O	O
between	between	IN	B-PP	O	O
February	February	NNP	B-NP	O	O
1996	1996	CD	I-NP	O	O
and	and	CC	O	O	O
December	December	NNP	B-NP	O	O
2006	2006	CD	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tertiary	tertiary	JJ	I-NP	O	O
HIV	HIV	NN	I-NP	O	O
care	care	NN	I-NP	O	O
referral	referral	JJ	I-NP	O	O
center	center	NN	I-NP	O	O
in	in	IN	B-PP	O	O
South	South	NNP	B-NP	O	O
India	India	NNP	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
3TC	3TC	NN	B-NP	B	B-Chemical
+	+	SYM	B-NP	O	O
d4T	d4T	NN	I-NP	B	B-Chemical
+	+	SYM	O	O	O
nevirapine	nevirapine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
NVP	NVP	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
(	(	(	O	O	O
54.8	54.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
zidovudine	zidovudine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
AZT	AZT	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
+	+	SYM	B-NP	O	O
3TC	3TC	NN	I-NP	B	B-Chemical
+	+	SYM	B-NP	O	O
NVP	NVP	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
14.5	14.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
3TC	3TC	NN	B-NP	B	B-Chemical
+	+	SYM	B-NP	O	O
d4T	d4T	NN	I-NP	B	B-Chemical
+	+	SYM	O	O	O
efavirenz	efavirenz	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
EFV	EFV	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
(	(	(	O	O	O
20.1	20.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AZT	AZT	NN	B-NP	B	B-Chemical
+	+	SYM	I-NP	O	O
3TC	3TC	NN	I-NP	B	B-Chemical
+	+	SYM	B-NP	O	O
EFV	EFV	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
5.4	5.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
and	and	CC	O	O	O
median	median	JJ	B-NP	O	O
CD4	CD4	NN	I-NP	O	O
at	at	IN	B-PP	O	O
time	time	NN	B-NP	O	O
of	of	IN	B-PP	O	O
event	event	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
rash	rash	NN	B-NP	O	B-Disease
(	(	(	O	O	O
15.2	15.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
CD4	CD4	NN	B-NP	O	O
,	,	,	O	O	O
285	285	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	O	O	O
microL	microL	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
(	(	(	O	O	O
9.0	9.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
348	348	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	O	O	O
microL	microL	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Clinically	Clinically	RB	B-NP	O	O
significant	significant	JJ	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
hemoglobin	hemoglobin	NN	B-NP	B	O
<	<	SYM	O	O	O
7	7	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
5.4	5.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
CD4	CD4	NN	B-NP	O	O
,	,	,	O	O	O
165	165	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	O	O	O
microL	microL	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
hepatitis	hepatitis	NN	B-NP	O	B-Disease
(	(	(	O	O	O
clinical	clinical	JJ	B-NP	O	O
jaundice	jaundice	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
alanine	alanine	NN	B-NP	B	B-Chemical
aminotransferase	aminotransferase	NN	I-NP	O	O
>	>	SYM	B-VP	O	O
5	5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
upper	upper	JJ	I-NP	O	O
limits	limit	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
3.5	3.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
(	(	(	O	O	O
CD4	CD4	NN	B-NP	O	O
,	,	,	O	O	O
260	260	CD	B-NP	O	O
cells	cell	NNS	I-NP	O	O
/	/	SYM	O	O	O
microL	microL	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Women	Woman	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
experience	experience	VB	I-VP	O	O
lactic	lactic	JJ	B-NP	O	B-Disease
acidosis	acidosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
men	man	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
more	more	RBR	I-ADJP	O	O
likely	likely	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
experience	experience	VB	I-VP	O	O
immune	immune	JJ	B-NP	O	B-Disease
reconstitution	reconstitution	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Among	Among	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
1	1	CD	B-NP	O	O
year	year	NN	I-NP	O	O
of	of	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
,	,	,	O	O	O
NVP	NVP	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
rash	rash	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
d4T	d4T	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
peripheral	peripheral	JJ	B-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.05	0.05	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Anemia	Anemia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
hepatitis	hepatitis	NN	I-NP	O	B-Disease
often	often	RB	B-ADVP	O	O
occur	occur	VBP	B-VP	O	O
within	within	IN	B-PP	O	O
12	12	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
initiating	initiate	VBG	B-VP	O	O
generic	generic	JJ	B-NP	O	O
HAART	HAART	NN	I-NP	O	O
.	.	.	O	O	O

Frequent	Frequent	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
early	early	JJ	I-NP	O	O
monitoring	monitoring	NN	I-NP	O	O
for	for	IN	B-PP	O	O
these	these	DT	B-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
developing	develop	VBG	B-NP	O	O
countries	country	NNS	I-NP	O	O
where	where	WRB	B-ADVP	O	O
generic	generic	JJ	B-NP	O	O
HAART	HAART	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
increasingly	increasingly	RB	B-ADJP	O	O
available	available	JJ	I-ADJP	O	O
.	.	.	O	O	O

Thalidomide	Thalidomide	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
sensory	sensory	JJ	B-NP	O	B-Disease
neurotoxicity	neurotoxicity	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
neurophysiological	neurophysiological	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Recent	Recent	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensory	sensory	JJ	B-NP	O	B-Disease
axonal	axonal	JJ	I-NP	O	I-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
's	's	POS	B-NP	O	O
aims	aim	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
measure	measure	VB	I-VP	O	O
variations	variation	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
sural	sural	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
sensory	sensory	JJ	I-NP	O	O
action	action	NN	I-NP	O	O
potential	potential	NN	I-NP	O	O
(	(	(	O	O	O
SAP	SAP	NN	B-NP	B	O
)	)	)	O	O	O
amplitude	amplitude	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
cutaneous	cutaneous	JJ	I-NP	O	B-Disease
lupus	lupus	NN	I-NP	O	I-Disease
erythematosus	erythematosus	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CLE	CLE	NN	B-NP	O	B-Disease
)	)	)	O	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
use	use	VB	B-VP	O	O
these	these	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
identify	identify	VB	I-VP	O	O
the	the	DT	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
capacity	capacity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensory	sensory	JJ	B-NP	O	O
fibres	fibre	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

PATIENTS	PATIENTS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
Clinical	Clinical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
electrophysiological	electrophysiological	JJ	I-NP	O	O
data	datum	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
CLE	CLE	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
47	47	CD	I-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
discontinuation	discontinuation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
analysed	analyse	VBN	I-VP	O	O
.	.	.	O	O	O

Sural	Sural	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
SAP	SAP	NN	I-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
40	40	CD	B-NP	O	O
%	%	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
criteria	criterion	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
therapy	therapy	NN	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
During	During	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
11	11	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
sural	sural	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
SAP	SAP	NN	I-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
baseline	baseline	NN	B-NP	O	O
values	value	NNS	I-NP	O	O
(	(	(	O	O	O
9	9	CD	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	I-NP	O	O
2	2	CD	I-NP	O	O
<	<	SYM	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
patient	patient	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
SAP	SAP	NN	B-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
complained	complain	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
paresthesias	paresthesia	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
leg	leg	NN	B-NP	O	O
cramps	cramp	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
sural	sural	JJ	B-NP	O	O
SAP	SAP	NN	I-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
recovered	recover	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
3	3	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
detection	detection	NN	B-NP	O	O
of	of	IN	B-PP	O	O
reduction	reduction	NN	B-NP	O	O
in	in	IN	B-PP	O	O
sural	sural	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
SAP	SAP	NN	I-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
thalidomide	thalidomide	NN	I-NP	B	B-Chemical
cumulative	cumulative	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
21.4	21.4	CD	B-NP	O	O
g	g	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
threshold	threshold	NN	I-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
dosage	dosage	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
lower	low	JJR	B-ADJP	O	O
than	than	IN	B-SBAR	O	O
previously	previously	RB	B-ADVP	O	O
reported	report	VBN	B-VP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Sural	Sural	JJ	B-NP	O	O
nerve	nerve	NN	I-NP	O	O
SAP	SAP	NN	I-NP	B	O
amplitude	amplitude	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
reliable	reliable	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
sensitive	sensitive	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
of	of	IN	B-PP	O	O
degeneration	degeneration	NN	B-NP	O	O
and	and	CC	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensory	sensory	JJ	B-NP	O	O
fibres	fibre	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
electrophysiological	electrophysiological	JJ	I-NP	O	O
parameter	parameter	NN	I-NP	O	O
provides	provide	VBZ	B-VP	O	O
information	information	NN	B-NP	O	O
about	about	IN	B-PP	O	O
subclinical	subclinical	JJ	B-NP	O	O
neurotoxic	neurotoxic	JJ	I-NP	O	B-Disease
potential	potential	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thalidomide	thalidomide	NN	B-NP	B	B-Chemical
but	but	CC	O	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
helpful	helpful	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
predicting	predict	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensory	sensory	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-VP	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
mass	mass	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
unique	unique	JJ	B-NP	O	O
membranous	membranous	JJ	I-NP	O	B-Disease
glomerulonephritis	glomerulonephritis	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
valvular	valvular	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
:	:	:	O	O	O
Diagnostic	Diagnostic	JJ	B-NP	O	O
pitfall	pitfall	NN	I-NP	O	O
and	and	CC	O	O	O
new	new	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
.	.	.	O	O	O

Amiodarone	Amiodarone	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
anti	anti	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
arrhythmic	arrhythmic	JJ	I-NP	O	B-Disease
drug	drug	NN	I-NP	O	O
for	for	IN	B-PP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
tachycardia	tachycardia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
various	various	JJ	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
reported	report	VBN	I-VP	O	O
.	.	.	O	O	O

Reported	Report	VBN	B-VP	O	O
herein	herein	RB	B-ADVP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
autopsy	autopsy	NN	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
valvular	valvular	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
,	,	,	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
lung	lung	NN	I-NP	O	B-Disease
mass	mass	NN	I-NP	O	I-Disease
(	(	(	O	O	O
1.5	1.5	CD	B-NP	O	O
cm	cm	NN	I-NP	O	O
in	in	IN	B-PP	O	O
diameter	diameter	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
proteinuria	proteinuria	NN	B-NP	O	B-Disease
(	(	(	O	O	O
2.76	2.76	CD	B-NP	O	O
g	g	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
lung	lung	NN	I-NP	O	B-Disease
mass	mass	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
highly	highly	RB	I-VP	O	O
suspected	suspect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
lung	lung	NN	B-NP	O	B-Disease
cancer	cancer	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
CT	CT	NN	B-NP	B	O
and	and	CC	I-NP	O	O
positron	positron	NN	I-NP	O	O
emission	emission	NN	I-NP	O	O
tomography	tomography	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
histologically	histologically	RB	B-ADVP	O	O
the	the	DT	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
composed	compose	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
lymphoplasmacytic	lymphoplasmacytic	JJ	B-NP	O	O
infiltrates	infiltrate	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
alveolar	alveolar	JJ	B-NP	O	O
walls	wall	NNS	I-NP	O	O
and	and	CC	O	O	O
intra	intra	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
alveolar	alveolar	JJ	I-NP	O	O
accumulation	accumulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
foamy	foamy	JJ	B-NP	O	O
macrophages	macrophage	NNS	I-NP	O	O
containing	contain	VBG	B-VP	O	O
characteristic	characteristic	JJ	B-NP	O	O
myelinoid	myelinoid	JJ	I-NP	O	O
bodies	body	NNS	I-NP	O	O
,	,	,	O	O	O
indicating	indicate	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
related	relate	VBN	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
lung	lung	NN	I-NP	O	O
tissue	tissue	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
unevenly	unevenly	RB	I-VP	O	O
distributed	distribute	VBN	I-VP	O	O
hemosiderin	hemosiderin	NN	B-NP	B	B-Disease
deposition	deposition	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
abnormally	abnormally	RB	B-NP	O	O
tortuous	tortuous	JJ	I-NP	O	O
capillaries	capillary	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
seen	see	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mass	mass	NN	I-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
heavily	heavily	RB	B-NP	O	O
hemosiderotic	hemosiderotic	JJ	I-NP	O	B-Disease
lung	lung	NN	I-NP	O	O
portions	portion	NNS	I-NP	O	O
outside	outside	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mass	mass	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidneys	kidney	NNS	I-NP	O	O
,	,	,	O	O	O
glomeruli	glomerulus	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
membrane	membrane	NN	B-NP	O	O
spikes	spike	NNS	I-NP	O	O
,	,	,	O	O	O
prominent	prominent	JJ	B-NP	O	O
swelling	swelling	NN	I-NP	O	O
of	of	IN	B-PP	O	O
podocytes	podocyte	NNS	B-NP	O	O
and	and	CC	O	O	O
subepithelial	subepithelial	JJ	B-NP	O	O
deposits	deposit	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
were	be	VBD	B-VP	O	O
sometimes	sometimes	RB	B-ADJP	O	O
large	large	JJ	I-ADJP	O	O
and	and	CC	I-ADJP	O	O
hump	hump	JJ	I-ADJP	O	O
-	-	HYPH	B-ADJP	O	O
like	like	JJ	I-ADJP	O	O
.	.	.	O	O	O

Autoimmune	Autoimmune	JJ	B-NP	O	B-Disease
diseases	disease	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
viral	viral	JJ	B-NP	O	B-Disease
hepatitis	hepatitis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
malignant	malignant	JJ	B-NP	O	O
neoplasms	neoplasm	NNS	I-NP	O	B-Disease
or	or	CC	O	O	O
other	other	JJ	B-NP	O	O
diseases	disease	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
known	know	VBN	I-NP	O	O
relationship	relationship	NN	I-NP	O	O
to	to	TO	B-PP	O	O
membranous	membranous	JJ	B-NP	O	B-Disease
glomerulonephritis	glomerulonephritis	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
found	find	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
highlights	highlight	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
differential	differential	JJ	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
between	between	IN	B-PP	O	O
an	an	DT	B-NP	O	O
amiodarone	amiodarone	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-VP	O	O
pulmonary	pulmonary	JJ	B-NP	O	B-Disease
lesion	lesion	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
neoplasm	neoplasm	NN	I-NP	O	B-Disease
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
very	very	RB	B-ADJP	O	O
difficult	difficult	JJ	I-ADJP	O	O
radiologically	radiologically	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
membranous	membranous	JJ	B-NP	O	B-Disease
glomerulonephritis	glomerulonephritis	NN	I-NP	O	I-Disease
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
another	another	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
amiodarone	amiodarone	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Risk	Risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
sulphonylurea	sulphonylurea	NN	I-NP	O	B-Chemical
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
type	type	NN	B-NP	O	B-Disease
2	2	CD	I-NP	O	I-Disease
diabetes	diabete	NNS	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
matched	match	VBN	I-NP	B	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

AIMS	AIMS	NNS	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
sought	seek	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
assess	assess	VB	I-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
artery	artery	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CAD	CAD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
type	type	NN	B-NP	O	B-Disease
2	2	CD	I-NP	O	I-Disease
diabetes	diabete	NNS	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
sulphonylureas	sulphonylurea	NNS	I-NP	O	B-Chemical
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
type	type	NN	B-NP	O	B-Disease
2	2	CD	I-NP	O	I-Disease
diabetic	diabetic	JJ	I-NP	O	I-Disease
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
cases	case	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
CAD	CAD	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
retrospectively	retrospectively	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
20	20	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CAD	CAD	NN	B-NP	O	B-Disease
at	at	IN	B-PP	O	O
diagnosis	diagnosis	NN	B-NP	O	O
of	of	IN	B-PP	O	O
diabetes	diabete	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
UKPDS	UKPDS	NN	I-NP	O	O
risk	risk	NN	I-NP	O	O
engine	engine	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
match	match	VB	I-VP	B	O
cases	case	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
76	76	CD	I-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
CAD	CAD	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
152	152	CD	B-NP	O	O
controls	control	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hazard	hazard	NN	I-NP	O	O
of	of	IN	B-PP	O	O
developing	develop	VBG	B-VP	O	O
CAD	CAD	NN	B-NP	O	B-Disease
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
)	)	)	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
initial	initial	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
by	by	IN	B-PP	O	O
2.4	2.4	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
1.3	1.3	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
4.3	4.3	CD	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.004	0.004	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
glibenclamide	glibenclamide	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
2	2	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
0.9	0.9	CD	B-NP	O	O
-	-	HYPH	O	O	O
4.6	4.6	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.099	0.099	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
glipizide	glipizide	NN	B-NP	B	B-Chemical
;	;	:	O	O	O
2.9	2.9	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
1.6	1.6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5.1	5.1	CD	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.000	0.000	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
either	either	CC	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
metformin	metformin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
hazard	hazard	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
0.3	0.3	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
0.7	0.7	CD	B-NP	O	O
-	-	HYPH	O	O	O
1.7	1.7	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.385	0.385	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
glimepiride	glimepiride	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
0.4	0.4	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
0.7	0.7	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.3	1.3	CD	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.192	0.192	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
gliclazide	gliclazide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
0.4	0.4	CD	B-NP	O	O
-	-	HYPH	O	O	O
fold	fold	RB	B-ADVP	O	O
(	(	(	O	O	O
0.7	0.7	CD	B-NP	O	O
-	-	HYPH	O	O	O
1.1	1.1	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.09	0.09	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
either	either	RB	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Initiating	Initiate	VBG	B-VP	O	O
treatment	treatment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
type	type	NN	B-NP	O	B-Disease
2	2	CD	I-NP	O	I-Disease
diabetes	diabete	NNS	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
glibenclamide	glibenclamide	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
glipizide	glipizide	NN	I-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CAD	CAD	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
comparison	comparison	NN	B-NP	O	O
to	to	TO	B-PP	O	O
gliclazide	gliclazide	NN	B-NP	B	B-Chemical
or	or	CC	I-NP	O	O
glimepiride	glimepiride	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

If	If	IN	B-SBAR	O	O
confirmed	confirm	VBN	B-VP	O	O
,	,	,	O	O	O
this	this	DT	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
important	important	JJ	B-ADJP	O	O
because	because	IN	B-SBAR	O	O
most	most	JJS	B-NP	O	O
Indian	Indian	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
receive	receive	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
cheaper	cheap	JJR	I-NP	O	O
older	old	JJR	I-NP	O	O
sulphonylureas	sulphonylurea	NNS	I-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
present	present	JJ	B-NP	O	O
guidelines	guideline	NNS	I-NP	O	O
do	do	VBP	B-VP	O	O
not	not	RB	I-VP	O	O
distinguish	distinguish	VB	I-VP	O	O
between	between	IN	B-PP	O	O
individual	individual	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
.	.	.	O	O	O

Reduced	Reduce	VBN	B-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
spontaneously	spontaneously	RB	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
losartan	losartan	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
the	the	DT	B-NP	O	O
antihypertensive	antihypertensive	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
angiotensin	angiotensin	NN	B-NP	B	B-Chemical
II	II	CD	I-NP	I	I-Chemical
type	type	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
1	1	CD	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
losartan	losartan	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
potential	potential	NN	I-NP	O	O
in	in	IN	B-PP	O	O
slowing	slow	VBG	B-VP	O	O
down	down	RP	B-PRT	O	O
renal	renal	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
progression	progression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
spontaneously	spontaneously	RB	B-NP	O	O
hypertensive	hypertensive	JJ	I-NP	O	B-Disease
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
SHR	SHR	NN	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
adriamycin	adriamycin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
nephropathy	nephropathy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Six	Six	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
month	month	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
female	female	JJ	I-NP	O	O
SHR	SHR	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
selected	select	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
six	six	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
control	control	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
SH	SH	NN	B-NP	B	O
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
SH	SH	NN	B-NP	B	O
(	(	(	O	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
vehicle	vehicle	NN	B-NP	O	O
.	.	.	O	O	O

Groups	Group	NNS	B-NP	O	O
ADR	ADR	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
+	+	SYM	O	O	O
LOS	LOS	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
+	+	SYM	O	O	O
LOS	LOS	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
2	2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
b.w.	b.w.	NN	I-NP	O	O
i.v.	i.v.	JJ	I-NP	O	O
)	)	)	O	O	O
twice	twice	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
week	week	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
.	.	.	O	O	O

Group	Group	NN	B-NP	O	O
ADR	ADR	NN	I-NP	B	B-Chemical
+	+	SYM	B-NP	O	O
LOS	LOS	NN	I-NP	O	B-Chemical
(	(	(	O	O	O
6	6	CD	B-NP	O	O
)	)	)	O	O	O
received	receive	VBD	B-VP	O	O
losartan	losartan	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
10	10	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	I-NP	O	O
b.w.	b.w.	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
by	by	IN	B-PP	O	O
gavages	gavage	NNS	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
group	group	NN	I-NP	O	O
ADR	ADR	NN	I-NP	B	B-Chemical
+	+	SYM	B-NP	O	O
LOS	LOS	NN	I-NP	O	B-Chemical
(	(	(	O	O	O
12	12	CD	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
12	12	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
second	second	JJ	B-NP	O	O
injection	injection	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
killed	kill	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
6	6	CD	B-NP	O	O
or	or	CC	I-NP	O	O
12	12	CD	I-NP	O	O
weeks	week	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

Haemodynamic	Haemodynamic	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
anaesthetized	anaesthetize	VBN	B-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
blood	blood	NN	B-NP	O	O
and	and	CC	I-NP	O	O
urine	urine	NN	I-NP	O	O
samples	sample	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
taken	take	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
biochemical	biochemical	JJ	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
left	left	JJ	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
processed	process	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
morphological	morphological	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Short	Short	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
losartan	losartan	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
besides	besides	IN	B-PP	O	O
antihypertensive	antihypertensive	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
improved	improve	VBD	B-VP	O	O
glomerular	glomerular	JJ	B-NP	O	O
filtration	filtration	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
and	and	CC	O	O	O
ameliorated	ameliorate	VBN	B-NP	O	O
glomerulosclerosis	glomerulosclerosis	NN	I-NP	O	B-Disease
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
proteinuria	proteinuria	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Prolonged	Prolonged	JJ	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
losartan	losartan	NN	B-NP	B	B-Chemical
showed	show	VBD	B-VP	O	O
further	further	JJ	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
of	of	IN	B-PP	O	O
glomerulosclerosis	glomerulosclerosis	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
reduced	reduce	VBN	B-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
atrophy	atrophy	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
interstitial	interstitial	JJ	B-NP	O	B-Disease
fibrosis	fibrosis	NN	I-NP	O	I-Disease
,	,	,	O	O	O
thus	thus	RB	B-ADVP	O	O
preventing	prevent	VBG	B-VP	O	O
heavy	heavy	JJ	B-NP	O	O
proteinuria	proteinuria	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Losartan	Losartan	NNP	B-NP	B	B-Chemical
reduced	reduce	VBD	B-VP	O	O
uraemia	uraemia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
urea	urea	NN	B-NP	B	B-Chemical
clearance	clearance	NN	I-NP	O	O
in	in	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
ADR	ADR	NN	I-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
SHR	SHR	NN	B-NP	O	O
.	.	.	O	O	O

Histological	Histological	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
losartan	losartan	NN	B-NP	B	B-Chemical
could	could	MD	B-VP	O	O
prevent	prevent	VB	I-VP	O	O
tubular	tubular	JJ	B-NP	O	O
atrophy	atrophy	NN	I-NP	O	B-Disease
,	,	,	O	O	O
interstitial	interstitial	JJ	B-NP	O	O
infiltration	infiltration	NN	I-NP	O	O
and	and	CC	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Losartan	Losartan	NNP	B-NP	B	B-Chemical
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
rate	rate	NN	I-NP	O	O
of	of	IN	B-PP	O	O
progression	progression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ADR	ADR	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
focal	focal	JJ	I-NP	O	B-Disease
segmental	segmental	JJ	I-NP	O	I-Disease
glomerulosclerosis	glomerulosclerosis	NN	I-NP	O	I-Disease
to	to	TO	B-VP	O	O
end	end	VB	I-VP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
stage	stage	NN	I-NP	O	I-Disease
renal	renal	JJ	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
SHR	SHR	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
risks	risk	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aprotinin	aprotinin	NN	B-NP	B	O
and	and	CC	O	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
:	:	:	O	O	O
a	a	DT	B-NP	O	O
one	one	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
of	of	IN	B-PP	O	O
1188	1188	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
aim	aim	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
investigate	investigate	VB	I-VP	O	O
postoperative	postoperative	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
aprotinin	aprotinin	NN	B-NP	B	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
unselected	unselected	JJ	I-NP	O	O
,	,	,	I-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
cohort	cohort	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Perioperative	Perioperative	JJ	B-NP	O	O
data	datum	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
consecutive	consecutive	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
prospectively	prospectively	RB	I-VP	O	O
collected	collect	VBN	I-VP	O	O
between	between	IN	B-PP	O	O
September	September	NNP	B-NP	O	O
2005	2005	CD	I-NP	O	O
and	and	CC	O	O	O
June	June	NNP	B-NP	O	O
2006	2006	CD	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
university	university	NN	I-NP	O	O
-	-	HYPH	O	O	O
affiliated	affiliate	VBN	B-VP	O	O
clinic	clinic	NN	B-NP	O	O
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
1188	1188	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
5	5	CD	I-NP	O	O
mo	mo	NN	I-NP	O	O
,	,	,	O	O	O
596	596	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
aprotinin	aprotinin	NN	B-NP	B	O
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
A	A	NN	I-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
next	next	JJ	I-NP	O	O
5	5	CD	I-NP	O	O
mo	mo	NN	I-NP	O	O
,	,	,	O	O	O
592	592	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
Group	Group	NN	B-NP	O	O
T	T	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Except	Except	IN	B-PP	O	O
for	for	IN	B-PP	O	O
antifibrinolytic	antifibrinolytic	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
anesthetic	anesthetic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
surgical	surgical	JJ	I-NP	O	O
protocols	protocol	NNS	I-NP	O	O
remained	remain	VBD	B-VP	O	O
unchanged	unchanged	JJ	B-ADJP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
pre	pre	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
intraoperative	intraoperative	JJ	I-NP	O	O
variables	variable	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Postoperatively	Postoperatively	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
significantly	significantly	RB	I-NP	O	O
higher	high	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
T	T	NN	I-NP	O	O
(	(	(	O	O	O
4.6	4.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
1.2	1.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-NP	O	O
0.001	0.001	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
significant	significant	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
valve	valve	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
subgroups	subgroup	NNS	I-NP	O	O
(	(	(	O	O	O
7.9	7.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
1.2	1.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.003	0.003	CD	B-NP	O	O
;	;	:	O	O	O
7.3	7.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
2.4	2.4	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.035	0.035	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Persistent	Persistent	JJ	B-NP	O	O
atrial	atrial	JJ	I-NP	O	O
fibrillation	fibrillation	NN	I-NP	O	O
(	(	(	O	O	O
7.9	7.9	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
2.3	2.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.020	0.020	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
9.7	9.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
1.7	1.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.002	0.002	CD	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
more	more	RBR	B-ADJP	O	O
common	common	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
Group	Group	NNP	B-NP	O	O
T	T	NNP	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
valve	valve	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
subgroup	subgroup	NN	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contrary	contrary	NN	I-NP	O	O
,	,	,	O	O	O
among	among	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
artery	artery	NN	I-NP	O	O
bypass	bypass	IN	B-PP	O	O
surgery	surgery	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	B-NP	O	O
acute	acute	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarctions	infarction	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
renal	renal	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Group	Group	NN	B-NP	O	O
A	A	NN	I-NP	O	O
(	(	(	O	O	O
5.8	5.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
2.0	2.0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.027	0.027	CD	B-NP	O	O
;	;	:	O	O	O
22.5	22.5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
15.2	15.2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.036	0.036	CD	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
yr	yr	NN	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
after	after	IN	B-PP	O	O
aprotinin	aprotinin	NN	B-NP	B	O
treatment	treatment	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
17.7	17.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
vs	vs	IN	B-PP	O	O
9.8	9.8	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.034	0.034	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Both	Both	CC	O	O	O
antifibrinolytic	antifibrinolytic	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
bear	bear	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adverse	adverse	JJ	B-NP	O	O
outcome	outcome	NN	I-NP	O	O
depending	depend	VBG	B-PP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

Administration	Administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
aprotinin	aprotinin	NN	B-NP	B	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
avoided	avoid	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
bypass	bypass	IN	B-PP	O	O
graft	graft	NN	B-NP	O	O
and	and	CC	O	O	O
high	high	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tranexamic	tranexamic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
is	be	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
recommended	recommend	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
valve	valve	NN	B-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
biological	biological	JJ	I-NP	O	O
properties	property	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
optical	optical	JJ	I-NP	O	O
isomers	isomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
arrhythmias	arrhythmia	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

1	1	LS	B-LST	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
optical	optical	JJ	I-NP	O	O
isomers	isomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
compared	compare	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
beta	beta	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
blocking	block	VBG	I-NP	O	O
and	and	CC	I-NP	O	O
antiarrhythmic	antiarrhythmic	JJ	I-NP	O	O
activities.2	activities.2	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
blocking	block	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
positive	positive	JJ	I-NP	O	O
inotropic	inotropic	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
chronotropic	chronotropic	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
isoprenaline	isoprenaline	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
(	(	(	O	B	O
+	+	SYM	O	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	I	O
propranolol	propranolol	NN	I-NP	I	B-Chemical
had	have	VBD	B-VP	O	O
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
one	one	CD	I-NP	O	O
hundredth	hundredth	NN	I-NP	O	O
the	the	DT	B-NP	O	O
potency	potency	NN	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

At	At	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	B	O
+	+	SYM	O	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	I	O
propranolol	propranolol	NN	I-NP	I	B-Chemical
which	which	WDT	B-NP	O	O
attenuated	attenuate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
isoprenaline	isoprenaline	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PR	PR	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
electrocardiogram.3	electrocardiogram.3	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
responses	response	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
isoprenaline	isoprenaline	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
dogs	dog	NNS	B-NP	O	O
(	(	(	O	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
circulating	circulate	VBG	B-VP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
lactate	lactate	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
fatty	fatty	JJ	I-NP	O	B-Chemical
acids	acid	NNS	I-NP	O	I-Chemical
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
all	all	DT	O	O	O
blocked	block	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

(	(	(	O	B	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	I	O
Propranolol	Propranolol	NN	I-NP	I	B-Chemical
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
fatty	fatty	JJ	B-NP	O	B-Chemical
acid	acid	NN	I-NP	O	I-Chemical
mobilization	mobilization	NN	I-NP	O	O
but	but	CC	O	O	O
significantly	significantly	RB	B-VP	O	O
reduced	reduce	VBD	I-VP	O	O
the	the	DT	B-NP	O	O
increments	increment	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
lactate	lactate	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
.4	.4	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
isomers	isomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
possessed	possess	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
depressant	depressant	NN	I-NP	O	O
potency	potency	NN	I-NP	O	O
on	on	IN	B-PP	O	O
isolated	isolate	VBN	B-NP	O	O
atrial	atrial	JJ	I-NP	O	O
muscle	muscle	NN	I-NP	O	O
taken	take	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
guinea	guinea	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
pigs.5	pigs.5	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
isomers	isomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
exhibited	exhibit	VBD	B-VP	O	O
similar	similar	JJ	B-NP	O	O
local	local	JJ	I-NP	O	O
anaesthetic	anaesthetic	JJ	I-NP	O	O
potencies	potency	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
an	an	DT	B-NP	O	O
isolated	isolate	VBN	I-NP	O	O
frog	frog	NN	I-NP	O	O
nerve	nerve	NN	I-NP	O	O
preparation	preparation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
a	a	DT	B-NP	O	O
level	level	NN	I-NP	O	O
approximately	approximately	RB	B-NP	O	O
three	three	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
that	that	DT	I-NP	O	O
of	of	IN	B-PP	O	O
procaine	procaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
racemic	racemic	JJ	I-NP	O	O
compound	compound	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
less	less	RBR	I-ADJP	O	O
potent	potent	JJ	I-ADJP	O	O
than	than	IN	B-PP	O	O
either	either	DT	B-NP	O	O
isomer.6	isomer.6	NN	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
isomers	isomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
preventing	prevent	VBG	B-VP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
arrhythmias	arrhythmia	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
cats	cat	NNS	B-NP	O	O
anaesthetized	anaesthetize	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
halothane	halothane	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
0.09	0.09	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.02	0.02	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
whereas	whereas	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	B	O
+	+	SYM	O	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	I	O
propranolol	propranolol	NN	I-NP	I	B-Chemical
was	be	VBD	B-VP	O	O
4.2	4.2	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
1.2	1.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
the	the	DT	B-NP	O	O
effective	effective	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	B	O
+	+	SYM	O	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	I	O
propranolol	propranolol	NN	I-NP	I	B-Chemical
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
prolongation	prolongation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PR	PR	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
electrocardiogram	electrocardiogram	NN	I-NP	O	O
.	.	.	O	O	O

Blockade	Blockade	NN	B-NP	O	O
of	of	IN	B-PP	O	O
arrhythmias	arrhythmia	NNS	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
both	both	DT	B-NP	O	O
isomers	isomer	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
surmountable	surmountable	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
adrenaline	adrenaline	NN	B-NP	B	B-Chemical
.7	.7	CD	I-NP	O	O
.	.	.	O	O	O

Both	Both	DT	B-NP	O	O
isomers	isomer	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
propranolol	propranolol	NN	B-NP	B	B-Chemical
were	be	VBD	B-VP	O	O
also	also	RB	B-ADVP	O	O
capable	capable	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
reversing	reverse	VBG	B-VP	O	O
ventricular	ventricular	JJ	B-NP	O	B-Disease
tachycardia	tachycardia	NN	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
anaesthetized	anaesthetize	VBN	B-NP	O	O
cats	cat	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
dogs	dog	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
propranolol	propranolol	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
smaller	small	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
(	(	(	O	B	O
+	+	SYM	O	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	I	O
propranolol	propranolol	NN	I-NP	I	B-Chemical
in	in	IN	B-PP	O	O
both	both	CC	O	O	O
species	specie	NNS	B-NP	O	O
but	but	CC	O	O	O
much	much	RB	B-ADJP	O	O
higher	high	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
that	that	DT	B-NP	O	O
required	require	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
produce	produce	VB	I-VP	O	O
evidence	evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
beta	beta	SYM	B-NP	O	O
-	-	HYPH	B-NP	O	O
blockade.8	blockade.8	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
implications	implication	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Topotecan	Topotecan	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
radiotherapy	radiotherapy	NN	B-NP	O	O
in	in	IN	B-PP	O	O
unresectable	unresectable	JJ	B-NP	O	O
glioblastoma	glioblastoma	NN	I-NP	O	B-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
phase	phase	NN	I-NP	O	O
2	2	CD	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Improving	Improve	VBG	B-VP	O	O
glioblastoma	glioblastoma	NN	B-NP	O	B-Disease
multiforme	multiforme	NN	I-NP	O	I-Disease
(	(	(	O	O	O
GBM	GBM	NN	B-NP	O	B-Disease
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
radio	radio	AFX	B-NP	B	O
-	-	HYPH	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
remains	remain	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
challenge	challenge	NN	I-NP	O	O
.	.	.	O	O	O

Topotecan	Topotecan	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
attractive	attractive	JJ	I-NP	O	O
option	option	NN	I-NP	O	O
as	as	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
exhibits	exhibit	VBZ	B-VP	O	O
growth	growth	NN	B-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
glioma	glioma	NN	I-NP	O	B-Disease
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
brain	brain	NN	B-NP	O	O
penetration	penetration	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
assessed	assess	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
combination	combination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
radiotherapy	radiotherapy	NN	B-NP	O	O
(	(	(	O	O	O
60	60	CD	B-NP	O	O
Gy	Gy	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
30	30	CD	B-NP	O	O
fractions	fraction	NNS	I-NP	O	O
/	/	SYM	B-NP	O	O
40	40	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
topotecan	topotecan	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.9	0.9	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
m	m	NN	I-NP	O	O
(	(	(	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
on	on	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
5	5	CD	I-NP	O	O
on	on	IN	B-PP	O	O
weeks	week	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
3	3	CD	I-NP	O	O
and	and	CC	I-NP	O	O
5	5	CD	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
50	50	CD	B-NP	O	O
adults	adult	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
histologically	histologically	RB	B-NP	O	O
proven	proven	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
untreated	untreated	JJ	I-NP	O	O
GBM	GBM	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
hematological	hematological	JJ	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
low	low	JJ	B-ADJP	O	O
and	and	CC	O	O	O
grade	grade	NN	B-NP	O	O
3	3	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
4	4	CD	I-NP	O	O
hematological	hematological	JJ	I-NP	O	O
toxicities	toxicity	NNS	I-NP	O	B-Disease
were	be	VBD	B-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
20	20	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
(	(	(	O	O	O
mainly	mainly	RB	B-NP	O	O
lymphopenia	lymphopenia	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
neutropenia	neutropenia	NN	I-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Partial	Partial	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
and	and	CC	I-NP	O	O
stabilization	stabilization	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
2	2	CD	B-NP	O	O
%	%	NN	I-NP	O	O
and	and	CC	O	O	O
32	32	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
overall	overall	JJ	I-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
progression	progression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
12	12	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
overall	overall	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
(	(	(	O	O	O
OS	OS	NN	B-NP	B	O
)	)	)	O	O	O
rate	rate	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
42	42	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
median	median	JJ	I-NP	O	O
OS	OS	NN	I-NP	B	O
of	of	IN	B-PP	O	O
40	40	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
.	.	.	O	O	O

Topotecan	Topotecan	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
radiotherapy	radiotherapy	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
response	response	NN	B-NP	O	O
and	and	CC	I-NP	O	O
stabilization	stabilization	NN	I-NP	O	O
concerned	concern	VBN	B-VP	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
third	third	JJ	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
show	show	VB	I-VP	O	O
increased	increase	VBN	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
survival	survival	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
unresectable	unresectable	JJ	B-NP	O	O
GBM	GBM	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
hyperparathyroidism	hyperparathyroidism	NN	B-NP	O	B-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
report	report	NN	I-NP	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
paper	paper	NN	I-NP	O	O
reviews	review	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
on	on	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
and	and	CC	O	O	O
parathyroid	parathyroid	JJ	B-NP	O	O
glands	gland	NNS	I-NP	O	O
,	,	,	O	O	O
its	its	PRP$	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
treatment	treatment	NN	B-NP	O	O
options	option	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
examined	examine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
treated	treat	VBN	B-NP	O	O
patient	patient	NN	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
recurrent	recurrent	JJ	B-NP	O	O
hypercalcemia	hypercalcemia	NN	I-NP	O	B-Disease
to	to	TO	B-VP	O	O
better	well	RBR	I-VP	O	O
understand	understand	VB	I-VP	O	O
the	the	DT	B-NP	O	O
disease	disease	NN	I-NP	O	O
process	process	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Primary	Primary	JJ	B-NP	O	B-Disease
hyperparathyroidism	hyperparathyroidism	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
but	but	CC	O	O	O
potentially	potentially	RB	B-ADVP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
side	side	NN	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
lithium	lithium	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Careful	Careful	JJ	B-NP	O	O
patient	patient	NN	I-NP	O	O
selection	selection	NN	I-NP	O	O
and	and	CC	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
can	can	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
morbidity	morbidity	NN	B-NP	O	O
.	.	.	O	O	O

PRACTICAL	PRACTICAL	JJ	B-NP	O	O
IMPLICATIONS	IMPLICATIONS	NNS	I-NP	O	O
:	:	:	O	O	O
As	As	RB	B-NP	O	O
much	much	RB	I-NP	O	O
as	as	IN	I-NP	O	O
15	15	CD	I-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lithium	lithium	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
become	become	VBP	B-VP	O	O
hypercalcemic	hypercalcemic	JJ	B-ADJP	O	B-Disease
.	.	.	O	O	O

By	By	IN	B-PP	O	O
routinely	routinely	RB	B-ADVP	O	O
monitoring	monitor	VBG	B-VP	O	O
serum	serum	NN	B-NP	O	O
calcium	calcium	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
,	,	,	O	O	O
healthcare	healthcare	NN	B-NP	O	O
providers	provider	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
improve	improve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
quality	quality	NN	I-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
group	group	NN	I-NP	O	O
.	.	.	O	O	O

Comparison	Comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
laryngeal	laryngeal	JJ	B-NP	O	O
mask	mask	NN	I-NP	O	O
with	with	IN	B-PP	O	O
endotracheal	endotracheal	JJ	B-NP	O	O
tube	tube	NN	I-NP	O	O
for	for	IN	B-PP	O	O
anesthesia	anesthesia	NN	B-NP	O	O
in	in	IN	B-PP	O	O
endoscopic	endoscopic	JJ	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
purpose	purpose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
compare	compare	VB	I-VP	O	O
surgical	surgical	JJ	B-NP	O	O
conditions	condition	NNS	I-NP	O	O
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
the	the	DT	B-NP	O	O
amount	amount	NN	I-NP	O	O
of	of	IN	B-PP	O	O
intraoperative	intraoperative	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
intraoperative	intraoperative	JJ	B-NP	O	O
blood	blood	NN	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
,	,	,	O	O	O
during	during	IN	B-PP	O	O
functional	functional	JJ	B-NP	O	O
endoscopic	endoscopic	JJ	I-NP	O	O
sinus	sinus	NN	I-NP	O	O
surgery	surgery	NN	I-NP	O	O
(	(	(	O	O	O
FESS	FESS	NN	B-NP	O	O
)	)	)	O	O	O
using	use	VBG	B-VP	O	O
flexible	flexible	JJ	B-NP	O	O
reinforced	reinforced	JJ	I-NP	O	O
laryngeal	laryngeal	JJ	I-NP	O	O
mask	mask	NN	I-NP	O	O
airway	airway	NN	I-NP	O	O
(	(	(	O	O	O
FRLMA	FRLMA	NN	B-NP	O	O
)	)	)	O	O	O
versus	versus	IN	B-PP	O	O
endotracheal	endotracheal	JJ	B-NP	O	O
tube	tube	NN	I-NP	O	O
(	(	(	O	O	O
ETT	ETT	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
maintaining	maintain	VBG	B-VP	O	O
controlled	control	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
anesthesia	anesthesia	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
remifentanil	remifentanil	NN	I-NP	B	B-Chemical
total	total	JJ	I-NP	O	O
i.v.	i.v.	JJ	I-NP	O	O
anesthesia	anesthesia	NN	I-NP	O	O
(	(	(	O	O	O
TIVA	TIVA	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Sixty	Sixty	CD	B-NP	O	O
normotensive	normotensive	JJ	I-NP	O	O
American	American	JJ	I-NP	O	O
Society	Society	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Anesthesiologists	Anesthesiologist	NNS	B-NP	O	O
I	I	CD	B-NP	B	O
-	-	HYPH	I-NP	I	O
II	II	CD	I-NP	O	O
adult	adult	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
FESS	FESS	NN	B-NP	O	O
under	under	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
anesthesia	anesthesia	NN	I-NP	O	O
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
propofol	propofol	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
remifentanil	remifentanil	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
TIVA	TIVA	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
assigned	assign	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
two	two	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
:	:	:	O	O	O
group	group	NN	B-NP	O	O
I	I	CD	I-NP	O	O
,	,	,	O	O	O
FRLMA	FRLMA	NNP	B-NP	O	O
;	;	:	O	O	O
group	group	NN	B-NP	O	O
II	II	CD	I-NP	O	O
,	,	,	O	O	O
ETT	ETT	NNP	B-NP	O	O
.	.	.	O	O	O

Hemorrhage	Hemorrhage	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
visibility	visibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
operative	operative	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
according	accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
six	six	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
point	point	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Controlled	Controlled	JJ	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
achieved	achieve	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
a	a	DT	B-NP	O	O
shorter	short	JJR	I-NP	O	O
period	period	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
laryngeal	laryngeal	JJ	B-NP	O	O
mask	mask	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
lower	low	JJR	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
remifentanil	remifentanil	NN	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
and	and	CC	O	O	O
lower	low	JJR	B-NP	O	O
total	total	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
remifentanil	remifentanil	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
summary	summary	NN	B-NP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
results	result	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
airway	airway	NN	B-NP	O	O
management	management	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
FRLMA	FRLMA	NN	B-NP	O	O
during	during	IN	B-PP	O	O
controlled	control	VBN	B-NP	O	O
hypotension	hypotension	NN	I-NP	O	B-Disease
anesthesia	anesthesia	NN	I-NP	O	O
provided	provide	VBD	B-VP	O	O
better	good	JJR	B-NP	O	O
surgical	surgical	JJ	I-NP	O	O
conditions	condition	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
terms	term	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
quality	quality	NN	B-NP	O	O
of	of	IN	B-PP	O	O
operative	operative	JJ	B-NP	O	O
field	field	NN	I-NP	O	O
and	and	CC	I-NP	O	O
blood	blood	NN	I-NP	O	O
loss	loss	NN	I-NP	O	O
and	and	CC	O	O	O
allowed	allow	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
convenient	convenient	NN	B-NP	O	O
induced	induce	VBD	B-VP	O	O
hypotension	hypotension	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
remifentanil	remifentanil	NN	B-NP	B	B-Chemical
during	during	IN	B-PP	O	O
TIVA	TIVA	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
FESS	FESS	NNS	B-NP	O	O
.	.	.	O	O	O

Nonalcoholic	Nonalcoholic	JJ	B-NP	O	B-Disease
fatty	fatty	JJ	I-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
valproate	valproate	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Valproic	Valproic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
VPA	VPA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
many	many	JJ	B-NP	O	O
types	type	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
but	but	CC	O	O	O
its	its	PRP$	B-NP	O	O
use	use	NN	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
an	an	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nonalcoholic	nonalcoholic	JJ	B-NP	O	B-Disease
fatty	fatty	JJ	I-NP	O	I-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
NAFLD	NAFLD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
arising	arise	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
child	child	NN	I-NP	O	O
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
obesity	obesity	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
VPA	VPA	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
data	datum	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
hyperinsulinemia	hyperinsulinemia	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
the	the	DT	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
VPA	VPA	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
weight	weight	NN	I-NP	O	B-Disease
loss	loss	NN	I-NP	O	I-Disease
,	,	,	O	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
body	body	NN	B-NP	O	O
mass	mass	NN	I-NP	O	O
index	index	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
normalization	normalization	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metabolic	metabolic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
endocrine	endocrine	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
;	;	:	O	O	O
moreover	moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
ultrasound	ultrasound	JJ	B-NP	O	O
measurements	measurement	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
normalization	normalization	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
suggests	suggest	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
obesity	obesity	NN	B-NP	O	B-Disease
,	,	,	O	O	O
hyperinsulinemia	hyperinsulinemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
insulin	insulin	NN	B-NP	B	B-Disease
resistance	resistance	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
with	with	IN	B-PP	O	O
VPA	VPA	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
all	all	DT	O	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
NAFLD	NAFLD	NN	B-NP	O	B-Disease
;	;	:	O	O	O
this	this	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
reversible	reversible	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
VPA	VPA	NN	B-NP	B	B-Chemical
withdrawal	withdrawal	NN	I-NP	O	O
.	.	.	O	O	O

Carbimazole	Carbimazole	NN	B-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
ANCA	ANCA	CC	B-NP	B	B-Disease
positive	positive	JJ	I-NP	O	I-Disease
vasculitis	vasculitis	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Anti	Anti	AFX	B-NP	O	B-Chemical
-	-	HYPH	I-NP	O	I-Chemical
thyroid	thyroid	JJ	B-NP	O	I-Chemical
drugs	drug	NNS	I-NP	O	I-Chemical
,	,	,	O	O	O
like	like	IN	B-PP	O	O
carbimazole	carbimazole	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
propylthiouracil	propylthiouracil	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PTU	PTU	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
commonly	commonly	RB	I-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperthyroidism	hyperthyroidism	NN	B-NP	O	B-Disease
.	.	.	O	O	O

One	One	CD	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
aware	aware	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
antithyroid	antithyroid	JJ	B-NP	O	B-Chemical
medications	medication	NNS	I-NP	O	I-Chemical
.	.	.	O	O	O

Antineutrophil	Antineutrophil	NN	B-NP	O	B-Disease
cytoplasmic	cytoplasmic	JJ	I-NP	O	I-Disease
antibody	antibody	NN	I-NP	O	I-Disease
(	(	(	O	O	I-Disease
ANCA	ANCA	NN	B-NP	B	I-Disease
)	)	)	O	O	I-Disease
-	-	HYPH	O	O	I-Disease
-	-	HYPH	B-NP	O	I-Disease
associated	associate	VBN	I-NP	O	I-Disease
vasculitis	vasculitis	NN	I-NP	O	I-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
adverse	adverse	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antithyroidmedications	antithyroidmedication	NNS	B-NP	O	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
Graves	Graves	NN	B-NP	O	B-Disease
'	'	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
who	who	WP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
ANCA	ANCA	NN	B-NP	B	O
positive	positive	JJ	I-NP	O	O
carbimazole	carbimazole	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
vasculitis	vasculitis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
episode	episode	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
characterized	characterize	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
vasculitic	vasculitic	JJ	I-NP	O	B-Disease
skin	skin	NN	I-NP	O	B-Disease
rash	rash	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
large	large	JJ	B-NP	O	O
joint	joint	JJ	I-NP	O	O
arthritis	arthritis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
pyrexia	pyrexia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
parotiditis	parotiditis	NN	I-NP	O	B-Disease
but	but	CC	O	O	O
no	no	DT	B-NP	O	O
renal	renal	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
pulmonary	pulmonary	JJ	I-NP	O	O
involvement	involvement	NN	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
referred	refer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
us	us	PRP	B-NP	O	O
for	for	IN	B-PP	O	O
neurological	neurological	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
because	because	IN	B-SBAR	O	O
he	he	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
difficulty	difficulty	NN	B-NP	O	O
in	in	IN	B-PP	O	O
getting	get	VBG	B-VP	O	O
up	up	RP	B-PRT	O	O
from	from	IN	B-PP	O	O
squatting	squat	VBG	B-VP	O	O
position	position	NN	B-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
suspected	suspect	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
myositis	myositis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Carbimazole	Carbimazole	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
methimazole	methimazole	NN	I-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
reported	report	VBN	B-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
positive	positive	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effects	effect	NNS	I-NP	O	O
than	than	IN	B-PP	O	O
PUT	PUT	NN	B-NP	O	O
.	.	.	O	O	O

To	To	TO	B-PP	O	O
the	the	DT	B-NP	O	O
best	good	JJS	I-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
first	first	JJ	I-NP	O	O
ANCA	ANCA	NN	I-NP	B	O
positive	positive	JJ	I-NP	O	O
carbimazole	carbimazole	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
vasculitis	vasculitis	NN	B-NP	O	B-Disease
case	case	NN	I-NP	O	O
reported	report	VBN	B-VP	O	O
from	from	IN	B-PP	O	O
India	India	NNP	B-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
:	:	:	O	O	O
an	an	DT	B-NP	O	O
update	update	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
U.S	U.S	NNP	I-NP	O	O
.	.	.	O	O	O

Preventive	Preventive	JJ	B-NP	O	O
Services	Services	NNP	I-NP	O	O
Task	Task	NNP	I-NP	O	O
Force	Force	NNP	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Coronary	Coronary	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
cerebrovascular	cerebrovascular	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
leading	lead	VBG	I-VP	O	O
causes	cause	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
death	death	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
United	United	NNP	I-NP	O	O
States	State	NNPS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
2002	2002	CD	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
U.S	U.S	NNP	I-NP	O	O
.	.	.	O	O	O

Preventive	Preventive	JJ	B-NP	O	O
Services	Services	NNP	I-NP	O	O
Task	Task	NNP	I-NP	O	O
Force	Force	NNP	I-NP	O	O
(	(	(	O	O	O
USPSTF	USPSTF	NNP	B-NP	O	O
)	)	)	O	O	O
strongly	strongly	RB	B-VP	O	O
recommended	recommend	VBD	I-VP	O	O
that	that	IN	B-SBAR	O	O
clinicians	clinician	NNS	B-NP	O	O
discuss	discuss	VBP	B-VP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
with	with	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
at	at	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
heart	heart	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
benefits	benefit	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
harms	harm	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
taking	take	VBG	B-VP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarctions	infarction	NNS	I-NP	O	I-Disease
,	,	,	O	O	O
strokes	stroke	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
death	death	NN	B-NP	O	O
.	.	.	O	O	O

DATA	DATA	NN	B-NP	O	O
SOURCES	SOURCES	NNS	I-NP	O	O
:	:	:	O	O	O
MEDLINE	MEDLINE	NNP	B-NP	O	O
and	and	CC	I-NP	O	O
Cochrane	Cochrane	NNP	I-NP	O	O
Library	Library	NNP	I-NP	O	O
(	(	(	O	O	O
search	search	NN	B-NP	O	O
dates	date	NNS	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
January	January	NNP	I-NP	O	O
2001	2001	CD	I-NP	O	O
to	to	TO	I-NP	O	O
28	28	CD	I-NP	O	O
August	August	NNP	I-NP	O	O
2008	2008	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
recent	recent	JJ	B-NP	O	O
systematic	systematic	JJ	I-NP	O	O
reviews	review	NNS	I-NP	O	O
,	,	,	O	O	O
reference	reference	NN	B-NP	O	O
lists	list	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
retrieved	retrieved	JJ	B-NP	O	O
articles	article	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
suggestions	suggestion	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
experts	expert	NNS	B-NP	O	O
.	.	.	O	O	O

STUDY	STUDY	NN	B-NP	O	O
SELECTION	SELECTION	NN	I-NP	O	O
:	:	:	O	O	O
English	English	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
language	language	NN	I-NP	O	O
randomized	randomize	VBN	B-VP	O	O
,	,	,	O	O	O
controlled	control	VBN	B-NP	O	O
trials	trial	NNS	I-NP	O	O
(	(	(	O	O	O
RCTs	RCT	NNS	B-NP	O	O
)	)	)	O	O	O
;	;	:	O	O	O
case	case	NN	O	O	O
-	-	HYPH	O	O	O
control	control	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
;	;	:	O	O	O
meta	meta	SYM	O	B	O
-	-	HYPH	O	O	O
analyses	analysis	NNS	B-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
systematic	systematic	JJ	B-NP	O	O
reviews	review	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
versus	versus	CC	I-NP	O	O
control	control	NN	I-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiovascular	cardiovascular	JJ	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CVD	CVD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
selected	select	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
answer	answer	VB	I-VP	O	O
the	the	DT	B-NP	O	O
following	follow	VBG	I-NP	O	O
questions	question	NNS	I-NP	O	O
:	:	:	O	O	O
Does	Do	VBZ	B-VP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
decrease	decrease	NN	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
heart	heart	NN	I-NP	O	O
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
strokes	stroke	NNS	B-NP	O	B-Disease
,	,	,	O	O	O
death	death	NN	B-NP	O	O
from	from	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
heart	heart	NN	I-NP	O	O
events	event	NNS	I-NP	O	O
or	or	CC	O	O	O
stroke	stroke	VB	B-VP	O	B-Disease
,	,	,	O	O	O
or	or	CC	O	O	O
all	all	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
cause	cause	NN	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
in	in	IN	B-PP	O	O
adults	adult	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
CVD	CVD	NN	I-NP	O	B-Disease
?	?	.	O	O	O

Does	Do	VBZ	O	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
increase	increase	NN	I-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	B-Disease
bleeding	bleeding	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
strokes	stroke	NNS	I-NP	O	I-Disease
?	?	.	O	O	O

DATA	DATA	NN	B-NP	O	O
EXTRACTION	EXTRACTION	NN	I-NP	O	O
:	:	:	O	O	O
All	All	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
reviewed	review	VBN	I-VP	O	O
,	,	,	O	O	O
abstracted	abstract	VBN	B-VP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
rated	rat	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
quality	quality	NN	B-NP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
predefined	predefined	JJ	B-NP	O	O
USPSTF	USPSTF	NN	I-NP	O	O
criteria	criterion	NNS	I-NP	O	O
.	.	.	O	O	O

DATA	DATA	NN	B-NP	O	O
SYNTHESIS	SYNTHESIS	NN	I-NP	O	O
:	:	:	O	O	O
New	New	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
from	from	IN	B-PP	O	O
1	1	CD	B-NP	O	O
good	good	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
quality	quality	NN	I-NP	O	O
RCT	RCT	NN	I-NP	O	O
,	,	,	O	O	O
1	1	CD	B-NP	O	O
good	good	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
quality	quality	NN	I-NP	O	O
meta	meta	SYM	O	B	O
-	-	HYPH	O	O	O
analysis	analysis	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
2	2	CD	B-NP	O	O
fair	fair	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
quality	quality	NN	I-NP	O	O
subanalyses	subanalys	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
RCTs	RCT	NNS	B-NP	O	O
demonstrates	demonstrate	VBZ	B-VP	O	O
that	that	IN	B-SBAR	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CVD	CVD	NN	B-NP	O	B-Disease
events	event	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
known	known	JJ	B-NP	O	O
CVD	CVD	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Men	Men	NN	B-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
studies	study	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
fewer	few	JJR	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarctions	infarction	NNS	I-NP	O	I-Disease
and	and	CC	I-NP	O	O
women	woman	NNS	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
fewer	few	JJR	B-NP	O	O
ischemic	ischemic	JJ	I-NP	O	O
strokes	stroke	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	B	B-Chemical
does	do	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
seem	seem	VB	I-VP	O	O
to	to	TO	I-VP	O	O
affect	affect	VB	I-VP	O	O
CVD	CVD	NN	B-NP	O	B-Disease
mortality	mortality	NN	I-NP	O	O
or	or	CC	O	O	O
all	all	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
cause	cause	NN	I-NP	O	O
mortality	mortality	NN	I-NP	O	O
in	in	IN	B-PP	O	O
either	either	CC	O	O	O
men	man	NNS	B-NP	O	O
or	or	CC	I-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
major	major	JJ	B-NP	O	O
bleeding	bleed	VBG	I-NP	O	B-Disease
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
primarily	primarily	RB	B-NP	O	O
gastrointestinal	gastrointestinal	JJ	I-NP	O	B-Disease
bleeding	bleed	VBG	I-NP	O	I-Disease
events	event	NNS	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
both	both	CC	B-NP	O	O
men	man	NNS	I-NP	O	O
and	and	CC	I-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Men	Men	NN	B-NP	O	O
have	have	VBP	B-VP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
strokes	stroke	NNS	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
RCT	RCT	NN	I-NP	O	O
and	and	CC	I-NP	O	O
meta	meta	NN	I-NP	B	O
-	-	HYPH	O	O	O
analysis	analysis	NN	B-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
hemorrhagic	hemorrhagic	JJ	B-NP	O	B-Disease
strokes	stroke	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
statistically	statistically	RB	B-ADVP	O	O
significantly	significantly	RB	B-ADJP	O	O
increased	increase	VBN	I-ADJP	O	O
.	.	.	O	O	O

LIMITATIONS	LIMITATIONS	NNS	B-NP	O	O
:	:	:	O	O	O
New	New	JJ	B-NP	O	O
evidence	evidence	NN	I-NP	O	O
on	on	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CVD	CVD	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
limited	limit	VBN	B-ADJP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
aspirin	aspirin	NN	B-NP	B	B-Chemical
used	use	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
RCTs	RCT	NNS	I-NP	O	O
varied	vary	VBD	B-VP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
prevented	prevent	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
estimation	estimation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
appropriate	appropriate	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
for	for	IN	B-PP	O	O
primary	primary	JJ	B-NP	O	O
prevention	prevention	NN	I-NP	O	O
.	.	.	O	O	O

Several	Several	JJ	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
RCTs	RCT	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
conducted	conduct	VBN	I-VP	O	O
within	within	IN	B-PP	O	O
populations	population	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
health	health	NN	B-NP	O	O
professionals	professional	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
potentially	potentially	RB	B-ADVP	O	O
limits	limit	VBZ	B-VP	O	O
generalizability	generalizability	NN	B-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Aspirin	Aspirin	NN	B-NP	B	B-Chemical
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
men	man	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
strokes	stroke	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
.	.	.	O	O	O

Aspirin	Aspirin	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
increases	increase	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
serious	serious	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Reducing	Reduce	VBG	B-NP	O	O
harm	harm	NN	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
:	:	:	O	O	O
practical	practical	JJ	B-NP	O	O
considerations	consideration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
argatroban	argatroban	JJ	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Argatroban	Argatroban	NNP	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
hepatically	hepatically	RB	I-NP	O	O
metabolized	metabolize	VBN	I-NP	O	O
,	,	,	I-NP	O	O
direct	direct	JJ	I-NP	O	O
thrombin	thrombin	NN	I-NP	B	O
inhibitor	inhibitor	NN	I-NP	I	O
used	use	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
prophylaxis	prophylaxis	NN	B-NP	O	O
or	or	CC	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
HIT	HIT	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
at	at	IN	B-PP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
undergoing	undergo	VBG	B-VP	O	O
percutaneous	percutaneous	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
intervention	intervention	NN	I-NP	O	O
(	(	(	O	O	O
PCI	PCI	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
objective	objective	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
review	review	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
to	to	TO	B-VP	O	O
summarize	summarize	VB	I-VP	O	O
practical	practical	JJ	B-NP	O	O
considerations	consideration	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
argatroban	argatroban	JJ	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
US	US	NNP	I-NP	O	O
FDA	FDA	NNP	I-NP	B	O
-	-	HYPH	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
argatroban	argatroban	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
2	2	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
(	(	(	O	O	O
reduced	reduce	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
paediatric	paediatric	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
adjusted	adjust	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
activated	activate	VBN	B-NP	O	O
partial	partial	JJ	I-NP	O	O
thromboplastin	thromboplastin	NN	I-NP	B	O
times	time	NNS	I-NP	O	O
(	(	(	O	O	O
aPTTs	aPTT	NNS	B-NP	O	O
)	)	)	O	O	O
1.5	1.5	CD	B-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
times	time	NNS	I-NP	O	O
baseline	baseline	NN	I-NP	O	O
(	(	(	O	O	O
not	not	RB	O	O	O
>	>	SYM	O	O	O
100	100	CD	B-NP	O	O
seconds	second	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Contemporary	Contemporary	JJ	B-NP	O	O
experiences	experience	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
reduced	reduce	VBN	B-NP	O	O
doses	dose	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
also	also	RB	I-VP	O	O
needed	need	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
conditions	condition	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
hypoperfusion	hypoperfusion	NN	I-NP	O	O
,	,	,	O	O	O
e.g	e.g	NN	B-NP	O	O
.	.	.	O	O	O

heart	heart	NN	B-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
,	,	,	O	O	O
yet	yet	CC	O	O	O
are	be	VBP	B-VP	O	O
unnecessary	unnecessary	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
,	,	,	O	O	O
adult	adult	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	O	O
,	,	,	O	O	O
race	race	NN	B-NP	O	O
/	/	SYM	B-VP	O	O
ethnicity	ethnicity	NN	B-NP	O	O
or	or	CC	I-NP	O	O
obesity	obesity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Argatroban	Argatroban	IN	B-PP	B	B-Chemical
0.5	0.5	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1.2	1.2	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
typically	typically	RB	B-VP	O	O
supports	support	VBZ	I-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
aPTTs	aPTT	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
FDA	FDA	NNP	I-NP	B	O
-	-	HYPH	I-NP	O	O
recommended	recommend	VBN	I-NP	O	O
dose	dose	NN	I-NP	O	O
during	during	IN	B-PP	O	O
PCI	PCI	NN	B-NP	B	O
is	be	VBZ	B-VP	O	O
25	25	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
min	min	NN	I-NP	O	O
(	(	(	O	O	O
350	350	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
initial	initial	JJ	I-NP	O	O
bolus	bolus	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
adjusted	adjust	VBN	B-VP	O	O
to	to	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
activated	activate	VBN	B-NP	O	O
clotting	clotting	NN	I-NP	O	O
times	time	NNS	I-NP	O	O
(	(	(	O	O	O
ACTs	ACT	NNS	B-NP	O	O
)	)	)	O	O	O
of	of	IN	B-PP	O	O
300	300	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
450	450	CD	I-NP	O	O
sec	sec	NN	I-NP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
PCI	PCI	NN	B-NP	B	O
,	,	,	O	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
not	not	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
investigated	investigate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hepatically	hepatically	RB	B-NP	O	O
impaired	impaired	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
;	;	:	O	O	O
dose	dose	NN	B-NP	O	O
adjustment	adjustment	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unnecessary	unnecessary	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	O	O
,	,	,	O	O	O
race	race	NN	B-NP	O	O
/	/	SYM	B-VP	O	O
ethnicity	ethnicity	NN	B-NP	O	O
or	or	CC	I-NP	O	O
obesity	obesity	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
lesser	less	JJR	B-NP	O	O
doses	dose	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
adequate	adequate	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
glycoprotein	glycoprotein	NN	I-NP	B	O
IIb	IIb	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
IIIa	IIIa	NN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
.	.	.	O	O	O

Argatroban	Argatroban	NNP	B-NP	B	B-Chemical
prolongs	prolong	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
International	International	NNP	I-NP	O	O
Normalized	Normalized	NNP	I-NP	O	O
Ratio	Ratio	NNP	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
published	publish	VBN	B-NP	O	O
approaches	approach	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
monitoring	monitor	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
argatroban	argatroban	NN	I-NP	B	B-Chemical
-	-	HYPH	B-ADJP	O	O
to	to	TO	B-PP	O	O
-	-	HYPH	B-NP	O	O
warfarin	warfarin	NN	I-NP	B	B-Chemical
transition	transition	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
followed	follow	VBN	I-VP	O	O
.	.	.	O	O	O

Major	Major	JJ	B-NP	O	O
bleeding	bleeding	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
argatroban	argatroban	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
10	10	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
interventional	interventional	JJ	I-NP	O	O
setting	setting	NN	I-NP	O	O
and	and	CC	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
5.8	5.8	CD	I-NP	O	O
%	%	NN	I-NP	O	O
periprocedurally	periprocedurally	RB	B-ADVP	O	O
.	.	.	O	O	O

Argatroban	Argatroban	NNP	B-NP	B	B-Chemical
has	have	VBZ	B-VP	O	O
no	no	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
antidote	antidote	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
if	if	IN	B-SBAR	O	O
excessive	excessive	JJ	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
occurs	occur	VBZ	B-VP	O	O
,	,	,	O	O	O
argatroban	argatroban	JJ	B-NP	B	B-Chemical
infusion	infusion	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
stopped	stop	VBN	I-VP	O	O
or	or	CC	I-VP	O	O
reduced	reduce	VBN	I-VP	O	O
.	.	.	O	O	O

Improved	Improve	VBN	B-NP	O	O
familiarity	familiarity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
healthcare	healthcare	NN	B-NP	O	O
professionals	professional	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
argatroban	argatroban	JJ	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
in	in	IN	B-PP	O	O
special	special	JJ	B-NP	O	O
populations	population	NNS	I-NP	O	O
and	and	CC	B-PP	O	O
during	during	IN	B-PP	O	O
PCI	PCI	NN	B-NP	B	O
,	,	,	O	O	O
may	may	MD	B-VP	O	O
facilitate	facilitate	VB	I-VP	O	O
reduction	reduction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
harm	harm	NN	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
(	(	(	O	O	O
e.g.	e.g.	FW	B-NP	O	O
fewer	few	JJR	I-NP	O	O
thromboses	thrombos	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
its	its	PRP$	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
(	(	(	O	O	O
e.g.	e.g.	FW	B-NP	O	O
fewer	few	JJR	I-NP	O	O
argatroban	argatroban	JJ	I-NP	B	B-Chemical
medication	medication	NN	I-NP	O	O
errors	error	NNS	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Rhabdomyolysis	Rhabdomyolysis	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
brain	brain	NN	I-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
stroke	stroke	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
heroin	heroin	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
male	male	NN	I-NP	O	O
under	under	IN	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
maintenance	maintenance	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
There	There	EX	B-NP	O	O
are	be	VBP	B-VP	O	O
several	several	JJ	B-NP	O	O
complications	complication	NNS	I-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
heroin	heroin	NN	B-NP	B	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
,	,	,	O	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
are	be	VBP	B-VP	O	O
life	life	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
threatening	threatening	NN	I-NP	O	O
.	.	.	O	O	O

Methadone	Methadone	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
aggravate	aggravate	VB	I-VP	O	O
this	this	DT	B-NP	O	O
problem	problem	NN	I-NP	O	O
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
description	description	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
33	33	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
man	man	NN	I-NP	O	O
presented	present	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
cerebral	cerebral	JJ	B-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
stroke	stroke	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
intravenous	intravenous	JJ	B-NP	O	O
heroin	heroin	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
heroin	heroin	NN	B-NP	B	B-Chemical
since	since	IN	B-PP	O	O
age	age	NN	B-NP	O	O
20	20	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
had	have	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
150	150	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
methadone	methadone	NN	I-NP	B	B-Chemical
daily	daily	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
6	6	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

He	He	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
unconsciousness	unconsciousness	NN	B-NP	O	B-Disease
at	at	IN	B-PP	O	O
home	home	NN	B-NP	O	O
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
sent	send	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
hospital	hospital	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ER	ER	NN	I-NP	B	O
,	,	,	O	O	O
his	his	PRP$	B-NP	O	O
opiate	opiate	JJ	I-NP	O	O
level	level	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
4497	4497	CD	B-NP	O	O
ng	ng	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
ml	ml	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ICU	ICU	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
acute	acute	JJ	B-NP	O	O
respiratory	respiratory	JJ	I-NP	O	B-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

After	After	IN	B-PP	O	O
transfer	transfer	NN	B-NP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
internal	internal	JJ	I-NP	O	O
ward	ward	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
noted	note	VBD	B-VP	O	O
aphasia	aphasia	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
weakness	weakness	NN	I-NP	O	B-Disease
of	of	IN	B-PP	O	O
his	his	PRP$	B-NP	O	O
left	left	JJ	I-NP	O	O
limbs	limb	NNS	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
MRI	MRI	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
ischemic	ischemic	JJ	I-NP	O	I-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
Those	Those	DT	B-NP	O	O
using	use	VBG	I-NP	O	O
methadone	methadone	NN	I-NP	B	B-Chemical
and	and	CC	I-NP	O	O
heroin	heroin	NN	I-NP	B	B-Chemical
simultaneously	simultaneously	RB	B-ADVP	O	O
may	may	MD	B-VP	O	O
increase	increase	VB	I-VP	O	O
risk	risk	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rhabdomyolysis	rhabdomyolysis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
ischemic	ischemic	JJ	B-NP	O	B-Disease
stroke	stroke	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
under	under	IN	B-PP	O	O
methadone	methadone	NN	B-NP	B	B-Chemical
maintenance	maintenance	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
warned	warn	VBN	I-VP	O	O
regarding	regard	VBG	B-PP	O	O
these	these	DT	B-NP	O	O
serious	serious	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Hypotheses	Hypothesis	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
heroin	heroin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
rhabdomyolysis	rhabdomyolysis	NN	I-NP	O	B-Disease
and	and	CC	I-NP	O	O
stroke	stroke	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
heroin	heroin	NN	B-NP	B	B-Chemical
abusers	abuser	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
discussed	discuss	VBN	I-VP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
vulnerability	vulnerability	NN	I-NP	O	O
to	to	TO	B-PP	O	O
6	6	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
hydroxydopamine	hydroxydopamine	NN	I-NP	I	I-Chemical
lesion	lesion	NN	I-NP	O	O
and	and	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dyskinesias	dyskinesia	NNS	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
lacking	lack	VBG	B-VP	O	O
CB1	CB1	NN	B-NP	O	O
cannabinoid	cannabinoid	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
.	.	.	O	O	O

Motor	Motor	NNP	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
,	,	,	O	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
DA	DA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
neuronal	neuronal	JJ	B-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	O	O	O
proenkephalin	proenkephalin	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
PENK	PENK	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
gene	gene	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
caudate	caudate	NN	I-NP	O	O
-	-	HYPH	O	O	O
putamen	putaman	NNS	B-NP	O	O
(	(	(	O	O	O
CPu	CPu	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
6	6	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
OHDA	OHDA	NN	I-NP	I	I-Chemical
-	-	HYPH	I-NP	O	O
lesioned	lesione	VBN	B-VP	O	O
and	and	CC	I-VP	O	O
treated	treat	VBN	I-VP	O	O
(	(	(	O	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
DOPA	DOPA	NN	I-NP	I	I-Chemical
+	+	SYM	I-NP	O	I-Chemical
benserazide	benserazide	NN	I-NP	B	I-Chemical
)	)	)	O	O	O
CB1	CB1	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
and	and	CC	O	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
6	6	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
OHDA	OHDA	NN	I-NP	I	I-Chemical
produced	produce	VBD	B-VP	O	O
more	more	RBR	B-NP	O	O
severe	severe	JJ	I-NP	O	O
motor	motor	NN	I-NP	O	O
deterioration	deterioration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
CB1	CB1	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
accompanied	accompany	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
loss	loss	NN	I-NP	O	O
of	of	IN	B-PP	O	O
DA	DA	NN	B-NP	B	B-Chemical
neurons	neuron	NNS	I-NP	O	O
and	and	CC	O	O	O
increased	increase	VBN	B-NP	O	O
PENK	PENK	NN	I-NP	O	B-Chemical
gene	gene	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CPu	CPu	NN	I-NP	O	O
.	.	.	O	O	O

Oxidative	Oxidative	JJ	B-NP	O	O
/	/	SYM	I-NP	O	O
nitrosative	nitrosative	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
neuroinflammatory	neuroinflammatory	JJ	I-NP	O	O
parameters	parameter	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
estimated	estimate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CPu	CPu	NN	I-NP	O	O
and	and	CC	O	O	O
cingulate	cingulate	VBP	B-VP	O	O
cortex	cortex	NN	B-NP	O	O
(	(	(	O	O	O
Cg	Cg	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CB1	CB1	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
higher	high	JJR	B-NP	O	O
MDA	MDA	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
iNOS	iNOS	NN	B-NP	O	O
protein	protein	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
CPu	CPu	NN	I-NP	O	O
and	and	CC	I-NP	O	O
Cg	Cg	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
DOPA	DOPA	NN	I-NP	I	I-Chemical
+	+	SYM	B-NP	O	I-Chemical
benserazide	benserazide	NN	I-NP	B	I-Chemical
(	(	(	O	O	O
12	12	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
less	less	RBR	B-NP	O	O
severe	severe	JJ	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
CB1	CB1	NN	B-NP	O	O
KO	KO	NN	I-NP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
WT	WT	JJ	B-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
lack	lack	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cannabinoid	cannabinoid	NN	B-NP	O	O
CB1	CB1	NN	I-NP	O	O
receptors	receptor	NNS	I-NP	O	O
increased	increase	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
motor	motor	NN	B-NP	O	O
impairment	impairment	NN	I-NP	O	O
and	and	CC	O	O	O
DA	DA	NN	B-NP	B	B-Chemical
lesion	lesion	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
L	L	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
DOPA	DOPA	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
activation	activation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CB1	CB1	NN	B-NP	O	O
receptors	receptor	NNS	I-NP	O	O
offers	offer	VBZ	B-VP	O	O
neuroprotection	neuroprotection	NN	B-NP	O	O
against	against	IN	B-PP	O	O
dopaminergic	dopaminergic	JJ	B-NP	O	O
lesion	lesion	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	I	I-Chemical
DOPA	DOPA	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
dyskinesias	dyskinesia	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Animal	Animal	NN	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
mania	mania	NN	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
:	:	:	O	O	O
Evidence	Evidence	NN	B-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
submitochondrial	submitochondrial	JJ	B-NP	O	O
particles	particle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
intracerebroventricular	intracerebroventricular	JJ	I-NP	O	O
(	(	(	O	O	O
ICV	ICV	NN	B-NP	O	O
)	)	)	O	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
a	a	DT	B-NP	O	O
Na	Na	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
/	/	SYM	B-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
ATPase	ATPase	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
suggested	suggest	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
mimic	mimic	VB	I-VP	O	O
some	some	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
human	human	JJ	B-NP	O	O
bipolar	bipolar	JJ	I-NP	O	B-Disease
mania	mania	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Clinical	Clinical	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
shown	show	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Herein	Herein	RB	B-ADVP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
biochemical	biochemical	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ICV	ICV	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
achieve	achieve	VB	I-VP	O	O
this	this	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
and	and	CC	O	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
ICV	ICV	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
(	(	(	O	O	O
at	at	IN	B-PP	O	O
concentrations	concentration	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
3	3	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
)	)	)	O	O	O
on	on	IN	B-PP	O	O
locomotion	locomotion	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
open	open	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
field	field	NN	I-NP	O	O
test	test	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
thiobarbituric	thiobarbituric	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
reactive	reactive	JJ	I-NP	O	O
substances	substance	NNS	I-NP	O	O
(	(	(	O	O	O
TBARSs	TBARS	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
production	production	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
submitochondrial	submitochondrial	JJ	B-NP	O	O
particles	particle	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prefrontal	prefrontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
,	,	,	I-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
,	,	,	I-NP	O	O
striatum	striatum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
amygdala	amygdala	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
at	at	IN	B-PP	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
2	2	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
(	(	(	O	O	O
-	-	SYM	O	O	O
3	3	CD	O	O	O
)	)	)	O	O	O
M	M	NN	B-NP	O	O
induced	induce	VBD	B-VP	O	O
hyperlocomotion	hyperlocomotion	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
this	this	DT	B-NP	O	O
response	response	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
up	up	RB	B-NP	O	O
to	to	TO	I-NP	O	O
7	7	CD	I-NP	O	O
days	day	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
ICV	ICV	NN	I-NP	O	O
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
observed	observe	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
persistent	persistent	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
spontaneous	spontaneous	JJ	I-NP	O	O
locomotion	locomotion	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
TBARS	TBARS	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
and	and	CC	O	O	O
superoxide	superoxide	NN	B-NP	B	B-Chemical
generation	generation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
submitochondrial	submitochondrial	JJ	B-NP	O	O
particles	particle	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
prefrontal	prefrontal	JJ	I-NP	O	O
cortex	cortex	NN	I-NP	O	O
,	,	,	I-NP	O	O
striatum	striatum	NN	I-NP	O	O
and	and	CC	I-NP	O	O
amygdala	amygdala	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
ouabain	ouabain	NN	B-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
induced	induce	VBN	B-NP	O	O
mania	mania	NN	I-NP	O	B-Disease
-	-	HYPH	O	O	O
like	like	JJ	B-NP	O	O
behavior	behavior	NN	I-NP	O	O
may	may	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
a	a	DT	B-NP	O	O
useful	useful	JJ	I-NP	O	O
animal	animal	NN	I-NP	O	O
model	model	NN	I-NP	O	O
to	to	TO	B-VP	O	O
test	test	VB	I-VP	O	O
the	the	DT	B-NP	O	O
hypothesis	hypothesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
involvement	involvement	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
stress	stress	NN	I-NP	O	O
in	in	IN	B-PP	O	O
bipolar	bipolar	JJ	B-NP	O	B-Disease
disorder	disorder	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Intraoperative	Intraoperative	JJ	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
during	during	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
with	with	IN	B-PP	O	O
citrate	citrate	NN	B-NP	B	B-Chemical
dialysate	dialysate	NN	I-NP	O	O
.	.	.	O	O	O

Liver	Liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
acutely	acutely	RB	B-NP	O	O
ill	ill	JJ	I-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
carries	carry	VBZ	B-VP	O	O
high	high	JJ	B-NP	O	O
intraoperative	intraoperative	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
immediate	immediate	JJ	I-NP	O	O
postoperative	postoperative	JJ	I-NP	O	O
risks	risk	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
are	be	VBP	B-VP	O	O
increased	increase	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
concomitant	concomitant	JJ	B-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
kidney	kidney	NN	I-NP	O	I-Disease
injury	injury	NN	I-NP	O	I-Disease
(	(	(	O	O	O
AKI	AKI	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
intraoperative	intraoperative	JJ	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
sometimes	sometimes	RB	I-VP	O	O
required	require	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
allow	allow	VB	I-VP	O	O
the	the	DT	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
to	to	TO	B-VP	O	O
proceed	proceed	VB	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
derangements	derangement	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
procoagulant	procoagulant	NN	I-NP	O	O
and	and	CC	O	O	O
anticoagulant	anticoagulant	JJ	B-NP	O	O
pathways	pathway	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
difficulties	difficulty	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
during	during	IN	B-PP	O	O
dialysis	dialysis	NN	B-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
continued	continue	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
operating	operating	NN	I-NP	O	O
room	room	NN	I-NP	O	O
.	.	.	O	O	O

Systemic	Systemic	JJ	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
unsafe	unsafe	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
regional	regional	JJ	I-NP	O	O
citrate	citrate	NN	I-NP	B	B-Chemical
anticoagulation	anticoagulation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
absence	absence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
functional	functional	JJ	I-NP	O	O
liver	liver	NN	I-NP	O	O
carries	carry	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
citrate	citrate	NN	B-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Citrate	Citrate	JJ	B-NP	B	B-Chemical
dialysate	dialysate	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
dialysate	dialysate	NN	I-NP	O	O
with	with	IN	B-PP	O	O
citric	citric	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
anticoagulation	anticoagulation	NN	B-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
cannot	cannot	MD	B-VP	O	O
tolerate	tolerate	VB	I-VP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
or	or	CC	O	O	O
regional	regional	JJ	B-NP	O	O
citrate	citrate	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
40	40	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
female	female	NN	I-NP	O	O
with	with	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
fulminant	fulminant	JJ	I-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
with	with	IN	B-PP	O	O
associated	associate	VBN	B-NP	O	O
AKI	AKI	NN	I-NP	O	B-Disease
who	who	WP	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
intraoperative	intraoperative	JJ	B-NP	O	O
dialytic	dialytic	JJ	I-NP	O	O
support	support	NN	I-NP	O	O
during	during	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
anticoagulated	anticoagulate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
citrate	citrate	NN	B-NP	B	B-Chemical
dialysate	dialysate	NN	I-NP	O	O
during	during	IN	B-PP	O	O
the	the	DT	B-NP	O	O
entire	entire	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
tolerated	tolerate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
procedure	procedure	NN	I-NP	O	O
well	well	RB	B-ADVP	O	O
without	without	IN	B-PP	O	O
any	any	DT	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
citrate	citrate	NN	B-NP	B	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
maintained	maintain	VBD	B-VP	O	O
adequate	adequate	JJ	B-NP	O	O
anticoagulation	anticoagulation	NN	I-NP	O	O
for	for	IN	B-PP	O	O
patency	patency	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dialysis	dialysis	NN	I-NP	O	O
circuit	circuit	NN	I-NP	O	O
.	.	.	O	O	O

Citrate	Citrate	JJ	B-NP	B	B-Chemical
dialysate	dialysate	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
safe	safe	JJ	I-NP	O	O
alternative	alternative	NN	I-NP	O	O
for	for	IN	B-PP	O	O
intradialytic	intradialytic	JJ	B-NP	O	O
support	support	NN	I-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Delirium	Delirium	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
with	with	IN	B-PP	O	O
toxic	toxic	JJ	B-NP	O	O
flecainide	flecainide	NN	I-NP	B	B-Chemical
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
:	:	:	O	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
describe	describe	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
with	with	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
SUMMARY	SUMMARY	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
69	69	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
white	white	JJ	I-NP	O	O
female	female	JJ	I-NP	O	O
presented	present	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
department	department	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
confusion	confusion	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
paranoia	paranoia	NN	I-NP	O	B-Disease
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
past	past	JJ	I-NP	O	O
several	several	JJ	I-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
taking	take	VBG	I-VP	O	O
carvedilol	carvedilol	NN	B-NP	B	B-Chemical
12	12	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
,	,	,	O	O	O
warfarin	warfarin	NN	B-NP	B	B-Chemical
2	2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
folic	folic	JJ	B-NP	B	B-Chemical
acid	acid	NN	I-NP	I	I-Chemical
1	1	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
levothyroxine	levothyroxine	NN	B-NP	B	B-Chemical
100	100	CD	I-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
pantoprazole	pantoprazole	NN	B-NP	B	B-Chemical
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
paroxetine	paroxetine	NN	B-NP	B	B-Chemical
40	40	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Flecainide	Flecainide	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
started	start	VBN	I-VP	O	O
2	2	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
atrial	atrial	JJ	B-NP	O	B-Disease
fibrillation	fibrillation	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Laboratory	Laboratory	NN	B-NP	O	O
test	test	NN	I-NP	O	O
findings	finding	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
were	be	VBD	B-VP	O	O
notable	notable	JJ	B-ADJP	O	O
only	only	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
flecainide	flecainide	NN	I-NP	B	B-Chemical
plasma	plasma	NN	I-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
1360	1360	CD	B-NP	O	O
microg	microg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
L	L	NN	B-NP	O	O
(	(	(	O	O	O
reference	reference	NN	B-NP	O	O
range	range	NN	I-NP	O	O
200	200	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
1000	1000	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
metabolic	metabolic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
taking	take	VBG	I-VP	O	O
for	for	IN	B-PP	O	O
more	more	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
5	5	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
.	.	.	O	O	O

Paroxetine	Paroxetine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
reduced	reduce	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
50	50	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
daily	daily	RB	I-ADVP	O	O
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
resolved	resolve	VBD	B-VP	O	O
3	3	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
later	later	RB	B-ADVP	O	O
.	.	.	O	O	O

DISCUSSION	DISCUSSION	NN	B-NP	O	O
:	:	:	O	O	O
Flecainide	Flecainide	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
pharmacologically	pharmacologically	RB	B-NP	O	O
similar	similar	JJ	I-NP	O	O
agents	agent	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
interact	interact	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
channels	channel	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
delirium	delirium	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
susceptible	susceptible	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
MEDLINE	MEDLINE	NNP	I-NP	O	O
search	search	NN	I-NP	O	O
(	(	(	O	O	O
1966	1966	CD	B-NP	O	O
-	-	HYPH	O	O	O
January	January	NNP	B-NP	O	O
2009	2009	CD	I-NP	O	O
)	)	)	O	O	O
revealed	reveal	VBD	B-VP	O	O
one	one	CD	B-NP	O	O
in	in	FW	I-NP	O	O
vivo	vivo	FW	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
substrate	substrate	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
paroxetine	paroxetine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
3	3	CD	B-NP	O	O
case	case	NN	I-NP	O	O
reports	report	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
.	.	.	O	O	O

According	Accord	VBG	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
Naranjo	Naranjo	NNP	I-NP	O	O
probability	probability	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
probable	probable	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
delirium	delirium	NN	I-NP	O	B-Disease
;	;	:	O	O	O
the	the	DT	B-NP	O	O
Horn	Horn	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Interaction	Interaction	NNP	I-NP	O	O
Probability	Probability	NNP	I-NP	O	O
Scale	Scale	NNP	I-NP	O	O
indicates	indicate	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
pharmacokinetic	pharmacokinetic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
paroxetine	paroxetine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Supratherapeutic	Supratherapeutic	JJ	B-NP	O	O
flecainide	flecainide	NN	I-NP	B	B-Chemical
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
delirium	delirium	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Because	Because	IN	B-SBAR	O	O
toxicity	toxicity	NN	B-NP	O	B-Disease
may	may	MD	B-VP	O	O
occur	occur	VB	I-VP	O	O
when	when	WRB	B-ADVP	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
prescribed	prescribe	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
paroxetine	paroxetine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
potent	potent	JJ	I-NP	O	O
CYP2D6	CYP2D6	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
,	,	,	O	O	O
flecainide	flecainide	NN	B-NP	B	B-Chemical
plasma	plasma	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
monitored	monitor	VBN	I-VP	O	O
closely	closely	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
commencement	commencement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CYP2D6	CYP2D6	NN	B-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

Efficacy	Efficacy	NN	B-NP	O	O
of	of	IN	B-PP	O	O
everolimus	everolimus	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
RAD001	RAD001	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
NSCLC	NSCLC	NN	I-NP	O	B-Disease
previously	previously	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
alone	alone	RB	B-ADVP	O	O
or	or	CC	O	O	O
with	with	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
and	and	CC	I-NP	O	O
EGFR	EGFR	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Treatment	Treatment	NN	B-NP	O	O
options	option	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
scarce	scarce	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
pretreated	pretreate	VBN	B-VP	O	O
advanced	advance	VBN	I-VP	B	O
non	non	AFX	O	O	B-Disease
-	-	HYPH	O	O	I-Disease
small	small	JJ	B-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
lung	lung	NN	I-NP	O	I-Disease
cancer	cancer	NN	I-NP	O	I-Disease
(	(	(	O	O	O
NSCLC	NSCLC	NN	B-NP	O	B-Disease
)	)	)	O	O	O
patients	patient	NNS	B-NP	O	O
.	.	.	O	O	O

RAD001	RAD001	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
oral	oral	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mammalian	mammalian	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rapamycin	rapamycin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
mTOR	mTOR	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
shown	show	VBN	I-VP	O	O
phase	phase	NN	B-NP	O	O
I	I	CD	I-NP	O	O
efficacy	efficacy	NN	I-NP	O	O
in	in	IN	B-PP	O	O
NSCLC	NSCLC	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Stage	Stage	NN	B-NP	O	O
IIIb	IIIb	NN	I-NP	O	O
or	or	CC	O	O	O
IV	IV	CD	B-NP	O	O
NSCLC	NSCLC	NN	I-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
two	two	CD	B-NP	O	O
or	or	CC	I-NP	O	O
fewer	few	JJR	I-NP	O	O
prior	prior	JJ	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
regimens	regimen	NNS	I-NP	O	O
,	,	,	O	O	O
one	one	CD	B-NP	O	O
platinum	platinum	NN	I-NP	B	B-Chemical
based	base	VBN	B-VP	O	O
(	(	(	O	O	O
stratum	stratum	NN	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
both	both	CC	O	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
and	and	CC	O	O	O
epidermal	epidermal	JJ	B-NP	B	O
growth	growth	NN	I-NP	I	O
factor	factor	NN	I-NP	I	O
receptor	receptor	NN	I-NP	O	O
tyrosine	tyrosine	NN	I-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
inhibitors	inhibitor	NNS	I-NP	O	O
(	(	(	O	O	O
stratum	stratum	NN	B-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
received	receive	VBD	B-VP	O	O
RAD001	RAD001	NN	B-NP	B	B-Chemical
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
until	until	IN	B-PP	O	O
progression	progression	NN	B-NP	O	O
or	or	CC	O	O	O
unacceptable	unacceptable	JJ	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Primary	Primary	JJ	B-NP	O	O
objective	objective	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
overall	overall	JJ	B-NP	O	O
response	response	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
(	(	(	O	O	O
ORR	ORR	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Analyses	Analysis	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
markers	marker	NNS	B-NP	O	O
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
mTOR	mTOR	NN	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
carried	carry	VBN	I-VP	O	O
out	out	RP	B-PRT	O	O
on	on	IN	B-PP	O	O
archival	archival	JJ	B-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
subgroup	subgroup	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
immunohistochemistry	immunohistochemistry	NN	B-NP	O	O
(	(	(	O	O	O
IHC	IHC	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
direct	direct	JJ	B-NP	O	O
mutation	mutation	NN	I-NP	O	O
sequencing	sequencing	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Eighty	Eighty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
five	five	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
enrolled	enrol	VBN	I-VP	O	O
,	,	,	O	O	O
42	42	CD	B-NP	O	O
in	in	IN	B-PP	O	O
stratum	stratum	NN	B-NP	O	O
1	1	CD	I-NP	O	O
and	and	CC	I-NP	O	O
43	43	CD	I-NP	O	O
in	in	IN	B-PP	O	O
stratum	stratum	NN	B-NP	O	O
.	.	.	O	O	O

ORR	ORR	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
4.7	4.7	CD	B-NP	O	O
%	%	NN	I-NP	O	O
(	(	(	O	O	O
7.1	7.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
stratum	stratum	NN	I-NP	O	O
1	1	CD	I-NP	O	O
;	;	:	O	O	O
2.3	2.3	CD	B-NP	O	O
%	%	NN	I-NP	O	O
stratum	stratum	NN	I-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Overall	Overall	JJ	B-NP	O	O
disease	disease	NN	I-NP	O	O
control	control	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
47.1	47.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Median	Median	JJ	B-NP	O	O
progression	progression	NN	I-NP	O	O
-	-	HYPH	O	O	O
free	free	JJ	B-NP	O	O
survivals	survival	NNS	I-NP	O	O
(	(	(	O	O	O
PFSs	PFS	NNS	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
2.6	2.6	CD	B-NP	O	O
(	(	(	O	O	O
stratum	stratum	NN	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
2.7	2.7	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
(	(	(	O	O	O
stratum	stratum	NN	B-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Common	Common	JJ	B-ADJP	O	O
>	>	SYM	B-NP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
grade	grade	NN	B-NP	O	O
3	3	CD	B-NP	O	O
events	event	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
fatigue	fatigue	NN	B-NP	O	B-Disease
,	,	,	O	O	O
dyspnea	dyspnea	NN	B-NP	O	B-Disease
,	,	,	O	O	O
stomatitis	stomatitis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
anemia	anemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
thrombocytopenia	thrombocytopenia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Pneumonitis	Pneumonitis	NN	B-NP	O	B-Disease
,	,	,	O	O	O
probably	probably	RB	B-ADVP	O	O
or	or	CC	I-ADVP	O	O
possibly	possibly	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
,	,	,	O	O	O
mainly	mainly	RB	B-ADVP	O	O
grade	grade	NN	B-NP	O	O
1	1	CD	I-NP	O	O
/	/	SYM	I-NP	O	O
2	2	CD	I-NP	O	O
,	,	,	O	O	O
occurred	occur	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

Cox	Cox	NNP	B-NP	O	O
regression	regression	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
IHC	IHC	NN	B-NP	O	O
scores	score	NNS	I-NP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
only	only	RB	B-NP	O	O
phospho	phospho	JJ	I-NP	O	O
AKT	AKT	NN	I-NP	O	O
(	(	(	O	O	O
pAKT	pAKT	NN	B-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
independent	independent	JJ	I-NP	O	O
predictor	predictor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
worse	worse	JJR	B-NP	O	O
PFS	PFS	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
RAD001	RAD001	NN	B-NP	B	B-Chemical
10	10	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
well	well	RB	I-VP	O	O
tolerated	tolerate	VBN	I-VP	O	O
,	,	,	O	O	O
showing	show	VBG	B-VP	O	O
modest	modest	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
pretreated	pretreate	VBN	B-NP	O	O
NSCLC	NSCLC	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Evaluation	Evaluation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
RAD001	RAD001	NN	B-NP	B	B-Chemical
plus	plus	CC	O	O	O
standard	standard	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
for	for	IN	B-PP	O	O
metastatic	metastatic	JJ	B-NP	O	O
NSCLC	NSCLC	NN	I-NP	O	B-Disease
continues	continue	VBZ	B-VP	O	O
.	.	.	O	O	O

Posttransplant	Posttransplant	NN	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
:	:	:	O	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Posttransplant	Posttransplant	NN	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
common	common	JJ	I-NP	O	O
problem	problem	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
may	may	MD	B-VP	O	O
hinder	hinder	VB	I-VP	O	O
patients	patient	NNS	B-NP	O	O
'	'	POS	B-NP	O	O
quality	quality	NN	I-NP	O	O
of	of	IN	B-PP	O	O
life	life	NN	B-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
occurs	occur	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
12	12	CD	B-NP	O	O
to	to	TO	B-PP	O	O
76	76	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
most	most	RBS	B-ADJP	O	O
common	common	JJ	I-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
immediate	immediate	JJ	I-NP	O	O
posttransplant	posttransplant	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
variety	variety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
factors	factor	NNS	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
identified	identify	VBN	I-VP	O	O
that	that	WDT	B-NP	O	O
increase	increase	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
posttransplant	posttransplant	NN	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
,	,	,	O	O	O
of	of	IN	B-PP	O	O
which	which	WDT	B-NP	O	O
the	the	DT	B-NP	O	O
level	level	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
most	most	RBS	B-ADJP	O	O
important	important	JJ	I-ADJP	O	O
.	.	.	O	O	O

Sirolimus	Sirolimus	NNP	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
mammalian	mammalian	JJ	I-NP	O	O
target	target	NN	I-NP	O	O
of	of	IN	B-PP	O	O
rapamycin	rapamycin	NN	B-NP	B	B-Chemical
inhibitor	inhibitor	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
implicated	implicate	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
playing	play	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
special	special	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
posttransplant	posttransplant	NN	B-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

This	This	DT	B-NP	O	O
review	review	NN	I-NP	O	O
considers	consider	VBZ	B-VP	O	O
anemia	anemia	NN	B-NP	O	B-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
sirolimus	sirolimus	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
including	include	VBG	B-PP	O	O
its	its	PRP$	B-NP	O	O
presentation	presentation	NN	I-NP	O	O
,	,	,	O	O	O
mechanisms	mechanism	NNS	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
management	management	NN	B-NP	O	O
.	.	.	O	O	O

Coronary	Coronary	JJ	B-NP	O	O
computerized	computerized	JJ	I-NP	O	O
tomography	tomography	NN	I-NP	O	O
angiography	angiography	NN	I-NP	O	O
for	for	IN	B-PP	O	O
rapid	rapid	JJ	B-NP	O	O
discharge	discharge	NN	I-NP	O	O
of	of	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
risk	risk	NN	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Most	Most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
presenting	present	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
emergency	emergency	NN	B-NP	O	O
departments	department	NNS	I-NP	O	O
(	(	(	O	O	O
EDs	ED	NNS	B-NP	B	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
12	12	CD	I-NP	O	O
hours	hour	NNS	I-NP	O	O
and	and	CC	O	O	O
receive	receive	VB	B-VP	O	O
a	a	DT	B-NP	O	O
"	"	``	I-NP	O	O
rule	rule	NN	I-NP	O	O
out	out	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
coronary	coronary	JJ	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
"	"	''	I-NP	O	O
protocol	protocol	NN	I-NP	O	O
,	,	,	O	O	O
often	often	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
noninvasive	noninvasive	JJ	B-NP	O	O
testing	testing	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-VP	O	O
discharge	discharge	VB	I-VP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
without	without	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
,	,	,	O	O	O
coronary	coronary	JJ	B-NP	O	O
computerized	computerized	JJ	I-NP	O	O
tomography	tomography	NN	I-NP	O	O
angiography	angiography	NN	I-NP	O	O
(	(	(	O	O	O
CTA	CTA	NN	B-NP	B	O
)	)	)	O	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
useful	useful	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
identifying	identify	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
risk	risk	NN	I-NP	O	O
for	for	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	I-VP	O	O
discharged	discharge	VBN	I-VP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
is	be	VBZ	B-VP	O	O
unclear	unclear	JJ	B-ADJP	O	O
whether	whether	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
CTA	CTA	NN	I-NP	B	O
strategy	strategy	NN	I-NP	O	O
would	would	MD	B-VP	O	O
be	be	VB	I-VP	O	O
efficacious	efficacious	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
vasospasm	vasospasm	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
account	account	VB	I-VP	O	O
for	for	IN	B-PP	O	O
some	some	DT	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ischemia	ischemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
studied	study	VBD	B-VP	O	O
whether	whether	IN	B-SBAR	O	O
a	a	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
CTA	CTA	NN	I-NP	B	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
could	could	MD	B-VP	O	O
identify	identify	VB	I-VP	O	O
a	a	DT	B-NP	O	O
subset	subset	NN	I-NP	O	O
safe	safe	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
discharge	discharge	NN	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
prospectively	prospectively	RB	B-ADVP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
safety	safety	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
CTA	CTA	NN	I-NP	B	O
for	for	IN	B-PP	O	O
low	low	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
risk	risk	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
presented	present	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
ED	ED	NN	I-NP	B	O
with	with	IN	B-PP	O	O
cocaineassociated	cocaineassociate	VBN	B-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
(	(	(	O	O	O
self	self	NN	B-NP	O	O
-	-	HYPH	B-VP	O	O
reported	report	VBN	I-VP	O	O
or	or	CC	O	O	O
positive	positive	JJ	B-NP	O	O
urine	urine	NN	I-NP	O	O
test	test	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Consecutive	Consecutive	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
either	either	CC	O	O	O
immediate	immediate	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
CTA	CTA	NN	I-NP	B	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ED	ED	NN	I-NP	B	O
(	(	(	O	O	O
without	without	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
markers	marker	NNS	I-NP	O	O
)	)	)	O	O	O
or	or	CC	O	O	O
underwent	undergo	VBD	B-VP	O	O
coronary	coronary	JJ	B-NP	O	O
CTA	CTA	NN	I-NP	B	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
brief	brief	JJ	I-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
with	with	IN	B-PP	O	O
serial	serial	JJ	B-NP	O	O
cardiac	cardiac	JJ	I-NP	O	O
marker	marker	NN	I-NP	O	O
measurements	measurement	NNS	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
negative	negative	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
CTA	CTA	NN	I-NP	B	O
(	(	(	O	O	O
maximal	maximal	JJ	B-NP	O	O
stenosis	stenosis	NN	I-NP	O	B-Disease
less	less	JJR	B-NP	O	O
than	than	IN	I-NP	O	O
50	50	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
discharged	discharge	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
main	main	JJ	I-NP	O	O
outcome	outcome	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
death	death	NN	I-NP	O	O
or	or	CC	O	O	O
myocardial	myocardial	JJ	B-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
59	59	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
associated	associate	VBN	I-NP	O	O
chest	chest	NN	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
45.6	45.6	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	B-NP	O	O
6.6	6.6	CD	B-NP	O	O
yrs	yr	NNS	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
86	86	CD	B-NP	O	O
%	%	NN	I-NP	O	O
black	black	JJ	B-ADJP	O	O
,	,	,	O	O	O
66	66	CD	B-NP	O	O
%	%	NN	I-NP	O	O
male	male	NN	I-NP	O	O
.	.	.	O	O	O

Seventy	Seventy	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nine	nine	CD	I-NP	O	O
percent	percent	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
normal	normal	JJ	I-NP	O	O
or	or	CC	I-NP	O	O
nonspecific	nonspecific	JJ	I-NP	O	O
ECG	ECG	NN	I-NP	O	O
and	and	CC	O	O	O
85	85	CD	B-NP	O	O
%	%	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
TIMI	TIMI	NN	I-NP	O	O
score	score	NN	I-NP	O	O
<	<	SYM	B-NP	O	O
2	2	CD	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
received	receive	VBD	B-VP	O	O
coronary	coronary	JJ	B-NP	O	O
CTA	CTA	NN	I-NP	B	O
immediately	immediately	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ED	ED	NN	I-NP	B	O
,	,	,	O	O	O
18	18	CD	B-NP	O	O
of	of	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
discharged	discharge	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
CTA	CTA	NN	B-NP	B	O
(	(	(	O	O	O
90	90	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Thirty	Thirty	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
nine	nine	CD	I-NP	O	O
received	receive	VBD	B-VP	O	O
coronary	coronary	JJ	B-NP	O	O
CTA	CTA	NN	I-NP	B	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
brief	brief	JJ	I-NP	O	O
observation	observation	NN	I-NP	O	O
period	period	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
37	37	CD	B-NP	O	O
discharged	discharged	JJ	I-NP	O	O
home	home	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
CTA	CTA	NN	B-NP	B	O
(	(	(	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Six	Six	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
coronary	coronary	JJ	B-NP	O	B-Disease
stenosis	stenosis	NN	I-NP	O	I-Disease
>	>	SYM	B-VP	O	O
or	or	CC	O	O	O
=	=	SYM	B-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
the	the	DT	B-NP	O	O
30	30	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
period	period	NN	B-NP	O	O
,	,	,	O	O	O
no	no	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
died	die	VBD	B-VP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
(	(	(	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6.1	6.1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
sustained	sustain	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
nonfatal	nonfatal	JJ	I-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
(	(	(	O	O	O
0	0	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
,	,	,	O	O	O
0	0	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
6.1	6.1	CD	I-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Although	Although	IN	B-SBAR	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
ischemia	ischemia	NN	I-NP	O	I-Disease
can	can	MD	B-VP	O	O
result	result	VB	I-VP	O	O
from	from	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
vasoconstriction	vasoconstriction	NN	I-NP	O	O
,	,	,	O	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
associated	associate	VBN	B-VP	O	O
chest	chest	NN	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
a	a	DT	B-NP	O	O
non	non	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
ischemic	ischemic	JJ	I-NP	O	B-Disease
ECG	ECG	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
TIMI	TIMI	NN	I-NP	O	O
risk	risk	NN	I-NP	O	O
score	score	NN	I-NP	O	O
<	<	SYM	B-NP	O	O
2	2	CD	B-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
safely	safely	RB	I-VP	O	O
discharged	discharge	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ED	ED	NN	I-NP	B	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
negative	negative	JJ	I-NP	O	O
coronary	coronary	JJ	I-NP	O	O
CTA	CTA	NN	I-NP	B	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
low	low	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
30	30	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Late	Late	JJ	B-NP	O	O
fulminant	fulminant	JJ	I-NP	O	O
posterior	posterior	JJ	I-NP	O	B-Disease
reversible	reversible	JJ	I-NP	O	I-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
Posterior	Posterior	JJ	B-NP	O	B-Disease
leukoencephalopathy	leukoencephalopathy	NN	I-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
calcineurin	calcineurin	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
related	relate	VBN	I-NP	O	O
neurotoxicity	neurotoxicity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
but	but	CC	I-NP	O	O
severe	severe	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
results	result	VBZ	B-VP	O	O
from	from	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
immunosuppressive	immunosuppressive	JJ	B-NP	O	O
agents	agent	NNS	I-NP	O	O
(	(	(	O	O	O
primarily	primarily	RB	B-NP	O	O
those	those	DT	I-NP	O	O
administered	administer	VBN	B-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
or	or	CC	I-NP	O	O
kidney	kidney	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
pathophysiologic	pathophysiologic	JJ	I-NP	O	O
mechanisms	mechanism	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
disorder	disorder	NN	I-NP	O	O
remain	remain	VBP	B-VP	O	O
unknown	unknown	JJ	B-ADJP	O	O
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
46	46	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
old	old	JJ	I-NP	O	O
woman	woman	NN	I-NP	O	O
who	who	WP	B-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
center	center	NN	I-NP	O	O
as	as	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
for	for	IN	B-PP	O	O
alcoholic	alcoholic	JJ	B-NP	O	B-Disease
cirrhosis	cirrhosis	NN	I-NP	O	I-Disease
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
whom	whom	WP	B-NP	O	O
either	either	CC	O	O	O
a	a	DT	B-NP	O	O
fulminant	fulminant	JJ	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
posterior	posterior	JJ	B-NP	O	B-Disease
leukoencephalopathy	leukoencephalopathy	NN	I-NP	O	I-Disease
or	or	CC	O	O	O
posterior	posterior	JJ	B-NP	O	B-Disease
reversible	reversible	JJ	I-NP	O	I-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
developed	develop	VBD	B-VP	O	O
110	110	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
transplant	transplant	NN	B-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
an	an	DT	B-NP	O	O
initially	initially	RB	I-NP	O	O
uneventful	uneventful	JJ	I-NP	O	O
course	course	NN	I-NP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
rapidly	rapidly	RB	B-ADVP	O	O
fell	fall	VBD	B-VP	O	O
into	into	IN	B-PP	O	O
deep	deep	JJ	B-NP	O	O
coma	coma	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Cerebral	Cerebral	JJ	B-NP	O	O
MRI	MRI	NN	I-NP	O	O
scan	scan	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
typical	typical	JJ	B-NP	O	O
signs	sign	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
enhancement	enhancement	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pontine	pontine	NN	I-NP	O	O
and	and	CC	O	O	O
posterior	posterior	JJ	B-NP	O	O
regions	region	NNS	I-NP	O	O
.	.	.	O	O	O

Switching	Switch	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
immunosuppressive	immunosuppressive	JJ	I-NP	O	O
regimen	regimen	NN	I-NP	O	O
from	from	IN	B-PP	O	O
tacrolimus	tacrolimus	NN	B-NP	B	B-Chemical
to	to	TO	B-PP	O	O
cyclosporine	cyclosporine	NN	B-NP	B	B-Chemical
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
improve	improve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
situation	situation	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
termination	termination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
any	any	DT	B-NP	O	O
calcineurin	calcineurin	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
resolution	resolution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
that	that	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Posterior	Posterior	JJ	B-NP	O	B-Disease
reversible	reversible	JJ	I-NP	O	I-Disease
encephalopathy	encephalopathy	NN	I-NP	O	I-Disease
syndrome	syndrome	NN	I-NP	O	I-Disease
after	after	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
transplant	transplant	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
rare	rare	JJ	B-ADJP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
recommend	recommend	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
complete	complete	JJ	I-NP	O	O
cessation	cessation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
any	any	DT	B-NP	O	O
calcineurin	calcineurin	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
rather	rather	RB	B-CONJP	O	O
than	than	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
.	.	.	O	O	O

Prolonged	Prolonged	JJ	B-NP	O	O
hypothermia	hypothermia	NN	I-NP	O	B-Disease
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
bridge	bridge	NN	I-NP	O	O
to	to	TO	B-PP	O	O
recovery	recovery	NN	B-NP	O	O
for	for	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
intracranial	intracranial	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
hepatic	hepatic	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
review	review	VB	I-VP	O	O
evidence	evidence	NN	B-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
options	option	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
complicating	complicate	VBG	B-VP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
hepatic	hepatic	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
FHF	FHF	NN	B-NP	O	B-Disease
)	)	)	O	O	O
and	and	CC	O	O	O
discuss	discuss	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
potential	potential	JJ	I-NP	O	O
applications	application	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
hypothermia	hypothermia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

METHOD	METHOD	NN	B-NP	O	O
:	:	:	O	O	O
Case	Case	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
based	base	VBN	I-NP	O	O
observations	observation	NNS	I-NP	O	O
from	from	IN	B-PP	O	O
a	a	DT	B-NP	O	O
medical	medical	JJ	I-NP	O	O
intensive	intensive	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
unit	unit	NN	I-NP	O	O
(	(	(	O	O	O
MICU	MICU	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
tertiary	tertiary	JJ	I-NP	O	O
care	care	NN	I-NP	O	O
facility	facility	NN	I-NP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
27	27	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
female	female	NN	I-NP	O	O
with	with	IN	B-PP	O	O
FHF	FHF	NN	B-NP	O	B-Disease
from	from	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
resultant	resultant	JJ	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Our	Our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
admitted	admit	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
MICU	MICU	NN	I-NP	O	O
after	after	IN	B-PP	O	O
being	be	VBG	B-VP	O	O
found	find	VBN	I-VP	O	O
unresponsive	unresponsive	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
presumed	presume	VBN	B-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
from	from	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
ingested	ingest	VBN	I-VP	O	O
over	over	IN	B-PP	O	O
a	a	DT	B-NP	O	O
2	2	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
day	day	NN	I-NP	O	O
period	period	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
depressed	depress	VBN	I-VP	O	O
of	of	IN	B-PP	O	O
mental	mental	JJ	B-NP	O	O
status	status	NN	I-NP	O	O
lasting	last	VBG	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
24	24	CD	I-NP	O	O
h	h	NN	I-NP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
admission	admission	NN	B-NP	O	O
.	.	.	O	O	O

Initial	Initial	JJ	B-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
confirmed	confirm	VBD	B-VP	O	O
FHF	FHF	NN	B-NP	O	B-Disease
from	from	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
hyperosmolar	hyperosmolar	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
hyperventilation	hyperventilation	NN	B-NP	O	B-Disease
,	,	,	O	O	O
sedation	sedation	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
chemical	chemical	NN	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Her	Her	PRP$	B-NP	O	O
intracranial	intracranial	JJ	I-NP	O	O
pressure	pressure	NN	I-NP	O	O
remained	remain	VBD	B-VP	O	O
elevated	elevated	JJ	B-ADJP	O	O
despite	despite	IN	B-PP	O	O
maximal	maximal	JJ	B-NP	O	O
medical	medical	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
then	then	RB	B-ADVP	O	O
initiated	initiate	VBD	B-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
hypothermia	hypothermia	NN	I-NP	O	B-Disease
which	which	WDT	B-NP	O	O
was	be	VBD	B-VP	O	O
continued	continue	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
5	5	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

At	At	IN	B-PP	O	O
re	re	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
warming	warm	VBG	B-VP	O	O
,	,	,	O	O	O
patient	patient	NN	B-NP	O	O
had	have	VBD	B-VP	O	O
resolution	resolution	NN	B-NP	O	O
of	of	IN	B-PP	O	O
her	her	PRP$	B-NP	O	O
cerebral	cerebral	JJ	I-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
intracranial	intracranial	JJ	B-NP	O	B-Disease
hypertension	hypertension	NN	I-NP	O	I-Disease
.	.	.	O	O	O

At	At	IN	B-PP	O	O
discharge	discharge	NN	B-NP	O	O
,	,	,	O	O	O
she	she	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
complete	complete	JJ	B-NP	O	O
recovery	recovery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neurological	neurological	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
hepatic	hepatic	JJ	I-NP	O	O
functions	function	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
FHF	FHF	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
cerebral	cerebral	JJ	B-NP	O	B-Disease
edema	edema	NN	I-NP	O	I-Disease
from	from	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
overdose	overdose	NN	I-NP	O	B-Disease
,	,	,	O	O	O
prolonged	prolong	VBD	B-VP	O	O
therapeutic	therapeutic	JJ	B-NP	O	O
hypothermia	hypothermia	NN	I-NP	O	B-Disease
could	could	MD	B-VP	O	O
potentially	potentially	RB	I-VP	O	O
be	be	VB	I-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
life	life	NN	I-NP	O	O
saving	save	VBG	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
bridge	bridge	NN	I-NP	O	O
to	to	TO	B-PP	O	O
hepatic	hepatic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neurological	neurological	JJ	I-NP	O	O
recovery	recovery	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
trial	trial	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypothermia	hypothermia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
this	this	DT	B-NP	O	O
condition	condition	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

Binasal	Binasal	JJ	B-NP	O	B-Disease
visual	visual	JJ	I-NP	O	I-Disease
field	field	NN	I-NP	O	I-Disease
defects	defect	NNS	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
not	not	RB	O	O	O
specific	specific	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
vigabatrin	vigabatrin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigated	investigate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
visual	visual	JJ	I-NP	O	B-Disease
defects	defect	NNS	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antiepileptic	antiepileptic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
vigabatrin	vigabatrin	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
hundred	hundred	CD	I-NP	O	O
four	four	CD	I-NP	O	O
people	people	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
epilepsy	epilepsy	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
grouped	group	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
basis	basis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
antiepileptic	antiepileptic	JJ	B-NP	O	O
drug	drug	NN	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
current	current	JJ	B-ADJP	O	O
,	,	,	O	O	O
previous	previous	JJ	B-ADJP	O	O
,	,	,	O	O	O
or	or	CC	O	O	O
no	no	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Groups	Group	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
matched	match	VBN	I-VP	B	O
with	with	IN	B-PP	O	O
respect	respect	NN	B-NP	O	O
to	to	TO	B-PP	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
gender	gender	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
seizure	seizure	NN	B-NP	O	B-Disease
frequency	frequency	NN	I-NP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
underwent	undergo	VBD	B-VP	O	O
objective	objective	JJ	B-NP	O	O
assessment	assessment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
electrophysiological	electrophysiological	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
(	(	(	O	O	O
wide	wide	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
field	field	NN	I-NP	O	O
multifocal	multifocal	JJ	I-NP	O	O
electroretinography	electroretinography	NN	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
conventional	conventional	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
testing	testing	NN	I-NP	O	O
(	(	(	O	O	O
static	static	JJ	B-NP	O	O
perimetry	perimetry	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	O
visual	visual	JJ	I-NP	O	O
field	field	NN	I-NP	O	O
constriction	constriction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
59	59	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
currently	currently	RB	B-VP	O	O
taking	take	VBG	I-VP	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
43	43	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
previously	previously	RB	B-ADVP	O	O
took	take	VBD	B-VP	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
24	24	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Assessment	Assessment	NN	B-NP	O	O
of	of	IN	B-PP	O	O
retinal	retinal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
abnormal	abnormal	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
48	48	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
current	current	JJ	B-NP	O	O
VGB	VGB	NN	I-NP	O	B-Chemical
users	user	NNS	I-NP	O	O
and	and	CC	O	O	O
22	22	CD	B-NP	O	O
%	%	NN	I-NP	O	O
of	of	IN	B-PP	O	O
prior	prior	JJ	B-NP	O	O
VGB	VGB	NN	I-NP	O	B-Chemical
users	user	NNS	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
in	in	IN	B-PP	O	O
none	none	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
without	without	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Bilateral	Bilateral	JJ	B-NP	O	B-Disease
visual	visual	JJ	I-NP	O	I-Disease
field	field	NN	I-NP	O	I-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
are	be	VBP	B-VP	O	O
common	common	JJ	B-ADJP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
treated	treat	VBN	I-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	B-Disease
population	population	NN	I-NP	O	O
,	,	,	O	O	O
irrespective	irrespective	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	O
history	history	NN	I-NP	O	O
.	.	.	O	O	O

Assessment	Assessment	NN	B-NP	O	O
by	by	IN	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
static	static	JJ	I-NP	O	O
perimetry	perimetry	NN	I-NP	O	O
may	may	MD	B-VP	O	O
neither	neither	CC	I-VP	O	O
be	be	VB	I-VP	O	O
sufficiently	sufficiently	RB	B-ADJP	O	O
sensitive	sensitive	JJ	I-ADJP	O	O
nor	nor	CC	I-ADJP	O	O
specific	specific	JJ	I-ADJP	O	O
to	to	TO	B-VP	O	O
reliably	reliably	RB	I-VP	O	O
identify	identify	VB	I-VP	O	O
retinal	retinal	JJ	B-NP	O	B-Disease
toxicity	toxicity	NN	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
VGB	VGB	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Smoking	Smoking	NN	B-NP	O	O
of	of	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
use	use	VBP	B-VP	O	O
injection	injection	NN	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Little	Little	JJ	B-ADJP	O	O
is	be	VBZ	B-VP	O	O
known	know	VBN	I-VP	O	O
about	about	IN	B-PP	O	O
the	the	DT	B-NP	O	O
possible	possible	JJ	I-NP	O	O
role	role	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
smoking	smoke	VBG	B-VP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
has	have	VBZ	B-VP	O	O
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Given	Give	VBN	B-PP	O	O
the	the	DT	B-NP	O	O
increasing	increase	VBG	I-NP	O	O
use	use	NN	I-NP	O	O
of	of	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
sought	seek	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
examine	examine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
illicit	illicit	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
become	become	VBN	I-VP	O	O
a	a	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
included	include	VBD	B-VP	O	O
data	datum	NNS	B-NP	O	O
from	from	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
participating	participate	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Vancouver	Vancouver	NNP	I-NP	O	O
Injection	Injection	NNP	I-NP	O	O
Drug	Drug	NNP	I-NP	O	O
Users	Users	NNP	I-NP	O	O
Study	Study	NNP	I-NP	O	O
who	who	WP	B-NP	O	O
reported	report	VBD	B-VP	O	O
injecting	inject	VBG	I-VP	O	O
illicit	illicit	JJ	B-NP	O	O
drugs	drug	NNS	I-NP	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
once	once	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
month	month	NN	I-NP	O	O
before	before	IN	B-PP	O	O
enrolment	enrolment	NN	B-NP	O	O
,	,	,	O	O	O
lived	live	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
Vancouver	Vancouver	NNP	I-NP	O	O
area	area	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
HIV	HIV	NN	B-NP	O	O
-	-	HYPH	O	O	O
negative	negative	JJ	B-ADJP	O	O
at	at	IN	B-PP	O	O
enrolment	enrolment	NN	B-NP	O	O
and	and	CC	O	O	O
completed	complete	VBD	B-VP	O	O
at	at	IN	B-NP	O	O
least	least	JJS	I-NP	O	O
1	1	CD	I-NP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
study	study	NN	B-NP	O	O
visit	visit	NN	I-NP	O	O
.	.	.	O	O	O

To	To	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
seroconversion	seroconversion	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
daily	daily	JJ	B-NP	O	O
smokers	smoker	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
changed	change	VBD	B-VP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
used	use	VBD	B-VP	O	O
Cox	Cox	NNP	B-NP	O	O
proportional	proportional	JJ	I-NP	O	O
hazards	hazard	NNS	I-NP	O	O
regression	regression	NN	I-NP	O	O
and	and	CC	O	O	O
divided	divide	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
study	study	NN	I-NP	O	O
into	into	IN	B-PP	O	O
3	3	CD	B-NP	O	O
periods	period	NNS	I-NP	O	O
:	:	:	O	O	O
May	May	NNP	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
1996	1996	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
Nov	Nov	NNP	I-NP	O	O
.	.	.	O	O	O

30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
1999	1999	CD	I-NP	O	O
(	(	(	O	O	O
period	period	NN	B-NP	O	O
1	1	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
Dec	Dec	NNP	B-NP	O	O
.	.	.	O	O	O

1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
1999	1999	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
Nov	Nov	NNP	I-NP	O	O
.	.	.	O	O	O

30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
2002	2002	CD	I-NP	O	O
(	(	(	O	O	O
period	period	NN	B-NP	O	O
2	2	CD	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
Dec	Dec	NNP	B-NP	O	O
.	.	.	O	O	O

1	1	CD	B-NP	O	O
,	,	,	I-NP	O	O
2002	2002	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
Dec	Dec	NNP	I-NP	O	O
.	.	.	O	O	O

30	30	CD	B-NP	O	O
,	,	,	I-NP	O	O
2005	2005	CD	I-NP	O	O
(	(	(	O	O	O
period	period	NN	B-NP	O	O
3	3	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Overall	Overall	JJ	B-ADVP	O	O
,	,	,	O	O	O
1048	1048	CD	B-NP	O	O
eligible	eligible	JJ	I-NP	O	O
injection	injection	NN	I-NP	O	O
drug	drug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
included	include	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
,	,	,	O	O	O
137	137	CD	B-NP	O	O
acquired	acquire	VBD	B-VP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
infection	infection	NN	I-NP	O	I-Disease
during	during	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mean	mean	JJ	I-NP	O	O
proportion	proportion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
participants	participant	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
reported	report	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
smoking	smoking	NN	I-NP	O	O
of	of	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
11.6	11.6	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
period	period	NN	B-NP	O	O
1	1	CD	I-NP	O	O
to	to	TO	I-NP	O	O
39.7	39.7	CD	I-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
period	period	NN	B-NP	O	O
3	3	CD	I-NP	O	O
.	.	.	O	O	O

After	After	IN	B-PP	O	O
adjusting	adjust	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
potential	potential	JJ	B-NP	O	O
confounders	confounder	NNS	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
found	find	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
risk	risk	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
seroconversion	seroconversion	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
participants	participant	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
daily	daily	JJ	B-NP	O	O
smokers	smoker	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
increased	increase	VBD	B-VP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
(	(	(	O	O	O
period	period	NN	B-NP	O	O
1	1	CD	I-NP	O	O
:	:	:	O	O	O
hazard	hazard	NN	B-NP	O	O
ratio	ratio	NN	I-NP	O	O
[	[	(	O	O	O
HR	HR	NN	B-NP	O	O
]	]	)	O	O	O
1.03	1.03	CD	B-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
confidence	confidence	NN	I-NP	O	O
interval	interval	NN	I-NP	O	O
[	[	(	O	O	O
CI	CI	NN	B-NP	O	O
]	]	)	O	O	O
0.57	0.57	CD	B-NP	O	O
-	-	:	O	O	O
1.85	1.85	CD	B-NP	O	O
;	;	:	O	O	O
period	period	NN	B-NP	O	O
2	2	CD	I-NP	O	O
:	:	:	O	O	O
HR	HR	NN	B-NP	O	O
1.68	1.68	CD	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
1.01	1.01	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
2.80	2.80	CD	I-NP	O	O
;	;	:	O	O	O
and	and	CC	O	O	O
period	period	NN	B-NP	O	O
3	3	CD	I-NP	O	O
:	:	:	O	O	O
HR	HR	NN	B-NP	O	O
2.74	2.74	CD	I-NP	O	O
,	,	,	O	O	O
95	95	CD	B-NP	O	O
%	%	NN	I-NP	O	O
CI	CI	NN	I-NP	O	O
1.06	1.06	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
7.11	7.11	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

INTERPRETATION	INTERPRETATION	NN	B-NP	O	O
:	:	:	O	O	O
Smoking	Smoking	NN	B-NP	O	O
of	of	IN	B-PP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
was	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
independent	independent	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
factor	factor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
seroconversion	seroconversion	NN	I-NP	O	I-Disease
among	among	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
injection	injection	NN	B-NP	O	O
drug	drug	NN	I-NP	O	O
users	user	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
finding	finding	NN	I-NP	O	O
points	point	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
urgent	urgent	JJ	I-NP	O	O
need	need	NN	I-NP	O	O
for	for	IN	B-PP	O	O
evidence	evidence	NN	B-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-VP	O	O
public	public	JJ	B-NP	O	O
health	health	NN	I-NP	O	O
initiatives	initiative	NNS	I-NP	O	O
targeted	target	VBN	B-VP	O	O
at	at	IN	B-PP	O	O
people	people	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
smoke	smoke	VBP	B-VP	O	O
crack	crack	NN	B-NP	B	B-Chemical
cocaine	cocaine	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	B	B-Chemical
improves	improve	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
memory	memory	NN	I-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
agent	agent	NN	I-NP	O	O
5	5	CD	I-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Cancer	Cancer	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
systemic	systemic	JJ	B-NP	O	O
adjuvant	adjuvant	JJ	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
have	have	VBP	B-VP	O	O
described	describe	VBN	I-VP	O	O
experiencing	experience	VBG	I-VP	O	O
deteriorations	deterioration	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
cognition	cognition	NN	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
widely	widely	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
chemotherapeutic	chemotherapeutic	JJ	I-NP	O	O
agent	agent	NN	I-NP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
fluorouracil	fluorouracil	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
readily	readily	RB	B-ADVP	O	O
crosses	cross	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
brain	brain	NN	I-NP	O	O
barrier	barrier	NN	I-NP	O	O
and	and	CC	O	O	O
so	so	RB	B-VP	O	O
could	could	MD	I-VP	O	O
have	have	VB	I-VP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
function	function	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
particular	particular	JJ	B-ADJP	O	O
this	this	DT	B-NP	O	O
anti	anti	JJ	I-NP	O	O
mitotic	mitotic	JJ	I-NP	O	O
drug	drug	NN	I-NP	O	O
could	could	MD	B-VP	O	O
reduce	reduce	VB	I-VP	O	O
cell	cell	NN	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neurogenic	neurogenic	JJ	I-NP	O	O
regions	region	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
adult	adult	JJ	I-NP	O	O
brain	brain	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
reports	report	NNS	I-NP	O	O
indicate	indicate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
neurogenesis	neurogenesis	NN	I-NP	O	O
and	and	CC	I-NP	O	O
cognition	cognition	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
enhanced	enhance	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
SSRI	SSRI	NN	I-NP	O	B-Chemical
antidepressant	antidepressant	NN	I-NP	O	O
Fluoxetine	Fluoxetine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
investigation	investigation	NN	I-NP	O	O
the	the	DT	B-NP	O	O
behavioural	behavioural	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	O
(	(	(	O	O	O
two	two	CD	B-NP	O	O
week	week	NN	I-NP	O	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
and	and	CC	O	O	O
(	(	(	O	O	O
three	three	CD	B-NP	O	O
weeks	week	NNS	I-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
Fluoxetine	Fluoxetine	NN	B-NP	B	B-Chemical
either	either	CC	O	O	O
separately	separately	RB	B-ADVP	O	O
or	or	CC	O	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
adult	adult	JJ	B-NP	O	O
Lister	Lister	NNP	I-NP	O	O
hooded	hood	VBD	B-VP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Behavioural	Behavioural	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
context	context	NN	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
conditioned	condition	VBN	I-NP	O	O
emotional	emotional	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
CER	CER	NN	B-NP	B	O
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
animals	animal	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
freezing	freeze	VBG	B-VP	O	O
time	time	NN	B-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
separate	separate	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
of	of	IN	B-PP	O	O
animals	animal	NNS	B-NP	O	O
was	be	VBD	B-VP	O	O
tested	test	VBN	I-VP	O	O
using	use	VBG	I-VP	O	O
a	a	DT	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
dependent	dependent	JJ	I-NP	O	O
spatial	spatial	JJ	I-NP	O	O
working	working	NN	I-NP	O	O
memory	memory	NN	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
object	object	NN	I-NP	O	O
location	location	NN	I-NP	O	O
recognition	recognition	NN	I-NP	O	O
test	test	NN	I-NP	O	O
(	(	(	O	O	O
OLR	OLR	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
only	only	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
showed	show	VBD	B-VP	O	O
significant	significant	JJ	B-NP	O	O
deficits	deficit	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
ability	ability	NN	I-NP	O	O
to	to	TO	B-VP	O	O
carry	carry	VB	I-VP	O	O
out	out	RP	B-PRT	O	O
the	the	DT	B-NP	O	O
OLR	OLR	NN	I-NP	O	O
task	task	NN	I-NP	O	O
but	but	CC	O	O	O
co	co	NN	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Fluoxetine	Fluoxetine	NN	B-NP	B	B-Chemical
improved	improve	VBD	B-VP	O	O
their	their	PRP$	B-NP	O	O
performance	performance	NN	I-NP	O	O
.	.	.	O	O	O

5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
chemotherapy	chemotherapy	NN	I-NP	O	O
caused	cause	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
proliferating	proliferate	VBG	B-VP	O	O
cells	cell	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
sub	sub	NN	I-NP	O	O
granular	granular	JJ	I-NP	O	O
zone	zone	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
dentate	dentate	NN	I-NP	O	O
gyrus	gyrus	NN	I-NP	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
controls	control	NNS	B-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
eliminated	eliminate	VBN	I-VP	O	O
when	when	WRB	B-ADVP	O	O
Fluoxetine	Fluoxetine	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
co	co	NN	B-NP	O	O
administered	administer	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Fluoxetine	Fluoxetine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
own	own	JJ	I-NP	O	O
had	have	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
proliferating	proliferate	VBG	B-VP	O	O
cell	cell	NN	B-NP	O	O
number	number	NN	I-NP	O	O
or	or	CC	O	O	O
behaviour	behaviour	NN	B-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
5	5	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
FU	FU	NN	I-NP	I	I-Chemical
can	can	MD	B-VP	O	O
negatively	negatively	RB	I-VP	O	O
affect	affect	VB	I-VP	O	O
both	both	CC	O	O	O
cell	cell	NN	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
and	and	CC	O	O	O
hippocampal	hippocampal	NN	B-NP	O	O
dependent	dependent	JJ	B-NP	O	O
working	work	VBG	I-NP	O	O
memory	memory	NN	I-NP	O	O
and	and	CC	O	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
deficits	deficit	NNS	I-NP	O	O
can	can	MD	B-VP	O	O
be	be	VB	I-VP	O	O
reversed	reverse	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
simultaneous	simultaneous	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
antidepressant	antidepressant	NN	I-NP	O	O
Fluoxetine	Fluoxetine	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

Liver	Liver	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
specific	specific	JJ	I-NP	O	O
ablation	ablation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
integrin	integrin	NN	B-NP	B	O
-	-	HYPH	O	O	O
linked	link	VBN	B-NP	O	O
kinase	kinase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
results	result	VBZ	B-VP	O	O
in	in	IN	B-PP	O	O
enhanced	enhance	VBN	B-NP	O	O
and	and	CC	I-NP	O	O
prolonged	prolong	VBN	I-NP	O	O
cell	cell	NN	I-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
and	and	CC	O	O	O
hepatomegaly	hepatomegaly	RB	B-ADVP	O	B-Disease
after	after	IN	B-SBAR	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
recently	recently	RB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
disruption	disruption	NN	B-NP	O	O
of	of	IN	B-PP	O	O
extracellular	extracellular	JJ	B-NP	O	O
matrix	matrix	NN	I-NP	O	O
(	(	(	O	O	O
ECM	ECM	NN	B-NP	B	O
)	)	)	O	O	O
/	/	SYM	B-NP	O	O
integrin	integrin	NN	I-NP	B	O
signaling	signaling	NN	I-NP	O	O
via	via	IN	B-PP	O	O
elimination	elimination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
integrin	integrin	NN	B-NP	B	O
-	-	HYPH	O	O	O
linked	link	VBN	B-NP	O	O
kinase	kinase	NN	I-NP	O	O
(	(	(	O	O	O
ILK	ILK	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
hepatocytes	hepatocyte	NNS	B-NP	O	O
interferes	interfere	VBZ	B-VP	O	O
with	with	IN	B-PP	O	O
signals	signal	NNS	B-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
termination	termination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
regeneration	regeneration	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
investigates	investigate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ILK	ILK	NN	B-NP	O	O
in	in	IN	B-PP	O	O
liver	liver	NN	B-NP	O	O
enlargement	enlargement	NN	I-NP	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
phenobarbital	phenobarbital	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
PB	PB	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
.	.	.	O	O	O

Wild	Wild	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
type	type	NN	I-NP	O	O
(	(	(	O	O	O
WT	WT	NN	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
ILK	ILK	NN	B-NP	O	O
:	:	:	O	O	O
liver	liver	NN	B-NP	O	O
-	-	HYPH	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
mice	mouse	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
given	give	VBN	I-VP	O	O
PB	PB	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
%	%	NN	I-NP	O	O
in	in	IN	B-PP	O	O
drinking	drinking	NN	B-NP	O	O
water	water	NN	I-NP	B	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Livers	Liver	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
harvested	harvest	VBN	I-VP	O	O
on	on	IN	B-PP	O	O
2	2	CD	B-NP	O	O
,	,	,	I-NP	O	O
5	5	CD	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
10	10	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
PB	PB	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatocyte	hepatocyte	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
specific	specific	JJ	I-NP	O	O
ILK	ILK	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
liver	liver	NN	I-NP	O	O
-	-	HYPH	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
mice	mouse	NNS	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
:	:	:	O	O	O
body	body	NN	B-NP	O	O
weight	weight	NN	I-NP	O	O
ratio	ratio	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
more	more	JJR	B-ADVP	O	O
than	than	IN	I-ADVP	O	O
double	double	JJ	I-ADVP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
0	0	CD	B-NP	O	O
h	h	NN	I-NP	O	O
at	at	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
(	(	(	O	O	O
2.5	2.5	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
at	at	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
5	5	CD	B-NP	O	O
and	and	CC	I-NP	O	O
10	10	CD	I-NP	O	O
,	,	,	O	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
enlarged	enlarge	VBN	I-VP	O	O
three	three	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
WT	WT	JJ	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
as	as	RB	B-VP	O	O
expected	expect	VBN	I-VP	O	O
from	from	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
literature	literature	NN	I-NP	O	O
(	(	(	O	O	O
1.8	1.8	CD	B-NP	O	O
times	time	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
have	have	VB	I-VP	O	O
leveled	level	VBN	I-VP	O	O
off	off	RP	B-PRT	O	O
after	after	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
slightly	slightly	RB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
proliferating	proliferate	VBG	B-VP	O	O
cell	cell	NN	B-NP	O	O
nuclear	nuclear	JJ	I-NP	O	O
antigen	antigen	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
positive	positive	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ILK	ILK	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
liver	liver	NN	I-NP	O	O
-	-	HYPH	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
animals	animal	NNS	B-NP	O	O
at	at	IN	B-PP	O	O
day	day	NN	B-NP	O	O
2	2	CD	I-NP	O	O
as	as	IN	B-SBAR	O	O
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
WT	WT	NN	B-NP	O	O
after	after	IN	B-PP	O	O
PB	PB	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
WT	WT	JJ	I-NP	O	O
animals	animal	NNS	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
proliferative	proliferative	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
had	have	VBD	B-VP	O	O
come	come	VBN	I-VP	O	O
back	back	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
normal	normal	JJ	B-ADJP	O	O
by	by	IN	B-PP	O	O
days	day	NNS	B-NP	O	O
5	5	CD	B-NP	O	O
and	and	CC	I-NP	O	O
10	10	CD	I-NP	O	O
.	.	.	O	O	O

Hepatocytes	Hepatocyte	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
ILK	ILK	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
liver	liver	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	HYPH	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
continued	continue	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
proliferate	proliferate	VB	I-VP	O	O
up	up	RP	B-PRT	O	O
until	until	IN	B-PP	O	O
day	day	NN	B-NP	O	O
10	10	CD	I-NP	O	O
.	.	.	O	O	O

ILK	ILK	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
liver	liver	NN	I-NP	O	O
-	-	HYPH	O	O	O
/	/	SYM	O	O	O
-	-	HYPH	O	O	O
mice	mouse	NNS	B-NP	O	O
also	also	RB	B-ADVP	O	O
showed	show	VBD	B-VP	O	O
increased	increase	VBN	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
key	key	JJ	B-NP	O	O
genes	gene	NNS	I-NP	O	O
involved	involve	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
hepatocyte	hepatocyte	NN	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
at	at	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
time	time	NN	I-NP	O	O
points	point	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
PB	PB	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
summary	summary	NN	B-NP	O	O
,	,	,	O	O	O
ECM	ECM	NN	B-NP	B	O
proteins	protein	NNS	I-NP	O	O
communicate	communicate	VBP	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
signaling	signaling	NN	I-NP	O	O
machinery	machinery	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dividing	divide	VBG	B-VP	O	O
cells	cell	NNS	B-NP	O	O
via	via	IN	B-PP	O	O
ILK	ILK	NN	B-NP	O	O
to	to	TO	B-VP	O	O
regulate	regulate	VB	I-VP	O	O
hepatocyte	hepatocyte	NN	B-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
and	and	CC	I-NP	O	O
termination	termination	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
proliferative	proliferative	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
.	.	.	O	O	O

Lack	Lack	NN	B-NP	O	O
of	of	IN	B-PP	O	O
ILK	ILK	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hepatocytes	hepatocyte	NNS	I-NP	O	O
imparts	impart	VBZ	B-VP	O	O
prolonged	prolonged	JJ	B-NP	O	O
proliferative	proliferative	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
not	not	RB	B-CONJP	O	O
only	only	RB	I-CONJP	O	O
to	to	TO	B-PP	O	O
stimuli	stimulus	NNS	B-NP	O	O
related	relate	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
liver	liver	NN	B-NP	O	O
regeneration	regeneration	NN	I-NP	O	O
but	but	CC	B-CONJP	O	O
also	also	RB	I-CONJP	O	O
to	to	TO	B-PP	O	O
xenobiotic	xenobiotic	JJ	B-NP	O	O
chemical	chemical	JJ	I-NP	O	O
mitogens	mitogen	NNS	I-NP	O	O
,	,	,	O	O	O
such	such	JJ	B-PP	O	O
as	as	IN	I-PP	O	O
PB	PB	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Decreased	Decrease	VBN	B-NP	O	O
Expression	Expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Na	Na	NN	B-NP	O	B-Chemical
/	/	SYM	B-NP	O	O
K	K	NN	I-NP	O	B-Chemical
-	-	HYPH	B-NP	O	O
ATPase	ATPase	NN	I-NP	O	O
,	,	,	O	O	O
NHE3	NHE3	NN	B-NP	O	O
,	,	,	O	O	O
NBC1	NBC1	NN	B-NP	O	O
,	,	,	O	O	O
AQP1	AQP1	NN	B-NP	O	O
and	and	CC	I-NP	O	O
OAT	OAT	NN	I-NP	O	O
in	in	IN	B-PP	O	O
Gentamicin	Gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
Nephropathy	Nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
aimed	aim	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
whether	whether	IN	B-SBAR	O	O
there	there	EX	B-NP	O	O
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
altered	altered	JJ	I-NP	O	O
regulation	regulation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
transporters	transporter	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Sprague	Sprague	NNP	B-NP	O	O
-	-	HYPH	I-NP	O	O
Dawley	Dawley	NNP	I-NP	O	O
male	male	JJ	I-NP	O	O
rats	rat	NNS	I-NP	O	O
(	(	(	O	O	O
200	200	CD	B-NP	O	O
~	~	SYM	I-NP	O	O
250	250	CD	I-NP	O	O
g	g	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
subcutaneously	subcutaneously	RB	I-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
100	100	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
per	per	IN	B-PP	O	O
day	day	NN	B-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
7	7	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
tubular	tubular	JJ	B-NP	O	O
transporters	transporter	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
immunoblotting	immunoblotting	NN	B-NP	O	O
and	and	CC	I-NP	O	O
immunohistochemistry	immunohistochemistry	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
mRNA	mRNA	NN	I-NP	O	O
and	and	CC	I-NP	O	O
protein	protein	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
OAT	OAT	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
determined	determine	VBN	I-VP	O	O
.	.	.	O	O	O

Gentamicin	Gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
significantly	significantly	RB	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
clearance	clearance	NN	I-NP	O	O
along	along	IN	B-PP	O	O
with	with	IN	B-PP	O	O
increased	increase	VBN	B-NP	O	O
plasma	plasma	NN	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
levels	level	NNS	I-NP	O	O
.	.	.	O	O	O

Accordingly	Accordingly	RB	B-ADVP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
fractional	fractional	JJ	I-NP	O	O
excretion	excretion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sodium	sodium	NN	B-NP	B	B-Chemical
increased	increase	VBD	B-VP	O	O
.	.	.	O	O	O

Urine	Urine	NN	B-NP	O	O
volume	volume	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
while	while	IN	B-SBAR	O	O
urine	urine	NN	B-NP	O	O
osmolality	osmolality	NN	I-NP	O	O
and	and	CC	O	O	O
free	free	JJ	B-NP	O	O
water	water	NN	I-NP	B	O
reabsorption	reabsorption	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Immunoblotting	Immunoblotting	NN	B-NP	O	O
and	and	CC	I-NP	O	O
immunohistochemistry	immunohistochemistry	NN	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
decreased	decrease	VBN	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Na	Na	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
/	/	SYM	B-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
ATPase	ATPase	NN	I-NP	O	O
,	,	,	O	O	O
NHE3	NHE3	NN	B-NP	O	O
,	,	,	O	O	O
NBC1	NBC1	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
AQP1	AQP1	NN	B-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
kidney	kidney	NN	I-NP	O	O
of	of	IN	B-PP	O	O
gentamicin	gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
OAT1	OAT1	NN	B-NP	O	O
and	and	CC	I-NP	O	O
OAT3	OAT3	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
also	also	RB	I-VP	O	O
decreased	decrease	VBN	I-VP	O	O
.	.	.	O	O	O

Gentamicin	Gentamicin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
nephropathy	nephropathy	NN	I-NP	O	B-Disease
may	may	MD	O	O	O
at	at	IN	B-ADVP	O	O
least	least	JJS	I-ADVP	O	O
in	in	IN	B-PP	O	O
part	part	NN	B-NP	O	O
be	be	VB	B-VP	O	O
causally	causally	RB	B-ADJP	O	O
related	related	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
decreased	decrease	VBN	I-NP	O	O
expression	expression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Na	Na	NN	B-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
/	/	SYM	B-NP	O	O
K	K	NN	I-NP	B	B-Chemical
(	(	(	O	I	O
+	+	SYM	B-NP	I	O
)	)	)	O	I	O
-	-	HYPH	B-NP	O	O
ATPase	ATPase	NN	I-NP	O	O
,	,	,	I-NP	O	O
NHE3	NHE3	NN	I-NP	O	O
,	,	,	I-NP	O	O
NBC1	NBC1	NN	I-NP	O	O
,	,	,	I-NP	O	O
AQP1	AQP1	NN	I-NP	O	O
and	and	CC	I-NP	O	O
OAT	OAT	NN	I-NP	O	O
.	.	.	O	O	O

Longitudinal	Longitudinal	JJ	B-NP	O	O
association	association	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
progression	progression	NN	I-NP	O	O
and	and	CC	O	O	O
psychological	psychological	JJ	B-NP	O	O
health	health	NN	I-NP	O	O
of	of	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
evaluated	evaluate	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
and	and	CC	I-NP	O	O
depression	depression	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
progression	progression	NN	I-NP	O	O
among	among	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
study	study	NN	I-NP	O	O
included	include	VBD	B-VP	O	O
871	871	CD	B-NP	O	O
women	woman	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
who	who	WP	B-NP	O	O
were	be	VBD	B-VP	O	O
recruited	recruit	VBN	I-VP	B	O
from	from	IN	B-PP	O	O
1993	1993	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
1995	1995	CD	I-NP	O	O
in	in	IN	B-PP	O	O
four	four	CD	B-NP	O	O
US	US	NNP	I-NP	O	O
cities	city	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
participants	participant	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
physical	physical	JJ	B-NP	O	O
examination	examination	NN	I-NP	O	O
,	,	,	O	O	O
medical	medical	JJ	B-NP	O	O
record	record	NN	I-NP	O	O
extraction	extraction	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
venipuncture	venipuncture	NN	B-NP	O	O
,	,	,	O	O	O
CD4	CD4	NN	B-NP	O	O
+	+	SYM	I-NP	O	O
T	T	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
cell	cell	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
determination	determination	NN	I-NP	O	O
,	,	,	O	O	O
measurement	measurement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
depression	depression	NN	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	O
(	(	(	O	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
self	self	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
report	report	NN	I-NP	O	O
Center	Center	NNP	I-NP	O	O
for	for	IN	B-PP	O	O
Epidemiological	Epidemiological	NNP	B-NP	O	O
Studies	Study	NNPS	I-NP	O	O
-	-	HYPH	I-NP	O	O
Depression	Depression	NN	I-NP	O	B-Disease
Scale	Scale	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
use	use	VBP	B-VP	O	O
assessment	assessment	NN	B-NP	O	O
at	at	IN	B-PP	O	O
enrollment	enrollment	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
semiannually	semiannually	RB	B-ADVP	O	O
until	until	IN	B-PP	O	O
March	March	NNP	B-NP	O	O
2000	2000	CD	I-NP	O	O
.	.	.	O	O	O

Multilevel	Multilevel	JJ	B-NP	O	O
random	random	JJ	I-NP	O	O
coefficient	coefficient	JJ	I-NP	O	O
ordinal	ordinal	JJ	I-NP	O	O
models	model	NNS	I-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
multilevel	multilevel	JJ	B-NP	O	O
models	model	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
joint	joint	JJ	B-NP	O	O
responses	response	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
analysis	analysis	NN	I-NP	O	O
.	.	.	O	O	O

There	There	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
level	level	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
and	and	CC	I-NP	O	O
CD4	CD4	NN	I-NP	O	O
+	+	SYM	I-NP	O	O
T	T	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
.	.	.	O	O	O

When	When	WRB	B-ADVP	O	O
participants	participant	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
stratified	stratify	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
antiretroviral	antiretroviral	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
(	(	(	O	O	O
ART	ART	NN	B-NP	O	O
)	)	)	O	O	O
use	use	NN	B-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
CD4	CD4	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
T	T	NN	I-NP	O	O
-	-	HYPH	O	O	O
cell	cell	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reach	reach	VB	I-VP	O	O
statistical	statistical	JJ	B-NP	O	O
significance	significance	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
association	association	NN	I-NP	O	O
between	between	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
and	and	CC	O	O	O
depression	depression	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
significant	significant	JJ	B-ADJP	O	O
(	(	(	O	O	O
p	p	NN	B-NP	O	O
<	<	SYM	O	O	O
0.001	0.001	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Depression	Depression	NN	B-NP	O	B-Disease
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
negative	negative	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
CD4	CD4	NN	B-NP	O	O
+	+	SYM	I-NP	O	O
T	T	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
cell	cell	NN	I-NP	O	O
counts	count	NNS	I-NP	O	O
over	over	IN	B-PP	O	O
time	time	NN	B-NP	O	O
regardless	regardless	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
ART	ART	NNP	B-NP	O	O
use	use	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
association	association	NN	I-NP	O	O
with	with	IN	B-PP	O	O
depression	depression	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
depression	depression	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	B-Disease
disease	disease	NN	I-NP	O	I-Disease
progression	progression	NN	I-NP	O	O
.	.	.	O	O	O

Our	Our	PRP$	B-NP	O	O
findings	finding	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
implications	implication	NNS	B-NP	O	O
for	for	IN	B-PP	O	O
the	the	DT	B-NP	O	O
provision	provision	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alcohol	alcohol	NN	B-NP	B	B-Chemical
use	use	NN	I-NP	O	O
interventions	intervention	NNS	I-NP	O	O
and	and	CC	O	O	O
psychological	psychological	JJ	B-NP	O	O
resources	resource	NNS	I-NP	O	O
to	to	TO	B-VP	O	O
improve	improve	VB	I-VP	O	O
the	the	DT	B-NP	O	O
health	health	NN	I-NP	O	O
of	of	IN	B-PP	O	O
women	woman	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
HIV	HIV	NN	B-NP	O	O
.	.	.	O	O	O

Chemokine	Chemokine	NN	B-NP	O	O
CCL2	CCL2	NN	I-NP	O	O
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
CCR2	CCR2	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
increased	increase	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
status	status	NN	I-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Neuroinflammation	Neuroinflammation	NN	B-NP	O	B-Disease
occurs	occur	VBZ	B-VP	O	O
after	after	IN	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
and	and	CC	O	O	O
is	be	VBZ	B-VP	O	O
implicated	implicate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
epileptogenesis	epileptogenesis	NN	B-NP	O	O
.	.	.	O	O	O

CCR2	CCR2	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
chemokine	chemokine	NN	I-NP	O	O
receptor	receptor	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CCL2	CCL2	NN	B-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
mediates	mediate	VBZ	B-VP	O	O
monocyte	monocyte	NN	B-NP	O	O
infiltration	infiltration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuroinflammatory	neuroinflammatory	JJ	I-NP	O	B-Disease
cascade	cascade	NN	I-NP	B	O
triggered	trigger	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
brain	brain	NN	I-NP	O	O
pathologies	pathology	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
work	work	NN	I-NP	O	O
CCR2	CCR2	NN	I-NP	O	O
and	and	CC	O	O	O
CCL2	CCL2	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
status	status	NN	B-NP	O	B-Disease
epilepticus	epilepticus	NN	I-NP	O	I-Disease
(	(	(	O	O	O
SE	SE	NN	B-NP	B	B-Disease
)	)	)	O	O	O
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
SE	SE	NN	B-NP	B	B-Disease
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
.	.	.	O	O	O

Control	Control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
injected	inject	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
saline	saline	NN	B-NP	B	O
instead	instead	RB	B-PP	O	O
of	of	IN	I-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Five	Five	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
after	after	IN	B-PP	O	O
SE	SE	NN	B-NP	B	B-Disease
,	,	,	O	O	O
CCR2	CCR2	NN	B-NP	O	O
staining	staining	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
and	and	CC	O	O	O
glial	glial	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
imunohistochemical	imunohistochemical	JJ	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CCR2	CCR2	NN	B-NP	O	O
positive	positive	JJ	I-NP	O	O
cells	cell	NNS	I-NP	O	O
was	be	VBD	B-VP	O	O
determined	determine	VBN	I-VP	O	O
using	use	VBG	B-VP	O	O
stereology	stereology	NN	B-NP	O	O
probes	probe	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
.	.	.	O	O	O

CCL2	CCL2	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
examined	examine	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
molecular	molecular	JJ	B-NP	O	O
assay	assay	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Increased	Increase	VBN	B-NP	O	O
CCR2	CCR2	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
after	after	IN	B-PP	O	O
SE	SE	NN	B-NP	B	B-Disease
.	.	.	O	O	O

Seizures	Seizure	NNS	B-NP	O	B-Disease
also	also	RB	B-ADVP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
alterations	alteration	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
cell	cell	NN	I-NP	O	O
types	type	NNS	I-NP	O	O
expressing	express	VBG	B-VP	O	O
CCR2	CCR2	NN	B-NP	O	O
.	.	.	O	O	O

Increased	Increase	VBN	B-NP	O	O
numbers	number	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
expressed	express	VBD	B-VP	O	O
CCR2	CCR2	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
following	follow	VBG	B-PP	O	O
SE	SE	NN	B-NP	B	B-Disease
.	.	.	O	O	O

Microglial	Microglial	JJ	B-NP	O	O
cells	cell	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
more	more	RBR	I-VP	O	O
closely	closely	RB	I-VP	O	O
apposed	appose	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
CCR2	CCR2	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
labeled	label	VBN	I-NP	O	O
cells	cell	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
SE	SE	NN	B-NP	B	B-Disease
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
,	,	,	O	O	O
rats	rat	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
experienced	experience	VBD	B-VP	O	O
SE	SE	NN	B-NP	B	B-Disease
exhibited	exhibit	VBD	B-VP	O	O
CCR2	CCR2	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
labeling	labeling	NN	I-NP	O	O
in	in	IN	B-PP	O	O
populations	population	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
hypertrophied	hypertrophied	JJ	B-NP	O	B-Disease
astrocytes	astrocyte	NNS	I-NP	O	O
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
CA1	CA1	NN	B-NP	O	O
and	and	CC	I-NP	O	O
dentate	dentate	NN	I-NP	O	O
gyrus	gyrus	NN	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
CCR2	CCR2	NN	I-NP	O	O
+	+	SYM	B-NP	O	O
astroctytes	astroctyte	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
control	control	NN	B-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Examination	Examination	NN	B-NP	O	O
of	of	IN	B-PP	O	O
CCL2	CCL2	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
was	be	VBD	B-VP	O	O
elevated	elevate	VBN	I-VP	B	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
following	follow	VBG	B-PP	O	O
SE	SE	NN	B-NP	B	B-Disease
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
show	show	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
CCR2	CCR2	NN	B-NP	O	O
and	and	CC	I-NP	O	O
CCL2	CCL2	NN	I-NP	O	O
are	be	VBP	B-VP	O	O
up	up	RB	B-ADVP	O	O
-	-	HYPH	B-NP	O	O
regulated	regulate	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
hippocampus	hippocampus	NN	I-NP	O	O
after	after	IN	B-PP	O	O
pilocarpine	pilocarpine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
SE	SE	NN	I-NP	B	B-Disease
.	.	.	O	O	O

Seizures	Seizure	NNS	B-NP	O	B-Disease
also	also	RB	B-ADVP	O	O
result	result	VBP	B-VP	O	O
in	in	IN	B-PP	O	O
changes	change	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
CCR2	CCR2	NN	B-NP	O	O
receptor	receptor	NN	I-NP	O	O
expression	expression	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neurons	neuron	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
astrocytes	astrocyte	NNS	I-NP	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
changes	change	NNS	I-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
detrimental	detrimental	JJ	B-NP	O	O
neuroplasticity	neuroplasticity	NN	I-NP	O	O
and	and	CC	O	O	O
neuroinflammatory	neuroinflammatory	JJ	B-NP	O	B-Disease
changes	change	NNS	I-NP	O	O
that	that	WDT	B-NP	O	O
occur	occur	VBP	B-VP	O	O
following	follow	VBG	B-PP	O	O
seizures	seizure	NNS	B-NP	O	B-Disease
.	.	.	O	O	O

Metallothionein	Metallothionein	NN	B-NP	B	B-Chemical
induction	induction	NN	I-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
caspase	caspase	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
activity	activity	NN	I-NP	O	O
and	and	CC	I-NP	O	O
TNFalpha	TNFalpha	NN	I-NP	B	O
levels	level	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
preservation	preservation	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	O	O	O
intact	intact	JJ	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
neurons	neuron	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
carmustine	carmustine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

Hippocampal	Hippocampal	JJ	B-NP	O	O
integrity	integrity	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
essential	essential	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	O
functions	function	NNS	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
hand	hand	NN	I-NP	O	O
,	,	,	O	O	O
induction	induction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
metallothionein	metallothionein	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
MT	MT	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
by	by	IN	B-PP	O	O
ZnSO	ZnSO	NN	B-NP	O	B-Chemical
(	(	(	O	O	I-Chemical
4	4	CD	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
and	and	CC	O	O	O
its	its	PRP$	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
neuroprotection	neuroprotection	NN	B-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
documented	document	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
aimed	aim	VBD	B-VP	O	O
to	to	TO	I-VP	O	O
explore	explore	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
MT	MT	NN	B-NP	B	B-Chemical
induction	induction	NN	I-NP	O	O
on	on	IN	B-PP	O	O
carmustine	carmustine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
cognitive	cognitive	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
60	60	CD	B-NP	O	O
male	male	JJ	I-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
albino	albino	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
randomly	randomly	RB	I-VP	O	O
divided	divide	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
four	four	CD	B-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
15	15	CD	B-NP	O	O
/	/	SYM	I-NP	O	O
group	group	NN	I-NP	O	O
)	)	)	O	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
control	control	NN	I-NP	O	O
group	group	NN	I-NP	O	O
injected	inject	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
single	single	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
normal	normal	JJ	B-NP	B	O
saline	saline	NN	I-NP	I	O
(	(	(	O	O	O
i.c.v	i.c.v	NN	B-NP	O	O
)	)	)	O	O	O
followed	follow	VBD	B-VP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
later	later	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
solvent	solvent	NN	I-NP	O	O
(	(	(	O	O	O
i.v	i.v	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
group	group	NN	I-NP	O	O
administered	administer	VBN	B-VP	O	O
ZnSO	ZnSO	NN	B-NP	O	B-Chemical
(	(	(	O	O	I-Chemical
4	4	CD	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
10	10	CD	I-NP	O	O
microl	microl	NN	I-NP	O	O
normal	normal	JJ	I-NP	B	O
saline	saline	NN	I-NP	I	O
,	,	,	O	O	O
i.c.v	i.c.v	NN	B-NP	O	O
,	,	,	O	O	O
once	once	RB	B-ADVP	O	O
)	)	)	O	O	O
then	then	RB	B-ADVP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
solvent	solvent	NN	I-NP	O	O
(	(	(	O	O	O
i.v	i.v	NN	B-NP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

Third	Third	JJ	B-NP	O	O
group	group	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
i.v	i.v	NN	B-NP	O	O
,	,	,	O	O	O
once	once	RB	B-ADVP	O	O
)	)	)	O	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
after	after	IN	B-PP	O	O
injection	injection	NN	B-NP	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	B	O
saline	saline	NN	I-NP	I	O
(	(	(	O	O	O
i.c.v	i.c.v	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Fourth	Fourth	JJ	B-NP	O	O
group	group	NN	I-NP	O	O
received	receive	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
single	single	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ZnSO	ZnSO	NN	B-NP	O	B-Chemical
(	(	(	O	O	I-Chemical
4	4	CD	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
(	(	(	O	O	O
0.1	0.1	CD	B-NP	O	O
micromol	micromol	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
10	10	CD	I-NP	O	O
microl	microl	NN	I-NP	O	O
normal	normal	JJ	I-NP	B	O
saline	saline	NN	I-NP	I	O
,	,	,	O	O	O
i.c.v	i.c.v	JJ	B-ADJP	O	O
)	)	)	O	O	O
then	then	RB	B-NP	O	O
BCNU	BCNU	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
20	20	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
,	,	,	O	O	O
i.v	i.v	NN	B-NP	O	O
,	,	,	O	O	O
once	once	RB	B-ADVP	O	O
)	)	)	O	O	O
after	after	IN	B-PP	O	O
24	24	CD	B-NP	O	O
h	h	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
obtained	obtain	VBN	I-NP	O	O
data	datum	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
deterioration	deterioration	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
learning	learning	NN	B-NP	O	I-Disease
and	and	CC	O	O	I-Disease
short	short	JJ	B-NP	O	I-Disease
-	-	HYPH	I-NP	O	I-Disease
term	term	NN	I-NP	O	I-Disease
memory	memory	NN	I-NP	O	I-Disease
(	(	(	O	O	O
STM	STM	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
measured	measure	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
using	use	VBG	B-VP	O	O
radial	radial	JJ	B-NP	O	O
arm	arm	NN	I-NP	O	O
water	water	NN	I-NP	B	O
maze	maze	NN	I-NP	O	O
,	,	,	O	O	O
accompanied	accompany	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
glutathione	glutathione	NN	I-NP	O	B-Chemical
reductase	reductase	NN	I-NP	O	O
(	(	(	O	O	O
GR	GR	NN	B-NP	B	O
)	)	)	O	O	O
activity	activity	NN	B-NP	O	O
and	and	CC	O	O	O
reduced	reduce	VBN	B-NP	O	O
glutathione	glutathione	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
GSH	GSH	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
content	content	NN	B-NP	O	O
.	.	.	O	O	O

Also	Also	RB	B-ADVP	O	O
,	,	,	O	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
increased	increase	VBD	B-VP	O	O
serum	serum	NN	B-NP	O	O
tumor	tumor	NN	I-NP	B	B-Disease
necrosis	necrosis	NN	I-NP	I	B-Disease
factor	factor	NN	I-NP	I	O
-	-	HYPH	O	I	O
alpha	alpha	SYM	B-NP	I	O
(	(	(	O	O	O
TNFalpha	TNFalpha	NN	B-NP	B	O
)	)	)	O	O	O
,	,	,	O	O	O
hippocampal	hippocampal	JJ	B-NP	O	O
MT	MT	NN	I-NP	B	B-Chemical
and	and	CC	O	O	O
malondialdehyde	malondialdehyde	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
MDA	MDA	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
contents	content	NNS	B-NP	O	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
caspase	caspase	NN	B-NP	O	O
-	-	HYPH	O	O	O
3	3	CD	B-NP	O	O
activity	activity	NN	I-NP	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
histological	histological	JJ	B-NP	O	O
alterations	alteration	NNS	I-NP	O	O
.	.	.	O	O	O

ZnSO	ZnSO	NN	B-NP	O	B-Chemical
(	(	(	O	O	I-Chemical
4	4	CD	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
pretreatment	pretreatment	NN	B-NP	O	O
counteracted	counteract	VBD	B-VP	O	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
inhibition	inhibition	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GR	GR	NN	B-NP	B	O
and	and	CC	I-NP	O	O
depletion	depletion	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GSH	GSH	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
resulted	result	VBD	B-VP	O	O
in	in	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
reduction	reduction	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
MDA	MDA	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
TNFalpha	TNFalpha	NN	I-NP	B	O
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
the	the	DT	B-NP	O	O
activity	activity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
caspase	caspase	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
3	3	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
histological	histological	JJ	I-NP	O	O
features	feature	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
improved	improve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
hippocampus	hippocampus	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
ZnSO	ZnSO	NN	B-NP	O	B-Chemical
(	(	(	O	O	I-Chemical
4	4	CD	B-NP	O	I-Chemical
)	)	)	O	O	I-Chemical
+	+	SYM	B-NP	O	O
BCNU	BCNU	NN	I-NP	B	B-Chemical
compared	compare	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
only	only	RB	B-NP	O	O
BCNU	BCNU	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
treated	treat	VBN	I-NP	O	O
animals	animal	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
conclusion	conclusion	NN	B-NP	O	O
,	,	,	O	O	O
MT	MT	NN	B-NP	B	B-Chemical
induction	induction	NN	I-NP	O	O
halts	halt	VBZ	B-VP	B	O
BCNU	BCNU	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
hippocampal	hippocampal	JJ	I-NP	O	O
toxicity	toxicity	NN	I-NP	O	B-Disease
as	as	IN	B-SBAR	O	O
it	it	PRP	B-NP	O	O
prevented	prevent	VBD	B-VP	O	O
GR	GR	NN	B-NP	B	O
inhibition	inhibition	NN	I-NP	O	O
and	and	CC	O	O	O
GSH	GSH	NN	B-NP	B	B-Chemical
depletion	depletion	NN	I-NP	O	O
and	and	CC	O	O	O
counteracted	counteract	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
levels	level	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
TNFalpha	TNFalpha	NN	B-NP	B	O
,	,	,	O	O	O
MDA	MDA	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
caspase	caspase	NN	I-NP	O	O
-	-	HYPH	O	O	O
3	3	CD	B-NP	O	O
activity	activity	NN	I-NP	O	O
with	with	IN	B-PP	O	O
subsequent	subsequent	JJ	B-NP	O	O
preservation	preservation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cognition	cognition	NN	B-NP	O	O
.	.	.	O	O	O

Fatal	Fatal	JJ	B-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
fulminant	fulminant	JJ	B-NP	O	B-Disease
eosinophilic	eosinophilic	JJ	I-NP	O	I-Disease
(	(	(	O	O	O
hypersensitivity	hypersensitivity	NN	B-NP	O	B-Disease
)	)	)	O	O	O
myocarditis	myocarditis	NN	B-NP	O	B-Disease
:	:	:	O	O	O
emphasis	emphasis	NN	B-NP	O	O
on	on	IN	B-PP	O	O
anatomical	anatomical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
histological	histological	JJ	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
,	,	,	O	O	O
mechanisms	mechanism	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
genetics	genetic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
drug	drug	NN	B-NP	O	B-Disease
hypersensitivity	hypersensitivity	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
differential	differential	JJ	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
severe	severe	JJ	I-NP	O	O
adverse	adverse	JJ	I-NP	O	O
reactions	reaction	NNS	I-NP	O	O
to	to	TO	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
have	have	VBP	B-VP	O	O
been	be	VBN	I-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
haemopoietic	haemopoietic	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
liver	liver	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
cardiovascular	cardiovascular	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
frequently	frequently	RB	I-NP	O	O
fatal	fatal	JJ	I-NP	O	O
,	,	,	O	O	O
although	although	IN	B-SBAR	O	O
exceptionally	exceptionally	RB	B-NP	O	O
rare	rare	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
necrotizing	necrotize	VBG	I-VP	O	O
eosinophilic	eosinophilic	JJ	B-NP	O	O
(	(	(	O	O	O
hypersensitivity	hypersensitivity	NN	B-NP	O	B-Disease
)	)	)	O	O	O
myocarditis	myocarditis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hypersensitivity	hypersensitivity	NN	B-NP	O	B-Disease
myocarditis	myocarditis	NN	I-NP	O	B-Disease
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
carbamazepine	carbamazepine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Acute	Acute	JJ	B-NP	O	O
hypersensitivity	hypersensitivity	NN	I-NP	O	B-Disease
myocarditis	myocarditis	NN	I-NP	O	B-Disease
was	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
suspected	suspect	VBN	I-VP	O	O
clinically	clinically	RB	B-ADVP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
made	make	VBN	I-VP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
mortem	mortem	NN	B-NP	O	O
.	.	.	O	O	O

Histology	Histology	NNP	B-NP	O	O
revealed	reveal	VBD	B-VP	O	O
diffuse	diffuse	JJ	B-NP	O	O
infiltration	infiltration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
myocardium	myocardium	NN	I-NP	O	O
by	by	IN	B-PP	O	O
eosinophils	eosinophil	NNS	B-NP	O	O
and	and	CC	I-NP	O	O
lymphocytes	lymphocyte	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
myocyte	myocyte	NN	B-NP	O	O
damage	damage	NN	I-NP	O	O
.	.	.	O	O	O

Clinically	Clinically	RB	B-ADVP	O	O
,	,	,	O	O	O
death	death	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
cardiogenic	cardiogenic	JJ	B-NP	O	B-Disease
shock	shock	NN	I-NP	O	I-Disease
.	.	.	O	O	O

To	To	TO	B-PP	O	O
best	good	JJS	B-NP	O	O
of	of	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
knowledge	knowledge	NN	I-NP	O	O
this	this	DT	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
second	second	JJ	I-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
fatal	fatal	JJ	B-NP	O	O
carbamazepine	carbamazepine	NN	I-NP	B	B-Chemical
induced	induce	VBD	B-VP	O	O
myocarditis	myocarditis	NN	B-NP	O	B-Disease
reported	report	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
English	English	JJ	B-NP	O	O
literature	literature	NN	I-NP	O	O
.	.	.	O	O	O

Neuropsychiatric	Neuropsychiatric	JJ	B-NP	O	O
behaviors	behavior	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
MPTP	MPTP	NN	I-NP	B	B-Chemical
marmoset	marmoset	NN	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NNS	B-NP	O	O
:	:	:	O	O	O
Neuropsychiatric	Neuropsychiatric	JJ	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
increasingly	increasingly	RB	I-VP	O	O
recognised	recognise	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
problem	problem	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
Parkinson	Parkinson	NNP	B-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
PD	PD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
symptoms	symptom	NNS	I-NP	O	O
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
'	'	``	B-NP	O	O
sensitisation	sensitisation	NN	I-NP	O	O
'	'	''	O	O	O
following	follow	VBG	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
or	or	CC	O	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
dopamine	dopamine	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
disease	disease	NN	I-NP	O	O
state	state	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
levodopa	levodopa	NN	I-NP	B	B-Chemical
-	-	HYPH	B-VP	O	O
treated	treat	VBN	B-NP	O	O
MPTP	MPTP	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
lesioned	lesione	VBN	B-NP	O	O
marmoset	marmoset	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
used	use	VBN	I-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
neuropsychiatric	neuropsychiatric	JJ	B-NP	O	B-Disease
symptoms	symptom	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
we	we	PRP	B-NP	O	O
compare	compare	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
time	time	NN	I-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
motor	motor	NN	I-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
and	and	CC	O	O	O
neuropsychiatric	neuropsychiatric	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
like	like	JJ	I-NP	O	I-Disease
behaviors	behavior	NNS	I-NP	O	I-Disease
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
relationship	relationship	NN	I-NP	O	O
between	between	IN	B-PP	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
and	and	CC	I-NP	O	O
onset	onset	NN	I-NP	O	O
of	of	IN	B-PP	O	O
symptoms	symptom	NNS	B-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Marmosets	Marmoset	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
1	1	CD	B-NP	B	B-Chemical
-	-	HYPH	I-NP	I	I-Chemical
methyl	methyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
4	4	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
phenyl	phenyl	NN	I-NP	I	I-Chemical
-	-	HYPH	B-NP	I	I-Chemical
1,2,3,6	1,2,3,6	CD	I-NP	I	I-Chemical
-	-	HYPH	I-NP	I	I-Chemical
tetrahydropyridine	tetrahydropyridine	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
2.0	2.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
s.c.	s.c.	NN	I-NP	O	O
)	)	)	O	O	O
for	for	IN	B-PP	O	O
five	five	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
,	,	,	O	O	O
resulting	result	VBG	B-VP	O	O
in	in	IN	B-PP	O	O
stable	stable	JJ	B-NP	O	O
parkinsonism	parkinsonism	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Levodopa	Levodopa	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
15	15	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
and	and	CC	I-NP	O	O
benserazide	benserazide	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
3.75	3.75	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
p.o.	p.o.	FW	B-NP	O	O
b.i.d	b.i.d	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
administered	administer	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
30	30	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
.	.	.	O	O	O

Animals	Animal	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
parkinsonian	parkinsonian	JJ	B-NP	O	B-Disease
disability	disability	NN	I-NP	O	I-Disease
,	,	,	O	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
and	and	CC	B-PP	O	O
on	on	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
time	time	NN	I-NP	O	O
(	(	(	O	O	O
motor	motor	NN	B-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
neuropsychiatric	neuropsychiatric	JJ	B-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
like	like	JJ	I-NP	O	I-Disease
behaviors	behavior	NNS	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
0	0	CD	I-NP	O	O
(	(	(	O	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
and	and	CC	O	O	O
on	on	IN	B-PP	O	O
Days	Day	NNS	B-NP	O	O
1	1	CD	I-NP	O	O
,	,	,	I-NP	O	O
7	7	CD	I-NP	O	O
,	,	,	I-NP	O	O
13	13	CD	I-NP	O	O
,	,	,	I-NP	O	O
27	27	CD	I-NP	O	O
and	and	CC	I-NP	O	O
30	30	CD	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
using	use	VBG	B-VP	O	O
post	post	NN	B-NP	O	O
hoc	hoc	NN	I-NP	O	O
DVD	DVD	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
trained	trained	JJ	I-NP	O	O
rater	rater	NN	I-NP	O	O
,	,	,	O	O	O
blind	blind	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
neuropsychiatric	neuropsychiatric	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
like	like	JJ	I-NP	O	I-Disease
behavior	behavior	NN	I-NP	O	I-Disease
rating	rating	NN	I-NP	O	O
scale	scale	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
high	high	JJ	B-NP	O	O
interrater	interrater	NN	I-NP	O	O
reliability	reliability	NN	I-NP	O	O
between	between	IN	B-PP	O	O
three	three	CD	B-NP	O	O
trained	train	VBN	I-NP	O	O
raters	rater	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
differing	differ	VBG	B-VP	O	O
professional	professional	JJ	B-NP	O	O
backgrounds	background	NNS	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
anticipated	anticipate	VBN	B-VP	O	O
,	,	,	O	O	O
animals	animal	NNS	B-NP	O	O
exhibited	exhibit	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
progressive	progressive	JJ	I-NP	O	O
increase	increase	NN	I-NP	O	O
in	in	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
motor	motor	NN	I-NP	O	O
fluctuations	fluctuation	NNS	I-NP	O	O
,	,	,	O	O	O
dyskinesia	dyskinesia	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
wearing	wearing	VB	B-VP	O	O
-	-	HYPH	B-ADJP	O	O
off	off	RP	B-PRT	O	O
,	,	,	O	O	O
that	that	WDT	B-NP	O	O
correlated	correlate	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
contrast	contrast	NN	B-NP	O	O
,	,	,	O	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
neuropsychiatric	neuropsychiatric	JJ	I-NP	O	B-Disease
-	-	HYPH	I-NP	O	I-Disease
like	like	JJ	I-NP	O	I-Disease
behaviors	behavior	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
present	present	JJ	B-ADJP	O	O
on	on	IN	B-PP	O	O
Day	Day	NN	B-NP	O	O
1	1	CD	I-NP	O	O
of	of	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
severity	severity	NN	I-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
correlate	correlate	VB	I-VP	O	O
with	with	IN	B-PP	O	O
duration	duration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
data	datum	NNS	I-NP	O	O
suggest	suggest	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
neuropsychiatric	neuropsychiatric	JJ	B-NP	O	B-Disease
disorders	disorder	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
PD	PD	NN	B-NP	O	B-Disease
are	be	VBP	B-VP	O	O
more	more	RBR	B-ADVP	O	O
likely	likely	RB	I-ADVP	O	O
an	an	DT	B-NP	O	O
interaction	interaction	NN	I-NP	O	O
between	between	IN	B-PP	O	O
levodopa	levodopa	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
disease	disease	NN	I-NP	O	O
state	state	NN	I-NP	O	O
than	than	IN	B-PP	O	O
a	a	DT	B-NP	O	O
consequence	consequence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sensitisation	sensitisation	NN	B-NP	O	O
to	to	TO	B-PP	O	O
repeated	repeat	VBN	B-NP	O	O
dopaminergic	dopaminergic	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Contrast	Contrast	NN	B-NP	O	B-Chemical
medium	medium	NN	I-NP	O	I-Chemical
nephrotoxicity	nephrotoxicity	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
and	and	CC	O	O	O
coronary	coronary	JJ	B-NP	O	O
angioplasty	angioplasty	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Renal	Renal	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
iodinated	iodinate	VBN	B-NP	O	O
contrast	contrast	NN	I-NP	O	B-Chemical
medium	medium	NN	I-NP	O	I-Chemical
(	(	(	O	O	O
CM	CM	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
administration	administration	NN	B-NP	O	O
can	can	MD	B-VP	O	O
minimize	minimize	VB	I-VP	O	O
the	the	DT	B-NP	O	O
benefit	benefit	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
interventional	interventional	JJ	I-NP	O	O
procedure	procedure	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
renal	renal	JJ	B-NP	O	O
angioplasty	angioplasty	JJ	I-NP	O	O
(	(	(	O	O	O
PTRA	PTRA	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

PURPOSE	PURPOSE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
compare	compare	VB	I-VP	O	O
the	the	DT	B-NP	O	O
susceptibility	susceptibility	NN	I-NP	O	O
to	to	TO	B-PP	O	O
nephrotoxic	nephrotoxic	JJ	B-NP	O	B-Disease
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CM	CM	NN	B-NP	O	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
PTRA	PTRA	NN	B-NP	O	O
with	with	IN	B-PP	O	O
that	that	DT	B-NP	O	O
of	of	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
submitted	submit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
percutaneous	percutaneous	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
intervention	intervention	NN	I-NP	O	O
(	(	(	O	O	O
PCI	PCI	NN	B-NP	B	O
)	)	)	O	O	O
.	.	.	O	O	O

MATERIAL	MATERIAL	NN	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
total	total	NN	I-NP	O	O
of	of	IN	B-PP	O	O
33	33	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
successfully	successfully	RB	B-VP	O	O
treated	treat	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
PTRA	PTRA	NN	B-NP	O	O
(	(	(	O	O	O
PTRA	PTRA	NN	B-NP	O	O
group	group	NN	I-NP	O	O
,	,	,	O	O	O
mean	mean	JJ	B-NP	O	O
age	age	NN	I-NP	O	O
70	70	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	I-NP	O	O
-	-	SYM	I-NP	O	O
12	12	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
,	,	,	O	O	O
23	23	CD	B-NP	O	O
female	female	JJ	I-NP	O	O
,	,	,	I-NP	O	O
basal	basal	JJ	I-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
1.46	1.46	CD	I-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.79	0.79	CD	B-NP	O	O
,	,	,	O	O	O
range	range	NN	B-NP	O	O
0.7	0.7	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
4.9	4.9	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
compared	compare	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
33	33	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
successful	successful	JJ	B-NP	O	O
PCI	PCI	NN	I-NP	B	O
(	(	(	O	O	O
PCI	PCI	NN	B-NP	B	O
group	group	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
matched	match	VBN	B-VP	B	O
for	for	IN	B-PP	O	O
basal	basal	JJ	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
1.44	1.44	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
,	,	,	O	O	O
range	range	NN	B-NP	O	O
0.7	0.7	CD	I-NP	O	O
-	-	HYPH	B-NP	O	O
3.4	3.4	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dl	dl	NN	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
gender	gender	NN	B-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
age	age	NN	B-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
both	both	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
postprocedural	postprocedural	JJ	B-ADJP	O	O
(	(	(	O	O	O
48	48	CD	B-NP	O	O
h	h	NN	I-NP	O	O
)	)	)	O	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
measured	measure	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Postprocedural	Postprocedural	JJ	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
decreased	decrease	VBD	B-VP	O	O
nonsignificantly	nonsignificantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PTRA	PTRA	NN	I-NP	O	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
1.46	1.46	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.8	0.8	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

1.34	1.34	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.5	0.5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
dl	dl	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
NS	NS	NN	B-NP	B	O
)	)	)	O	O	O
and	and	CC	O	O	O
increased	increase	VBD	B-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PCI	PCI	NN	I-NP	B	O
group	group	NN	I-NP	O	O
(	(	(	O	O	O
1.44	1.44	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

1.57	1.57	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.7	0.7	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	O	O	O
dl	dl	NN	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
<	<	JJR	B-NP	O	O
0.02	0.02	CD	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Changes	Change	NNS	B-NP	O	O
in	in	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
after	after	IN	B-PP	O	O
intervention	intervention	NN	B-NP	O	O
(	(	(	O	O	O
after	after	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
before	before	IN	B-SBAR	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
significantly	significantly	RB	B-ADJP	O	O
different	different	JJ	I-ADJP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
PTRA	PTRA	NN	I-NP	O	O
and	and	CC	I-NP	O	O
PCI	PCI	NN	I-NP	B	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
-	-	SYM	B-NP	O	O
0.12	0.12	CD	I-NP	O	O
+	+	SYM	B-NP	O	O
/	/	SYM	B-NP	O	O
-	-	SYM	B-VP	O	O
0.5	0.5	CD	B-NP	O	O
vs	v	NNS	I-NP	O	O
.	.	.	O	O	O

0.13	0.13	CD	B-NP	O	O
+	+	SYM	O	O	O
/	/	SYM	O	O	O
-	-	SYM	O	O	O
0.3	0.3	CD	B-NP	O	O
,	,	,	O	O	O
P	P	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
0.014	0.014	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
related	related	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
either	either	CC	O	O	O
a	a	DT	B-NP	O	O
different	different	JJ	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
risk	risk	NN	I-NP	O	O
profile	profile	NN	I-NP	O	O
or	or	CC	B-PP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
volume	volume	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CM	CM	NN	B-NP	O	B-Chemical
administered	administer	VBN	B-VP	O	O
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
preliminary	preliminary	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
submitted	submit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
PTRA	PTRA	NN	B-NP	O	O
showed	show	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
lower	low	JJR	I-NP	O	O
susceptibility	susceptibility	NN	I-NP	O	O
to	to	TO	B-PP	O	O
renal	renal	JJ	B-NP	O	B-Disease
damage	damage	NN	I-NP	O	I-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
CM	CM	NN	B-NP	O	B-Chemical
administration	administration	NN	I-NP	O	O
than	than	IN	B-PP	O	O
PCI	PCI	NN	B-NP	B	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
effectiveness	effectiveness	NN	I-NP	O	O
of	of	IN	B-PP	O	O
PTRA	PTRA	NN	B-NP	O	O
on	on	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
seems	seem	VBZ	B-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
barely	barely	RB	I-VP	O	O
influenced	influence	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
CM	CM	NN	B-NP	O	B-Chemical
toxicity	toxicity	NN	I-NP	O	B-Disease
.	.	.	O	O	O

Medical	Medical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
psychiatric	psychiatric	JJ	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
transplanted	transplant	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
acute	acute	JJ	I-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
control	control	NN	I-NP	O	O
study	study	NN	I-NP	O	O
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Acetaminophen	Acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
common	common	JJ	I-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ALF	ALF	NN	B-NP	B	B-Disease
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
UK	UK	NNP	I-NP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
often	often	RB	B-ADVP	O	O
consume	consume	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
with	with	IN	B-PP	O	O
suicidal	suicidal	JJ	B-NP	O	O
intent	intent	NN	I-NP	O	O
or	or	CC	B-PP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
background	background	NN	I-NP	O	O
of	of	IN	B-PP	O	O
substance	substance	NN	B-NP	O	O
dependence	dependence	NN	I-NP	O	O
.	.	.	O	O	O

AIMS	AIMS	NNS	B-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
compared	compare	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pretransplant	pretransplant	NN	B-NP	O	O
illness	illness	NN	I-NP	O	O
,	,	,	O	O	O
psychiatric	psychiatric	JJ	B-NP	O	O
co	co	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
morbidity	morbidity	NN	I-NP	O	O
,	,	,	O	O	O
medical	medical	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
psychosocial	psychosocial	JJ	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
undergone	undergo	VBN	I-VP	O	O
liver	liver	NN	B-NP	O	O
transplantation	transplantation	NN	I-NP	O	O
(	(	(	O	O	O
LT	LT	NN	B-NP	O	O
)	)	)	O	O	O
emergently	emergently	RB	B-ADVP	O	O
between	between	IN	B-PP	O	O
1999	1999	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
2004	2004	CD	I-NP	O	O
for	for	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
36	36	CD	B-NP	O	O
)	)	)	O	O	O
with	with	IN	B-PP	O	O
age	age	NN	B-NP	O	O
-	-	HYPH	O	O	O
and	and	CC	O	O	O
sex	sex	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
matched	match	VBN	B-VP	B	O
patients	patient	NNS	B-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
emergent	emergent	JJ	B-NP	O	O
LT	LT	NN	I-NP	O	O
for	for	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
(	(	(	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
35	35	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
elective	elective	JJ	B-NP	O	O
LT	LT	NN	I-NP	O	O
for	for	IN	B-PP	O	O
chronic	chronic	JJ	B-NP	O	B-Disease
liver	liver	NN	I-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
CLD	CLD	NN	B-NP	O	B-Disease
,	,	,	O	O	O
n	n	NN	B-NP	O	O
=	=	SYM	B-VP	O	O
34	34	CD	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Acetaminophen	Acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
patients	patient	NNS	I-NP	O	O
undergoing	undergo	VBG	B-VP	O	O
LT	LT	NN	B-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
greater	great	JJR	I-NP	O	O
severity	severity	NN	I-NP	O	O
of	of	IN	B-PP	O	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
LT	LT	NN	I-NP	O	O
illness	illness	NN	I-NP	O	O
reflected	reflect	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
higher	high	JJR	B-NP	O	O
Acute	Acute	NNP	I-NP	O	O
Physiology	Physiology	NNP	I-NP	O	O
and	and	CC	O	O	O
Chronic	Chronic	NNP	B-NP	O	O
Health	Health	NNP	I-NP	O	O
Evaluation	Evaluation	NN	I-NP	O	O
II	II	CD	B-NP	O	O
scores	score	NNS	I-NP	O	O
and	and	CC	O	O	O
requirement	requirement	NN	B-NP	O	O
for	for	IN	B-PP	O	O
organ	organ	NN	B-NP	O	O
support	support	NN	I-NP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
other	other	JJ	I-NP	O	O
two	two	CD	I-NP	O	O
groups	group	NNS	I-NP	O	O
.	.	.	O	O	O

Twenty	Twenty	CD	B-NP	O	O
(	(	(	O	O	O
56	56	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
formal	formal	JJ	I-NP	O	O
psychiatric	psychiatric	JJ	I-NP	O	O
diagnosis	diagnosis	NN	I-NP	O	O
before	before	IN	B-PP	O	O
LT	LT	NN	B-NP	O	O
(	(	(	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	B-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
=	=	SYM	B-VP	O	O
0	0	CD	B-NP	O	O
/	/	SYM	B-NP	O	O
35	35	CD	I-NP	O	O
,	,	,	O	O	O
CLD	CLD	NN	B-NP	O	B-Disease
=	=	SYM	B-VP	O	O
2	2	CD	B-NP	O	O
/	/	SYM	O	O	O
34	34	CD	B-NP	O	O
;	;	:	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	B-VP	O	O
0.01	0.01	CD	B-NP	O	O
for	for	IN	B-PP	O	O
all	all	DT	O	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
nine	nine	CD	B-NP	O	O
(	(	(	O	O	O
25	25	CD	B-NP	O	O
%	%	NN	I-NP	O	O
)	)	)	O	O	O
had	have	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
suicide	suicide	NN	I-NP	O	O
attempt	attempt	NN	I-NP	O	O
.	.	.	O	O	O

During	During	IN	B-PP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
(	(	(	O	O	O
median	median	JJ	B-NP	O	O
5	5	CD	I-NP	O	O
years	year	NNS	I-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
there	there	EX	B-NP	O	O
were	be	VBD	B-VP	O	O
no	no	DT	B-NP	O	O
significant	significant	JJ	I-NP	O	O
differences	difference	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
rejection	rejection	NN	B-NP	O	O
(	(	(	O	O	O
acute	acute	JJ	B-ADJP	O	O
and	and	CC	O	O	O
chronic	chronic	JJ	B-ADJP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
graft	graft	NN	B-NP	O	O
failure	failure	NN	I-NP	O	O
or	or	CC	I-NP	O	O
survival	survival	NN	I-NP	O	O
between	between	IN	B-PP	O	O
the	the	DT	B-NP	O	O
groups	group	NNS	I-NP	O	O
(	(	(	O	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
1	1	CD	I-NP	O	O
year	year	NN	I-NP	O	O
87	87	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
5	5	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
75	75	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
non	non	AFX	O	O	O
-	-	HYPH	B-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
88	88	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
78	78	CD	B-NP	O	O
%	%	NN	I-NP	O	O
;	;	:	O	O	O
CLD	CLD	NN	B-NP	O	B-Disease
93	93	CD	B-NP	O	O
%	%	NN	I-NP	O	O
,	,	,	O	O	O
82	82	CD	B-NP	O	O
%	%	NN	I-NP	O	O
:	:	:	O	O	O
P	P	NN	B-NP	O	O
>	>	SYM	O	O	O
0.6	0.6	CD	B-NP	O	O
log	log	NN	I-NP	O	O
rank	rank	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

Two	Two	CD	B-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
patients	patient	NNS	I-NP	O	O
reattempted	reattempte	VBD	B-VP	O	O
suicide	suicide	NN	B-NP	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
LT	LT	NN	B-NP	O	O
(	(	(	O	O	O
one	one	CD	B-NP	O	O
died	die	VBD	B-VP	O	O
8	8	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
post	post	AFX	O	O	O
-	-	HYPH	O	O	O
LT	LT	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Despite	Despite	IN	B-PP	O	O
a	a	DT	B-NP	O	O
high	high	JJ	I-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
psychiatric	psychiatric	JJ	B-NP	O	O
disturbance	disturbance	NN	I-NP	O	O
,	,	,	O	O	O
outcomes	outcome	VBZ	B-VP	O	O
for	for	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
transplanted	transplant	VBN	B-VP	O	O
emergently	emergently	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
acetaminophen	acetaminophen	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
were	be	VBD	B-VP	O	O
comparable	comparable	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
those	those	DT	B-NP	O	O
transplanted	transplant	VBN	B-VP	O	O
for	for	IN	B-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
acetaminophen	acetaminophen	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
ALF	ALF	NN	I-NP	B	B-Disease
and	and	CC	O	O	O
electively	electively	RB	B-ADVP	O	O
for	for	IN	B-PP	O	O
CLD	CLD	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Multidisciplinary	Multidisciplinary	JJ	B-NP	O	O
approaches	approach	NNS	I-NP	O	O
with	with	IN	B-PP	O	O
long	long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
psychiatric	psychiatric	JJ	B-ADJP	O	O
follow	follow	VB	B-VP	O	O
-	-	HYPH	O	O	O
up	up	RP	B-PRT	O	O
may	may	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
low	low	JJ	B-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
transplant	transplant	NN	I-NP	O	O
suicide	suicide	NN	I-NP	O	O
rates	rate	NNS	I-NP	O	O
seen	see	VBN	B-VP	O	O
and	and	CC	O	O	O
low	low	JJ	B-NP	O	O
rates	rate	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
graft	graft	NN	B-NP	O	O
loss	loss	NN	I-NP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
non	non	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
compliance	compliance	NN	I-NP	O	O
.	.	.	O	O	O

Studies	Study	NNS	B-NP	O	O
of	of	IN	B-PP	O	O
synergy	synergy	NN	B-NP	O	O
between	between	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
,	,	,	O	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neuropathic	neuropathic	JJ	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
This	This	DT	B-NP	O	O
study	study	NN	I-NP	O	O
determined	determine	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
antihyperalgesic	antihyperalgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
sodium	sodium	NN	I-NP	B	B-Chemical
channel	channel	NN	I-NP	O	O
blocker	blocker	NN	I-NP	O	O
with	with	IN	B-PP	O	O
antioxidant	antioxidant	JJ	B-NP	O	O
properties	property	NNS	I-NP	O	O
given	give	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
combinations	combination	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
models	model	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
inflammatory	inflammatory	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
neuropathic	neuropathic	JJ	I-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
.	.	.	O	O	O

DESIGN	DESIGN	NN	B-NP	O	O
:	:	:	O	O	O
Dose	Dose	NN	B-NP	O	O
response	response	NN	I-NP	O	O
curves	curve	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
nonsedating	nonsedating	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
CNSB002	CNSB002	NN	I-NP	O	B-Chemical
given	give	VBN	B-VP	O	O
intraperitoneally	intraperitoneally	RB	B-ADVP	O	O
alone	alone	RB	I-ADVP	O	O
and	and	CC	I-ADVP	O	O
together	together	RB	I-ADVP	O	O
in	in	IN	B-PP	O	O
combinations	combination	NNS	B-NP	O	O
were	be	VBD	B-VP	O	O
constructed	construct	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
antihyperalgesic	antihyperalgesic	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
using	use	VBG	B-VP	O	O
paw	paw	NN	B-NP	O	O
withdrawal	withdrawal	NN	I-NP	O	O
from	from	IN	B-PP	O	O
noxious	noxious	JJ	B-NP	O	O
heat	heat	NN	I-NP	O	O
in	in	IN	B-PP	O	O
two	two	CD	B-NP	O	O
rat	rat	NN	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
:	:	:	O	O	O
carrageenan	carrageenan	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
paw	paw	NN	I-NP	O	O
inflammation	inflammation	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
neuropathy	neuropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
nonsedating	nonsedating	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
:	:	:	O	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
3.2	3.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
;	;	:	O	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
10.0	10.0	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
;	;	:	O	O	O
5.0	5.0	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
CNSB002	CNSB002	NN	I-NP	O	B-Chemical
with	with	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
3.2	3.2	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
doses	dose	NNS	I-NP	O	O
calculated	calculate	VBN	B-VP	O	O
to	to	TO	I-VP	O	O
cause	cause	VB	I-VP	O	O
50	50	CD	B-NP	O	O
%	%	NN	I-NP	O	O
reversal	reversal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperalgesia	hyperalgesia	NN	B-NP	O	B-Disease
(	(	(	O	O	O
ED50	ED50	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
7.54	7.54	CD	B-NP	O	O
(	(	(	O	O	O
1.81	1.81	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
4.83	4.83	CD	B-NP	O	O
(	(	(	O	O	O
1.54	1.54	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
carrageenan	carrageenan	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
and	and	CC	O	O	O
44.18	44.18	CD	B-NP	O	O
(	(	(	O	O	O
1.37	1.37	CD	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
9.14	9.14	CD	B-NP	O	O
(	(	(	O	O	O
1.24	1.24	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STZ	STZ	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	B-Disease
model	model	NN	I-NP	O	O
for	for	IN	B-PP	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
and	and	CC	I-NP	O	O
morphine	morphine	NN	I-NP	B	B-Chemical
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
(	(	(	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
;	;	:	O	O	O
mean	mean	NN	B-NP	O	O
,	,	,	I-NP	O	O
SEM	SEM	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

These	These	DT	B-NP	O	O
values	value	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
greater	great	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
nonsedating	nonsedating	JJ	I-NP	O	O
doses	dose	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
ED50	ED50	NN	I-NP	O	O
values	value	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
when	when	WRB	B-ADVP	O	O
given	give	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
(	(	(	O	O	O
5	5	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
less	less	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
the	the	DT	B-NP	O	O
maximum	maximum	NN	I-NP	O	O
nonsedating	nonsedating	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
:	:	:	O	O	O
0.56	0.56	CD	B-NP	O	O
(	(	(	O	O	O
1.55	1.55	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
carrageenan	carrageenan	NN	I-NP	B	B-Chemical
model	model	NN	I-NP	O	O
and	and	CC	O	O	O
1.37	1.37	CD	B-NP	O	O
(	(	(	O	O	O
1.23	1.23	CD	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
neuropathy	neuropathy	NN	I-NP	O	B-Disease
model	model	NN	I-NP	O	O
(	(	(	O	O	O
mg	mg	NN	B-NP	O	O
/	/	SYM	O	O	O
kg	kg	NN	B-NP	O	O
;	;	:	O	O	O
mean	mean	NN	B-NP	O	O
,	,	,	I-NP	O	O
SEM	SEM	NN	I-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
antinociception	antinociception	NN	I-NP	O	O
after	after	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
3.2	3.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
)	)	)	O	O	O
was	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
co	co	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
administration	administration	NN	I-NP	O	O
with	with	IN	B-PP	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
from	from	IN	B-PP	O	O
28.0	28.0	CD	B-NP	O	O
and	and	CC	I-NP	O	O
31.7	31.7	CD	I-NP	O	O
%	%	NN	I-NP	O	O
to	to	TO	I-NP	O	O
114.6	114.6	CD	I-NP	O	O
and	and	CC	I-NP	O	O
56.9	56.9	CD	I-NP	O	O
%	%	NN	I-NP	O	O
reversal	reversal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperalgesia	hyperalgesia	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
inflammatory	inflammatory	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
neuropathic	neuropathic	JJ	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
(	(	(	O	O	O
P	P	NN	B-NP	O	O
<	<	SYM	O	O	O
0.01	0.01	CD	B-NP	O	O
;	;	:	O	O	O
one	one	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
way	way	NN	I-NP	O	O
analysis	analysis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
variance	variance	NN	B-NP	O	O
-	-	HYPH	O	O	O
significantly	significantly	RB	B-ADJP	O	O
greater	great	JJR	I-ADJP	O	O
than	than	IN	B-PP	O	O
either	either	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
given	give	VBN	B-VP	O	O
alone	alone	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
The	The	DT	B-NP	O	O
maximum	maximum	JJ	I-NP	O	O
antihyperalgesic	antihyperalgesic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
achievable	achievable	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
nonsedating	nonsedating	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
morphine	morphine	NN	B-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
increased	increase	VBN	I-VP	O	O
significantly	significantly	RB	B-ADVP	O	O
when	when	WRB	B-ADVP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
used	use	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
CNSB002	CNSB002	NN	B-NP	O	B-Chemical
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
:	:	:	O	O	O
a	a	DT	B-NP	O	O
practical	practical	JJ	I-NP	O	O
review	review	NN	I-NP	O	O
.	.	.	O	O	O

Heparin	Heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-PP	O	O
induced	induce	VBN	B-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
(	(	(	O	O	O
HIT	HIT	NN	B-NP	O	B-Disease
)	)	)	O	O	O
remains	remain	VBZ	B-VP	O	O
under	under	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
recognized	recognize	VBN	B-VP	O	O
despite	despite	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
potentially	potentially	RB	I-NP	O	O
devastating	devastate	VBG	I-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
begins	begin	VBZ	B-VP	O	O
when	when	WRB	B-ADVP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
stimulates	stimulate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
formation	formation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
platelet	platelet	NN	I-NP	B	O
factor	factor	NN	I-NP	I	O
4	4	CD	B-NP	I	O
antibodies	antibody	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
triggers	trigger	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
release	release	NN	I-NP	O	O
of	of	IN	B-PP	O	O
procoagulant	procoagulant	JJ	B-NP	O	O
platelet	platelet	NN	I-NP	O	O
particles	particle	NNS	I-NP	O	O
.	.	.	O	O	O

Thrombosis	Thrombosis	NN	B-NP	O	B-Disease
and	and	CC	I-NP	O	O
thrombocytopenia	thrombocytopenia	NN	I-NP	O	B-Disease
that	that	WDT	B-NP	O	O
follow	follow	VBP	B-VP	O	O
comprise	comprise	VB	I-VP	O	O
the	the	DT	B-NP	O	O
2	2	CD	I-NP	O	O
hallmark	hallmark	NN	I-NP	O	O
traits	trait	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
,	,	,	O	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
former	former	JJ	I-NP	O	O
largely	largely	RB	B-ADJP	O	O
responsible	responsible	JJ	I-ADJP	O	O
for	for	IN	B-PP	O	O
significant	significant	JJ	B-NP	O	O
vascular	vascular	JJ	I-NP	O	O
complications	complication	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
prevalence	prevalence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
varies	vary	VBZ	B-VP	O	O
among	among	IN	B-PP	O	O
several	several	JJ	B-NP	O	O
subgroups	subgroup	NNS	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
greater	great	JJR	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
surgical	surgical	JJ	B-NP	O	O
as	as	IN	B-PP	O	O
compared	compare	VBN	B-PP	O	O
with	with	IN	B-PP	O	O
medical	medical	JJ	B-NP	O	O
populations	population	NNS	I-NP	O	O
.	.	.	O	O	O

HIT	HIT	NN	B-NP	O	B-Disease
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
acknowledged	acknowledge	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
its	its	PRP$	B-NP	O	O
intense	intense	JJ	I-NP	O	O
predilection	predilection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
and	and	CC	O	O	O
suspected	suspect	VBN	B-VP	O	O
whenever	whenever	WRB	B-ADVP	O	O
thrombosis	thrombosis	NN	B-NP	O	B-Disease
occurs	occur	VBZ	B-VP	O	O
after	after	IN	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
.	.	.	O	O	O

Early	Early	JJ	B-NP	O	O
recognition	recognition	NN	I-NP	O	O
that	that	WDT	B-NP	O	O
incorporates	incorporate	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
serologic	serologic	JJ	I-NP	O	O
clues	clue	NNS	I-NP	O	O
is	be	VBZ	B-VP	O	O
paramount	paramount	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
timely	timely	JJ	B-NP	O	O
institution	institution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
,	,	,	O	O	O
as	as	IN	B-SBAR	O	O
its	its	PRP$	B-NP	O	O
delay	delay	NN	I-NP	O	O
may	may	MD	B-VP	O	O
result	result	VB	I-VP	O	O
in	in	IN	B-PP	O	O
catastrophic	catastrophic	JJ	B-NP	O	O
outcomes	outcome	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
mandates	mandate	VBZ	B-VP	B	O
an	an	DT	B-NP	O	O
immediate	immediate	JJ	I-NP	O	O
cessation	cessation	NN	I-NP	O	O
of	of	IN	B-PP	O	O
all	all	DT	B-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
and	and	CC	O	O	O
the	the	DT	B-NP	O	O
institution	institution	NN	I-NP	O	O
of	of	IN	B-PP	O	O
an	an	DT	B-NP	O	O
antithrombotic	antithrombotic	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
,	,	,	O	O	O
most	most	RBS	B-ADVP	O	O
commonly	commonly	RB	I-ADVP	O	O
using	use	VBG	B-VP	O	O
a	a	DT	B-NP	O	O
direct	direct	JJ	I-NP	O	B-Chemical
thrombin	thrombin	NN	I-NP	B	I-Chemical
inhibitor	inhibitor	NN	I-NP	I	I-Chemical
.	.	.	O	O	O

Current	Current	JJ	B-NP	O	O
"	"	``	I-NP	O	O
diagnostic	diagnostic	JJ	I-NP	O	O
"	"	''	I-NP	O	O
tests	test	NNS	I-NP	O	O
,	,	,	O	O	O
which	which	WDT	B-NP	O	O
primarily	primarily	RB	B-ADVP	O	O
include	include	VBP	B-VP	O	O
functional	functional	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
antigenic	antigenic	JJ	I-NP	O	O
assays	assay	NNS	I-NP	O	O
,	,	,	O	O	O
have	have	VBP	B-VP	O	O
more	more	JJR	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
confirmatory	confirmatory	JJ	I-NP	O	O
than	than	IN	B-PP	O	O
diagnostic	diagnostic	JJ	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
management	management	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Special	Special	JJ	B-NP	O	O
attention	attention	NN	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
paid	pay	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
who	who	WP	B-NP	O	O
are	be	VBP	B-VP	O	O
often	often	RB	I-VP	O	O
exposed	expose	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
heparin	heparin	VB	I-VP	B	B-Chemical
multiple	multiple	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
during	during	IN	B-PP	O	O
their	their	PRP$	B-NP	O	O
course	course	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatment	treatment	NN	B-NP	O	O
.	.	.	O	O	O

Direct	Direct	JJ	B-NP	O	B-Chemical
thrombin	thrombin	NN	I-NP	B	I-Chemical
inhibitors	inhibitor	NNS	I-NP	I	I-Chemical
are	be	VBP	B-VP	O	O
appropriate	appropriate	JJ	B-ADJP	O	O
,	,	,	O	O	O
evidence	evidence	NN	B-NP	O	O
-	-	HYPH	O	O	O
based	base	VBN	B-VP	O	O
alternatives	alternative	NNS	B-NP	O	O
to	to	TO	B-PP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
,	,	,	O	O	O
who	who	WP	B-NP	O	O
need	need	VBP	B-VP	O	O
to	to	TO	I-VP	O	O
undergo	undergo	VB	I-VP	O	O
percutaneous	percutaneous	JJ	B-NP	O	O
coronary	coronary	JJ	I-NP	O	O
intervention	intervention	NN	I-NP	O	O
.	.	.	O	O	O

As	As	IN	B-SBAR	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
remains	remain	VBZ	B-VP	O	O
one	one	CD	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
most	most	RBS	I-NP	O	O
frequently	frequently	RB	I-NP	O	O
used	use	VBN	I-NP	O	O
medications	medication	NNS	I-NP	O	O
today	today	NN	B-NP	O	O
with	with	IN	B-PP	O	O
potential	potential	NN	B-NP	O	O
for	for	IN	B-PP	O	O
HIT	HIT	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
every	every	DT	B-NP	O	O
heparin	heparin	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
close	close	JJ	I-NP	O	O
vigilance	vigilance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
platelet	platelet	NN	B-NP	O	O
counts	count	NNS	I-NP	O	O
must	must	MD	B-VP	O	O
be	be	VB	I-VP	O	O
practiced	practice	VBN	I-VP	O	O
whenever	whenever	WRB	B-ADVP	O	O
heparin	heparin	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
.	.	.	O	O	O

Abductor	Abductor	NN	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
botox	botox	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
adductor	adductor	NN	B-NP	O	B-Disease
spasmodic	spasmodic	JJ	I-NP	O	I-Disease
dysphonia	dysphonia	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVES	OBJECTIVES	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
HYPOTHESIS	HYPOTHESIS	NN	I-NP	O	O
:	:	SYM	O	O	O
Botulinum	Botulinum	NN	B-NP	O	O
toxin	toxin	NN	I-NP	O	O
(	(	(	O	O	O
Botox	Botox	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
injections	injection	NNS	B-NP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
thyroarytenoid	thyroarytenoid	JJ	I-NP	O	O
muscles	muscle	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
standard	standard	NN	I-NP	O	O
of	of	IN	B-PP	O	O
care	care	NN	B-NP	O	O
for	for	IN	B-PP	O	O
adductor	adductor	NN	B-NP	O	B-Disease
spasmodic	spasmodic	JJ	I-NP	O	I-Disease
dysphonia	dysphonia	NN	I-NP	O	I-Disease
(	(	(	O	O	O
ADSD	ADSD	NN	B-NP	O	B-Disease
)	)	)	O	O	O
.	.	.	O	O	O

Reported	Report	VBN	B-NP	O	O
adverse	adverse	JJ	I-NP	O	O
effects	effect	NNS	I-NP	O	O
include	include	VBP	B-VP	O	O
a	a	DT	B-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
breathiness	breathiness	NN	B-NP	O	O
,	,	,	O	O	O
throat	throat	DT	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
difficulty	difficulty	NN	B-NP	O	O
with	with	IN	B-PP	O	O
swallowing	swallow	VBG	B-NP	O	O
liquids	liquid	NNS	I-NP	O	O
.	.	.	O	O	O

Here	Here	RB	B-ADVP	O	O
we	we	PRP	B-NP	O	O
report	report	VBP	B-VP	O	O
multiple	multiple	JJ	B-NP	O	O
cases	case	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
abductor	abductor	NN	I-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
Botox	Botox	NN	B-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
ADSD	ADSD	NN	B-NP	O	B-Disease
,	,	,	O	O	O
a	a	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
previously	previously	RB	B-ADJP	O	O
unreported	unreported	JJ	I-ADJP	O	O
.	.	.	O	O	O

STUDY	STUDY	NN	B-NP	O	O
DESIGN	DESIGN	NN	I-NP	O	O
:	:	:	O	O	O
Retrospective	Retrospective	JJ	B-NP	O	O
case	case	NN	I-NP	O	O
series	series	NN	I-NP	O	O
.	.	.	O	O	O

METHODS	METHODS	NNS	B-NP	O	O
:	:	:	O	O	O
Patients	Patient	NNS	B-NP	O	O
that	that	WDT	B-NP	O	O
received	receive	VBD	B-VP	O	O
Botox	Botox	NN	B-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
spasmodic	spasmodic	JJ	B-NP	O	B-Disease
dysphonia	dysphonia	NN	I-NP	O	I-Disease
between	between	IN	B-PP	O	O
January	January	NNP	B-NP	O	O
2000	2000	CD	I-NP	O	O
and	and	CC	O	O	O
October	October	NNP	B-NP	O	O
2009	2009	CD	I-NP	O	O
were	be	VBD	B-VP	O	O
evaluated	evaluate	VBN	I-VP	O	O
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
ADSD	ADSD	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
identified	identify	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
treatments	treatment	NNS	B-NP	O	O
received	receive	VBN	B-VP	O	O
and	and	CC	O	O	O
adverse	adverse	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
.	.	.	O	O	O

For	For	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
bilateral	bilateral	JJ	B-NP	O	O
abductor	abductor	NN	I-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
age	age	NN	B-NP	O	O
,	,	,	O	O	O
sex	sex	NN	B-NP	O	O
,	,	,	O	O	O
paralytic	paralytic	JJ	B-NP	O	O
Botox	Botox	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
prior	prior	JJ	B-NP	O	O
Botox	Botox	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
course	course	NN	B-NP	O	O
following	follow	VBG	B-PP	O	O
paralysis	paralysis	NN	B-NP	O	B-Disease
were	be	VBD	B-VP	O	O
noted	note	VBN	I-VP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
From	From	IN	B-PP	O	O
a	a	DT	B-NP	O	O
database	database	NN	I-NP	O	O
of	of	IN	B-PP	O	O
452	452	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
receiving	receive	VBG	B-VP	O	O
Botox	Botox	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
352	352	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
been	be	VBN	I-VP	O	O
diagnosed	diagnose	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
ADSD	ADSD	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Of	Of	IN	B-PP	O	O
these	these	DT	B-NP	O	O
352	352	CD	I-NP	O	O
patients	patient	NNS	I-NP	O	O
,	,	,	O	O	O
eight	eight	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
suffered	suffer	VBD	B-VP	O	O
bilateral	bilateral	JJ	B-NP	O	O
abductor	abductor	NN	I-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
two	two	CD	B-NP	O	O
suffered	suffer	VBD	B-VP	O	O
this	this	DT	B-NP	O	O
complication	complication	NN	I-NP	O	O
twice	twice	RB	B-ADVP	O	O
.	.	.	O	O	O

All	All	DT	B-NP	O	O
affected	affect	VBN	I-NP	O	O
patients	patient	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
females	female	NNS	B-NP	O	O
over	over	IN	B-PP	O	O
the	the	DT	B-NP	O	O
age	age	NN	I-NP	O	O
of	of	IN	B-PP	O	O
50	50	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Most	Most	JJS	B-NP	O	O
patients	patient	NNS	I-NP	O	O
had	have	VBD	B-VP	O	O
received	receive	VBN	I-VP	O	O
treatments	treatment	NNS	B-NP	O	O
prior	prior	RB	B-ADVP	O	O
to	to	TO	B-PP	O	O
abductor	abductor	NN	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
continued	continue	VBD	B-VP	O	O
receiving	receive	VBG	I-VP	O	O
after	after	IN	B-PP	O	O
paralysis	paralysis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Seven	Seven	CD	B-NP	O	O
patients	patient	NNS	I-NP	O	O
recovered	recover	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
a	a	DT	B-NP	O	O
brief	brief	JJ	I-NP	O	O
period	period	NN	I-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
restrictions	restriction	NNS	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
one	one	CD	B-NP	O	O
underwent	undergo	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
tracheotomy	tracheotomy	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
incidence	incidence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
abductor	abductor	NN	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
Botox	Botox	NN	B-NP	B	B-Chemical
injection	injection	NN	I-NP	O	O
for	for	IN	B-PP	O	O
ADSD	ADSD	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
0.34	0.34	CD	B-NP	O	O
%	%	NN	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
Bilateral	Bilateral	JJ	B-NP	O	O
abductor	abductor	NN	I-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
complication	complication	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Botox	Botox	NN	B-NP	B	B-Chemical
injections	injection	NNS	I-NP	O	O
for	for	IN	B-PP	O	O
ADSD	ADSD	NN	B-NP	O	B-Disease
,	,	,	O	O	O
causing	cause	VBG	B-VP	O	O
difficulty	difficulty	NN	B-NP	O	O
with	with	IN	B-PP	O	O
breathing	breathing	NN	B-NP	O	O
upon	upon	IN	B-PP	O	O
exertion	exertion	NN	B-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
likely	likely	JJ	I-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
of	of	IN	B-PP	O	O
paralysis	paralysis	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
diffusion	diffusion	NN	B-NP	O	O
of	of	IN	B-PP	O	O
Botox	Botox	NNP	B-NP	B	B-Chemical
around	around	IN	B-PP	O	O
the	the	DT	B-NP	O	O
muscular	muscular	JJ	I-NP	O	O
process	process	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
arytenoid	arytenoid	NN	I-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
posterior	posterior	JJ	I-NP	O	O
cricoarytenoid	cricoarytenoid	JJ	I-NP	O	O
muscles	muscle	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
paralysis	paralysis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
temporary	temporary	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
watchful	watchful	JJ	B-NP	O	O
waiting	waiting	NN	I-NP	O	O
with	with	IN	B-PP	O	O
restriction	restriction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
activity	activity	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
recommended	recommend	VBN	I-NP	O	O
management	management	NN	I-NP	O	O
.	.	.	O	O	O

Mitochondrial	Mitochondrial	JJ	B-NP	O	B-Disease
impairment	impairment	NN	I-NP	O	I-Disease
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
:	:	:	O	O	O
Prevention	Prevention	NN	B-NP	O	O
by	by	IN	B-PP	O	O
the	the	DT	B-NP	O	O
targeted	target	VBN	I-NP	O	O
antioxidant	antioxidant	NN	I-NP	O	O
MitoQ	MitoQ	NNP	I-NP	O	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
goal	goal	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
assess	assess	VB	I-VP	O	O
mitochondrial	mitochondrial	JJ	B-NP	O	O
function	function	NN	I-NP	O	O
and	and	CC	I-NP	O	O
ROS	ROS	NN	I-NP	B	O
production	production	NN	I-NP	O	O
in	in	IN	B-PP	O	O
an	an	DT	B-NP	O	O
experimental	experimental	JJ	I-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
hypothesized	hypothesize	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
cocaine	cocaine	NN	B-NP	B	B-Disease
abuse	abuse	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
lead	lead	VB	I-VP	O	O
to	to	TO	B-PP	O	O
altered	altered	JJ	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
function	function	NN	I-NP	O	O
that	that	IN	B-NP	O	O
in	in	IN	B-PP	O	O
turn	turn	NN	B-NP	O	O
may	may	MD	B-VP	O	O
cause	cause	VB	I-VP	O	O
left	left	JJ	B-NP	O	B-Disease
ventricular	ventricular	JJ	I-NP	O	I-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Seven	Seven	CD	B-NP	O	O
days	day	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
to	to	TO	B-PP	O	O
rats	rat	NNS	B-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
an	an	DT	B-NP	O	O
increased	increase	VBN	I-NP	O	O
oxygen	oxygen	NN	I-NP	B	B-Chemical
consumption	consumption	NN	I-NP	O	O
detected	detect	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	O
fibers	fiber	NNS	I-NP	O	O
,	,	,	O	O	O
specifically	specifically	RB	B-ADVP	O	O
through	through	IN	B-PP	O	O
complex	complex	NN	B-NP	O	O
I	I	CD	I-NP	O	O
and	and	CC	O	O	O
complex	complex	NN	B-NP	O	O
III	III	CD	I-NP	O	O
.	.	.	O	O	O

ROS	ROS	NN	B-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
increased	increase	VBN	I-VP	O	O
,	,	,	O	O	O
specifically	specifically	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
interfibrillar	interfibrillar	JJ	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
parallel	parallel	NN	B-NP	O	O
there	there	EX	B-NP	O	O
was	be	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
decrease	decrease	NN	I-NP	O	O
in	in	IN	B-PP	O	O
ATP	ATP	NN	B-NP	B	B-Chemical
synthesis	synthesis	NN	I-NP	O	O
,	,	,	O	O	O
whereas	whereas	IN	O	O	O
no	no	DT	B-NP	O	O
difference	difference	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
observed	observe	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
subsarcolemmal	subsarcolemmal	JJ	B-NP	O	O
mitochondria	mitochondrion	NNS	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
uncoupling	uncoupling	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
on	on	IN	B-PP	O	O
oxidative	oxidative	JJ	B-NP	O	O
phosphorylation	phosphorylation	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
not	not	RB	O	O	O
detectable	detectable	JJ	B-ADJP	O	O
after	after	IN	B-PP	O	O
short	short	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
exposure	exposure	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
these	these	DT	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
were	be	VBD	B-VP	O	O
a	a	DT	O	O	O
late	late	JJ	O	O	O
rather	rather	RB	B-CONJP	O	O
than	than	IN	I-CONJP	O	O
a	a	DT	B-NP	O	O
primary	primary	JJ	I-NP	O	O
event	event	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathological	pathological	JJ	I-NP	O	O
response	response	NN	I-NP	O	O
to	to	TO	B-PP	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

MitoQ	MitoQ	NNP	B-NP	O	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
targeted	target	VBN	I-NP	O	O
antioxidant	antioxidant	NN	I-NP	O	O
,	,	,	O	O	O
was	be	VBD	B-VP	O	O
shown	show	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
completely	completely	RB	I-VP	O	O
prevent	prevent	VB	I-VP	O	O
these	these	DT	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	B-Disease
abnormalities	abnormality	NNS	I-NP	O	I-Disease
as	as	RB	B-CONJP	O	O
well	well	RB	I-CONJP	O	O
as	as	IN	I-CONJP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
characterized	characterize	VBN	B-VP	O	O
here	here	RB	B-ADVP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
diastolic	diastolic	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
studied	study	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
conductance	conductance	NN	I-NP	O	O
catheter	catheter	NN	I-NP	O	O
to	to	TO	B-VP	O	O
obtain	obtain	VB	I-VP	O	O
pressure	pressure	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
volume	volume	NN	I-NP	O	O
data	datum	NNS	I-NP	O	O
.	.	.	O	O	O

Taken	Take	VBN	B-VP	O	O
together	together	RB	B-ADVP	O	O
,	,	,	O	O	O
these	these	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
extend	extend	VBP	B-VP	O	O
previous	previous	JJ	B-NP	O	O
studies	study	NNS	I-NP	O	O
and	and	CC	O	O	O
demonstrate	demonstrate	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
cocaine	cocaine	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
cardiac	cardiac	JJ	I-NP	O	B-Disease
dysfunction	dysfunction	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
due	due	JJ	B-ADVP	O	O
to	to	TO	B-PP	O	O
a	a	DT	B-NP	O	O
mitochondrial	mitochondrial	JJ	I-NP	O	B-Disease
defect	defect	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Trimethoprim	Trimethoprim	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
immune	immune	JJ	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
pediatric	pediatric	JJ	I-NP	O	O
oncology	oncology	NN	I-NP	O	O
patient	patient	NN	I-NP	O	O
presenting	present	VBG	B-VP	O	O
as	as	IN	B-PP	O	O
an	an	DT	B-NP	O	O
acute	acute	JJ	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

A	A	DT	B-NP	O	O
10	10	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	NN	I-NP	O	O
with	with	IN	B-PP	O	O
acute	acute	JJ	B-NP	O	B-Disease
leukemia	leukemia	NN	I-NP	O	I-Disease
presented	present	VBD	B-VP	O	O
with	with	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
.	.	.	O	O	O

During	During	IN	B-PP	O	O
red	red	JJ	B-NP	O	O
cell	cell	NN	I-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
,	,	,	O	O	O
he	he	PRP	B-NP	O	O
developed	develop	VBD	B-VP	O	O
hemoglobinuria	hemoglobinuria	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Transfusion	Transfusion	NN	B-NP	O	O
reaction	reaction	NN	I-NP	O	O
workup	workup	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
negative	negative	JJ	B-ADJP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
immune	immune	JJ	I-NP	O	O
hemolytic	hemolytic	JJ	I-NP	O	B-Disease
anemia	anemia	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
suspected	suspect	VBN	I-VP	O	O
because	because	IN	B-PP	O	O
of	of	IN	I-PP	O	O
positive	positive	JJ	B-NP	O	O
direct	direct	JJ	I-NP	O	O
antiglobulin	antiglobulin	NN	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
negative	negative	JJ	B-NP	O	O
eluate	eluate	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
microspherocytes	microspherocyte	NNS	B-NP	O	O
on	on	IN	B-PP	O	O
smear	smear	NN	B-NP	B	O
pre	pre	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
and	and	CC	I-NP	O	O
post	post	AFX	I-NP	O	O
-	-	HYPH	I-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
.	.	.	O	O	O

Drug	Drug	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
indirect	indirect	JJ	I-NP	O	O
antiglobulin	antiglobulin	NN	I-NP	O	O
test	test	NN	I-NP	O	O
were	be	VBD	B-VP	O	O
strongly	strongly	RB	B-ADJP	O	O
positive	positive	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
trimethoprim	trimethoprim	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
trimethoprim	trimethoprim	NN	I-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
sulfamethoxazole	sulfamethoxazole	NN	B-NP	I	I-Chemical
but	but	CC	O	O	O
negative	negative	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
sulfamethoxazole	sulfamethoxazole	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
recovered	recover	VBD	B-VP	O	O
after	after	IN	B-PP	O	O
discontinuing	discontinue	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
drug	drug	NN	I-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
no	no	DT	B-NP	O	O
recurrence	recurrence	NN	I-NP	O	O
in	in	IN	B-PP	O	O
2	2	CD	B-NP	O	O
years	year	NNS	I-NP	O	O
.	.	.	O	O	O

Other	Other	JJ	B-NP	O	O
causes	cause	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
anemia	anemia	NN	B-NP	O	B-Disease
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
worse	worse	JJR	B-NP	O	O
-	-	HYPH	I-NP	O	O
than	than	IN	B-PP	O	O
-	-	HYPH	B-NP	O	O
expected	expect	VBN	I-NP	O	O
anemia	anemia	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
chemotherapy	chemotherapy	NN	B-NP	O	O
.	.	.	O	O	O

Furthermore	Furthermore	RB	B-ADVP	O	O
,	,	,	O	O	O
hemolysis	hemolysis	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
transfusion	transfusion	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
not	not	RB	O	O	O
always	always	RB	B-ADVP	O	O
a	a	DT	B-NP	O	O
transfusion	transfusion	NN	I-NP	O	O
reaction	reaction	NN	I-NP	O	O
.	.	.	O	O	O

Blockade	Blockade	NN	B-NP	O	O
of	of	IN	B-PP	O	O
endothelial	endothelial	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
mesenchymal	mesenchymal	JJ	I-NP	O	O
transition	transition	NN	I-NP	O	O
by	by	IN	B-PP	O	O
a	a	DT	B-NP	O	O
Smad3	Smad3	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
delays	delay	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
multicenter	multicenter	NN	I-NP	O	O
,	,	,	O	O	O
controlled	control	VBN	B-NP	O	O
trial	trial	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
early	early	JJ	B-NP	O	O
blockade	blockade	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
renin	renin	NN	I-NP	O	O
-	-	HYPH	I-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
system	system	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
type	type	NN	B-NP	O	B-Disease
1	1	CD	I-NP	O	I-Disease
diabetes	diabete	NNS	I-NP	O	I-Disease
and	and	CC	O	O	O
normoalbuminuria	normoalbuminuria	NN	B-NP	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
retard	retard	VB	I-VP	B	O
the	the	DT	B-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nephropathy	nephropathy	NN	B-NP	O	B-Disease
,	,	,	O	O	O
suggesting	suggest	VBG	B-VP	O	O
that	that	IN	B-SBAR	O	O
other	other	JJ	B-NP	O	O
mechanism	mechanism	NN	I-NP	O	O
(	(	(	I-NP	O	O
s	s	NNS	I-NP	O	O
)	)	)	O	O	O
are	be	VBP	B-VP	O	O
involved	involve	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
pathogenesis	pathogenesis	NN	I-NP	O	O
of	of	IN	B-PP	O	O
early	early	JJ	B-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
(	(	(	O	O	O
diabetic	diabetic	JJ	B-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
)	)	)	O	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
previously	previously	RB	I-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
endothelial	endothelial	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
mesenchymal	mesenchymal	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
transition	transition	NN	I-NP	O	O
(	(	(	O	O	O
EndoMT	EndoMT	NN	B-NP	O	O
)	)	)	O	O	O
contributes	contribute	VBZ	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
renal	renal	JJ	B-NP	O	O
interstitial	interstitial	JJ	I-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
independently	independently	RB	B-ADVP	O	O
of	of	IN	B-PP	O	O
microalbuminuria	microalbuminuria	NN	B-NP	O	O
in	in	IN	B-PP	O	O
mice	mouse	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
)	)	)	O	O	O
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diabetes	diabete	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

In	In	IN	B-PP	O	O
the	the	DT	B-NP	O	O
present	present	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
,	,	,	O	O	O
we	we	PRP	B-NP	O	O
hypothesized	hypothesize	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
blocking	block	VBG	B-VP	O	O
EndoMT	EndoMT	NNP	B-NP	O	O
reduces	reduce	VBZ	B-VP	O	O
the	the	DT	B-NP	O	O
early	early	JJ	I-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

RESEARCH	RESEARCH	NN	B-NP	O	O
DESIGN	DESIGN	NN	I-NP	O	O
AND	AND	CC	I-NP	O	O
METHODS	METHODS	NNS	I-NP	O	O
:	:	:	O	O	O
EndoMT	EndoMT	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
induced	induce	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
a	a	DT	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
pancreatic	pancreatic	JJ	I-NP	O	O
microvascular	microvascular	JJ	I-NP	O	O
endothelial	endothelial	JJ	I-NP	O	O
cell	cell	NN	I-NP	O	O
line	line	NN	I-NP	O	O
(	(	(	O	O	O
MMEC	MMEC	NN	B-NP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
presence	presence	NN	I-NP	O	O
of	of	IN	B-PP	O	O
advanced	advance	VBN	B-NP	B	O
glycation	glycation	NN	I-NP	O	O
end	end	NN	I-NP	O	O
products	product	NNS	I-NP	O	O
(	(	(	O	O	O
AGEs	AGE	NNS	B-NP	O	O
)	)	)	O	O	O
and	and	CC	O	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
endothelial	endothelial	JJ	I-NP	O	O
lineage	lineage	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
traceble	traceble	JJ	I-NP	O	O
mouse	mouse	NN	I-NP	O	O
line	line	NN	I-NP	O	O
Tie2	Tie2	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
Cre	Cre	NN	I-NP	O	O
;	;	:	O	O	O
Loxp	Loxp	NN	B-NP	O	O
-	-	HYPH	O	O	O
EGFP	EGFP	NN	B-NP	O	O
by	by	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
AGEs	AGE	NNS	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
nonglycated	nonglycated	JJ	B-NP	O	O
mouse	mouse	NN	I-NP	O	O
albumin	albumin	NN	I-NP	O	O
serving	serve	VBG	B-VP	O	O
as	as	IN	B-PP	O	O
a	a	DT	B-NP	O	O
control	control	NN	I-NP	O	O
.	.	.	O	O	O

Phosphorylated	Phosphorylate	VBN	B-NP	O	O
Smad3	Smad3	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
detected	detect	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
immunoprecipitation	immunoprecipitation	NN	B-NP	O	O
/	/	SYM	O	O	O
Western	Western	NN	B-NP	O	O
blotting	blotting	NN	I-NP	O	O
and	and	CC	O	O	O
confocal	confocal	JJ	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
.	.	.	O	O	O

Blocking	Blocking	NN	B-NP	O	O
studies	study	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
receptor	receptor	NN	B-NP	O	O
for	for	IN	B-PP	O	O
AGE	AGE	NN	B-NP	O	O
siRNA	siRNA	NN	I-NP	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
specific	specific	JJ	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
of	of	IN	B-PP	O	O
Smad3	Smad3	NN	B-NP	O	O
(	(	(	O	O	O
SIS3	SIS3	NN	B-NP	O	O
)	)	)	O	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
MMECs	MMEC	NNS	B-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
Tie2	Tie2	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
Cre	Cre	NN	I-NP	O	O
;	;	:	O	O	O
Loxp	Loxp	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
EGFP	EGFP	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

RESULTS	RESULTS	NNS	B-NP	O	O
:	:	:	O	O	O
Confocal	Confocal	JJ	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
and	and	CC	O	O	O
real	real	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
time	time	NN	I-NP	O	O
PCR	PCR	NN	I-NP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
AGEs	AGE	NNS	B-NP	O	O
induced	induce	VBD	B-VP	O	O
EndoMT	EndoMT	NN	B-NP	O	O
in	in	IN	B-PP	O	O
MMECs	MMEC	NNS	B-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
Tie2	Tie2	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
Cre	Cre	NN	I-NP	O	O
;	;	:	O	O	O
Loxp	Loxp	NN	B-NP	O	O
-	-	HYPH	I-NP	O	O
EGFP	EGFP	NN	I-NP	O	O
mice	mouse	NNS	I-NP	O	O
.	.	.	O	O	O

Immunoprecipitation	Immunoprecipitation	NN	B-NP	O	O
/	/	SYM	I-NP	O	O
Western	Western	NN	I-NP	O	O
blotting	blotting	NN	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
Smad3	Smad3	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
activated	activate	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
AGEs	AGE	NNS	B-NP	O	O
but	but	CC	O	O	O
was	be	VBD	B-VP	O	O
inhibited	inhibit	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
SIS3	SIS3	NN	B-NP	O	O
in	in	IN	B-PP	O	O
MMECs	MMEC	NNS	B-NP	O	O
and	and	CC	B-PP	O	O
in	in	IN	B-PP	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
diabetic	diabetic	JJ	I-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Confocal	Confocal	JJ	B-NP	O	O
microscopy	microscopy	NN	I-NP	O	O
and	and	CC	O	O	O
real	real	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
time	time	NN	I-NP	O	O
PCR	PCR	NN	I-NP	O	O
further	further	RBR	B-ADVP	O	O
demonstrated	demonstrate	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
SIS3	SIS3	NN	B-NP	O	O
abrogated	abrogate	VBD	B-VP	O	O
EndoMT	EndoMT	NNP	B-NP	O	O
,	,	,	O	O	O
reduced	reduce	VBD	B-VP	O	O
renal	renal	JJ	B-NP	O	O
fibrosis	fibrosis	NN	I-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
retarded	retard	VBN	B-VP	B	O
progression	progression	NN	B-NP	O	O
of	of	IN	B-PP	O	O
nephropathy	nephropathy	NN	B-NP	O	B-Disease
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
EndoMT	EndoMT	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
novel	novel	JJ	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
leading	lead	VBG	B-VP	O	O
to	to	TO	B-PP	O	O
early	early	JJ	B-NP	O	O
development	development	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Blockade	Blockade	NN	B-NP	O	O
of	of	IN	B-PP	O	O
EndoMT	EndoMT	NN	B-NP	O	O
by	by	IN	B-PP	O	O
SIS3	SIS3	NN	B-NP	O	O
may	may	MD	B-VP	O	O
provide	provide	VB	I-VP	O	O
a	a	DT	B-NP	O	O
new	new	JJ	I-NP	O	O
strategy	strategy	NN	I-NP	O	O
to	to	TO	B-VP	O	O
retard	retard	VB	I-VP	B	O
the	the	DT	B-NP	O	O
progression	progression	NN	I-NP	O	O
of	of	IN	B-PP	O	O
diabetic	diabetic	JJ	B-NP	O	B-Disease
nephropathy	nephropathy	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
other	other	JJ	B-NP	O	O
diabetes	diabetes	NN	I-NP	O	B-Disease
complications	complication	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Cytostatic	Cytostatic	JJ	B-ADJP	O	O
and	and	CC	O	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	O	O	O
angiogenic	angiogenic	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
mantle	mantle	NN	I-NP	O	B-Disease
cell	cell	NN	I-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Mantle	Mantle	NN	B-NP	O	B-Disease
cell	cell	NN	I-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
(	(	(	O	O	O
MCL	MCL	NN	B-NP	O	B-Disease
)	)	)	O	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
rare	rare	JJ	I-NP	O	O
and	and	CC	I-NP	O	O
aggressive	aggressive	JJ	I-NP	O	O
type	type	NN	I-NP	O	O
of	of	IN	B-PP	O	O
B	B	NN	B-NP	O	B-Disease
-	-	HYPH	B-NP	O	I-Disease
cell	cell	NN	I-NP	O	I-Disease
non	non	AFX	O	O	I-Disease
-	-	HYPH	O	O	I-Disease
Hodgkin	Hodgkin	NNP	B-NP	O	I-Disease
's	's	POS	B-NP	O	I-Disease
lymphoma	lymphoma	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Patients	Patient	NNS	B-NP	O	O
become	become	VBP	B-VP	O	O
progressively	progressively	RB	B-ADJP	O	O
refractory	refractory	JJ	I-ADJP	O	O
to	to	TO	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
their	their	PRP$	B-NP	O	O
prognosis	prognosis	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
poor	poor	JJ	B-ADJP	O	O
.	.	.	O	O	O

However	However	RB	B-ADVP	O	O
,	,	,	O	O	O
a	a	DT	B-NP	O	O
38	38	CD	I-NP	O	O
%	%	NN	I-NP	O	O
remission	remission	NN	I-NP	O	O
rate	rate	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
been	be	VBN	I-VP	O	O
recently	recently	RB	I-VP	O	O
reported	report	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
MCL	MCL	NN	I-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
mTOR	mTOR	NN	I-NP	O	O
inhibitor.Here	inhibitor.Here	NN	I-NP	O	O
we	we	PRP	B-NP	O	O
had	have	VBD	B-VP	O	O
the	the	DT	B-NP	O	O
opportunity	opportunity	NN	I-NP	O	O
to	to	TO	B-VP	O	O
study	study	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
MCL	MCL	NN	I-NP	O	B-Disease
who	who	WP	B-NP	O	O
had	have	VBD	B-VP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
regression	regression	NN	I-NP	O	O
two	two	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-SBAR	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
a	a	DT	B-NP	O	O
progression	progression	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
free	free	JJ	I-NP	O	O
survival	survival	NN	I-NP	O	O
of	of	IN	B-PP	O	O
10	10	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
.	.	.	O	O	O

In	In	IN	B-PP	O	O
this	this	DT	B-NP	O	O
case	case	NN	I-NP	O	O
,	,	,	O	O	O
lymph	lymph	NN	B-NP	O	O
node	node	NN	I-NP	O	O
biopsies	biopsy	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
performed	perform	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
and	and	CC	O	O	O
six	six	CD	B-NP	O	O
months	month	NNS	I-NP	O	O
after	after	IN	B-SBAR	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Comparison	Comparison	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
two	two	CD	I-NP	O	O
biopsies	biopsy	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
that	that	IN	B-SBAR	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
inhibited	inhibit	VBD	B-VP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
cell	cell	NN	I-NP	O	O
proliferation	proliferation	NN	I-NP	O	O
through	through	IN	B-PP	O	O
cell	cell	NN	B-NP	O	O
cycle	cycle	NN	I-NP	O	O
arrest	arrest	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
did	do	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
induce	induce	VB	I-VP	O	O
any	any	DT	B-NP	O	O
change	change	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
number	number	NN	I-NP	O	O
of	of	IN	B-PP	O	O
apoptotic	apoptotic	JJ	B-NP	O	O
tumor	tumor	NN	I-NP	O	B-Disease
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

Apart	Apart	RB	B-ADVP	O	O
from	from	IN	B-PP	O	O
this	this	DT	B-NP	O	O
cytostatic	cytostatic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
,	,	,	O	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
had	have	VBD	B-VP	O	O
an	an	DT	B-NP	O	O
antiangiogenic	antiangiogenic	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
with	with	IN	B-PP	O	O
decrease	decrease	NN	B-NP	O	O
of	of	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
microvessel	microvessel	NN	I-NP	O	O
density	density	NN	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
VEGF	VEGF	NN	B-NP	O	O
expression	expression	NN	I-NP	O	O
.	.	.	O	O	O

Moreover	Moreover	RB	B-ADVP	O	O
,	,	,	O	O	O
numerous	numerous	JJ	B-NP	O	O
patchy	patchy	NN	I-NP	O	O
,	,	,	O	O	O
well	well	RB	B-NP	O	O
-	-	HYPH	I-NP	O	O
limited	limited	JJ	I-NP	O	O
fibrotic	fibrotic	JJ	I-NP	O	O
areas	area	NNS	I-NP	O	O
,	,	,	O	O	O
compatible	compatible	JJ	B-ADJP	O	O
with	with	IN	B-PP	O	O
post	post	AFX	B-NP	O	O
-	-	HYPH	I-NP	O	O
necrotic	necrotic	JJ	I-NP	O	B-Disease
tissue	tissue	NN	I-NP	O	O
repair	repair	NN	I-NP	O	O
,	,	,	O	O	O
were	be	VBD	B-VP	O	O
found	find	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
6	6	CD	B-NP	O	O
-	-	HYPH	I-NP	O	O
month	month	NN	I-NP	O	O
temsirolimus	temsirolimus	NN	I-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Thus	Thus	RB	B-ADVP	O	O
,	,	,	O	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
reduced	reduce	VBD	B-VP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
burden	burden	NN	I-NP	O	O
through	through	IN	B-PP	O	O
associated	associate	VBN	B-NP	O	O
cytostatic	cytostatic	JJ	I-NP	O	O
and	and	CC	O	O	O
anti	anti	AFX	O	O	O
-	-	HYPH	B-NP	O	O
angiogenic	angiogenic	JJ	I-NP	O	O
effects.This	effects.This	NN	I-NP	O	O
dual	dual	JJ	I-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
temsirolimus	temsirolimus	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
tumor	tumor	NN	B-NP	O	B-Disease
tissue	tissue	NN	I-NP	O	O
could	could	MD	B-VP	O	O
contribute	contribute	VB	I-VP	O	O
to	to	TO	B-PP	O	O
its	its	PRP$	B-NP	O	O
recently	recently	RB	I-NP	O	O
reported	report	VBN	I-NP	O	O
efficiency	efficiency	NN	I-NP	O	O
in	in	IN	B-PP	O	O
refractory	refractory	JJ	B-NP	O	O
MCL	MCL	NN	I-NP	O	B-Disease
resistant	resistant	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
conventional	conventional	JJ	B-NP	O	O
chemotherapy	chemotherapy	NN	I-NP	O	O
.	.	.	O	O	O

Syncope	Syncope	NN	B-NP	O	B-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
during	during	IN	B-PP	O	O
use	use	NN	B-NP	O	O
of	of	IN	B-PP	O	O
a	a	DT	B-NP	O	O
combined	combined	JJ	I-NP	O	O
therapy	therapy	NN	I-NP	O	O
with	with	IN	B-PP	O	O
the	the	DT	B-NP	O	O
angiotensin	angiotensin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
converting	convert	VBG	B-VP	O	O
enzyme	enzyme	NN	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
and	and	CC	I-NP	O	O
spironolactone	spironolactone	NN	I-NP	B	B-Chemical
.	.	.	O	O	O

A	A	DT	B-NP	O	O
76	76	CD	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
woman	woman	NN	I-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
history	history	NN	I-NP	O	O
of	of	IN	B-PP	O	O
coronary	coronary	JJ	B-NP	O	O
artery	artery	NN	I-NP	O	O
bypass	bypass	IN	B-PP	O	O
grafting	graft	VBG	B-VP	O	O
and	and	CC	O	O	O
prior	prior	JJ	B-NP	O	O
myocardial	myocardial	JJ	I-NP	O	B-Disease
infarction	infarction	NN	I-NP	O	I-Disease
was	be	VBD	B-VP	O	O
transferred	transfer	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
room	room	NN	I-NP	O	O
with	with	IN	B-PP	O	O
loss	loss	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	I-Disease
consciousness	consciousness	NN	B-NP	O	I-Disease
due	due	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
marked	marked	JJ	B-NP	O	O
bradycardia	bradycardia	NN	I-NP	O	B-Disease
caused	cause	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

The	The	DT	B-NP	O	O
concentration	concentration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
serum	serum	NN	B-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
high	high	JJ	B-ADJP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
normal	normal	JJ	B-NP	O	O
sinus	sinus	NN	I-NP	O	O
rhythm	rhythm	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
restored	restore	VBN	I-VP	O	O
after	after	IN	B-PP	O	O
correction	correction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
serum	serum	NN	I-NP	O	O
potassium	potassium	NN	I-NP	B	B-Chemical
level	level	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
cause	cause	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
was	be	VBD	B-VP	O	O
considered	consider	VBN	I-VP	O	O
to	to	TO	I-VP	O	O
be	be	VB	I-VP	O	O
several	several	JJ	B-NP	O	O
doses	dose	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
spiranolactone	spiranolactone	NN	B-NP	O	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
aldosterone	aldosterone	NN	I-NP	B	B-Chemical
antagonist	antagonist	NN	I-NP	O	O
,	,	,	O	O	O
in	in	IN	B-PP	O	O
addition	addition	NN	B-NP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
long	long	JJ	I-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
intake	intake	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ramipril	ramipril	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
an	an	DT	B-NP	O	O
ACE	ACE	NN	I-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
.	.	.	O	O	O

This	This	DT	B-NP	O	O
case	case	NN	I-NP	O	O
is	be	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
good	good	JJ	I-NP	O	O
example	example	NN	I-NP	O	O
of	of	IN	B-PP	O	O
electrolyte	electrolyte	NN	B-NP	O	O
imbalance	imbalance	NN	I-NP	O	O
causing	cause	VBG	B-VP	O	O
acute	acute	JJ	B-NP	O	O
life	life	NN	I-NP	O	O
-	-	HYPH	O	O	O
threatening	threaten	VBG	B-VP	O	O
cardiac	cardiac	JJ	B-NP	O	O
events	event	NNS	I-NP	O	O
.	.	.	O	O	O

Clinicians	Clinician	NNS	B-NP	O	O
should	should	MD	B-VP	O	O
be	be	VB	I-VP	O	O
alert	alert	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
possibility	possibility	NN	I-NP	O	O
of	of	IN	B-PP	O	O
hyperkalemia	hyperkalemia	NN	B-NP	O	B-Disease
,	,	,	O	O	O
especially	especially	RB	B-ADVP	O	O
in	in	IN	B-PP	O	O
elderly	elderly	JJ	B-NP	O	O
patients	patient	NNS	I-NP	O	O
using	use	VBG	B-VP	O	O
ACE	ACE	NN	B-NP	O	O
/	/	SYM	B-NP	O	O
ARB	ARB	NN	I-NP	O	O
in	in	IN	B-PP	O	O
combination	combination	NN	B-NP	O	O
with	with	IN	B-PP	O	O
potassium	potassium	NN	B-NP	B	B-Chemical
sparing	spar	VBG	I-NP	O	O
agents	agent	NNS	I-NP	O	O
and	and	CC	O	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
mild	mild	JJ	B-NP	O	O
renal	renal	JJ	I-NP	O	B-Disease
disturbance	disturbance	NN	I-NP	O	I-Disease
.	.	.	O	O	O

Diffuse	Diffuse	NN	B-NP	O	O
skeletal	skeletal	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
administration	administration	NN	B-NP	O	O
of	of	IN	B-PP	O	O
alendronate	alendronate	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

BACKGROUND	BACKGROUND	NN	B-NP	O	O
:	:	:	O	O	O
Osteoporosis	Osteoporosis	NN	B-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
caused	cause	VBN	I-VP	O	O
by	by	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
resorption	resorption	NN	I-NP	O	O
in	in	IN	B-PP	O	O
excess	excess	NN	B-NP	O	O
of	of	IN	B-PP	O	O
bone	bone	NN	B-NP	O	O
formation	formation	NN	I-NP	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
bisphosphonates	bisphosphonate	NNS	B-NP	O	B-Chemical
,	,	,	O	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
inhibit	inhibit	VB	I-VP	O	O
bone	bone	NN	B-NP	O	O
resorption	resorption	NN	I-NP	O	O
.	.	.	O	O	O

Alendronate	Alendronate	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
a	a	DT	B-NP	O	O
biphosphonate	biphosphonate	NN	I-NP	O	B-Chemical
,	,	,	O	O	O
is	be	VBZ	B-VP	O	O
effective	effective	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
both	both	CC	O	O	O
the	the	DT	B-NP	O	O
treatment	treatment	NN	I-NP	O	O
and	and	CC	I-NP	O	O
prevention	prevention	NN	I-NP	O	O
of	of	IN	B-PP	O	O
osteoporosis	osteoporosis	NN	B-NP	O	B-Disease
in	in	IN	B-PP	O	O
postmenopausal	postmenopausal	JJ	B-NP	O	O
women	woman	NNS	I-NP	O	O
.	.	.	O	O	O

Side	Side	NN	B-NP	O	O
effects	effect	NNS	I-NP	O	O
are	be	VBP	B-VP	O	O
relatively	relatively	RB	B-ADJP	O	O
few	few	JJ	I-ADJP	O	O
and	and	CC	O	O	O
prominently	prominently	RB	B-ADJP	O	O
gastrointestinal	gastrointestinal	JJ	I-ADJP	O	O
.	.	.	O	O	O

Musculoskeletal	Musculoskeletal	JJ	B-NP	O	B-Disease
pain	pain	NN	I-NP	O	I-Disease
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
important	important	JJ	I-NP	O	O
side	side	NN	I-NP	O	O
effect	effect	NN	I-NP	O	O
in	in	IN	B-PP	O	O
these	these	DT	B-NP	O	O
patients	patient	NNS	I-NP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
presented	present	VBD	B-VP	O	O
a	a	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
admitted	admit	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
our	our	PRP$	B-NP	O	O
out	out	RP	I-NP	O	O
-	-	HYPH	I-NP	O	O
patient	patient	NN	I-NP	O	O
clinic	clinic	NN	I-NP	O	O
with	with	IN	B-PP	O	O
diffuse	diffuse	JJ	B-NP	O	O
skeletal	skeletal	JJ	I-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
after	after	IN	B-PP	O	O
three	three	CD	B-NP	O	O
consecutive	consecutive	JJ	I-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
alendronate	alendronate	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

CONCLUSION	CONCLUSION	NN	B-NP	O	O
:	:	:	O	O	O
We	We	PRP	B-NP	O	O
conclude	conclude	VBP	B-VP	O	O
that	that	IN	B-SBAR	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
osteoporosis	osteoporosis	NN	B-NP	O	B-Disease
can	can	MD	B-VP	O	O
report	report	VB	I-VP	O	O
pain	pain	NN	B-NP	O	B-Disease
,	,	,	O	O	O
and	and	CC	O	O	O
bisphosphonate	bisphosphonate	NN	B-NP	O	B-Chemical
-	-	HYPH	O	O	O
related	relate	VBN	B-NP	O	O
pain	pain	NN	I-NP	O	B-Disease
should	should	MD	B-VP	O	O
also	also	RB	I-VP	O	O
be	be	VB	I-VP	O	O
considered	consider	VBN	I-VP	O	O
before	before	IN	B-PP	O	O
ascribing	ascribe	VBG	B-VP	O	O
this	this	DT	B-NP	O	O
complaint	complaint	NN	I-NP	O	O
to	to	TO	B-PP	O	O
osteoporosis	osteoporosis	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Cerebrospinal	Cerebrospinal	JJ	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
penetration	penetration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
daptomycin	daptomycin	NN	I-NP	B	B-Chemical
in	in	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
Staphylococcus	Staphylococcus	FW	I-NP	O	O
aureus	aureus	FW	I-NP	O	O
meningitis	meningitis	NN	I-NP	O	B-Disease
.	.	.	O	O	O

OBJECTIVE	OBJECTIVE	NN	B-NP	O	O
:	:	:	O	O	O
To	To	TO	B-VP	O	O
report	report	VB	I-VP	O	O
a	a	DT	B-NP	O	O
case	case	NN	I-NP	O	O
of	of	IN	B-PP	O	O
methicillin	methicillin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
sensitive	sensitive	JJ	B-NP	O	O
Staphylococcus	Staphylococcus	FW	I-NP	O	O
aureus	aureus	FW	I-NP	O	O
(	(	(	O	O	O
MSSA	MSSA	NN	B-NP	O	O
)	)	)	O	O	O
bacteremia	bacteremia	NN	B-NP	O	B-Disease
with	with	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
MSSA	MSSA	NN	I-NP	O	O
meningitis	meningitis	NN	I-NP	O	B-Disease
treated	treat	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
high	high	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
daptomycin	daptomycin	NN	I-NP	B	B-Chemical
assessed	assess	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
concurrent	concurrent	JJ	B-NP	O	O
serum	serum	NN	I-NP	O	O
and	and	CC	O	O	O
cerebrospinal	cerebrospinal	JJ	B-NP	O	O
fluid	fluid	NN	I-NP	O	O
(	(	(	O	O	O
CSF	CSF	NN	B-NP	B	O
)	)	)	O	O	O
concentrations	concentration	NNS	B-NP	O	O
.	.	.	O	O	O

CASE	CASE	NN	B-NP	O	O
SUMMARY	SUMMARY	NN	I-NP	O	O
:	:	:	O	O	O
A	A	DT	B-NP	O	O
54	54	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
year	year	NN	I-NP	O	O
-	-	HYPH	O	O	O
old	old	JJ	B-NP	O	O
male	male	JJ	I-NP	O	O
presented	present	VBN	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
emergency	emergency	NN	I-NP	O	O
department	department	NN	I-NP	O	O
with	with	IN	B-PP	O	O
generalized	generalize	VBN	B-NP	O	O
weakness	weakness	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
presumed	presume	VBN	B-NP	O	O
health	health	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
care	care	NN	I-NP	O	O
-	-	HYPH	O	O	O
associated	associate	VBN	B-NP	O	O
pneumonia	pneumonia	NN	I-NP	O	B-Disease
shown	show	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
chest	chest	NN	B-NP	O	O
radiograph	radiograph	NN	I-NP	O	O
.	.	.	O	O	O

Treatment	Treatment	NN	B-NP	O	O
was	be	VBD	B-VP	O	O
empirically	empirically	RB	I-VP	O	O
initiated	initiate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
vancomycin	vancomycin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
levofloxacin	levofloxacin	NN	B-NP	B	B-Chemical
,	,	,	O	O	O
and	and	CC	O	O	O
piperacillin	piperacillin	NN	B-NP	B	B-Chemical
/	/	SYM	B-NP	I	O
tazobactam	tazobactam	NN	I-NP	I	B-Chemical
.	.	.	O	O	O

Blood	Blood	NN	B-NP	O	O
cultures	culture	NNS	I-NP	O	O
revealed	reveal	VBD	B-VP	O	O
S.	S.	NNP	B-NP	O	O
aureus	aureus	NN	I-NP	O	O
susceptible	susceptible	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
oxacillin	oxacillin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Empiric	Empiric	JJ	B-NP	O	O
antibiotic	antibiotic	JJ	I-NP	O	O
treatment	treatment	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
narrowed	narrow	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
nafcillin	nafcillin	NN	B-NP	B	B-Chemical
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
4	4	CD	I-NP	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
day	day	NN	B-NP	O	O
8	8	CD	I-NP	O	O
,	,	,	O	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
developed	develop	VBD	B-VP	O	O
acute	acute	JJ	B-NP	O	B-Disease
renal	renal	JJ	I-NP	O	I-Disease
failure	failure	NN	I-NP	O	I-Disease
(	(	(	O	O	O
serum	serum	NN	B-NP	O	O
creatinine	creatinine	NN	I-NP	B	B-Chemical
1.9	1.9	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
,	,	,	O	O	O
increased	increase	VBD	B-VP	O	O
from	from	IN	B-PP	O	O
1.2	1.2	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
the	the	DT	B-NP	O	O
previous	previous	JJ	I-NP	O	O
day	day	NN	I-NP	O	O
and	and	CC	O	O	O
0.8	0.8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
dL	dL	NN	I-NP	O	O
on	on	IN	B-PP	O	O
admission	admission	NN	B-NP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
Glasgow	Glasgow	NNP	I-NP	O	O
Coma	Coma	NNP	I-NP	O	O
Score	Score	NNP	I-NP	O	O
was	be	VBD	B-VP	O	O
3	3	CD	B-NP	O	O
,	,	,	O	O	O
with	with	IN	B-PP	O	O
normal	normal	JJ	B-NP	O	O
findings	finding	NNS	I-NP	O	O
shown	show	VBN	B-VP	O	O
on	on	IN	B-PP	O	O
computed	compute	VBN	B-NP	O	O
tomography	tomography	NN	I-NP	O	O
scan	scan	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
head	head	NN	I-NP	O	O
72	72	CD	B-NP	O	O
hours	hour	NNS	I-NP	O	O
following	follow	VBG	B-PP	O	O
an	an	DT	B-NP	O	O
episode	episode	NN	I-NP	O	O
of	of	IN	B-PP	O	O
cardiac	cardiac	JJ	B-NP	O	B-Disease
arrest	arrest	NN	I-NP	O	I-Disease
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
10	10	CD	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
experienced	experience	VBD	B-VP	O	O
relapsing	relapse	VBG	I-VP	O	O
MSSA	MSSA	NN	B-NP	O	O
bacteremia	bacteremia	NN	I-NP	O	B-Disease
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
9	9	CD	I-NP	O	O
,	,	,	O	O	O
increasing	increase	VBG	B-VP	O	O
the	the	DT	B-NP	O	O
suspicion	suspicion	NN	I-NP	O	O
for	for	IN	B-PP	O	O
a	a	DT	B-NP	O	O
central	central	JJ	I-NP	O	O
nervous	nervous	JJ	I-NP	O	O
system	system	NN	I-NP	O	O
(	(	(	O	O	O
CNS	CNS	NN	B-NP	O	O
)	)	)	O	O	O
infection	infection	NN	B-NP	O	B-Disease
.	.	.	O	O	O

Nafcillin	Nafcillin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
discontinued	discontinue	VBN	I-VP	O	O
and	and	CC	O	O	O
daptomycin	daptomycin	NN	B-NP	B	B-Chemical
9	9	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
daily	daily	RB	B-ADVP	O	O
was	be	VBD	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
for	for	IN	B-PP	O	O
suspected	suspect	VBN	B-NP	O	O
meningitis	meningitis	NN	I-NP	O	B-Disease
and	and	CC	O	O	O
was	be	VBD	B-VP	O	O
continued	continue	VBN	I-VP	O	O
until	until	IN	B-SBAR	O	O
the	the	DT	B-NP	O	O
patient	patient	NN	I-NP	O	O
's	's	POS	B-NP	O	O
death	death	NN	I-NP	O	O
on	on	IN	B-PP	O	O
day	day	NN	B-NP	O	O
16	16	CD	I-NP	O	O
.	.	.	O	O	O

Daptomycin	Daptomycin	NN	B-NP	B	B-Chemical
serum	serum	NN	I-NP	O	O
and	and	CC	O	O	O
CSF	CSF	NN	B-NP	B	O
trough	trough	NN	I-NP	O	O
concentrations	concentration	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
11.21	11.21	CD	B-NP	O	O
ug	ug	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
mL	mL	NN	I-NP	O	O
and	and	CC	O	O	O
0.52	0.52	CD	B-NP	O	O
ug	ug	NN	I-NP	O	O
/	/	SYM	O	O	O
mL	mL	NN	B-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
,	,	,	O	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
third	third	JJ	I-NP	O	O
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Lumbar	Lumbar	JJ	B-NP	O	O
puncture	puncture	NN	I-NP	O	O
results	result	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
inconclusive	inconclusive	JJ	B-ADJP	O	O
and	and	CC	O	O	O
no	no	DT	B-NP	O	O
further	further	JJ	I-NP	O	O
blood	blood	NN	I-NP	O	O
cultures	culture	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
positive	positive	JJ	B-ADJP	O	O
for	for	IN	B-PP	O	O
MSSA	MSSA	NN	B-NP	O	O
.	.	.	O	O	O

Creatine	Creatine	NN	B-NP	B	B-Chemical
kinase	kinase	NN	I-NP	O	O
levels	level	NNS	I-NP	O	O
were	be	VBD	B-VP	O	O
normal	normal	JJ	B-ADJP	O	O
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
daptomycin	daptomycin	NN	B-NP	B	B-Chemical
therapy	therapy	NN	I-NP	O	O
and	and	CC	O	O	O
were	be	VBD	B-VP	O	O
not	not	RB	I-VP	O	O
reassessed	reassess	VBN	I-VP	O	O
.	.	.	O	O	O

DISCUSSION	DISCUSSION	NN	B-NP	O	O
:	:	:	O	O	O
Daptomycin	Daptomycin	NN	B-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
initiated	initiate	VBN	I-VP	O	O
in	in	IN	B-PP	O	O
our	our	PRP$	B-NP	O	O
patient	patient	NN	I-NP	O	O
secondary	secondary	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
possible	possible	JJ	B-NP	O	O
nafcillin	nafcillin	NN	I-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
acute	acute	JJ	I-NP	O	O
interstitial	interstitial	JJ	I-NP	O	B-Disease
nephritis	nephritis	NN	I-NP	O	I-Disease
and	and	CC	O	O	O
relapsing	relapse	VBG	B-VP	O	O
bacteremia	bacteremia	NN	B-NP	O	B-Disease
.	.	.	O	O	O

At	At	IN	B-PP	O	O
a	a	DT	B-NP	O	O
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
9	9	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
resultant	resultant	JJ	B-NP	O	O
penetration	penetration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
5	5	CD	B-NP	O	O
%	%	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
higher	high	JJR	B-ADJP	O	O
than	than	IN	B-PP	O	O
in	in	IN	B-PP	O	O
previous	previous	JJ	B-NP	O	O
reports	report	NNS	I-NP	O	O
,	,	,	O	O	O
more	more	RBR	B-ADJP	O	O
consistent	consistent	JJ	I-ADJP	O	O
with	with	IN	B-PP	O	O
inflamed	inflamed	JJ	B-NP	O	O
meninges	meninge	NNS	I-NP	O	O
.	.	.	O	O	O

CONCLUSIONS	CONCLUSIONS	NNS	B-NP	O	O
:	:	:	O	O	O
High	High	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
dose	dose	NN	I-NP	O	O
daptomycin	daptomycin	NN	I-NP	B	B-Chemical
may	may	MD	B-VP	O	O
be	be	VB	I-VP	O	O
an	an	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
option	option	NN	I-NP	O	O
for	for	IN	B-PP	O	O
MSSA	MSSA	NN	B-NP	O	O
bacteremia	bacteremia	NN	I-NP	O	B-Disease
with	with	IN	B-PP	O	O
or	or	CC	B-PP	O	O
without	without	IN	B-PP	O	O
a	a	DT	B-NP	O	O
CNS	CNS	NN	I-NP	O	O
source	source	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
who	who	WP	B-NP	O	O
have	have	VBP	B-VP	O	O
failed	fail	VBN	I-VP	O	O
or	or	CC	O	O	O
cannot	cannot	MD	B-VP	O	O
tolerate	tolerate	VB	I-VP	O	O
standard	standard	JJ	B-NP	O	O
therapy	therapy	NN	I-NP	O	O
.	.	.	O	O	O

Further	Further	JJ	B-NP	O	O
clinical	clinical	JJ	I-NP	O	O
evaluation	evaluation	NN	I-NP	O	O
in	in	IN	B-PP	O	O
patients	patient	NNS	B-NP	O	O
with	with	IN	B-PP	O	O
confirmed	confirm	VBN	B-NP	O	O
meningitis	meningitis	NN	I-NP	O	B-Disease
is	be	VBZ	B-VP	O	O
warranted	warrant	VBN	I-VP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
nitric	nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
in	in	IN	B-PP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
induced	induce	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
.	.	.	O	O	O

Lindane	Lindane	NN	B-NP	B	B-Chemical
is	be	VBZ	B-VP	O	O
an	an	DT	B-NP	O	O
organochloride	organochloride	NN	I-NP	O	O
pesticide	pesticide	NN	I-NP	O	O
and	and	CC	I-NP	O	O
scabicide	scabicide	NN	I-NP	O	O
.	.	.	O	O	O

It	It	PRP	B-NP	O	O
evokes	evoke	VBZ	B-VP	O	O
convulsions	convulsion	NNS	B-NP	O	B-Disease
mainly	mainly	RB	B-ADVP	O	O
trough	trough	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blockage	blockage	NN	I-NP	O	O
of	of	IN	B-PP	O	O
GABA	GABA	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
A	A	NN	B-NP	O	O
)	)	)	O	O	O
receptors	receptor	NNS	B-NP	O	O
.	.	.	O	O	O

Nitric	Nitric	JJ	B-NP	B	B-Chemical
oxide	oxide	NN	I-NP	I	I-Chemical
(	(	(	O	O	O
NO	NO	NN	B-NP	O	B-Chemical
)	)	)	O	O	O
,	,	,	O	O	O
gaseous	gaseous	JJ	B-NP	O	O
neurotransmitter	neurotransmitter	NN	I-NP	O	O
,	,	,	O	O	O
has	have	VBZ	B-VP	O	O
contradictor	contradictor	NN	B-NP	O	O
role	role	NN	I-NP	O	O
in	in	IN	B-PP	O	O
epileptogenesis	epileptogenesis	NN	B-NP	O	O
due	due	JJ	B-PP	O	O
to	to	TO	B-PP	O	O
opposite	opposite	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
arginine	arginine	NN	B-NP	I	I-Chemical
,	,	,	O	O	O
precursor	precursor	NN	B-NP	O	O
of	of	IN	B-PP	O	O
NO	NO	NN	B-NP	O	B-Chemical
syntheses	synthesis	NNS	I-NP	O	O
(	(	(	O	O	O
NOS	NOS	NN	B-NP	O	O
)	)	)	O	O	O
,	,	,	O	O	O
and	and	CC	O	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
NAME	NAME	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
NOS	NOS	NN	B-NP	O	O
inhibitor	inhibitor	NN	I-NP	O	O
)	)	)	O	O	O
observed	observe	VBN	B-VP	O	O
in	in	IN	B-PP	O	O
different	different	JJ	B-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	B-Disease
models	model	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
aim	aim	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
current	current	JJ	I-NP	O	O
study	study	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
to	to	TO	B-VP	O	O
determine	determine	VB	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
NO	NO	NN	B-NP	O	B-Chemical
on	on	IN	B-PP	O	O
the	the	DT	B-NP	O	O
behavioral	behavioral	NN	I-NP	O	O
and	and	CC	I-NP	O	O
EEG	EEG	NN	I-NP	O	O
characteristics	characteristic	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
induced	induce	VBN	I-NP	O	O
epilepsy	epilepsy	NN	I-NP	O	B-Disease
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
albino	albino	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
arginine	arginine	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
600	600	CD	B-NP	O	O
,	,	,	I-NP	O	O
800	800	CD	I-NP	O	O
and	and	CC	I-NP	O	O
1000	1000	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
in	in	IN	B-PP	O	O
dose	dose	NN	B-NP	O	O
-	-	HYPH	B-NP	O	O
dependent	dependent	JJ	I-NP	O	O
manner	manner	NN	I-NP	O	O
significantly	significantly	RB	B-ADVP	O	O
increased	increase	VBD	B-VP	O	O
convulsion	convulsion	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
and	and	CC	O	O	O
shortened	shorten	VBD	B-VP	O	O
latency	latency	NN	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
first	first	JJ	B-NP	O	O
convulsion	convulsion	NN	I-NP	O	B-Disease
elicited	elicit	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
lower	low	JJR	B-NP	O	O
lindane	lindane	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
(	(	(	O	O	O
4	4	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

On	On	IN	B-PP	O	O
the	the	DT	B-NP	O	O
contrary	contrary	NN	I-NP	O	O
,	,	,	O	O	O
pretreatment	pretreatment	NN	B-NP	O	O
with	with	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
NAME	NAME	NN	B-NP	I	I-Chemical
(	(	(	O	O	O
500	500	CD	B-NP	O	O
,	,	,	I-NP	O	O
700	700	CD	I-NP	O	O
and	and	CC	I-NP	O	O
900	900	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
decreased	decrease	VBD	B-VP	O	O
convulsion	convulsion	NN	B-NP	O	B-Disease
incidence	incidence	NN	I-NP	O	O
and	and	CC	I-NP	O	O
severity	severity	NN	I-NP	O	O
and	and	CC	O	O	O
prolonged	prolong	VBD	B-VP	O	O
latency	latency	NN	B-NP	O	O
time	time	NN	I-NP	O	O
to	to	TO	B-PP	O	O
convulsion	convulsion	NN	B-NP	O	B-Disease
following	follow	VBG	B-PP	O	O
injection	injection	NN	B-NP	O	O
with	with	IN	B-PP	O	O
a	a	DT	B-NP	O	O
convulsive	convulsive	JJ	I-NP	O	B-Disease
dose	dose	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
(	(	(	O	O	O
8	8	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
,	,	,	O	O	O
i.p.	i.p.	RB	B-ADVP	O	O
)	)	)	O	O	O
.	.	.	O	O	O

EEG	EEG	NN	B-NP	O	O
analyses	analysis	NNS	I-NP	O	O
showed	show	VBD	B-VP	O	O
increase	increase	NN	B-NP	O	O
of	of	IN	B-PP	O	O
number	number	NN	B-NP	O	O
and	and	CC	I-NP	O	O
duration	duration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
ictal	ictal	JJ	B-NP	O	O
periods	period	NNS	I-NP	O	O
in	in	IN	B-PP	O	O
EEG	EEG	NN	B-NP	O	O
of	of	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
receiving	receive	VBG	B-VP	O	O
l	l	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
arginine	arginine	NN	I-NP	B	I-Chemical
prior	prior	JJ	B-ADJP	O	O
to	to	TO	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
and	and	CC	I-NP	O	O
decrease	decrease	NN	I-NP	O	O
of	of	IN	B-PP	O	O
this	this	DT	B-NP	O	O
number	number	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rats	rat	NNS	B-NP	O	O
pretreated	pretreate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
L	L	NN	B-NP	B	B-Chemical
-	-	HYPH	O	I	I-Chemical
NAME	NAME	NN	B-NP	I	I-Chemical
.	.	.	O	O	O

These	These	DT	B-NP	O	O
results	result	NNS	I-NP	O	O
support	support	VBP	B-VP	O	O
the	the	DT	B-NP	O	O
conclusion	conclusion	NN	I-NP	O	O
that	that	IN	B-SBAR	O	O
NO	NO	NN	B-NP	O	B-Chemical
plays	play	VBZ	B-VP	O	O
a	a	DT	B-NP	O	O
role	role	NN	I-NP	O	O
of	of	IN	B-PP	O	O
endogenous	endogenous	JJ	B-NP	O	O
convulsant	convulsant	NN	I-NP	O	O
in	in	IN	B-PP	O	O
rat	rat	NN	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
lindane	lindane	NN	B-NP	B	B-Chemical
seizures	seizure	NNS	I-NP	O	B-Disease
.	.	.	O	O	O

Long	Long	JJ	B-NP	O	O
-	-	HYPH	I-NP	O	O
term	term	NN	I-NP	O	O
oral	oral	JJ	I-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
prevents	prevent	VBZ	B-VP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
male	male	JJ	B-NP	O	O
Wistar	Wistar	NNP	I-NP	O	O
rats	rat	NNS	I-NP	O	O
treated	treat	VBN	B-VP	O	O
intracerebroventricularly	intracerebroventricularly	RB	B-ADVP	O	O
with	with	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
.	.	.	O	O	O

Basic	Basic	JJ	B-NP	O	O
and	and	CC	I-NP	O	O
clinical	clinical	JJ	I-NP	O	O
research	research	NN	I-NP	O	O
has	have	VBZ	B-VP	O	O
demonstrated	demonstrate	VBN	I-VP	O	O
that	that	IN	B-SBAR	O	O
dementia	dementia	NN	B-NP	O	B-Disease
of	of	IN	B-PP	O	O
sporadic	sporadic	JJ	B-NP	O	O
Alzheimer	Alzheimer	NNP	I-NP	O	B-Disease
's	's	POS	B-NP	O	I-Disease
disease	disease	NN	I-NP	O	I-Disease
(	(	(	O	O	O
sAD	sAD	NN	B-NP	O	O
)	)	)	O	O	O
type	type	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
associated	associate	VBN	I-VP	O	O
with	with	IN	B-PP	O	O
dysfunction	dysfunction	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
insulin	insulin	NN	I-NP	B	O
-	-	HYPH	O	O	O
receptor	receptor	NN	B-NP	O	O
(	(	(	O	O	O
IR	IR	NN	B-NP	O	O
)	)	)	O	O	O
system	system	NN	B-NP	O	O
followed	follow	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
decreased	decrease	VBN	B-NP	O	O
glucose	glucose	NN	I-NP	B	B-Chemical
transport	transport	NN	I-NP	O	O
via	via	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
transporter	transporter	NN	I-NP	O	O
GLUT4	GLUT4	NN	I-NP	O	O
and	and	CC	O	O	O
decreased	decrease	VBD	B-VP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
metabolism	metabolism	NN	I-NP	O	O
in	in	IN	B-PP	O	O
brain	brain	NN	B-NP	O	O
cells	cell	NNS	I-NP	O	O
.	.	.	O	O	O

An	An	DT	B-NP	O	O
alternative	alternative	JJ	I-NP	O	O
source	source	NN	I-NP	O	O
of	of	IN	B-PP	O	O
energy	energy	NN	B-NP	O	O
is	be	VBZ	B-VP	O	O
d	d	VBN	I-VP	O	B-Chemical
-	-	:	O	O	I-Chemical
galactose	galactose	NN	B-NP	B	I-Chemical
(	(	(	O	O	O
the	the	DT	B-NP	O	O
C	C	NN	I-NP	O	O
-	-	HYPH	B-NP	O	O
4	4	CD	I-NP	O	O
-	-	HYPH	I-NP	O	O
epimer	epimer	NN	I-NP	O	O
of	of	IN	B-PP	O	O
d	d	NN	B-NP	O	B-Chemical
-	-	HYPH	B-NP	O	I-Chemical
glucose	glucose	NN	I-NP	B	I-Chemical
)	)	)	O	O	O
which	which	WDT	B-NP	O	O
is	be	VBZ	B-VP	O	O
transported	transport	VBN	I-VP	O	O
into	into	IN	B-PP	O	O
the	the	DT	B-NP	O	O
brain	brain	NN	I-NP	O	O
by	by	IN	B-PP	O	O
insulin	insulin	NN	B-NP	B	O
-	-	HYPH	B-NP	O	O
independent	independent	JJ	I-NP	O	O
GLUT3	GLUT3	NN	I-NP	O	O
transporter	transporter	NN	I-NP	O	O
where	where	WRB	B-ADVP	O	O
it	it	PRP	B-NP	O	O
might	might	MD	B-VP	O	O
be	be	VB	I-VP	O	O
metabolized	metabolize	VBN	I-VP	O	O
to	to	TO	B-PP	O	O
glucose	glucose	NN	B-NP	B	B-Chemical
via	via	IN	B-PP	O	O
the	the	DT	B-NP	O	O
Leloir	Leloir	NNP	I-NP	O	O
pathway	pathway	NN	I-NP	O	O
.	.	.	O	O	O

Exclusively	Exclusively	RB	B-NP	O	O
parenteral	parenteral	JJ	I-NP	O	O
daily	daily	JJ	I-NP	O	O
injections	injection	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
galactose	galactose	NN	B-NP	B	B-Chemical
induce	induce	VBP	B-VP	O	O
memory	memory	NN	B-NP	O	B-Disease
deterioration	deterioration	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
rodents	rodent	NNS	B-NP	O	O
and	and	CC	O	O	O
are	be	VBP	B-VP	O	O
used	use	VBN	I-VP	O	O
to	to	TO	B-VP	O	O
generate	generate	VB	I-VP	O	O
animal	animal	NN	B-NP	O	O
aging	aging	NN	I-NP	O	O
model	model	NN	I-NP	O	O
,	,	,	O	O	O
but	but	CC	O	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
on	on	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	O
functions	function	NNS	I-NP	O	O
have	have	VBP	B-VP	O	O
never	never	RB	I-VP	O	O
been	be	VBN	I-VP	O	O
tested	test	VBN	I-VP	O	O
.	.	.	O	O	O

We	We	PRP	B-NP	O	O
have	have	VBP	B-VP	O	O
investigated	investigate	VBN	I-VP	O	O
the	the	DT	B-NP	O	O
effects	effect	NNS	I-NP	O	O
of	of	IN	B-PP	O	O
continuous	continuous	JJ	B-NP	O	O
daily	daily	JJ	I-NP	O	O
oral	oral	JJ	I-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
(	(	(	O	O	O
200	200	CD	B-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
)	)	)	O	O	O
treatment	treatment	NN	B-NP	O	O
on	on	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
streptozotocin	streptozotocin	NN	B-NP	B	B-Chemical
-	-	HYPH	O	O	O
induced	induce	VBN	B-VP	O	O
(	(	(	O	O	O
STZ	STZ	NN	B-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
icv	icv	NN	I-NP	O	O
)	)	)	O	O	O
rat	rat	NN	B-NP	O	O
model	model	NN	I-NP	O	O
of	of	IN	B-PP	O	O
sAD	sAD	NN	B-NP	O	O
,	,	,	O	O	O
tested	test	VBN	B-VP	O	O
by	by	IN	B-PP	O	O
Morris	Morris	NNP	B-NP	O	O
Water	Water	NNP	I-NP	B	O
Maze	Maze	NNP	I-NP	O	O
and	and	CC	O	O	O
Passive	Passive	NNP	B-NP	O	O
Avoidance	Avoidance	NNP	I-NP	O	O
test	test	NN	I-NP	O	O
,	,	,	O	O	O
respectively	respectively	RB	B-ADVP	O	O
.	.	.	O	O	O

One	One	CD	B-NP	O	O
month	month	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
treatment	treatment	NN	I-NP	O	O
initiated	initiate	VBN	B-VP	O	O
immediately	immediately	RB	B-ADVP	O	O
after	after	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STZ	STZ	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
icv	icv	NN	I-NP	O	O
administration	administration	NN	I-NP	O	O
,	,	,	O	O	O
successfully	successfully	RB	B-VP	O	O
prevented	prevent	VBD	I-VP	O	O
development	development	NN	B-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
STZ	STZ	NN	I-NP	B	B-Chemical
-	-	HYPH	B-NP	O	O
icv	icv	NN	I-NP	O	O
-	-	HYPH	O	O	O
induced	induce	VBN	B-NP	O	O
cognitive	cognitive	JJ	I-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
.	.	.	O	O	O

Beneficial	Beneficial	JJ	B-NP	O	O
effect	effect	NN	I-NP	O	O
of	of	IN	B-PP	O	O
oral	oral	JJ	B-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
was	be	VBD	B-VP	O	O
independent	independent	JJ	B-ADJP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
rat	rat	NN	I-NP	O	O
age	age	NN	I-NP	O	O
and	and	CC	B-PP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
ranging	range	VBG	B-VP	O	O
from	from	IN	B-PP	O	O
100	100	CD	B-NP	O	O
to	to	TO	I-NP	O	O
300	300	CD	I-NP	O	O
mg	mg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
kg	kg	NN	I-NP	O	O
/	/	SYM	B-NP	O	O
day	day	NN	I-NP	O	O
.	.	.	O	O	O

Additionally	Additionally	RB	B-ADVP	O	O
,	,	,	O	O	O
oral	oral	JJ	B-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
administration	administration	NN	I-NP	O	O
led	lead	VBD	B-VP	O	O
to	to	TO	B-PP	O	O
the	the	DT	B-NP	O	O
appearance	appearance	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galactose	galactose	NN	B-NP	B	B-Chemical
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
blood	blood	NN	I-NP	O	O
.	.	.	O	O	O

The	The	DT	B-NP	O	O
increase	increase	NN	I-NP	O	O
of	of	IN	B-PP	O	O
galactose	galactose	NN	B-NP	B	B-Chemical
concentration	concentration	NN	I-NP	O	O
in	in	IN	B-PP	O	O
the	the	DT	B-NP	O	O
cerebrospinal	cerebrospinal	JJ	I-NP	O	O
fluid	fluid	NN	I-NP	O	O
was	be	VBD	B-VP	O	O
several	several	JJ	B-NP	O	O
times	time	NNS	I-NP	O	O
lower	low	JJR	I-NP	O	O
after	after	IN	B-PP	O	O
oral	oral	JJ	B-ADJP	O	O
than	than	IN	B-PP	O	O
after	after	IN	B-SBAR	O	O
parenteral	parenteral	JJ	B-NP	O	O
administration	administration	NN	I-NP	O	O
of	of	IN	B-PP	O	O
the	the	DT	B-NP	O	O
same	same	JJ	I-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
dose	dose	NN	I-NP	O	O
.	.	.	O	O	O

Oral	Oral	JJ	B-NP	O	O
galactose	galactose	NN	I-NP	B	B-Chemical
exposure	exposure	NN	I-NP	O	O
might	might	MD	B-VP	O	O
have	have	VB	I-VP	O	O
beneficial	beneficial	JJ	B-NP	O	O
effects	effect	NNS	I-NP	O	O
on	on	IN	B-PP	O	O
learning	learning	NN	B-NP	O	O
and	and	CC	I-NP	O	O
memory	memory	NN	I-NP	O	O
ability	ability	NN	I-NP	O	O
and	and	CC	O	O	O
could	could	MD	B-VP	O	O
be	be	VB	I-VP	O	O
worth	worth	JJ	B-PP	O	O
investigating	investigate	VBG	B-VP	O	O
for	for	IN	B-PP	O	O
improvement	improvement	NN	B-NP	O	O
of	of	IN	B-PP	O	O
cognitive	cognitive	JJ	B-NP	O	B-Disease
deficits	deficit	NNS	I-NP	O	I-Disease
associated	associate	VBN	B-VP	O	O
with	with	IN	B-PP	O	O
glucose	glucose	NN	B-NP	B	B-Disease
hypometabolism	hypometabolism	NN	I-NP	O	I-Disease
in	in	IN	B-PP	O	O
AD	AD	NN	B-NP	B	B-Disease
.	.	.	O	O	O

